data_2mfk_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2mfk _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . 0.579 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 8.2 p-10 . . . . . 0 N--CA 1.448 -0.53 0 CA-C-O 121.362 0.601 . . . . 0.0 111.571 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 48.8 tp -102.79 145.47 29.7 Favored 'General case' 0 C--N 1.308 -1.236 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.148 176.472 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.456 ' CG2' HG23 ' A' ' 89' ' ' THR . 14.0 mt -97.54 143.96 11.75 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.111 0 C-N-CA 120.599 -0.44 . . . . 0.0 111.083 -178.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 30.7 m -135.75 174.37 12.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.828 -179.285 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' HIS . . . . . 0.417 ' CE1' HG22 ' A' ' 89' ' ' THR . 45.9 m-70 -122.89 115.88 22.69 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 120.967 0.413 . . . . 0.0 111.704 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 59.6 mm-40 -109.12 104.19 13.32 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.209 176.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 59.98 45.33 96.08 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.321 -0.942 . . . . 0.0 111.713 -178.755 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 85.4 -31.7 3.77 Favored Glycine 0 CA--C 1.524 0.619 0 C-N-CA 121.036 -0.602 . . . . 0.0 113.593 -179.143 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 14.2 mptt -82.07 141.77 32.88 Favored 'General case' 0 CA--C 1.51 -0.59 0 CA-C-N 117.373 0.587 . . . . 0.0 111.555 -176.126 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.456 HG23 ' CG2' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -84.63 134.19 34.39 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.908 179.856 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 63.9 m-85 -132.22 154.29 49.75 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.761 176.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 19.2 m-70 -102.42 144.8 30.42 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-O 120.823 0.344 . . . . 0.0 110.57 179.469 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.579 ' O ' ' HA ' ' A' ' 80' ' ' ASP . 93.7 t -120.06 117.87 55.03 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.19 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 177.547 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 3.3 p -124.6 138.8 52.81 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 CA-C-N 116.112 -0.495 . . . . 0.0 109.93 -178.52 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 92.3 m -110.94 123.92 51.1 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 120.895 0.379 . . . . 0.0 110.946 179.514 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 52.1 m80 -102.15 -22.35 14.22 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.376 -179.766 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -141.03 152.47 44.89 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.478 -178.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -76.23 106.35 7.79 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.659 -0.701 . . . . 0.0 110.508 177.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 156.24 169.51 20.46 Favored Glycine 0 N--CA 1.434 -1.474 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 -179.581 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_endo -78.53 132.91 11.35 Favored 'Trans proline' 0 N--CA 1.456 -0.691 0 C-N-CA 122.406 2.071 . . . . 0.0 112.394 178.62 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 2.0 pp -137.12 157.82 73.75 Favored Pre-proline 0 C--N 1.319 -0.726 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.517 178.21 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -69.51 171.86 13.43 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.271 1.981 . . . . 0.0 112.492 -178.29 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' HIS . . . . . 0.572 ' HB3' ' O ' ' A' ' 105' ' ' ASN . 30.3 t-80 -89.85 128.1 51.48 Favored Pre-proline 0 C--N 1.309 -1.177 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 179.727 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -50.52 -54.91 4.67 Favored 'Trans proline' 0 N--CA 1.477 0.524 0 C-N-CA 122.932 2.421 . . . . 0.0 112.604 -176.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -63.17 -62.2 5.65 Favored Glycine 0 CA--C 1.526 0.776 0 CA-C-N 115.813 -0.63 . . . . 0.0 113.15 178.237 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.572 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 9.9 p-10 -122.8 103.22 8.5 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 -177.004 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 31.1 m -58.29 -10.67 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.089 0 N-CA-C 114.0 1.111 . . . . 0.0 114.0 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 14.0 t-80 -66.27 -10.39 41.93 Favored 'General case' 0 N--CA 1.47 0.56 0 CA-C-O 121.451 0.643 . . . . 0.0 110.299 176.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.403 ' HG2' ' HA ' ' A' ' 125' ' ' PRO . 44.7 mtmt -126.55 158.69 35.53 Favored 'General case' 0 N--CA 1.434 -1.237 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 178.196 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 7.7 p90 -141.72 165.49 27.34 Favored 'General case' 0 C--N 1.302 -1.492 0 C-N-CA 120.642 -0.423 . . . . 0.0 110.517 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 3.9 mp -123.32 139.81 48.84 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 -179.062 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.406 ' N ' HD11 ' A' ' 111' ' ' ILE . 4.3 mp -99.98 118.09 46.12 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.179 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 177.502 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 23.5 m -101.78 122.72 44.48 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.222 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 49.1 m -131.7 146.73 52.33 Favored 'General case' 0 C--N 1.312 -1.064 0 CA-C-O 121.074 0.464 . . . . 0.0 111.44 -177.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . 0.4 ' HD2' ' O ' ' A' ' 116' ' ' GLY . 5.0 tppp? -97.28 139.6 33.0 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.527 179.312 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 68.2 m -128.71 85.78 2.37 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 174.474 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.4 ' O ' ' HD2' ' A' ' 114' ' ' LYS . . . 72.68 -104.53 1.55 Allowed Glycine 0 N--CA 1.437 -1.296 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 -174.55 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 50.6 m -115.07 11.81 16.5 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-O 120.779 0.323 . . . . 0.0 110.885 175.17 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 34.0 tp -111.36 143.39 42.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.672 -0.24 . . . . 0.0 110.627 -177.367 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 54.0 m95 -100.23 133.14 45.08 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.034 0.445 . . . . 0.0 112.128 179.198 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -119.53 132.35 55.74 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.647 -0.706 . . . . 0.0 109.463 174.044 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 1.9 pp -123.72 149.89 27.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-O 120.78 0.324 . . . . 0.0 111.074 -179.1 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 28.4 m -146.06 122.93 11.3 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.152 178.312 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.6 p -95.93 111.13 25.65 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.417 0 CA-C-O 121.363 0.601 . . . . 0.0 111.34 -178.333 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.434 ' HA ' ' HE2' ' A' ' 124' ' ' MET . 5.5 mmt -114.36 142.59 28.33 Favored Pre-proline 0 C--N 1.318 -0.762 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.525 -179.314 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . 0.403 ' HA ' ' HG2' ' A' ' 108' ' ' LYS . 97.3 Cg_endo -86.5 143.11 7.32 Favored 'Trans proline' 0 N--CA 1.449 -1.092 0 C-N-CA 122.378 2.052 . . . . 0.0 111.641 176.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 4.9 t -92.98 -179.6 5.16 Favored 'General case' 0 C--N 1.319 -0.756 0 C-N-CA 120.541 -0.463 . . . . 0.0 109.91 178.228 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 34.3 m -65.32 144.53 57.06 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-O 120.881 0.372 . . . . 0.0 110.579 -178.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . 0.415 ' N ' HD12 ' A' ' 128' ' ' ILE . 2.8 mp -68.04 132.33 32.75 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.786 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 103.68 -18.45 47.28 Favored Glycine 0 N--CA 1.439 -1.11 0 CA-C-N 115.797 -0.638 . . . . 0.0 112.019 -176.141 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 40.3 p -116.76 158.53 23.73 Favored 'General case' 0 N--CA 1.445 -0.713 0 O-C-N 122.67 -0.312 . . . . 0.0 110.854 179.02 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 49.9 pttt -132.17 148.64 52.48 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 116.146 -0.479 . . . . 0.0 109.863 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 23.4 t80 -86.4 139.67 30.72 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-O 121.015 0.436 . . . . 0.0 111.691 -177.319 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -107.6 136.58 19.62 Favored Pre-proline 0 N--CA 1.469 0.502 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.784 177.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -68.11 -44.7 3.51 Favored 'Trans proline' 0 C--N 1.347 0.468 0 C-N-CA 122.948 2.432 . . . . 0.0 114.285 -176.464 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 39.5 mm -78.55 -46.34 24.99 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 CA-C-O 120.823 0.344 . . . . 0.0 111.715 -176.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.7 m -69.06 -34.89 75.9 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 120.909 0.385 . . . . 0.0 110.199 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 81.8 mtt-85 69.01 41.34 1.45 Allowed 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.144 177.479 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -152.54 176.28 11.87 Favored 'General case' 0 C--N 1.316 -0.863 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 178.49 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 87.8 m -100.93 126.82 47.58 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 120.888 0.375 . . . . 0.0 110.538 -179.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.2 m -109.41 157.78 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.018 0 CA-C-N 115.811 -0.632 . . . . 0.0 109.824 179.584 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 58.5 tp -69.55 115.58 8.97 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-O 120.94 0.4 . . . . 0.0 111.138 -179.374 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 30.9 t70 . . . . . 0 C--N 1.321 -0.673 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.619 177.215 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 22.1 t70 . . . . . 0 CA--C 1.52 -0.199 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.411 ' CD2' HD11 ' A' ' 121' ' ' ILE . 39.4 tp -117.53 132.63 56.5 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.13 176.254 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 10.4 mt -98.73 144.41 11.72 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.09 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 178.734 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 19.1 m -136.88 162.86 33.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-O 120.765 0.317 . . . . 0.0 110.296 -177.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 12.7 m-70 -94.34 115.32 27.52 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.334 178.229 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -128.8 106.65 9.07 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 -178.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 67.18 29.89 74.96 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 110.794 -0.923 . . . . 0.0 110.794 -177.092 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 85.29 -22.95 8.94 Favored Glycine 0 N--CA 1.443 -0.892 0 CA-C-N 115.318 -0.441 . . . . 0.0 112.672 -178.357 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 75.1 mmtt -91.85 146.59 23.63 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.843 0.354 . . . . 0.0 111.14 -177.69 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -82.22 125.98 31.56 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.601 179.602 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -124.48 143.36 50.69 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 176.823 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 22.0 m-70 -90.05 146.6 24.21 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-O 121.097 0.475 . . . . 0.0 111.465 -178.553 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 49.5 t -120.44 119.0 58.52 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 175.562 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 58.0 t -130.4 135.64 60.2 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.256 0 CA-C-N 116.141 -0.481 . . . . 0.0 109.972 -177.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 91.5 m -119.11 113.3 20.7 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.03 0.443 . . . . 0.0 110.645 178.68 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 43.0 t-80 -91.89 -22.07 20.27 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.223 179.823 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 -146.58 157.82 43.79 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.769 -176.755 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -79.18 145.66 33.54 Favored 'General case' 0 C--N 1.312 -1.032 0 CA-C-O 120.955 0.407 . . . . 0.0 110.962 -177.222 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 125.39 163.65 11.66 Favored Glycine 0 N--CA 1.437 -1.261 0 C-N-CA 120.976 -0.63 . . . . 0.0 111.926 -178.441 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.403 ' HD2' ' HD3' ' A' ' 137' ' ' ARG . 84.4 Cg_endo -84.4 135.19 6.03 Favored 'Trans proline' 0 CA--C 1.538 0.7 0 C-N-CA 122.721 2.28 . . . . 0.0 112.997 179.168 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -142.28 154.96 64.76 Favored Pre-proline 0 C--O 1.216 -0.707 0 CA-C-N 115.76 -0.654 . . . . 0.0 109.724 177.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -67.85 169.29 16.53 Favored 'Trans proline' 0 C--N 1.348 0.54 0 C-N-CA 122.349 2.033 . . . . 0.0 112.365 -178.537 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' HIS . . . . . . . . . . . . . 12.1 t-80 -85.54 135.5 38.37 Favored Pre-proline 0 C--N 1.319 -0.719 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -178.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -57.8 -25.33 68.34 Favored 'Trans proline' 0 C--N 1.353 0.779 0 C-N-CA 122.93 2.42 . . . . 0.0 112.028 -179.368 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -84.35 -65.86 1.5 Allowed Glycine 0 N--CA 1.441 -0.971 0 CA-C-N 115.522 -0.763 . . . . 0.0 111.765 178.212 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.412 ' OD1' ' HE2' ' A' ' 108' ' ' LYS . 36.8 p-10 -124.37 114.02 18.97 Favored 'General case' 0 CA--C 1.543 0.693 0 CA-C-O 121.364 0.602 . . . . 0.0 111.878 -179.616 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 15.9 m -58.76 -10.63 1.58 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 N-CA-C 112.854 0.687 . . . . 0.0 112.854 177.284 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 35.5 m80 -68.22 -7.17 28.1 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 121.06 0.457 . . . . 0.0 110.362 176.44 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.481 ' HG2' ' HA ' ' A' ' 125' ' ' PRO . 47.4 mtmt -131.5 157.07 44.51 Favored 'General case' 0 CA--C 1.5 -0.953 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.465 179.045 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 8.5 p90 -142.15 161.73 37.26 Favored 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 120.773 -0.371 . . . . 0.0 110.71 179.436 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 3.2 mp -119.78 137.22 54.37 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 -179.505 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -96.71 116.85 39.91 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.359 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 175.551 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 56.2 m -95.77 122.13 38.23 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 109.333 -0.618 . . . . 0.0 109.333 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 49.6 m -122.56 127.56 49.61 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.314 -179.733 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 85.4 tttt -100.29 116.22 31.77 Favored 'General case' 0 N--CA 1.432 -1.366 0 CA-C-O 121.118 0.485 . . . . 0.0 109.926 178.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 53.7 m -106.18 83.57 1.91 Allowed 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.581 179.149 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 67.77 -100.24 0.6 Allowed Glycine 0 N--CA 1.44 -1.082 0 CA-C-N 115.521 -0.763 . . . . 0.0 111.593 -178.348 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 16.2 m -111.52 5.73 19.68 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-O 120.828 0.347 . . . . 0.0 110.46 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 22.8 tp -118.51 134.49 55.04 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.092 -177.643 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 77.4 m95 -97.3 132.76 42.72 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-O 121.105 0.479 . . . . 0.0 111.978 178.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 51.5 m-85 -115.95 130.21 56.72 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.828 174.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.411 HD11 ' CD2' ' A' ' 81' ' ' LEU . 2.2 pp -119.87 148.98 22.6 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-O 121.172 0.511 . . . . 0.0 110.786 179.646 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 16.5 m -142.99 114.05 7.72 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.7 178.007 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.9 p -96.04 103.72 15.01 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-O 121.747 0.784 . . . . 0.0 111.06 -177.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.498 ' HA ' ' HE2' ' A' ' 124' ' ' MET . 3.7 mmt -107.37 137.65 19.69 Favored Pre-proline 0 C--N 1.313 -1.02 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.922 -178.462 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . 0.481 ' HA ' ' HG2' ' A' ' 108' ' ' LYS . 72.9 Cg_endo -80.72 142.79 14.46 Favored 'Trans proline' 0 N--CA 1.448 -1.199 0 C-N-CA 122.142 1.894 . . . . 0.0 111.315 176.543 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 9.6 t -91.97 -178.24 4.95 Favored 'General case' 0 C--N 1.313 -1.021 0 C-N-CA 120.393 -0.523 . . . . 0.0 109.779 178.03 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 7.6 t -61.3 138.64 58.24 Favored 'General case' 0 N--CA 1.434 -1.23 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.016 179.396 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . 0.404 ' N ' HD12 ' A' ' 128' ' ' ILE . 2.7 mp -64.24 138.75 22.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 178.384 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 92.89 -12.74 69.26 Favored Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 120.421 -0.895 . . . . 0.0 112.606 -175.779 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 63.9 p -120.45 161.43 21.26 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 117.045 0.422 . . . . 0.0 110.696 178.424 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.473 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 58.9 pttt -133.57 146.62 51.16 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 116.338 -0.392 . . . . 0.0 109.985 179.476 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 31.4 t80 -85.9 136.62 33.22 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.688 -178.375 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -97.68 136.04 21.38 Favored Pre-proline 0 C--N 1.319 -0.741 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.569 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -68.48 -46.33 2.02 Favored 'Trans proline' 0 C--N 1.346 0.447 0 C-N-CA 122.684 2.256 . . . . 0.0 113.591 -178.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.9 mp -77.56 -54.27 12.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 111.706 0.261 . . . . 0.0 111.706 -177.779 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 21.5 m -68.02 -32.32 72.61 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 120.645 0.26 . . . . 0.0 110.916 -178.621 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' ARG . . . . . 0.403 ' HD3' ' HD2' ' A' ' 99' ' ' PRO . 98.4 mtt180 66.47 48.55 1.51 Allowed 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 121.411 0.624 . . . . 0.0 111.29 177.62 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 23.9 p-10 -151.42 172.9 15.23 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 115.254 -0.884 . . . . 0.0 108.762 177.731 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 67.9 m -101.82 126.94 48.8 Favored 'General case' 0 C--N 1.308 -1.208 0 CA-C-O 121.222 0.534 . . . . 0.0 111.154 179.041 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 35.1 m -116.46 161.35 15.27 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-N 115.43 -0.805 . . . . 0.0 108.941 178.053 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 45.2 tp -54.03 125.79 20.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.054 0.454 . . . . 0.0 110.113 178.6 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' ASP . . . . . 0.473 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 9.8 t70 . . . . . 0 C--N 1.316 -0.85 0 CA-C-N 115.999 -0.546 . . . . 0.0 112.289 -175.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 24.9 t70 . . . . . 0 CA--C 1.512 -0.498 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 45.7 tp -109.9 135.39 50.85 Favored 'General case' 0 C--N 1.31 -1.152 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 177.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 11.5 mt -96.82 142.55 13.85 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 C-N-CA 120.57 -0.452 . . . . 0.0 110.391 179.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 22.9 m -139.35 178.27 3.92 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 -178.106 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' HIS . . . . . 0.47 ' HA ' ' O ' ' A' ' 88' ' ' LYS . 66.3 m-70 -117.99 124.61 48.6 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-O 121.253 0.549 . . . . 0.0 111.868 179.49 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 -114.62 103.91 11.47 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.062 -0.972 . . . . 0.0 108.967 177.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 67.73 18.36 70.18 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.607 -0.806 . . . . 0.0 111.329 -177.739 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 106.75 -29.39 10.93 Favored Glycine 0 N--CA 1.445 -0.753 0 C-N-CA 121.28 -0.486 . . . . 0.0 112.635 -179.206 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . 0.47 ' O ' ' HA ' ' A' ' 84' ' ' HIS . 47.5 mmtm -80.79 154.03 27.41 Favored 'General case' 0 C--O 1.22 -0.457 0 CA-C-N 116.732 0.266 . . . . 0.0 110.534 -178.103 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -87.7 128.44 35.3 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.306 0.574 . . . . 0.0 112.512 -178.774 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 17.9 m-85 -125.74 152.2 45.65 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.34 -0.846 . . . . 0.0 109.985 177.399 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 24.3 m-70 -100.88 149.06 24.27 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-O 121.016 0.436 . . . . 0.0 111.361 -179.516 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 44.1 t -120.79 118.35 56.12 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.002 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 176.187 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 58.8 t -132.16 131.39 61.1 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.532 -179.242 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 94.9 m -113.76 138.69 49.9 Favored 'General case' 0 C--N 1.313 -1.012 0 CA-C-O 120.799 0.333 . . . . 0.0 110.894 -179.424 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 77.8 m-70 -119.03 -19.63 8.39 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.364 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 5.4 mp0 -126.05 142.21 51.62 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.011 -0.54 . . . . 0.0 109.699 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 -76.97 103.8 7.1 Favored 'General case' 0 C--N 1.314 -0.937 0 N-CA-C 109.794 -0.446 . . . . 0.0 109.794 177.177 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 164.26 169.35 27.69 Favored Glycine 0 N--CA 1.436 -1.349 0 N-CA-C 111.267 -0.733 . . . . 0.0 111.267 -179.178 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.437 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 95.4 Cg_endo -83.34 133.51 6.37 Favored 'Trans proline' 0 N--CA 1.454 -0.806 0 C-N-CA 122.582 2.188 . . . . 0.0 112.709 179.031 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.9 pp -140.12 156.6 70.13 Favored Pre-proline 0 C--N 1.32 -0.704 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.996 178.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -62.96 167.29 12.45 Favored 'Trans proline' 0 C--N 1.351 0.695 0 C-N-CA 122.743 2.296 . . . . 0.0 112.87 -178.547 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' HIS . . . . . . . . . . . . . 5.0 t-80 -91.68 133.15 31.46 Favored Pre-proline 0 C--N 1.322 -0.597 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.822 -178.366 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_endo -53.46 -37.62 82.31 Favored 'Trans proline' 0 C--N 1.353 0.799 0 C-N-CA 123.414 2.743 . . . . 0.0 113.344 -177.654 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -70.8 -64.82 2.68 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.087 179.462 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 3.0 p30 -132.6 120.29 21.61 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 121.045 0.45 . . . . 0.0 111.421 178.531 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 28.3 m -57.07 -10.25 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 CA-C-N 115.573 -0.74 . . . . 0.0 112.835 177.768 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 66.4 m170 -69.84 -1.03 8.24 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-O 121.158 0.504 . . . . 0.0 110.636 176.553 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 33.1 mtmm -137.31 157.72 46.01 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.109 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -143.47 173.33 11.72 Favored 'General case' 0 C--N 1.308 -1.21 0 C-N-CA 120.825 -0.35 . . . . 0.0 110.921 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.437 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 1.9 mp -131.04 142.82 42.58 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.966 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 178.786 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -99.68 115.17 39.99 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.968 0 N-CA-C 107.424 -1.325 . . . . 0.0 107.424 174.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 29.2 m -95.41 121.75 37.41 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 -178.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 16.4 m -126.56 140.79 52.17 Favored 'General case' 0 C--N 1.307 -1.282 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 -179.32 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -118.19 104.86 11.21 Favored 'General case' 0 C--N 1.308 -1.23 0 CA-C-O 121.083 0.468 . . . . 0.0 110.569 -178.435 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 67.5 m -82.89 89.06 6.8 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.444 178.704 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 68.78 -100.26 0.67 Allowed Glycine 0 N--CA 1.432 -1.575 0 C-N-CA 120.461 -0.876 . . . . 0.0 111.084 -177.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 14.5 t -114.5 7.46 16.19 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-O 120.9 0.381 . . . . 0.0 110.383 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 21.8 tp -117.1 131.11 56.99 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.584 -0.28 . . . . 0.0 110.438 -177.712 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 77.0 m95 -92.14 131.75 37.15 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 121.038 0.447 . . . . 0.0 111.84 -179.457 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 64.4 m-85 -120.89 129.79 53.64 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.471 174.085 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.5 pp -120.82 151.51 23.78 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.043 0 CA-C-O 121.129 0.49 . . . . 0.0 111.736 -179.518 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 27.8 m -139.66 118.81 12.69 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.892 178.495 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 6.0 p -92.09 124.6 44.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 120.951 0.405 . . . . 0.0 111.081 -178.621 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.403 ' HA ' ' HE2' ' A' ' 124' ' ' MET . 4.0 mmt -125.77 139.22 33.62 Favored Pre-proline 0 C--N 1.318 -0.766 0 CA-C-N 115.822 -0.627 . . . . 0.0 109.838 -179.48 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -86.8 143.14 6.97 Favored 'Trans proline' 0 N--CA 1.453 -0.911 0 C-N-CA 122.241 1.961 . . . . 0.0 111.883 177.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' CYS . . . . . 0.496 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 55.3 m -81.81 169.39 16.95 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 176.529 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 1.6 p -58.36 148.52 27.45 Favored 'General case' 0 N--CA 1.435 -1.198 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.604 176.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . 0.417 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.9 mp -62.74 129.0 25.56 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 CA-C-O 121.135 0.493 . . . . 0.0 110.445 -179.348 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 92.04 5.31 66.1 Favored Glycine 0 N--CA 1.44 -1.061 0 CA-C-N 115.694 -0.684 . . . . 0.0 112.882 -178.21 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 60.5 p -126.33 162.6 25.13 Favored 'General case' 0 C--O 1.236 0.347 0 CA-C-N 117.269 0.534 . . . . 0.0 111.133 179.166 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 58.0 pttt -131.9 143.99 50.54 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 179.387 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.496 ' HB2' ' SG ' ' A' ' 126' ' ' CYS . 46.5 t80 -82.74 133.6 35.15 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-O 120.919 0.39 . . . . 0.0 111.712 -178.489 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -100.55 128.57 29.81 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 115.877 -0.601 . . . . 0.0 109.907 177.453 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -64.56 -41.22 20.44 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.973 2.449 . . . . 0.0 113.514 -176.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 28.1 mm -75.89 -53.01 16.58 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 N-CA-C 112.097 0.406 . . . . 0.0 112.097 -175.738 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 4.8 m -68.78 -31.96 71.35 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.727 -178.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 57.5 mtm180 70.73 51.02 0.33 Allowed 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 121.428 0.632 . . . . 0.0 110.752 178.328 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 29.7 p-10 -159.23 173.41 16.39 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-N 115.483 -0.78 . . . . 0.0 109.004 179.067 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 21.1 m -101.85 125.26 48.49 Favored 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 178.503 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 27.2 m -112.8 163.2 10.2 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.767 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.159 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 6.9 tt -57.56 123.6 16.13 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-O 121.081 0.467 . . . . 0.0 111.225 -178.692 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 17.1 t70 . . . . . 0 C--N 1.322 -0.594 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.209 178.836 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . 0.516 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 11.9 p-10 . . . . . 0 N--CA 1.44 -0.944 0 CA-C-O 121.604 0.716 . . . . 0.0 111.437 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 39.0 tp -107.25 137.88 44.47 Favored 'General case' 0 C--N 1.301 -1.504 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.502 177.224 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.447 ' CG2' HG21 ' A' ' 89' ' ' THR . 16.8 mt -96.81 143.29 12.62 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.07 0 C-N-CA 120.511 -0.476 . . . . 0.0 110.187 -179.547 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.417 HG21 ' HE2' ' A' ' 102' ' ' HIS . 28.7 m -138.41 157.37 30.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-N 116.174 -0.466 . . . . 0.0 109.804 -179.203 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 60.8 m-70 -104.2 104.33 14.23 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 116.468 -0.333 . . . . 0.0 111.019 179.454 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 70.4 mm-40 -100.79 104.97 16.23 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 177.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 66.37 30.62 76.95 Favored Glycine 0 N--CA 1.444 -0.776 0 C-N-CA 120.262 -0.971 . . . . 0.0 110.783 -176.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 89.42 -21.89 26.57 Favored Glycine 0 N--CA 1.442 -0.947 0 CA-C-N 115.195 -0.502 . . . . 0.0 112.726 -178.549 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 14.0 mmmm -83.75 135.2 34.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.799 0.333 . . . . 0.0 111.024 -176.027 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.447 HG21 ' CG2' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -81.42 112.26 18.52 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -178.52 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -112.26 146.68 37.77 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.744 -0.662 . . . . 0.0 109.649 176.301 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 21.6 m-70 -99.05 142.44 30.53 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-O 120.715 0.293 . . . . 0.0 110.498 178.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.516 ' O ' ' HA ' ' A' ' 80' ' ' ASP . 79.5 t -117.65 120.33 64.4 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.955 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 179.097 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 14.9 p -138.79 142.21 34.97 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.028 -178.031 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 33.1 m -138.31 127.95 25.01 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.662 177.854 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 14.0 p80 -101.71 -0.32 34.7 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-O 121.447 0.641 . . . . 0.0 109.701 177.71 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 56.5 mt-10 -142.67 157.95 44.15 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 114.755 -1.111 . . . . 0.0 109.702 178.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -85.46 153.75 22.27 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 120.917 0.389 . . . . 0.0 110.77 178.295 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 126.8 161.77 10.99 Favored Glycine 0 N--CA 1.438 -1.168 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.037 178.34 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.471 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 72.9 Cg_endo -82.62 134.59 7.58 Favored 'Trans proline' 0 N--CA 1.447 -1.248 0 C-N-CA 122.376 2.051 . . . . 0.0 111.855 177.896 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -141.65 157.4 65.22 Favored Pre-proline 0 C--N 1.314 -0.968 0 CA-C-N 115.934 -0.576 . . . . 0.0 109.733 178.515 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -62.42 164.64 17.31 Favored 'Trans proline' 0 C--N 1.348 0.544 0 C-N-CA 122.356 2.038 . . . . 0.0 112.468 -178.813 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' HIS . . . . . 0.417 ' HE2' HG21 ' A' ' 83' ' ' VAL . 27.6 t-80 -92.02 121.95 65.95 Favored Pre-proline 0 C--N 1.315 -0.899 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -59.0 -19.3 47.58 Favored 'Trans proline' 0 N--CA 1.486 1.041 0 C-N-CA 123.116 2.544 . . . . 0.0 113.543 -176.581 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -93.35 -19.3 35.98 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.469 -0.872 . . . . 0.0 112.809 -179.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 2.4 p30 -167.32 102.04 0.52 Allowed 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 122.479 0.311 . . . . 0.0 110.985 -177.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 28.3 m -54.91 -14.34 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 N-CA-C 113.674 0.99 . . . . 0.0 113.674 179.552 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 17.2 t-80 -73.21 -0.52 14.57 Favored 'General case' 0 CA--C 1.542 0.655 0 CA-C-O 121.61 0.719 . . . . 0.0 110.435 176.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.41 ' HG2' ' HA ' ' A' ' 125' ' ' PRO . 47.4 mtmt -136.89 160.88 37.58 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.473 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 11.1 p90 -142.37 173.67 11.32 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.546 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.471 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.7 mt -131.91 142.24 43.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 -178.584 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.6 mp -101.89 112.5 35.24 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.12 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 175.783 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 86.3 m -102.3 123.52 46.26 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-O 121.181 0.515 . . . . 0.0 111.178 -176.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 19.3 m -128.56 144.61 51.18 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.529 -179.057 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . 0.585 ' HD3' ' CE2' ' A' ' 119' ' ' TRP . 24.1 tptm -113.16 103.84 11.75 Favored 'General case' 0 C--N 1.313 -0.985 0 N-CA-C 109.152 -0.685 . . . . 0.0 109.152 179.247 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 62.2 m -91.28 78.92 5.72 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-O 121.436 0.636 . . . . 0.0 109.524 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.519 ' O ' ' HE2' ' A' ' 114' ' ' LYS . . . 75.44 -99.06 1.18 Allowed Glycine 0 N--CA 1.433 -1.507 0 N-CA-C 110.593 -1.003 . . . . 0.0 110.593 -178.897 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 20.4 m -113.46 0.92 14.88 Favored 'General case' 0 N--CA 1.445 -0.722 0 CA-C-O 121.312 0.577 . . . . 0.0 110.068 -179.752 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 87.6 mt -112.02 122.97 49.23 Favored 'General case' 0 N--CA 1.435 -1.21 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.555 -176.538 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . 0.585 ' CE2' ' HD3' ' A' ' 114' ' ' LYS . 81.3 m95 -85.32 131.34 34.42 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 121.015 0.436 . . . . 0.0 111.107 177.37 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -125.48 124.0 40.41 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 115.881 -0.6 . . . . 0.0 109.849 174.55 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.5 pp -126.45 146.97 31.38 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.955 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.33 -178.494 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 34.5 m -134.24 124.93 26.75 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 116.013 -0.54 . . . . 0.0 109.672 178.212 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 2.8 p -95.68 110.99 25.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-O 121.393 0.615 . . . . 0.0 111.252 -179.057 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.469 ' HE1' ' HA ' ' A' ' 124' ' ' MET . 9.1 mmt -113.32 145.8 33.98 Favored Pre-proline 0 C--N 1.318 -0.767 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.062 -178.719 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . 0.41 ' HA ' ' HG2' ' A' ' 108' ' ' LYS . 79.4 Cg_endo -89.25 151.15 5.55 Favored 'Trans proline' 0 N--CA 1.453 -0.865 0 C-N-CA 122.353 2.035 . . . . 0.0 113.074 179.605 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 35.9 m -90.87 171.14 9.52 Favored 'General case' 0 C--O 1.243 0.727 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.153 175.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 22.9 t -54.28 148.32 11.74 Favored 'General case' 0 C--O 1.237 0.413 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 177.298 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . 0.445 HD11 ' N ' ' A' ' 128' ' ' ILE . 1.9 mp -63.7 129.07 26.97 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 CA-C-O 120.912 0.387 . . . . 0.0 110.234 -179.032 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 89.38 6.03 71.55 Favored Glycine 0 N--CA 1.444 -0.791 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.783 -177.669 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 46.2 p -121.33 158.94 27.1 Favored 'General case' 0 N--CA 1.452 -0.36 0 O-C-N 122.343 -0.504 . . . . 0.0 110.757 178.236 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 59.0 pttt -128.0 144.26 51.1 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 32.8 t80 -84.46 137.22 33.48 Favored 'General case' 0 C--N 1.311 -1.098 0 C-N-CA 120.9 -0.32 . . . . 0.0 110.743 -179.644 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -100.05 133.83 21.31 Favored Pre-proline 0 C--N 1.325 -0.472 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.333 179.314 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -67.68 -41.84 7.71 Favored 'Trans proline' 0 C--N 1.346 0.418 0 C-N-CA 122.877 2.385 . . . . 0.0 113.949 -177.51 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 34.8 mm -82.35 -49.25 17.45 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 N-CA-C 111.951 0.352 . . . . 0.0 111.951 -176.45 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 2.4 m -69.1 -37.49 78.42 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.847 0.356 . . . . 0.0 110.1 179.512 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 67.5 mtt180 68.36 55.36 0.52 Allowed 'General case' 0 CA--C 1.514 -0.414 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.572 178.686 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 29.4 p-10 -154.61 172.93 17.06 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 114.86 -1.064 . . . . 0.0 108.374 178.221 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 27.3 m -101.03 124.83 47.36 Favored 'General case' 0 C--N 1.316 -0.891 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 177.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 35.8 m -117.54 157.16 18.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.296 -178.301 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 7.2 mp -64.56 119.75 11.06 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 112.186 0.439 . . . . 0.0 112.186 -178.328 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 38.7 t70 . . . . . 0 C--N 1.319 -0.734 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 174.032 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 24.3 t70 . . . . . 0 CA--C 1.517 -0.297 0 CA-C-O 120.722 0.296 . . . . 0.0 110.386 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 54.6 tp -108.6 131.65 54.65 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 178.298 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 12.3 mt -91.69 139.97 16.9 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 C-N-CA 120.408 -0.517 . . . . 0.0 109.651 179.068 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 29.4 m -136.52 175.12 10.98 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 CA-C-N 116.137 -0.483 . . . . 0.0 109.84 -177.536 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 16.2 m-70 -114.57 117.24 30.36 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.109 0.48 . . . . 0.0 111.426 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.448 ' HB2' ' CD1' ' A' ' 90' ' ' TYR . 11.8 mm-40 -115.19 104.45 11.86 Favored 'General case' 0 C--N 1.311 -1.074 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 177.228 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 64.39 34.05 88.87 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.382 -0.913 . . . . 0.0 111.448 -177.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 88.28 -26.9 7.34 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 121.436 -0.411 . . . . 0.0 113.021 -178.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -82.23 146.74 29.33 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.818 0.342 . . . . 0.0 111.169 -178.341 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -85.08 122.42 29.26 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-O 121.233 0.54 . . . . 0.0 112.153 -179.79 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.448 ' CD1' ' HB2' ' A' ' 85' ' ' GLU . 18.0 m-85 -117.03 148.79 41.18 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.252 176.711 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 31.4 m-70 -97.74 144.22 27.58 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-N 116.526 -0.306 . . . . 0.0 110.202 178.731 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 44.2 t -121.12 117.54 53.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.256 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 178.413 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.6 p -130.77 131.32 64.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 CA-C-N 115.424 -0.807 . . . . 0.0 109.096 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -106.3 138.44 42.48 Favored 'General case' 0 N--CA 1.435 -1.223 0 C-N-CA 119.579 -0.848 . . . . 0.0 111.456 -177.874 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 36.1 m80 -108.84 -25.07 10.97 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 115.329 -0.851 . . . . 0.0 110.365 -178.388 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -131.98 143.43 50.08 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.776 -177.664 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -74.67 108.6 7.53 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.203 178.317 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 156.25 -178.64 32.65 Favored Glycine 0 N--CA 1.439 -1.135 0 N-CA-C 111.637 -0.585 . . . . 0.0 111.637 -178.18 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.465 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 69.5 Cg_endo -91.12 127.31 1.16 Allowed 'Trans proline' 0 N--CA 1.445 -1.333 0 C-N-CA 123.149 2.566 . . . . 0.0 112.742 179.529 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.6 pp -138.02 156.12 74.21 Favored Pre-proline 0 C--N 1.313 -0.993 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.387 179.232 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.411 ' HG3' ' HD3' ' A' ' 134' ' ' PRO . 37.3 Cg_endo -62.92 165.25 16.86 Favored 'Trans proline' 0 C--N 1.352 0.746 0 C-N-CA 122.634 2.223 . . . . 0.0 112.522 -178.435 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' HIS . . . . . . . . . . . . . 11.9 t-80 -88.51 132.6 38.47 Favored Pre-proline 0 C--N 1.32 -0.716 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -178.601 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 17.5 Cg_endo -58.65 -19.95 48.12 Favored 'Trans proline' 0 C--N 1.35 0.631 0 C-N-CA 123.0 2.467 . . . . 0.0 112.806 -179.26 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -91.13 -67.68 1.17 Allowed Glycine 0 N--CA 1.447 -0.591 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.101 179.13 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 45.6 m-80 -118.56 109.95 16.78 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.592 0.196 . . . . 0.0 111.053 179.441 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 32.8 m -55.41 -13.62 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.791 0 N-CA-C 113.075 0.769 . . . . 0.0 113.075 176.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 41.1 m170 -73.92 3.78 6.26 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-O 120.934 0.397 . . . . 0.0 110.547 177.12 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 47.7 mtmt -140.62 157.75 45.0 Favored 'General case' 0 CA--C 1.506 -0.743 0 CA-C-N 115.833 -0.622 . . . . 0.0 109.43 179.78 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 8.5 p90 -143.03 170.07 16.39 Favored 'General case' 0 C--N 1.306 -1.284 0 C-N-CA 120.829 -0.348 . . . . 0.0 111.264 -179.433 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.465 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.1 mp -125.09 139.13 52.06 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.598 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -100.96 113.13 36.05 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 175.357 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 59.6 m -95.14 123.18 38.49 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 109.314 -0.625 . . . . 0.0 109.314 179.132 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 52.7 p -122.56 136.7 54.95 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.835 -176.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 19.5 tptm -96.41 115.54 27.59 Favored 'General case' 0 N--CA 1.435 -1.202 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.682 -179.032 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 59.7 m -108.23 79.81 1.3 Allowed 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 176.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 73.45 -104.57 1.61 Allowed Glycine 0 N--CA 1.438 -1.189 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 -176.273 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 8.4 t -113.33 13.02 18.98 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 121.226 0.536 . . . . 0.0 109.865 179.229 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 81.4 mt -116.96 135.4 53.73 Favored 'General case' 0 N--CA 1.435 -1.223 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.043 -177.378 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 50.1 m95 -96.98 131.69 43.53 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.005 0.431 . . . . 0.0 111.069 178.395 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -129.24 128.59 43.6 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 174.855 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.448 ' HB ' ' CG2' ' A' ' 110' ' ' ILE . 2.5 pp -119.05 158.91 20.05 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-O 120.952 0.406 . . . . 0.0 111.698 -176.915 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 44.2 m -146.01 121.65 10.46 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.882 177.369 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.7 p -94.62 110.13 23.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 121.549 0.69 . . . . 0.0 111.411 -179.024 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.449 ' HE1' ' HA ' ' A' ' 124' ' ' MET . 7.2 mmt -111.86 142.8 27.39 Favored Pre-proline 0 C--N 1.313 -1.007 0 CA-C-N 115.49 -0.777 . . . . 0.0 110.004 -179.459 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -86.71 144.62 7.61 Favored 'Trans proline' 0 N--CA 1.453 -0.89 0 C-N-CA 122.461 2.107 . . . . 0.0 112.722 178.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 12.2 m -82.65 174.69 10.78 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.488 177.133 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 13.1 m -61.8 144.45 54.76 Favored 'General case' 0 N--CA 1.436 -1.16 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.88 176.678 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . 0.413 ' N ' HD13 ' A' ' 128' ' ' ILE . 2.2 mp -63.34 126.74 22.41 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.553 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 99.25 -6.87 59.83 Favored Glycine 0 N--CA 1.441 -1.0 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.735 -176.483 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 69.1 p -121.66 157.2 31.38 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-N 117.183 0.492 . . . . 0.0 111.449 179.139 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.41 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 62.4 pttt -124.35 147.64 48.06 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 179.0 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 46.9 t80 -81.46 134.37 35.53 Favored 'General case' 0 C--N 1.31 -1.132 0 C-N-CA 120.459 -0.496 . . . . 0.0 111.125 -179.363 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -104.33 127.83 28.29 Favored Pre-proline 0 C--N 1.317 -0.843 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.533 178.76 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' PRO . . . . . 0.411 ' HD3' ' HG3' ' A' ' 101' ' ' PRO . 27.3 Cg_endo -61.99 -42.43 30.49 Favored 'Trans proline' 0 C--O 1.235 0.338 0 C-N-CA 123.024 2.483 . . . . 0.0 113.48 -176.035 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 33.9 mm -79.03 -49.63 19.76 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.612 -176.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' SER . . . . . 0.411 ' O ' ' HB2' ' A' ' 137' ' ' ARG . 5.1 m -62.41 -37.51 86.11 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.54 0.209 . . . . 0.0 111.134 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' ARG . . . . . 0.411 ' HB2' ' O ' ' A' ' 136' ' ' SER . 44.2 mtp180 74.62 41.91 0.32 Allowed 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 123.407 0.683 . . . . 0.0 111.33 178.763 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 -161.55 -179.27 7.18 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 178.828 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 10.6 m -100.45 125.93 46.8 Favored 'General case' 0 C--N 1.31 -1.147 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 -178.681 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.5 m -113.34 165.9 7.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.704 -178.253 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -55.08 116.02 2.55 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.625 -179.78 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' ASP . . . . . 0.41 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 21.4 t70 . . . . . 0 C--N 1.323 -0.558 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.58 -178.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 18.4 t70 . . . . . 0 N--CA 1.45 -0.44 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -107.2 127.79 53.83 Favored 'General case' 0 C--N 1.31 -1.131 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.404 ' CG2' HG21 ' A' ' 89' ' ' THR . 12.5 mt -98.19 144.5 11.24 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.918 0 C-N-CA 120.951 -0.3 . . . . 0.0 110.419 -178.071 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.443 HG22 ' CE1' ' A' ' 102' ' ' HIS . 22.2 m -128.74 151.41 35.49 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.009 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 179.792 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 22.3 m-70 -107.76 100.09 9.5 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-O 120.879 0.371 . . . . 0.0 110.709 179.741 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.411 ' CD ' ' HZ1' ' A' ' 108' ' ' LYS . 79.4 mm-40 -105.54 105.21 15.14 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.95 179.718 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 62.47 37.67 95.06 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.73 -0.748 . . . . 0.0 111.873 -179.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 80.52 -6.11 62.19 Favored Glycine 0 CA--C 1.52 0.376 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.612 -178.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 32.0 mmmt -96.97 129.02 44.49 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.922 0.391 . . . . 0.0 110.288 -178.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.404 HG21 ' CG2' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -86.07 124.28 32.32 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.408 179.714 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 89.8 m-85 -121.48 141.04 51.41 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 177.538 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 37.8 m-70 -98.85 138.46 35.95 Favored 'General case' 0 C--N 1.312 -1.062 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.29 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 49.4 t -115.58 122.68 69.89 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.015 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 178.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 84.6 t -132.38 128.08 57.83 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.027 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 -179.421 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 66.9 m -98.61 131.6 44.68 Favored 'General case' 0 C--N 1.307 -1.277 0 CA-C-O 120.893 0.378 . . . . 0.0 110.899 -178.201 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 37.1 m80 -80.53 -29.45 37.18 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 179.597 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -158.32 -179.09 7.78 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 114.81 -1.086 . . . . 0.0 108.168 -177.528 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -84.55 154.25 22.75 Favored 'General case' 0 C--N 1.31 -1.138 0 CA-C-O 121.002 0.43 . . . . 0.0 111.001 -179.538 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 124.96 167.17 12.54 Favored Glycine 0 N--CA 1.442 -0.945 0 N-CA-C 111.478 -0.649 . . . . 0.0 111.478 -178.263 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -87.18 134.36 3.55 Favored 'Trans proline' 0 N--CA 1.454 -0.85 0 C-N-CA 122.681 2.254 . . . . 0.0 112.816 178.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.5 pp -140.56 156.21 69.38 Favored Pre-proline 0 C--N 1.323 -0.575 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.168 178.416 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo -61.46 165.97 12.25 Favored 'Trans proline' 0 C--N 1.352 0.746 0 C-N-CA 122.895 2.397 . . . . 0.0 113.577 -177.687 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' HIS . . . . . 0.443 ' CE1' HG22 ' A' ' 83' ' ' VAL . 3.5 t-80 -89.06 128.13 52.97 Favored Pre-proline 0 C--N 1.321 -0.645 0 CA-C-N 115.329 -0.85 . . . . 0.0 108.93 -179.407 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 10.5 Cg_endo -51.56 -50.53 13.64 Favored 'Trans proline' 0 C--N 1.352 0.73 0 C-N-CA 123.123 2.549 . . . . 0.0 113.25 -176.432 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -67.44 -64.44 3.22 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.677 -179.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.434 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 2.6 p30 -119.89 105.0 10.66 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 120.972 0.415 . . . . 0.0 111.705 -178.824 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 27.3 m -56.08 -10.6 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 N-CA-C 113.574 0.953 . . . . 0.0 113.574 178.791 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 23.6 m170 -73.45 4.55 4.64 Favored 'General case' 0 N--CA 1.472 0.675 0 CA-C-O 121.245 0.545 . . . . 0.0 110.646 176.7 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.411 ' HZ1' ' CD ' ' A' ' 85' ' ' GLU . 45.1 mtmt -138.1 160.38 39.54 Favored 'General case' 0 N--CA 1.445 -0.708 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 177.844 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 13.4 p90 -143.5 173.18 11.86 Favored 'General case' 0 C--N 1.313 -0.982 0 C-N-CA 120.466 -0.494 . . . . 0.0 111.611 179.668 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.413 ' CG2' ' HB ' ' A' ' 121' ' ' ILE . 2.9 mp -129.57 142.36 44.11 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.908 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.065 179.688 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -100.32 119.44 48.41 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.88 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 175.203 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 61.9 m -98.22 123.8 42.48 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-O 120.927 0.394 . . . . 0.0 111.177 -177.324 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 23.5 t -130.82 137.63 49.5 Favored 'General case' 0 C--N 1.312 -1.056 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 177.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . 0.448 ' HE2' ' O ' ' A' ' 116' ' ' GLY . 86.6 tttt -116.34 109.61 17.59 Favored 'General case' 0 C--N 1.316 -0.872 0 C-N-CA 120.552 -0.459 . . . . 0.0 110.515 -178.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 53.4 m -92.09 76.76 5.38 Favored 'General case' 0 C--N 1.31 -1.128 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.018 178.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.448 ' O ' ' HE2' ' A' ' 114' ' ' LYS . . . 77.99 -98.93 1.49 Allowed Glycine 0 N--CA 1.44 -1.052 0 C-N-CA 120.434 -0.888 . . . . 0.0 111.199 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 25.3 m -114.09 8.94 17.15 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 121.086 0.47 . . . . 0.0 110.177 179.746 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 19.7 tp -122.69 125.64 45.99 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.66 -177.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . 0.446 ' CZ2' ' HD2' ' A' ' 114' ' ' LYS . 86.6 m95 -89.86 133.13 34.91 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-O 121.045 0.45 . . . . 0.0 111.632 179.363 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 87.6 m-85 -118.22 120.88 39.01 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 173.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.413 ' HB ' ' CG2' ' A' ' 110' ' ' ILE . 2.3 pp -125.51 142.94 40.76 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 CA-C-O 121.001 0.429 . . . . 0.0 111.14 -178.539 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 49.8 m -129.54 123.77 32.24 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-N 115.958 -0.564 . . . . 0.0 109.875 179.394 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.7 p -94.08 112.37 26.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 121.513 0.673 . . . . 0.0 111.342 -178.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.479 ' HA ' ' HE3' ' A' ' 124' ' ' MET . 5.8 mmt -110.7 138.8 21.15 Favored Pre-proline 0 C--N 1.318 -0.786 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.289 -179.9 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -86.11 140.39 6.64 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 122.455 2.103 . . . . 0.0 112.359 178.61 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' CYS . . . . . 0.431 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 65.6 m -83.26 170.97 14.08 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.283 177.825 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 30.9 m -57.08 141.51 45.69 Favored 'General case' 0 N--CA 1.446 -0.64 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.173 176.491 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . 0.419 ' N ' HD13 ' A' ' 128' ' ' ILE . 1.9 mp -59.9 131.76 24.73 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 179.37 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.28 -7.26 72.24 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.762 -0.732 . . . . 0.0 113.045 -176.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 59.7 p -117.2 164.91 14.07 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-N 117.174 0.487 . . . . 0.0 111.114 179.664 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.55 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 65.0 pttt -132.03 148.59 52.51 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 178.896 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.431 ' HB2' ' SG ' ' A' ' 126' ' ' CYS . 44.4 t80 -84.63 130.4 34.72 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 120.571 -0.452 . . . . 0.0 110.559 178.715 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -98.34 129.8 29.72 Favored Pre-proline 0 C--N 1.314 -0.948 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.924 179.271 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -64.21 -40.83 24.09 Favored 'Trans proline' 0 C--N 1.342 0.224 0 C-N-CA 122.803 2.335 . . . . 0.0 113.28 -176.805 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 27.6 mm -78.96 -51.67 16.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.599 -176.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 14.0 m -64.0 -32.73 74.38 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.836 0.351 . . . . 0.0 110.657 178.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 67.6 mtm180 68.83 41.95 1.45 Allowed 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 115.509 -0.769 . . . . 0.0 111.274 176.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 10.7 p30 -157.64 176.77 12.19 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.249 -0.887 . . . . 0.0 108.779 177.556 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 9.2 m -100.28 124.92 46.33 Favored 'General case' 0 C--N 1.319 -0.727 0 C-N-CA 120.209 -0.596 . . . . 0.0 109.734 -178.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.0 m -117.88 167.87 10.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.201 -178.295 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -57.35 120.85 8.89 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 178.873 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' ASP . . . . . 0.55 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 8.8 t70 . . . . . 0 C--N 1.317 -0.835 0 N-CA-C 113.674 0.99 . . . . 0.0 113.674 -173.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 . . . . . 0 N--CA 1.449 -0.494 0 CA-C-O 121.188 0.518 . . . . 0.0 110.299 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -129.97 126.1 37.0 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.024 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.448 ' CG2' HG23 ' A' ' 89' ' ' THR . 26.0 mt -93.79 147.94 5.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.226 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.545 HG22 ' CE1' ' A' ' 102' ' ' HIS . 10.9 m -138.92 167.14 21.18 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 N-CA-C 110.103 -0.332 . . . . 0.0 110.103 -178.902 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 73.2 m-70 -114.75 99.96 7.89 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.579 177.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -87.1 98.28 11.21 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 179.775 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 74.27 1.79 61.26 Favored Glycine 0 C--N 1.324 -0.136 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 -177.622 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 123.28 -23.17 6.9 Favored Glycine 0 N--CA 1.437 -1.292 0 N-CA-C 111.374 -0.691 . . . . 0.0 111.374 -178.624 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 32.2 mmmt -85.08 137.83 32.8 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 110.218 -0.29 . . . . 0.0 110.218 -178.165 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.452 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.0 OUTLIER -76.84 128.16 34.08 Favored 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 112.748 0.647 . . . . 0.0 112.748 -178.502 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.526 ' CE2' ' HA2' ' A' ' 104' ' ' GLY . 35.2 m-85 -126.29 148.8 49.45 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 176.385 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 17.6 m-70 -101.37 139.27 37.26 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-O 120.792 0.33 . . . . 0.0 110.587 -178.079 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 60.5 t -122.3 118.04 54.09 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 179.127 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 49.0 t -128.78 132.96 67.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.145 179.431 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 82.8 m -110.38 118.94 37.63 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 -178.682 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 43.7 m80 -103.17 -15.95 15.87 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.987 -179.786 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -131.21 144.33 51.25 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.985 0.422 . . . . 0.0 111.059 -179.307 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -71.02 112.96 7.58 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.31 177.542 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 146.74 168.7 13.86 Favored Glycine 0 N--CA 1.437 -1.245 0 C-N-CA 121.092 -0.575 . . . . 0.0 111.953 179.502 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.423 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 73.4 Cg_endo -78.64 136.08 13.43 Favored 'Trans proline' 0 N--CA 1.457 -0.623 0 C-N-CA 122.656 2.237 . . . . 0.0 112.644 178.321 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -138.24 158.1 71.48 Favored Pre-proline 0 C--N 1.32 -0.688 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.846 178.072 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo -62.05 166.04 13.31 Favored 'Trans proline' 0 C--N 1.353 0.795 0 C-N-CA 122.69 2.26 . . . . 0.0 113.083 -177.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' HIS . . . . . 0.545 ' CE1' HG22 ' A' ' 83' ' ' VAL . 7.2 t-80 -92.35 133.7 29.46 Favored Pre-proline 0 C--N 1.321 -0.673 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.1 -178.041 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -57.89 -31.72 93.28 Favored 'Trans proline' 0 C--N 1.353 0.766 0 C-N-CA 123.039 2.493 . . . . 0.0 112.94 -178.581 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.526 ' HA2' ' CE2' ' A' ' 90' ' ' TYR . . . -70.29 -63.65 3.18 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.751 -0.738 . . . . 0.0 111.803 179.324 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.523 ' OD1' ' HB2' ' A' ' 107' ' ' HIS . 10.5 p30 -139.6 130.06 25.6 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-O 121.058 0.456 . . . . 0.0 110.743 176.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 29.5 m -58.73 -10.43 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.555 0 N-CA-C 113.487 0.921 . . . . 0.0 113.487 178.817 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . 0.523 ' HB2' ' OD1' ' A' ' 105' ' ' ASN . 36.8 m80 -71.11 -6.93 43.03 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 121.127 0.489 . . . . 0.0 110.193 177.686 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.404 ' HG2' ' HA ' ' A' ' 125' ' ' PRO . 43.1 mtmt -130.51 159.11 38.08 Favored 'General case' 0 CA--C 1.507 -0.71 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.835 177.795 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 9.6 p90 -143.33 173.18 11.83 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.724 179.675 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.423 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 2.4 mp -128.61 141.22 47.13 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.121 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 177.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.7 mp -97.58 117.35 42.15 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 N-CA-C 107.753 -1.202 . . . . 0.0 107.753 175.732 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 21.3 m -104.51 121.46 43.52 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 -179.197 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 36.7 m -122.92 133.33 54.4 Favored 'General case' 0 C--N 1.308 -1.203 0 CA-C-N 116.07 -0.513 . . . . 0.0 109.69 179.673 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . 0.483 ' HD2' ' CZ2' ' A' ' 119' ' ' TRP . 80.8 tttt -105.53 112.24 25.25 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 120.489 -0.484 . . . . 0.0 110.179 -179.705 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 68.2 m -102.15 77.98 1.73 Allowed 'General case' 0 C--N 1.308 -1.213 0 CA-C-N 115.738 -0.664 . . . . 0.0 109.962 179.078 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 77.89 -99.67 1.54 Allowed Glycine 0 N--CA 1.44 -1.062 0 CA-C-N 115.317 -0.856 . . . . 0.0 111.485 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 31.7 t -114.48 3.97 15.1 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-O 121.051 0.453 . . . . 0.0 109.807 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 19.5 mt -119.13 125.83 50.18 Favored 'General case' 0 N--CA 1.432 -1.35 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.11 -177.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . 0.483 ' CZ2' ' HD2' ' A' ' 114' ' ' LYS . 60.6 m95 -91.82 134.01 35.13 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-O 121.071 0.463 . . . . 0.0 111.083 178.942 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 87.5 m-85 -117.51 128.39 54.93 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.259 175.647 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.408 ' C ' ' HG1' ' A' ' 122' ' ' THR . 2.8 pp -127.73 156.36 39.53 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 N-CA-C 112.189 0.44 . . . . 0.0 112.189 -176.054 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.408 ' HG1' ' C ' ' A' ' 121' ' ' ILE . 38.9 m -151.24 123.21 8.14 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.132 176.051 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.8 p -92.06 115.23 30.6 Favored 'Isoleucine or valine' 0 C--O 1.235 0.322 0 CA-C-O 121.301 0.572 . . . . 0.0 111.245 179.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.461 ' HA ' ' HE3' ' A' ' 124' ' ' MET . 4.6 mmt -117.16 149.7 44.86 Favored Pre-proline 0 C--N 1.32 -0.678 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.198 -179.542 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . 0.404 ' HA ' ' HG2' ' A' ' 108' ' ' LYS . 88.0 Cg_endo -92.07 147.76 3.09 Favored 'Trans proline' 0 N--CA 1.45 -1.074 0 C-N-CA 122.433 2.089 . . . . 0.0 112.431 177.647 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 18.2 m -80.94 174.38 11.68 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 120.911 0.386 . . . . 0.0 110.197 176.672 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 18.9 m -62.38 147.08 49.57 Favored 'General case' 0 N--CA 1.437 -1.08 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.79 176.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . 0.414 HD11 ' N ' ' A' ' 128' ' ' ILE . 1.8 mp -59.11 123.72 11.94 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 CA-C-O 121.167 0.508 . . . . 0.0 110.218 -179.204 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 97.26 -1.67 60.74 Favored Glycine 0 N--CA 1.438 -1.22 0 CA-C-N 115.56 -0.745 . . . . 0.0 113.175 -178.786 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 80.8 p -120.81 162.88 19.03 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 117.447 0.624 . . . . 0.0 111.472 179.477 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.417 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 60.7 pttt -132.51 145.93 51.53 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.469 179.151 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 26.2 t80 -81.58 137.74 35.48 Favored 'General case' 0 C--N 1.31 -1.144 0 CA-C-O 121.15 0.5 . . . . 0.0 111.685 -178.339 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -103.35 132.5 21.04 Favored Pre-proline 0 C--N 1.323 -0.569 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.144 177.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -68.77 -39.82 8.06 Favored 'Trans proline' 0 CA--C 1.531 0.347 0 C-N-CA 122.871 2.38 . . . . 0.0 113.885 -176.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 27.2 mm -78.17 -52.49 15.79 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 N-CA-C 112.121 0.415 . . . . 0.0 112.121 -176.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 35.5 p -73.75 -29.84 62.46 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 120.695 0.283 . . . . 0.0 111.154 -178.326 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 95.6 mtt180 68.24 57.84 0.46 Allowed 'General case' 0 N--CA 1.465 0.28 0 C-N-CA 123.471 0.709 . . . . 0.0 112.288 176.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 4.1 p-10 -164.09 177.09 8.7 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 176.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 31.5 m -100.35 125.35 46.58 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 -178.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 33.1 m -112.75 167.59 5.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.561 -177.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -58.01 117.08 3.96 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.997 0.427 . . . . 0.0 111.177 179.309 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' ASP . . . . . 0.417 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 17.2 t70 . . . . . 0 CA--C 1.506 -0.713 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.399 178.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . 0.427 ' OD1' ' HB3' ' A' ' 91' ' ' HIS . 25.4 t70 . . . . . 0 N--CA 1.446 -0.633 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -107.66 123.86 49.12 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 108.92 -0.771 . . . . 0.0 108.92 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.404 HG22 HG23 ' A' ' 89' ' ' THR . 3.2 mt -101.49 145.3 11.77 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.677 -177.157 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.435 ' O ' ' HA ' ' A' ' 89' ' ' THR . 16.7 m -134.36 165.53 31.25 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 116.084 -0.507 . . . . 0.0 109.812 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 18.6 m-70 -114.7 113.0 23.72 Favored 'General case' 0 C--N 1.31 -1.118 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.407 179.014 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.459 ' CD ' ' HZ1' ' A' ' 108' ' ' LYS . 76.5 mm-40 -107.63 95.9 6.02 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.603 179.235 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 73.94 -6.17 21.3 Favored Glycine 0 CA--C 1.52 0.347 0 C-N-CA 121.093 -0.575 . . . . 0.0 112.932 178.655 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 134.64 -12.71 4.55 Favored Glycine 0 N--CA 1.443 -0.883 0 N-CA-C 111.698 -0.561 . . . . 0.0 111.698 -179.25 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -96.32 130.99 43.3 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 110.368 -0.234 . . . . 0.0 110.368 178.56 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.435 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.0 OUTLIER -85.75 107.34 17.56 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-O 120.969 0.414 . . . . 0.0 111.452 179.391 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 78.1 m-85 -102.21 146.87 27.36 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.914 178.261 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . 0.427 ' HB3' ' OD1' ' A' ' 80' ' ' ASP . 36.1 m-70 -101.96 143.73 31.45 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.543 -178.669 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 89.8 t -114.29 122.18 67.9 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.461 179.102 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 64.2 t -136.77 124.99 34.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.24 0 CA-C-N 115.48 -0.782 . . . . 0.0 108.903 -179.681 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 81.7 m -101.9 127.98 48.5 Favored 'General case' 0 C--N 1.31 -1.139 0 CA-C-O 120.932 0.396 . . . . 0.0 111.059 -179.09 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 68.3 t60 -91.08 -25.45 19.63 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.291 0.567 . . . . 0.0 109.518 178.337 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -149.1 164.69 33.94 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.218 -177.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -78.69 142.13 37.37 Favored 'General case' 0 N--CA 1.438 -1.065 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.001 178.08 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 130.05 167.31 12.03 Favored Glycine 0 N--CA 1.438 -1.223 0 C-N-CA 120.907 -0.663 . . . . 0.0 111.621 -178.174 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -85.6 137.99 6.04 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 122.582 2.188 . . . . 0.0 112.766 179.462 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.8 pp -142.86 158.04 60.16 Favored Pre-proline 0 C--N 1.319 -0.747 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.628 178.713 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -64.56 166.63 17.08 Favored 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 122.462 2.108 . . . . 0.0 112.75 -177.619 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' HIS . . . . . . . . . . . . . 14.1 t-80 -89.49 130.09 44.81 Favored Pre-proline 0 C--N 1.318 -0.762 0 CA-C-N 115.923 -0.581 . . . . 0.0 109.906 -178.206 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -62.19 -24.32 76.14 Favored 'Trans proline' 0 N--CA 1.48 0.716 0 C-N-CA 123.013 2.475 . . . . 0.0 113.456 -177.317 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -93.44 -17.87 40.81 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.201 -1.0 . . . . 0.0 113.482 -178.571 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 1.9 p30 -167.63 105.31 0.52 Allowed 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.657 0.265 . . . . 0.0 111.199 -177.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 27.0 m -55.05 -11.69 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 N-CA-C 113.509 0.929 . . . . 0.0 113.509 178.145 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 91.0 m-70 -77.57 7.03 6.06 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 121.194 0.521 . . . . 0.0 110.951 178.016 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.459 ' HZ1' ' CD ' ' A' ' 85' ' ' GLU . 47.9 mtmt -143.29 162.84 34.63 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.221 179.342 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 11.1 p90 -142.64 173.72 11.28 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-O 120.919 0.39 . . . . 0.0 111.238 179.727 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 3.8 mt -132.87 143.62 39.01 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.651 -179.24 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.409 ' N ' HD11 ' A' ' 111' ' ' ILE . 4.3 mp -103.09 122.28 55.34 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 176.641 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 58.7 m -103.08 122.51 44.82 Favored 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 178.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 29.1 t -133.59 140.25 47.02 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-O 120.894 0.378 . . . . 0.0 110.672 -177.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . 0.417 ' HD2' ' CZ2' ' A' ' 119' ' ' TRP . 59.9 tttm -107.54 104.74 14.36 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-O 121.106 0.479 . . . . 0.0 110.178 179.125 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 23.3 t -90.76 88.45 7.08 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.58 -179.48 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 66.1 -100.76 0.54 Allowed Glycine 0 N--CA 1.438 -1.195 0 CA-C-N 115.474 -0.784 . . . . 0.0 111.664 -178.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 16.3 m -109.32 3.8 21.97 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -179.054 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 35.5 tp -126.98 141.01 51.9 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 120.563 -0.455 . . . . 0.0 111.452 -178.654 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . 0.417 ' CZ2' ' HD2' ' A' ' 114' ' ' LYS . 72.6 m95 -93.8 133.47 37.15 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.348 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 77.4 m-85 -121.7 130.78 53.69 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.606 175.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.4 pp -125.11 146.96 29.91 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 CA-C-O 120.973 0.416 . . . . 0.0 110.891 179.706 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 22.9 m -137.98 125.43 21.97 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-N 115.964 -0.562 . . . . 0.0 109.94 179.4 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.3 p -94.9 112.02 26.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 121.424 0.63 . . . . 0.0 111.018 179.167 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.469 ' HA ' ' HE3' ' A' ' 124' ' ' MET . 6.8 mmt -111.49 141.92 25.48 Favored Pre-proline 0 C--N 1.314 -0.942 0 CA-C-N 115.454 -0.793 . . . . 0.0 110.182 -179.442 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -87.05 154.4 8.37 Favored 'Trans proline' 0 N--CA 1.457 -0.664 0 C-N-CA 122.587 2.191 . . . . 0.0 113.365 -179.72 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 56.5 m -92.72 165.09 13.13 Favored 'General case' 0 C--O 1.241 0.653 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.448 175.618 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 14.9 m -59.93 148.88 33.5 Favored 'General case' 0 N--CA 1.445 -0.693 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.304 176.738 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . 0.401 HD11 ' N ' ' A' ' 128' ' ' ILE . 1.8 mp -60.04 129.73 22.85 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.246 179.749 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 93.9 -2.13 69.0 Favored Glycine 0 N--CA 1.439 -1.136 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.883 -178.242 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 68.7 p -121.06 164.02 17.45 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-N 117.257 0.528 . . . . 0.0 111.382 179.422 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.522 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 57.8 pttt -139.18 145.07 38.88 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 178.67 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 38.3 t80 -82.8 137.79 34.21 Favored 'General case' 0 C--N 1.311 -1.084 0 N-CA-C 112.365 0.505 . . . . 0.0 112.365 -176.034 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -106.52 131.55 21.62 Favored Pre-proline 0 C--N 1.327 -0.408 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.811 176.264 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.05 -36.58 21.59 Favored 'Trans proline' 0 N--CA 1.471 0.203 0 C-N-CA 122.904 2.403 . . . . 0.0 113.935 -176.803 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 34.3 mm -79.28 -56.34 7.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 N-CA-C 111.932 0.345 . . . . 0.0 111.932 -176.061 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 26.8 p -66.69 -31.76 72.63 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 120.528 0.204 . . . . 0.0 110.911 179.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 72.25 48.6 0.25 Allowed 'General case' 0 CA--C 1.518 -0.268 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.342 176.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 32.9 p30 -154.9 175.98 13.09 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.434 178.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 27.8 m -100.86 124.65 46.85 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 177.622 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 29.8 m -107.65 160.58 6.75 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.877 -177.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -61.45 119.02 7.75 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.187 179.79 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' ASP . . . . . 0.522 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 28.2 t70 . . . . . 0 C--N 1.32 -0.717 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.934 179.188 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 27.1 t70 . . . . . 0 CA--C 1.509 -0.598 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -112.14 126.31 55.05 Favored 'General case' 0 C--N 1.306 -1.288 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 -177.43 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 15.0 mt -94.4 140.14 17.21 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 C-N-CA 120.869 -0.333 . . . . 0.0 110.395 -178.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 27.1 m -127.82 162.53 33.46 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.171 -178.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 35.7 m170 -108.87 112.66 25.01 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.293 179.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.541 ' HB2' ' CE1' ' A' ' 90' ' ' TYR . 71.8 mm-40 -116.81 103.96 10.85 Favored 'General case' 0 C--N 1.312 -1.033 0 N-CA-C 109.206 -0.665 . . . . 0.0 109.206 178.28 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 69.38 23.9 76.26 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.631 -0.795 . . . . 0.0 111.971 -179.261 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 95.53 -19.28 55.04 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.627 -179.421 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 56.4 mtmt -91.16 157.37 17.23 Favored 'General case' 0 CA--C 1.512 -0.486 0 CA-C-O 120.797 0.332 . . . . 0.0 111.357 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -94.68 132.62 39.23 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-N 115.879 -0.6 . . . . 0.0 112.602 -177.621 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.541 ' CE1' ' HB2' ' A' ' 85' ' ' GLU . 42.4 m-85 -127.04 140.54 52.22 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 115.133 -0.94 . . . . 0.0 108.915 176.68 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 21.2 m-70 -97.83 145.36 26.48 Favored 'General case' 0 C--N 1.307 -1.246 0 CA-C-O 120.826 0.345 . . . . 0.0 110.672 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.411 HG12 HD12 ' A' ' 110' ' ' ILE . 81.8 t -114.81 126.38 72.36 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.001 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.074 178.477 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 91.2 t -136.43 123.5 32.22 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 179.227 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 73.0 m -94.64 132.05 39.78 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-O 121.435 0.636 . . . . 0.0 112.345 -175.667 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 70.7 m-70 -86.31 -31.22 21.7 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.036 -0.984 . . . . 0.0 110.783 -178.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -148.36 167.39 25.35 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.282 -178.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -79.21 103.36 9.09 Favored 'General case' 0 N--CA 1.446 -0.66 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 174.627 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 163.92 169.85 28.0 Favored Glycine 0 N--CA 1.431 -1.698 0 N-CA-C 111.126 -0.79 . . . . 0.0 111.126 -178.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.548 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 72.1 Cg_endo -81.55 128.73 6.22 Favored 'Trans proline' 0 N--CA 1.443 -1.485 0 C-N-CA 122.283 1.989 . . . . 0.0 112.256 178.563 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -135.04 157.64 76.55 Favored Pre-proline 0 C--N 1.312 -1.058 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.654 178.569 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -64.55 167.21 15.6 Favored 'Trans proline' 0 C--O 1.233 0.263 0 C-N-CA 122.49 2.127 . . . . 0.0 112.72 -177.573 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' HIS . . . . . 0.435 ' HB3' ' O ' ' A' ' 105' ' ' ASN . 4.5 t-80 -88.85 125.08 63.84 Favored Pre-proline 0 C--N 1.315 -0.891 0 N-CA-C 108.814 -0.809 . . . . 0.0 108.814 -179.007 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -53.41 -37.69 82.06 Favored 'Trans proline' 0 N--CA 1.485 0.984 0 C-N-CA 123.286 2.657 . . . . 0.0 113.417 -176.275 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -74.57 -61.81 3.04 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.335 179.127 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.435 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 2.4 p30 -125.21 109.27 12.65 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 120.992 0.425 . . . . 0.0 111.63 -179.13 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.3 t -56.21 -13.91 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.172 0 C-N-CA 123.584 0.754 . . . . 0.0 112.747 179.278 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 12.1 t-80 -69.06 -1.72 8.29 Favored 'General case' 0 CA--C 1.551 1.019 0 CA-C-O 121.533 0.682 . . . . 0.0 110.644 177.316 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 46.4 mtmt -134.83 160.72 37.31 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 178.604 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 11.3 p90 -142.41 173.33 11.63 Favored 'General case' 0 C--N 1.307 -1.269 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.674 179.178 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.548 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.4 mt -132.03 142.48 42.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -178.383 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.7 mp -101.7 114.17 40.19 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 176.16 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 61.8 m -102.15 122.88 45.01 Favored 'General case' 0 C--N 1.307 -1.273 0 CA-C-O 120.989 0.423 . . . . 0.0 111.252 -177.057 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 28.0 m -131.01 145.64 52.11 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 178.02 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -118.17 114.1 22.55 Favored 'General case' 0 C--N 1.31 -1.132 0 CA-C-O 121.201 0.524 . . . . 0.0 110.3 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 63.1 m -88.2 79.94 7.72 Favored 'General case' 0 N--CA 1.432 -1.366 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.354 179.039 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 75.8 -99.06 1.22 Allowed Glycine 0 N--CA 1.435 -1.392 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 -178.442 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 18.8 m -114.06 6.32 16.37 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 120.844 0.355 . . . . 0.0 110.47 179.341 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 18.2 tp -119.12 124.62 47.3 Favored 'General case' 0 C--O 1.221 -0.405 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.768 -177.251 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 88.4 m95 -84.41 133.89 34.49 Favored 'General case' 0 C--N 1.317 -0.832 0 N-CA-C 112.069 0.396 . . . . 0.0 112.069 -179.423 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 71.9 m-85 -123.38 124.83 43.81 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.531 172.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.4 pp -123.91 155.93 30.91 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.86 0 CA-C-O 121.23 0.538 . . . . 0.0 112.06 -177.338 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 34.3 m -142.6 121.21 12.53 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.712 177.535 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.8 p -95.25 117.68 39.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 121.231 0.539 . . . . 0.0 111.268 -178.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.447 ' HA ' ' HE3' ' A' ' 124' ' ' MET . 5.0 mmt -120.16 149.66 49.73 Favored Pre-proline 0 C--N 1.32 -0.692 0 CA-C-N 115.703 -0.68 . . . . 0.0 109.999 -178.55 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -91.64 148.02 3.37 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 122.415 2.076 . . . . 0.0 113.483 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 58.7 m -90.84 172.51 8.57 Favored 'General case' 0 C--O 1.242 0.677 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.783 175.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 39.0 m -65.23 147.87 52.69 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.498 178.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . 0.422 ' N ' HD13 ' A' ' 128' ' ' ILE . 1.9 mp -65.2 129.08 29.0 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.001 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 178.713 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 99.81 -16.22 58.79 Favored Glycine 0 N--CA 1.439 -1.112 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.079 -177.023 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 65.8 p -108.85 159.41 16.81 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-O 120.887 0.375 . . . . 0.0 110.93 178.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.464 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 63.7 pttt -128.83 143.58 50.94 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 178.723 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.422 ' HA ' ' HA ' ' A' ' 139' ' ' CYS . 36.8 t80 -80.73 137.06 36.26 Favored 'General case' 0 C--N 1.314 -0.956 0 C-N-CA 120.294 -0.562 . . . . 0.0 111.324 -179.34 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -108.36 127.13 28.09 Favored Pre-proline 0 C--N 1.32 -0.707 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.105 178.47 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -65.99 -36.89 28.41 Favored 'Trans proline' 0 CA--C 1.53 0.292 0 C-N-CA 122.96 2.44 . . . . 0.0 113.553 -177.062 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.8 mp -77.0 -49.99 21.85 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.322 -177.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 13.1 m -67.83 -35.65 78.98 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 120.728 0.299 . . . . 0.0 110.378 178.893 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 66.5 mtt85 71.31 46.21 0.44 Allowed 'General case' 0 CA--C 1.517 -0.297 0 CA-C-N 115.692 -0.685 . . . . 0.0 111.217 178.555 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 11.4 p30 -162.37 177.72 9.3 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 177.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' CYS . . . . . 0.422 ' HA ' ' HA ' ' A' ' 132' ' ' PHE . 6.3 m -100.45 125.26 46.73 Favored 'General case' 0 C--N 1.313 -1.019 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -178.914 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 28.4 m -111.97 163.48 8.86 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.09 -178.169 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -70.52 127.3 32.24 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 -179.256 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' ASP . . . . . 0.464 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 22.5 t70 . . . . . 0 CA--C 1.502 -0.882 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.271 -179.312 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 27.0 t70 . . . . . 0 C--O 1.233 0.201 0 CA-C-O 120.863 0.363 . . . . 0.0 110.06 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.409 ' CD2' HD13 ' A' ' 121' ' ' ILE . 38.6 tp -92.37 145.88 24.13 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.046 179.759 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.41 HG23 HG21 ' A' ' 89' ' ' THR . 4.9 mt -105.1 144.7 14.43 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 178.427 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 15.3 m -141.9 130.69 22.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.042 0.449 . . . . 0.0 110.778 -177.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 8.6 p80 -78.9 122.98 26.8 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.27 177.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 7.5 tp10 -136.88 113.87 10.54 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 116.109 -0.496 . . . . 0.0 109.85 179.028 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 68.04 24.19 74.52 Favored Glycine 0 N--CA 1.447 -0.584 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.043 -179.6 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 91.2 -10.53 74.7 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.997 -0.62 . . . . 0.0 112.688 -179.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -102.77 139.6 38.14 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.666 0.269 . . . . 0.0 110.359 -179.749 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.41 HG21 HG23 ' A' ' 82' ' ' ILE . 0.1 OUTLIER -87.53 106.67 18.15 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-O 120.821 0.343 . . . . 0.0 110.505 179.676 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 75.6 m-85 -96.2 151.99 18.98 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.562 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 36.4 m-70 -106.85 138.86 42.24 Favored 'General case' 0 C--N 1.308 -1.206 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.041 178.814 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 57.4 t -119.13 118.21 56.8 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 177.435 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.8 p -125.52 138.89 52.97 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.072 -178.774 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 82.1 m -121.97 115.11 21.96 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.213 0.53 . . . . 0.0 111.069 -179.355 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 42.8 t60 -92.67 -18.17 23.36 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.565 178.31 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 74.5 mm-40 -142.02 159.85 41.4 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.452 -0.795 . . . . 0.0 109.835 -178.358 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 -79.66 148.37 31.64 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-O 120.992 0.425 . . . . 0.0 110.549 177.784 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 128.06 164.83 11.69 Favored Glycine 0 N--CA 1.434 -1.488 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 -179.528 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.463 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 91.9 Cg_endo -88.5 142.34 5.04 Favored 'Trans proline' 0 N--CA 1.441 -1.591 0 C-N-CA 122.565 2.176 . . . . 0.0 112.817 179.323 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -141.36 156.53 67.21 Favored Pre-proline 0 C--N 1.316 -0.876 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.19 177.752 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -62.66 165.65 15.4 Favored 'Trans proline' 0 C--N 1.346 0.437 0 C-N-CA 122.316 2.011 . . . . 0.0 112.901 -177.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' HIS . . . . . 0.469 ' HB3' ' O ' ' A' ' 105' ' ' ASN . 42.8 t-80 -87.12 121.77 71.34 Favored Pre-proline 0 C--N 1.315 -0.913 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.399 -179.266 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 13.7 Cg_endo -56.41 -25.44 57.56 Favored 'Trans proline' 0 N--CA 1.48 0.678 0 C-N-CA 122.887 2.391 . . . . 0.0 112.938 -176.604 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -87.06 -20.14 53.87 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.506 -0.854 . . . . 0.0 113.205 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.469 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 9.5 p30 -168.88 117.7 0.68 Allowed 'General case' 0 N--CA 1.472 0.639 0 CA-C-N 117.213 0.506 . . . . 0.0 110.909 -179.74 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 35.1 m -56.32 -11.38 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 N-CA-C 113.756 1.021 . . . . 0.0 113.756 177.205 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 44.7 m170 -76.76 -0.72 24.84 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 111.957 0.354 . . . . 0.0 111.957 179.67 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.466 ' HG2' ' HA ' ' A' ' 125' ' ' PRO . 39.1 mtmt -139.3 163.82 31.47 Favored 'General case' 0 CA--C 1.503 -0.863 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 179.164 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 12.4 p90 -144.02 173.27 11.87 Favored 'General case' 0 C--N 1.311 -1.094 0 CA-C-N 116.555 -0.293 . . . . 0.0 111.112 179.533 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.463 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.7 mp -131.18 141.19 46.67 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.968 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 178.276 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.6 mp -99.04 122.72 51.1 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 176.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 58.8 m -98.14 123.35 42.14 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -178.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 18.9 m -130.1 134.24 47.22 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 120.797 0.332 . . . . 0.0 111.226 -178.729 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . 0.464 ' HE3' ' O ' ' A' ' 116' ' ' GLY . 58.9 tptt -107.31 103.3 12.62 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 178.458 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 51.0 m -101.78 103.01 13.72 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.88 179.757 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.464 ' O ' ' HE3' ' A' ' 114' ' ' LYS . . . 59.8 -106.19 0.92 Allowed Glycine 0 N--CA 1.443 -0.857 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.256 -176.852 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 11.6 t -111.28 3.48 18.38 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-O 120.818 0.342 . . . . 0.0 110.683 178.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -113.16 132.37 55.5 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 120.89 0.376 . . . . 0.0 111.426 -176.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . 0.434 ' CE2' ' HD3' ' A' ' 114' ' ' LYS . 67.1 m95 -90.85 132.1 36.1 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.894 0.378 . . . . 0.0 110.092 175.847 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -123.36 124.64 43.39 Favored 'General case' 0 C--N 1.309 -1.181 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.631 175.801 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.409 HD13 ' CD2' ' A' ' 81' ' ' LEU . 2.4 pp -124.46 142.13 42.28 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.52 -178.871 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 33.5 m -130.13 126.5 37.67 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-N 116.18 -0.464 . . . . 0.0 109.778 179.377 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.1 p -95.26 110.38 23.98 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 121.413 0.625 . . . . 0.0 110.746 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.44 ' HA ' ' HE3' ' A' ' 124' ' ' MET . 3.6 mmt -111.02 144.29 30.07 Favored Pre-proline 0 C--N 1.316 -0.856 0 CA-C-N 115.367 -0.833 . . . . 0.0 109.772 -179.8 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . 0.466 ' HA ' ' HG2' ' A' ' 108' ' ' LYS . 83.6 Cg_endo -89.26 148.62 5.43 Favored 'Trans proline' 0 N--CA 1.45 -1.075 0 C-N-CA 122.237 1.958 . . . . 0.0 112.737 178.388 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' CYS . . . . . 0.403 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 53.3 m -81.97 161.06 23.17 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.095 -0.502 . . . . 0.0 109.794 176.465 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 16.7 t -61.07 142.38 56.7 Favored 'General case' 0 N--CA 1.442 -0.833 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 177.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 1.8 mp -54.22 129.6 15.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.468 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 100.15 -7.91 58.84 Favored Glycine 0 N--CA 1.444 -0.79 0 C-N-CA 120.934 -0.65 . . . . 0.0 113.269 -177.776 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 69.5 p -123.49 164.82 18.19 Favored 'General case' 0 C--O 1.237 0.405 0 CA-C-N 117.087 0.443 . . . . 0.0 111.383 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 60.1 pttt -134.74 147.39 50.02 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 178.762 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.403 ' HB2' ' SG ' ' A' ' 126' ' ' CYS . 30.4 t80 -81.78 138.89 35.08 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-O 121.23 0.538 . . . . 0.0 112.355 -177.168 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -108.01 126.98 28.51 Favored Pre-proline 0 C--N 1.324 -0.5 0 CA-C-N 115.51 -0.768 . . . . 0.0 109.533 177.059 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -63.97 -40.17 28.88 Favored 'Trans proline' 0 N--CA 1.474 0.369 0 C-N-CA 122.961 2.441 . . . . 0.0 113.561 -176.55 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 30.8 mm -77.4 -51.96 17.39 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.46 -176.787 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 8.7 m -62.86 -36.12 82.24 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.741 0.305 . . . . 0.0 110.508 178.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 85.9 mtm180 73.11 41.52 0.49 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.909 178.625 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 3.5 p-10 -158.03 178.0 10.7 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 178.543 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 31.4 m -100.51 125.54 46.85 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-O 121.146 0.498 . . . . 0.0 110.034 -178.74 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.3 m -111.9 165.03 7.23 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 CA-C-N 115.859 -0.61 . . . . 0.0 109.881 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 54.9 tp -57.29 125.0 20.81 Favored 'General case' 0 C--N 1.313 -0.979 0 CA-C-O 121.152 0.501 . . . . 0.0 111.842 -178.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 18.0 t0 . . . . . 0 N--CA 1.442 -0.873 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.958 178.002 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . 0.413 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 15.1 t70 . . . . . 0 C--O 1.233 0.229 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -102.63 130.74 49.61 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.147 -179.16 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 6.8 mt -96.17 143.84 11.4 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.848 0 C-N-CA 120.707 -0.397 . . . . 0.0 110.486 -177.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.413 HG23 ' HE2' ' A' ' 102' ' ' HIS . 20.6 m -133.94 167.21 26.79 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 179.796 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' HIS . . . . . 0.443 ' HA ' ' O ' ' A' ' 88' ' ' LYS . 72.0 m-70 -106.95 115.02 29.46 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-O 121.053 0.454 . . . . 0.0 110.969 178.559 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.413 ' CD ' ' HZ2' ' A' ' 108' ' ' LYS . 66.4 mm-40 -109.04 104.56 13.79 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 177.378 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 68.0 27.35 73.7 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.301 -0.952 . . . . 0.0 111.224 -178.428 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 95.1 -25.03 26.01 Favored Glycine 0 N--CA 1.443 -0.872 0 C-N-CA 121.41 -0.424 . . . . 0.0 112.73 -179.123 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . 0.443 ' O ' ' HA ' ' A' ' 84' ' ' HIS . 33.4 mmtp -85.93 149.68 25.03 Favored 'General case' 0 C--O 1.222 -0.368 0 CA-C-O 120.64 0.257 . . . . 0.0 110.618 -176.356 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -87.97 121.44 30.38 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-O 121.155 0.502 . . . . 0.0 112.108 -179.314 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.411 ' CD1' ' HB2' ' A' ' 85' ' ' GLU . 38.2 m-85 -119.19 141.95 48.42 Favored 'General case' 0 C--N 1.313 -1.02 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 176.691 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 32.9 m-70 -92.09 144.77 25.1 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-O 121.051 0.453 . . . . 0.0 111.376 -177.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.413 ' O ' ' HA ' ' A' ' 80' ' ' ASP . 97.9 t -118.04 117.9 56.4 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 176.046 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.6 p -125.83 137.92 56.16 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.847 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.259 -178.072 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 84.9 m -120.73 113.25 19.92 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 46.7 t60 -92.86 -19.2 21.93 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.921 -179.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -138.77 157.36 46.22 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.548 -178.025 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 35.7 mt-10 -77.68 135.79 38.12 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.871 176.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 130.03 168.37 12.28 Favored Glycine 0 C--N 1.313 -0.7 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.12 -178.102 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -85.0 135.33 5.49 Favored 'Trans proline' 0 N--CA 1.453 -0.872 0 C-N-CA 122.636 2.224 . . . . 0.0 112.613 178.845 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.405 ' O ' ' HB2' ' A' ' 109' ' ' TYR . 1.9 pp -138.76 157.07 72.5 Favored Pre-proline 0 C--N 1.321 -0.666 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.028 178.359 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.401 ' HG3' ' HD3' ' A' ' 134' ' ' PRO . 56.6 Cg_endo -68.06 171.17 12.93 Favored 'Trans proline' 0 C--N 1.348 0.523 0 C-N-CA 122.286 1.991 . . . . 0.0 112.081 -179.527 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' HIS . . . . . 0.413 ' HE2' HG23 ' A' ' 83' ' ' VAL . 62.5 t-80 -92.34 132.62 31.6 Favored Pre-proline 0 C--N 1.314 -0.943 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -53.34 -49.52 17.15 Favored 'Trans proline' 0 CA--C 1.536 0.594 0 C-N-CA 122.957 2.438 . . . . 0.0 112.533 -177.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -63.33 -66.22 2.66 Favored Glycine 0 CA--C 1.526 0.721 0 C-N-CA 121.067 -0.587 . . . . 0.0 113.086 178.787 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.402 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 4.2 p30 -120.95 111.79 17.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.825 0.345 . . . . 0.0 111.63 -179.558 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 20.0 t -59.2 -14.6 5.6 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.904 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.529 177.345 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 22.5 t-80 -66.92 -5.52 12.94 Favored 'General case' 0 CA--C 1.543 0.686 0 CA-C-O 121.355 0.597 . . . . 0.0 110.694 177.739 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.451 ' HG2' ' HA ' ' A' ' 125' ' ' PRO . 7.5 mtmp? -135.04 156.17 49.49 Favored 'General case' 0 N--CA 1.439 -0.996 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 178.46 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . 0.405 ' HB2' ' O ' ' A' ' 100' ' ' ILE . 12.6 p90 -141.56 170.08 16.39 Favored 'General case' 0 C--N 1.306 -1.284 0 CA-C-O 120.689 0.281 . . . . 0.0 110.405 -178.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 3.3 mp -126.3 140.68 48.04 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 -179.675 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.413 ' O ' ' HA ' ' A' ' 121' ' ' ILE . 4.6 mp -97.9 117.69 43.12 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.031 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 176.076 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 34.7 m -104.38 123.69 47.86 Favored 'General case' 0 C--N 1.312 -1.022 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -178.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 14.3 p -135.87 147.86 48.39 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.55 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . 0.565 ' HE2' ' O ' ' A' ' 116' ' ' GLY . 84.4 tttt -117.34 112.84 21.27 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-O 121.085 0.469 . . . . 0.0 110.552 -178.253 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 75.4 m -97.98 73.02 2.23 Favored 'General case' 0 C--N 1.31 -1.13 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.888 178.295 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.565 ' O ' ' HE2' ' A' ' 114' ' ' LYS . . . 80.97 -98.9 1.87 Allowed Glycine 0 N--CA 1.437 -1.256 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -178.822 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 50.2 m -114.54 5.39 15.49 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 120.856 0.36 . . . . 0.0 110.122 177.282 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 50.1 tp -114.85 121.34 42.94 Favored 'General case' 0 C--O 1.222 -0.383 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.49 -178.062 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 57.4 m95 -89.45 132.5 34.99 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 121.045 0.45 . . . . 0.0 111.932 179.504 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -110.6 126.31 54.32 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.884 175.096 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.487 ' O ' HD12 ' A' ' 121' ' ' ILE . 2.5 pp -126.28 150.62 32.0 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.129 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.709 -179.012 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 26.9 m -151.72 123.57 8.03 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.569 177.487 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 5.3 p -93.64 112.01 25.91 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.324 0 CA-C-O 121.58 0.705 . . . . 0.0 110.912 179.087 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.467 ' HA ' ' HE3' ' A' ' 124' ' ' MET . 6.4 mmt -113.54 144.15 30.79 Favored Pre-proline 0 C--N 1.318 -0.792 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.399 -178.807 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . 0.451 ' HA ' ' HG2' ' A' ' 108' ' ' LYS . 92.4 Cg_endo -88.01 144.71 6.22 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 122.564 2.176 . . . . 0.0 112.648 178.666 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' CYS . . . . . 0.438 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 26.3 m -83.26 171.83 13.2 Favored 'General case' 0 C--O 1.244 0.779 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.069 176.066 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 35.7 t -61.15 151.77 30.35 Favored 'General case' 0 N--CA 1.445 -0.687 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 177.451 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . 0.419 HD11 ' N ' ' A' ' 128' ' ' ILE . 1.8 mp -64.21 124.69 19.48 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.193 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.664 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 99.69 -12.96 61.18 Favored Glycine 0 N--CA 1.44 -1.042 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.439 -177.279 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 76.5 p -111.67 149.7 31.21 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-O 121.158 0.504 . . . . 0.0 111.784 179.782 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 58.8 pttt -121.37 144.71 48.51 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 178.869 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.438 ' HB2' ' SG ' ' A' ' 126' ' ' CYS . 45.0 t80 -82.53 136.15 34.93 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-O 121.178 0.513 . . . . 0.0 111.927 -177.497 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . 0.42 ' HB3' ' OG ' ' A' ' 136' ' ' SER . 19.8 t70 -105.16 130.2 23.51 Favored Pre-proline 0 C--N 1.321 -0.659 0 CA-C-N 115.945 -0.571 . . . . 0.0 109.786 177.366 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' PRO . . . . . 0.401 ' HD3' ' HG3' ' A' ' 101' ' ' PRO . 28.2 Cg_endo -64.68 -42.95 14.13 Favored 'Trans proline' 0 N--CA 1.473 0.317 0 C-N-CA 123.018 2.479 . . . . 0.0 114.236 -176.17 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 2.0 mp -77.61 -50.64 19.74 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 N-CA-C 111.943 0.349 . . . . 0.0 111.943 -175.752 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' SER . . . . . 0.42 ' OG ' ' HB3' ' A' ' 133' ' ' ASP . 64.1 p -70.44 -29.68 66.33 Favored 'General case' 0 C--N 1.325 -0.498 0 C-N-CA 121.037 -0.265 . . . . 0.0 111.184 -179.058 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 71.21 48.83 0.34 Allowed 'General case' 0 C--O 1.234 0.251 0 CA-C-N 115.813 -0.63 . . . . 0.0 111.783 175.331 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 9.5 p30 -160.83 176.58 11.31 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 177.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 17.3 m -101.43 124.72 47.56 Favored 'General case' 0 C--N 1.313 -1.02 0 C-N-CA 120.414 -0.514 . . . . 0.0 109.969 -178.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 31.7 m -111.66 160.05 11.26 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.889 0 CA-C-N 116.062 -0.517 . . . . 0.0 109.802 -179.588 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 78.7 mt -63.22 132.94 53.36 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-O 121.1 0.476 . . . . 0.0 111.367 -179.037 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 24.5 t70 . . . . . 0 C--N 1.313 -1.001 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 177.493 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 32.1 t70 . . . . . 0 C--O 1.235 0.298 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.403 ' CD2' HD13 ' A' ' 121' ' ' ILE . 52.9 tp -111.57 135.78 51.67 Favored 'General case' 0 C--N 1.312 -1.043 0 C-N-CA 120.939 -0.305 . . . . 0.0 110.687 179.562 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 3.8 mt -100.1 145.95 9.88 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.163 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 179.323 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.558 ' O ' ' HA ' ' A' ' 89' ' ' THR . 30.9 m -141.22 170.83 13.11 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 -179.822 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 50.3 m-70 -114.13 113.27 24.48 Favored 'General case' 0 C--N 1.316 -0.888 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 -179.085 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.418 ' CD ' ' HZ2' ' A' ' 108' ' ' LYS . 4.3 mm-40 -112.31 111.84 23.0 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 174.839 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 71.76 13.22 75.02 Favored Glycine 0 N--CA 1.452 -0.235 0 N-CA-C 110.679 -0.968 . . . . 0.0 110.679 -176.633 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 99.76 -17.46 57.39 Favored Glycine 0 N--CA 1.437 -1.295 0 CA-C-N 114.999 -0.601 . . . . 0.0 111.905 -178.18 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 35.3 mmtp -87.16 143.05 27.47 Favored 'General case' 0 CA--C 1.515 -0.397 0 CA-C-O 120.712 0.292 . . . . 0.0 110.691 -177.728 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.558 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.1 OUTLIER -85.62 130.71 34.5 Favored 'General case' 0 N--CA 1.434 -1.234 0 N-CA-C 112.541 0.571 . . . . 0.0 112.541 -179.076 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.442 ' CD1' ' HA3' ' A' ' 104' ' ' GLY . 82.3 m-85 -128.58 138.68 52.34 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 115.608 -0.723 . . . . 0.0 109.854 176.76 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 17.6 m-70 -88.82 143.5 26.86 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 120.831 0.348 . . . . 0.0 110.668 -179.784 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 62.2 t -117.17 122.72 70.64 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.064 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 177.724 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 52.8 t -125.37 131.13 72.64 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.176 0 CA-C-N 116.079 -0.509 . . . . 0.0 109.671 -178.805 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 87.2 m -104.8 114.28 28.39 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-O 121.182 0.515 . . . . 0.0 109.892 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 26.5 m80 -84.25 -23.46 30.39 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.151 -177.71 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -160.67 176.58 11.38 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.692 -0.686 . . . . 0.0 109.389 -179.043 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -79.89 142.8 34.84 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.885 0.374 . . . . 0.0 110.217 178.291 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 130.71 167.77 12.08 Favored Glycine 0 N--CA 1.442 -0.955 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.405 -178.412 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -89.59 133.13 2.17 Favored 'Trans proline' 0 N--CA 1.449 -1.116 0 C-N-CA 122.918 2.412 . . . . 0.0 112.93 179.415 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -138.04 157.31 73.25 Favored Pre-proline 0 C--N 1.318 -0.776 0 CA-C-N 115.71 -0.677 . . . . 0.0 109.463 177.891 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.472 ' HG3' ' HD3' ' A' ' 134' ' ' PRO . 59.4 Cg_endo -68.8 171.14 13.9 Favored 'Trans proline' 0 CA--C 1.515 -0.427 0 C-N-CA 122.234 1.956 . . . . 0.0 112.234 -178.021 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' HIS . . . . . 0.63 ' HB3' ' O ' ' A' ' 105' ' ' ASN . 50.2 t-80 -90.35 126.68 55.78 Favored Pre-proline 0 N--CA 1.43 -1.434 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 178.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -54.58 -43.74 56.14 Favored 'Trans proline' 0 N--CA 1.474 0.38 0 C-N-CA 122.959 2.439 . . . . 0.0 113.126 -174.03 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.442 ' HA3' ' CD1' ' A' ' 90' ' ' TYR . . . -96.68 4.54 63.76 Favored Glycine 0 N--CA 1.442 -0.951 0 C-N-CA 120.057 -1.068 . . . . 0.0 113.633 -178.452 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.63 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 52.2 t30 -163.84 87.3 0.51 Allowed 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 117.683 0.741 . . . . 0.0 111.17 -179.534 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.9 m -54.93 -11.95 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 N-CA-C 113.859 1.059 . . . . 0.0 113.859 178.177 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 19.1 t-80 -77.21 0.39 22.05 Favored 'General case' 0 CA--C 1.543 0.704 0 CA-C-O 121.413 0.625 . . . . 0.0 110.203 177.169 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.418 ' HZ2' ' CD ' ' A' ' 85' ' ' GLU . 39.8 mttp -133.8 156.29 48.29 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.576 178.516 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 9.1 p90 -141.92 162.54 35.22 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 176.497 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 3.3 mp -123.83 140.03 48.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 -178.327 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -99.29 118.84 46.48 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 176.259 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 65.3 m -100.25 123.23 44.23 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 120.743 0.306 . . . . 0.0 110.571 -178.015 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 34.0 t -130.84 139.8 50.19 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.328 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . 0.416 ' HD2' ' CZ2' ' A' ' 119' ' ' TRP . 88.6 tttt -113.92 113.63 25.11 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 120.999 0.428 . . . . 0.0 110.541 -178.707 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 73.4 m -100.52 80.72 2.24 Favored 'General case' 0 N--CA 1.441 -0.887 0 CA-C-O 121.356 0.598 . . . . 0.0 109.974 178.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 76.1 -99.62 1.3 Allowed Glycine 0 N--CA 1.442 -0.914 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.367 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 32.8 m -112.55 4.58 17.44 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.772 0.32 . . . . 0.0 110.59 -179.436 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 12.4 mt -122.77 133.28 54.47 Favored 'General case' 0 N--CA 1.439 -0.995 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.238 -176.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . 0.416 ' CZ2' ' HD2' ' A' ' 114' ' ' LYS . 70.7 m95 -96.04 133.5 40.22 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-O 121.076 0.465 . . . . 0.0 111.472 179.549 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -121.25 122.63 40.35 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 115.785 -0.643 . . . . 0.0 109.38 176.12 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.403 HD13 ' CD2' ' A' ' 81' ' ' LEU . 2.4 pp -122.5 156.22 27.59 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.86 -175.343 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 22.6 m -140.95 123.17 15.72 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.935 178.415 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 5.2 p -95.95 105.29 16.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-O 121.621 0.725 . . . . 0.0 110.841 -179.742 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.455 ' HE1' ' HA ' ' A' ' 124' ' ' MET . 3.5 mmt -106.18 139.48 20.32 Favored Pre-proline 0 C--N 1.314 -0.973 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.139 -178.885 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -85.09 144.63 9.56 Favored 'Trans proline' 0 N--CA 1.448 -1.151 0 C-N-CA 122.2 1.934 . . . . 0.0 112.324 178.617 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' CYS . . . . . 0.533 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 65.7 m -80.61 164.24 23.04 Favored 'General case' 0 C--O 1.242 0.675 0 CA-C-N 116.247 -0.433 . . . . 0.0 109.857 176.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 32.3 t -56.29 148.36 18.8 Favored 'General case' 0 N--CA 1.443 -0.82 0 CA-C-N 116.056 -0.52 . . . . 0.0 109.66 177.082 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . 0.457 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.8 mp -62.97 128.92 25.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.333 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 96.37 -9.04 67.08 Favored Glycine 0 N--CA 1.443 -0.871 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.625 -177.028 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 72.1 p -118.46 153.88 33.39 Favored 'General case' 0 C--O 1.236 0.342 0 CA-C-N 117.292 0.546 . . . . 0.0 111.127 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.407 ' HE2' ' HA ' ' A' ' 142' ' ' ASP . 49.3 pttt -130.0 145.28 51.64 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 116.022 -0.535 . . . . 0.0 109.606 -179.248 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.533 ' HB2' ' SG ' ' A' ' 126' ' ' CYS . 29.4 t80 -84.46 136.88 33.65 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-O 121.088 0.471 . . . . 0.0 111.988 -176.329 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 32.2 t70 -108.56 134.78 20.15 Favored Pre-proline 0 C--N 1.323 -0.556 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.52 177.056 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' PRO . . . . . 0.472 ' HD3' ' HG3' ' A' ' 101' ' ' PRO . 42.0 Cg_endo -68.82 -37.36 11.87 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.577 2.185 . . . . 0.0 113.27 -176.045 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 22.7 mm -77.85 -53.55 14.08 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.881 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.827 -176.426 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 67.0 m -68.98 -29.98 68.3 Favored 'General case' 0 C--N 1.321 -0.662 0 C-N-CA 120.822 -0.351 . . . . 0.0 111.307 178.476 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 89.0 mtm180 70.76 41.57 0.88 Allowed 'General case' 0 N--CA 1.473 0.704 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.656 175.665 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 10.7 p30 -155.66 174.35 15.42 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 177.404 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' CYS . . . . . 0.433 ' SG ' ' HD1' ' A' ' 132' ' ' PHE . 6.4 m -101.26 124.88 47.64 Favored 'General case' 0 C--N 1.314 -0.943 0 C-N-CA 120.341 -0.544 . . . . 0.0 109.62 -179.28 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 33.9 m -107.01 159.8 6.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.833 -179.236 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 55.4 tp -63.47 119.82 10.5 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-O 120.972 0.415 . . . . 0.0 111.456 -178.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' ASP . . . . . 0.407 ' HA ' ' HE2' ' A' ' 131' ' ' LYS . 21.2 t70 . . . . . 0 N--CA 1.442 -0.85 0 CA-C-O 121.463 0.649 . . . . 0.0 109.309 176.653 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . 0.625 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 7.6 p-10 . . . . . 0 N--CA 1.451 -0.392 0 CA-C-O 121.352 0.596 . . . . 0.0 111.028 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 47.0 tp -97.04 140.47 31.51 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.417 177.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 5.5 mt -100.26 145.95 9.97 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.996 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 179.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.475 ' O ' ' HA ' ' A' ' 89' ' ' THR . 17.1 m -142.87 176.01 3.76 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.88 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -179.611 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 41.7 m-70 -117.13 120.93 39.81 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-O 121.108 0.48 . . . . 0.0 111.9 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.419 ' HB2' ' CE1' ' A' ' 90' ' ' TYR . 45.2 mt-10 -126.17 116.09 20.79 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.264 176.51 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 67.16 23.76 73.17 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.624 -0.798 . . . . 0.0 111.232 -178.557 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 93.55 -28.0 11.0 Favored Glycine 0 N--CA 1.443 -0.858 0 C-N-CA 121.437 -0.411 . . . . 0.0 112.725 -178.282 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 44.3 mmtm -84.91 155.01 21.86 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.69 0.281 . . . . 0.0 111.136 -177.058 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.475 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.0 OUTLIER -92.42 137.4 32.4 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.488 -179.949 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.419 ' CE1' ' HB2' ' A' ' 85' ' ' GLU . 89.7 m-85 -131.6 145.38 51.67 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 178.583 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 20.0 m-70 -98.88 143.6 29.01 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-O 120.951 0.405 . . . . 0.0 110.579 179.606 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.625 ' O ' ' HA ' ' A' ' 80' ' ' ASP . 57.2 t -113.93 118.55 58.68 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.161 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 177.109 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 37.3 t -121.15 137.54 54.52 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.242 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 -178.282 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 72.4 m -114.53 113.61 24.66 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-O 120.988 0.423 . . . . 0.0 111.13 -179.751 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 20.8 t60 -81.03 -24.14 38.1 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.769 -0.651 . . . . 0.0 111.076 -178.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -154.34 169.6 23.3 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.551 -0.295 . . . . 0.0 110.615 -178.281 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 21.0 mp0 -76.61 110.61 11.32 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.378 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 161.87 165.84 19.52 Favored Glycine 0 N--CA 1.446 -0.663 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.315 179.85 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.416 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 92.3 Cg_endo -85.75 135.11 4.81 Favored 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 122.907 2.404 . . . . 0.0 112.503 178.628 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -139.92 156.95 70.39 Favored Pre-proline 0 C--N 1.319 -0.724 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.525 179.394 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -63.51 169.21 10.1 Favored 'Trans proline' 0 C--N 1.353 0.775 0 C-N-CA 122.683 2.255 . . . . 0.0 112.54 -179.649 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' HIS . . . . . 0.447 ' CD2' HD12 ' A' ' 110' ' ' ILE . 5.2 t-80 -94.31 138.46 22.47 Favored Pre-proline 0 C--N 1.322 -0.602 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 -178.108 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -53.45 -50.2 14.72 Favored 'Trans proline' 0 CA--C 1.536 0.584 0 C-N-CA 123.109 2.539 . . . . 0.0 113.121 -178.624 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -71.1 -65.21 2.53 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.591 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 43.7 m-80 -115.06 104.94 12.38 Favored 'General case' 0 C--N 1.321 -0.658 0 O-C-N 122.865 -0.197 . . . . 0.0 111.365 -179.806 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 18.5 m -56.25 -12.04 0.99 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 N-CA-C 112.011 0.374 . . . . 0.0 112.011 173.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 24.3 t-80 -66.36 -8.26 24.28 Favored 'General case' 0 CA--C 1.544 0.719 0 CA-C-O 121.407 0.622 . . . . 0.0 110.076 175.58 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 48.4 mtmt -129.55 157.25 42.55 Favored 'General case' 0 N--CA 1.439 -1.001 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.623 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 12.9 p90 -142.14 167.38 22.26 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 120.181 -0.608 . . . . 0.0 111.133 -179.804 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.447 HD12 ' CD2' ' A' ' 102' ' ' HIS . 2.3 mp -126.43 139.4 51.78 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.112 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.173 -179.146 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.7 mp -98.74 116.45 41.73 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.144 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 175.336 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 39.9 m -95.99 121.82 38.14 Favored 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 16.6 t -130.36 149.4 52.06 Favored 'General case' 0 N--CA 1.437 -1.098 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.117 -178.624 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . 0.495 ' HE3' ' CE2' ' A' ' 119' ' ' TRP . 9.1 mmtp -103.23 140.46 37.34 Favored 'General case' 0 C--N 1.308 -1.203 0 CA-C-O 121.224 0.535 . . . . 0.0 111.732 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 57.7 m -124.26 79.92 1.78 Allowed 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 174.207 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 73.39 -104.4 1.58 Allowed Glycine 0 N--CA 1.431 -1.68 0 CA-C-N 114.788 -1.096 . . . . 0.0 110.517 -174.851 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 12.1 p -113.01 16.39 19.35 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-O 120.899 0.38 . . . . 0.0 111.134 178.719 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 24.2 tp -122.14 142.92 49.89 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.289 -177.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . 0.495 ' CE2' ' HE3' ' A' ' 114' ' ' LYS . 91.1 m95 -92.15 133.39 35.82 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 120.984 0.421 . . . . 0.0 111.67 179.161 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 49.2 m-85 -124.19 122.81 38.81 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.123 172.3 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.5 pp -119.78 155.95 22.46 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.44 -176.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 25.7 m -141.06 119.74 12.49 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.655 178.353 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 4.2 p -94.02 109.06 21.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-O 121.684 0.754 . . . . 0.0 111.108 -179.138 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.448 ' HA ' ' HE2' ' A' ' 124' ' ' MET . 5.3 mmt -107.82 127.4 27.79 Favored Pre-proline 0 C--N 1.309 -1.183 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.288 -179.893 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -78.75 142.08 17.64 Favored 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 122.325 2.017 . . . . 0.0 110.819 176.21 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 10.4 t -93.62 -179.08 4.91 Favored 'General case' 0 C--N 1.317 -0.824 0 C-N-CA 120.484 -0.487 . . . . 0.0 110.382 179.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 34.0 t -62.94 146.51 52.86 Favored 'General case' 0 N--CA 1.438 -1.035 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.691 -179.472 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . 0.407 ' N ' HD12 ' A' ' 128' ' ' ILE . 2.0 mp -62.91 129.82 26.78 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-N 116.131 -0.486 . . . . 0.0 109.839 179.397 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.86 -4.04 68.05 Favored Glycine 0 N--CA 1.44 -1.099 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.949 -178.343 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 34.9 p -128.14 150.39 50.01 Favored 'General case' 0 C--O 1.237 0.447 0 CA-C-N 117.28 0.54 . . . . 0.0 110.885 178.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.415 ' O ' ' HA ' ' A' ' 139' ' ' CYS . 62.7 pttt -127.03 154.96 43.98 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.966 -179.616 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 40.3 t80 -87.18 136.87 32.76 Favored 'General case' 0 C--N 1.311 -1.078 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.109 -178.682 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -99.01 134.41 21.44 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.782 178.748 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 26.6 Cg_endo -62.04 -51.3 3.85 Favored 'Trans proline' 0 CA--C 1.532 0.39 0 C-N-CA 123.017 2.478 . . . . 0.0 114.116 -176.63 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 47.2 mm -81.23 -47.25 20.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 112.112 0.412 . . . . 0.0 112.112 -175.803 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.5 m -65.98 -34.46 78.15 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.833 0.349 . . . . 0.0 110.446 -179.228 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 87.7 mtm180 66.14 53.05 1.1 Allowed 'General case' 0 CA--C 1.516 -0.337 0 CA-C-N 115.404 -0.817 . . . . 0.0 110.554 177.757 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 28.2 p-10 -157.47 176.52 12.55 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.034 -0.985 . . . . 0.0 109.191 179.443 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' CYS . . . . . 0.415 ' HA ' ' O ' ' A' ' 131' ' ' LYS . 68.0 m -102.62 131.07 49.64 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-O 121.006 0.431 . . . . 0.0 111.91 178.628 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 33.8 m -125.55 165.85 22.42 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.216 177.288 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -50.26 118.18 2.82 Favored 'General case' 0 N--CA 1.474 0.739 0 CA-C-O 121.108 0.48 . . . . 0.0 111.644 179.809 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 15.3 t0 . . . . . 0 N--CA 1.445 -0.698 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 177.35 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 11.0 t70 . . . . . 0 N--CA 1.454 -0.232 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 23.9 tp -90.54 148.57 22.63 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-O 120.865 0.364 . . . . 0.0 110.978 -177.387 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.402 HG23 HG21 ' A' ' 89' ' ' THR . 7.7 mt -105.92 144.77 14.79 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 175.835 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.435 ' O ' ' HA ' ' A' ' 89' ' ' THR . 16.1 m -132.27 158.16 43.23 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 -178.473 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 6.8 p80 -116.49 101.98 9.1 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-O 121.226 0.536 . . . . 0.0 111.571 -177.721 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.4 ' HG2' ' CE1' ' A' ' 102' ' ' HIS . 0.7 OUTLIER -117.27 114.09 23.11 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.12 179.116 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 67.05 22.58 72.48 Favored Glycine 0 CA--C 1.519 0.337 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.478 179.67 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 90.02 -4.71 83.23 Favored Glycine 0 N--CA 1.445 -0.707 0 C-N-CA 121.174 -0.536 . . . . 0.0 112.365 -179.686 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 35.0 mmtp -100.26 134.34 43.34 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 120.716 0.293 . . . . 0.0 110.349 -179.411 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.435 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.0 OUTLIER -88.03 107.74 18.89 Favored 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.257 179.466 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -101.23 146.91 26.9 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.598 178.364 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 18.2 m-70 -98.22 140.04 33.1 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-O 120.881 0.372 . . . . 0.0 110.612 177.653 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 44.5 t -122.04 118.43 55.48 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.481 178.323 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.3 p -129.44 132.76 66.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.494 179.356 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 77.2 m -111.96 123.1 49.53 Favored 'General case' 0 C--N 1.308 -1.228 0 CA-C-O 121.059 0.457 . . . . 0.0 111.11 -178.47 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 34.2 m80 -100.7 -21.6 15.16 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 178.436 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -129.14 144.2 51.12 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.14 -0.937 . . . . 0.0 109.526 -178.83 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . 0.447 ' HG3' ' HA ' ' A' ' 113' ' ' SER . 42.3 tt0 -76.23 138.73 40.79 Favored 'General case' 0 N--CA 1.43 -1.432 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 177.883 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 132.17 173.86 13.45 Favored Glycine 0 N--CA 1.439 -1.107 0 C-N-CA 120.902 -0.666 . . . . 0.0 111.77 -178.21 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -87.36 134.07 3.39 Favored 'Trans proline' 0 N--CA 1.452 -0.961 0 C-N-CA 122.912 2.408 . . . . 0.0 112.951 179.142 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.8 pp -137.02 157.24 75.0 Favored Pre-proline 0 C--N 1.323 -0.544 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.899 178.43 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -65.34 162.58 32.89 Favored 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.41 2.073 . . . . 0.0 113.126 -177.794 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' HIS . . . . . 0.408 ' NE2' HG21 ' A' ' 83' ' ' VAL . 59.5 t-80 -91.78 120.93 67.83 Favored Pre-proline 0 C--N 1.316 -0.881 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.536 179.676 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_endo -60.72 -16.93 46.71 Favored 'Trans proline' 0 N--CA 1.482 0.841 0 C-N-CA 123.132 2.555 . . . . 0.0 113.466 -175.842 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -89.99 -24.09 30.73 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.556 -0.83 . . . . 0.0 112.563 179.874 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 25.7 p-10 -167.4 106.89 0.57 Allowed 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 110.108 -0.33 . . . . 0.0 110.108 -179.174 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 31.2 m -53.09 -11.32 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.045 0 N-CA-C 114.01 1.115 . . . . 0.0 114.01 -179.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -80.48 2.31 25.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.154 0.502 . . . . 0.0 110.935 178.49 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 34.1 mtmt -133.76 156.5 47.86 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 177.736 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 6.6 p90 -142.51 166.21 25.28 Favored 'General case' 0 C--N 1.311 -1.099 0 C-N-CA 120.871 -0.332 . . . . 0.0 110.476 179.331 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 3.7 mp -123.74 137.67 56.09 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.47 ' O ' ' HA ' ' A' ' 121' ' ' ILE . 4.2 mp -95.64 121.74 46.47 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.997 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 176.696 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 25.4 m -105.46 127.16 52.85 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 -178.859 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' SER . . . . . 0.447 ' HA ' ' HG3' ' A' ' 97' ' ' GLU . 52.5 m -126.52 131.79 51.51 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.402 179.251 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . 0.628 ' HE2' ' O ' ' A' ' 116' ' ' GLY . 23.7 tptm -97.49 113.57 25.28 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 120.705 0.288 . . . . 0.0 110.659 -178.87 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 72.1 m -112.99 80.03 1.3 Allowed 'General case' 0 N--CA 1.442 -0.863 0 CA-C-O 121.265 0.555 . . . . 0.0 110.286 178.447 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.628 ' O ' ' HE2' ' A' ' 114' ' ' LYS . . . 74.35 -99.28 1.07 Allowed Glycine 0 N--CA 1.446 -0.679 0 CA-C-N 115.349 -0.841 . . . . 0.0 111.037 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 48.8 p -113.52 4.1 16.05 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 121.12 0.486 . . . . 0.0 110.433 178.065 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 26.8 tp -117.5 132.16 56.59 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.954 -175.479 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . 0.431 ' CZ2' ' HD3' ' A' ' 114' ' ' LYS . 86.3 m95 -94.78 132.06 39.96 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 120.883 0.373 . . . . 0.0 110.746 177.116 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 51.0 m-85 -108.65 128.04 54.5 Favored 'General case' 0 C--N 1.309 -1.162 0 N-CA-C 108.876 -0.786 . . . . 0.0 108.876 174.156 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.47 ' HA ' ' O ' ' A' ' 111' ' ' ILE . 1.8 pp -133.2 153.4 37.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-O 121.367 0.603 . . . . 0.0 112.616 -175.695 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 19.4 m -150.44 127.58 11.24 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.188 178.074 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 4.0 p -98.77 106.74 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 CA-C-O 121.57 0.7 . . . . 0.0 111.061 -178.504 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.454 ' HA ' ' HE3' ' A' ' 124' ' ' MET . 3.5 mmt -108.03 140.27 21.49 Favored Pre-proline 0 C--N 1.309 -1.166 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.654 -179.325 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_endo -82.48 141.47 11.23 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 122.386 2.058 . . . . 0.0 111.36 176.649 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 5.9 t -94.16 -174.87 3.51 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 120.648 -0.421 . . . . 0.0 110.667 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 15.5 m -61.53 137.16 58.23 Favored 'General case' 0 N--CA 1.441 -0.896 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.627 178.413 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 2.4 mp -65.84 139.35 21.41 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.914 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 178.33 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 93.55 -13.93 66.42 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.313 -176.03 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 73.6 p -117.41 159.53 22.64 Favored 'General case' 0 N--CA 1.447 -0.614 0 O-C-N 122.479 -0.424 . . . . 0.0 110.735 179.319 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 59.8 pttt -129.07 148.29 51.0 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.698 179.609 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.442 ' HD1' ' SG ' ' A' ' 139' ' ' CYS . 25.5 t80 -87.68 135.63 33.29 Favored 'General case' 0 C--N 1.308 -1.229 0 CA-C-O 120.825 0.345 . . . . 0.0 110.714 -178.58 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 30.5 t70 -102.47 134.99 19.64 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.015 178.706 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.23 -41.16 13.28 Favored 'Trans proline' 0 C--N 1.346 0.419 0 C-N-CA 123.021 2.481 . . . . 0.0 113.862 -176.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 33.1 mm -81.39 -52.69 13.57 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 C-N-CA 120.819 -0.353 . . . . 0.0 111.525 -176.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 7.2 m -62.69 -36.79 84.06 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 120.855 0.359 . . . . 0.0 110.394 179.153 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 80.5 mtm180 69.36 42.83 1.12 Allowed 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 115.356 -0.838 . . . . 0.0 111.157 177.24 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 10.5 p30 -154.39 177.57 11.01 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 108.393 -0.965 . . . . 0.0 108.393 177.197 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' CYS . . . . . 0.442 ' SG ' ' HD1' ' A' ' 132' ' ' PHE . 78.1 m -101.77 126.68 48.68 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-O 121.385 0.612 . . . . 0.0 111.737 -177.91 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 26.8 m -115.2 159.1 15.26 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-N 115.185 -0.916 . . . . 0.0 109.553 179.436 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 2.3 tm? -55.41 123.24 13.23 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 120.963 0.411 . . . . 0.0 110.915 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 16.5 t70 . . . . . 0 C--N 1.324 -0.539 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.045 -179.467 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 10.2 t70 . . . . . 0 C--O 1.237 0.396 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.415 ' CD2' HD11 ' A' ' 121' ' ' ILE . 35.3 tp -101.26 147.14 26.64 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.244 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.404 HG23 HG23 ' A' ' 89' ' ' THR . 4.0 mt -110.24 148.29 13.88 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.869 0 C-N-CA 120.561 -0.455 . . . . 0.0 110.374 178.553 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.51 HG22 ' HE2' ' A' ' 102' ' ' HIS . 4.8 m -142.44 174.72 5.39 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 179.58 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 11.0 p80 -128.21 108.36 10.55 Favored 'General case' 0 C--N 1.313 -1.0 0 N-CA-C 112.503 0.557 . . . . 0.0 112.503 -177.751 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 3.9 mp0 -116.65 113.63 22.94 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.105 178.708 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 66.68 31.64 79.05 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.628 178.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 86.19 -11.75 62.15 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.839 -0.696 . . . . 0.0 113.201 179.243 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 30.2 mmtp -99.09 136.94 38.32 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.871 0.336 . . . . 0.0 111.166 -179.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.48 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.0 OUTLIER -86.54 107.77 18.27 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.474 179.268 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -100.3 145.14 28.48 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.816 179.258 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 27.1 m-70 -99.43 144.09 28.94 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.36 178.355 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 46.2 t -120.51 118.38 56.39 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.078 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 178.452 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 44.1 t -124.56 132.6 71.1 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.274 179.478 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 71.3 m -104.43 113.77 27.55 Favored 'General case' 0 C--N 1.31 -1.141 0 CA-C-O 121.113 0.482 . . . . 0.0 110.305 -179.564 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 19.0 t60 -79.49 -21.2 45.66 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.509 -178.144 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -161.53 175.81 11.72 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.654 179.714 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -77.92 144.6 36.73 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 120.735 0.302 . . . . 0.0 110.461 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 126.45 164.41 11.74 Favored Glycine 0 N--CA 1.446 -0.658 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.41 -179.685 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 92.1 Cg_endo -86.78 138.28 5.09 Favored 'Trans proline' 0 CA--C 1.54 0.814 0 C-N-CA 122.869 2.379 . . . . 0.0 113.179 179.376 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -140.91 157.27 67.75 Favored Pre-proline 0 C--N 1.325 -0.482 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.169 177.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -64.22 166.94 15.54 Favored 'Trans proline' 0 C--N 1.353 0.763 0 C-N-CA 122.666 2.244 . . . . 0.0 112.848 -179.138 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' HIS . . . . . 0.51 ' HE2' HG22 ' A' ' 83' ' ' VAL . 56.5 t-80 -92.82 128.36 44.09 Favored Pre-proline 0 C--N 1.318 -0.769 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.592 -179.088 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -63.09 -19.25 68.46 Favored 'Trans proline' 0 N--CA 1.484 0.934 0 C-N-CA 123.146 2.564 . . . . 0.0 113.398 -176.841 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -96.81 -17.54 32.58 Favored Glycine 0 C--O 1.228 -0.275 0 C-N-CA 120.485 -0.865 . . . . 0.0 113.226 -178.846 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 28.2 p-10 -169.23 104.21 0.37 Allowed 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.698 0.285 . . . . 0.0 110.8 -179.36 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 26.0 m -53.82 -13.14 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 N-CA-C 113.935 1.087 . . . . 0.0 113.935 179.069 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 36.4 m170 -74.88 0.11 16.7 Favored 'General case' 0 N--CA 1.471 0.621 0 CA-C-O 121.081 0.467 . . . . 0.0 110.858 177.043 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 31.2 mtmt -134.91 156.69 48.52 Favored 'General case' 0 CA--C 1.507 -0.705 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 178.555 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 9.9 p90 -142.47 168.74 19.01 Favored 'General case' 0 C--N 1.31 -1.135 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.433 178.828 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 3.5 mp -126.2 140.02 49.89 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -98.7 118.16 44.83 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 176.287 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 68.8 m -100.4 123.61 44.85 Favored 'General case' 0 C--N 1.308 -1.232 0 CA-C-O 120.873 0.368 . . . . 0.0 110.418 -178.462 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 56.0 p -131.87 141.19 49.32 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 178.42 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 81.2 tttt -116.52 106.24 13.36 Favored 'General case' 0 C--N 1.311 -1.087 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.621 -178.611 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 69.6 m -88.59 84.48 6.75 Favored 'General case' 0 N--CA 1.436 -1.154 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.52 179.094 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 73.98 -100.2 1.11 Allowed Glycine 0 N--CA 1.439 -1.103 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -178.153 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 50.3 m -115.04 3.62 14.49 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-O 121.203 0.525 . . . . 0.0 109.826 178.633 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 92.2 mt -108.54 122.82 47.85 Favored 'General case' 0 N--CA 1.435 -1.209 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.542 -176.248 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 86.6 m95 -87.65 130.51 34.76 Favored 'General case' 0 C--N 1.315 -0.903 0 C-N-CA 120.414 -0.514 . . . . 0.0 111.315 179.145 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 85.6 m-85 -122.61 125.73 46.25 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.585 174.133 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.415 HD11 ' CD2' ' A' ' 81' ' ' LEU . 2.2 pp -124.95 157.88 33.06 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.177 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.035 -178.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 32.7 m -145.32 121.66 10.93 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 116.148 -0.478 . . . . 0.0 109.718 177.178 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.5 p -93.81 106.41 18.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 CA-C-O 121.491 0.663 . . . . 0.0 110.775 -178.685 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.45 ' HA ' ' HE2' ' A' ' 124' ' ' MET . 4.2 mmt -106.75 136.3 19.44 Favored Pre-proline 0 C--N 1.31 -1.111 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.97 -178.662 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -82.54 139.3 10.09 Favored 'Trans proline' 0 N--CA 1.45 -1.062 0 C-N-CA 122.411 2.074 . . . . 0.0 110.87 176.078 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 4.7 t -94.61 -178.62 4.61 Favored 'General case' 0 C--N 1.311 -1.071 0 C-N-CA 120.104 -0.639 . . . . 0.0 109.325 177.831 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 15.4 m -63.56 135.1 56.58 Favored 'General case' 0 N--CA 1.435 -1.204 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.408 179.756 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . 0.402 ' N ' HD13 ' A' ' 128' ' ' ILE . 2.2 mp -62.62 141.36 18.07 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 N-CA-C 109.014 -0.735 . . . . 0.0 109.014 178.264 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.8 -10.61 74.17 Favored Glycine 0 N--CA 1.441 -0.985 0 C-N-CA 120.285 -0.959 . . . . 0.0 112.551 -175.186 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 73.5 p -125.02 152.96 43.57 Favored 'General case' 0 N--CA 1.45 -0.438 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 177.003 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 60.5 pttt -126.85 146.69 50.18 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 110.327 -0.249 . . . . 0.0 110.327 -178.366 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 37.9 t80 -84.42 131.38 34.68 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.87 -178.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 23.1 t70 -97.41 133.84 23.32 Favored Pre-proline 0 C--N 1.321 -0.65 0 CA-C-N 116.068 -0.515 . . . . 0.0 109.907 179.29 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -68.02 -40.83 8.43 Favored 'Trans proline' 0 CA--C 1.531 0.371 0 C-N-CA 122.69 2.26 . . . . 0.0 113.842 -177.242 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.8 mp -80.3 -52.05 15.09 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 111.778 0.288 . . . . 0.0 111.778 -177.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 2.1 m -67.03 -35.11 79.17 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.079 0.466 . . . . 0.0 110.092 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 50.7 mtm180 66.37 56.22 0.8 Allowed 'General case' 0 C--O 1.238 0.464 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.645 178.402 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 29.4 p-10 -162.18 174.92 12.26 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 114.647 -1.16 . . . . 0.0 108.75 178.785 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 79.2 m -102.72 126.48 49.84 Favored 'General case' 0 C--N 1.311 -1.068 0 CA-C-O 121.023 0.44 . . . . 0.0 110.805 179.152 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 32.3 m -120.33 170.29 10.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.738 -0.664 . . . . 0.0 110.293 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -51.11 116.89 2.22 Favored 'General case' 0 C--O 1.241 0.615 0 O-C-N 123.545 0.528 . . . . 0.0 110.722 178.794 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 9.7 t70 . . . . . 0 CA--C 1.508 -0.669 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.606 179.766 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 . . . . . 0 N--CA 1.447 -0.594 0 CA-C-O 121.244 0.545 . . . . 0.0 110.012 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 49.4 tp -127.2 135.73 51.06 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 115.417 -0.811 . . . . 0.0 111.276 178.312 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 22.1 mt -94.84 144.58 9.52 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.131 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 176.017 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.525 HG21 ' CE1' ' A' ' 102' ' ' HIS . 20.5 m -131.34 174.22 13.44 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 N-CA-C 109.997 -0.371 . . . . 0.0 109.997 -177.261 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 27.2 m-70 -122.07 101.92 7.83 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 116.528 -0.305 . . . . 0.0 110.93 -178.822 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 34.8 mm-40 -111.32 117.57 33.5 Favored 'General case' 0 C--N 1.32 -0.697 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 178.121 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 63.33 29.24 73.91 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.863 -0.684 . . . . 0.0 111.867 -179.427 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 84.96 -9.35 66.35 Favored Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 121.087 -0.578 . . . . 0.0 113.132 -179.79 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 13.6 mptt -100.57 141.58 33.23 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.993 0.425 . . . . 0.0 111.327 -179.359 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.485 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.0 OUTLIER -82.97 122.24 28.03 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.67 179.47 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 76.1 m-85 -118.21 143.08 46.82 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 176.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 17.7 m-70 -94.46 139.59 30.94 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-O 120.65 0.262 . . . . 0.0 110.664 -178.275 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 60.4 t -119.46 118.14 56.36 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.88 0 N-CA-C 108.99 -0.745 . . . . 0.0 108.99 177.126 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 53.3 t -126.21 133.96 67.58 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.945 -178.741 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 66.6 m -114.64 121.25 42.83 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-O 120.779 0.323 . . . . 0.0 110.372 -178.819 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 39.1 m80 -90.23 -18.45 25.66 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.183 -179.811 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -150.11 170.05 19.82 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.648 -177.509 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -87.46 114.23 23.88 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.182 177.414 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 167.46 166.11 25.99 Favored Glycine 0 N--CA 1.436 -1.351 0 C-N-CA 121.049 -0.596 . . . . 0.0 111.624 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.464 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 87.6 Cg_endo -87.21 130.98 3.0 Favored 'Trans proline' 0 N--CA 1.45 -1.068 0 C-N-CA 122.761 2.307 . . . . 0.0 112.773 178.763 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.5 pp -140.94 156.74 68.41 Favored Pre-proline 0 C--N 1.319 -0.751 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.908 178.264 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -64.72 167.32 15.69 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 122.824 2.349 . . . . 0.0 113.163 -177.538 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' HIS . . . . . 0.525 ' CE1' HG21 ' A' ' 83' ' ' VAL . 4.9 t-80 -93.18 123.77 59.85 Favored Pre-proline 0 C--N 1.316 -0.87 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 -179.207 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 23.2 Cg_endo -58.64 -29.56 89.62 Favored 'Trans proline' 0 N--CA 1.482 0.817 0 C-N-CA 123.147 2.565 . . . . 0.0 114.155 -174.326 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -90.21 -16.08 56.29 Favored Glycine 0 C--N 1.319 -0.389 0 C-N-CA 120.085 -1.055 . . . . 0.0 113.238 -178.547 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 9.3 p-10 -168.07 97.47 0.44 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 120.773 0.321 . . . . 0.0 110.61 -177.122 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 30.5 m -56.07 -10.52 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 N-CA-C 113.768 1.025 . . . . 0.0 113.768 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 32.2 m170 -70.38 0.23 6.95 Favored 'General case' 0 N--CA 1.478 0.927 0 CA-C-O 121.352 0.596 . . . . 0.0 110.327 175.499 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.461 ' HG2' ' HA ' ' A' ' 125' ' ' PRO . 86.5 mttt -134.16 157.99 44.81 Favored 'General case' 0 CA--C 1.505 -0.758 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.021 178.91 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 12.3 p90 -143.44 165.83 26.45 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.391 176.616 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.464 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 2.3 mp -124.52 140.59 47.32 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.166 0 CA-C-O 120.798 0.333 . . . . 0.0 110.233 -178.758 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.4 mp -103.33 114.09 41.96 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 175.595 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 34.4 m -96.88 123.02 40.48 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -178.119 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 29.7 p -134.62 145.65 48.82 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-O 120.955 0.407 . . . . 0.0 111.087 -178.497 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . 0.518 ' HE2' ' O ' ' A' ' 116' ' ' GLY . 87.2 tttt -111.3 120.46 42.31 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-N 115.99 -0.55 . . . . 0.0 109.545 179.195 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 57.6 m -103.33 85.86 2.56 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.75 178.828 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . 0.518 ' O ' ' HE2' ' A' ' 114' ' ' LYS . . . 66.91 -100.65 0.58 Allowed Glycine 0 N--CA 1.442 -0.958 0 CA-C-N 115.221 -0.899 . . . . 0.0 111.882 -178.58 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 15.1 m -110.3 6.58 22.56 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 120.741 0.305 . . . . 0.0 111.332 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -124.89 135.67 53.08 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 122.235 -0.291 . . . . 0.0 110.469 -178.768 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 52.6 m95 -94.65 135.79 35.71 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 120.945 0.402 . . . . 0.0 111.73 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -129.23 129.58 45.19 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.999 176.485 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.6 pp -123.86 147.63 28.21 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 120.82 0.343 . . . . 0.0 110.819 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 25.0 m -132.01 124.35 29.13 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.515 -179.326 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 4.4 p -98.25 108.71 22.46 Favored 'Isoleucine or valine' 0 C--O 1.236 0.373 0 CA-C-O 121.496 0.665 . . . . 0.0 110.813 179.38 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.476 ' HA ' ' HE2' ' A' ' 124' ' ' MET . 5.5 mmt -107.33 129.95 23.54 Favored Pre-proline 0 C--N 1.307 -1.253 0 CA-C-N 115.424 -0.807 . . . . 0.0 110.658 -179.054 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . 0.461 ' HA ' ' HG2' ' A' ' 108' ' ' LYS . 74.5 Cg_endo -79.52 134.48 11.16 Favored 'Trans proline' 0 N--CA 1.452 -0.92 0 C-N-CA 122.244 1.963 . . . . 0.0 110.817 176.463 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 5.0 t -88.57 -177.51 5.6 Favored 'General case' 0 C--N 1.311 -1.095 0 C-N-CA 120.267 -0.573 . . . . 0.0 110.354 -179.075 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 4.9 m -63.41 147.61 50.77 Favored 'General case' 0 N--CA 1.441 -0.894 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.188 -179.838 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 2.1 mp -65.97 139.13 21.75 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.584 178.36 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 88.72 -12.21 66.26 Favored Glycine 0 N--CA 1.441 -1.018 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.556 -177.781 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 64.1 p -118.41 156.48 28.91 Favored 'General case' 0 N--CA 1.448 -0.547 0 CA-C-N 117.163 0.481 . . . . 0.0 110.847 178.73 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.448 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 62.1 pttt -133.28 152.16 51.92 Favored 'General case' 0 C--N 1.316 -0.886 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 20.8 t80 -86.1 136.16 33.33 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-O 121.004 0.431 . . . . 0.0 111.348 -179.062 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -101.48 134.64 20.13 Favored Pre-proline 0 C--N 1.325 -0.461 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.909 178.05 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -71.99 -33.06 10.26 Favored 'Trans proline' 0 CA--C 1.533 0.467 0 C-N-CA 122.65 2.233 . . . . 0.0 113.924 -177.258 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.7 mp -81.04 -55.12 8.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 111.697 0.258 . . . . 0.0 111.697 -177.737 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 49.9 m -72.84 -30.82 64.32 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.602 0.239 . . . . 0.0 111.073 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 68.54 50.32 0.7 Allowed 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.102 178.73 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 30.1 p-10 -151.96 176.43 11.49 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-N 115.262 -0.881 . . . . 0.0 108.954 178.855 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' CYS . . . . . 0.403 ' HA ' ' O ' ' A' ' 131' ' ' LYS . 85.5 m -102.36 126.18 49.3 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-O 121.037 0.446 . . . . 0.0 110.474 178.333 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.6 m -118.62 166.6 12.83 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.919 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.917 179.791 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -54.25 117.28 3.15 Favored 'General case' 0 CA--C 1.537 0.467 0 CA-C-O 121.003 0.43 . . . . 0.0 110.361 179.244 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' ASP . . . . . 0.448 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 18.9 t70 . . . . . 0 C--N 1.325 -0.483 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.449 -178.456 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . 0.505 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 4.8 p-10 . . . . . 0 N--CA 1.446 -0.645 0 CA-C-O 121.537 0.684 . . . . 0.0 111.255 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -98.19 127.55 44.19 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.068 -0.969 . . . . 0.0 108.45 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.469 ' CG2' HG22 ' A' ' 89' ' ' THR . 24.9 mt -90.5 145.09 7.84 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.958 0 CA-C-O 120.952 0.406 . . . . 0.0 111.247 -177.128 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 20.7 m -131.82 168.22 24.5 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.007 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 179.441 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 12.1 p80 -127.15 113.18 16.04 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-O 121.035 0.445 . . . . 0.0 111.601 -178.614 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.438 ' CD ' ' HZ3' ' A' ' 108' ' ' LYS . 64.1 mm-40 -119.95 102.42 8.54 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.663 -179.47 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 65.29 40.16 96.41 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.934 -0.651 . . . . 0.0 112.589 178.734 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 84.66 -8.66 68.03 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.976 179.777 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 34.7 mmtp -100.69 128.68 46.65 Favored 'General case' 0 CA--C 1.511 -0.526 0 CA-C-O 120.95 0.405 . . . . 0.0 110.91 -178.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.469 HG22 ' CG2' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -86.4 127.31 34.81 Favored 'General case' 0 C--N 1.307 -1.281 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.102 178.607 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 88.0 m-85 -121.51 148.96 43.78 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.048 178.782 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 25.1 m-70 -102.4 143.24 32.39 Favored 'General case' 0 C--N 1.307 -1.249 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.049 179.217 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.505 ' O ' ' HA ' ' A' ' 80' ' ' ASP . 99.1 t -118.76 126.29 75.13 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.379 179.534 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.4 p -143.21 131.59 19.59 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.959 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.6 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 64.7 m -128.62 131.25 48.09 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 120.838 0.351 . . . . 0.0 110.858 179.804 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 28.5 m80 -105.02 -11.07 16.8 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.117 0.484 . . . . 0.0 109.961 179.71 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 6.9 mp0 -127.35 143.36 51.23 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.206 179.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -78.46 109.99 13.12 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-O 120.917 0.389 . . . . 0.0 110.896 -179.565 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 167.94 168.35 29.94 Favored Glycine 0 N--CA 1.434 -1.434 0 N-CA-C 111.566 -0.614 . . . . 0.0 111.566 -179.645 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.434 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 83.1 Cg_endo -87.12 137.75 4.58 Favored 'Trans proline' 0 N--CA 1.451 -1.016 0 C-N-CA 122.841 2.361 . . . . 0.0 112.559 178.447 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.8 pp -139.01 157.64 71.09 Favored Pre-proline 0 C--N 1.317 -0.812 0 CA-C-N 115.987 -0.551 . . . . 0.0 109.586 178.36 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -63.16 168.65 10.52 Favored 'Trans proline' 0 C--N 1.35 0.609 0 C-N-CA 122.471 2.114 . . . . 0.0 112.856 -178.175 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' HIS . . . . . . . . . . . . . 3.6 t-80 -92.87 122.95 62.78 Favored Pre-proline 0 C--N 1.315 -0.899 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 -179.617 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -59.83 -21.8 65.47 Favored 'Trans proline' 0 N--CA 1.483 0.888 0 C-N-CA 122.99 2.46 . . . . 0.0 113.786 -176.361 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -95.93 -16.57 38.18 Favored Glycine 0 CA--C 1.519 0.283 0 C-N-CA 120.165 -1.017 . . . . 0.0 113.216 -178.798 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 3.0 p30 -168.24 101.86 0.44 Allowed 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 122.596 0.358 . . . . 0.0 110.904 -178.736 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . 0.451 ' CG1' ' HB2' ' A' ' 131' ' ' LYS . 6.0 t -53.23 -16.86 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.064 0 N-CA-C 113.596 0.962 . . . . 0.0 113.596 -179.584 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 8.5 m170 -72.88 5.48 3.22 Favored 'General case' 0 N--CA 1.479 0.999 0 O-C-N 121.936 -0.478 . . . . 0.0 111.39 177.732 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.438 ' HZ3' ' CD ' ' A' ' 85' ' ' GLU . 46.4 mtmt -139.74 158.93 43.29 Favored 'General case' 0 N--CA 1.44 -0.958 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 178.773 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 6.5 p90 -142.87 173.73 11.28 Favored 'General case' 0 C--N 1.302 -1.463 0 CA-C-O 120.866 0.365 . . . . 0.0 110.849 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.434 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 4.1 mt -130.6 138.55 53.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.936 -179.156 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -102.31 117.45 47.69 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 176.334 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 74.0 m -107.46 123.7 48.79 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-O 121.231 0.539 . . . . 0.0 110.709 -177.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 13.9 t -131.05 148.44 52.74 Favored 'General case' 0 C--N 1.311 -1.107 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.53 -178.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 34.1 tttm -116.87 112.1 20.6 Favored 'General case' 0 N--CA 1.435 -1.191 0 CA-C-O 121.28 0.562 . . . . 0.0 110.624 -178.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 8.5 t -94.44 100.49 12.49 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 179.598 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 64.29 -104.63 0.93 Allowed Glycine 0 N--CA 1.439 -1.101 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -175.852 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 31.3 m -114.11 9.51 17.24 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 116.674 0.237 . . . . 0.0 111.624 178.798 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 6.9 tt -121.54 135.79 54.99 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.809 0.337 . . . . 0.0 110.636 -176.725 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 84.2 m95 -93.74 133.27 37.28 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.141 0.496 . . . . 0.0 112.295 -177.615 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -117.65 127.31 53.82 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.65 -0.704 . . . . 0.0 109.161 174.38 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.5 pp -123.41 146.72 28.34 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.944 0 CA-C-O 121.1 0.476 . . . . 0.0 111.22 -178.596 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 18.6 m -136.83 122.85 20.25 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.765 179.231 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 2.7 p -94.99 111.31 25.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 121.344 0.593 . . . . 0.0 110.782 179.279 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.459 ' HA ' ' HE3' ' A' ' 124' ' ' MET . 5.3 mmt -112.25 151.23 43.54 Favored Pre-proline 0 C--N 1.314 -0.977 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.512 -178.844 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . 0.419 ' HA ' ' HG2' ' A' ' 108' ' ' LYS . 89.6 Cg_endo -89.18 143.84 4.82 Favored 'Trans proline' 0 N--CA 1.452 -0.913 0 C-N-CA 122.409 2.072 . . . . 0.0 112.414 177.9 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' CYS . . . . . 0.503 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 56.9 m -80.42 169.61 17.48 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.396 176.937 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 23.9 m -54.77 146.21 17.66 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.156 176.542 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . 0.469 HD11 ' N ' ' A' ' 128' ' ' ILE . 1.8 mp -61.86 123.57 14.83 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.146 0 CA-C-O 121.026 0.441 . . . . 0.0 110.598 -178.712 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.02 5.48 62.47 Favored Glycine 0 N--CA 1.445 -0.706 0 CA-C-N 115.731 -0.668 . . . . 0.0 113.048 -177.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 48.2 p -121.14 167.34 12.76 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 117.117 0.458 . . . . 0.0 111.265 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.504 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 61.4 pttt -138.56 145.56 40.79 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 178.755 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.54 ' HD1' ' SG ' ' A' ' 139' ' ' CYS . 33.3 t80 -85.32 132.75 34.2 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 121.018 0.437 . . . . 0.0 111.995 -176.86 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -99.83 130.9 25.45 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.729 177.681 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_endo -62.78 -42.68 24.02 Favored 'Trans proline' 0 C--N 1.346 0.445 0 C-N-CA 123.087 2.525 . . . . 0.0 113.993 -176.06 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 35.5 mm -81.04 -48.73 18.94 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 C-N-CA 120.879 -0.328 . . . . 0.0 111.567 -176.668 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.6 m -63.69 -34.06 77.03 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.704 0.288 . . . . 0.0 110.705 179.248 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 79.5 mtm180 68.66 42.53 1.45 Allowed 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.454 177.6 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 10.5 p30 -157.27 171.35 20.57 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.301 -0.863 . . . . 0.0 108.766 176.706 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' CYS . . . . . 0.54 ' SG ' ' HD1' ' A' ' 132' ' ' PHE . 8.9 m -101.36 125.45 48.0 Favored 'General case' 0 C--N 1.318 -0.79 0 C-N-CA 120.696 -0.402 . . . . 0.0 110.405 -178.286 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.6 m -110.06 163.41 7.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.657 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 32.0 tp -59.74 119.98 8.66 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.799 0.333 . . . . 0.0 111.111 -178.758 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' ASP . . . . . 0.504 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 18.9 t70 . . . . . 0 C--N 1.32 -0.71 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.407 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . 0.468 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 4.3 p-10 . . . . . 0 N--CA 1.452 -0.332 0 CA-C-O 121.54 0.686 . . . . 0.0 109.658 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -103.44 133.97 47.59 Favored 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 -179.62 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.569 ' CG2' HG23 ' A' ' 89' ' ' THR . 20.9 mt -94.66 140.65 16.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-O 121.076 0.465 . . . . 0.0 111.223 -177.63 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.44 HG22 ' NE2' ' A' ' 102' ' ' HIS . 28.2 m -129.68 160.84 40.27 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.122 -179.182 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 84.3 m-70 -116.72 102.59 9.56 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.312 -179.446 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 53.6 mm-40 -109.81 104.76 13.77 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.258 -179.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 60.2 40.64 97.55 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.797 -179.786 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 81.75 -14.21 32.2 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 121.193 -0.527 . . . . 0.0 113.076 -178.737 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 35.5 mmtp -90.2 126.85 35.96 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 117.062 0.431 . . . . 0.0 110.838 -178.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.569 HG23 ' CG2' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -83.49 121.95 27.88 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.985 178.742 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 78.9 m-85 -117.78 154.4 31.8 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 116.241 -0.436 . . . . 0.0 109.977 177.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 28.3 m-70 -106.2 141.1 38.12 Favored 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 176.891 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . 0.468 ' O ' ' HA ' ' A' ' 80' ' ' ASP . 55.1 t -115.86 120.66 65.45 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 178.494 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 57.2 t -124.44 131.21 73.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 -178.733 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 81.5 m -113.66 112.56 23.69 Favored 'General case' 0 C--N 1.313 -1.019 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 179.373 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 27.9 t60 -91.77 -17.06 25.94 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.086 -178.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -137.12 150.84 48.24 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.769 -178.63 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -75.23 141.19 43.58 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.39 179.015 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 125.37 172.09 13.38 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.528 -0.844 . . . . 0.0 112.522 -179.616 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -84.25 131.02 4.83 Favored 'Trans proline' 0 CA--C 1.537 0.666 0 C-N-CA 122.919 2.413 . . . . 0.0 112.857 178.757 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.9 pp -137.69 158.94 70.81 Favored Pre-proline 0 C--N 1.32 -0.68 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.395 178.367 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -64.66 168.96 12.19 Favored 'Trans proline' 0 C--N 1.351 0.686 0 C-N-CA 122.674 2.25 . . . . 0.0 112.821 -179.275 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' HIS . . . . . 0.472 ' HB3' ' O ' ' A' ' 105' ' ' ASN . 8.5 t-80 -92.21 129.93 39.63 Favored Pre-proline 0 C--N 1.318 -0.804 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 -178.71 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_endo -53.45 -44.09 51.97 Favored 'Trans proline' 0 C--N 1.356 0.967 0 C-N-CA 123.164 2.576 . . . . 0.0 113.42 -175.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -71.02 -62.31 3.61 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.235 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.472 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 2.7 p30 -122.91 107.59 12.02 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-O 120.819 0.342 . . . . 0.0 111.382 -179.542 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . 0.4 ' C ' ' H ' ' A' ' 108' ' ' LYS . 30.1 m -57.28 -10.18 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 113.064 0.765 . . . . 0.0 113.064 177.825 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 94.7 m-70 -74.13 3.74 6.63 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-O 121.505 0.669 . . . . 0.0 110.375 177.02 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.4 ' H ' ' C ' ' A' ' 106' ' ' VAL . 58.7 mttp -131.2 156.75 44.81 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 177.228 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 7.1 p90 -142.28 161.74 37.25 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 120.334 -0.546 . . . . 0.0 110.352 177.22 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.425 HD11 ' HA ' ' A' ' 102' ' ' HIS . 2.9 mp -123.47 141.31 44.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 -178.624 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.6 mp -97.45 112.48 29.6 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 175.371 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 42.0 m -97.93 122.04 40.58 Favored 'General case' 0 C--N 1.311 -1.081 0 CA-C-O 120.989 0.423 . . . . 0.0 110.675 -177.455 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 27.6 t -126.35 137.34 53.45 Favored 'General case' 0 N--CA 1.437 -1.116 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 178.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -108.49 122.15 46.44 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-O 120.817 0.342 . . . . 0.0 110.423 -179.143 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 43.1 m -116.42 105.82 12.93 Favored 'General case' 0 N--CA 1.434 -1.274 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.173 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 59.89 -110.9 3.12 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.343 -175.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 20.8 m -113.2 16.27 19.18 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.095 0.474 . . . . 0.0 110.144 179.143 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 6.0 mp -124.51 141.79 51.82 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.474 -177.168 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 47.3 m95 -107.18 138.02 44.15 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-O 121.329 0.585 . . . . 0.0 111.61 179.513 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 78.7 m-85 -121.31 121.94 38.78 Favored 'General case' 0 C--N 1.309 -1.184 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.608 176.597 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.406 ' HB ' ' CG2' ' A' ' 110' ' ' ILE . 2.4 pp -123.28 159.25 27.75 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.755 -176.439 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 37.3 m -146.25 120.99 9.86 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.848 177.443 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 5.1 p -93.46 110.44 23.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 121.601 0.715 . . . . 0.0 111.22 -178.299 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.453 ' HA ' ' HE3' ' A' ' 124' ' ' MET . 3.6 mmt -108.71 125.18 32.31 Favored Pre-proline 0 C--N 1.307 -1.248 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.111 -179.915 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -75.14 135.43 18.83 Favored 'Trans proline' 0 N--CA 1.456 -0.726 0 C-N-CA 122.149 1.9 . . . . 0.0 111.288 178.419 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 6.2 t -90.71 -173.52 3.76 Favored 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 -179.573 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 46.8 m -64.69 137.66 57.94 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 120.928 0.395 . . . . 0.0 111.004 179.665 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 2.0 mp -60.5 134.56 25.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.819 178.609 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.2 -17.72 58.31 Favored Glycine 0 N--CA 1.444 -0.772 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.918 -177.007 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 77.0 p -109.72 158.18 18.36 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 117.456 0.628 . . . . 0.0 110.541 178.833 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 59.2 pttt -130.19 144.8 51.57 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.089 -179.041 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 39.9 t80 -83.71 134.52 34.75 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.849 -179.218 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -99.16 130.52 27.08 Favored Pre-proline 0 C--N 1.321 -0.647 0 CA-C-N 116.243 -0.435 . . . . 0.0 109.939 178.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -65.49 -43.98 9.5 Favored 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.792 2.328 . . . . 0.0 113.607 -176.579 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.8 mp -76.5 -50.48 21.77 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 116.632 -0.258 . . . . 0.0 111.605 -177.18 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.1 m -68.65 -33.2 73.59 Favored 'General case' 0 C--O 1.239 0.52 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.025 -179.022 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 89.3 mtm180 70.33 43.22 0.84 Allowed 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.067 177.771 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 26.0 p-10 -152.5 176.27 11.87 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 179.267 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 95.8 m -102.41 126.51 49.46 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 121.179 0.514 . . . . 0.0 111.315 179.411 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 27.0 m -114.88 159.94 14.5 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 CA-C-N 115.698 -0.683 . . . . 0.0 109.22 177.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 55.8 tp -63.65 135.5 56.8 Favored 'General case' 0 C--N 1.312 -1.045 0 CA-C-O 121.054 0.454 . . . . 0.0 111.364 -179.637 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 30.3 t70 . . . . . 0 CA--C 1.507 -0.688 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 177.709 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 31.8 t70 . . . . . 0 CA--C 1.515 -0.378 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.491 ' HG ' ' CD1' ' A' ' 121' ' ' ILE . 3.1 tm? -101.93 130.33 48.42 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 -179.676 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.545 ' CG2' HG23 ' A' ' 89' ' ' THR . 23.3 mt -94.29 144.04 10.46 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 CA-C-O 120.742 0.306 . . . . 0.0 110.435 -178.439 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 29.8 m -134.78 165.63 30.7 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.9 0 CA-C-N 116.212 -0.449 . . . . 0.0 109.952 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 85.3 m-70 -114.93 121.82 44.38 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 179.452 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 3.8 tp10 -145.62 115.45 7.33 Favored 'General case' 0 C--N 1.318 -0.765 0 C-N-CA 120.693 -0.403 . . . . 0.0 111.008 -178.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 62.16 29.74 73.75 Favored Glycine 0 CA--C 1.518 0.274 0 CA-C-N 116.129 -0.487 . . . . 0.0 113.359 177.593 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 89.51 -5.94 83.52 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.351 179.087 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . 0.48 ' HB2' ' CE1' ' A' ' 90' ' ' TYR . 68.4 mmtt -102.16 153.07 20.29 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-O 120.593 0.235 . . . . 0.0 110.685 179.878 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.545 HG23 ' CG2' ' A' ' 82' ' ' ILE . 0.2 OUTLIER -106.82 106.75 17.42 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 177.024 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.48 ' CE1' ' HB2' ' A' ' 88' ' ' LYS . 96.1 m-85 -98.19 145.84 26.21 Favored 'General case' 0 C--N 1.313 -1.022 0 CA-C-O 120.983 0.421 . . . . 0.0 111.183 -177.035 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 31.1 m-70 -101.72 134.66 44.53 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 177.068 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 46.7 t -113.25 118.47 58.16 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 179.141 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 91.4 t -119.27 131.71 71.19 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.518 -179.045 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 73.8 m -114.76 113.18 23.92 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-O 120.994 0.426 . . . . 0.0 109.956 -179.579 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 67.9 t60 -93.2 -17.46 23.68 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.819 -178.758 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -145.24 158.58 43.79 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.887 -178.034 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -74.24 129.92 38.73 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.48 179.378 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 137.07 158.81 8.07 Favored Glycine 0 N--CA 1.44 -1.05 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.192 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.441 ' HD2' ' HD2' ' A' ' 137' ' ' ARG . 77.3 Cg_endo -78.02 140.1 17.75 Favored 'Trans proline' 0 CA--C 1.537 0.649 0 C-N-CA 122.791 2.327 . . . . 0.0 112.987 178.751 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.8 pp -138.02 157.7 72.56 Favored Pre-proline 0 C--N 1.32 -0.687 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.701 177.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -62.22 164.75 16.5 Favored 'Trans proline' 0 C--N 1.35 0.633 0 C-N-CA 122.4 2.067 . . . . 0.0 113.107 -178.409 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' HIS . . . . . . . . . . . . . 42.0 t-80 -89.66 120.1 69.51 Favored Pre-proline 0 C--N 1.319 -0.721 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.479 -179.087 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 14.1 Cg_endo -56.62 -21.97 41.43 Favored 'Trans proline' 0 N--CA 1.482 0.847 0 C-N-CA 123.08 2.52 . . . . 0.0 113.376 -176.816 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -89.33 -20.57 44.71 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.36 -0.924 . . . . 0.0 113.308 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 16.7 p30 -169.15 109.85 0.47 Allowed 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 122.69 0.396 . . . . 0.0 110.361 -179.134 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 34.8 m -57.17 -11.37 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.076 0 N-CA-C 113.833 1.049 . . . . 0.0 113.833 -179.629 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 42.5 m170 -76.29 3.71 10.32 Favored 'General case' 0 N--CA 1.475 0.786 0 CA-C-O 121.145 0.498 . . . . 0.0 111.266 177.556 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.416 ' HG2' ' HA ' ' A' ' 125' ' ' PRO . 42.2 mtmt -138.87 161.03 38.3 Favored 'General case' 0 CA--C 1.506 -0.72 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 178.634 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 9.3 p90 -143.83 172.31 13.02 Favored 'General case' 0 C--N 1.313 -0.988 0 C-N-CA 120.647 -0.421 . . . . 0.0 111.246 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.433 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.9 mp -129.3 140.64 48.64 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.965 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 178.652 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -96.44 122.08 47.59 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 176.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 57.9 m -106.0 125.23 50.75 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-O 120.679 0.276 . . . . 0.0 110.279 -178.405 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 19.8 m -130.83 139.7 50.2 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.253 179.044 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -112.12 104.37 12.6 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-O 120.994 0.426 . . . . 0.0 110.041 179.482 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 14.2 t -91.79 88.8 6.8 Favored 'General case' 0 C--N 1.309 -1.185 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 179.508 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 70.37 -100.79 0.83 Allowed Glycine 0 N--CA 1.443 -0.85 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 -177.581 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 50.6 m -114.58 5.62 15.52 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.895 0.379 . . . . 0.0 110.735 178.357 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 21.4 tp -116.68 129.53 56.19 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.622 -176.32 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 83.1 m95 -92.97 132.04 37.42 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -178.832 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 51.2 m-85 -113.06 137.27 51.67 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 115.457 -0.792 . . . . 0.0 109.422 175.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.517 ' O ' HD12 ' A' ' 121' ' ' ILE . 2.1 pp -134.28 152.27 33.64 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.998 0 N-CA-C 112.364 0.505 . . . . 0.0 112.364 -176.576 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 25.7 m -151.35 122.14 7.53 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.293 176.909 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.8 p -95.07 112.91 28.37 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 CA-C-O 121.348 0.594 . . . . 0.0 111.305 -179.13 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.465 ' HE1' ' HA ' ' A' ' 124' ' ' MET . 4.5 mmt -112.1 139.8 22.81 Favored Pre-proline 0 C--N 1.316 -0.867 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.621 -179.165 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . 0.416 ' HA ' ' HG2' ' A' ' 108' ' ' LYS . 91.6 Cg_endo -83.85 140.56 9.16 Favored 'Trans proline' 0 N--CA 1.452 -0.958 0 C-N-CA 122.408 2.072 . . . . 0.0 111.551 177.168 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 7.1 t -94.36 -179.19 4.83 Favored 'General case' 0 C--N 1.319 -0.75 0 C-N-CA 120.381 -0.527 . . . . 0.0 109.828 177.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 10.4 t -68.33 140.22 55.91 Favored 'General case' 0 N--CA 1.436 -1.129 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.238 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 2.1 mp -61.56 141.78 17.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 178.393 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.22 -19.85 51.07 Favored Glycine 0 N--CA 1.438 -1.229 0 C-N-CA 120.592 -0.813 . . . . 0.0 112.499 -176.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 68.8 p -114.76 154.72 28.02 Favored 'General case' 0 N--CA 1.448 -0.528 0 CA-C-N 117.261 0.53 . . . . 0.0 111.104 179.655 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 59.8 pttt -126.63 145.03 50.71 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.959 179.369 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -83.94 132.74 34.74 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-O 120.874 0.369 . . . . 0.0 110.963 -178.486 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -94.57 133.59 26.63 Favored Pre-proline 0 C--N 1.323 -0.576 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.418 179.576 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -67.77 -41.33 8.25 Favored 'Trans proline' 0 CA--C 1.535 0.57 0 C-N-CA 122.919 2.413 . . . . 0.0 114.512 -177.541 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.8 mp -82.5 -51.81 14.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 N-CA-C 111.82 0.304 . . . . 0.0 111.82 -177.029 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 4.2 m -69.24 -35.7 76.41 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.139 0.495 . . . . 0.0 110.194 -179.232 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' ARG . . . . . 0.441 ' HD2' ' HD2' ' A' ' 99' ' ' PRO . 56.1 mtm180 66.81 62.87 0.5 Allowed 'General case' 0 N--CA 1.452 -0.341 0 CA-C-N 115.274 -0.875 . . . . 0.0 111.528 178.458 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -165.42 173.16 11.37 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 114.559 -1.2 . . . . 0.0 108.118 176.717 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 88.9 m -100.49 126.5 46.92 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-O 121.083 0.468 . . . . 0.0 111.118 -179.177 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.8 m -113.13 158.3 13.54 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.804 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.279 178.341 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -61.31 117.38 5.56 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.796 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 35.3 t0 . . . . . 0 C--N 1.323 -0.569 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.473 -178.641 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 . . . . . 0 N--CA 1.452 -0.374 0 CA-C-O 121.44 0.638 . . . . 0.0 110.78 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.5 tm? -100.23 134.57 42.97 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.488 ' CG2' HG23 ' A' ' 89' ' ' THR . 20.8 mt -95.51 142.63 13.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-O 120.937 0.399 . . . . 0.0 110.897 -177.215 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.458 HG22 ' NE2' ' A' ' 102' ' ' HIS . 31.2 m -130.39 154.2 40.17 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.964 -179.358 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 42.6 m-70 -114.57 101.49 9.15 Favored 'General case' 0 C--N 1.311 -1.1 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.115 -178.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.455 ' HB2' ' CE1' ' A' ' 90' ' ' TYR . 50.2 mm-40 -105.86 110.42 22.7 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.052 178.119 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 64.73 30.54 78.21 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 121.148 -0.549 . . . . 0.0 111.951 -179.235 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 86.05 -9.3 69.92 Favored Glycine 0 N--CA 1.444 -0.771 0 C-N-CA 120.928 -0.654 . . . . 0.0 112.385 -179.299 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 1.3 mptm? -91.74 140.52 29.62 Favored 'General case' 0 CA--C 1.507 -0.698 0 CA-C-O 120.911 0.386 . . . . 0.0 110.463 -179.731 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.488 HG23 ' CG2' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -91.21 129.8 37.16 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.767 179.165 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.455 ' CE1' ' HB2' ' A' ' 85' ' ' GLU . 88.1 m-85 -127.3 148.28 50.23 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 177.887 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 40.1 m-70 -103.89 138.3 40.67 Favored 'General case' 0 C--N 1.305 -1.343 0 N-CA-C 110.059 -0.348 . . . . 0.0 110.059 178.473 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 58.3 t -111.23 122.75 66.24 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.217 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 178.446 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 38.3 t -126.04 132.18 70.89 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 -179.057 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 88.8 m -102.0 126.5 48.94 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.019 0.438 . . . . 0.0 111.033 -179.155 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 77.9 m-70 -90.12 -30.51 17.62 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.573 -179.083 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -151.88 172.95 15.4 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-N 115.747 -0.66 . . . . 0.0 109.886 -177.384 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 5.3 mp0 -74.81 137.13 41.7 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.138 178.143 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 124.57 158.83 10.19 Favored Glycine 0 N--CA 1.443 -0.889 0 C-N-CA 120.681 -0.771 . . . . 0.0 111.973 -179.597 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.434 ' HA ' ' HA ' ' A' ' 111' ' ' ILE . 78.1 Cg_endo -77.32 139.56 18.75 Favored 'Trans proline' 0 N--CA 1.46 -0.482 0 C-N-CA 122.613 2.209 . . . . 0.0 113.259 179.13 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.8 pp -137.36 158.13 72.82 Favored Pre-proline 0 C--N 1.319 -0.723 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.64 178.107 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -64.24 169.39 10.89 Favored 'Trans proline' 0 C--N 1.351 0.692 0 C-N-CA 122.593 2.195 . . . . 0.0 113.207 -177.784 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' HIS . . . . . 0.458 ' NE2' HG22 ' A' ' 83' ' ' VAL . 2.3 t-80 -88.73 128.49 52.3 Favored Pre-proline 0 C--N 1.317 -0.827 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 -179.613 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_endo -53.28 -42.5 64.74 Favored 'Trans proline' 0 C--N 1.351 0.699 0 C-N-CA 122.994 2.463 . . . . 0.0 113.032 -177.141 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -74.62 -61.74 3.05 Favored Glycine 0 C--N 1.316 -0.565 0 C-N-CA 120.713 -0.756 . . . . 0.0 113.002 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' ASN . . . . . 0.415 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 6.1 p-10 -125.03 107.95 11.33 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-O 120.973 0.416 . . . . 0.0 111.97 -176.757 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 8.5 p -56.65 -11.97 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.12 0 N-CA-C 113.607 0.965 . . . . 0.0 113.607 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 51.6 m170 -70.42 -4.19 21.31 Favored 'General case' 0 N--CA 1.474 0.748 0 CA-C-O 121.135 0.493 . . . . 0.0 111.055 178.502 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 39.8 mtmt -135.2 159.91 40.04 Favored 'General case' 0 N--CA 1.44 -0.972 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 177.692 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 14.6 p90 -142.8 173.57 11.43 Favored 'General case' 0 C--N 1.307 -1.281 0 CA-C-N 116.577 -0.283 . . . . 0.0 110.78 -178.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.429 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 2.3 mp -130.19 140.33 49.17 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.166 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 178.753 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.434 ' HA ' ' HA ' ' A' ' 99' ' ' PRO . 4.9 mp -97.47 118.47 44.0 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 177.299 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 62.8 m -97.17 121.71 39.37 Favored 'General case' 0 N--CA 1.437 -1.102 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 17.3 m -124.11 136.85 54.51 Favored 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.706 -179.531 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 23.0 ttmt -112.02 109.41 19.14 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-O 121.157 0.504 . . . . 0.0 111.143 -179.488 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 15.8 t -92.28 88.89 6.62 Favored 'General case' 0 N--CA 1.43 -1.432 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 176.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 72.1 -99.87 0.9 Allowed Glycine 0 N--CA 1.437 -1.294 0 N-CA-C 110.705 -0.958 . . . . 0.0 110.705 -176.416 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 24.3 p -116.41 6.24 13.6 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-O 120.893 0.378 . . . . 0.0 111.298 177.824 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 53.6 tp -113.04 135.88 53.3 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.818 0.342 . . . . 0.0 111.255 -175.644 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 96.4 m95 -89.62 131.85 35.41 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 121.336 0.588 . . . . 0.0 112.466 -179.707 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 73.5 m-85 -119.34 124.19 46.02 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 170.423 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.0 pp -124.45 146.87 29.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 120.502 -0.479 . . . . 0.0 111.689 -176.828 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 20.2 m -137.06 122.63 19.69 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.375 178.81 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 4.0 p -93.39 113.72 28.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 121.346 0.593 . . . . 0.0 111.211 -179.385 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.424 ' HA ' ' HE3' ' A' ' 124' ' ' MET . 3.6 mmt -117.23 151.44 47.82 Favored Pre-proline 0 C--N 1.322 -0.628 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.805 -179.088 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 90.7 Cg_endo -92.25 151.36 3.1 Favored 'Trans proline' 0 N--CA 1.448 -1.156 0 C-N-CA 122.399 2.066 . . . . 0.0 112.441 177.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 56.2 m -84.99 167.92 15.42 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 174.515 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 10.9 p -59.89 144.23 49.35 Favored 'General case' 0 N--CA 1.439 -0.996 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 176.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' ILE . . . . . 0.44 ' N ' HD13 ' A' ' 128' ' ' ILE . 2.0 mp -60.74 122.51 11.38 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 CA-C-O 121.175 0.512 . . . . 0.0 110.327 -178.186 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 103.26 1.91 47.86 Favored Glycine 0 N--CA 1.437 -1.248 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.995 -176.397 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 80.7 p -126.77 160.08 31.89 Favored 'General case' 0 CA--C 1.539 0.533 0 CA-C-N 117.456 0.628 . . . . 0.0 111.634 179.773 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 55.0 pttt -125.87 145.54 50.2 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.384 179.633 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.463 ' HD1' ' SG ' ' A' ' 139' ' ' CYS . 29.1 t80 -85.64 137.53 32.77 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-O 121.01 0.434 . . . . 0.0 111.556 -179.23 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -103.48 132.18 21.33 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.181 179.246 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -69.5 -45.06 1.89 Allowed 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 123.11 2.54 . . . . 0.0 114.393 -177.222 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 34.9 mm -74.7 -46.62 41.31 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 N-CA-C 112.035 0.383 . . . . 0.0 112.035 -176.326 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 39.5 t -75.63 -31.79 59.99 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-O 120.861 0.362 . . . . 0.0 110.146 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' ARG . . . . . 0.401 ' HB3' ' HG2' ' A' ' 99' ' ' PRO . 66.0 mtm180 66.42 62.02 0.56 Allowed 'General case' 0 N--CA 1.463 0.223 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.354 178.59 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' ASN . . . . . 0.438 ' N ' HD21 ' A' ' 138' ' ' ASN . 0.1 OUTLIER -165.31 172.45 12.31 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.175 -0.92 . . . . 0.0 109.082 179.603 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' CYS . . . . . 0.463 ' SG ' ' HD1' ' A' ' 132' ' ' PHE . 38.6 m -101.05 124.58 46.99 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 178.862 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 36.0 m -113.96 164.38 10.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.807 0 CA-C-N 115.883 -0.598 . . . . 0.0 109.759 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 34.2 tp -58.46 123.86 17.63 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-O 121.024 0.44 . . . . 0.0 111.75 -178.324 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 18.0 t70 . . . . . 0 C--N 1.321 -0.668 0 CA-C-N 115.879 -0.6 . . . . 0.0 109.642 178.104 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.384 0 N-CA-C 112.123 -0.391 . . . . 0.0 112.123 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -87.36 28.7 0.51 Allowed 'Trans proline' 0 CA--C 1.533 0.441 0 C-N-CA 123.036 2.49 . . . . 0.0 112.848 -177.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 7.6 tt -71.18 113.75 8.53 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.734 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -130.3 9.46 5.92 Favored Glycine 0 N--CA 1.441 -1.015 0 C-N-CA 120.86 -0.686 . . . . 0.0 111.915 -179.293 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.434 ' O ' HG23 ' A' ' 93' ' ' VAL . 57.6 p -60.23 -52.73 64.04 Favored 'General case' 0 N--CA 1.446 -0.634 0 CA-C-O 120.601 0.239 . . . . 0.0 110.812 179.098 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.579 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 8.2 p-10 -158.03 127.62 5.91 Favored 'General case' 0 N--CA 1.448 -0.53 0 CA-C-O 121.362 0.601 . . . . 0.0 111.571 -177.793 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 48.8 tp -102.79 145.47 29.7 Favored 'General case' 0 C--N 1.308 -1.236 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.148 176.472 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.456 ' CG2' HG23 ' A' ' 89' ' ' THR . 14.0 mt -97.54 143.96 11.75 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.111 0 C-N-CA 120.599 -0.44 . . . . 0.0 111.083 -178.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 30.7 m -135.75 174.37 12.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.828 -179.285 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' HIS . . . . . 0.417 ' CE1' HG22 ' A' ' 89' ' ' THR . 45.9 m-70 -122.89 115.88 22.69 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 120.967 0.413 . . . . 0.0 111.704 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 59.6 mm-40 -109.12 104.19 13.32 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.209 176.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 59.98 45.33 96.08 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.321 -0.942 . . . . 0.0 111.713 -178.755 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 85.4 -31.7 3.77 Favored Glycine 0 CA--C 1.524 0.619 0 C-N-CA 121.036 -0.602 . . . . 0.0 113.593 -179.143 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 14.2 mptt -82.07 141.77 32.88 Favored 'General case' 0 CA--C 1.51 -0.59 0 CA-C-N 117.373 0.587 . . . . 0.0 111.555 -176.126 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.456 HG23 ' CG2' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -84.63 134.19 34.39 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.908 179.856 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 63.9 m-85 -132.22 154.29 49.75 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.761 176.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 19.2 m-70 -102.42 144.8 30.42 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-O 120.823 0.344 . . . . 0.0 110.57 179.469 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.579 ' O ' ' HA ' ' A' ' 80' ' ' ASP . 93.7 t -120.06 117.87 55.03 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.19 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 177.547 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.434 HG23 ' O ' ' A' ' 79' ' ' SER . 3.3 p -124.6 138.8 52.81 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 CA-C-N 116.112 -0.495 . . . . 0.0 109.93 -178.52 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 92.3 m -110.94 123.92 51.1 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 120.895 0.379 . . . . 0.0 110.946 179.514 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 52.1 m80 -102.15 -22.35 14.22 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.376 -179.766 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -141.03 152.47 44.89 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.478 -178.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -76.23 106.35 7.79 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.659 -0.701 . . . . 0.0 110.508 177.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 156.24 169.51 20.46 Favored Glycine 0 N--CA 1.434 -1.474 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 -179.581 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_endo -78.53 132.91 11.35 Favored 'Trans proline' 0 N--CA 1.456 -0.691 0 C-N-CA 122.406 2.071 . . . . 0.0 112.394 178.62 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 2.0 pp -137.12 157.82 73.75 Favored Pre-proline 0 C--N 1.319 -0.726 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.517 178.21 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -69.51 171.86 13.43 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.271 1.981 . . . . 0.0 112.492 -178.29 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' HIS . . . . . 0.572 ' HB3' ' O ' ' A' ' 105' ' ' ASN . 30.3 t-80 -89.85 128.1 51.48 Favored Pre-proline 0 C--N 1.309 -1.177 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 179.727 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -50.52 -54.91 4.67 Favored 'Trans proline' 0 N--CA 1.477 0.524 0 C-N-CA 122.932 2.421 . . . . 0.0 112.604 -176.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -63.17 -62.2 5.65 Favored Glycine 0 CA--C 1.526 0.776 0 CA-C-N 115.813 -0.63 . . . . 0.0 113.15 178.237 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.572 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 9.9 p-10 -122.8 103.22 8.5 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 -177.004 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 31.1 m -58.29 -10.67 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.089 0 N-CA-C 114.0 1.111 . . . . 0.0 114.0 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 14.0 t-80 -66.27 -10.39 41.93 Favored 'General case' 0 N--CA 1.47 0.56 0 CA-C-O 121.451 0.643 . . . . 0.0 110.299 176.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.403 ' HG2' ' HA ' ' A' ' 125' ' ' PRO . 44.7 mtmt -126.55 158.69 35.53 Favored 'General case' 0 N--CA 1.434 -1.237 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 178.196 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 7.7 p90 -141.72 165.49 27.34 Favored 'General case' 0 C--N 1.302 -1.492 0 C-N-CA 120.642 -0.423 . . . . 0.0 110.517 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 3.9 mp -123.32 139.81 48.84 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 -179.062 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.406 ' N ' HD11 ' A' ' 111' ' ' ILE . 4.3 mp -99.98 118.09 46.12 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.179 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 177.502 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 23.5 m -101.78 122.72 44.48 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.222 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 49.1 m -131.7 146.73 52.33 Favored 'General case' 0 C--N 1.312 -1.064 0 CA-C-O 121.074 0.464 . . . . 0.0 111.44 -177.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.4 ' HD2' ' O ' ' A' ' 116' ' ' GLY . 5.0 tppp? -97.28 139.6 33.0 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.527 179.312 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 68.2 m -128.71 85.78 2.37 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 174.474 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.4 ' O ' ' HD2' ' A' ' 114' ' ' LYS . . . 72.68 -104.53 1.55 Allowed Glycine 0 N--CA 1.437 -1.296 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 -174.55 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 50.6 m -115.07 11.81 16.5 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-O 120.779 0.323 . . . . 0.0 110.885 175.17 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 34.0 tp -111.36 143.39 42.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.672 -0.24 . . . . 0.0 110.627 -177.367 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 54.0 m95 -100.23 133.14 45.08 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.034 0.445 . . . . 0.0 112.128 179.198 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -119.53 132.35 55.74 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.647 -0.706 . . . . 0.0 109.463 174.044 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 1.9 pp -123.72 149.89 27.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-O 120.78 0.324 . . . . 0.0 111.074 -179.1 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 28.4 m -146.06 122.93 11.3 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.152 178.312 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.6 p -95.93 111.13 25.65 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.417 0 CA-C-O 121.363 0.601 . . . . 0.0 111.34 -178.333 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.434 ' HA ' ' HE2' ' A' ' 124' ' ' MET . 5.5 mmt -114.36 142.59 28.33 Favored Pre-proline 0 C--N 1.318 -0.762 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.525 -179.314 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . 0.403 ' HA ' ' HG2' ' A' ' 108' ' ' LYS . 97.3 Cg_endo -86.5 143.11 7.32 Favored 'Trans proline' 0 N--CA 1.449 -1.092 0 C-N-CA 122.378 2.052 . . . . 0.0 111.641 176.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 4.9 t -92.98 -179.6 5.16 Favored 'General case' 0 C--N 1.319 -0.756 0 C-N-CA 120.541 -0.463 . . . . 0.0 109.91 178.228 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 34.3 m -65.32 144.53 57.06 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-O 120.881 0.372 . . . . 0.0 110.579 -178.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . 0.415 ' N ' HD12 ' A' ' 128' ' ' ILE . 2.8 mp -68.04 132.33 32.75 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.786 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 103.68 -18.45 47.28 Favored Glycine 0 N--CA 1.439 -1.11 0 CA-C-N 115.797 -0.638 . . . . 0.0 112.019 -176.141 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 40.3 p -116.76 158.53 23.73 Favored 'General case' 0 N--CA 1.445 -0.713 0 O-C-N 122.67 -0.312 . . . . 0.0 110.854 179.02 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 49.9 pttt -132.17 148.64 52.48 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 116.146 -0.479 . . . . 0.0 109.863 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 23.4 t80 -86.4 139.67 30.72 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-O 121.015 0.436 . . . . 0.0 111.691 -177.319 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -107.6 136.58 19.62 Favored Pre-proline 0 N--CA 1.469 0.502 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.784 177.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -68.11 -44.7 3.51 Favored 'Trans proline' 0 C--N 1.347 0.468 0 C-N-CA 122.948 2.432 . . . . 0.0 114.285 -176.464 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 39.5 mm -78.55 -46.34 24.99 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 CA-C-O 120.823 0.344 . . . . 0.0 111.715 -176.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.7 m -69.06 -34.89 75.9 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 120.909 0.385 . . . . 0.0 110.199 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 81.8 mtt-85 69.01 41.34 1.45 Allowed 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.144 177.479 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -152.54 176.28 11.87 Favored 'General case' 0 C--N 1.316 -0.863 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 178.49 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 87.8 m -100.93 126.82 47.58 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 120.888 0.375 . . . . 0.0 110.538 -179.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.2 m -109.41 157.78 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.018 0 CA-C-N 115.811 -0.632 . . . . 0.0 109.824 179.584 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 58.5 tp -69.55 115.58 8.97 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-O 120.94 0.4 . . . . 0.0 111.138 -179.374 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -73.57 101.57 3.62 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.619 177.215 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 27.3 t-20 . . . . . 0 C--N 1.307 -1.262 0 CA-C-O 118.195 -0.907 . . . . 0.0 109.099 -177.28 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.413 0 N-CA-C 111.694 -0.562 . . . . 0.0 111.694 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_exo -65.62 99.83 0.39 Allowed 'Trans proline' 0 C--O 1.241 0.668 0 C-N-CA 122.646 2.231 . . . . 0.0 111.271 179.308 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 85.7 mt -83.27 167.79 17.31 Favored 'General case' 0 C--N 1.314 -0.935 0 CA-C-N 115.72 -0.673 . . . . 0.0 111.199 -177.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -150.84 -31.1 0.05 OUTLIER Glycine 0 C--N 1.314 -0.681 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.856 -179.469 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 5.0 m -74.6 -35.45 62.97 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 110.168 -0.308 . . . . 0.0 110.168 178.744 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -160.14 104.8 1.5 Allowed 'General case' 0 CA--C 1.52 -0.199 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.215 -179.059 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.411 ' CD2' HD11 ' A' ' 121' ' ' ILE . 39.4 tp -117.53 132.63 56.5 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.13 176.254 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 10.4 mt -98.73 144.41 11.72 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.09 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 178.734 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 19.1 m -136.88 162.86 33.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-O 120.765 0.317 . . . . 0.0 110.296 -177.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 12.7 m-70 -94.34 115.32 27.52 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.334 178.229 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -128.8 106.65 9.07 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 -178.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 67.18 29.89 74.96 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 110.794 -0.923 . . . . 0.0 110.794 -177.092 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 85.29 -22.95 8.94 Favored Glycine 0 N--CA 1.443 -0.892 0 CA-C-N 115.318 -0.441 . . . . 0.0 112.672 -178.357 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 75.1 mmtt -91.85 146.59 23.63 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.843 0.354 . . . . 0.0 111.14 -177.69 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -82.22 125.98 31.56 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.601 179.602 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -124.48 143.36 50.69 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 176.823 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 22.0 m-70 -90.05 146.6 24.21 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-O 121.097 0.475 . . . . 0.0 111.465 -178.553 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 49.5 t -120.44 119.0 58.52 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 175.562 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 58.0 t -130.4 135.64 60.2 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.256 0 CA-C-N 116.141 -0.481 . . . . 0.0 109.972 -177.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 91.5 m -119.11 113.3 20.7 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.03 0.443 . . . . 0.0 110.645 178.68 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 43.0 t-80 -91.89 -22.07 20.27 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.223 179.823 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 -146.58 157.82 43.79 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.769 -176.755 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -79.18 145.66 33.54 Favored 'General case' 0 C--N 1.312 -1.032 0 CA-C-O 120.955 0.407 . . . . 0.0 110.962 -177.222 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 125.39 163.65 11.66 Favored Glycine 0 N--CA 1.437 -1.261 0 C-N-CA 120.976 -0.63 . . . . 0.0 111.926 -178.441 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.403 ' HD2' ' HD3' ' A' ' 137' ' ' ARG . 84.4 Cg_endo -84.4 135.19 6.03 Favored 'Trans proline' 0 CA--C 1.538 0.7 0 C-N-CA 122.721 2.28 . . . . 0.0 112.997 179.168 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -142.28 154.96 64.76 Favored Pre-proline 0 C--O 1.216 -0.707 0 CA-C-N 115.76 -0.654 . . . . 0.0 109.724 177.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -67.85 169.29 16.53 Favored 'Trans proline' 0 C--N 1.348 0.54 0 C-N-CA 122.349 2.033 . . . . 0.0 112.365 -178.537 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' HIS . . . . . . . . . . . . . 12.1 t-80 -85.54 135.5 38.37 Favored Pre-proline 0 C--N 1.319 -0.719 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -178.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -57.8 -25.33 68.34 Favored 'Trans proline' 0 C--N 1.353 0.779 0 C-N-CA 122.93 2.42 . . . . 0.0 112.028 -179.368 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -84.35 -65.86 1.5 Allowed Glycine 0 N--CA 1.441 -0.971 0 CA-C-N 115.522 -0.763 . . . . 0.0 111.765 178.212 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.412 ' OD1' ' HE2' ' A' ' 108' ' ' LYS . 36.8 p-10 -124.37 114.02 18.97 Favored 'General case' 0 CA--C 1.543 0.693 0 CA-C-O 121.364 0.602 . . . . 0.0 111.878 -179.616 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 15.9 m -58.76 -10.63 1.58 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 N-CA-C 112.854 0.687 . . . . 0.0 112.854 177.284 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 35.5 m80 -68.22 -7.17 28.1 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 121.06 0.457 . . . . 0.0 110.362 176.44 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.481 ' HG2' ' HA ' ' A' ' 125' ' ' PRO . 47.4 mtmt -131.5 157.07 44.51 Favored 'General case' 0 CA--C 1.5 -0.953 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.465 179.045 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 8.5 p90 -142.15 161.73 37.26 Favored 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 120.773 -0.371 . . . . 0.0 110.71 179.436 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 3.2 mp -119.78 137.22 54.37 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 -179.505 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -96.71 116.85 39.91 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.359 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 175.551 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 56.2 m -95.77 122.13 38.23 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 109.333 -0.618 . . . . 0.0 109.333 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 49.6 m -122.56 127.56 49.61 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.314 -179.733 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 85.4 tttt -100.29 116.22 31.77 Favored 'General case' 0 N--CA 1.432 -1.366 0 CA-C-O 121.118 0.485 . . . . 0.0 109.926 178.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 53.7 m -106.18 83.57 1.91 Allowed 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.581 179.149 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 67.77 -100.24 0.6 Allowed Glycine 0 N--CA 1.44 -1.082 0 CA-C-N 115.521 -0.763 . . . . 0.0 111.593 -178.348 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 16.2 m -111.52 5.73 19.68 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-O 120.828 0.347 . . . . 0.0 110.46 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 22.8 tp -118.51 134.49 55.04 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.092 -177.643 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 77.4 m95 -97.3 132.76 42.72 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-O 121.105 0.479 . . . . 0.0 111.978 178.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 51.5 m-85 -115.95 130.21 56.72 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.828 174.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.411 HD11 ' CD2' ' A' ' 81' ' ' LEU . 2.2 pp -119.87 148.98 22.6 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-O 121.172 0.511 . . . . 0.0 110.786 179.646 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 16.5 m -142.99 114.05 7.72 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.7 178.007 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.9 p -96.04 103.72 15.01 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-O 121.747 0.784 . . . . 0.0 111.06 -177.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.498 ' HA ' ' HE2' ' A' ' 124' ' ' MET . 3.7 mmt -107.37 137.65 19.69 Favored Pre-proline 0 C--N 1.313 -1.02 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.922 -178.462 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . 0.481 ' HA ' ' HG2' ' A' ' 108' ' ' LYS . 72.9 Cg_endo -80.72 142.79 14.46 Favored 'Trans proline' 0 N--CA 1.448 -1.199 0 C-N-CA 122.142 1.894 . . . . 0.0 111.315 176.543 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 9.6 t -91.97 -178.24 4.95 Favored 'General case' 0 C--N 1.313 -1.021 0 C-N-CA 120.393 -0.523 . . . . 0.0 109.779 178.03 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 7.6 t -61.3 138.64 58.24 Favored 'General case' 0 N--CA 1.434 -1.23 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.016 179.396 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . 0.404 ' N ' HD12 ' A' ' 128' ' ' ILE . 2.7 mp -64.24 138.75 22.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 178.384 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 92.89 -12.74 69.26 Favored Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 120.421 -0.895 . . . . 0.0 112.606 -175.779 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 63.9 p -120.45 161.43 21.26 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 117.045 0.422 . . . . 0.0 110.696 178.424 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.473 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 58.9 pttt -133.57 146.62 51.16 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 116.338 -0.392 . . . . 0.0 109.985 179.476 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 31.4 t80 -85.9 136.62 33.22 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.688 -178.375 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -97.68 136.04 21.38 Favored Pre-proline 0 C--N 1.319 -0.741 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.569 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -68.48 -46.33 2.02 Favored 'Trans proline' 0 C--N 1.346 0.447 0 C-N-CA 122.684 2.256 . . . . 0.0 113.591 -178.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.9 mp -77.56 -54.27 12.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 111.706 0.261 . . . . 0.0 111.706 -177.779 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 21.5 m -68.02 -32.32 72.61 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 120.645 0.26 . . . . 0.0 110.916 -178.621 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' ARG . . . . . 0.403 ' HD3' ' HD2' ' A' ' 99' ' ' PRO . 98.4 mtt180 66.47 48.55 1.51 Allowed 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 121.411 0.624 . . . . 0.0 111.29 177.62 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 23.9 p-10 -151.42 172.9 15.23 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 115.254 -0.884 . . . . 0.0 108.762 177.731 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 67.9 m -101.82 126.94 48.8 Favored 'General case' 0 C--N 1.308 -1.208 0 CA-C-O 121.222 0.534 . . . . 0.0 111.154 179.041 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 35.1 m -116.46 161.35 15.27 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-N 115.43 -0.805 . . . . 0.0 108.941 178.053 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 45.2 tp -54.03 125.79 20.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.054 0.454 . . . . 0.0 110.113 178.6 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' ASP . . . . . 0.473 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 9.8 t70 -77.9 91.27 4.16 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 115.999 -0.546 . . . . 0.0 112.289 -175.916 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 . . . . . 0 C--N 1.314 -0.967 0 CA-C-O 118.196 -0.907 . . . . 0.0 108.861 172.758 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.468 0.795 0 N-CA-C 111.757 -0.537 . . . . 0.0 111.757 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_exo -64.98 124.89 13.73 Favored 'Trans proline' 0 N--CA 1.462 -0.376 0 C-N-CA 122.583 2.189 . . . . 0.0 111.545 178.58 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.419 ' O ' HD13 ' A' ' 77' ' ' LEU . 4.1 pp -77.21 139.57 39.91 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.809 179.6 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -117.48 35.1 4.25 Favored Glycine 0 N--CA 1.437 -1.267 0 N-CA-C 110.874 -0.891 . . . . 0.0 110.874 179.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 43.4 t -75.45 -20.44 58.84 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 179.418 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -161.8 94.57 0.95 Allowed 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.397 -0.819 . . . . 0.0 109.341 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 45.7 tp -109.9 135.39 50.85 Favored 'General case' 0 C--N 1.31 -1.152 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 177.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 11.5 mt -96.82 142.55 13.85 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 C-N-CA 120.57 -0.452 . . . . 0.0 110.391 179.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 22.9 m -139.35 178.27 3.92 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 -178.106 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' HIS . . . . . 0.47 ' HA ' ' O ' ' A' ' 88' ' ' LYS . 66.3 m-70 -117.99 124.61 48.6 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-O 121.253 0.549 . . . . 0.0 111.868 179.49 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 -114.62 103.91 11.47 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.062 -0.972 . . . . 0.0 108.967 177.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 67.73 18.36 70.18 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.607 -0.806 . . . . 0.0 111.329 -177.739 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 106.75 -29.39 10.93 Favored Glycine 0 N--CA 1.445 -0.753 0 C-N-CA 121.28 -0.486 . . . . 0.0 112.635 -179.206 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . 0.47 ' O ' ' HA ' ' A' ' 84' ' ' HIS . 47.5 mmtm -80.79 154.03 27.41 Favored 'General case' 0 C--O 1.22 -0.457 0 CA-C-N 116.732 0.266 . . . . 0.0 110.534 -178.103 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -87.7 128.44 35.3 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.306 0.574 . . . . 0.0 112.512 -178.774 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 17.9 m-85 -125.74 152.2 45.65 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.34 -0.846 . . . . 0.0 109.985 177.399 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 24.3 m-70 -100.88 149.06 24.27 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-O 121.016 0.436 . . . . 0.0 111.361 -179.516 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 44.1 t -120.79 118.35 56.12 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.002 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 176.187 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 58.8 t -132.16 131.39 61.1 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.532 -179.242 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 94.9 m -113.76 138.69 49.9 Favored 'General case' 0 C--N 1.313 -1.012 0 CA-C-O 120.799 0.333 . . . . 0.0 110.894 -179.424 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 77.8 m-70 -119.03 -19.63 8.39 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.364 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 5.4 mp0 -126.05 142.21 51.62 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.011 -0.54 . . . . 0.0 109.699 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 -76.97 103.8 7.1 Favored 'General case' 0 C--N 1.314 -0.937 0 N-CA-C 109.794 -0.446 . . . . 0.0 109.794 177.177 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 164.26 169.35 27.69 Favored Glycine 0 N--CA 1.436 -1.349 0 N-CA-C 111.267 -0.733 . . . . 0.0 111.267 -179.178 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.437 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 95.4 Cg_endo -83.34 133.51 6.37 Favored 'Trans proline' 0 N--CA 1.454 -0.806 0 C-N-CA 122.582 2.188 . . . . 0.0 112.709 179.031 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.9 pp -140.12 156.6 70.13 Favored Pre-proline 0 C--N 1.32 -0.704 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.996 178.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -62.96 167.29 12.45 Favored 'Trans proline' 0 C--N 1.351 0.695 0 C-N-CA 122.743 2.296 . . . . 0.0 112.87 -178.547 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' HIS . . . . . . . . . . . . . 5.0 t-80 -91.68 133.15 31.46 Favored Pre-proline 0 C--N 1.322 -0.597 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.822 -178.366 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_endo -53.46 -37.62 82.31 Favored 'Trans proline' 0 C--N 1.353 0.799 0 C-N-CA 123.414 2.743 . . . . 0.0 113.344 -177.654 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -70.8 -64.82 2.68 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.087 179.462 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 3.0 p30 -132.6 120.29 21.61 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 121.045 0.45 . . . . 0.0 111.421 178.531 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 28.3 m -57.07 -10.25 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 CA-C-N 115.573 -0.74 . . . . 0.0 112.835 177.768 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 66.4 m170 -69.84 -1.03 8.24 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-O 121.158 0.504 . . . . 0.0 110.636 176.553 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 33.1 mtmm -137.31 157.72 46.01 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.109 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -143.47 173.33 11.72 Favored 'General case' 0 C--N 1.308 -1.21 0 C-N-CA 120.825 -0.35 . . . . 0.0 110.921 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.437 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 1.9 mp -131.04 142.82 42.58 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.966 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 178.786 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -99.68 115.17 39.99 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.968 0 N-CA-C 107.424 -1.325 . . . . 0.0 107.424 174.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 29.2 m -95.41 121.75 37.41 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 -178.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 16.4 m -126.56 140.79 52.17 Favored 'General case' 0 C--N 1.307 -1.282 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 -179.32 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -118.19 104.86 11.21 Favored 'General case' 0 C--N 1.308 -1.23 0 CA-C-O 121.083 0.468 . . . . 0.0 110.569 -178.435 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 67.5 m -82.89 89.06 6.8 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.444 178.704 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 68.78 -100.26 0.67 Allowed Glycine 0 N--CA 1.432 -1.575 0 C-N-CA 120.461 -0.876 . . . . 0.0 111.084 -177.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 14.5 t -114.5 7.46 16.19 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-O 120.9 0.381 . . . . 0.0 110.383 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 21.8 tp -117.1 131.11 56.99 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.584 -0.28 . . . . 0.0 110.438 -177.712 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 77.0 m95 -92.14 131.75 37.15 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 121.038 0.447 . . . . 0.0 111.84 -179.457 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 64.4 m-85 -120.89 129.79 53.64 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.471 174.085 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.5 pp -120.82 151.51 23.78 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.043 0 CA-C-O 121.129 0.49 . . . . 0.0 111.736 -179.518 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 27.8 m -139.66 118.81 12.69 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.892 178.495 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 6.0 p -92.09 124.6 44.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 120.951 0.405 . . . . 0.0 111.081 -178.621 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.403 ' HA ' ' HE2' ' A' ' 124' ' ' MET . 4.0 mmt -125.77 139.22 33.62 Favored Pre-proline 0 C--N 1.318 -0.766 0 CA-C-N 115.822 -0.627 . . . . 0.0 109.838 -179.48 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -86.8 143.14 6.97 Favored 'Trans proline' 0 N--CA 1.453 -0.911 0 C-N-CA 122.241 1.961 . . . . 0.0 111.883 177.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' CYS . . . . . 0.496 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 55.3 m -81.81 169.39 16.95 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 176.529 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 1.6 p -58.36 148.52 27.45 Favored 'General case' 0 N--CA 1.435 -1.198 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.604 176.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . 0.417 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.9 mp -62.74 129.0 25.56 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 CA-C-O 121.135 0.493 . . . . 0.0 110.445 -179.348 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 92.04 5.31 66.1 Favored Glycine 0 N--CA 1.44 -1.061 0 CA-C-N 115.694 -0.684 . . . . 0.0 112.882 -178.21 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 60.5 p -126.33 162.6 25.13 Favored 'General case' 0 C--O 1.236 0.347 0 CA-C-N 117.269 0.534 . . . . 0.0 111.133 179.166 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 58.0 pttt -131.9 143.99 50.54 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 179.387 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.496 ' HB2' ' SG ' ' A' ' 126' ' ' CYS . 46.5 t80 -82.74 133.6 35.15 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-O 120.919 0.39 . . . . 0.0 111.712 -178.489 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -100.55 128.57 29.81 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 115.877 -0.601 . . . . 0.0 109.907 177.453 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -64.56 -41.22 20.44 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.973 2.449 . . . . 0.0 113.514 -176.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 28.1 mm -75.89 -53.01 16.58 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 N-CA-C 112.097 0.406 . . . . 0.0 112.097 -175.738 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 4.8 m -68.78 -31.96 71.35 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.727 -178.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 57.5 mtm180 70.73 51.02 0.33 Allowed 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 121.428 0.632 . . . . 0.0 110.752 178.328 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 29.7 p-10 -159.23 173.41 16.39 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-N 115.483 -0.78 . . . . 0.0 109.004 179.067 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 21.1 m -101.85 125.26 48.49 Favored 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 178.503 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 27.2 m -112.8 163.2 10.2 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.767 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.159 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 6.9 tt -57.56 123.6 16.13 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-O 121.081 0.467 . . . . 0.0 111.225 -178.692 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 17.1 t70 -91.46 99.28 12.25 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.209 178.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 25.0 t-20 . . . . . 0 C--N 1.313 -1.007 0 CA-C-O 118.59 -0.719 . . . . 0.0 109.808 -179.891 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.105 0 N-CA-C 111.521 -0.632 . . . . 0.0 111.521 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.459 ' HA ' ' OD1' ' A' ' 80' ' ' ASP . 8.7 Cg_endo -88.63 89.55 0.45 Allowed 'Trans proline' 0 N--CA 1.449 -1.126 0 C-N-CA 122.937 2.425 . . . . 0.0 111.912 179.172 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -173.04 136.73 0.67 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.674 -179.379 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 81.33 -65.01 4.08 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.872 -0.68 . . . . 0.0 111.752 178.061 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.402 ' O ' HG23 ' A' ' 93' ' ' VAL . 66.9 m -71.83 -30.26 65.29 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 115.434 -0.383 . . . . 0.0 111.234 179.108 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.516 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 11.9 p-10 -139.74 132.99 29.85 Favored 'General case' 0 N--CA 1.44 -0.944 0 CA-C-O 121.604 0.716 . . . . 0.0 111.437 -176.495 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 39.0 tp -107.25 137.88 44.47 Favored 'General case' 0 C--N 1.301 -1.504 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.502 177.224 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.447 ' CG2' HG21 ' A' ' 89' ' ' THR . 16.8 mt -96.81 143.29 12.62 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.07 0 C-N-CA 120.511 -0.476 . . . . 0.0 110.187 -179.547 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.417 HG21 ' HE2' ' A' ' 102' ' ' HIS . 28.7 m -138.41 157.37 30.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-N 116.174 -0.466 . . . . 0.0 109.804 -179.203 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 60.8 m-70 -104.2 104.33 14.23 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 116.468 -0.333 . . . . 0.0 111.019 179.454 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 70.4 mm-40 -100.79 104.97 16.23 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 177.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 66.37 30.62 76.95 Favored Glycine 0 N--CA 1.444 -0.776 0 C-N-CA 120.262 -0.971 . . . . 0.0 110.783 -176.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 89.42 -21.89 26.57 Favored Glycine 0 N--CA 1.442 -0.947 0 CA-C-N 115.195 -0.502 . . . . 0.0 112.726 -178.549 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 14.0 mmmm -83.75 135.2 34.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.799 0.333 . . . . 0.0 111.024 -176.027 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.447 HG21 ' CG2' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -81.42 112.26 18.52 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -178.52 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -112.26 146.68 37.77 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.744 -0.662 . . . . 0.0 109.649 176.301 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 21.6 m-70 -99.05 142.44 30.53 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-O 120.715 0.293 . . . . 0.0 110.498 178.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.516 ' O ' ' HA ' ' A' ' 80' ' ' ASP . 79.5 t -117.65 120.33 64.4 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.955 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 179.097 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.402 HG23 ' O ' ' A' ' 79' ' ' SER . 14.9 p -138.79 142.21 34.97 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.028 -178.031 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 33.1 m -138.31 127.95 25.01 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.662 177.854 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 14.0 p80 -101.71 -0.32 34.7 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-O 121.447 0.641 . . . . 0.0 109.701 177.71 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 56.5 mt-10 -142.67 157.95 44.15 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 114.755 -1.111 . . . . 0.0 109.702 178.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -85.46 153.75 22.27 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 120.917 0.389 . . . . 0.0 110.77 178.295 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 126.8 161.77 10.99 Favored Glycine 0 N--CA 1.438 -1.168 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.037 178.34 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.471 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 72.9 Cg_endo -82.62 134.59 7.58 Favored 'Trans proline' 0 N--CA 1.447 -1.248 0 C-N-CA 122.376 2.051 . . . . 0.0 111.855 177.896 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -141.65 157.4 65.22 Favored Pre-proline 0 C--N 1.314 -0.968 0 CA-C-N 115.934 -0.576 . . . . 0.0 109.733 178.515 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -62.42 164.64 17.31 Favored 'Trans proline' 0 C--N 1.348 0.544 0 C-N-CA 122.356 2.038 . . . . 0.0 112.468 -178.813 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' HIS . . . . . 0.417 ' HE2' HG21 ' A' ' 83' ' ' VAL . 27.6 t-80 -92.02 121.95 65.95 Favored Pre-proline 0 C--N 1.315 -0.899 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -59.0 -19.3 47.58 Favored 'Trans proline' 0 N--CA 1.486 1.041 0 C-N-CA 123.116 2.544 . . . . 0.0 113.543 -176.581 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -93.35 -19.3 35.98 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.469 -0.872 . . . . 0.0 112.809 -179.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 2.4 p30 -167.32 102.04 0.52 Allowed 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 122.479 0.311 . . . . 0.0 110.985 -177.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 28.3 m -54.91 -14.34 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 N-CA-C 113.674 0.99 . . . . 0.0 113.674 179.552 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 17.2 t-80 -73.21 -0.52 14.57 Favored 'General case' 0 CA--C 1.542 0.655 0 CA-C-O 121.61 0.719 . . . . 0.0 110.435 176.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.41 ' HG2' ' HA ' ' A' ' 125' ' ' PRO . 47.4 mtmt -136.89 160.88 37.58 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.473 179.889 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 11.1 p90 -142.37 173.67 11.32 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.546 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.471 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.7 mt -131.91 142.24 43.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 -178.584 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.6 mp -101.89 112.5 35.24 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.12 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 175.783 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 86.3 m -102.3 123.52 46.26 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-O 121.181 0.515 . . . . 0.0 111.178 -176.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 19.3 m -128.56 144.61 51.18 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.529 -179.057 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.585 ' HD3' ' CE2' ' A' ' 119' ' ' TRP . 24.1 tptm -113.16 103.84 11.75 Favored 'General case' 0 C--N 1.313 -0.985 0 N-CA-C 109.152 -0.685 . . . . 0.0 109.152 179.247 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 62.2 m -91.28 78.92 5.72 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-O 121.436 0.636 . . . . 0.0 109.524 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.519 ' O ' ' HE2' ' A' ' 114' ' ' LYS . . . 75.44 -99.06 1.18 Allowed Glycine 0 N--CA 1.433 -1.507 0 N-CA-C 110.593 -1.003 . . . . 0.0 110.593 -178.897 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 20.4 m -113.46 0.92 14.88 Favored 'General case' 0 N--CA 1.445 -0.722 0 CA-C-O 121.312 0.577 . . . . 0.0 110.068 -179.752 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 87.6 mt -112.02 122.97 49.23 Favored 'General case' 0 N--CA 1.435 -1.21 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.555 -176.538 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . 0.585 ' CE2' ' HD3' ' A' ' 114' ' ' LYS . 81.3 m95 -85.32 131.34 34.42 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 121.015 0.436 . . . . 0.0 111.107 177.37 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -125.48 124.0 40.41 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 115.881 -0.6 . . . . 0.0 109.849 174.55 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.5 pp -126.45 146.97 31.38 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.955 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.33 -178.494 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 34.5 m -134.24 124.93 26.75 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 116.013 -0.54 . . . . 0.0 109.672 178.212 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 2.8 p -95.68 110.99 25.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-O 121.393 0.615 . . . . 0.0 111.252 -179.057 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.469 ' HE1' ' HA ' ' A' ' 124' ' ' MET . 9.1 mmt -113.32 145.8 33.98 Favored Pre-proline 0 C--N 1.318 -0.767 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.062 -178.719 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . 0.41 ' HA ' ' HG2' ' A' ' 108' ' ' LYS . 79.4 Cg_endo -89.25 151.15 5.55 Favored 'Trans proline' 0 N--CA 1.453 -0.865 0 C-N-CA 122.353 2.035 . . . . 0.0 113.074 179.605 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 35.9 m -90.87 171.14 9.52 Favored 'General case' 0 C--O 1.243 0.727 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.153 175.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 22.9 t -54.28 148.32 11.74 Favored 'General case' 0 C--O 1.237 0.413 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 177.298 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . 0.445 HD11 ' N ' ' A' ' 128' ' ' ILE . 1.9 mp -63.7 129.07 26.97 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 CA-C-O 120.912 0.387 . . . . 0.0 110.234 -179.032 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 89.38 6.03 71.55 Favored Glycine 0 N--CA 1.444 -0.791 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.783 -177.669 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 46.2 p -121.33 158.94 27.1 Favored 'General case' 0 N--CA 1.452 -0.36 0 O-C-N 122.343 -0.504 . . . . 0.0 110.757 178.236 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 59.0 pttt -128.0 144.26 51.1 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 32.8 t80 -84.46 137.22 33.48 Favored 'General case' 0 C--N 1.311 -1.098 0 C-N-CA 120.9 -0.32 . . . . 0.0 110.743 -179.644 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -100.05 133.83 21.31 Favored Pre-proline 0 C--N 1.325 -0.472 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.333 179.314 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -67.68 -41.84 7.71 Favored 'Trans proline' 0 C--N 1.346 0.418 0 C-N-CA 122.877 2.385 . . . . 0.0 113.949 -177.51 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 34.8 mm -82.35 -49.25 17.45 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 N-CA-C 111.951 0.352 . . . . 0.0 111.951 -176.45 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 2.4 m -69.1 -37.49 78.42 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.847 0.356 . . . . 0.0 110.1 179.512 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 67.5 mtt180 68.36 55.36 0.52 Allowed 'General case' 0 CA--C 1.514 -0.414 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.572 178.686 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 29.4 p-10 -154.61 172.93 17.06 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 114.86 -1.064 . . . . 0.0 108.374 178.221 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 27.3 m -101.03 124.83 47.36 Favored 'General case' 0 C--N 1.316 -0.891 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 177.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 35.8 m -117.54 157.16 18.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.296 -178.301 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 7.2 mp -64.56 119.75 11.06 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 112.186 0.439 . . . . 0.0 112.186 -178.328 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -83.5 90.87 7.28 Favored 'General case' 0 C--N 1.319 -0.734 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 174.032 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 10.2 t30 . . . . . 0 C--N 1.306 -1.298 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.44 -174.488 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.27 0 N-CA-C 111.93 -0.468 . . . . 0.0 111.93 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.495 ' HA ' ' O ' ' A' ' 80' ' ' ASP . 81.0 Cg_endo -76.51 34.57 0.44 Allowed 'Trans proline' 0 C--N 1.349 0.557 0 C-N-CA 123.227 2.618 . . . . 0.0 112.498 -178.741 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 20.4 mt -88.52 33.99 0.76 Allowed 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.006 -178.391 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 87.58 -22.75 15.26 Favored Glycine 0 N--CA 1.449 -0.488 0 N-CA-C 111.069 -0.812 . . . . 0.0 111.069 -176.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 15.0 m -74.33 -49.49 22.69 Favored 'General case' 0 N--CA 1.443 -0.802 0 CA-C-N 115.482 -0.359 . . . . 0.0 111.264 179.758 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.495 ' O ' ' HA ' ' A' ' 76' ' ' PRO . 24.3 t70 -139.26 106.8 5.57 Favored 'General case' 0 CA--C 1.517 -0.297 0 CA-C-O 120.722 0.296 . . . . 0.0 110.386 -179.191 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 54.6 tp -108.6 131.65 54.65 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 178.298 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 12.3 mt -91.69 139.97 16.9 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 C-N-CA 120.408 -0.517 . . . . 0.0 109.651 179.068 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 29.4 m -136.52 175.12 10.98 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 CA-C-N 116.137 -0.483 . . . . 0.0 109.84 -177.536 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 16.2 m-70 -114.57 117.24 30.36 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.109 0.48 . . . . 0.0 111.426 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.448 ' HB2' ' CD1' ' A' ' 90' ' ' TYR . 11.8 mm-40 -115.19 104.45 11.86 Favored 'General case' 0 C--N 1.311 -1.074 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 177.228 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 64.39 34.05 88.87 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.382 -0.913 . . . . 0.0 111.448 -177.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 88.28 -26.9 7.34 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 121.436 -0.411 . . . . 0.0 113.021 -178.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -82.23 146.74 29.33 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.818 0.342 . . . . 0.0 111.169 -178.341 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -85.08 122.42 29.26 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-O 121.233 0.54 . . . . 0.0 112.153 -179.79 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.448 ' CD1' ' HB2' ' A' ' 85' ' ' GLU . 18.0 m-85 -117.03 148.79 41.18 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.252 176.711 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 31.4 m-70 -97.74 144.22 27.58 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-N 116.526 -0.306 . . . . 0.0 110.202 178.731 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 44.2 t -121.12 117.54 53.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.256 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 178.413 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.6 p -130.77 131.32 64.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 CA-C-N 115.424 -0.807 . . . . 0.0 109.096 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -106.3 138.44 42.48 Favored 'General case' 0 N--CA 1.435 -1.223 0 C-N-CA 119.579 -0.848 . . . . 0.0 111.456 -177.874 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 36.1 m80 -108.84 -25.07 10.97 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 115.329 -0.851 . . . . 0.0 110.365 -178.388 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -131.98 143.43 50.08 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.776 -177.664 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -74.67 108.6 7.53 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.203 178.317 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 156.25 -178.64 32.65 Favored Glycine 0 N--CA 1.439 -1.135 0 N-CA-C 111.637 -0.585 . . . . 0.0 111.637 -178.18 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.465 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 69.5 Cg_endo -91.12 127.31 1.16 Allowed 'Trans proline' 0 N--CA 1.445 -1.333 0 C-N-CA 123.149 2.566 . . . . 0.0 112.742 179.529 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.6 pp -138.02 156.12 74.21 Favored Pre-proline 0 C--N 1.313 -0.993 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.387 179.232 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.411 ' HG3' ' HD3' ' A' ' 134' ' ' PRO . 37.3 Cg_endo -62.92 165.25 16.86 Favored 'Trans proline' 0 C--N 1.352 0.746 0 C-N-CA 122.634 2.223 . . . . 0.0 112.522 -178.435 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' HIS . . . . . . . . . . . . . 11.9 t-80 -88.51 132.6 38.47 Favored Pre-proline 0 C--N 1.32 -0.716 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -178.601 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 17.5 Cg_endo -58.65 -19.95 48.12 Favored 'Trans proline' 0 C--N 1.35 0.631 0 C-N-CA 123.0 2.467 . . . . 0.0 112.806 -179.26 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -91.13 -67.68 1.17 Allowed Glycine 0 N--CA 1.447 -0.591 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.101 179.13 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 45.6 m-80 -118.56 109.95 16.78 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.592 0.196 . . . . 0.0 111.053 179.441 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 32.8 m -55.41 -13.62 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.791 0 N-CA-C 113.075 0.769 . . . . 0.0 113.075 176.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 41.1 m170 -73.92 3.78 6.26 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-O 120.934 0.397 . . . . 0.0 110.547 177.12 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 47.7 mtmt -140.62 157.75 45.0 Favored 'General case' 0 CA--C 1.506 -0.743 0 CA-C-N 115.833 -0.622 . . . . 0.0 109.43 179.78 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 8.5 p90 -143.03 170.07 16.39 Favored 'General case' 0 C--N 1.306 -1.284 0 C-N-CA 120.829 -0.348 . . . . 0.0 111.264 -179.433 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.465 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.1 mp -125.09 139.13 52.06 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.598 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -100.96 113.13 36.05 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 175.357 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 59.6 m -95.14 123.18 38.49 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 109.314 -0.625 . . . . 0.0 109.314 179.132 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 52.7 p -122.56 136.7 54.95 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.835 -176.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 19.5 tptm -96.41 115.54 27.59 Favored 'General case' 0 N--CA 1.435 -1.202 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.682 -179.032 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 59.7 m -108.23 79.81 1.3 Allowed 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 176.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 73.45 -104.57 1.61 Allowed Glycine 0 N--CA 1.438 -1.189 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 -176.273 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 8.4 t -113.33 13.02 18.98 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 121.226 0.536 . . . . 0.0 109.865 179.229 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 81.4 mt -116.96 135.4 53.73 Favored 'General case' 0 N--CA 1.435 -1.223 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.043 -177.378 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 50.1 m95 -96.98 131.69 43.53 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.005 0.431 . . . . 0.0 111.069 178.395 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -129.24 128.59 43.6 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 174.855 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.448 ' HB ' ' CG2' ' A' ' 110' ' ' ILE . 2.5 pp -119.05 158.91 20.05 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-O 120.952 0.406 . . . . 0.0 111.698 -176.915 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 44.2 m -146.01 121.65 10.46 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.882 177.369 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.7 p -94.62 110.13 23.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 121.549 0.69 . . . . 0.0 111.411 -179.024 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.449 ' HE1' ' HA ' ' A' ' 124' ' ' MET . 7.2 mmt -111.86 142.8 27.39 Favored Pre-proline 0 C--N 1.313 -1.007 0 CA-C-N 115.49 -0.777 . . . . 0.0 110.004 -179.459 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -86.71 144.62 7.61 Favored 'Trans proline' 0 N--CA 1.453 -0.89 0 C-N-CA 122.461 2.107 . . . . 0.0 112.722 178.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 12.2 m -82.65 174.69 10.78 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.488 177.133 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 13.1 m -61.8 144.45 54.76 Favored 'General case' 0 N--CA 1.436 -1.16 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.88 176.678 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . 0.413 ' N ' HD13 ' A' ' 128' ' ' ILE . 2.2 mp -63.34 126.74 22.41 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.553 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 99.25 -6.87 59.83 Favored Glycine 0 N--CA 1.441 -1.0 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.735 -176.483 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 69.1 p -121.66 157.2 31.38 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-N 117.183 0.492 . . . . 0.0 111.449 179.139 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.41 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 62.4 pttt -124.35 147.64 48.06 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 179.0 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 46.9 t80 -81.46 134.37 35.53 Favored 'General case' 0 C--N 1.31 -1.132 0 C-N-CA 120.459 -0.496 . . . . 0.0 111.125 -179.363 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -104.33 127.83 28.29 Favored Pre-proline 0 C--N 1.317 -0.843 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.533 178.76 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' PRO . . . . . 0.411 ' HD3' ' HG3' ' A' ' 101' ' ' PRO . 27.3 Cg_endo -61.99 -42.43 30.49 Favored 'Trans proline' 0 C--O 1.235 0.338 0 C-N-CA 123.024 2.483 . . . . 0.0 113.48 -176.035 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 33.9 mm -79.03 -49.63 19.76 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.612 -176.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' SER . . . . . 0.411 ' O ' ' HB2' ' A' ' 137' ' ' ARG . 5.1 m -62.41 -37.51 86.11 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.54 0.209 . . . . 0.0 111.134 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' ARG . . . . . 0.411 ' HB2' ' O ' ' A' ' 136' ' ' SER . 44.2 mtp180 74.62 41.91 0.32 Allowed 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 123.407 0.683 . . . . 0.0 111.33 178.763 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 -161.55 -179.27 7.18 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 178.828 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 10.6 m -100.45 125.93 46.8 Favored 'General case' 0 C--N 1.31 -1.147 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 -178.681 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.5 m -113.34 165.9 7.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.704 -178.253 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -55.08 116.02 2.55 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.625 -179.78 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' ASP . . . . . 0.41 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 21.4 t70 -91.47 101.23 13.9 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.58 -178.85 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 48.8 m-80 . . . . . 0 C--N 1.312 -1.055 0 CA-C-O 118.501 -0.761 . . . . 0.0 109.399 176.596 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.377 0 N-CA-C 111.99 -0.444 . . . . 0.0 111.99 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -78.66 92.73 1.12 Allowed 'Trans proline' 0 C--O 1.238 0.511 0 C-N-CA 122.739 2.292 . . . . 0.0 112.376 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -120.05 105.15 10.75 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.19 0.519 . . . . 0.0 111.395 -179.365 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -133.43 9.64 5.0 Favored Glycine 0 C--N 1.312 -0.771 0 N-CA-C 109.797 -1.321 . . . . 0.0 109.797 176.314 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 17.3 m -76.53 -20.4 56.94 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 114.766 -0.717 . . . . 0.0 110.951 -177.07 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -144.46 104.19 4.04 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 -178.39 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -107.2 127.79 53.83 Favored 'General case' 0 C--N 1.31 -1.131 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.404 ' CG2' HG21 ' A' ' 89' ' ' THR . 12.5 mt -98.19 144.5 11.24 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.918 0 C-N-CA 120.951 -0.3 . . . . 0.0 110.419 -178.071 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.443 HG22 ' CE1' ' A' ' 102' ' ' HIS . 22.2 m -128.74 151.41 35.49 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.009 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 179.792 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 22.3 m-70 -107.76 100.09 9.5 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-O 120.879 0.371 . . . . 0.0 110.709 179.741 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.411 ' CD ' ' HZ1' ' A' ' 108' ' ' LYS . 79.4 mm-40 -105.54 105.21 15.14 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.95 179.718 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 62.47 37.67 95.06 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.73 -0.748 . . . . 0.0 111.873 -179.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 80.52 -6.11 62.19 Favored Glycine 0 CA--C 1.52 0.376 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.612 -178.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 32.0 mmmt -96.97 129.02 44.49 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.922 0.391 . . . . 0.0 110.288 -178.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.404 HG21 ' CG2' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -86.07 124.28 32.32 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.408 179.714 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 89.8 m-85 -121.48 141.04 51.41 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 177.538 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 37.8 m-70 -98.85 138.46 35.95 Favored 'General case' 0 C--N 1.312 -1.062 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.29 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 49.4 t -115.58 122.68 69.89 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.015 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 178.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 84.6 t -132.38 128.08 57.83 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.027 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 -179.421 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 66.9 m -98.61 131.6 44.68 Favored 'General case' 0 C--N 1.307 -1.277 0 CA-C-O 120.893 0.378 . . . . 0.0 110.899 -178.201 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 37.1 m80 -80.53 -29.45 37.18 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 179.597 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -158.32 -179.09 7.78 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 114.81 -1.086 . . . . 0.0 108.168 -177.528 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -84.55 154.25 22.75 Favored 'General case' 0 C--N 1.31 -1.138 0 CA-C-O 121.002 0.43 . . . . 0.0 111.001 -179.538 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 124.96 167.17 12.54 Favored Glycine 0 N--CA 1.442 -0.945 0 N-CA-C 111.478 -0.649 . . . . 0.0 111.478 -178.263 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -87.18 134.36 3.55 Favored 'Trans proline' 0 N--CA 1.454 -0.85 0 C-N-CA 122.681 2.254 . . . . 0.0 112.816 178.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.5 pp -140.56 156.21 69.38 Favored Pre-proline 0 C--N 1.323 -0.575 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.168 178.416 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo -61.46 165.97 12.25 Favored 'Trans proline' 0 C--N 1.352 0.746 0 C-N-CA 122.895 2.397 . . . . 0.0 113.577 -177.687 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' HIS . . . . . 0.443 ' CE1' HG22 ' A' ' 83' ' ' VAL . 3.5 t-80 -89.06 128.13 52.97 Favored Pre-proline 0 C--N 1.321 -0.645 0 CA-C-N 115.329 -0.85 . . . . 0.0 108.93 -179.407 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 10.5 Cg_endo -51.56 -50.53 13.64 Favored 'Trans proline' 0 C--N 1.352 0.73 0 C-N-CA 123.123 2.549 . . . . 0.0 113.25 -176.432 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -67.44 -64.44 3.22 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.677 -179.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.434 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 2.6 p30 -119.89 105.0 10.66 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 120.972 0.415 . . . . 0.0 111.705 -178.824 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 27.3 m -56.08 -10.6 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 N-CA-C 113.574 0.953 . . . . 0.0 113.574 178.791 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 23.6 m170 -73.45 4.55 4.64 Favored 'General case' 0 N--CA 1.472 0.675 0 CA-C-O 121.245 0.545 . . . . 0.0 110.646 176.7 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.411 ' HZ1' ' CD ' ' A' ' 85' ' ' GLU . 45.1 mtmt -138.1 160.38 39.54 Favored 'General case' 0 N--CA 1.445 -0.708 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 177.844 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 13.4 p90 -143.5 173.18 11.86 Favored 'General case' 0 C--N 1.313 -0.982 0 C-N-CA 120.466 -0.494 . . . . 0.0 111.611 179.668 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.413 ' CG2' ' HB ' ' A' ' 121' ' ' ILE . 2.9 mp -129.57 142.36 44.11 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.908 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.065 179.688 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -100.32 119.44 48.41 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.88 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 175.203 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 61.9 m -98.22 123.8 42.48 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-O 120.927 0.394 . . . . 0.0 111.177 -177.324 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 23.5 t -130.82 137.63 49.5 Favored 'General case' 0 C--N 1.312 -1.056 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 177.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.448 ' HE2' ' O ' ' A' ' 116' ' ' GLY . 86.6 tttt -116.34 109.61 17.59 Favored 'General case' 0 C--N 1.316 -0.872 0 C-N-CA 120.552 -0.459 . . . . 0.0 110.515 -178.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 53.4 m -92.09 76.76 5.38 Favored 'General case' 0 C--N 1.31 -1.128 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.018 178.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.448 ' O ' ' HE2' ' A' ' 114' ' ' LYS . . . 77.99 -98.93 1.49 Allowed Glycine 0 N--CA 1.44 -1.052 0 C-N-CA 120.434 -0.888 . . . . 0.0 111.199 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 25.3 m -114.09 8.94 17.15 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 121.086 0.47 . . . . 0.0 110.177 179.746 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 19.7 tp -122.69 125.64 45.99 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.66 -177.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . 0.446 ' CZ2' ' HD2' ' A' ' 114' ' ' LYS . 86.6 m95 -89.86 133.13 34.91 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-O 121.045 0.45 . . . . 0.0 111.632 179.363 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 87.6 m-85 -118.22 120.88 39.01 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 173.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.413 ' HB ' ' CG2' ' A' ' 110' ' ' ILE . 2.3 pp -125.51 142.94 40.76 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 CA-C-O 121.001 0.429 . . . . 0.0 111.14 -178.539 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 49.8 m -129.54 123.77 32.24 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-N 115.958 -0.564 . . . . 0.0 109.875 179.394 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.7 p -94.08 112.37 26.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 121.513 0.673 . . . . 0.0 111.342 -178.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.479 ' HA ' ' HE3' ' A' ' 124' ' ' MET . 5.8 mmt -110.7 138.8 21.15 Favored Pre-proline 0 C--N 1.318 -0.786 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.289 -179.9 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -86.11 140.39 6.64 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 122.455 2.103 . . . . 0.0 112.359 178.61 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' CYS . . . . . 0.431 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 65.6 m -83.26 170.97 14.08 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.283 177.825 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 30.9 m -57.08 141.51 45.69 Favored 'General case' 0 N--CA 1.446 -0.64 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.173 176.491 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . 0.419 ' N ' HD13 ' A' ' 128' ' ' ILE . 1.9 mp -59.9 131.76 24.73 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 179.37 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.28 -7.26 72.24 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.762 -0.732 . . . . 0.0 113.045 -176.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 59.7 p -117.2 164.91 14.07 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-N 117.174 0.487 . . . . 0.0 111.114 179.664 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.55 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 65.0 pttt -132.03 148.59 52.51 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 178.896 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.431 ' HB2' ' SG ' ' A' ' 126' ' ' CYS . 44.4 t80 -84.63 130.4 34.72 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 120.571 -0.452 . . . . 0.0 110.559 178.715 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -98.34 129.8 29.72 Favored Pre-proline 0 C--N 1.314 -0.948 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.924 179.271 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -64.21 -40.83 24.09 Favored 'Trans proline' 0 C--N 1.342 0.224 0 C-N-CA 122.803 2.335 . . . . 0.0 113.28 -176.805 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 27.6 mm -78.96 -51.67 16.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.599 -176.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 14.0 m -64.0 -32.73 74.38 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.836 0.351 . . . . 0.0 110.657 178.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 67.6 mtm180 68.83 41.95 1.45 Allowed 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 115.509 -0.769 . . . . 0.0 111.274 176.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 10.7 p30 -157.64 176.77 12.19 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.249 -0.887 . . . . 0.0 108.779 177.556 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 9.2 m -100.28 124.92 46.33 Favored 'General case' 0 C--N 1.319 -0.727 0 C-N-CA 120.209 -0.596 . . . . 0.0 109.734 -178.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.0 m -117.88 167.87 10.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.201 -178.295 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -57.35 120.85 8.89 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 178.873 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' ASP . . . . . 0.55 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 8.8 t70 -74.89 90.15 2.39 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 113.674 0.99 . . . . 0.0 113.674 -173.721 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 47.3 m-80 . . . . . 0 C--O 1.248 1.017 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 169.328 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.326 0 N-CA-C 112.143 -0.383 . . . . 0.0 112.143 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 151.45 69.26 Favored 'Trans proline' 0 C--O 1.235 0.37 0 C-N-CA 122.638 2.225 . . . . 0.0 112.287 -179.803 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 73.8 mt -77.81 -18.64 56.13 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.499 -179.645 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 103.18 -13.24 55.48 Favored Glycine 0 C--N 1.313 -0.715 0 CA-C-N 115.39 -0.823 . . . . 0.0 112.037 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 21.9 p -74.99 -32.88 61.78 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.211 0.529 . . . . 0.0 110.401 179.632 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -145.17 120.87 10.5 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.316 -0.857 . . . . 0.0 110.299 -177.526 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -129.97 126.1 37.0 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.024 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.448 ' CG2' HG23 ' A' ' 89' ' ' THR . 26.0 mt -93.79 147.94 5.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.226 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.545 HG22 ' CE1' ' A' ' 102' ' ' HIS . 10.9 m -138.92 167.14 21.18 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 N-CA-C 110.103 -0.332 . . . . 0.0 110.103 -178.902 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 73.2 m-70 -114.75 99.96 7.89 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.579 177.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -87.1 98.28 11.21 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 179.775 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 74.27 1.79 61.26 Favored Glycine 0 C--N 1.324 -0.136 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 -177.622 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 123.28 -23.17 6.9 Favored Glycine 0 N--CA 1.437 -1.292 0 N-CA-C 111.374 -0.691 . . . . 0.0 111.374 -178.624 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 32.2 mmmt -85.08 137.83 32.8 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 110.218 -0.29 . . . . 0.0 110.218 -178.165 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.452 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.0 OUTLIER -76.84 128.16 34.08 Favored 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 112.748 0.647 . . . . 0.0 112.748 -178.502 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.526 ' CE2' ' HA2' ' A' ' 104' ' ' GLY . 35.2 m-85 -126.29 148.8 49.45 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 176.385 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 17.6 m-70 -101.37 139.27 37.26 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-O 120.792 0.33 . . . . 0.0 110.587 -178.079 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 60.5 t -122.3 118.04 54.09 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 179.127 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 49.0 t -128.78 132.96 67.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.145 179.431 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 82.8 m -110.38 118.94 37.63 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 -178.682 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 43.7 m80 -103.17 -15.95 15.87 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.987 -179.786 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -131.21 144.33 51.25 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.985 0.422 . . . . 0.0 111.059 -179.307 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -71.02 112.96 7.58 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.31 177.542 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 146.74 168.7 13.86 Favored Glycine 0 N--CA 1.437 -1.245 0 C-N-CA 121.092 -0.575 . . . . 0.0 111.953 179.502 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.423 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 73.4 Cg_endo -78.64 136.08 13.43 Favored 'Trans proline' 0 N--CA 1.457 -0.623 0 C-N-CA 122.656 2.237 . . . . 0.0 112.644 178.321 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -138.24 158.1 71.48 Favored Pre-proline 0 C--N 1.32 -0.688 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.846 178.072 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo -62.05 166.04 13.31 Favored 'Trans proline' 0 C--N 1.353 0.795 0 C-N-CA 122.69 2.26 . . . . 0.0 113.083 -177.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' HIS . . . . . 0.545 ' CE1' HG22 ' A' ' 83' ' ' VAL . 7.2 t-80 -92.35 133.7 29.46 Favored Pre-proline 0 C--N 1.321 -0.673 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.1 -178.041 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -57.89 -31.72 93.28 Favored 'Trans proline' 0 C--N 1.353 0.766 0 C-N-CA 123.039 2.493 . . . . 0.0 112.94 -178.581 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.526 ' HA2' ' CE2' ' A' ' 90' ' ' TYR . . . -70.29 -63.65 3.18 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.751 -0.738 . . . . 0.0 111.803 179.324 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.523 ' OD1' ' HB2' ' A' ' 107' ' ' HIS . 10.5 p30 -139.6 130.06 25.6 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-O 121.058 0.456 . . . . 0.0 110.743 176.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 29.5 m -58.73 -10.43 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.555 0 N-CA-C 113.487 0.921 . . . . 0.0 113.487 178.817 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . 0.523 ' HB2' ' OD1' ' A' ' 105' ' ' ASN . 36.8 m80 -71.11 -6.93 43.03 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 121.127 0.489 . . . . 0.0 110.193 177.686 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.404 ' HG2' ' HA ' ' A' ' 125' ' ' PRO . 43.1 mtmt -130.51 159.11 38.08 Favored 'General case' 0 CA--C 1.507 -0.71 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.835 177.795 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 9.6 p90 -143.33 173.18 11.83 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.724 179.675 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.423 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 2.4 mp -128.61 141.22 47.13 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.121 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 177.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.7 mp -97.58 117.35 42.15 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 N-CA-C 107.753 -1.202 . . . . 0.0 107.753 175.732 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 21.3 m -104.51 121.46 43.52 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 -179.197 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 36.7 m -122.92 133.33 54.4 Favored 'General case' 0 C--N 1.308 -1.203 0 CA-C-N 116.07 -0.513 . . . . 0.0 109.69 179.673 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.483 ' HD2' ' CZ2' ' A' ' 119' ' ' TRP . 80.8 tttt -105.53 112.24 25.25 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 120.489 -0.484 . . . . 0.0 110.179 -179.705 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 68.2 m -102.15 77.98 1.73 Allowed 'General case' 0 C--N 1.308 -1.213 0 CA-C-N 115.738 -0.664 . . . . 0.0 109.962 179.078 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 77.89 -99.67 1.54 Allowed Glycine 0 N--CA 1.44 -1.062 0 CA-C-N 115.317 -0.856 . . . . 0.0 111.485 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 31.7 t -114.48 3.97 15.1 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-O 121.051 0.453 . . . . 0.0 109.807 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 19.5 mt -119.13 125.83 50.18 Favored 'General case' 0 N--CA 1.432 -1.35 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.11 -177.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . 0.483 ' CZ2' ' HD2' ' A' ' 114' ' ' LYS . 60.6 m95 -91.82 134.01 35.13 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-O 121.071 0.463 . . . . 0.0 111.083 178.942 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 87.5 m-85 -117.51 128.39 54.93 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.259 175.647 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.408 ' C ' ' HG1' ' A' ' 122' ' ' THR . 2.8 pp -127.73 156.36 39.53 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 N-CA-C 112.189 0.44 . . . . 0.0 112.189 -176.054 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.408 ' HG1' ' C ' ' A' ' 121' ' ' ILE . 38.9 m -151.24 123.21 8.14 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.132 176.051 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.8 p -92.06 115.23 30.6 Favored 'Isoleucine or valine' 0 C--O 1.235 0.322 0 CA-C-O 121.301 0.572 . . . . 0.0 111.245 179.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.461 ' HA ' ' HE3' ' A' ' 124' ' ' MET . 4.6 mmt -117.16 149.7 44.86 Favored Pre-proline 0 C--N 1.32 -0.678 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.198 -179.542 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . 0.404 ' HA ' ' HG2' ' A' ' 108' ' ' LYS . 88.0 Cg_endo -92.07 147.76 3.09 Favored 'Trans proline' 0 N--CA 1.45 -1.074 0 C-N-CA 122.433 2.089 . . . . 0.0 112.431 177.647 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 18.2 m -80.94 174.38 11.68 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 120.911 0.386 . . . . 0.0 110.197 176.672 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 18.9 m -62.38 147.08 49.57 Favored 'General case' 0 N--CA 1.437 -1.08 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.79 176.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . 0.414 HD11 ' N ' ' A' ' 128' ' ' ILE . 1.8 mp -59.11 123.72 11.94 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 CA-C-O 121.167 0.508 . . . . 0.0 110.218 -179.204 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 97.26 -1.67 60.74 Favored Glycine 0 N--CA 1.438 -1.22 0 CA-C-N 115.56 -0.745 . . . . 0.0 113.175 -178.786 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 80.8 p -120.81 162.88 19.03 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 117.447 0.624 . . . . 0.0 111.472 179.477 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.417 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 60.7 pttt -132.51 145.93 51.53 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.469 179.151 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 26.2 t80 -81.58 137.74 35.48 Favored 'General case' 0 C--N 1.31 -1.144 0 CA-C-O 121.15 0.5 . . . . 0.0 111.685 -178.339 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -103.35 132.5 21.04 Favored Pre-proline 0 C--N 1.323 -0.569 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.144 177.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -68.77 -39.82 8.06 Favored 'Trans proline' 0 CA--C 1.531 0.347 0 C-N-CA 122.871 2.38 . . . . 0.0 113.885 -176.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 27.2 mm -78.17 -52.49 15.79 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 N-CA-C 112.121 0.415 . . . . 0.0 112.121 -176.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 35.5 p -73.75 -29.84 62.46 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 120.695 0.283 . . . . 0.0 111.154 -178.326 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 95.6 mtt180 68.24 57.84 0.46 Allowed 'General case' 0 N--CA 1.465 0.28 0 C-N-CA 123.471 0.709 . . . . 0.0 112.288 176.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 4.1 p-10 -164.09 177.09 8.7 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 176.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 31.5 m -100.35 125.35 46.58 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 -178.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 33.1 m -112.75 167.59 5.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.561 -177.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -58.01 117.08 3.96 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.997 0.427 . . . . 0.0 111.177 179.309 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' ASP . . . . . 0.417 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 17.2 t70 -93.85 104.64 16.7 Favored 'General case' 0 CA--C 1.506 -0.713 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.399 178.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 31.4 t-20 . . . . . 0 C--N 1.303 -1.429 0 CA-C-O 118.789 -0.624 . . . . 0.0 109.379 179.229 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.382 0 N-CA-C 111.89 -0.484 . . . . 0.0 111.89 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 94.8 Cg_endo -79.83 166.4 21.38 Favored 'Trans proline' 0 CA--C 1.533 0.452 0 C-N-CA 122.739 2.292 . . . . 0.0 112.238 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.486 HD11 ' N ' ' A' ' 77' ' ' LEU . 0.0 OUTLIER -135.2 36.3 3.0 Favored 'General case' 0 CA--C 1.535 0.38 0 CA-C-O 121.297 0.57 . . . . 0.0 112.053 -179.564 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 77.9 -62.96 3.55 Favored Glycine 0 C--O 1.225 -0.433 0 CA-C-N 115.851 -0.613 . . . . 0.0 113.859 178.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 7.1 m -73.51 -20.97 60.53 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.289 0.566 . . . . 0.0 110.469 -178.601 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.427 ' OD1' ' HB3' ' A' ' 91' ' ' HIS . 25.4 t70 -134.61 116.01 14.51 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.468 -179.389 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -107.66 123.86 49.12 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 108.92 -0.771 . . . . 0.0 108.92 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.404 HG22 HG23 ' A' ' 89' ' ' THR . 3.2 mt -101.49 145.3 11.77 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.677 -177.157 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.435 ' O ' ' HA ' ' A' ' 89' ' ' THR . 16.7 m -134.36 165.53 31.25 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 116.084 -0.507 . . . . 0.0 109.812 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 18.6 m-70 -114.7 113.0 23.72 Favored 'General case' 0 C--N 1.31 -1.118 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.407 179.014 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.459 ' CD ' ' HZ1' ' A' ' 108' ' ' LYS . 76.5 mm-40 -107.63 95.9 6.02 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.603 179.235 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 73.94 -6.17 21.3 Favored Glycine 0 CA--C 1.52 0.347 0 C-N-CA 121.093 -0.575 . . . . 0.0 112.932 178.655 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 134.64 -12.71 4.55 Favored Glycine 0 N--CA 1.443 -0.883 0 N-CA-C 111.698 -0.561 . . . . 0.0 111.698 -179.25 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -96.32 130.99 43.3 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 110.368 -0.234 . . . . 0.0 110.368 178.56 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.435 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.0 OUTLIER -85.75 107.34 17.56 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-O 120.969 0.414 . . . . 0.0 111.452 179.391 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 78.1 m-85 -102.21 146.87 27.36 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.914 178.261 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . 0.427 ' HB3' ' OD1' ' A' ' 80' ' ' ASP . 36.1 m-70 -101.96 143.73 31.45 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.543 -178.669 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 89.8 t -114.29 122.18 67.9 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.461 179.102 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 64.2 t -136.77 124.99 34.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.24 0 CA-C-N 115.48 -0.782 . . . . 0.0 108.903 -179.681 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 81.7 m -101.9 127.98 48.5 Favored 'General case' 0 C--N 1.31 -1.139 0 CA-C-O 120.932 0.396 . . . . 0.0 111.059 -179.09 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 68.3 t60 -91.08 -25.45 19.63 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.291 0.567 . . . . 0.0 109.518 178.337 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -149.1 164.69 33.94 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.218 -177.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -78.69 142.13 37.37 Favored 'General case' 0 N--CA 1.438 -1.065 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.001 178.08 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 130.05 167.31 12.03 Favored Glycine 0 N--CA 1.438 -1.223 0 C-N-CA 120.907 -0.663 . . . . 0.0 111.621 -178.174 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -85.6 137.99 6.04 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 122.582 2.188 . . . . 0.0 112.766 179.462 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.8 pp -142.86 158.04 60.16 Favored Pre-proline 0 C--N 1.319 -0.747 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.628 178.713 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -64.56 166.63 17.08 Favored 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 122.462 2.108 . . . . 0.0 112.75 -177.619 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' HIS . . . . . . . . . . . . . 14.1 t-80 -89.49 130.09 44.81 Favored Pre-proline 0 C--N 1.318 -0.762 0 CA-C-N 115.923 -0.581 . . . . 0.0 109.906 -178.206 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -62.19 -24.32 76.14 Favored 'Trans proline' 0 N--CA 1.48 0.716 0 C-N-CA 123.013 2.475 . . . . 0.0 113.456 -177.317 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -93.44 -17.87 40.81 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.201 -1.0 . . . . 0.0 113.482 -178.571 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 1.9 p30 -167.63 105.31 0.52 Allowed 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.657 0.265 . . . . 0.0 111.199 -177.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 27.0 m -55.05 -11.69 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 N-CA-C 113.509 0.929 . . . . 0.0 113.509 178.145 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 91.0 m-70 -77.57 7.03 6.06 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 121.194 0.521 . . . . 0.0 110.951 178.016 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.459 ' HZ1' ' CD ' ' A' ' 85' ' ' GLU . 47.9 mtmt -143.29 162.84 34.63 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.221 179.342 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 11.1 p90 -142.64 173.72 11.28 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-O 120.919 0.39 . . . . 0.0 111.238 179.727 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 3.8 mt -132.87 143.62 39.01 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.651 -179.24 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.409 ' N ' HD11 ' A' ' 111' ' ' ILE . 4.3 mp -103.09 122.28 55.34 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 176.641 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 58.7 m -103.08 122.51 44.82 Favored 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 178.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 29.1 t -133.59 140.25 47.02 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-O 120.894 0.378 . . . . 0.0 110.672 -177.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.417 ' HD2' ' CZ2' ' A' ' 119' ' ' TRP . 59.9 tttm -107.54 104.74 14.36 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-O 121.106 0.479 . . . . 0.0 110.178 179.125 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 23.3 t -90.76 88.45 7.08 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.58 -179.48 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 66.1 -100.76 0.54 Allowed Glycine 0 N--CA 1.438 -1.195 0 CA-C-N 115.474 -0.784 . . . . 0.0 111.664 -178.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 16.3 m -109.32 3.8 21.97 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -179.054 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 35.5 tp -126.98 141.01 51.9 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 120.563 -0.455 . . . . 0.0 111.452 -178.654 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . 0.417 ' CZ2' ' HD2' ' A' ' 114' ' ' LYS . 72.6 m95 -93.8 133.47 37.15 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.348 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 77.4 m-85 -121.7 130.78 53.69 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.606 175.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.4 pp -125.11 146.96 29.91 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 CA-C-O 120.973 0.416 . . . . 0.0 110.891 179.706 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 22.9 m -137.98 125.43 21.97 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-N 115.964 -0.562 . . . . 0.0 109.94 179.4 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.3 p -94.9 112.02 26.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 121.424 0.63 . . . . 0.0 111.018 179.167 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.469 ' HA ' ' HE3' ' A' ' 124' ' ' MET . 6.8 mmt -111.49 141.92 25.48 Favored Pre-proline 0 C--N 1.314 -0.942 0 CA-C-N 115.454 -0.793 . . . . 0.0 110.182 -179.442 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -87.05 154.4 8.37 Favored 'Trans proline' 0 N--CA 1.457 -0.664 0 C-N-CA 122.587 2.191 . . . . 0.0 113.365 -179.72 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 56.5 m -92.72 165.09 13.13 Favored 'General case' 0 C--O 1.241 0.653 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.448 175.618 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 14.9 m -59.93 148.88 33.5 Favored 'General case' 0 N--CA 1.445 -0.693 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.304 176.738 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . 0.401 HD11 ' N ' ' A' ' 128' ' ' ILE . 1.8 mp -60.04 129.73 22.85 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.246 179.749 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 93.9 -2.13 69.0 Favored Glycine 0 N--CA 1.439 -1.136 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.883 -178.242 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 68.7 p -121.06 164.02 17.45 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-N 117.257 0.528 . . . . 0.0 111.382 179.422 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.522 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 57.8 pttt -139.18 145.07 38.88 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 178.67 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 38.3 t80 -82.8 137.79 34.21 Favored 'General case' 0 C--N 1.311 -1.084 0 N-CA-C 112.365 0.505 . . . . 0.0 112.365 -176.034 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -106.52 131.55 21.62 Favored Pre-proline 0 C--N 1.327 -0.408 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.811 176.264 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.05 -36.58 21.59 Favored 'Trans proline' 0 N--CA 1.471 0.203 0 C-N-CA 122.904 2.403 . . . . 0.0 113.935 -176.803 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 34.3 mm -79.28 -56.34 7.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 N-CA-C 111.932 0.345 . . . . 0.0 111.932 -176.061 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 26.8 p -66.69 -31.76 72.63 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 120.528 0.204 . . . . 0.0 110.911 179.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 72.25 48.6 0.25 Allowed 'General case' 0 CA--C 1.518 -0.268 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.342 176.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 32.9 p30 -154.9 175.98 13.09 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.434 178.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 27.8 m -100.86 124.65 46.85 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 177.622 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 29.8 m -107.65 160.58 6.75 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.877 -177.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -61.45 119.02 7.75 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.187 179.79 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' ASP . . . . . 0.522 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 28.2 t70 -85.97 101.35 12.82 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.934 179.188 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 17.7 m120 . . . . . 0 C--N 1.314 -0.951 0 CA-C-O 118.398 -0.811 . . . . 0.0 110.156 179.997 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.246 0 N-CA-C 112.01 -0.436 . . . . 0.0 112.01 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -84.06 170.75 10.81 Favored 'Trans proline' 0 N--CA 1.457 -0.659 0 C-N-CA 122.698 2.265 . . . . 0.0 112.189 179.64 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 93.0 mt -87.95 -177.08 5.68 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.345 179.325 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.658 ' HA3' ' O ' ' A' ' 119' ' ' TRP . . . -155.48 -33.19 0.03 OUTLIER Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 120.267 -0.968 . . . . 0.0 112.741 -178.706 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 11.3 t -67.86 -44.43 77.11 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 178.742 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -140.41 101.33 4.09 Favored 'General case' 0 C--N 1.317 -0.831 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -112.14 126.31 55.05 Favored 'General case' 0 C--N 1.306 -1.288 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 -177.43 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 15.0 mt -94.4 140.14 17.21 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 C-N-CA 120.869 -0.333 . . . . 0.0 110.395 -178.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 27.1 m -127.82 162.53 33.46 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.171 -178.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 35.7 m170 -108.87 112.66 25.01 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.293 179.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.541 ' HB2' ' CE1' ' A' ' 90' ' ' TYR . 71.8 mm-40 -116.81 103.96 10.85 Favored 'General case' 0 C--N 1.312 -1.033 0 N-CA-C 109.206 -0.665 . . . . 0.0 109.206 178.28 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 69.38 23.9 76.26 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.631 -0.795 . . . . 0.0 111.971 -179.261 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 95.53 -19.28 55.04 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.627 -179.421 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 56.4 mtmt -91.16 157.37 17.23 Favored 'General case' 0 CA--C 1.512 -0.486 0 CA-C-O 120.797 0.332 . . . . 0.0 111.357 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -94.68 132.62 39.23 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-N 115.879 -0.6 . . . . 0.0 112.602 -177.621 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.541 ' CE1' ' HB2' ' A' ' 85' ' ' GLU . 42.4 m-85 -127.04 140.54 52.22 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 115.133 -0.94 . . . . 0.0 108.915 176.68 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 21.2 m-70 -97.83 145.36 26.48 Favored 'General case' 0 C--N 1.307 -1.246 0 CA-C-O 120.826 0.345 . . . . 0.0 110.672 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.411 HG12 HD12 ' A' ' 110' ' ' ILE . 81.8 t -114.81 126.38 72.36 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.001 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.074 178.477 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 91.2 t -136.43 123.5 32.22 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 179.227 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 73.0 m -94.64 132.05 39.78 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-O 121.435 0.636 . . . . 0.0 112.345 -175.667 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 70.7 m-70 -86.31 -31.22 21.7 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.036 -0.984 . . . . 0.0 110.783 -178.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -148.36 167.39 25.35 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.282 -178.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -79.21 103.36 9.09 Favored 'General case' 0 N--CA 1.446 -0.66 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 174.627 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 163.92 169.85 28.0 Favored Glycine 0 N--CA 1.431 -1.698 0 N-CA-C 111.126 -0.79 . . . . 0.0 111.126 -178.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.548 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 72.1 Cg_endo -81.55 128.73 6.22 Favored 'Trans proline' 0 N--CA 1.443 -1.485 0 C-N-CA 122.283 1.989 . . . . 0.0 112.256 178.563 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -135.04 157.64 76.55 Favored Pre-proline 0 C--N 1.312 -1.058 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.654 178.569 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -64.55 167.21 15.6 Favored 'Trans proline' 0 C--O 1.233 0.263 0 C-N-CA 122.49 2.127 . . . . 0.0 112.72 -177.573 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' HIS . . . . . 0.435 ' HB3' ' O ' ' A' ' 105' ' ' ASN . 4.5 t-80 -88.85 125.08 63.84 Favored Pre-proline 0 C--N 1.315 -0.891 0 N-CA-C 108.814 -0.809 . . . . 0.0 108.814 -179.007 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -53.41 -37.69 82.06 Favored 'Trans proline' 0 N--CA 1.485 0.984 0 C-N-CA 123.286 2.657 . . . . 0.0 113.417 -176.275 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -74.57 -61.81 3.04 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.335 179.127 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.435 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 2.4 p30 -125.21 109.27 12.65 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 120.992 0.425 . . . . 0.0 111.63 -179.13 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.3 t -56.21 -13.91 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.172 0 C-N-CA 123.584 0.754 . . . . 0.0 112.747 179.278 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 12.1 t-80 -69.06 -1.72 8.29 Favored 'General case' 0 CA--C 1.551 1.019 0 CA-C-O 121.533 0.682 . . . . 0.0 110.644 177.316 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 46.4 mtmt -134.83 160.72 37.31 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 178.604 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 11.3 p90 -142.41 173.33 11.63 Favored 'General case' 0 C--N 1.307 -1.269 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.674 179.178 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.548 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.4 mt -132.03 142.48 42.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -178.383 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.7 mp -101.7 114.17 40.19 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 176.16 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 61.8 m -102.15 122.88 45.01 Favored 'General case' 0 C--N 1.307 -1.273 0 CA-C-O 120.989 0.423 . . . . 0.0 111.252 -177.057 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 28.0 m -131.01 145.64 52.11 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 178.02 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -118.17 114.1 22.55 Favored 'General case' 0 C--N 1.31 -1.132 0 CA-C-O 121.201 0.524 . . . . 0.0 110.3 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 63.1 m -88.2 79.94 7.72 Favored 'General case' 0 N--CA 1.432 -1.366 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.354 179.039 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 75.8 -99.06 1.22 Allowed Glycine 0 N--CA 1.435 -1.392 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 -178.442 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 18.8 m -114.06 6.32 16.37 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 120.844 0.355 . . . . 0.0 110.47 179.341 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 18.2 tp -119.12 124.62 47.3 Favored 'General case' 0 C--O 1.221 -0.405 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.768 -177.251 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . 0.658 ' O ' ' HA3' ' A' ' 78' ' ' GLY . 88.4 m95 -84.41 133.89 34.49 Favored 'General case' 0 C--N 1.317 -0.832 0 N-CA-C 112.069 0.396 . . . . 0.0 112.069 -179.423 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 71.9 m-85 -123.38 124.83 43.81 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.531 172.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.4 pp -123.91 155.93 30.91 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.86 0 CA-C-O 121.23 0.538 . . . . 0.0 112.06 -177.338 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 34.3 m -142.6 121.21 12.53 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.712 177.535 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.8 p -95.25 117.68 39.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 121.231 0.539 . . . . 0.0 111.268 -178.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.447 ' HA ' ' HE3' ' A' ' 124' ' ' MET . 5.0 mmt -120.16 149.66 49.73 Favored Pre-proline 0 C--N 1.32 -0.692 0 CA-C-N 115.703 -0.68 . . . . 0.0 109.999 -178.55 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -91.64 148.02 3.37 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 122.415 2.076 . . . . 0.0 113.483 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 58.7 m -90.84 172.51 8.57 Favored 'General case' 0 C--O 1.242 0.677 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.783 175.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 39.0 m -65.23 147.87 52.69 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.498 178.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . 0.422 ' N ' HD13 ' A' ' 128' ' ' ILE . 1.9 mp -65.2 129.08 29.0 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.001 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 178.713 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 99.81 -16.22 58.79 Favored Glycine 0 N--CA 1.439 -1.112 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.079 -177.023 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 65.8 p -108.85 159.41 16.81 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-O 120.887 0.375 . . . . 0.0 110.93 178.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.464 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 63.7 pttt -128.83 143.58 50.94 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 178.723 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.422 ' HA ' ' HA ' ' A' ' 139' ' ' CYS . 36.8 t80 -80.73 137.06 36.26 Favored 'General case' 0 C--N 1.314 -0.956 0 C-N-CA 120.294 -0.562 . . . . 0.0 111.324 -179.34 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -108.36 127.13 28.09 Favored Pre-proline 0 C--N 1.32 -0.707 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.105 178.47 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -65.99 -36.89 28.41 Favored 'Trans proline' 0 CA--C 1.53 0.292 0 C-N-CA 122.96 2.44 . . . . 0.0 113.553 -177.062 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.8 mp -77.0 -49.99 21.85 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.322 -177.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 13.1 m -67.83 -35.65 78.98 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 120.728 0.299 . . . . 0.0 110.378 178.893 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 66.5 mtt85 71.31 46.21 0.44 Allowed 'General case' 0 CA--C 1.517 -0.297 0 CA-C-N 115.692 -0.685 . . . . 0.0 111.217 178.555 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 11.4 p30 -162.37 177.72 9.3 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 177.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' CYS . . . . . 0.422 ' HA ' ' HA ' ' A' ' 132' ' ' PHE . 6.3 m -100.45 125.26 46.73 Favored 'General case' 0 C--N 1.313 -1.019 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -178.914 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 28.4 m -111.97 163.48 8.86 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.09 -178.169 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -70.52 127.3 32.24 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 -179.256 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' ASP . . . . . 0.464 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 22.5 t70 -94.83 100.58 12.44 Favored 'General case' 0 CA--C 1.502 -0.882 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.271 -179.312 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 34.7 t30 . . . . . 0 C--N 1.302 -1.465 0 N-CA-C 109.041 -0.725 . . . . 0.0 109.041 177.917 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.133 0 N-CA-C 111.662 -0.575 . . . . 0.0 111.662 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -79.51 155.21 24.49 Favored 'Trans proline' 0 N--CA 1.455 -0.771 0 C-N-CA 122.874 2.382 . . . . 0.0 111.978 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 55.4 tp -84.21 114.17 21.62 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.85 -0.613 . . . . 0.0 109.904 178.608 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -145.22 -16.82 0.18 Allowed Glycine 0 C--N 1.318 -0.431 0 C-N-CA 120.573 -0.822 . . . . 0.0 112.834 -179.391 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 14.5 m -75.48 -34.27 60.87 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.789 0.328 . . . . 0.0 110.689 -178.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 27.0 t70 -147.37 97.35 2.84 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.06 -177.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.409 ' CD2' HD13 ' A' ' 121' ' ' ILE . 38.6 tp -92.37 145.88 24.13 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.046 179.759 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.41 HG23 HG21 ' A' ' 89' ' ' THR . 4.9 mt -105.1 144.7 14.43 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 178.427 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 15.3 m -141.9 130.69 22.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.042 0.449 . . . . 0.0 110.778 -177.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 8.6 p80 -78.9 122.98 26.8 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.27 177.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 7.5 tp10 -136.88 113.87 10.54 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 116.109 -0.496 . . . . 0.0 109.85 179.028 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 68.04 24.19 74.52 Favored Glycine 0 N--CA 1.447 -0.584 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.043 -179.6 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 91.2 -10.53 74.7 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.997 -0.62 . . . . 0.0 112.688 -179.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -102.77 139.6 38.14 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.666 0.269 . . . . 0.0 110.359 -179.749 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.41 HG21 HG23 ' A' ' 82' ' ' ILE . 0.1 OUTLIER -87.53 106.67 18.15 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-O 120.821 0.343 . . . . 0.0 110.505 179.676 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 75.6 m-85 -96.2 151.99 18.98 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.562 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 36.4 m-70 -106.85 138.86 42.24 Favored 'General case' 0 C--N 1.308 -1.206 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.041 178.814 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 57.4 t -119.13 118.21 56.8 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 177.435 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.8 p -125.52 138.89 52.97 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.072 -178.774 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 82.1 m -121.97 115.11 21.96 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.213 0.53 . . . . 0.0 111.069 -179.355 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 42.8 t60 -92.67 -18.17 23.36 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.565 178.31 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 74.5 mm-40 -142.02 159.85 41.4 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.452 -0.795 . . . . 0.0 109.835 -178.358 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 -79.66 148.37 31.64 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-O 120.992 0.425 . . . . 0.0 110.549 177.784 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 128.06 164.83 11.69 Favored Glycine 0 N--CA 1.434 -1.488 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 -179.528 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.463 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 91.9 Cg_endo -88.5 142.34 5.04 Favored 'Trans proline' 0 N--CA 1.441 -1.591 0 C-N-CA 122.565 2.176 . . . . 0.0 112.817 179.323 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -141.36 156.53 67.21 Favored Pre-proline 0 C--N 1.316 -0.876 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.19 177.752 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -62.66 165.65 15.4 Favored 'Trans proline' 0 C--N 1.346 0.437 0 C-N-CA 122.316 2.011 . . . . 0.0 112.901 -177.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' HIS . . . . . 0.469 ' HB3' ' O ' ' A' ' 105' ' ' ASN . 42.8 t-80 -87.12 121.77 71.34 Favored Pre-proline 0 C--N 1.315 -0.913 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.399 -179.266 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 13.7 Cg_endo -56.41 -25.44 57.56 Favored 'Trans proline' 0 N--CA 1.48 0.678 0 C-N-CA 122.887 2.391 . . . . 0.0 112.938 -176.604 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -87.06 -20.14 53.87 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.506 -0.854 . . . . 0.0 113.205 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.469 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 9.5 p30 -168.88 117.7 0.68 Allowed 'General case' 0 N--CA 1.472 0.639 0 CA-C-N 117.213 0.506 . . . . 0.0 110.909 -179.74 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 35.1 m -56.32 -11.38 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 N-CA-C 113.756 1.021 . . . . 0.0 113.756 177.205 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 44.7 m170 -76.76 -0.72 24.84 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 111.957 0.354 . . . . 0.0 111.957 179.67 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.466 ' HG2' ' HA ' ' A' ' 125' ' ' PRO . 39.1 mtmt -139.3 163.82 31.47 Favored 'General case' 0 CA--C 1.503 -0.863 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 179.164 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 12.4 p90 -144.02 173.27 11.87 Favored 'General case' 0 C--N 1.311 -1.094 0 CA-C-N 116.555 -0.293 . . . . 0.0 111.112 179.533 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.463 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.7 mp -131.18 141.19 46.67 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.968 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 178.276 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.6 mp -99.04 122.72 51.1 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 176.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 58.8 m -98.14 123.35 42.14 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -178.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 18.9 m -130.1 134.24 47.22 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 120.797 0.332 . . . . 0.0 111.226 -178.729 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.464 ' HE3' ' O ' ' A' ' 116' ' ' GLY . 58.9 tptt -107.31 103.3 12.62 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 178.458 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 51.0 m -101.78 103.01 13.72 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.88 179.757 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.464 ' O ' ' HE3' ' A' ' 114' ' ' LYS . . . 59.8 -106.19 0.92 Allowed Glycine 0 N--CA 1.443 -0.857 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.256 -176.852 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 11.6 t -111.28 3.48 18.38 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-O 120.818 0.342 . . . . 0.0 110.683 178.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -113.16 132.37 55.5 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 120.89 0.376 . . . . 0.0 111.426 -176.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . 0.434 ' CE2' ' HD3' ' A' ' 114' ' ' LYS . 67.1 m95 -90.85 132.1 36.1 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.894 0.378 . . . . 0.0 110.092 175.847 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -123.36 124.64 43.39 Favored 'General case' 0 C--N 1.309 -1.181 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.631 175.801 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.409 HD13 ' CD2' ' A' ' 81' ' ' LEU . 2.4 pp -124.46 142.13 42.28 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.52 -178.871 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 33.5 m -130.13 126.5 37.67 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-N 116.18 -0.464 . . . . 0.0 109.778 179.377 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.1 p -95.26 110.38 23.98 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 121.413 0.625 . . . . 0.0 110.746 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.44 ' HA ' ' HE3' ' A' ' 124' ' ' MET . 3.6 mmt -111.02 144.29 30.07 Favored Pre-proline 0 C--N 1.316 -0.856 0 CA-C-N 115.367 -0.833 . . . . 0.0 109.772 -179.8 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . 0.466 ' HA ' ' HG2' ' A' ' 108' ' ' LYS . 83.6 Cg_endo -89.26 148.62 5.43 Favored 'Trans proline' 0 N--CA 1.45 -1.075 0 C-N-CA 122.237 1.958 . . . . 0.0 112.737 178.388 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' CYS . . . . . 0.403 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 53.3 m -81.97 161.06 23.17 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.095 -0.502 . . . . 0.0 109.794 176.465 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 16.7 t -61.07 142.38 56.7 Favored 'General case' 0 N--CA 1.442 -0.833 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 177.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 1.8 mp -54.22 129.6 15.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.468 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 100.15 -7.91 58.84 Favored Glycine 0 N--CA 1.444 -0.79 0 C-N-CA 120.934 -0.65 . . . . 0.0 113.269 -177.776 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 69.5 p -123.49 164.82 18.19 Favored 'General case' 0 C--O 1.237 0.405 0 CA-C-N 117.087 0.443 . . . . 0.0 111.383 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 60.1 pttt -134.74 147.39 50.02 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 178.762 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.403 ' HB2' ' SG ' ' A' ' 126' ' ' CYS . 30.4 t80 -81.78 138.89 35.08 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-O 121.23 0.538 . . . . 0.0 112.355 -177.168 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -108.01 126.98 28.51 Favored Pre-proline 0 C--N 1.324 -0.5 0 CA-C-N 115.51 -0.768 . . . . 0.0 109.533 177.059 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -63.97 -40.17 28.88 Favored 'Trans proline' 0 N--CA 1.474 0.369 0 C-N-CA 122.961 2.441 . . . . 0.0 113.561 -176.55 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 30.8 mm -77.4 -51.96 17.39 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.46 -176.787 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 8.7 m -62.86 -36.12 82.24 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.741 0.305 . . . . 0.0 110.508 178.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 85.9 mtm180 73.11 41.52 0.49 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.909 178.625 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 3.5 p-10 -158.03 178.0 10.7 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 178.543 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 31.4 m -100.51 125.54 46.85 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-O 121.146 0.498 . . . . 0.0 110.034 -178.74 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.3 m -111.9 165.03 7.23 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 CA-C-N 115.859 -0.61 . . . . 0.0 109.881 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 54.9 tp -57.29 125.0 20.81 Favored 'General case' 0 C--N 1.313 -0.979 0 CA-C-O 121.152 0.501 . . . . 0.0 111.842 -178.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 18.0 t0 -90.45 94.53 9.76 Favored 'General case' 0 N--CA 1.442 -0.873 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.958 178.002 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 . . . . . 0 C--N 1.312 -1.033 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 178.579 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.375 0 N-CA-C 112.058 -0.417 . . . . 0.0 112.058 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_exo -63.61 135.12 47.5 Favored 'Trans proline' 0 C--O 1.242 0.7 0 C-N-CA 122.643 2.229 . . . . 0.0 111.839 178.564 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 84.0 mt -122.74 172.4 8.46 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.711 -179.709 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -140.82 -36.43 0.1 Allowed Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.133 -1.032 . . . . 0.0 112.929 -179.346 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 26.4 t -73.14 -45.25 57.86 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 120.537 0.208 . . . . 0.0 110.629 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.413 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 15.1 t70 -147.81 96.05 2.6 Favored 'General case' 0 C--O 1.233 0.229 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 179.013 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -102.63 130.74 49.61 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.147 -179.16 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 6.8 mt -96.17 143.84 11.4 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.848 0 C-N-CA 120.707 -0.397 . . . . 0.0 110.486 -177.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.413 HG23 ' HE2' ' A' ' 102' ' ' HIS . 20.6 m -133.94 167.21 26.79 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 179.796 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' HIS . . . . . 0.443 ' HA ' ' O ' ' A' ' 88' ' ' LYS . 72.0 m-70 -106.95 115.02 29.46 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-O 121.053 0.454 . . . . 0.0 110.969 178.559 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.413 ' CD ' ' HZ2' ' A' ' 108' ' ' LYS . 66.4 mm-40 -109.04 104.56 13.79 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 177.378 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 68.0 27.35 73.7 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.301 -0.952 . . . . 0.0 111.224 -178.428 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 95.1 -25.03 26.01 Favored Glycine 0 N--CA 1.443 -0.872 0 C-N-CA 121.41 -0.424 . . . . 0.0 112.73 -179.123 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . 0.443 ' O ' ' HA ' ' A' ' 84' ' ' HIS . 33.4 mmtp -85.93 149.68 25.03 Favored 'General case' 0 C--O 1.222 -0.368 0 CA-C-O 120.64 0.257 . . . . 0.0 110.618 -176.356 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -87.97 121.44 30.38 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-O 121.155 0.502 . . . . 0.0 112.108 -179.314 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.411 ' CD1' ' HB2' ' A' ' 85' ' ' GLU . 38.2 m-85 -119.19 141.95 48.42 Favored 'General case' 0 C--N 1.313 -1.02 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 176.691 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 32.9 m-70 -92.09 144.77 25.1 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-O 121.051 0.453 . . . . 0.0 111.376 -177.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.413 ' O ' ' HA ' ' A' ' 80' ' ' ASP . 97.9 t -118.04 117.9 56.4 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 176.046 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.6 p -125.83 137.92 56.16 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.847 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.259 -178.072 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 84.9 m -120.73 113.25 19.92 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 46.7 t60 -92.86 -19.2 21.93 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.921 -179.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -138.77 157.36 46.22 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.548 -178.025 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 35.7 mt-10 -77.68 135.79 38.12 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.871 176.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 130.03 168.37 12.28 Favored Glycine 0 C--N 1.313 -0.7 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.12 -178.102 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -85.0 135.33 5.49 Favored 'Trans proline' 0 N--CA 1.453 -0.872 0 C-N-CA 122.636 2.224 . . . . 0.0 112.613 178.845 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.405 ' O ' ' HB2' ' A' ' 109' ' ' TYR . 1.9 pp -138.76 157.07 72.5 Favored Pre-proline 0 C--N 1.321 -0.666 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.028 178.359 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.401 ' HG3' ' HD3' ' A' ' 134' ' ' PRO . 56.6 Cg_endo -68.06 171.17 12.93 Favored 'Trans proline' 0 C--N 1.348 0.523 0 C-N-CA 122.286 1.991 . . . . 0.0 112.081 -179.527 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' HIS . . . . . 0.413 ' HE2' HG23 ' A' ' 83' ' ' VAL . 62.5 t-80 -92.34 132.62 31.6 Favored Pre-proline 0 C--N 1.314 -0.943 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -53.34 -49.52 17.15 Favored 'Trans proline' 0 CA--C 1.536 0.594 0 C-N-CA 122.957 2.438 . . . . 0.0 112.533 -177.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -63.33 -66.22 2.66 Favored Glycine 0 CA--C 1.526 0.721 0 C-N-CA 121.067 -0.587 . . . . 0.0 113.086 178.787 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.402 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 4.2 p30 -120.95 111.79 17.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.825 0.345 . . . . 0.0 111.63 -179.558 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 20.0 t -59.2 -14.6 5.6 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.904 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.529 177.345 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 22.5 t-80 -66.92 -5.52 12.94 Favored 'General case' 0 CA--C 1.543 0.686 0 CA-C-O 121.355 0.597 . . . . 0.0 110.694 177.739 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.451 ' HG2' ' HA ' ' A' ' 125' ' ' PRO . 7.5 mtmp? -135.04 156.17 49.49 Favored 'General case' 0 N--CA 1.439 -0.996 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 178.46 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . 0.405 ' HB2' ' O ' ' A' ' 100' ' ' ILE . 12.6 p90 -141.56 170.08 16.39 Favored 'General case' 0 C--N 1.306 -1.284 0 CA-C-O 120.689 0.281 . . . . 0.0 110.405 -178.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 3.3 mp -126.3 140.68 48.04 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 -179.675 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.413 ' O ' ' HA ' ' A' ' 121' ' ' ILE . 4.6 mp -97.9 117.69 43.12 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.031 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 176.076 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 34.7 m -104.38 123.69 47.86 Favored 'General case' 0 C--N 1.312 -1.022 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -178.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 14.3 p -135.87 147.86 48.39 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.55 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.565 ' HE2' ' O ' ' A' ' 116' ' ' GLY . 84.4 tttt -117.34 112.84 21.27 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-O 121.085 0.469 . . . . 0.0 110.552 -178.253 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 75.4 m -97.98 73.02 2.23 Favored 'General case' 0 C--N 1.31 -1.13 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.888 178.295 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.565 ' O ' ' HE2' ' A' ' 114' ' ' LYS . . . 80.97 -98.9 1.87 Allowed Glycine 0 N--CA 1.437 -1.256 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -178.822 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 50.2 m -114.54 5.39 15.49 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 120.856 0.36 . . . . 0.0 110.122 177.282 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 50.1 tp -114.85 121.34 42.94 Favored 'General case' 0 C--O 1.222 -0.383 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.49 -178.062 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 57.4 m95 -89.45 132.5 34.99 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 121.045 0.45 . . . . 0.0 111.932 179.504 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -110.6 126.31 54.32 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.884 175.096 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.487 ' O ' HD12 ' A' ' 121' ' ' ILE . 2.5 pp -126.28 150.62 32.0 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.129 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.709 -179.012 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 26.9 m -151.72 123.57 8.03 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.569 177.487 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 5.3 p -93.64 112.01 25.91 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.324 0 CA-C-O 121.58 0.705 . . . . 0.0 110.912 179.087 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.467 ' HA ' ' HE3' ' A' ' 124' ' ' MET . 6.4 mmt -113.54 144.15 30.79 Favored Pre-proline 0 C--N 1.318 -0.792 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.399 -178.807 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . 0.451 ' HA ' ' HG2' ' A' ' 108' ' ' LYS . 92.4 Cg_endo -88.01 144.71 6.22 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 122.564 2.176 . . . . 0.0 112.648 178.666 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' CYS . . . . . 0.438 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 26.3 m -83.26 171.83 13.2 Favored 'General case' 0 C--O 1.244 0.779 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.069 176.066 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 35.7 t -61.15 151.77 30.35 Favored 'General case' 0 N--CA 1.445 -0.687 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 177.451 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . 0.419 HD11 ' N ' ' A' ' 128' ' ' ILE . 1.8 mp -64.21 124.69 19.48 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.193 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.664 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 99.69 -12.96 61.18 Favored Glycine 0 N--CA 1.44 -1.042 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.439 -177.279 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 76.5 p -111.67 149.7 31.21 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-O 121.158 0.504 . . . . 0.0 111.784 179.782 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 58.8 pttt -121.37 144.71 48.51 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 178.869 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.438 ' HB2' ' SG ' ' A' ' 126' ' ' CYS . 45.0 t80 -82.53 136.15 34.93 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-O 121.178 0.513 . . . . 0.0 111.927 -177.497 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . 0.42 ' HB3' ' OG ' ' A' ' 136' ' ' SER . 19.8 t70 -105.16 130.2 23.51 Favored Pre-proline 0 C--N 1.321 -0.659 0 CA-C-N 115.945 -0.571 . . . . 0.0 109.786 177.366 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' PRO . . . . . 0.401 ' HD3' ' HG3' ' A' ' 101' ' ' PRO . 28.2 Cg_endo -64.68 -42.95 14.13 Favored 'Trans proline' 0 N--CA 1.473 0.317 0 C-N-CA 123.018 2.479 . . . . 0.0 114.236 -176.17 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 2.0 mp -77.61 -50.64 19.74 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 N-CA-C 111.943 0.349 . . . . 0.0 111.943 -175.752 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' SER . . . . . 0.42 ' OG ' ' HB3' ' A' ' 133' ' ' ASP . 64.1 p -70.44 -29.68 66.33 Favored 'General case' 0 C--N 1.325 -0.498 0 C-N-CA 121.037 -0.265 . . . . 0.0 111.184 -179.058 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 71.21 48.83 0.34 Allowed 'General case' 0 C--O 1.234 0.251 0 CA-C-N 115.813 -0.63 . . . . 0.0 111.783 175.331 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 9.5 p30 -160.83 176.58 11.31 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 177.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 17.3 m -101.43 124.72 47.56 Favored 'General case' 0 C--N 1.313 -1.02 0 C-N-CA 120.414 -0.514 . . . . 0.0 109.969 -178.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 31.7 m -111.66 160.05 11.26 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.889 0 CA-C-N 116.062 -0.517 . . . . 0.0 109.802 -179.588 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 78.7 mt -63.22 132.94 53.36 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-O 121.1 0.476 . . . . 0.0 111.367 -179.037 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -97.61 91.09 5.25 Favored 'General case' 0 C--N 1.313 -1.001 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 177.493 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 . . . . . 0 C--N 1.304 -1.397 0 CA-C-O 118.295 -0.859 . . . . 0.0 109.537 -177.157 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.539 0 N-CA-C 111.889 -0.484 . . . . 0.0 111.889 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_exo -58.15 129.67 34.16 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.929 2.42 . . . . 0.0 112.286 179.428 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 4.8 mp -96.52 1.91 51.89 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.82 -179.113 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 101.62 -10.92 57.82 Favored Glycine 0 C--O 1.225 -0.448 0 C-N-CA 120.496 -0.859 . . . . 0.0 111.451 -179.128 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 6.3 m -75.33 -32.64 60.97 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.019 0.438 . . . . 0.0 110.701 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -151.9 98.93 2.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.573 -0.74 . . . . 0.0 109.538 -179.448 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.403 ' CD2' HD13 ' A' ' 121' ' ' ILE . 52.9 tp -111.57 135.78 51.67 Favored 'General case' 0 C--N 1.312 -1.043 0 C-N-CA 120.939 -0.305 . . . . 0.0 110.687 179.562 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 3.8 mt -100.1 145.95 9.88 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.163 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 179.323 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.558 ' O ' ' HA ' ' A' ' 89' ' ' THR . 30.9 m -141.22 170.83 13.11 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 -179.822 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 50.3 m-70 -114.13 113.27 24.48 Favored 'General case' 0 C--N 1.316 -0.888 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 -179.085 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.418 ' CD ' ' HZ2' ' A' ' 108' ' ' LYS . 4.3 mm-40 -112.31 111.84 23.0 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 174.839 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 71.76 13.22 75.02 Favored Glycine 0 N--CA 1.452 -0.235 0 N-CA-C 110.679 -0.968 . . . . 0.0 110.679 -176.633 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 99.76 -17.46 57.39 Favored Glycine 0 N--CA 1.437 -1.295 0 CA-C-N 114.999 -0.601 . . . . 0.0 111.905 -178.18 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 35.3 mmtp -87.16 143.05 27.47 Favored 'General case' 0 CA--C 1.515 -0.397 0 CA-C-O 120.712 0.292 . . . . 0.0 110.691 -177.728 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.558 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.1 OUTLIER -85.62 130.71 34.5 Favored 'General case' 0 N--CA 1.434 -1.234 0 N-CA-C 112.541 0.571 . . . . 0.0 112.541 -179.076 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.442 ' CD1' ' HA3' ' A' ' 104' ' ' GLY . 82.3 m-85 -128.58 138.68 52.34 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 115.608 -0.723 . . . . 0.0 109.854 176.76 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 17.6 m-70 -88.82 143.5 26.86 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 120.831 0.348 . . . . 0.0 110.668 -179.784 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 62.2 t -117.17 122.72 70.64 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.064 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 177.724 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 52.8 t -125.37 131.13 72.64 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.176 0 CA-C-N 116.079 -0.509 . . . . 0.0 109.671 -178.805 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 87.2 m -104.8 114.28 28.39 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-O 121.182 0.515 . . . . 0.0 109.892 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 26.5 m80 -84.25 -23.46 30.39 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.151 -177.71 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -160.67 176.58 11.38 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.692 -0.686 . . . . 0.0 109.389 -179.043 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -79.89 142.8 34.84 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.885 0.374 . . . . 0.0 110.217 178.291 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 130.71 167.77 12.08 Favored Glycine 0 N--CA 1.442 -0.955 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.405 -178.412 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -89.59 133.13 2.17 Favored 'Trans proline' 0 N--CA 1.449 -1.116 0 C-N-CA 122.918 2.412 . . . . 0.0 112.93 179.415 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -138.04 157.31 73.25 Favored Pre-proline 0 C--N 1.318 -0.776 0 CA-C-N 115.71 -0.677 . . . . 0.0 109.463 177.891 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.472 ' HG3' ' HD3' ' A' ' 134' ' ' PRO . 59.4 Cg_endo -68.8 171.14 13.9 Favored 'Trans proline' 0 CA--C 1.515 -0.427 0 C-N-CA 122.234 1.956 . . . . 0.0 112.234 -178.021 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' HIS . . . . . 0.63 ' HB3' ' O ' ' A' ' 105' ' ' ASN . 50.2 t-80 -90.35 126.68 55.78 Favored Pre-proline 0 N--CA 1.43 -1.434 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 178.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -54.58 -43.74 56.14 Favored 'Trans proline' 0 N--CA 1.474 0.38 0 C-N-CA 122.959 2.439 . . . . 0.0 113.126 -174.03 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.442 ' HA3' ' CD1' ' A' ' 90' ' ' TYR . . . -96.68 4.54 63.76 Favored Glycine 0 N--CA 1.442 -0.951 0 C-N-CA 120.057 -1.068 . . . . 0.0 113.633 -178.452 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.63 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 52.2 t30 -163.84 87.3 0.51 Allowed 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 117.683 0.741 . . . . 0.0 111.17 -179.534 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.9 m -54.93 -11.95 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 N-CA-C 113.859 1.059 . . . . 0.0 113.859 178.177 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 19.1 t-80 -77.21 0.39 22.05 Favored 'General case' 0 CA--C 1.543 0.704 0 CA-C-O 121.413 0.625 . . . . 0.0 110.203 177.169 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.418 ' HZ2' ' CD ' ' A' ' 85' ' ' GLU . 39.8 mttp -133.8 156.29 48.29 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.576 178.516 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 9.1 p90 -141.92 162.54 35.22 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 176.497 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 3.3 mp -123.83 140.03 48.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 -178.327 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -99.29 118.84 46.48 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 176.259 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 65.3 m -100.25 123.23 44.23 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 120.743 0.306 . . . . 0.0 110.571 -178.015 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 34.0 t -130.84 139.8 50.19 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.328 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.416 ' HD2' ' CZ2' ' A' ' 119' ' ' TRP . 88.6 tttt -113.92 113.63 25.11 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 120.999 0.428 . . . . 0.0 110.541 -178.707 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 73.4 m -100.52 80.72 2.24 Favored 'General case' 0 N--CA 1.441 -0.887 0 CA-C-O 121.356 0.598 . . . . 0.0 109.974 178.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 76.1 -99.62 1.3 Allowed Glycine 0 N--CA 1.442 -0.914 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.367 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 32.8 m -112.55 4.58 17.44 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.772 0.32 . . . . 0.0 110.59 -179.436 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 12.4 mt -122.77 133.28 54.47 Favored 'General case' 0 N--CA 1.439 -0.995 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.238 -176.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . 0.416 ' CZ2' ' HD2' ' A' ' 114' ' ' LYS . 70.7 m95 -96.04 133.5 40.22 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-O 121.076 0.465 . . . . 0.0 111.472 179.549 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -121.25 122.63 40.35 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 115.785 -0.643 . . . . 0.0 109.38 176.12 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.403 HD13 ' CD2' ' A' ' 81' ' ' LEU . 2.4 pp -122.5 156.22 27.59 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.86 -175.343 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 22.6 m -140.95 123.17 15.72 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.935 178.415 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 5.2 p -95.95 105.29 16.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-O 121.621 0.725 . . . . 0.0 110.841 -179.742 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.455 ' HE1' ' HA ' ' A' ' 124' ' ' MET . 3.5 mmt -106.18 139.48 20.32 Favored Pre-proline 0 C--N 1.314 -0.973 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.139 -178.885 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -85.09 144.63 9.56 Favored 'Trans proline' 0 N--CA 1.448 -1.151 0 C-N-CA 122.2 1.934 . . . . 0.0 112.324 178.617 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' CYS . . . . . 0.533 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 65.7 m -80.61 164.24 23.04 Favored 'General case' 0 C--O 1.242 0.675 0 CA-C-N 116.247 -0.433 . . . . 0.0 109.857 176.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 32.3 t -56.29 148.36 18.8 Favored 'General case' 0 N--CA 1.443 -0.82 0 CA-C-N 116.056 -0.52 . . . . 0.0 109.66 177.082 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . 0.457 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.8 mp -62.97 128.92 25.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.333 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 96.37 -9.04 67.08 Favored Glycine 0 N--CA 1.443 -0.871 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.625 -177.028 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 72.1 p -118.46 153.88 33.39 Favored 'General case' 0 C--O 1.236 0.342 0 CA-C-N 117.292 0.546 . . . . 0.0 111.127 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.407 ' HE2' ' HA ' ' A' ' 142' ' ' ASP . 49.3 pttt -130.0 145.28 51.64 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 116.022 -0.535 . . . . 0.0 109.606 -179.248 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.533 ' HB2' ' SG ' ' A' ' 126' ' ' CYS . 29.4 t80 -84.46 136.88 33.65 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-O 121.088 0.471 . . . . 0.0 111.988 -176.329 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 32.2 t70 -108.56 134.78 20.15 Favored Pre-proline 0 C--N 1.323 -0.556 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.52 177.056 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' PRO . . . . . 0.472 ' HD3' ' HG3' ' A' ' 101' ' ' PRO . 42.0 Cg_endo -68.82 -37.36 11.87 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.577 2.185 . . . . 0.0 113.27 -176.045 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 22.7 mm -77.85 -53.55 14.08 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.881 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.827 -176.426 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 67.0 m -68.98 -29.98 68.3 Favored 'General case' 0 C--N 1.321 -0.662 0 C-N-CA 120.822 -0.351 . . . . 0.0 111.307 178.476 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 89.0 mtm180 70.76 41.57 0.88 Allowed 'General case' 0 N--CA 1.473 0.704 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.656 175.665 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 10.7 p30 -155.66 174.35 15.42 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 177.404 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' CYS . . . . . 0.433 ' SG ' ' HD1' ' A' ' 132' ' ' PHE . 6.4 m -101.26 124.88 47.64 Favored 'General case' 0 C--N 1.314 -0.943 0 C-N-CA 120.341 -0.544 . . . . 0.0 109.62 -179.28 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 33.9 m -107.01 159.8 6.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.833 -179.236 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 55.4 tp -63.47 119.82 10.5 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-O 120.972 0.415 . . . . 0.0 111.456 -178.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' ASP . . . . . 0.407 ' HA ' ' HE2' ' A' ' 131' ' ' LYS . 21.2 t70 -78.76 91.53 4.71 Favored 'General case' 0 N--CA 1.442 -0.85 0 CA-C-O 121.463 0.649 . . . . 0.0 109.309 176.653 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 . . . . . 0 C--N 1.305 -1.326 0 CA-C-N 114.978 -1.01 . . . . 0.0 110.41 -177.22 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.314 0 N-CA-C 111.866 -0.494 . . . . 0.0 111.866 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -76.73 154.75 34.72 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 122.541 2.161 . . . . 0.0 111.577 178.569 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 89.3 mt -135.62 157.05 47.83 Favored 'General case' 0 C--N 1.316 -0.871 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.494 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -109.11 -48.58 0.82 Allowed Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.595 -178.258 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 22.7 t -61.71 -45.47 93.83 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 120.687 0.28 . . . . 0.0 110.648 -179.189 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.625 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 7.6 p-10 -155.43 114.93 3.64 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.352 0.596 . . . . 0.0 111.028 178.025 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 47.0 tp -97.04 140.47 31.51 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.417 177.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 5.5 mt -100.26 145.95 9.97 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.996 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 179.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.475 ' O ' ' HA ' ' A' ' 89' ' ' THR . 17.1 m -142.87 176.01 3.76 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.88 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -179.611 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 41.7 m-70 -117.13 120.93 39.81 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-O 121.108 0.48 . . . . 0.0 111.9 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.419 ' HB2' ' CE1' ' A' ' 90' ' ' TYR . 45.2 mt-10 -126.17 116.09 20.79 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.264 176.51 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 67.16 23.76 73.17 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.624 -0.798 . . . . 0.0 111.232 -178.557 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 93.55 -28.0 11.0 Favored Glycine 0 N--CA 1.443 -0.858 0 C-N-CA 121.437 -0.411 . . . . 0.0 112.725 -178.282 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 44.3 mmtm -84.91 155.01 21.86 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.69 0.281 . . . . 0.0 111.136 -177.058 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.475 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.0 OUTLIER -92.42 137.4 32.4 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.488 -179.949 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.419 ' CE1' ' HB2' ' A' ' 85' ' ' GLU . 89.7 m-85 -131.6 145.38 51.67 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 178.583 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 20.0 m-70 -98.88 143.6 29.01 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-O 120.951 0.405 . . . . 0.0 110.579 179.606 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.625 ' O ' ' HA ' ' A' ' 80' ' ' ASP . 57.2 t -113.93 118.55 58.68 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.161 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 177.109 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 37.3 t -121.15 137.54 54.52 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.242 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 -178.282 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 72.4 m -114.53 113.61 24.66 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-O 120.988 0.423 . . . . 0.0 111.13 -179.751 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 20.8 t60 -81.03 -24.14 38.1 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.769 -0.651 . . . . 0.0 111.076 -178.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -154.34 169.6 23.3 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.551 -0.295 . . . . 0.0 110.615 -178.281 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 21.0 mp0 -76.61 110.61 11.32 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.378 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 161.87 165.84 19.52 Favored Glycine 0 N--CA 1.446 -0.663 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.315 179.85 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.416 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 92.3 Cg_endo -85.75 135.11 4.81 Favored 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 122.907 2.404 . . . . 0.0 112.503 178.628 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -139.92 156.95 70.39 Favored Pre-proline 0 C--N 1.319 -0.724 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.525 179.394 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -63.51 169.21 10.1 Favored 'Trans proline' 0 C--N 1.353 0.775 0 C-N-CA 122.683 2.255 . . . . 0.0 112.54 -179.649 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' HIS . . . . . 0.447 ' CD2' HD12 ' A' ' 110' ' ' ILE . 5.2 t-80 -94.31 138.46 22.47 Favored Pre-proline 0 C--N 1.322 -0.602 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 -178.108 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -53.45 -50.2 14.72 Favored 'Trans proline' 0 CA--C 1.536 0.584 0 C-N-CA 123.109 2.539 . . . . 0.0 113.121 -178.624 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -71.1 -65.21 2.53 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.591 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 43.7 m-80 -115.06 104.94 12.38 Favored 'General case' 0 C--N 1.321 -0.658 0 O-C-N 122.865 -0.197 . . . . 0.0 111.365 -179.806 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 18.5 m -56.25 -12.04 0.99 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 N-CA-C 112.011 0.374 . . . . 0.0 112.011 173.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 24.3 t-80 -66.36 -8.26 24.28 Favored 'General case' 0 CA--C 1.544 0.719 0 CA-C-O 121.407 0.622 . . . . 0.0 110.076 175.58 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 48.4 mtmt -129.55 157.25 42.55 Favored 'General case' 0 N--CA 1.439 -1.001 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.623 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 12.9 p90 -142.14 167.38 22.26 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 120.181 -0.608 . . . . 0.0 111.133 -179.804 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.447 HD12 ' CD2' ' A' ' 102' ' ' HIS . 2.3 mp -126.43 139.4 51.78 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.112 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.173 -179.146 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.7 mp -98.74 116.45 41.73 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.144 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 175.336 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 39.9 m -95.99 121.82 38.14 Favored 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 16.6 t -130.36 149.4 52.06 Favored 'General case' 0 N--CA 1.437 -1.098 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.117 -178.624 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.495 ' HE3' ' CE2' ' A' ' 119' ' ' TRP . 9.1 mmtp -103.23 140.46 37.34 Favored 'General case' 0 C--N 1.308 -1.203 0 CA-C-O 121.224 0.535 . . . . 0.0 111.732 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 57.7 m -124.26 79.92 1.78 Allowed 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 174.207 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 73.39 -104.4 1.58 Allowed Glycine 0 N--CA 1.431 -1.68 0 CA-C-N 114.788 -1.096 . . . . 0.0 110.517 -174.851 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 12.1 p -113.01 16.39 19.35 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-O 120.899 0.38 . . . . 0.0 111.134 178.719 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 24.2 tp -122.14 142.92 49.89 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.289 -177.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . 0.495 ' CE2' ' HE3' ' A' ' 114' ' ' LYS . 91.1 m95 -92.15 133.39 35.82 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 120.984 0.421 . . . . 0.0 111.67 179.161 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 49.2 m-85 -124.19 122.81 38.81 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.123 172.3 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.5 pp -119.78 155.95 22.46 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.44 -176.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 25.7 m -141.06 119.74 12.49 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.655 178.353 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 4.2 p -94.02 109.06 21.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-O 121.684 0.754 . . . . 0.0 111.108 -179.138 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.448 ' HA ' ' HE2' ' A' ' 124' ' ' MET . 5.3 mmt -107.82 127.4 27.79 Favored Pre-proline 0 C--N 1.309 -1.183 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.288 -179.893 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -78.75 142.08 17.64 Favored 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 122.325 2.017 . . . . 0.0 110.819 176.21 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 10.4 t -93.62 -179.08 4.91 Favored 'General case' 0 C--N 1.317 -0.824 0 C-N-CA 120.484 -0.487 . . . . 0.0 110.382 179.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 34.0 t -62.94 146.51 52.86 Favored 'General case' 0 N--CA 1.438 -1.035 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.691 -179.472 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . 0.407 ' N ' HD12 ' A' ' 128' ' ' ILE . 2.0 mp -62.91 129.82 26.78 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-N 116.131 -0.486 . . . . 0.0 109.839 179.397 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.86 -4.04 68.05 Favored Glycine 0 N--CA 1.44 -1.099 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.949 -178.343 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 34.9 p -128.14 150.39 50.01 Favored 'General case' 0 C--O 1.237 0.447 0 CA-C-N 117.28 0.54 . . . . 0.0 110.885 178.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.415 ' O ' ' HA ' ' A' ' 139' ' ' CYS . 62.7 pttt -127.03 154.96 43.98 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.966 -179.616 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 40.3 t80 -87.18 136.87 32.76 Favored 'General case' 0 C--N 1.311 -1.078 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.109 -178.682 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -99.01 134.41 21.44 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.782 178.748 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 26.6 Cg_endo -62.04 -51.3 3.85 Favored 'Trans proline' 0 CA--C 1.532 0.39 0 C-N-CA 123.017 2.478 . . . . 0.0 114.116 -176.63 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 47.2 mm -81.23 -47.25 20.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 112.112 0.412 . . . . 0.0 112.112 -175.803 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.5 m -65.98 -34.46 78.15 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.833 0.349 . . . . 0.0 110.446 -179.228 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 87.7 mtm180 66.14 53.05 1.1 Allowed 'General case' 0 CA--C 1.516 -0.337 0 CA-C-N 115.404 -0.817 . . . . 0.0 110.554 177.757 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 28.2 p-10 -157.47 176.52 12.55 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.034 -0.985 . . . . 0.0 109.191 179.443 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' CYS . . . . . 0.415 ' HA ' ' O ' ' A' ' 131' ' ' LYS . 68.0 m -102.62 131.07 49.64 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-O 121.006 0.431 . . . . 0.0 111.91 178.628 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 33.8 m -125.55 165.85 22.42 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.216 177.288 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -50.26 118.18 2.82 Favored 'General case' 0 N--CA 1.474 0.739 0 CA-C-O 121.108 0.48 . . . . 0.0 111.644 179.809 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 15.3 t0 -84.98 90.77 7.9 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 177.35 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 . . . . . 0 C--N 1.308 -1.212 0 CA-C-N 115.354 -0.839 . . . . 0.0 109.744 -177.622 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.34 0 N-CA-C 111.851 -0.5 . . . . 0.0 111.851 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_exo -65.34 108.47 1.18 Allowed 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 122.836 2.357 . . . . 0.0 111.863 -179.311 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 65.6 mt -88.9 170.6 10.57 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-O 121.309 0.575 . . . . 0.0 111.88 -179.133 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 157.77 -42.61 0.51 Allowed Glycine 0 CA--C 1.499 -0.958 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 -178.578 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 17.2 m -75.43 -40.31 57.81 Favored 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 176.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -136.21 86.4 2.22 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 177.848 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 23.9 tp -90.54 148.57 22.63 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-O 120.865 0.364 . . . . 0.0 110.978 -177.387 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.402 HG23 HG21 ' A' ' 89' ' ' THR . 7.7 mt -105.92 144.77 14.79 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 175.835 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.435 ' O ' ' HA ' ' A' ' 89' ' ' THR . 16.1 m -132.27 158.16 43.23 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 -178.473 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 6.8 p80 -116.49 101.98 9.1 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-O 121.226 0.536 . . . . 0.0 111.571 -177.721 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.4 ' HG2' ' CE1' ' A' ' 102' ' ' HIS . 0.7 OUTLIER -117.27 114.09 23.11 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.12 179.116 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 67.05 22.58 72.48 Favored Glycine 0 CA--C 1.519 0.337 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.478 179.67 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 90.02 -4.71 83.23 Favored Glycine 0 N--CA 1.445 -0.707 0 C-N-CA 121.174 -0.536 . . . . 0.0 112.365 -179.686 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 35.0 mmtp -100.26 134.34 43.34 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 120.716 0.293 . . . . 0.0 110.349 -179.411 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.435 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.0 OUTLIER -88.03 107.74 18.89 Favored 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.257 179.466 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -101.23 146.91 26.9 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.598 178.364 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 18.2 m-70 -98.22 140.04 33.1 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-O 120.881 0.372 . . . . 0.0 110.612 177.653 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 44.5 t -122.04 118.43 55.48 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.481 178.323 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.3 p -129.44 132.76 66.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.494 179.356 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 77.2 m -111.96 123.1 49.53 Favored 'General case' 0 C--N 1.308 -1.228 0 CA-C-O 121.059 0.457 . . . . 0.0 111.11 -178.47 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 34.2 m80 -100.7 -21.6 15.16 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 178.436 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -129.14 144.2 51.12 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.14 -0.937 . . . . 0.0 109.526 -178.83 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . 0.447 ' HG3' ' HA ' ' A' ' 113' ' ' SER . 42.3 tt0 -76.23 138.73 40.79 Favored 'General case' 0 N--CA 1.43 -1.432 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 177.883 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 132.17 173.86 13.45 Favored Glycine 0 N--CA 1.439 -1.107 0 C-N-CA 120.902 -0.666 . . . . 0.0 111.77 -178.21 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -87.36 134.07 3.39 Favored 'Trans proline' 0 N--CA 1.452 -0.961 0 C-N-CA 122.912 2.408 . . . . 0.0 112.951 179.142 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.8 pp -137.02 157.24 75.0 Favored Pre-proline 0 C--N 1.323 -0.544 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.899 178.43 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -65.34 162.58 32.89 Favored 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.41 2.073 . . . . 0.0 113.126 -177.794 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' HIS . . . . . 0.408 ' NE2' HG21 ' A' ' 83' ' ' VAL . 59.5 t-80 -91.78 120.93 67.83 Favored Pre-proline 0 C--N 1.316 -0.881 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.536 179.676 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_endo -60.72 -16.93 46.71 Favored 'Trans proline' 0 N--CA 1.482 0.841 0 C-N-CA 123.132 2.555 . . . . 0.0 113.466 -175.842 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -89.99 -24.09 30.73 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.556 -0.83 . . . . 0.0 112.563 179.874 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 25.7 p-10 -167.4 106.89 0.57 Allowed 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 110.108 -0.33 . . . . 0.0 110.108 -179.174 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 31.2 m -53.09 -11.32 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.045 0 N-CA-C 114.01 1.115 . . . . 0.0 114.01 -179.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -80.48 2.31 25.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.154 0.502 . . . . 0.0 110.935 178.49 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 34.1 mtmt -133.76 156.5 47.86 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 177.736 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 6.6 p90 -142.51 166.21 25.28 Favored 'General case' 0 C--N 1.311 -1.099 0 C-N-CA 120.871 -0.332 . . . . 0.0 110.476 179.331 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 3.7 mp -123.74 137.67 56.09 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.47 ' O ' ' HA ' ' A' ' 121' ' ' ILE . 4.2 mp -95.64 121.74 46.47 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.997 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 176.696 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 25.4 m -105.46 127.16 52.85 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 -178.859 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' SER . . . . . 0.447 ' HA ' ' HG3' ' A' ' 97' ' ' GLU . 52.5 m -126.52 131.79 51.51 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.402 179.251 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.628 ' HE2' ' O ' ' A' ' 116' ' ' GLY . 23.7 tptm -97.49 113.57 25.28 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 120.705 0.288 . . . . 0.0 110.659 -178.87 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 72.1 m -112.99 80.03 1.3 Allowed 'General case' 0 N--CA 1.442 -0.863 0 CA-C-O 121.265 0.555 . . . . 0.0 110.286 178.447 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.628 ' O ' ' HE2' ' A' ' 114' ' ' LYS . . . 74.35 -99.28 1.07 Allowed Glycine 0 N--CA 1.446 -0.679 0 CA-C-N 115.349 -0.841 . . . . 0.0 111.037 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 48.8 p -113.52 4.1 16.05 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 121.12 0.486 . . . . 0.0 110.433 178.065 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 26.8 tp -117.5 132.16 56.59 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.954 -175.479 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . 0.431 ' CZ2' ' HD3' ' A' ' 114' ' ' LYS . 86.3 m95 -94.78 132.06 39.96 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 120.883 0.373 . . . . 0.0 110.746 177.116 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 51.0 m-85 -108.65 128.04 54.5 Favored 'General case' 0 C--N 1.309 -1.162 0 N-CA-C 108.876 -0.786 . . . . 0.0 108.876 174.156 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.47 ' HA ' ' O ' ' A' ' 111' ' ' ILE . 1.8 pp -133.2 153.4 37.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-O 121.367 0.603 . . . . 0.0 112.616 -175.695 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 19.4 m -150.44 127.58 11.24 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.188 178.074 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 4.0 p -98.77 106.74 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 CA-C-O 121.57 0.7 . . . . 0.0 111.061 -178.504 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.454 ' HA ' ' HE3' ' A' ' 124' ' ' MET . 3.5 mmt -108.03 140.27 21.49 Favored Pre-proline 0 C--N 1.309 -1.166 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.654 -179.325 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_endo -82.48 141.47 11.23 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 122.386 2.058 . . . . 0.0 111.36 176.649 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 5.9 t -94.16 -174.87 3.51 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 120.648 -0.421 . . . . 0.0 110.667 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 15.5 m -61.53 137.16 58.23 Favored 'General case' 0 N--CA 1.441 -0.896 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.627 178.413 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 2.4 mp -65.84 139.35 21.41 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.914 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 178.33 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 93.55 -13.93 66.42 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.313 -176.03 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 73.6 p -117.41 159.53 22.64 Favored 'General case' 0 N--CA 1.447 -0.614 0 O-C-N 122.479 -0.424 . . . . 0.0 110.735 179.319 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 59.8 pttt -129.07 148.29 51.0 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.698 179.609 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.442 ' HD1' ' SG ' ' A' ' 139' ' ' CYS . 25.5 t80 -87.68 135.63 33.29 Favored 'General case' 0 C--N 1.308 -1.229 0 CA-C-O 120.825 0.345 . . . . 0.0 110.714 -178.58 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 30.5 t70 -102.47 134.99 19.64 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.015 178.706 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.23 -41.16 13.28 Favored 'Trans proline' 0 C--N 1.346 0.419 0 C-N-CA 123.021 2.481 . . . . 0.0 113.862 -176.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 33.1 mm -81.39 -52.69 13.57 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 C-N-CA 120.819 -0.353 . . . . 0.0 111.525 -176.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 7.2 m -62.69 -36.79 84.06 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 120.855 0.359 . . . . 0.0 110.394 179.153 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 80.5 mtm180 69.36 42.83 1.12 Allowed 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 115.356 -0.838 . . . . 0.0 111.157 177.24 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 10.5 p30 -154.39 177.57 11.01 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 108.393 -0.965 . . . . 0.0 108.393 177.197 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' CYS . . . . . 0.442 ' SG ' ' HD1' ' A' ' 132' ' ' PHE . 78.1 m -101.77 126.68 48.68 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-O 121.385 0.612 . . . . 0.0 111.737 -177.91 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 26.8 m -115.2 159.1 15.26 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-N 115.185 -0.916 . . . . 0.0 109.553 179.436 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 2.3 tm? -55.41 123.24 13.23 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 120.963 0.411 . . . . 0.0 110.915 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -89.17 101.42 14.08 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.045 -179.467 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 37.8 t30 . . . . . 0 C--O 1.251 1.171 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.619 177.58 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.349 0 N-CA-C 111.892 -0.483 . . . . 0.0 111.892 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -78.46 44.11 1.56 Allowed 'Trans proline' 0 C--N 1.348 0.53 0 C-N-CA 123.116 2.544 . . . . 0.0 112.416 -178.242 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 84.8 mt -89.54 -175.02 4.56 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.496 -179.089 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -119.74 -38.59 0.7 Allowed Glycine 0 N--CA 1.442 -0.901 0 C-N-CA 120.8 -0.714 . . . . 0.0 111.534 179.607 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 20.1 m -77.85 -32.15 51.9 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.893 0.378 . . . . 0.0 111.108 179.823 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -138.13 100.2 4.08 Favored 'General case' 0 C--O 1.237 0.396 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 -176.161 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.415 ' CD2' HD11 ' A' ' 121' ' ' ILE . 35.3 tp -101.26 147.14 26.64 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.244 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.404 HG23 HG23 ' A' ' 89' ' ' THR . 4.0 mt -110.24 148.29 13.88 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.869 0 C-N-CA 120.561 -0.455 . . . . 0.0 110.374 178.553 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.51 HG22 ' HE2' ' A' ' 102' ' ' HIS . 4.8 m -142.44 174.72 5.39 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 179.58 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 11.0 p80 -128.21 108.36 10.55 Favored 'General case' 0 C--N 1.313 -1.0 0 N-CA-C 112.503 0.557 . . . . 0.0 112.503 -177.751 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 3.9 mp0 -116.65 113.63 22.94 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.105 178.708 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 66.68 31.64 79.05 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.628 178.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 86.19 -11.75 62.15 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.839 -0.696 . . . . 0.0 113.201 179.243 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 30.2 mmtp -99.09 136.94 38.32 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.871 0.336 . . . . 0.0 111.166 -179.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.48 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.0 OUTLIER -86.54 107.77 18.27 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.474 179.268 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -100.3 145.14 28.48 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.816 179.258 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 27.1 m-70 -99.43 144.09 28.94 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.36 178.355 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 46.2 t -120.51 118.38 56.39 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.078 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 178.452 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 44.1 t -124.56 132.6 71.1 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.274 179.478 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 71.3 m -104.43 113.77 27.55 Favored 'General case' 0 C--N 1.31 -1.141 0 CA-C-O 121.113 0.482 . . . . 0.0 110.305 -179.564 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 19.0 t60 -79.49 -21.2 45.66 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.509 -178.144 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -161.53 175.81 11.72 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.654 179.714 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -77.92 144.6 36.73 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 120.735 0.302 . . . . 0.0 110.461 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 126.45 164.41 11.74 Favored Glycine 0 N--CA 1.446 -0.658 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.41 -179.685 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 92.1 Cg_endo -86.78 138.28 5.09 Favored 'Trans proline' 0 CA--C 1.54 0.814 0 C-N-CA 122.869 2.379 . . . . 0.0 113.179 179.376 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -140.91 157.27 67.75 Favored Pre-proline 0 C--N 1.325 -0.482 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.169 177.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -64.22 166.94 15.54 Favored 'Trans proline' 0 C--N 1.353 0.763 0 C-N-CA 122.666 2.244 . . . . 0.0 112.848 -179.138 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' HIS . . . . . 0.51 ' HE2' HG22 ' A' ' 83' ' ' VAL . 56.5 t-80 -92.82 128.36 44.09 Favored Pre-proline 0 C--N 1.318 -0.769 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.592 -179.088 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -63.09 -19.25 68.46 Favored 'Trans proline' 0 N--CA 1.484 0.934 0 C-N-CA 123.146 2.564 . . . . 0.0 113.398 -176.841 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -96.81 -17.54 32.58 Favored Glycine 0 C--O 1.228 -0.275 0 C-N-CA 120.485 -0.865 . . . . 0.0 113.226 -178.846 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 28.2 p-10 -169.23 104.21 0.37 Allowed 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.698 0.285 . . . . 0.0 110.8 -179.36 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 26.0 m -53.82 -13.14 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 N-CA-C 113.935 1.087 . . . . 0.0 113.935 179.069 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 36.4 m170 -74.88 0.11 16.7 Favored 'General case' 0 N--CA 1.471 0.621 0 CA-C-O 121.081 0.467 . . . . 0.0 110.858 177.043 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 31.2 mtmt -134.91 156.69 48.52 Favored 'General case' 0 CA--C 1.507 -0.705 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 178.555 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 9.9 p90 -142.47 168.74 19.01 Favored 'General case' 0 C--N 1.31 -1.135 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.433 178.828 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 3.5 mp -126.2 140.02 49.89 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 -179.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -98.7 118.16 44.83 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 176.287 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 68.8 m -100.4 123.61 44.85 Favored 'General case' 0 C--N 1.308 -1.232 0 CA-C-O 120.873 0.368 . . . . 0.0 110.418 -178.462 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 56.0 p -131.87 141.19 49.32 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 178.42 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 81.2 tttt -116.52 106.24 13.36 Favored 'General case' 0 C--N 1.311 -1.087 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.621 -178.611 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 69.6 m -88.59 84.48 6.75 Favored 'General case' 0 N--CA 1.436 -1.154 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.52 179.094 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 73.98 -100.2 1.11 Allowed Glycine 0 N--CA 1.439 -1.103 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -178.153 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 50.3 m -115.04 3.62 14.49 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-O 121.203 0.525 . . . . 0.0 109.826 178.633 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 92.2 mt -108.54 122.82 47.85 Favored 'General case' 0 N--CA 1.435 -1.209 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.542 -176.248 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 86.6 m95 -87.65 130.51 34.76 Favored 'General case' 0 C--N 1.315 -0.903 0 C-N-CA 120.414 -0.514 . . . . 0.0 111.315 179.145 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 85.6 m-85 -122.61 125.73 46.25 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.585 174.133 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.415 HD11 ' CD2' ' A' ' 81' ' ' LEU . 2.2 pp -124.95 157.88 33.06 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.177 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.035 -178.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 32.7 m -145.32 121.66 10.93 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 116.148 -0.478 . . . . 0.0 109.718 177.178 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.5 p -93.81 106.41 18.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 CA-C-O 121.491 0.663 . . . . 0.0 110.775 -178.685 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.45 ' HA ' ' HE2' ' A' ' 124' ' ' MET . 4.2 mmt -106.75 136.3 19.44 Favored Pre-proline 0 C--N 1.31 -1.111 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.97 -178.662 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -82.54 139.3 10.09 Favored 'Trans proline' 0 N--CA 1.45 -1.062 0 C-N-CA 122.411 2.074 . . . . 0.0 110.87 176.078 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 4.7 t -94.61 -178.62 4.61 Favored 'General case' 0 C--N 1.311 -1.071 0 C-N-CA 120.104 -0.639 . . . . 0.0 109.325 177.831 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 15.4 m -63.56 135.1 56.58 Favored 'General case' 0 N--CA 1.435 -1.204 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.408 179.756 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . 0.402 ' N ' HD13 ' A' ' 128' ' ' ILE . 2.2 mp -62.62 141.36 18.07 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 N-CA-C 109.014 -0.735 . . . . 0.0 109.014 178.264 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.8 -10.61 74.17 Favored Glycine 0 N--CA 1.441 -0.985 0 C-N-CA 120.285 -0.959 . . . . 0.0 112.551 -175.186 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 73.5 p -125.02 152.96 43.57 Favored 'General case' 0 N--CA 1.45 -0.438 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 177.003 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 60.5 pttt -126.85 146.69 50.18 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 110.327 -0.249 . . . . 0.0 110.327 -178.366 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 37.9 t80 -84.42 131.38 34.68 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.87 -178.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 23.1 t70 -97.41 133.84 23.32 Favored Pre-proline 0 C--N 1.321 -0.65 0 CA-C-N 116.068 -0.515 . . . . 0.0 109.907 179.29 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -68.02 -40.83 8.43 Favored 'Trans proline' 0 CA--C 1.531 0.371 0 C-N-CA 122.69 2.26 . . . . 0.0 113.842 -177.242 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.8 mp -80.3 -52.05 15.09 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 111.778 0.288 . . . . 0.0 111.778 -177.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 2.1 m -67.03 -35.11 79.17 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.079 0.466 . . . . 0.0 110.092 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 50.7 mtm180 66.37 56.22 0.8 Allowed 'General case' 0 C--O 1.238 0.464 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.645 178.402 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 29.4 p-10 -162.18 174.92 12.26 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 114.647 -1.16 . . . . 0.0 108.75 178.785 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 79.2 m -102.72 126.48 49.84 Favored 'General case' 0 C--N 1.311 -1.068 0 CA-C-O 121.023 0.44 . . . . 0.0 110.805 179.152 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 32.3 m -120.33 170.29 10.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.738 -0.664 . . . . 0.0 110.293 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -51.11 116.89 2.22 Favored 'General case' 0 C--O 1.241 0.615 0 O-C-N 123.545 0.528 . . . . 0.0 110.722 178.794 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -85.41 100.02 11.58 Favored 'General case' 0 CA--C 1.508 -0.669 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.606 179.766 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 9.9 p-10 . . . . . 0 C--N 1.3 -1.547 0 CA-C-O 118.417 -0.801 . . . . 0.0 109.497 174.719 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.974 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_endo -61.97 -31.46 84.27 Favored 'Trans proline' 0 C--N 1.347 0.45 0 C-N-CA 122.478 2.119 . . . . 0.0 111.648 178.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 96.1 mt -93.3 168.78 10.86 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.46 179.599 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 158.44 -29.35 0.45 Allowed Glycine 0 C--N 1.308 -1.002 0 N-CA-C 110.709 -0.956 . . . . 0.0 110.709 -179.367 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 58.7 m -75.44 -28.63 59.42 Favored 'General case' 0 C--O 1.241 0.657 0 CA-C-O 121.34 0.591 . . . . 0.0 109.429 177.864 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -148.75 129.52 14.19 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-N 115.045 -0.98 . . . . 0.0 110.012 178.775 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 49.4 tp -127.2 135.73 51.06 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 115.417 -0.811 . . . . 0.0 111.276 178.312 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 22.1 mt -94.84 144.58 9.52 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.131 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 176.017 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.525 HG21 ' CE1' ' A' ' 102' ' ' HIS . 20.5 m -131.34 174.22 13.44 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 N-CA-C 109.997 -0.371 . . . . 0.0 109.997 -177.261 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 27.2 m-70 -122.07 101.92 7.83 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 116.528 -0.305 . . . . 0.0 110.93 -178.822 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 34.8 mm-40 -111.32 117.57 33.5 Favored 'General case' 0 C--N 1.32 -0.697 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 178.121 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 63.33 29.24 73.91 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.863 -0.684 . . . . 0.0 111.867 -179.427 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 84.96 -9.35 66.35 Favored Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 121.087 -0.578 . . . . 0.0 113.132 -179.79 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 13.6 mptt -100.57 141.58 33.23 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.993 0.425 . . . . 0.0 111.327 -179.359 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.485 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.0 OUTLIER -82.97 122.24 28.03 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.67 179.47 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 76.1 m-85 -118.21 143.08 46.82 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 176.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 17.7 m-70 -94.46 139.59 30.94 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-O 120.65 0.262 . . . . 0.0 110.664 -178.275 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 60.4 t -119.46 118.14 56.36 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.88 0 N-CA-C 108.99 -0.745 . . . . 0.0 108.99 177.126 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 53.3 t -126.21 133.96 67.58 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.945 -178.741 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 66.6 m -114.64 121.25 42.83 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-O 120.779 0.323 . . . . 0.0 110.372 -178.819 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 39.1 m80 -90.23 -18.45 25.66 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.183 -179.811 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -150.11 170.05 19.82 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.648 -177.509 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -87.46 114.23 23.88 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.182 177.414 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 167.46 166.11 25.99 Favored Glycine 0 N--CA 1.436 -1.351 0 C-N-CA 121.049 -0.596 . . . . 0.0 111.624 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.464 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 87.6 Cg_endo -87.21 130.98 3.0 Favored 'Trans proline' 0 N--CA 1.45 -1.068 0 C-N-CA 122.761 2.307 . . . . 0.0 112.773 178.763 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.5 pp -140.94 156.74 68.41 Favored Pre-proline 0 C--N 1.319 -0.751 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.908 178.264 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -64.72 167.32 15.69 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 122.824 2.349 . . . . 0.0 113.163 -177.538 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' HIS . . . . . 0.525 ' CE1' HG21 ' A' ' 83' ' ' VAL . 4.9 t-80 -93.18 123.77 59.85 Favored Pre-proline 0 C--N 1.316 -0.87 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 -179.207 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 23.2 Cg_endo -58.64 -29.56 89.62 Favored 'Trans proline' 0 N--CA 1.482 0.817 0 C-N-CA 123.147 2.565 . . . . 0.0 114.155 -174.326 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -90.21 -16.08 56.29 Favored Glycine 0 C--N 1.319 -0.389 0 C-N-CA 120.085 -1.055 . . . . 0.0 113.238 -178.547 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 9.3 p-10 -168.07 97.47 0.44 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 120.773 0.321 . . . . 0.0 110.61 -177.122 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 30.5 m -56.07 -10.52 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 N-CA-C 113.768 1.025 . . . . 0.0 113.768 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 32.2 m170 -70.38 0.23 6.95 Favored 'General case' 0 N--CA 1.478 0.927 0 CA-C-O 121.352 0.596 . . . . 0.0 110.327 175.499 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.461 ' HG2' ' HA ' ' A' ' 125' ' ' PRO . 86.5 mttt -134.16 157.99 44.81 Favored 'General case' 0 CA--C 1.505 -0.758 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.021 178.91 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 12.3 p90 -143.44 165.83 26.45 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.391 176.616 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.464 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 2.3 mp -124.52 140.59 47.32 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.166 0 CA-C-O 120.798 0.333 . . . . 0.0 110.233 -178.758 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.4 mp -103.33 114.09 41.96 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 175.595 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 34.4 m -96.88 123.02 40.48 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -178.119 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 29.7 p -134.62 145.65 48.82 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-O 120.955 0.407 . . . . 0.0 111.087 -178.497 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . 0.518 ' HE2' ' O ' ' A' ' 116' ' ' GLY . 87.2 tttt -111.3 120.46 42.31 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-N 115.99 -0.55 . . . . 0.0 109.545 179.195 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 57.6 m -103.33 85.86 2.56 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.75 178.828 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.518 ' O ' ' HE2' ' A' ' 114' ' ' LYS . . . 66.91 -100.65 0.58 Allowed Glycine 0 N--CA 1.442 -0.958 0 CA-C-N 115.221 -0.899 . . . . 0.0 111.882 -178.58 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 15.1 m -110.3 6.58 22.56 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 120.741 0.305 . . . . 0.0 111.332 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -124.89 135.67 53.08 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 122.235 -0.291 . . . . 0.0 110.469 -178.768 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 52.6 m95 -94.65 135.79 35.71 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 120.945 0.402 . . . . 0.0 111.73 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -129.23 129.58 45.19 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.999 176.485 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.6 pp -123.86 147.63 28.21 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 120.82 0.343 . . . . 0.0 110.819 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 25.0 m -132.01 124.35 29.13 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.515 -179.326 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 4.4 p -98.25 108.71 22.46 Favored 'Isoleucine or valine' 0 C--O 1.236 0.373 0 CA-C-O 121.496 0.665 . . . . 0.0 110.813 179.38 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.476 ' HA ' ' HE2' ' A' ' 124' ' ' MET . 5.5 mmt -107.33 129.95 23.54 Favored Pre-proline 0 C--N 1.307 -1.253 0 CA-C-N 115.424 -0.807 . . . . 0.0 110.658 -179.054 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . 0.461 ' HA ' ' HG2' ' A' ' 108' ' ' LYS . 74.5 Cg_endo -79.52 134.48 11.16 Favored 'Trans proline' 0 N--CA 1.452 -0.92 0 C-N-CA 122.244 1.963 . . . . 0.0 110.817 176.463 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 5.0 t -88.57 -177.51 5.6 Favored 'General case' 0 C--N 1.311 -1.095 0 C-N-CA 120.267 -0.573 . . . . 0.0 110.354 -179.075 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 4.9 m -63.41 147.61 50.77 Favored 'General case' 0 N--CA 1.441 -0.894 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.188 -179.838 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 2.1 mp -65.97 139.13 21.75 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.584 178.36 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 88.72 -12.21 66.26 Favored Glycine 0 N--CA 1.441 -1.018 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.556 -177.781 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 64.1 p -118.41 156.48 28.91 Favored 'General case' 0 N--CA 1.448 -0.547 0 CA-C-N 117.163 0.481 . . . . 0.0 110.847 178.73 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.448 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 62.1 pttt -133.28 152.16 51.92 Favored 'General case' 0 C--N 1.316 -0.886 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 20.8 t80 -86.1 136.16 33.33 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-O 121.004 0.431 . . . . 0.0 111.348 -179.062 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -101.48 134.64 20.13 Favored Pre-proline 0 C--N 1.325 -0.461 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.909 178.05 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -71.99 -33.06 10.26 Favored 'Trans proline' 0 CA--C 1.533 0.467 0 C-N-CA 122.65 2.233 . . . . 0.0 113.924 -177.258 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.7 mp -81.04 -55.12 8.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 111.697 0.258 . . . . 0.0 111.697 -177.737 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 49.9 m -72.84 -30.82 64.32 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.602 0.239 . . . . 0.0 111.073 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 68.54 50.32 0.7 Allowed 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.102 178.73 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 30.1 p-10 -151.96 176.43 11.49 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-N 115.262 -0.881 . . . . 0.0 108.954 178.855 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' CYS . . . . . 0.403 ' HA ' ' O ' ' A' ' 131' ' ' LYS . 85.5 m -102.36 126.18 49.3 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-O 121.037 0.446 . . . . 0.0 110.474 178.333 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.6 m -118.62 166.6 12.83 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.919 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.917 179.791 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -54.25 117.28 3.15 Favored 'General case' 0 CA--C 1.537 0.467 0 CA-C-O 121.003 0.43 . . . . 0.0 110.361 179.244 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' ASP . . . . . 0.448 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 18.9 t70 -81.63 91.94 6.49 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.449 -178.456 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 47.4 t30 . . . . . 0 C--O 1.244 0.801 0 CA-C-O 118.543 -0.742 . . . . 0.0 109.703 176.843 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.393 0 N-CA-C 111.829 -0.509 . . . . 0.0 111.829 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -69.36 125.06 11.89 Favored 'Trans proline' 0 C--O 1.236 0.381 0 C-N-CA 122.674 2.249 . . . . 0.0 112.068 -179.878 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -70.96 156.83 39.15 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.56 179.627 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -103.56 -48.13 1.23 Allowed Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 120.453 -0.88 . . . . 0.0 113.365 -176.768 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 25.0 t -59.33 -39.99 84.88 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.871 0.367 . . . . 0.0 110.669 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.505 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 4.8 p-10 -150.2 122.74 8.53 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-O 121.537 0.684 . . . . 0.0 111.255 178.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -98.19 127.55 44.19 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.068 -0.969 . . . . 0.0 108.45 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.469 ' CG2' HG22 ' A' ' 89' ' ' THR . 24.9 mt -90.5 145.09 7.84 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.958 0 CA-C-O 120.952 0.406 . . . . 0.0 111.247 -177.128 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 20.7 m -131.82 168.22 24.5 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.007 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 179.441 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 12.1 p80 -127.15 113.18 16.04 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-O 121.035 0.445 . . . . 0.0 111.601 -178.614 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.438 ' CD ' ' HZ3' ' A' ' 108' ' ' LYS . 64.1 mm-40 -119.95 102.42 8.54 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.663 -179.47 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 65.29 40.16 96.41 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.934 -0.651 . . . . 0.0 112.589 178.734 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 84.66 -8.66 68.03 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.976 179.777 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 34.7 mmtp -100.69 128.68 46.65 Favored 'General case' 0 CA--C 1.511 -0.526 0 CA-C-O 120.95 0.405 . . . . 0.0 110.91 -178.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.469 HG22 ' CG2' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -86.4 127.31 34.81 Favored 'General case' 0 C--N 1.307 -1.281 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.102 178.607 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 88.0 m-85 -121.51 148.96 43.78 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.048 178.782 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 25.1 m-70 -102.4 143.24 32.39 Favored 'General case' 0 C--N 1.307 -1.249 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.049 179.217 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.505 ' O ' ' HA ' ' A' ' 80' ' ' ASP . 99.1 t -118.76 126.29 75.13 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.379 179.534 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.4 p -143.21 131.59 19.59 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.959 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.6 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 64.7 m -128.62 131.25 48.09 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 120.838 0.351 . . . . 0.0 110.858 179.804 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 28.5 m80 -105.02 -11.07 16.8 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.117 0.484 . . . . 0.0 109.961 179.71 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 6.9 mp0 -127.35 143.36 51.23 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.206 179.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -78.46 109.99 13.12 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-O 120.917 0.389 . . . . 0.0 110.896 -179.565 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 167.94 168.35 29.94 Favored Glycine 0 N--CA 1.434 -1.434 0 N-CA-C 111.566 -0.614 . . . . 0.0 111.566 -179.645 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.434 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 83.1 Cg_endo -87.12 137.75 4.58 Favored 'Trans proline' 0 N--CA 1.451 -1.016 0 C-N-CA 122.841 2.361 . . . . 0.0 112.559 178.447 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.8 pp -139.01 157.64 71.09 Favored Pre-proline 0 C--N 1.317 -0.812 0 CA-C-N 115.987 -0.551 . . . . 0.0 109.586 178.36 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -63.16 168.65 10.52 Favored 'Trans proline' 0 C--N 1.35 0.609 0 C-N-CA 122.471 2.114 . . . . 0.0 112.856 -178.175 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' HIS . . . . . . . . . . . . . 3.6 t-80 -92.87 122.95 62.78 Favored Pre-proline 0 C--N 1.315 -0.899 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 -179.617 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -59.83 -21.8 65.47 Favored 'Trans proline' 0 N--CA 1.483 0.888 0 C-N-CA 122.99 2.46 . . . . 0.0 113.786 -176.361 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -95.93 -16.57 38.18 Favored Glycine 0 CA--C 1.519 0.283 0 C-N-CA 120.165 -1.017 . . . . 0.0 113.216 -178.798 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 3.0 p30 -168.24 101.86 0.44 Allowed 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 122.596 0.358 . . . . 0.0 110.904 -178.736 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . 0.451 ' CG1' ' HB2' ' A' ' 131' ' ' LYS . 6.0 t -53.23 -16.86 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.064 0 N-CA-C 113.596 0.962 . . . . 0.0 113.596 -179.584 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 8.5 m170 -72.88 5.48 3.22 Favored 'General case' 0 N--CA 1.479 0.999 0 O-C-N 121.936 -0.478 . . . . 0.0 111.39 177.732 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.438 ' HZ3' ' CD ' ' A' ' 85' ' ' GLU . 46.4 mtmt -139.74 158.93 43.29 Favored 'General case' 0 N--CA 1.44 -0.958 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 178.773 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 6.5 p90 -142.87 173.73 11.28 Favored 'General case' 0 C--N 1.302 -1.463 0 CA-C-O 120.866 0.365 . . . . 0.0 110.849 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.434 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 4.1 mt -130.6 138.55 53.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.936 -179.156 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -102.31 117.45 47.69 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 176.334 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 74.0 m -107.46 123.7 48.79 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-O 121.231 0.539 . . . . 0.0 110.709 -177.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 13.9 t -131.05 148.44 52.74 Favored 'General case' 0 C--N 1.311 -1.107 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.53 -178.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 34.1 tttm -116.87 112.1 20.6 Favored 'General case' 0 N--CA 1.435 -1.191 0 CA-C-O 121.28 0.562 . . . . 0.0 110.624 -178.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 8.5 t -94.44 100.49 12.49 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 179.598 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 64.29 -104.63 0.93 Allowed Glycine 0 N--CA 1.439 -1.101 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -175.852 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 31.3 m -114.11 9.51 17.24 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 116.674 0.237 . . . . 0.0 111.624 178.798 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 6.9 tt -121.54 135.79 54.99 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.809 0.337 . . . . 0.0 110.636 -176.725 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 84.2 m95 -93.74 133.27 37.28 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.141 0.496 . . . . 0.0 112.295 -177.615 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -117.65 127.31 53.82 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.65 -0.704 . . . . 0.0 109.161 174.38 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.5 pp -123.41 146.72 28.34 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.944 0 CA-C-O 121.1 0.476 . . . . 0.0 111.22 -178.596 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 18.6 m -136.83 122.85 20.25 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.765 179.231 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 2.7 p -94.99 111.31 25.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 121.344 0.593 . . . . 0.0 110.782 179.279 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.459 ' HA ' ' HE3' ' A' ' 124' ' ' MET . 5.3 mmt -112.25 151.23 43.54 Favored Pre-proline 0 C--N 1.314 -0.977 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.512 -178.844 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . 0.419 ' HA ' ' HG2' ' A' ' 108' ' ' LYS . 89.6 Cg_endo -89.18 143.84 4.82 Favored 'Trans proline' 0 N--CA 1.452 -0.913 0 C-N-CA 122.409 2.072 . . . . 0.0 112.414 177.9 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' CYS . . . . . 0.503 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 56.9 m -80.42 169.61 17.48 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.396 176.937 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 23.9 m -54.77 146.21 17.66 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.156 176.542 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . 0.469 HD11 ' N ' ' A' ' 128' ' ' ILE . 1.8 mp -61.86 123.57 14.83 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.146 0 CA-C-O 121.026 0.441 . . . . 0.0 110.598 -178.712 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.02 5.48 62.47 Favored Glycine 0 N--CA 1.445 -0.706 0 CA-C-N 115.731 -0.668 . . . . 0.0 113.048 -177.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 48.2 p -121.14 167.34 12.76 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 117.117 0.458 . . . . 0.0 111.265 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.504 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 61.4 pttt -138.56 145.56 40.79 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 178.755 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.54 ' HD1' ' SG ' ' A' ' 139' ' ' CYS . 33.3 t80 -85.32 132.75 34.2 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 121.018 0.437 . . . . 0.0 111.995 -176.86 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -99.83 130.9 25.45 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.729 177.681 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_endo -62.78 -42.68 24.02 Favored 'Trans proline' 0 C--N 1.346 0.445 0 C-N-CA 123.087 2.525 . . . . 0.0 113.993 -176.06 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 35.5 mm -81.04 -48.73 18.94 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 C-N-CA 120.879 -0.328 . . . . 0.0 111.567 -176.668 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.6 m -63.69 -34.06 77.03 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.704 0.288 . . . . 0.0 110.705 179.248 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 79.5 mtm180 68.66 42.53 1.45 Allowed 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.454 177.6 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 10.5 p30 -157.27 171.35 20.57 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.301 -0.863 . . . . 0.0 108.766 176.706 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' CYS . . . . . 0.54 ' SG ' ' HD1' ' A' ' 132' ' ' PHE . 8.9 m -101.36 125.45 48.0 Favored 'General case' 0 C--N 1.318 -0.79 0 C-N-CA 120.696 -0.402 . . . . 0.0 110.405 -178.286 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.6 m -110.06 163.41 7.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.657 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 32.0 tp -59.74 119.98 8.66 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.799 0.333 . . . . 0.0 111.111 -178.758 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' ASP . . . . . 0.504 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 18.9 t70 -83.4 97.34 8.9 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.407 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 7.3 p30 . . . . . 0 C--N 1.317 -0.826 0 CA-C-O 118.229 -0.891 . . . . 0.0 110.77 -178.03 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.129 0 N-CA-C 111.676 -0.57 . . . . 0.0 111.676 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 20.6 Cg_exo -66.21 100.06 0.44 Allowed 'Trans proline' 0 C--O 1.237 0.454 0 C-N-CA 122.566 2.177 . . . . 0.0 111.861 178.503 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 38.8 tp -87.6 -17.12 32.66 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-O 121.418 0.628 . . . . 0.0 110.409 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.485 ' HA3' ' HB2' ' A' ' 119' ' ' TRP . . . 93.72 -19.98 49.66 Favored Glycine 0 N--CA 1.444 -0.785 0 CA-C-N 115.534 -0.757 . . . . 0.0 113.367 178.114 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 50.5 m -65.61 -32.87 74.68 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.871 0.367 . . . . 0.0 110.151 178.708 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.468 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 4.3 p-10 -164.44 113.21 1.13 Allowed 'General case' 0 N--CA 1.452 -0.332 0 CA-C-O 121.54 0.686 . . . . 0.0 109.658 174.428 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -103.44 133.97 47.59 Favored 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 -179.62 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.569 ' CG2' HG23 ' A' ' 89' ' ' THR . 20.9 mt -94.66 140.65 16.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-O 121.076 0.465 . . . . 0.0 111.223 -177.63 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.44 HG22 ' NE2' ' A' ' 102' ' ' HIS . 28.2 m -129.68 160.84 40.27 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.122 -179.182 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 84.3 m-70 -116.72 102.59 9.56 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.312 -179.446 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 53.6 mm-40 -109.81 104.76 13.77 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.258 -179.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 60.2 40.64 97.55 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.797 -179.786 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 81.75 -14.21 32.2 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 121.193 -0.527 . . . . 0.0 113.076 -178.737 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 35.5 mmtp -90.2 126.85 35.96 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 117.062 0.431 . . . . 0.0 110.838 -178.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.569 HG23 ' CG2' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -83.49 121.95 27.88 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.985 178.742 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 78.9 m-85 -117.78 154.4 31.8 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 116.241 -0.436 . . . . 0.0 109.977 177.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 28.3 m-70 -106.2 141.1 38.12 Favored 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 176.891 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . 0.468 ' O ' ' HA ' ' A' ' 80' ' ' ASP . 55.1 t -115.86 120.66 65.45 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 178.494 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 57.2 t -124.44 131.21 73.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 -178.733 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 81.5 m -113.66 112.56 23.69 Favored 'General case' 0 C--N 1.313 -1.019 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 179.373 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 27.9 t60 -91.77 -17.06 25.94 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.086 -178.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -137.12 150.84 48.24 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.769 -178.63 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -75.23 141.19 43.58 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.39 179.015 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 125.37 172.09 13.38 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.528 -0.844 . . . . 0.0 112.522 -179.616 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -84.25 131.02 4.83 Favored 'Trans proline' 0 CA--C 1.537 0.666 0 C-N-CA 122.919 2.413 . . . . 0.0 112.857 178.757 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.9 pp -137.69 158.94 70.81 Favored Pre-proline 0 C--N 1.32 -0.68 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.395 178.367 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -64.66 168.96 12.19 Favored 'Trans proline' 0 C--N 1.351 0.686 0 C-N-CA 122.674 2.25 . . . . 0.0 112.821 -179.275 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' HIS . . . . . 0.472 ' HB3' ' O ' ' A' ' 105' ' ' ASN . 8.5 t-80 -92.21 129.93 39.63 Favored Pre-proline 0 C--N 1.318 -0.804 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 -178.71 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_endo -53.45 -44.09 51.97 Favored 'Trans proline' 0 C--N 1.356 0.967 0 C-N-CA 123.164 2.576 . . . . 0.0 113.42 -175.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -71.02 -62.31 3.61 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.235 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.472 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 2.7 p30 -122.91 107.59 12.02 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-O 120.819 0.342 . . . . 0.0 111.382 -179.542 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . 0.4 ' C ' ' H ' ' A' ' 108' ' ' LYS . 30.1 m -57.28 -10.18 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 113.064 0.765 . . . . 0.0 113.064 177.825 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 94.7 m-70 -74.13 3.74 6.63 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-O 121.505 0.669 . . . . 0.0 110.375 177.02 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.4 ' H ' ' C ' ' A' ' 106' ' ' VAL . 58.7 mttp -131.2 156.75 44.81 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 177.228 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 7.1 p90 -142.28 161.74 37.25 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 120.334 -0.546 . . . . 0.0 110.352 177.22 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.425 HD11 ' HA ' ' A' ' 102' ' ' HIS . 2.9 mp -123.47 141.31 44.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 -178.624 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.6 mp -97.45 112.48 29.6 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 175.371 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 42.0 m -97.93 122.04 40.58 Favored 'General case' 0 C--N 1.311 -1.081 0 CA-C-O 120.989 0.423 . . . . 0.0 110.675 -177.455 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 27.6 t -126.35 137.34 53.45 Favored 'General case' 0 N--CA 1.437 -1.116 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 178.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -108.49 122.15 46.44 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-O 120.817 0.342 . . . . 0.0 110.423 -179.143 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 43.1 m -116.42 105.82 12.93 Favored 'General case' 0 N--CA 1.434 -1.274 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.173 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 59.89 -110.9 3.12 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.343 -175.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 20.8 m -113.2 16.27 19.18 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.095 0.474 . . . . 0.0 110.144 179.143 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 6.0 mp -124.51 141.79 51.82 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.474 -177.168 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . 0.485 ' HB2' ' HA3' ' A' ' 78' ' ' GLY . 47.3 m95 -107.18 138.02 44.15 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-O 121.329 0.585 . . . . 0.0 111.61 179.513 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 78.7 m-85 -121.31 121.94 38.78 Favored 'General case' 0 C--N 1.309 -1.184 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.608 176.597 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.406 ' HB ' ' CG2' ' A' ' 110' ' ' ILE . 2.4 pp -123.28 159.25 27.75 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.755 -176.439 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 37.3 m -146.25 120.99 9.86 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.848 177.443 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 5.1 p -93.46 110.44 23.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 121.601 0.715 . . . . 0.0 111.22 -178.299 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.453 ' HA ' ' HE3' ' A' ' 124' ' ' MET . 3.6 mmt -108.71 125.18 32.31 Favored Pre-proline 0 C--N 1.307 -1.248 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.111 -179.915 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -75.14 135.43 18.83 Favored 'Trans proline' 0 N--CA 1.456 -0.726 0 C-N-CA 122.149 1.9 . . . . 0.0 111.288 178.419 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 6.2 t -90.71 -173.52 3.76 Favored 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 -179.573 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 46.8 m -64.69 137.66 57.94 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 120.928 0.395 . . . . 0.0 111.004 179.665 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 2.0 mp -60.5 134.56 25.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.819 178.609 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.2 -17.72 58.31 Favored Glycine 0 N--CA 1.444 -0.772 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.918 -177.007 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 77.0 p -109.72 158.18 18.36 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 117.456 0.628 . . . . 0.0 110.541 178.833 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 59.2 pttt -130.19 144.8 51.57 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.089 -179.041 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 39.9 t80 -83.71 134.52 34.75 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.849 -179.218 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -99.16 130.52 27.08 Favored Pre-proline 0 C--N 1.321 -0.647 0 CA-C-N 116.243 -0.435 . . . . 0.0 109.939 178.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -65.49 -43.98 9.5 Favored 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.792 2.328 . . . . 0.0 113.607 -176.579 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.8 mp -76.5 -50.48 21.77 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 116.632 -0.258 . . . . 0.0 111.605 -177.18 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.1 m -68.65 -33.2 73.59 Favored 'General case' 0 C--O 1.239 0.52 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.025 -179.022 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 89.3 mtm180 70.33 43.22 0.84 Allowed 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.067 177.771 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 26.0 p-10 -152.5 176.27 11.87 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 179.267 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 95.8 m -102.41 126.51 49.46 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 121.179 0.514 . . . . 0.0 111.315 179.411 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 27.0 m -114.88 159.94 14.5 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 CA-C-N 115.698 -0.683 . . . . 0.0 109.22 177.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 55.8 tp -63.65 135.5 56.8 Favored 'General case' 0 C--N 1.312 -1.045 0 CA-C-O 121.054 0.454 . . . . 0.0 111.364 -179.637 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -97.22 96.23 8.27 Favored 'General case' 0 CA--C 1.507 -0.688 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 177.709 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 60.7 t30 . . . . . 0 C--N 1.313 -0.999 0 CA-C-O 118.399 -0.81 . . . . 0.0 109.728 -179.297 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.371 0 N-CA-C 111.577 -0.609 . . . . 0.0 111.577 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -65.91 -47.29 3.84 Favored 'Trans proline' 0 C--N 1.346 0.428 0 C-N-CA 122.459 2.106 . . . . 0.0 112.343 -179.27 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 58.9 tp -94.92 123.8 38.6 Favored 'General case' 0 C--N 1.307 -1.241 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.19 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -107.8 40.93 2.35 Favored Glycine 0 N--CA 1.438 -1.213 0 N-CA-C 111.124 -0.79 . . . . 0.0 111.124 -179.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 23.3 t -75.96 -20.79 57.64 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 178.704 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -157.54 93.09 1.27 Allowed 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 114.539 -1.21 . . . . 0.0 108.554 178.375 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.491 ' HG ' ' CD1' ' A' ' 121' ' ' ILE . 3.1 tm? -101.93 130.33 48.42 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 -179.676 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.545 ' CG2' HG23 ' A' ' 89' ' ' THR . 23.3 mt -94.29 144.04 10.46 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 CA-C-O 120.742 0.306 . . . . 0.0 110.435 -178.439 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 29.8 m -134.78 165.63 30.7 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.9 0 CA-C-N 116.212 -0.449 . . . . 0.0 109.952 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 85.3 m-70 -114.93 121.82 44.38 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 179.452 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 3.8 tp10 -145.62 115.45 7.33 Favored 'General case' 0 C--N 1.318 -0.765 0 C-N-CA 120.693 -0.403 . . . . 0.0 111.008 -178.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 62.16 29.74 73.75 Favored Glycine 0 CA--C 1.518 0.274 0 CA-C-N 116.129 -0.487 . . . . 0.0 113.359 177.593 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 89.51 -5.94 83.52 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.351 179.087 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . 0.48 ' HB2' ' CE1' ' A' ' 90' ' ' TYR . 68.4 mmtt -102.16 153.07 20.29 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-O 120.593 0.235 . . . . 0.0 110.685 179.878 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.545 HG23 ' CG2' ' A' ' 82' ' ' ILE . 0.2 OUTLIER -106.82 106.75 17.42 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 177.024 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.48 ' CE1' ' HB2' ' A' ' 88' ' ' LYS . 96.1 m-85 -98.19 145.84 26.21 Favored 'General case' 0 C--N 1.313 -1.022 0 CA-C-O 120.983 0.421 . . . . 0.0 111.183 -177.035 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 31.1 m-70 -101.72 134.66 44.53 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 177.068 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 46.7 t -113.25 118.47 58.16 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 179.141 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 91.4 t -119.27 131.71 71.19 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.518 -179.045 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 73.8 m -114.76 113.18 23.92 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-O 120.994 0.426 . . . . 0.0 109.956 -179.579 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 67.9 t60 -93.2 -17.46 23.68 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.819 -178.758 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -145.24 158.58 43.79 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.887 -178.034 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -74.24 129.92 38.73 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.48 179.378 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 137.07 158.81 8.07 Favored Glycine 0 N--CA 1.44 -1.05 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.192 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.441 ' HD2' ' HD2' ' A' ' 137' ' ' ARG . 77.3 Cg_endo -78.02 140.1 17.75 Favored 'Trans proline' 0 CA--C 1.537 0.649 0 C-N-CA 122.791 2.327 . . . . 0.0 112.987 178.751 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.8 pp -138.02 157.7 72.56 Favored Pre-proline 0 C--N 1.32 -0.687 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.701 177.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -62.22 164.75 16.5 Favored 'Trans proline' 0 C--N 1.35 0.633 0 C-N-CA 122.4 2.067 . . . . 0.0 113.107 -178.409 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' HIS . . . . . . . . . . . . . 42.0 t-80 -89.66 120.1 69.51 Favored Pre-proline 0 C--N 1.319 -0.721 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.479 -179.087 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 14.1 Cg_endo -56.62 -21.97 41.43 Favored 'Trans proline' 0 N--CA 1.482 0.847 0 C-N-CA 123.08 2.52 . . . . 0.0 113.376 -176.816 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -89.33 -20.57 44.71 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.36 -0.924 . . . . 0.0 113.308 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 16.7 p30 -169.15 109.85 0.47 Allowed 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 122.69 0.396 . . . . 0.0 110.361 -179.134 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 34.8 m -57.17 -11.37 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.076 0 N-CA-C 113.833 1.049 . . . . 0.0 113.833 -179.629 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 42.5 m170 -76.29 3.71 10.32 Favored 'General case' 0 N--CA 1.475 0.786 0 CA-C-O 121.145 0.498 . . . . 0.0 111.266 177.556 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.416 ' HG2' ' HA ' ' A' ' 125' ' ' PRO . 42.2 mtmt -138.87 161.03 38.3 Favored 'General case' 0 CA--C 1.506 -0.72 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 178.634 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 9.3 p90 -143.83 172.31 13.02 Favored 'General case' 0 C--N 1.313 -0.988 0 C-N-CA 120.647 -0.421 . . . . 0.0 111.246 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.433 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.9 mp -129.3 140.64 48.64 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.965 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 178.652 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -96.44 122.08 47.59 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 176.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 57.9 m -106.0 125.23 50.75 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-O 120.679 0.276 . . . . 0.0 110.279 -178.405 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 19.8 m -130.83 139.7 50.2 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.253 179.044 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -112.12 104.37 12.6 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-O 120.994 0.426 . . . . 0.0 110.041 179.482 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 14.2 t -91.79 88.8 6.8 Favored 'General case' 0 C--N 1.309 -1.185 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 179.508 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 70.37 -100.79 0.83 Allowed Glycine 0 N--CA 1.443 -0.85 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 -177.581 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 50.6 m -114.58 5.62 15.52 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.895 0.379 . . . . 0.0 110.735 178.357 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 21.4 tp -116.68 129.53 56.19 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.622 -176.32 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 83.1 m95 -92.97 132.04 37.42 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -178.832 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 51.2 m-85 -113.06 137.27 51.67 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 115.457 -0.792 . . . . 0.0 109.422 175.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.517 ' O ' HD12 ' A' ' 121' ' ' ILE . 2.1 pp -134.28 152.27 33.64 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.998 0 N-CA-C 112.364 0.505 . . . . 0.0 112.364 -176.576 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 25.7 m -151.35 122.14 7.53 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.293 176.909 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.8 p -95.07 112.91 28.37 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 CA-C-O 121.348 0.594 . . . . 0.0 111.305 -179.13 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.465 ' HE1' ' HA ' ' A' ' 124' ' ' MET . 4.5 mmt -112.1 139.8 22.81 Favored Pre-proline 0 C--N 1.316 -0.867 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.621 -179.165 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . 0.416 ' HA ' ' HG2' ' A' ' 108' ' ' LYS . 91.6 Cg_endo -83.85 140.56 9.16 Favored 'Trans proline' 0 N--CA 1.452 -0.958 0 C-N-CA 122.408 2.072 . . . . 0.0 111.551 177.168 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 7.1 t -94.36 -179.19 4.83 Favored 'General case' 0 C--N 1.319 -0.75 0 C-N-CA 120.381 -0.527 . . . . 0.0 109.828 177.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 10.4 t -68.33 140.22 55.91 Favored 'General case' 0 N--CA 1.436 -1.129 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.238 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 2.1 mp -61.56 141.78 17.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 178.393 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.22 -19.85 51.07 Favored Glycine 0 N--CA 1.438 -1.229 0 C-N-CA 120.592 -0.813 . . . . 0.0 112.499 -176.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 68.8 p -114.76 154.72 28.02 Favored 'General case' 0 N--CA 1.448 -0.528 0 CA-C-N 117.261 0.53 . . . . 0.0 111.104 179.655 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 59.8 pttt -126.63 145.03 50.71 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.959 179.369 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -83.94 132.74 34.74 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-O 120.874 0.369 . . . . 0.0 110.963 -178.486 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -94.57 133.59 26.63 Favored Pre-proline 0 C--N 1.323 -0.576 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.418 179.576 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -67.77 -41.33 8.25 Favored 'Trans proline' 0 CA--C 1.535 0.57 0 C-N-CA 122.919 2.413 . . . . 0.0 114.512 -177.541 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.8 mp -82.5 -51.81 14.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 N-CA-C 111.82 0.304 . . . . 0.0 111.82 -177.029 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 4.2 m -69.24 -35.7 76.41 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.139 0.495 . . . . 0.0 110.194 -179.232 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' ARG . . . . . 0.441 ' HD2' ' HD2' ' A' ' 99' ' ' PRO . 56.1 mtm180 66.81 62.87 0.5 Allowed 'General case' 0 N--CA 1.452 -0.341 0 CA-C-N 115.274 -0.875 . . . . 0.0 111.528 178.458 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -165.42 173.16 11.37 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 114.559 -1.2 . . . . 0.0 108.118 176.717 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 88.9 m -100.49 126.5 46.92 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-O 121.083 0.468 . . . . 0.0 111.118 -179.177 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.8 m -113.13 158.3 13.54 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.804 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.279 178.341 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -61.31 117.38 5.56 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.796 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 35.3 t0 -78.59 92.11 4.67 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.473 -178.641 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 52.7 t-20 . . . . . 0 C--O 1.247 0.938 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 179.079 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.24 0 N-CA-C 112.186 -0.366 . . . . 0.0 112.186 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_exo -68.17 -34.23 22.64 Favored 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.453 2.102 . . . . 0.0 110.947 179.496 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 76.2 mt -123.49 151.8 42.39 Favored 'General case' 0 C--N 1.31 -1.115 0 CA-C-N 115.165 -0.925 . . . . 0.0 109.624 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -119.47 -37.16 0.8 Allowed Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 120.933 -0.651 . . . . 0.0 111.996 -179.735 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 34.1 m -60.41 -52.81 63.62 Favored 'General case' 0 C--O 1.236 0.392 0 CA-C-O 120.692 0.282 . . . . 0.0 111.15 179.174 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -153.78 121.53 5.96 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.44 0.638 . . . . 0.0 110.78 177.363 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.5 tm? -100.23 134.57 42.97 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.488 ' CG2' HG23 ' A' ' 89' ' ' THR . 20.8 mt -95.51 142.63 13.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-O 120.937 0.399 . . . . 0.0 110.897 -177.215 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.458 HG22 ' NE2' ' A' ' 102' ' ' HIS . 31.2 m -130.39 154.2 40.17 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.964 -179.358 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 42.6 m-70 -114.57 101.49 9.15 Favored 'General case' 0 C--N 1.311 -1.1 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.115 -178.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.455 ' HB2' ' CE1' ' A' ' 90' ' ' TYR . 50.2 mm-40 -105.86 110.42 22.7 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.052 178.119 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 64.73 30.54 78.21 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 121.148 -0.549 . . . . 0.0 111.951 -179.235 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 86.05 -9.3 69.92 Favored Glycine 0 N--CA 1.444 -0.771 0 C-N-CA 120.928 -0.654 . . . . 0.0 112.385 -179.299 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 1.3 mptm? -91.74 140.52 29.62 Favored 'General case' 0 CA--C 1.507 -0.698 0 CA-C-O 120.911 0.386 . . . . 0.0 110.463 -179.731 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.488 HG23 ' CG2' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -91.21 129.8 37.16 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.767 179.165 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.455 ' CE1' ' HB2' ' A' ' 85' ' ' GLU . 88.1 m-85 -127.3 148.28 50.23 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 177.887 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 40.1 m-70 -103.89 138.3 40.67 Favored 'General case' 0 C--N 1.305 -1.343 0 N-CA-C 110.059 -0.348 . . . . 0.0 110.059 178.473 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 58.3 t -111.23 122.75 66.24 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.217 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 178.446 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 38.3 t -126.04 132.18 70.89 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 -179.057 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 88.8 m -102.0 126.5 48.94 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.019 0.438 . . . . 0.0 111.033 -179.155 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 77.9 m-70 -90.12 -30.51 17.62 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.573 -179.083 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -151.88 172.95 15.4 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-N 115.747 -0.66 . . . . 0.0 109.886 -177.384 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 5.3 mp0 -74.81 137.13 41.7 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.138 178.143 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 124.57 158.83 10.19 Favored Glycine 0 N--CA 1.443 -0.889 0 C-N-CA 120.681 -0.771 . . . . 0.0 111.973 -179.597 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.434 ' HA ' ' HA ' ' A' ' 111' ' ' ILE . 78.1 Cg_endo -77.32 139.56 18.75 Favored 'Trans proline' 0 N--CA 1.46 -0.482 0 C-N-CA 122.613 2.209 . . . . 0.0 113.259 179.13 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.8 pp -137.36 158.13 72.82 Favored Pre-proline 0 C--N 1.319 -0.723 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.64 178.107 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -64.24 169.39 10.89 Favored 'Trans proline' 0 C--N 1.351 0.692 0 C-N-CA 122.593 2.195 . . . . 0.0 113.207 -177.784 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' HIS . . . . . 0.458 ' NE2' HG22 ' A' ' 83' ' ' VAL . 2.3 t-80 -88.73 128.49 52.3 Favored Pre-proline 0 C--N 1.317 -0.827 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 -179.613 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_endo -53.28 -42.5 64.74 Favored 'Trans proline' 0 C--N 1.351 0.699 0 C-N-CA 122.994 2.463 . . . . 0.0 113.032 -177.141 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -74.62 -61.74 3.05 Favored Glycine 0 C--N 1.316 -0.565 0 C-N-CA 120.713 -0.756 . . . . 0.0 113.002 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' ASN . . . . . 0.415 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 6.1 p-10 -125.03 107.95 11.33 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-O 120.973 0.416 . . . . 0.0 111.97 -176.757 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 8.5 p -56.65 -11.97 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.12 0 N-CA-C 113.607 0.965 . . . . 0.0 113.607 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 51.6 m170 -70.42 -4.19 21.31 Favored 'General case' 0 N--CA 1.474 0.748 0 CA-C-O 121.135 0.493 . . . . 0.0 111.055 178.502 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 39.8 mtmt -135.2 159.91 40.04 Favored 'General case' 0 N--CA 1.44 -0.972 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 177.692 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 14.6 p90 -142.8 173.57 11.43 Favored 'General case' 0 C--N 1.307 -1.281 0 CA-C-N 116.577 -0.283 . . . . 0.0 110.78 -178.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.429 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 2.3 mp -130.19 140.33 49.17 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.166 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 178.753 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.434 ' HA ' ' HA ' ' A' ' 99' ' ' PRO . 4.9 mp -97.47 118.47 44.0 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 177.299 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 62.8 m -97.17 121.71 39.37 Favored 'General case' 0 N--CA 1.437 -1.102 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 17.3 m -124.11 136.85 54.51 Favored 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.706 -179.531 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 23.0 ttmt -112.02 109.41 19.14 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-O 121.157 0.504 . . . . 0.0 111.143 -179.488 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 15.8 t -92.28 88.89 6.62 Favored 'General case' 0 N--CA 1.43 -1.432 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 176.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 72.1 -99.87 0.9 Allowed Glycine 0 N--CA 1.437 -1.294 0 N-CA-C 110.705 -0.958 . . . . 0.0 110.705 -176.416 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 24.3 p -116.41 6.24 13.6 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-O 120.893 0.378 . . . . 0.0 111.298 177.824 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 53.6 tp -113.04 135.88 53.3 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.818 0.342 . . . . 0.0 111.255 -175.644 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 96.4 m95 -89.62 131.85 35.41 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 121.336 0.588 . . . . 0.0 112.466 -179.707 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 73.5 m-85 -119.34 124.19 46.02 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 170.423 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.0 pp -124.45 146.87 29.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 120.502 -0.479 . . . . 0.0 111.689 -176.828 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 20.2 m -137.06 122.63 19.69 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.375 178.81 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 4.0 p -93.39 113.72 28.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 121.346 0.593 . . . . 0.0 111.211 -179.385 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.424 ' HA ' ' HE3' ' A' ' 124' ' ' MET . 3.6 mmt -117.23 151.44 47.82 Favored Pre-proline 0 C--N 1.322 -0.628 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.805 -179.088 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 90.7 Cg_endo -92.25 151.36 3.1 Favored 'Trans proline' 0 N--CA 1.448 -1.156 0 C-N-CA 122.399 2.066 . . . . 0.0 112.441 177.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 56.2 m -84.99 167.92 15.42 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 174.515 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 10.9 p -59.89 144.23 49.35 Favored 'General case' 0 N--CA 1.439 -0.996 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 176.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' ILE . . . . . 0.44 ' N ' HD13 ' A' ' 128' ' ' ILE . 2.0 mp -60.74 122.51 11.38 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 CA-C-O 121.175 0.512 . . . . 0.0 110.327 -178.186 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 103.26 1.91 47.86 Favored Glycine 0 N--CA 1.437 -1.248 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.995 -176.397 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 80.7 p -126.77 160.08 31.89 Favored 'General case' 0 CA--C 1.539 0.533 0 CA-C-N 117.456 0.628 . . . . 0.0 111.634 179.773 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 55.0 pttt -125.87 145.54 50.2 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.384 179.633 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.463 ' HD1' ' SG ' ' A' ' 139' ' ' CYS . 29.1 t80 -85.64 137.53 32.77 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-O 121.01 0.434 . . . . 0.0 111.556 -179.23 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -103.48 132.18 21.33 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.181 179.246 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -69.5 -45.06 1.89 Allowed 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 123.11 2.54 . . . . 0.0 114.393 -177.222 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 34.9 mm -74.7 -46.62 41.31 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 N-CA-C 112.035 0.383 . . . . 0.0 112.035 -176.326 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 39.5 t -75.63 -31.79 59.99 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-O 120.861 0.362 . . . . 0.0 110.146 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' ARG . . . . . 0.401 ' HB3' ' HG2' ' A' ' 99' ' ' PRO . 66.0 mtm180 66.42 62.02 0.56 Allowed 'General case' 0 N--CA 1.463 0.223 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.354 178.59 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . 0.438 ' N ' HD21 ' A' ' 138' ' ' ASN . 0.1 OUTLIER -165.31 172.45 12.31 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.175 -0.92 . . . . 0.0 109.082 179.603 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' CYS . . . . . 0.463 ' SG ' ' HD1' ' A' ' 132' ' ' PHE . 38.6 m -101.05 124.58 46.99 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 178.862 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 36.0 m -113.96 164.38 10.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.807 0 CA-C-N 115.883 -0.598 . . . . 0.0 109.759 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 34.2 tp -58.46 123.86 17.63 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-O 121.024 0.44 . . . . 0.0 111.75 -178.324 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -93.37 98.18 11.06 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.879 -0.6 . . . . 0.0 109.642 178.104 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 48.5 t30 . . . . . 0 C--N 1.305 -1.367 0 CA-C-O 118.475 -0.774 . . . . 0.0 110.051 -178.758 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 80' ' ' ASP . . . . . 0.582 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 8.2 p-10 . . . . . 0 N--CA 1.448 -0.53 0 CA-C-O 121.362 0.601 . . . . 0.0 111.571 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.422 HD23 HD11 ' A' ' 121' ' ' ILE . 48.8 tp -102.79 145.47 29.7 Favored 'General case' 0 C--N 1.308 -1.236 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.148 176.472 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.457 ' CG2' HG22 ' A' ' 89' ' ' THR . 14.0 mt -97.54 143.96 11.75 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.111 0 C-N-CA 120.599 -0.44 . . . . 0.0 111.083 -178.971 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 30.7 m -135.75 174.37 12.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.828 -179.285 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' HIS . . . . . 0.429 ' CE1' HG23 ' A' ' 89' ' ' THR . 45.9 m-70 -122.89 115.88 22.69 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 120.967 0.413 . . . . 0.0 111.704 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 59.6 mm-40 -109.12 104.19 13.32 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.209 176.677 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 59.98 45.33 96.08 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.321 -0.942 . . . . 0.0 111.713 -178.755 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 85.4 -31.7 3.77 Favored Glycine 0 CA--C 1.524 0.619 0 C-N-CA 121.036 -0.602 . . . . 0.0 113.593 -179.143 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 14.2 mptt -82.07 141.77 32.88 Favored 'General case' 0 CA--C 1.51 -0.59 0 CA-C-N 117.373 0.587 . . . . 0.0 111.555 -176.126 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.457 HG22 ' CG2' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -84.63 134.19 34.39 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.908 179.856 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 63.9 m-85 -132.22 154.29 49.75 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.761 176.969 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 19.2 m-70 -102.42 144.8 30.42 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-O 120.823 0.344 . . . . 0.0 110.57 179.469 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.582 ' O ' ' HA ' ' A' ' 80' ' ' ASP . 93.7 t -120.06 117.87 55.03 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.19 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 177.547 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 3.3 p -124.6 138.8 52.81 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 CA-C-N 116.112 -0.495 . . . . 0.0 109.93 -178.52 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 92.3 m -110.94 123.92 51.1 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 120.895 0.379 . . . . 0.0 110.946 179.514 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 52.1 m80 -102.15 -22.35 14.22 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.376 -179.766 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -141.03 152.47 44.89 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.478 -178.804 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -76.23 106.35 7.79 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.659 -0.701 . . . . 0.0 110.508 177.851 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 156.24 169.51 20.46 Favored Glycine 0 N--CA 1.434 -1.474 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 -179.581 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_endo -78.53 132.91 11.35 Favored 'Trans proline' 0 N--CA 1.456 -0.691 0 C-N-CA 122.406 2.071 . . . . 0.0 112.394 178.62 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 2.0 pp -137.12 157.82 73.75 Favored Pre-proline 0 C--N 1.319 -0.726 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.517 178.21 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -69.51 171.86 13.43 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.271 1.981 . . . . 0.0 112.492 -178.29 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' HIS . . . . . 0.585 ' HB3' ' O ' ' A' ' 105' ' ' ASN . 30.3 t-80 -89.85 128.1 51.48 Favored Pre-proline 0 C--N 1.309 -1.177 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 179.727 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -50.52 -54.91 4.67 Favored 'Trans proline' 0 N--CA 1.477 0.524 0 C-N-CA 122.932 2.421 . . . . 0.0 112.604 -176.883 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -63.17 -62.2 5.65 Favored Glycine 0 CA--C 1.526 0.776 0 CA-C-N 115.813 -0.63 . . . . 0.0 113.15 178.237 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.585 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 9.9 p-10 -122.8 103.22 8.5 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 -177.004 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 31.1 m -58.29 -10.67 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.089 0 N-CA-C 114.0 1.111 . . . . 0.0 114.0 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 14.0 t-80 -66.27 -10.39 41.93 Favored 'General case' 0 N--CA 1.47 0.56 0 CA-C-O 121.451 0.643 . . . . 0.0 110.299 176.802 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.404 ' HE2' HD21 ' A' ' 105' ' ' ASN . 44.7 mtmt -126.55 158.69 35.53 Favored 'General case' 0 N--CA 1.434 -1.237 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 178.196 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 7.7 p90 -141.72 165.49 27.34 Favored 'General case' 0 C--N 1.302 -1.492 0 C-N-CA 120.642 -0.423 . . . . 0.0 110.517 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.405 HG12 HG11 ' A' ' 92' ' ' VAL . 3.9 mp -123.32 139.81 48.84 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 -179.062 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.411 ' N ' HD12 ' A' ' 111' ' ' ILE . 4.3 mp -99.98 118.09 46.12 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.179 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 177.502 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 23.5 m -101.78 122.72 44.48 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.222 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 49.1 m -131.7 146.73 52.33 Favored 'General case' 0 C--N 1.312 -1.064 0 CA-C-O 121.074 0.464 . . . . 0.0 111.44 -177.752 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 5.0 tppp? -97.28 139.6 33.0 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.527 179.312 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 68.2 m -128.71 85.78 2.37 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 174.474 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 72.68 -104.53 1.55 Allowed Glycine 0 N--CA 1.437 -1.296 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 -174.55 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 50.6 m -115.07 11.81 16.5 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-O 120.779 0.323 . . . . 0.0 110.885 175.17 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 34.0 tp -111.36 143.39 42.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.672 -0.24 . . . . 0.0 110.627 -177.367 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 54.0 m95 -100.23 133.14 45.08 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.034 0.445 . . . . 0.0 112.128 179.198 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -119.53 132.35 55.74 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.647 -0.706 . . . . 0.0 109.463 174.044 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.422 HD11 HD23 ' A' ' 81' ' ' LEU . 1.9 pp -123.72 149.89 27.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-O 120.78 0.324 . . . . 0.0 111.074 -179.1 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 28.4 m -146.06 122.93 11.3 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.152 178.312 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.6 p -95.93 111.13 25.65 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.417 0 CA-C-O 121.363 0.601 . . . . 0.0 111.34 -178.333 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 5.5 mmt -114.36 142.59 28.33 Favored Pre-proline 0 C--N 1.318 -0.762 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.525 -179.314 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -86.5 143.11 7.32 Favored 'Trans proline' 0 N--CA 1.449 -1.092 0 C-N-CA 122.378 2.052 . . . . 0.0 111.641 176.991 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 4.9 t -92.98 -179.6 5.16 Favored 'General case' 0 C--N 1.319 -0.756 0 C-N-CA 120.541 -0.463 . . . . 0.0 109.91 178.228 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 34.3 m -65.32 144.53 57.06 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-O 120.881 0.372 . . . . 0.0 110.579 -178.85 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 128' ' ' ILE . . . . . 0.426 ' N ' HD12 ' A' ' 128' ' ' ILE . 2.8 mp -68.04 132.33 32.75 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.786 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 103.68 -18.45 47.28 Favored Glycine 0 N--CA 1.439 -1.11 0 CA-C-N 115.797 -0.638 . . . . 0.0 112.019 -176.141 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 40.3 p -116.76 158.53 23.73 Favored 'General case' 0 N--CA 1.445 -0.713 0 O-C-N 122.67 -0.312 . . . . 0.0 110.854 179.02 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.4 ' HE2' ' HA ' ' A' ' 142' ' ' ASP . 49.9 pttt -132.17 148.64 52.48 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 116.146 -0.479 . . . . 0.0 109.863 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 23.4 t80 -86.4 139.67 30.72 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-O 121.015 0.436 . . . . 0.0 111.691 -177.319 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -107.6 136.58 19.62 Favored Pre-proline 0 N--CA 1.469 0.502 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.784 177.345 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -68.11 -44.7 3.51 Favored 'Trans proline' 0 C--N 1.347 0.468 0 C-N-CA 122.948 2.432 . . . . 0.0 114.285 -176.464 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 39.5 mm -78.55 -46.34 24.99 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 CA-C-O 120.823 0.344 . . . . 0.0 111.715 -176.857 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.7 m -69.06 -34.89 75.9 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 120.909 0.385 . . . . 0.0 110.199 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 81.8 mtt-85 69.01 41.34 1.45 Allowed 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.144 177.479 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -152.54 176.28 11.87 Favored 'General case' 0 C--N 1.316 -0.863 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 178.49 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 87.8 m -100.93 126.82 47.58 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 120.888 0.375 . . . . 0.0 110.538 -179.825 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.2 m -109.41 157.78 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.018 0 CA-C-N 115.811 -0.632 . . . . 0.0 109.824 179.584 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 58.5 tp -69.55 115.58 8.97 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-O 120.94 0.4 . . . . 0.0 111.138 -179.374 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 142' ' ' ASP . . . . . 0.4 ' HA ' ' HE2' ' A' ' 131' ' ' LYS . 30.9 t70 . . . . . 0 C--N 1.321 -0.673 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.619 177.215 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 22.1 t70 . . . . . 0 CA--C 1.52 -0.199 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.526 HD23 HD11 ' A' ' 121' ' ' ILE . 39.4 tp -117.53 132.63 56.5 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.13 176.254 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.473 HG22 HG22 ' A' ' 89' ' ' THR . 10.4 mt -98.73 144.41 11.72 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.09 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 178.734 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 19.1 m -136.88 162.86 33.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-O 120.765 0.317 . . . . 0.0 110.296 -177.857 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 12.7 m-70 -94.34 115.32 27.52 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.334 178.229 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -128.8 106.65 9.07 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 -178.947 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 67.18 29.89 74.96 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 110.794 -0.923 . . . . 0.0 110.794 -177.092 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 85.29 -22.95 8.94 Favored Glycine 0 N--CA 1.443 -0.892 0 CA-C-N 115.318 -0.441 . . . . 0.0 112.672 -178.357 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 75.1 mmtt -91.85 146.59 23.63 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.843 0.354 . . . . 0.0 111.14 -177.69 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.473 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -82.22 125.98 31.56 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.601 179.602 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -124.48 143.36 50.69 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 176.823 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 22.0 m-70 -90.05 146.6 24.21 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-O 121.097 0.475 . . . . 0.0 111.465 -178.553 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 49.5 t -120.44 119.0 58.52 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 175.562 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 58.0 t -130.4 135.64 60.2 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.256 0 CA-C-N 116.141 -0.481 . . . . 0.0 109.972 -177.959 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 91.5 m -119.11 113.3 20.7 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.03 0.443 . . . . 0.0 110.645 178.68 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 43.0 t-80 -91.89 -22.07 20.27 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.223 179.823 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 -146.58 157.82 43.79 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.769 -176.755 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -79.18 145.66 33.54 Favored 'General case' 0 C--N 1.312 -1.032 0 CA-C-O 120.955 0.407 . . . . 0.0 110.962 -177.222 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 125.39 163.65 11.66 Favored Glycine 0 N--CA 1.437 -1.261 0 C-N-CA 120.976 -0.63 . . . . 0.0 111.926 -178.441 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.415 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 84.4 Cg_endo -84.4 135.19 6.03 Favored 'Trans proline' 0 CA--C 1.538 0.7 0 C-N-CA 122.721 2.28 . . . . 0.0 112.997 179.168 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -142.28 154.96 64.76 Favored Pre-proline 0 C--O 1.216 -0.707 0 CA-C-N 115.76 -0.654 . . . . 0.0 109.724 177.796 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -67.85 169.29 16.53 Favored 'Trans proline' 0 C--N 1.348 0.54 0 C-N-CA 122.349 2.033 . . . . 0.0 112.365 -178.537 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' HIS . . . . . 0.41 ' CD2' HD11 ' A' ' 110' ' ' ILE . 12.1 t-80 -85.54 135.5 38.37 Favored Pre-proline 0 C--N 1.319 -0.719 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -178.906 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -57.8 -25.33 68.34 Favored 'Trans proline' 0 C--N 1.353 0.779 0 C-N-CA 122.93 2.42 . . . . 0.0 112.028 -179.368 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -84.35 -65.86 1.5 Allowed Glycine 0 N--CA 1.441 -0.971 0 CA-C-N 115.522 -0.763 . . . . 0.0 111.765 178.212 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.431 ' OD1' ' HE2' ' A' ' 108' ' ' LYS . 36.8 p-10 -124.37 114.02 18.97 Favored 'General case' 0 CA--C 1.543 0.693 0 CA-C-O 121.364 0.602 . . . . 0.0 111.878 -179.616 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 15.9 m -58.76 -10.63 1.58 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 N-CA-C 112.854 0.687 . . . . 0.0 112.854 177.284 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 35.5 m80 -68.22 -7.17 28.1 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 121.06 0.457 . . . . 0.0 110.362 176.44 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.444 ' HG2' ' HA ' ' A' ' 125' ' ' PRO . 47.4 mtmt -131.5 157.07 44.51 Favored 'General case' 0 CA--C 1.5 -0.953 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.465 179.045 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 8.5 p90 -142.15 161.73 37.26 Favored 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 120.773 -0.371 . . . . 0.0 110.71 179.436 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.415 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.2 mp -119.78 137.22 54.37 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 -179.505 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -96.71 116.85 39.91 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.359 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 175.551 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 56.2 m -95.77 122.13 38.23 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 109.333 -0.618 . . . . 0.0 109.333 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 49.6 m -122.56 127.56 49.61 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.314 -179.733 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 85.4 tttt -100.29 116.22 31.77 Favored 'General case' 0 N--CA 1.432 -1.366 0 CA-C-O 121.118 0.485 . . . . 0.0 109.926 178.735 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 53.7 m -106.18 83.57 1.91 Allowed 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.581 179.149 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 67.77 -100.24 0.6 Allowed Glycine 0 N--CA 1.44 -1.082 0 CA-C-N 115.521 -0.763 . . . . 0.0 111.593 -178.348 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 16.2 m -111.52 5.73 19.68 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-O 120.828 0.347 . . . . 0.0 110.46 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 22.8 tp -118.51 134.49 55.04 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.092 -177.643 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 77.4 m95 -97.3 132.76 42.72 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-O 121.105 0.479 . . . . 0.0 111.978 178.654 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 51.5 m-85 -115.95 130.21 56.72 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.828 174.879 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.526 HD11 HD23 ' A' ' 81' ' ' LEU . 2.2 pp -119.87 148.98 22.6 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-O 121.172 0.511 . . . . 0.0 110.786 179.646 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 16.5 m -142.99 114.05 7.72 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.7 178.007 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.9 p -96.04 103.72 15.01 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-O 121.747 0.784 . . . . 0.0 111.06 -177.897 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 3.7 mmt -107.37 137.65 19.69 Favored Pre-proline 0 C--N 1.313 -1.02 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.922 -178.462 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 125' ' ' PRO . . . . . 0.444 ' HA ' ' HG2' ' A' ' 108' ' ' LYS . 72.9 Cg_endo -80.72 142.79 14.46 Favored 'Trans proline' 0 N--CA 1.448 -1.199 0 C-N-CA 122.142 1.894 . . . . 0.0 111.315 176.543 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 9.6 t -91.97 -178.24 4.95 Favored 'General case' 0 C--N 1.313 -1.021 0 C-N-CA 120.393 -0.523 . . . . 0.0 109.779 178.03 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 7.6 t -61.3 138.64 58.24 Favored 'General case' 0 N--CA 1.434 -1.23 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.016 179.396 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 128' ' ' ILE . . . . . 0.407 ' N ' HD12 ' A' ' 128' ' ' ILE . 2.7 mp -64.24 138.75 22.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 178.384 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 92.89 -12.74 69.26 Favored Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 120.421 -0.895 . . . . 0.0 112.606 -175.779 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 63.9 p -120.45 161.43 21.26 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 117.045 0.422 . . . . 0.0 110.696 178.424 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.483 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 58.9 pttt -133.57 146.62 51.16 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 116.338 -0.392 . . . . 0.0 109.985 179.476 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 31.4 t80 -85.9 136.62 33.22 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.688 -178.375 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -97.68 136.04 21.38 Favored Pre-proline 0 C--N 1.319 -0.741 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.569 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -68.48 -46.33 2.02 Favored 'Trans proline' 0 C--N 1.346 0.447 0 C-N-CA 122.684 2.256 . . . . 0.0 113.591 -178.66 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.9 mp -77.56 -54.27 12.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 111.706 0.261 . . . . 0.0 111.706 -177.779 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 21.5 m -68.02 -32.32 72.61 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 120.645 0.26 . . . . 0.0 110.916 -178.621 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 137' ' ' ARG . . . . . 0.403 ' HD3' ' HD2' ' A' ' 99' ' ' PRO . 98.4 mtt180 66.47 48.55 1.51 Allowed 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 121.411 0.624 . . . . 0.0 111.29 177.62 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 23.9 p-10 -151.42 172.9 15.23 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 115.254 -0.884 . . . . 0.0 108.762 177.731 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 67.9 m -101.82 126.94 48.8 Favored 'General case' 0 C--N 1.308 -1.208 0 CA-C-O 121.222 0.534 . . . . 0.0 111.154 179.041 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 35.1 m -116.46 161.35 15.27 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-N 115.43 -0.805 . . . . 0.0 108.941 178.053 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 45.2 tp -54.03 125.79 20.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.054 0.454 . . . . 0.0 110.113 178.6 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 142' ' ' ASP . . . . . 0.483 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 9.8 t70 . . . . . 0 C--N 1.316 -0.85 0 CA-C-N 115.999 -0.546 . . . . 0.0 112.289 -175.916 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 24.9 t70 . . . . . 0 CA--C 1.512 -0.498 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.415 HD23 HD11 ' A' ' 121' ' ' ILE . 45.7 tp -109.9 135.39 50.85 Favored 'General case' 0 C--N 1.31 -1.152 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 177.919 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.605 HG22 HG22 ' A' ' 89' ' ' THR . 11.5 mt -96.82 142.55 13.85 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 C-N-CA 120.57 -0.452 . . . . 0.0 110.391 179.658 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.405 HG21 ' CE1' ' A' ' 102' ' ' HIS . 22.9 m -139.35 178.27 3.92 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 -178.106 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' HIS . . . . . 0.478 ' HA ' ' O ' ' A' ' 88' ' ' LYS . 66.3 m-70 -117.99 124.61 48.6 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-O 121.253 0.549 . . . . 0.0 111.868 179.49 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 -114.62 103.91 11.47 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.062 -0.972 . . . . 0.0 108.967 177.841 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 67.73 18.36 70.18 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.607 -0.806 . . . . 0.0 111.329 -177.739 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 106.75 -29.39 10.93 Favored Glycine 0 N--CA 1.445 -0.753 0 C-N-CA 121.28 -0.486 . . . . 0.0 112.635 -179.206 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' LYS . . . . . 0.478 ' O ' ' HA ' ' A' ' 84' ' ' HIS . 47.5 mmtm -80.79 154.03 27.41 Favored 'General case' 0 C--O 1.22 -0.457 0 CA-C-N 116.732 0.266 . . . . 0.0 110.534 -178.103 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.605 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -87.7 128.44 35.3 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.306 0.574 . . . . 0.0 112.512 -178.774 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 17.9 m-85 -125.74 152.2 45.65 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.34 -0.846 . . . . 0.0 109.985 177.399 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 24.3 m-70 -100.88 149.06 24.27 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-O 121.016 0.436 . . . . 0.0 111.361 -179.516 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 44.1 t -120.79 118.35 56.12 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.002 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 176.187 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 58.8 t -132.16 131.39 61.1 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.532 -179.242 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 94.9 m -113.76 138.69 49.9 Favored 'General case' 0 C--N 1.313 -1.012 0 CA-C-O 120.799 0.333 . . . . 0.0 110.894 -179.424 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 77.8 m-70 -119.03 -19.63 8.39 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.364 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 5.4 mp0 -126.05 142.21 51.62 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.011 -0.54 . . . . 0.0 109.699 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 -76.97 103.8 7.1 Favored 'General case' 0 C--N 1.314 -0.937 0 N-CA-C 109.794 -0.446 . . . . 0.0 109.794 177.177 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 164.26 169.35 27.69 Favored Glycine 0 N--CA 1.436 -1.349 0 N-CA-C 111.267 -0.733 . . . . 0.0 111.267 -179.178 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.465 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 95.4 Cg_endo -83.34 133.51 6.37 Favored 'Trans proline' 0 N--CA 1.454 -0.806 0 C-N-CA 122.582 2.188 . . . . 0.0 112.709 179.031 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.9 pp -140.12 156.6 70.13 Favored Pre-proline 0 C--N 1.32 -0.704 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.996 178.287 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -62.96 167.29 12.45 Favored 'Trans proline' 0 C--N 1.351 0.695 0 C-N-CA 122.743 2.296 . . . . 0.0 112.87 -178.547 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' HIS . . . . . 0.405 ' CE1' HG21 ' A' ' 83' ' ' VAL . 5.0 t-80 -91.68 133.15 31.46 Favored Pre-proline 0 C--N 1.322 -0.597 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.822 -178.366 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_endo -53.46 -37.62 82.31 Favored 'Trans proline' 0 C--N 1.353 0.799 0 C-N-CA 123.414 2.743 . . . . 0.0 113.344 -177.654 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -70.8 -64.82 2.68 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.087 179.462 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 3.0 p30 -132.6 120.29 21.61 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 121.045 0.45 . . . . 0.0 111.421 178.531 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 28.3 m -57.07 -10.25 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 CA-C-N 115.573 -0.74 . . . . 0.0 112.835 177.768 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 66.4 m170 -69.84 -1.03 8.24 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-O 121.158 0.504 . . . . 0.0 110.636 176.553 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 33.1 mtmm -137.31 157.72 46.01 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.109 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -143.47 173.33 11.72 Favored 'General case' 0 C--N 1.308 -1.21 0 C-N-CA 120.825 -0.35 . . . . 0.0 110.921 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.465 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 1.9 mp -131.04 142.82 42.58 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.966 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 178.786 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -99.68 115.17 39.99 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.968 0 N-CA-C 107.424 -1.325 . . . . 0.0 107.424 174.885 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 29.2 m -95.41 121.75 37.41 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 -178.526 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 16.4 m -126.56 140.79 52.17 Favored 'General case' 0 C--N 1.307 -1.282 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 -179.32 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -118.19 104.86 11.21 Favored 'General case' 0 C--N 1.308 -1.23 0 CA-C-O 121.083 0.468 . . . . 0.0 110.569 -178.435 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 67.5 m -82.89 89.06 6.8 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.444 178.704 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 68.78 -100.26 0.67 Allowed Glycine 0 N--CA 1.432 -1.575 0 C-N-CA 120.461 -0.876 . . . . 0.0 111.084 -177.702 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 14.5 t -114.5 7.46 16.19 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-O 120.9 0.381 . . . . 0.0 110.383 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 21.8 tp -117.1 131.11 56.99 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.584 -0.28 . . . . 0.0 110.438 -177.712 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 77.0 m95 -92.14 131.75 37.15 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 121.038 0.447 . . . . 0.0 111.84 -179.457 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 64.4 m-85 -120.89 129.79 53.64 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.471 174.085 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.415 HD11 HD23 ' A' ' 81' ' ' LEU . 2.5 pp -120.82 151.51 23.78 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.043 0 CA-C-O 121.129 0.49 . . . . 0.0 111.736 -179.518 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 27.8 m -139.66 118.81 12.69 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.892 178.495 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 6.0 p -92.09 124.6 44.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 120.951 0.405 . . . . 0.0 111.081 -178.621 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 4.0 mmt -125.77 139.22 33.62 Favored Pre-proline 0 C--N 1.318 -0.766 0 CA-C-N 115.822 -0.627 . . . . 0.0 109.838 -179.48 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -86.8 143.14 6.97 Favored 'Trans proline' 0 N--CA 1.453 -0.911 0 C-N-CA 122.241 1.961 . . . . 0.0 111.883 177.786 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 126' ' ' CYS . . . . . 0.498 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 55.3 m -81.81 169.39 16.95 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 176.529 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 1.6 p -58.36 148.52 27.45 Favored 'General case' 0 N--CA 1.435 -1.198 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.604 176.964 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 128' ' ' ILE . . . . . 0.416 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.9 mp -62.74 129.0 25.56 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 CA-C-O 121.135 0.493 . . . . 0.0 110.445 -179.348 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 92.04 5.31 66.1 Favored Glycine 0 N--CA 1.44 -1.061 0 CA-C-N 115.694 -0.684 . . . . 0.0 112.882 -178.21 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 60.5 p -126.33 162.6 25.13 Favored 'General case' 0 C--O 1.236 0.347 0 CA-C-N 117.269 0.534 . . . . 0.0 111.133 179.166 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 58.0 pttt -131.9 143.99 50.54 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 179.387 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.498 ' HB2' ' SG ' ' A' ' 126' ' ' CYS . 46.5 t80 -82.74 133.6 35.15 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-O 120.919 0.39 . . . . 0.0 111.712 -178.489 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -100.55 128.57 29.81 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 115.877 -0.601 . . . . 0.0 109.907 177.453 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -64.56 -41.22 20.44 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.973 2.449 . . . . 0.0 113.514 -176.73 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 28.1 mm -75.89 -53.01 16.58 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 N-CA-C 112.097 0.406 . . . . 0.0 112.097 -175.738 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 4.8 m -68.78 -31.96 71.35 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.727 -178.899 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 57.5 mtm180 70.73 51.02 0.33 Allowed 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 121.428 0.632 . . . . 0.0 110.752 178.328 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 29.7 p-10 -159.23 173.41 16.39 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-N 115.483 -0.78 . . . . 0.0 109.004 179.067 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 139' ' ' CYS . . . . . 0.423 ' HA ' ' HA ' ' A' ' 132' ' ' PHE . 21.1 m -101.85 125.26 48.49 Favored 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 178.503 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 27.2 m -112.8 163.2 10.2 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.767 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.159 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 6.9 tt -57.56 123.6 16.13 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-O 121.081 0.467 . . . . 0.0 111.225 -178.692 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 17.1 t70 . . . . . 0 C--N 1.322 -0.594 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.209 178.836 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 80' ' ' ASP . . . . . 0.525 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 11.9 p-10 . . . . . 0 N--CA 1.44 -0.944 0 CA-C-O 121.604 0.716 . . . . 0.0 111.437 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.504 HD23 HD11 ' A' ' 121' ' ' ILE . 39.0 tp -107.25 137.88 44.47 Favored 'General case' 0 C--N 1.301 -1.504 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.502 177.224 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.469 HG22 HG22 ' A' ' 89' ' ' THR . 16.8 mt -96.81 143.29 12.62 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.07 0 C-N-CA 120.511 -0.476 . . . . 0.0 110.187 -179.547 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 28.7 m -138.41 157.37 30.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-N 116.174 -0.466 . . . . 0.0 109.804 -179.203 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 60.8 m-70 -104.2 104.33 14.23 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 116.468 -0.333 . . . . 0.0 111.019 179.454 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 70.4 mm-40 -100.79 104.97 16.23 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 177.529 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 66.37 30.62 76.95 Favored Glycine 0 N--CA 1.444 -0.776 0 C-N-CA 120.262 -0.971 . . . . 0.0 110.783 -176.901 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 89.42 -21.89 26.57 Favored Glycine 0 N--CA 1.442 -0.947 0 CA-C-N 115.195 -0.502 . . . . 0.0 112.726 -178.549 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 14.0 mmmm -83.75 135.2 34.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.799 0.333 . . . . 0.0 111.024 -176.027 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.469 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -81.42 112.26 18.52 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -178.52 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -112.26 146.68 37.77 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.744 -0.662 . . . . 0.0 109.649 176.301 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 21.6 m-70 -99.05 142.44 30.53 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-O 120.715 0.293 . . . . 0.0 110.498 178.921 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.67 HG13 HD13 ' A' ' 110' ' ' ILE . 79.5 t -117.65 120.33 64.4 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.955 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 179.097 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 14.9 p -138.79 142.21 34.97 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.028 -178.031 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 33.1 m -138.31 127.95 25.01 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.662 177.854 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 14.0 p80 -101.71 -0.32 34.7 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-O 121.447 0.641 . . . . 0.0 109.701 177.71 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 56.5 mt-10 -142.67 157.95 44.15 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 114.755 -1.111 . . . . 0.0 109.702 178.846 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -85.46 153.75 22.27 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 120.917 0.389 . . . . 0.0 110.77 178.295 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 126.8 161.77 10.99 Favored Glycine 0 N--CA 1.438 -1.168 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.037 178.34 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.494 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 72.9 Cg_endo -82.62 134.59 7.58 Favored 'Trans proline' 0 N--CA 1.447 -1.248 0 C-N-CA 122.376 2.051 . . . . 0.0 111.855 177.896 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -141.65 157.4 65.22 Favored Pre-proline 0 C--N 1.314 -0.968 0 CA-C-N 115.934 -0.576 . . . . 0.0 109.733 178.515 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -62.42 164.64 17.31 Favored 'Trans proline' 0 C--N 1.348 0.544 0 C-N-CA 122.356 2.038 . . . . 0.0 112.468 -178.813 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' HIS . . . . . . . . . . . . . 27.6 t-80 -92.02 121.95 65.95 Favored Pre-proline 0 C--N 1.315 -0.899 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 -179.506 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -59.0 -19.3 47.58 Favored 'Trans proline' 0 N--CA 1.486 1.041 0 C-N-CA 123.116 2.544 . . . . 0.0 113.543 -176.581 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -93.35 -19.3 35.98 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.469 -0.872 . . . . 0.0 112.809 -179.843 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 2.4 p30 -167.32 102.04 0.52 Allowed 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 122.479 0.311 . . . . 0.0 110.985 -177.894 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 28.3 m -54.91 -14.34 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 N-CA-C 113.674 0.99 . . . . 0.0 113.674 179.552 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 17.2 t-80 -73.21 -0.52 14.57 Favored 'General case' 0 CA--C 1.542 0.655 0 CA-C-O 121.61 0.719 . . . . 0.0 110.435 176.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 47.4 mtmt -136.89 160.88 37.58 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.473 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 11.1 p90 -142.37 173.67 11.32 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.546 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.67 HD13 HG13 ' A' ' 92' ' ' VAL . 3.7 mt -131.91 142.24 43.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 -178.584 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.6 mp -101.89 112.5 35.24 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.12 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 175.783 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 86.3 m -102.3 123.52 46.26 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-O 121.181 0.515 . . . . 0.0 111.178 -176.945 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 19.3 m -128.56 144.61 51.18 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.529 -179.057 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.597 ' HD3' ' CE2' ' A' ' 119' ' ' TRP . 24.1 tptm -113.16 103.84 11.75 Favored 'General case' 0 C--N 1.313 -0.985 0 N-CA-C 109.152 -0.685 . . . . 0.0 109.152 179.247 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 62.2 m -91.28 78.92 5.72 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-O 121.436 0.636 . . . . 0.0 109.524 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.523 ' O ' ' HE2' ' A' ' 114' ' ' LYS . . . 75.44 -99.06 1.18 Allowed Glycine 0 N--CA 1.433 -1.507 0 N-CA-C 110.593 -1.003 . . . . 0.0 110.593 -178.897 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 20.4 m -113.46 0.92 14.88 Favored 'General case' 0 N--CA 1.445 -0.722 0 CA-C-O 121.312 0.577 . . . . 0.0 110.068 -179.752 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 87.6 mt -112.02 122.97 49.23 Favored 'General case' 0 N--CA 1.435 -1.21 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.555 -176.538 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 119' ' ' TRP . . . . . 0.597 ' CE2' ' HD3' ' A' ' 114' ' ' LYS . 81.3 m95 -85.32 131.34 34.42 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 121.015 0.436 . . . . 0.0 111.107 177.37 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -125.48 124.0 40.41 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 115.881 -0.6 . . . . 0.0 109.849 174.55 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.504 HD11 HD23 ' A' ' 81' ' ' LEU . 2.5 pp -126.45 146.97 31.38 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.955 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.33 -178.494 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 34.5 m -134.24 124.93 26.75 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 116.013 -0.54 . . . . 0.0 109.672 178.212 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 2.8 p -95.68 110.99 25.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-O 121.393 0.615 . . . . 0.0 111.252 -179.057 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 9.1 mmt -113.32 145.8 33.98 Favored Pre-proline 0 C--N 1.318 -0.767 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.062 -178.719 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 79.4 Cg_endo -89.25 151.15 5.55 Favored 'Trans proline' 0 N--CA 1.453 -0.865 0 C-N-CA 122.353 2.035 . . . . 0.0 113.074 179.605 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 35.9 m -90.87 171.14 9.52 Favored 'General case' 0 C--O 1.243 0.727 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.153 175.977 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 22.9 t -54.28 148.32 11.74 Favored 'General case' 0 C--O 1.237 0.413 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 177.298 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 128' ' ' ILE . . . . . 0.455 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.9 mp -63.7 129.07 26.97 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 CA-C-O 120.912 0.387 . . . . 0.0 110.234 -179.032 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 89.38 6.03 71.55 Favored Glycine 0 N--CA 1.444 -0.791 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.783 -177.669 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 46.2 p -121.33 158.94 27.1 Favored 'General case' 0 N--CA 1.452 -0.36 0 O-C-N 122.343 -0.504 . . . . 0.0 110.757 178.236 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 59.0 pttt -128.0 144.26 51.1 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 32.8 t80 -84.46 137.22 33.48 Favored 'General case' 0 C--N 1.311 -1.098 0 C-N-CA 120.9 -0.32 . . . . 0.0 110.743 -179.644 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -100.05 133.83 21.31 Favored Pre-proline 0 C--N 1.325 -0.472 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.333 179.314 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -67.68 -41.84 7.71 Favored 'Trans proline' 0 C--N 1.346 0.418 0 C-N-CA 122.877 2.385 . . . . 0.0 113.949 -177.51 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 34.8 mm -82.35 -49.25 17.45 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 N-CA-C 111.951 0.352 . . . . 0.0 111.951 -176.45 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 2.4 m -69.1 -37.49 78.42 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.847 0.356 . . . . 0.0 110.1 179.512 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 67.5 mtt180 68.36 55.36 0.52 Allowed 'General case' 0 CA--C 1.514 -0.414 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.572 178.686 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 29.4 p-10 -154.61 172.93 17.06 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 114.86 -1.064 . . . . 0.0 108.374 178.221 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 27.3 m -101.03 124.83 47.36 Favored 'General case' 0 C--N 1.316 -0.891 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 177.912 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 35.8 m -117.54 157.16 18.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.296 -178.301 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 7.2 mp -64.56 119.75 11.06 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 112.186 0.439 . . . . 0.0 112.186 -178.328 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 38.7 t70 . . . . . 0 C--N 1.319 -0.734 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 174.032 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 24.3 t70 . . . . . 0 CA--C 1.517 -0.297 0 CA-C-O 120.722 0.296 . . . . 0.0 110.386 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.475 HD23 HD11 ' A' ' 121' ' ' ILE . 54.6 tp -108.6 131.65 54.65 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 178.298 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.548 HG22 HG22 ' A' ' 89' ' ' THR . 12.3 mt -91.69 139.97 16.9 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 C-N-CA 120.408 -0.517 . . . . 0.0 109.651 179.068 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 29.4 m -136.52 175.12 10.98 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 CA-C-N 116.137 -0.483 . . . . 0.0 109.84 -177.536 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 16.2 m-70 -114.57 117.24 30.36 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.109 0.48 . . . . 0.0 111.426 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.45 ' HB2' ' CD1' ' A' ' 90' ' ' TYR . 11.8 mm-40 -115.19 104.45 11.86 Favored 'General case' 0 C--N 1.311 -1.074 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 177.228 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 64.39 34.05 88.87 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.382 -0.913 . . . . 0.0 111.448 -177.889 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 88.28 -26.9 7.34 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 121.436 -0.411 . . . . 0.0 113.021 -178.999 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -82.23 146.74 29.33 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.818 0.342 . . . . 0.0 111.169 -178.341 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.548 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -85.08 122.42 29.26 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-O 121.233 0.54 . . . . 0.0 112.153 -179.79 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.45 ' CD1' ' HB2' ' A' ' 85' ' ' GLU . 18.0 m-85 -117.03 148.79 41.18 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.252 176.711 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 31.4 m-70 -97.74 144.22 27.58 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-N 116.526 -0.306 . . . . 0.0 110.202 178.731 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 44.2 t -121.12 117.54 53.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.256 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 178.413 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.6 p -130.77 131.32 64.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 CA-C-N 115.424 -0.807 . . . . 0.0 109.096 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -106.3 138.44 42.48 Favored 'General case' 0 N--CA 1.435 -1.223 0 C-N-CA 119.579 -0.848 . . . . 0.0 111.456 -177.874 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 36.1 m80 -108.84 -25.07 10.97 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 115.329 -0.851 . . . . 0.0 110.365 -178.388 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -131.98 143.43 50.08 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.776 -177.664 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -74.67 108.6 7.53 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.203 178.317 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' GLY . . . . . 0.424 ' H ' ' HB2' ' A' ' 112' ' ' CYS . . . 156.25 -178.64 32.65 Favored Glycine 0 N--CA 1.439 -1.135 0 N-CA-C 111.637 -0.585 . . . . 0.0 111.637 -178.18 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.493 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 69.5 Cg_endo -91.12 127.31 1.16 Allowed 'Trans proline' 0 N--CA 1.445 -1.333 0 C-N-CA 123.149 2.566 . . . . 0.0 112.742 179.529 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.6 pp -138.02 156.12 74.21 Favored Pre-proline 0 C--N 1.313 -0.993 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.387 179.232 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.408 ' HG3' ' HD3' ' A' ' 134' ' ' PRO . 37.3 Cg_endo -62.92 165.25 16.86 Favored 'Trans proline' 0 C--N 1.352 0.746 0 C-N-CA 122.634 2.223 . . . . 0.0 112.522 -178.435 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 102' ' ' HIS . . . . . 0.421 ' CD2' HD11 ' A' ' 110' ' ' ILE . 11.9 t-80 -88.51 132.6 38.47 Favored Pre-proline 0 C--N 1.32 -0.716 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -178.601 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 17.5 Cg_endo -58.65 -19.95 48.12 Favored 'Trans proline' 0 C--N 1.35 0.631 0 C-N-CA 123.0 2.467 . . . . 0.0 112.806 -179.26 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -91.13 -67.68 1.17 Allowed Glycine 0 N--CA 1.447 -0.591 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.101 179.13 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 45.6 m-80 -118.56 109.95 16.78 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.592 0.196 . . . . 0.0 111.053 179.441 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 32.8 m -55.41 -13.62 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.791 0 N-CA-C 113.075 0.769 . . . . 0.0 113.075 176.755 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 41.1 m170 -73.92 3.78 6.26 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-O 120.934 0.397 . . . . 0.0 110.547 177.12 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 47.7 mtmt -140.62 157.75 45.0 Favored 'General case' 0 CA--C 1.506 -0.743 0 CA-C-N 115.833 -0.622 . . . . 0.0 109.43 179.78 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 8.5 p90 -143.03 170.07 16.39 Favored 'General case' 0 C--N 1.306 -1.284 0 C-N-CA 120.829 -0.348 . . . . 0.0 111.264 -179.433 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.493 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.1 mp -125.09 139.13 52.06 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.598 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -100.96 113.13 36.05 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 175.357 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 112' ' ' CYS . . . . . 0.424 ' HB2' ' H ' ' A' ' 98' ' ' GLY . 59.6 m -95.14 123.18 38.49 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 109.314 -0.625 . . . . 0.0 109.314 179.132 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 52.7 p -122.56 136.7 54.95 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.835 -176.714 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 19.5 tptm -96.41 115.54 27.59 Favored 'General case' 0 N--CA 1.435 -1.202 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.682 -179.032 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 59.7 m -108.23 79.81 1.3 Allowed 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 176.856 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 73.45 -104.57 1.61 Allowed Glycine 0 N--CA 1.438 -1.189 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 -176.273 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 8.4 t -113.33 13.02 18.98 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 121.226 0.536 . . . . 0.0 109.865 179.229 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 81.4 mt -116.96 135.4 53.73 Favored 'General case' 0 N--CA 1.435 -1.223 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.043 -177.378 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 50.1 m95 -96.98 131.69 43.53 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.005 0.431 . . . . 0.0 111.069 178.395 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -129.24 128.59 43.6 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 174.855 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.475 HD11 HD23 ' A' ' 81' ' ' LEU . 2.5 pp -119.05 158.91 20.05 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-O 120.952 0.406 . . . . 0.0 111.698 -176.915 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 44.2 m -146.01 121.65 10.46 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.882 177.369 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.7 p -94.62 110.13 23.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 121.549 0.69 . . . . 0.0 111.411 -179.024 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 7.2 mmt -111.86 142.8 27.39 Favored Pre-proline 0 C--N 1.313 -1.007 0 CA-C-N 115.49 -0.777 . . . . 0.0 110.004 -179.459 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -86.71 144.62 7.61 Favored 'Trans proline' 0 N--CA 1.453 -0.89 0 C-N-CA 122.461 2.107 . . . . 0.0 112.722 178.922 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 12.2 m -82.65 174.69 10.78 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.488 177.133 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 13.1 m -61.8 144.45 54.76 Favored 'General case' 0 N--CA 1.436 -1.16 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.88 176.678 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 128' ' ' ILE . . . . . 0.423 ' N ' HD12 ' A' ' 128' ' ' ILE . 2.2 mp -63.34 126.74 22.41 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.553 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 99.25 -6.87 59.83 Favored Glycine 0 N--CA 1.441 -1.0 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.735 -176.483 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 69.1 p -121.66 157.2 31.38 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-N 117.183 0.492 . . . . 0.0 111.449 179.139 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.418 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 62.4 pttt -124.35 147.64 48.06 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 179.0 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 46.9 t80 -81.46 134.37 35.53 Favored 'General case' 0 C--N 1.31 -1.132 0 C-N-CA 120.459 -0.496 . . . . 0.0 111.125 -179.363 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -104.33 127.83 28.29 Favored Pre-proline 0 C--N 1.317 -0.843 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.533 178.76 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 134' ' ' PRO . . . . . 0.408 ' HD3' ' HG3' ' A' ' 101' ' ' PRO . 27.3 Cg_endo -61.99 -42.43 30.49 Favored 'Trans proline' 0 C--O 1.235 0.338 0 C-N-CA 123.024 2.483 . . . . 0.0 113.48 -176.035 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 33.9 mm -79.03 -49.63 19.76 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.612 -176.87 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 136' ' ' SER . . . . . 0.412 ' O ' ' HB2' ' A' ' 137' ' ' ARG . 5.1 m -62.41 -37.51 86.11 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.54 0.209 . . . . 0.0 111.134 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 137' ' ' ARG . . . . . 0.412 ' HB2' ' O ' ' A' ' 136' ' ' SER . 44.2 mtp180 74.62 41.91 0.32 Allowed 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 123.407 0.683 . . . . 0.0 111.33 178.763 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 -161.55 -179.27 7.18 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 178.828 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 10.6 m -100.45 125.93 46.8 Favored 'General case' 0 C--N 1.31 -1.147 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 -178.681 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.5 m -113.34 165.9 7.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.704 -178.253 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -55.08 116.02 2.55 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.625 -179.78 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 142' ' ' ASP . . . . . 0.418 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 21.4 t70 . . . . . 0 C--N 1.323 -0.558 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.58 -178.85 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 18.4 t70 . . . . . 0 N--CA 1.45 -0.44 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -107.2 127.79 53.83 Favored 'General case' 0 C--N 1.31 -1.131 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.407 ' CG2' HG22 ' A' ' 89' ' ' THR . 12.5 mt -98.19 144.5 11.24 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.918 0 C-N-CA 120.951 -0.3 . . . . 0.0 110.419 -178.071 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.46 HG21 ' CE1' ' A' ' 102' ' ' HIS . 22.2 m -128.74 151.41 35.49 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.009 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 179.792 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 22.3 m-70 -107.76 100.09 9.5 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-O 120.879 0.371 . . . . 0.0 110.709 179.741 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 79.4 mm-40 -105.54 105.21 15.14 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.95 179.718 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 62.47 37.67 95.06 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.73 -0.748 . . . . 0.0 111.873 -179.622 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 80.52 -6.11 62.19 Favored Glycine 0 CA--C 1.52 0.376 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.612 -178.905 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 32.0 mmmt -96.97 129.02 44.49 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.922 0.391 . . . . 0.0 110.288 -178.904 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.407 HG22 ' CG2' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -86.07 124.28 32.32 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.408 179.714 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 89.8 m-85 -121.48 141.04 51.41 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 177.538 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 37.8 m-70 -98.85 138.46 35.95 Favored 'General case' 0 C--N 1.312 -1.062 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.29 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 49.4 t -115.58 122.68 69.89 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.015 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 178.944 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 84.6 t -132.38 128.08 57.83 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.027 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 -179.421 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 66.9 m -98.61 131.6 44.68 Favored 'General case' 0 C--N 1.307 -1.277 0 CA-C-O 120.893 0.378 . . . . 0.0 110.899 -178.201 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 37.1 m80 -80.53 -29.45 37.18 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 179.597 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -158.32 -179.09 7.78 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 114.81 -1.086 . . . . 0.0 108.168 -177.528 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -84.55 154.25 22.75 Favored 'General case' 0 C--N 1.31 -1.138 0 CA-C-O 121.002 0.43 . . . . 0.0 111.001 -179.538 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 124.96 167.17 12.54 Favored Glycine 0 N--CA 1.442 -0.945 0 N-CA-C 111.478 -0.649 . . . . 0.0 111.478 -178.263 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.42 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 93.4 Cg_endo -87.18 134.36 3.55 Favored 'Trans proline' 0 N--CA 1.454 -0.85 0 C-N-CA 122.681 2.254 . . . . 0.0 112.816 178.898 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.5 pp -140.56 156.21 69.38 Favored Pre-proline 0 C--N 1.323 -0.575 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.168 178.416 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo -61.46 165.97 12.25 Favored 'Trans proline' 0 C--N 1.352 0.746 0 C-N-CA 122.895 2.397 . . . . 0.0 113.577 -177.687 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' HIS . . . . . 0.46 ' CE1' HG21 ' A' ' 83' ' ' VAL . 3.5 t-80 -89.06 128.13 52.97 Favored Pre-proline 0 C--N 1.321 -0.645 0 CA-C-N 115.329 -0.85 . . . . 0.0 108.93 -179.407 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 10.5 Cg_endo -51.56 -50.53 13.64 Favored 'Trans proline' 0 C--N 1.352 0.73 0 C-N-CA 123.123 2.549 . . . . 0.0 113.25 -176.432 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -67.44 -64.44 3.22 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.677 -179.672 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.446 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 2.6 p30 -119.89 105.0 10.66 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 120.972 0.415 . . . . 0.0 111.705 -178.824 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 27.3 m -56.08 -10.6 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 N-CA-C 113.574 0.953 . . . . 0.0 113.574 178.791 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 23.6 m170 -73.45 4.55 4.64 Favored 'General case' 0 N--CA 1.472 0.675 0 CA-C-O 121.245 0.545 . . . . 0.0 110.646 176.7 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 45.1 mtmt -138.1 160.38 39.54 Favored 'General case' 0 N--CA 1.445 -0.708 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 177.844 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 13.4 p90 -143.5 173.18 11.86 Favored 'General case' 0 C--N 1.313 -0.982 0 C-N-CA 120.466 -0.494 . . . . 0.0 111.611 179.668 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.431 ' CG2' ' HB ' ' A' ' 121' ' ' ILE . 2.9 mp -129.57 142.36 44.11 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.908 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.065 179.688 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -100.32 119.44 48.41 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.88 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 175.203 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 61.9 m -98.22 123.8 42.48 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-O 120.927 0.394 . . . . 0.0 111.177 -177.324 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 23.5 t -130.82 137.63 49.5 Favored 'General case' 0 C--N 1.312 -1.056 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 177.929 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.461 ' HE2' ' O ' ' A' ' 116' ' ' GLY . 86.6 tttt -116.34 109.61 17.59 Favored 'General case' 0 C--N 1.316 -0.872 0 C-N-CA 120.552 -0.459 . . . . 0.0 110.515 -178.881 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 53.4 m -92.09 76.76 5.38 Favored 'General case' 0 C--N 1.31 -1.128 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.018 178.988 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.461 ' O ' ' HE2' ' A' ' 114' ' ' LYS . . . 77.99 -98.93 1.49 Allowed Glycine 0 N--CA 1.44 -1.052 0 C-N-CA 120.434 -0.888 . . . . 0.0 111.199 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 25.3 m -114.09 8.94 17.15 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 121.086 0.47 . . . . 0.0 110.177 179.746 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 19.7 tp -122.69 125.64 45.99 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.66 -177.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 119' ' ' TRP . . . . . 0.446 ' CZ2' ' HD2' ' A' ' 114' ' ' LYS . 86.6 m95 -89.86 133.13 34.91 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-O 121.045 0.45 . . . . 0.0 111.632 179.363 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 87.6 m-85 -118.22 120.88 39.01 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 173.839 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.431 ' HB ' ' CG2' ' A' ' 110' ' ' ILE . 2.3 pp -125.51 142.94 40.76 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 CA-C-O 121.001 0.429 . . . . 0.0 111.14 -178.539 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 49.8 m -129.54 123.77 32.24 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-N 115.958 -0.564 . . . . 0.0 109.875 179.394 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.7 p -94.08 112.37 26.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 121.513 0.673 . . . . 0.0 111.342 -178.978 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 5.8 mmt -110.7 138.8 21.15 Favored Pre-proline 0 C--N 1.318 -0.786 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.289 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -86.11 140.39 6.64 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 122.455 2.103 . . . . 0.0 112.359 178.61 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 126' ' ' CYS . . . . . 0.435 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 65.6 m -83.26 170.97 14.08 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.283 177.825 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 30.9 m -57.08 141.51 45.69 Favored 'General case' 0 N--CA 1.446 -0.64 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.173 176.491 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 128' ' ' ILE . . . . . 0.415 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.9 mp -59.9 131.76 24.73 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 179.37 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.28 -7.26 72.24 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.762 -0.732 . . . . 0.0 113.045 -176.618 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 59.7 p -117.2 164.91 14.07 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-N 117.174 0.487 . . . . 0.0 111.114 179.664 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.554 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 65.0 pttt -132.03 148.59 52.51 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 178.896 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.435 ' HB2' ' SG ' ' A' ' 126' ' ' CYS . 44.4 t80 -84.63 130.4 34.72 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 120.571 -0.452 . . . . 0.0 110.559 178.715 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -98.34 129.8 29.72 Favored Pre-proline 0 C--N 1.314 -0.948 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.924 179.271 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -64.21 -40.83 24.09 Favored 'Trans proline' 0 C--N 1.342 0.224 0 C-N-CA 122.803 2.335 . . . . 0.0 113.28 -176.805 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 27.6 mm -78.96 -51.67 16.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.599 -176.948 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 14.0 m -64.0 -32.73 74.38 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.836 0.351 . . . . 0.0 110.657 178.937 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 67.6 mtm180 68.83 41.95 1.45 Allowed 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 115.509 -0.769 . . . . 0.0 111.274 176.919 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 2.3 p-10 -157.64 176.77 12.19 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.249 -0.887 . . . . 0.0 108.779 177.556 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 139' ' ' CYS . . . . . 0.412 ' HA ' ' HA ' ' A' ' 132' ' ' PHE . 9.2 m -100.28 124.92 46.33 Favored 'General case' 0 C--N 1.319 -0.727 0 C-N-CA 120.209 -0.596 . . . . 0.0 109.734 -178.612 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.0 m -117.88 167.87 10.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.201 -178.295 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -57.35 120.85 8.89 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 178.873 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 142' ' ' ASP . . . . . 0.554 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 8.8 t70 . . . . . 0 C--N 1.317 -0.835 0 N-CA-C 113.674 0.99 . . . . 0.0 113.674 -173.721 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 . . . . . 0 N--CA 1.449 -0.494 0 CA-C-O 121.188 0.518 . . . . 0.0 110.299 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.446 ' HG ' HD11 ' A' ' 121' ' ' ILE . 2.6 tm? -129.97 126.1 37.0 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.024 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.435 ' CG2' HG22 ' A' ' 89' ' ' THR . 26.0 mt -93.79 147.94 5.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.226 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.597 HG21 ' CE1' ' A' ' 102' ' ' HIS . 10.9 m -138.92 167.14 21.18 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 N-CA-C 110.103 -0.332 . . . . 0.0 110.103 -178.902 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 73.2 m-70 -114.75 99.96 7.89 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.579 177.965 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.425 ' OE2' ' ND1' ' A' ' 102' ' ' HIS . 1.0 OUTLIER -87.1 98.28 11.21 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 179.775 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 74.27 1.79 61.26 Favored Glycine 0 C--N 1.324 -0.136 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 -177.622 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 123.28 -23.17 6.9 Favored Glycine 0 N--CA 1.437 -1.292 0 N-CA-C 111.374 -0.691 . . . . 0.0 111.374 -178.624 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 32.2 mmmt -85.08 137.83 32.8 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 110.218 -0.29 . . . . 0.0 110.218 -178.165 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.463 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.0 OUTLIER -76.84 128.16 34.08 Favored 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 112.748 0.647 . . . . 0.0 112.748 -178.502 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.538 ' CE2' ' HA2' ' A' ' 104' ' ' GLY . 35.2 m-85 -126.29 148.8 49.45 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 176.385 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 17.6 m-70 -101.37 139.27 37.26 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-O 120.792 0.33 . . . . 0.0 110.587 -178.079 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 60.5 t -122.3 118.04 54.09 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 179.127 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 49.0 t -128.78 132.96 67.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.145 179.431 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 82.8 m -110.38 118.94 37.63 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 -178.682 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 43.7 m80 -103.17 -15.95 15.87 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.987 -179.786 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -131.21 144.33 51.25 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.985 0.422 . . . . 0.0 111.059 -179.307 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -71.02 112.96 7.58 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.31 177.542 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 146.74 168.7 13.86 Favored Glycine 0 N--CA 1.437 -1.245 0 C-N-CA 121.092 -0.575 . . . . 0.0 111.953 179.502 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.433 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 73.4 Cg_endo -78.64 136.08 13.43 Favored 'Trans proline' 0 N--CA 1.457 -0.623 0 C-N-CA 122.656 2.237 . . . . 0.0 112.644 178.321 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -138.24 158.1 71.48 Favored Pre-proline 0 C--N 1.32 -0.688 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.846 178.072 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo -62.05 166.04 13.31 Favored 'Trans proline' 0 C--N 1.353 0.795 0 C-N-CA 122.69 2.26 . . . . 0.0 113.083 -177.821 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' HIS . . . . . 0.597 ' CE1' HG21 ' A' ' 83' ' ' VAL . 7.2 t-80 -92.35 133.7 29.46 Favored Pre-proline 0 C--N 1.321 -0.673 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.1 -178.041 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -57.89 -31.72 93.28 Favored 'Trans proline' 0 C--N 1.353 0.766 0 C-N-CA 123.039 2.493 . . . . 0.0 112.94 -178.581 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.538 ' HA2' ' CE2' ' A' ' 90' ' ' TYR . . . -70.29 -63.65 3.18 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.751 -0.738 . . . . 0.0 111.803 179.324 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.531 ' OD1' ' HB2' ' A' ' 107' ' ' HIS . 10.5 p30 -139.6 130.06 25.6 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-O 121.058 0.456 . . . . 0.0 110.743 176.96 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 29.5 m -58.73 -10.43 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.555 0 N-CA-C 113.487 0.921 . . . . 0.0 113.487 178.817 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' HIS . . . . . 0.531 ' HB2' ' OD1' ' A' ' 105' ' ' ASN . 36.8 m80 -71.11 -6.93 43.03 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 121.127 0.489 . . . . 0.0 110.193 177.686 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 43.1 mtmt -130.51 159.11 38.08 Favored 'General case' 0 CA--C 1.507 -0.71 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.835 177.795 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 9.6 p90 -143.33 173.18 11.83 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.724 179.675 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.433 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 2.4 mp -128.61 141.22 47.13 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.121 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 177.934 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.7 mp -97.58 117.35 42.15 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 N-CA-C 107.753 -1.202 . . . . 0.0 107.753 175.732 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 21.3 m -104.51 121.46 43.52 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 -179.197 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 36.7 m -122.92 133.33 54.4 Favored 'General case' 0 C--N 1.308 -1.203 0 CA-C-N 116.07 -0.513 . . . . 0.0 109.69 179.673 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.486 ' HD2' ' CZ2' ' A' ' 119' ' ' TRP . 80.8 tttt -105.53 112.24 25.25 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 120.489 -0.484 . . . . 0.0 110.179 -179.705 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 68.2 m -102.15 77.98 1.73 Allowed 'General case' 0 C--N 1.308 -1.213 0 CA-C-N 115.738 -0.664 . . . . 0.0 109.962 179.078 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 77.89 -99.67 1.54 Allowed Glycine 0 N--CA 1.44 -1.062 0 CA-C-N 115.317 -0.856 . . . . 0.0 111.485 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 31.7 t -114.48 3.97 15.1 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-O 121.051 0.453 . . . . 0.0 109.807 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 19.5 mt -119.13 125.83 50.18 Favored 'General case' 0 N--CA 1.432 -1.35 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.11 -177.865 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 119' ' ' TRP . . . . . 0.486 ' CZ2' ' HD2' ' A' ' 114' ' ' LYS . 60.6 m95 -91.82 134.01 35.13 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-O 121.071 0.463 . . . . 0.0 111.083 178.942 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 87.5 m-85 -117.51 128.39 54.93 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.259 175.647 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.446 HD11 ' HG ' ' A' ' 81' ' ' LEU . 2.8 pp -127.73 156.36 39.53 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 N-CA-C 112.189 0.44 . . . . 0.0 112.189 -176.054 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 38.9 m -151.24 123.21 8.14 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.132 176.051 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.8 p -92.06 115.23 30.6 Favored 'Isoleucine or valine' 0 C--O 1.235 0.322 0 CA-C-O 121.301 0.572 . . . . 0.0 111.245 179.903 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.454 ' HA ' ' HE2' ' A' ' 124' ' ' MET . 4.6 mmt -117.16 149.7 44.86 Favored Pre-proline 0 C--N 1.32 -0.678 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.198 -179.542 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -92.07 147.76 3.09 Favored 'Trans proline' 0 N--CA 1.45 -1.074 0 C-N-CA 122.433 2.089 . . . . 0.0 112.431 177.647 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 18.2 m -80.94 174.38 11.68 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 120.911 0.386 . . . . 0.0 110.197 176.672 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 18.9 m -62.38 147.08 49.57 Favored 'General case' 0 N--CA 1.437 -1.08 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.79 176.982 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 128' ' ' ILE . . . . . 0.421 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.8 mp -59.11 123.72 11.94 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 CA-C-O 121.167 0.508 . . . . 0.0 110.218 -179.204 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 97.26 -1.67 60.74 Favored Glycine 0 N--CA 1.438 -1.22 0 CA-C-N 115.56 -0.745 . . . . 0.0 113.175 -178.786 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 80.8 p -120.81 162.88 19.03 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 117.447 0.624 . . . . 0.0 111.472 179.477 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.428 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 60.7 pttt -132.51 145.93 51.53 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.469 179.151 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 26.2 t80 -81.58 137.74 35.48 Favored 'General case' 0 C--N 1.31 -1.144 0 CA-C-O 121.15 0.5 . . . . 0.0 111.685 -178.339 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -103.35 132.5 21.04 Favored Pre-proline 0 C--N 1.323 -0.569 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.144 177.878 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -68.77 -39.82 8.06 Favored 'Trans proline' 0 CA--C 1.531 0.347 0 C-N-CA 122.871 2.38 . . . . 0.0 113.885 -176.984 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 27.2 mm -78.17 -52.49 15.79 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 N-CA-C 112.121 0.415 . . . . 0.0 112.121 -176.433 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 35.5 p -73.75 -29.84 62.46 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 120.695 0.283 . . . . 0.0 111.154 -178.326 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 95.6 mtt180 68.24 57.84 0.46 Allowed 'General case' 0 N--CA 1.465 0.28 0 C-N-CA 123.471 0.709 . . . . 0.0 112.288 176.962 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 4.1 p-10 -164.09 177.09 8.7 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 176.986 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 31.5 m -100.35 125.35 46.58 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 -178.988 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 33.1 m -112.75 167.59 5.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.561 -177.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -58.01 117.08 3.96 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.997 0.427 . . . . 0.0 111.177 179.309 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 142' ' ' ASP . . . . . 0.428 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 17.2 t70 . . . . . 0 CA--C 1.506 -0.713 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.399 178.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' ASP . . . . . 0.432 ' OD1' ' HB3' ' A' ' 91' ' ' HIS . 25.4 t70 . . . . . 0 N--CA 1.446 -0.633 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -107.66 123.86 49.12 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 108.92 -0.771 . . . . 0.0 108.92 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.624 HG22 HG22 ' A' ' 89' ' ' THR . 3.2 mt -101.49 145.3 11.77 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.677 -177.157 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.429 ' O ' ' HA ' ' A' ' 89' ' ' THR . 16.7 m -134.36 165.53 31.25 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 116.084 -0.507 . . . . 0.0 109.812 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 18.6 m-70 -114.7 113.0 23.72 Favored 'General case' 0 C--N 1.31 -1.118 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.407 179.014 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 76.5 mm-40 -107.63 95.9 6.02 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.603 179.235 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 73.94 -6.17 21.3 Favored Glycine 0 CA--C 1.52 0.347 0 C-N-CA 121.093 -0.575 . . . . 0.0 112.932 178.655 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 134.64 -12.71 4.55 Favored Glycine 0 N--CA 1.443 -0.883 0 N-CA-C 111.698 -0.561 . . . . 0.0 111.698 -179.25 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -96.32 130.99 43.3 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 110.368 -0.234 . . . . 0.0 110.368 178.56 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.624 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -85.75 107.34 17.56 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-O 120.969 0.414 . . . . 0.0 111.452 179.391 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 78.1 m-85 -102.21 146.87 27.36 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.914 178.261 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' HIS . . . . . 0.432 ' HB3' ' OD1' ' A' ' 80' ' ' ASP . 36.1 m-70 -101.96 143.73 31.45 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.543 -178.669 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.499 HG13 HD13 ' A' ' 110' ' ' ILE . 89.8 t -114.29 122.18 67.9 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.461 179.102 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 64.2 t -136.77 124.99 34.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.24 0 CA-C-N 115.48 -0.782 . . . . 0.0 108.903 -179.681 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 81.7 m -101.9 127.98 48.5 Favored 'General case' 0 C--N 1.31 -1.139 0 CA-C-O 120.932 0.396 . . . . 0.0 111.059 -179.09 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 68.3 t60 -91.08 -25.45 19.63 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.291 0.567 . . . . 0.0 109.518 178.337 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -149.1 164.69 33.94 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.218 -177.871 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -78.69 142.13 37.37 Favored 'General case' 0 N--CA 1.438 -1.065 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.001 178.08 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 130.05 167.31 12.03 Favored Glycine 0 N--CA 1.438 -1.223 0 C-N-CA 120.907 -0.663 . . . . 0.0 111.621 -178.174 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.402 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 98.5 Cg_endo -85.6 137.99 6.04 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 122.582 2.188 . . . . 0.0 112.766 179.462 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.8 pp -142.86 158.04 60.16 Favored Pre-proline 0 C--N 1.319 -0.747 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.628 178.713 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -64.56 166.63 17.08 Favored 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 122.462 2.108 . . . . 0.0 112.75 -177.619 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' HIS . . . . . . . . . . . . . 14.1 t-80 -89.49 130.09 44.81 Favored Pre-proline 0 C--N 1.318 -0.762 0 CA-C-N 115.923 -0.581 . . . . 0.0 109.906 -178.206 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -62.19 -24.32 76.14 Favored 'Trans proline' 0 N--CA 1.48 0.716 0 C-N-CA 123.013 2.475 . . . . 0.0 113.456 -177.317 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -93.44 -17.87 40.81 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.201 -1.0 . . . . 0.0 113.482 -178.571 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 1.9 p30 -167.63 105.31 0.52 Allowed 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.657 0.265 . . . . 0.0 111.199 -177.905 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 27.0 m -55.05 -11.69 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 N-CA-C 113.509 0.929 . . . . 0.0 113.509 178.145 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 91.0 m-70 -77.57 7.03 6.06 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 121.194 0.521 . . . . 0.0 110.951 178.016 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 47.9 mtmt -143.29 162.84 34.63 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.221 179.342 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 11.1 p90 -142.64 173.72 11.28 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-O 120.919 0.39 . . . . 0.0 111.238 179.727 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.499 HD13 HG13 ' A' ' 92' ' ' VAL . 3.8 mt -132.87 143.62 39.01 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.651 -179.24 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.414 ' N ' HD12 ' A' ' 111' ' ' ILE . 4.3 mp -103.09 122.28 55.34 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 176.641 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 58.7 m -103.08 122.51 44.82 Favored 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 178.847 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 29.1 t -133.59 140.25 47.02 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-O 120.894 0.378 . . . . 0.0 110.672 -177.972 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.427 ' HD2' ' CZ2' ' A' ' 119' ' ' TRP . 59.9 tttm -107.54 104.74 14.36 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-O 121.106 0.479 . . . . 0.0 110.178 179.125 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 23.3 t -90.76 88.45 7.08 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.58 -179.48 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 66.1 -100.76 0.54 Allowed Glycine 0 N--CA 1.438 -1.195 0 CA-C-N 115.474 -0.784 . . . . 0.0 111.664 -178.835 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 16.3 m -109.32 3.8 21.97 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -179.054 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 35.5 tp -126.98 141.01 51.9 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 120.563 -0.455 . . . . 0.0 111.452 -178.654 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 119' ' ' TRP . . . . . 0.427 ' CZ2' ' HD2' ' A' ' 114' ' ' LYS . 72.6 m95 -93.8 133.47 37.15 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.348 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 77.4 m-85 -121.7 130.78 53.69 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.606 175.898 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.4 pp -125.11 146.96 29.91 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 CA-C-O 120.973 0.416 . . . . 0.0 110.891 179.706 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 22.9 m -137.98 125.43 21.97 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-N 115.964 -0.562 . . . . 0.0 109.94 179.4 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.3 p -94.9 112.02 26.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 121.424 0.63 . . . . 0.0 111.018 179.167 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 6.8 mmt -111.49 141.92 25.48 Favored Pre-proline 0 C--N 1.314 -0.942 0 CA-C-N 115.454 -0.793 . . . . 0.0 110.182 -179.442 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -87.05 154.4 8.37 Favored 'Trans proline' 0 N--CA 1.457 -0.664 0 C-N-CA 122.587 2.191 . . . . 0.0 113.365 -179.72 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 56.5 m -92.72 165.09 13.13 Favored 'General case' 0 C--O 1.241 0.653 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.448 175.618 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 14.9 m -59.93 148.88 33.5 Favored 'General case' 0 N--CA 1.445 -0.693 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.304 176.738 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 128' ' ' ILE . . . . . 0.409 HD12 ' N ' ' A' ' 128' ' ' ILE . 1.8 mp -60.04 129.73 22.85 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.246 179.749 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 93.9 -2.13 69.0 Favored Glycine 0 N--CA 1.439 -1.136 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.883 -178.242 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 68.7 p -121.06 164.02 17.45 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-N 117.257 0.528 . . . . 0.0 111.382 179.422 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.523 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 57.8 pttt -139.18 145.07 38.88 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 178.67 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.406 ' HA ' ' HA ' ' A' ' 139' ' ' CYS . 38.3 t80 -82.8 137.79 34.21 Favored 'General case' 0 C--N 1.311 -1.084 0 N-CA-C 112.365 0.505 . . . . 0.0 112.365 -176.034 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -106.52 131.55 21.62 Favored Pre-proline 0 C--N 1.327 -0.408 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.811 176.264 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.05 -36.58 21.59 Favored 'Trans proline' 0 N--CA 1.471 0.203 0 C-N-CA 122.904 2.403 . . . . 0.0 113.935 -176.803 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 34.3 mm -79.28 -56.34 7.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 N-CA-C 111.932 0.345 . . . . 0.0 111.932 -176.061 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 26.8 p -66.69 -31.76 72.63 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 120.528 0.204 . . . . 0.0 110.911 179.629 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 72.25 48.6 0.25 Allowed 'General case' 0 CA--C 1.518 -0.268 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.342 176.909 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 32.9 p30 -154.9 175.98 13.09 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.434 178.814 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 139' ' ' CYS . . . . . 0.406 ' HA ' ' HA ' ' A' ' 132' ' ' PHE . 27.8 m -100.86 124.65 46.85 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 177.622 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 29.8 m -107.65 160.58 6.75 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.877 -177.69 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -61.45 119.02 7.75 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.187 179.79 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 142' ' ' ASP . . . . . 0.523 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 28.2 t70 . . . . . 0 C--N 1.32 -0.717 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.934 179.188 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 27.1 t70 . . . . . 0 CA--C 1.509 -0.598 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -112.14 126.31 55.05 Favored 'General case' 0 C--N 1.306 -1.288 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 -177.43 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 15.0 mt -94.4 140.14 17.21 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 C-N-CA 120.869 -0.333 . . . . 0.0 110.395 -178.999 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 27.1 m -127.82 162.53 33.46 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.171 -178.831 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 35.7 m170 -108.87 112.66 25.01 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.293 179.817 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.548 ' HB2' ' CE1' ' A' ' 90' ' ' TYR . 71.8 mm-40 -116.81 103.96 10.85 Favored 'General case' 0 C--N 1.312 -1.033 0 N-CA-C 109.206 -0.665 . . . . 0.0 109.206 178.28 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 69.38 23.9 76.26 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.631 -0.795 . . . . 0.0 111.971 -179.261 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 95.53 -19.28 55.04 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.627 -179.421 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 56.4 mtmt -91.16 157.37 17.23 Favored 'General case' 0 CA--C 1.512 -0.486 0 CA-C-O 120.797 0.332 . . . . 0.0 111.357 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -94.68 132.62 39.23 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-N 115.879 -0.6 . . . . 0.0 112.602 -177.621 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.548 ' CE1' ' HB2' ' A' ' 85' ' ' GLU . 42.4 m-85 -127.04 140.54 52.22 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 115.133 -0.94 . . . . 0.0 108.915 176.68 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 21.2 m-70 -97.83 145.36 26.48 Favored 'General case' 0 C--N 1.307 -1.246 0 CA-C-O 120.826 0.345 . . . . 0.0 110.672 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.548 HG13 HD13 ' A' ' 110' ' ' ILE . 81.8 t -114.81 126.38 72.36 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.001 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.074 178.477 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 91.2 t -136.43 123.5 32.22 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 179.227 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 73.0 m -94.64 132.05 39.78 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-O 121.435 0.636 . . . . 0.0 112.345 -175.667 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 70.7 m-70 -86.31 -31.22 21.7 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.036 -0.984 . . . . 0.0 110.783 -178.828 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -148.36 167.39 25.35 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.282 -178.861 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -79.21 103.36 9.09 Favored 'General case' 0 N--CA 1.446 -0.66 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 174.627 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 163.92 169.85 28.0 Favored Glycine 0 N--CA 1.431 -1.698 0 N-CA-C 111.126 -0.79 . . . . 0.0 111.126 -178.96 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.566 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 72.1 Cg_endo -81.55 128.73 6.22 Favored 'Trans proline' 0 N--CA 1.443 -1.485 0 C-N-CA 122.283 1.989 . . . . 0.0 112.256 178.563 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -135.04 157.64 76.55 Favored Pre-proline 0 C--N 1.312 -1.058 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.654 178.569 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -64.55 167.21 15.6 Favored 'Trans proline' 0 C--O 1.233 0.263 0 C-N-CA 122.49 2.127 . . . . 0.0 112.72 -177.573 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' HIS . . . . . 0.45 ' HB3' ' O ' ' A' ' 105' ' ' ASN . 4.5 t-80 -88.85 125.08 63.84 Favored Pre-proline 0 C--N 1.315 -0.891 0 N-CA-C 108.814 -0.809 . . . . 0.0 108.814 -179.007 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -53.41 -37.69 82.06 Favored 'Trans proline' 0 N--CA 1.485 0.984 0 C-N-CA 123.286 2.657 . . . . 0.0 113.417 -176.275 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -74.57 -61.81 3.04 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.335 179.127 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.45 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 2.4 p30 -125.21 109.27 12.65 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 120.992 0.425 . . . . 0.0 111.63 -179.13 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.3 t -56.21 -13.91 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.172 0 C-N-CA 123.584 0.754 . . . . 0.0 112.747 179.278 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 12.1 t-80 -69.06 -1.72 8.29 Favored 'General case' 0 CA--C 1.551 1.019 0 CA-C-O 121.533 0.682 . . . . 0.0 110.644 177.316 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 46.4 mtmt -134.83 160.72 37.31 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 178.604 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 11.3 p90 -142.41 173.33 11.63 Favored 'General case' 0 C--N 1.307 -1.269 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.674 179.178 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.566 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.4 mt -132.03 142.48 42.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -178.383 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.7 mp -101.7 114.17 40.19 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 176.16 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 61.8 m -102.15 122.88 45.01 Favored 'General case' 0 C--N 1.307 -1.273 0 CA-C-O 120.989 0.423 . . . . 0.0 111.252 -177.057 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 28.0 m -131.01 145.64 52.11 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 178.02 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -118.17 114.1 22.55 Favored 'General case' 0 C--N 1.31 -1.132 0 CA-C-O 121.201 0.524 . . . . 0.0 110.3 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 63.1 m -88.2 79.94 7.72 Favored 'General case' 0 N--CA 1.432 -1.366 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.354 179.039 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 75.8 -99.06 1.22 Allowed Glycine 0 N--CA 1.435 -1.392 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 -178.442 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 18.8 m -114.06 6.32 16.37 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 120.844 0.355 . . . . 0.0 110.47 179.341 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 18.2 tp -119.12 124.62 47.3 Favored 'General case' 0 C--O 1.221 -0.405 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.768 -177.251 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 88.4 m95 -84.41 133.89 34.49 Favored 'General case' 0 C--N 1.317 -0.832 0 N-CA-C 112.069 0.396 . . . . 0.0 112.069 -179.423 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 71.9 m-85 -123.38 124.83 43.81 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.531 172.976 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.4 pp -123.91 155.93 30.91 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.86 0 CA-C-O 121.23 0.538 . . . . 0.0 112.06 -177.338 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 34.3 m -142.6 121.21 12.53 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.712 177.535 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.8 p -95.25 117.68 39.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 121.231 0.539 . . . . 0.0 111.268 -178.951 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.411 ' HA ' ' HE2' ' A' ' 124' ' ' MET . 5.0 mmt -120.16 149.66 49.73 Favored Pre-proline 0 C--N 1.32 -0.692 0 CA-C-N 115.703 -0.68 . . . . 0.0 109.999 -178.55 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -91.64 148.02 3.37 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 122.415 2.076 . . . . 0.0 113.483 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 58.7 m -90.84 172.51 8.57 Favored 'General case' 0 C--O 1.242 0.677 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.783 175.828 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 39.0 m -65.23 147.87 52.69 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.498 178.931 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 128' ' ' ILE . . . . . 0.418 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.9 mp -65.2 129.08 29.0 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.001 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 178.713 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 99.81 -16.22 58.79 Favored Glycine 0 N--CA 1.439 -1.112 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.079 -177.023 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 65.8 p -108.85 159.41 16.81 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-O 120.887 0.375 . . . . 0.0 110.93 178.956 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.473 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 63.7 pttt -128.83 143.58 50.94 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 178.723 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.444 ' HA ' ' HA ' ' A' ' 139' ' ' CYS . 36.8 t80 -80.73 137.06 36.26 Favored 'General case' 0 C--N 1.314 -0.956 0 C-N-CA 120.294 -0.562 . . . . 0.0 111.324 -179.34 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -108.36 127.13 28.09 Favored Pre-proline 0 C--N 1.32 -0.707 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.105 178.47 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -65.99 -36.89 28.41 Favored 'Trans proline' 0 CA--C 1.53 0.292 0 C-N-CA 122.96 2.44 . . . . 0.0 113.553 -177.062 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.8 mp -77.0 -49.99 21.85 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.322 -177.897 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 13.1 m -67.83 -35.65 78.98 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 120.728 0.299 . . . . 0.0 110.378 178.893 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 137' ' ' ARG . . . . . 0.4 HH11 ' HD2' ' A' ' 137' ' ' ARG . 66.5 mtt85 71.31 46.21 0.44 Allowed 'General case' 0 CA--C 1.517 -0.297 0 CA-C-N 115.692 -0.685 . . . . 0.0 111.217 178.555 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -162.37 177.72 9.3 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 177.7 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 139' ' ' CYS . . . . . 0.444 ' HA ' ' HA ' ' A' ' 132' ' ' PHE . 6.3 m -100.45 125.26 46.73 Favored 'General case' 0 C--N 1.313 -1.019 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -178.914 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 28.4 m -111.97 163.48 8.86 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.09 -178.169 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -70.52 127.3 32.24 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 -179.256 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 142' ' ' ASP . . . . . 0.473 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 22.5 t70 . . . . . 0 CA--C 1.502 -0.882 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.271 -179.312 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 27.0 t70 . . . . . 0 C--O 1.233 0.201 0 CA-C-O 120.863 0.363 . . . . 0.0 110.06 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.452 HD23 HD11 ' A' ' 121' ' ' ILE . 38.6 tp -92.37 145.88 24.13 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.046 179.759 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.585 HG22 HG22 ' A' ' 89' ' ' THR . 4.9 mt -105.1 144.7 14.43 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 178.427 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 15.3 m -141.9 130.69 22.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.042 0.449 . . . . 0.0 110.778 -177.921 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 8.6 p80 -78.9 122.98 26.8 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.27 177.934 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.442 ' HG2' HD22 ' A' ' 105' ' ' ASN . 7.5 tp10 -136.88 113.87 10.54 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 116.109 -0.496 . . . . 0.0 109.85 179.028 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 68.04 24.19 74.52 Favored Glycine 0 N--CA 1.447 -0.584 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.043 -179.6 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 91.2 -10.53 74.7 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.997 -0.62 . . . . 0.0 112.688 -179.862 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -102.77 139.6 38.14 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.666 0.269 . . . . 0.0 110.359 -179.749 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.585 HG22 HG22 ' A' ' 82' ' ' ILE . 0.1 OUTLIER -87.53 106.67 18.15 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-O 120.821 0.343 . . . . 0.0 110.505 179.676 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 75.6 m-85 -96.2 151.99 18.98 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.562 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 36.4 m-70 -106.85 138.86 42.24 Favored 'General case' 0 C--N 1.308 -1.206 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.041 178.814 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 57.4 t -119.13 118.21 56.8 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 177.435 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.8 p -125.52 138.89 52.97 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.072 -178.774 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 82.1 m -121.97 115.11 21.96 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.213 0.53 . . . . 0.0 111.069 -179.355 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 42.8 t60 -92.67 -18.17 23.36 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.565 178.31 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 74.5 mm-40 -142.02 159.85 41.4 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.452 -0.795 . . . . 0.0 109.835 -178.358 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 -79.66 148.37 31.64 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-O 120.992 0.425 . . . . 0.0 110.549 177.784 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 128.06 164.83 11.69 Favored Glycine 0 N--CA 1.434 -1.488 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 -179.528 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.484 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 91.9 Cg_endo -88.5 142.34 5.04 Favored 'Trans proline' 0 N--CA 1.441 -1.591 0 C-N-CA 122.565 2.176 . . . . 0.0 112.817 179.323 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.41 ' O ' ' HB2' ' A' ' 109' ' ' TYR . 1.7 pp -141.36 156.53 67.21 Favored Pre-proline 0 C--N 1.316 -0.876 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.19 177.752 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -62.66 165.65 15.4 Favored 'Trans proline' 0 C--N 1.346 0.437 0 C-N-CA 122.316 2.011 . . . . 0.0 112.901 -177.767 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 102' ' ' HIS . . . . . 0.481 ' HB3' ' O ' ' A' ' 105' ' ' ASN . 42.8 t-80 -87.12 121.77 71.34 Favored Pre-proline 0 C--N 1.315 -0.913 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.399 -179.266 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 13.7 Cg_endo -56.41 -25.44 57.56 Favored 'Trans proline' 0 N--CA 1.48 0.678 0 C-N-CA 122.887 2.391 . . . . 0.0 112.938 -176.604 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -87.06 -20.14 53.87 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.506 -0.854 . . . . 0.0 113.205 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.481 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 9.5 p30 -168.88 117.7 0.68 Allowed 'General case' 0 N--CA 1.472 0.639 0 CA-C-N 117.213 0.506 . . . . 0.0 110.909 -179.74 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 35.1 m -56.32 -11.38 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 N-CA-C 113.756 1.021 . . . . 0.0 113.756 177.205 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 44.7 m170 -76.76 -0.72 24.84 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 111.957 0.354 . . . . 0.0 111.957 179.67 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.41 ' HG2' ' HA ' ' A' ' 125' ' ' PRO . 39.1 mtmt -139.3 163.82 31.47 Favored 'General case' 0 CA--C 1.503 -0.863 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 179.164 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 109' ' ' TYR . . . . . 0.41 ' HB2' ' O ' ' A' ' 100' ' ' ILE . 12.4 p90 -144.02 173.27 11.87 Favored 'General case' 0 C--N 1.311 -1.094 0 CA-C-N 116.555 -0.293 . . . . 0.0 111.112 179.533 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.484 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.7 mp -131.18 141.19 46.67 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.968 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 178.276 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.6 mp -99.04 122.72 51.1 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 176.824 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 112' ' ' CYS . . . . . 0.419 ' HA ' HG22 ' A' ' 121' ' ' ILE . 58.8 m -98.14 123.35 42.14 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -178.995 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 18.9 m -130.1 134.24 47.22 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 120.797 0.332 . . . . 0.0 111.226 -178.729 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.471 ' HE3' ' O ' ' A' ' 116' ' ' GLY . 58.9 tptt -107.31 103.3 12.62 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 178.458 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 51.0 m -101.78 103.01 13.72 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.88 179.757 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.471 ' O ' ' HE3' ' A' ' 114' ' ' LYS . . . 59.8 -106.19 0.92 Allowed Glycine 0 N--CA 1.443 -0.857 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.256 -176.852 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 11.6 t -111.28 3.48 18.38 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-O 120.818 0.342 . . . . 0.0 110.683 178.73 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -113.16 132.37 55.5 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 120.89 0.376 . . . . 0.0 111.426 -176.928 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 119' ' ' TRP . . . . . 0.449 ' CE2' ' HD3' ' A' ' 114' ' ' LYS . 67.1 m95 -90.85 132.1 36.1 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.894 0.378 . . . . 0.0 110.092 175.847 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -123.36 124.64 43.39 Favored 'General case' 0 C--N 1.309 -1.181 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.631 175.801 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.452 HD11 HD23 ' A' ' 81' ' ' LEU . 2.4 pp -124.46 142.13 42.28 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.52 -178.871 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 33.5 m -130.13 126.5 37.67 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-N 116.18 -0.464 . . . . 0.0 109.778 179.377 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.1 p -95.26 110.38 23.98 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 121.413 0.625 . . . . 0.0 110.746 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 3.6 mmt -111.02 144.29 30.07 Favored Pre-proline 0 C--N 1.316 -0.856 0 CA-C-N 115.367 -0.833 . . . . 0.0 109.772 -179.8 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 125' ' ' PRO . . . . . 0.41 ' HA ' ' HG2' ' A' ' 108' ' ' LYS . 83.6 Cg_endo -89.26 148.62 5.43 Favored 'Trans proline' 0 N--CA 1.45 -1.075 0 C-N-CA 122.237 1.958 . . . . 0.0 112.737 178.388 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 126' ' ' CYS . . . . . 0.407 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 53.3 m -81.97 161.06 23.17 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.095 -0.502 . . . . 0.0 109.794 176.465 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 16.7 t -61.07 142.38 56.7 Favored 'General case' 0 N--CA 1.442 -0.833 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 177.975 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 128' ' ' ILE . . . . . 0.405 HD12 ' N ' ' A' ' 128' ' ' ILE . 1.8 mp -54.22 129.6 15.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.468 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 100.15 -7.91 58.84 Favored Glycine 0 N--CA 1.444 -0.79 0 C-N-CA 120.934 -0.65 . . . . 0.0 113.269 -177.776 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 69.5 p -123.49 164.82 18.19 Favored 'General case' 0 C--O 1.237 0.405 0 CA-C-N 117.087 0.443 . . . . 0.0 111.383 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 60.1 pttt -134.74 147.39 50.02 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 178.762 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.42 ' HA ' ' HA ' ' A' ' 139' ' ' CYS . 30.4 t80 -81.78 138.89 35.08 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-O 121.23 0.538 . . . . 0.0 112.355 -177.168 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -108.01 126.98 28.51 Favored Pre-proline 0 C--N 1.324 -0.5 0 CA-C-N 115.51 -0.768 . . . . 0.0 109.533 177.059 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -63.97 -40.17 28.88 Favored 'Trans proline' 0 N--CA 1.474 0.369 0 C-N-CA 122.961 2.441 . . . . 0.0 113.561 -176.55 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 30.8 mm -77.4 -51.96 17.39 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.46 -176.787 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 8.7 m -62.86 -36.12 82.24 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.741 0.305 . . . . 0.0 110.508 178.969 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 85.9 mtm180 73.11 41.52 0.49 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.909 178.625 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 3.5 p-10 -158.03 178.0 10.7 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 178.543 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 139' ' ' CYS . . . . . 0.42 ' HA ' ' HA ' ' A' ' 132' ' ' PHE . 31.4 m -100.51 125.54 46.85 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-O 121.146 0.498 . . . . 0.0 110.034 -178.74 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.3 m -111.9 165.03 7.23 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 CA-C-N 115.859 -0.61 . . . . 0.0 109.881 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 54.9 tp -57.29 125.0 20.81 Favored 'General case' 0 C--N 1.313 -0.979 0 CA-C-O 121.152 0.501 . . . . 0.0 111.842 -178.873 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 18.0 t0 . . . . . 0 N--CA 1.442 -0.873 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.958 178.002 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 80' ' ' ASP . . . . . 0.409 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 15.1 t70 . . . . . 0 C--O 1.233 0.229 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.42 ' HG ' HD11 ' A' ' 121' ' ' ILE . 2.9 tm? -102.63 130.74 49.61 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.147 -179.16 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.42 HG22 HG22 ' A' ' 89' ' ' THR . 6.8 mt -96.17 143.84 11.4 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.848 0 C-N-CA 120.707 -0.397 . . . . 0.0 110.486 -177.931 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 20.6 m -133.94 167.21 26.79 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 179.796 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 84' ' ' HIS . . . . . 0.448 ' HA ' ' O ' ' A' ' 88' ' ' LYS . 72.0 m-70 -106.95 115.02 29.46 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-O 121.053 0.454 . . . . 0.0 110.969 178.559 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.408 ' HB2' ' CD1' ' A' ' 90' ' ' TYR . 66.4 mm-40 -109.04 104.56 13.79 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 177.378 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 68.0 27.35 73.7 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.301 -0.952 . . . . 0.0 111.224 -178.428 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 95.1 -25.03 26.01 Favored Glycine 0 N--CA 1.443 -0.872 0 C-N-CA 121.41 -0.424 . . . . 0.0 112.73 -179.123 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' LYS . . . . . 0.448 ' O ' ' HA ' ' A' ' 84' ' ' HIS . 33.4 mmtp -85.93 149.68 25.03 Favored 'General case' 0 C--O 1.222 -0.368 0 CA-C-O 120.64 0.257 . . . . 0.0 110.618 -176.356 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.42 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -87.97 121.44 30.38 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-O 121.155 0.502 . . . . 0.0 112.108 -179.314 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.408 ' CD1' ' HB2' ' A' ' 85' ' ' GLU . 38.2 m-85 -119.19 141.95 48.42 Favored 'General case' 0 C--N 1.313 -1.02 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 176.691 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 32.9 m-70 -92.09 144.77 25.1 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-O 121.051 0.453 . . . . 0.0 111.376 -177.911 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.409 ' O ' ' HA ' ' A' ' 80' ' ' ASP . 97.9 t -118.04 117.9 56.4 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 176.046 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.6 p -125.83 137.92 56.16 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.847 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.259 -178.072 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 84.9 m -120.73 113.25 19.92 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 46.7 t60 -92.86 -19.2 21.93 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.921 -179.919 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -138.77 157.36 46.22 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.548 -178.025 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 35.7 mt-10 -77.68 135.79 38.12 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.871 176.812 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 130.03 168.37 12.28 Favored Glycine 0 C--N 1.313 -0.7 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.12 -178.102 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -85.0 135.33 5.49 Favored 'Trans proline' 0 N--CA 1.453 -0.872 0 C-N-CA 122.636 2.224 . . . . 0.0 112.613 178.845 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.412 ' O ' ' HB2' ' A' ' 109' ' ' TYR . 1.9 pp -138.76 157.07 72.5 Favored Pre-proline 0 C--N 1.321 -0.666 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.028 178.359 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.401 ' HG3' ' HD3' ' A' ' 134' ' ' PRO . 56.6 Cg_endo -68.06 171.17 12.93 Favored 'Trans proline' 0 C--N 1.348 0.523 0 C-N-CA 122.286 1.991 . . . . 0.0 112.081 -179.527 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 102' ' ' HIS . . . . . 0.416 ' HB3' ' O ' ' A' ' 105' ' ' ASN . 62.5 t-80 -92.34 132.62 31.6 Favored Pre-proline 0 C--N 1.314 -0.943 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -53.34 -49.52 17.15 Favored 'Trans proline' 0 CA--C 1.536 0.594 0 C-N-CA 122.957 2.438 . . . . 0.0 112.533 -177.874 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -63.33 -66.22 2.66 Favored Glycine 0 CA--C 1.526 0.721 0 C-N-CA 121.067 -0.587 . . . . 0.0 113.086 178.787 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.416 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 4.2 p30 -120.95 111.79 17.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.825 0.345 . . . . 0.0 111.63 -179.558 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.421 HG12 ' HB2' ' A' ' 131' ' ' LYS . 20.0 t -59.2 -14.6 5.6 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.904 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.529 177.345 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 22.5 t-80 -66.92 -5.52 12.94 Favored 'General case' 0 CA--C 1.543 0.686 0 CA-C-O 121.355 0.597 . . . . 0.0 110.694 177.739 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 7.5 mtmp? -135.04 156.17 49.49 Favored 'General case' 0 N--CA 1.439 -0.996 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 178.46 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 109' ' ' TYR . . . . . 0.412 ' HB2' ' O ' ' A' ' 100' ' ' ILE . 12.6 p90 -141.56 170.08 16.39 Favored 'General case' 0 C--N 1.306 -1.284 0 CA-C-O 120.689 0.281 . . . . 0.0 110.405 -178.968 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 3.3 mp -126.3 140.68 48.04 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 -179.675 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.422 ' O ' ' HA ' ' A' ' 121' ' ' ILE . 4.6 mp -97.9 117.69 43.12 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.031 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 176.076 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 34.7 m -104.38 123.69 47.86 Favored 'General case' 0 C--N 1.312 -1.022 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -178.957 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 14.3 p -135.87 147.86 48.39 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.55 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.577 ' HE2' ' O ' ' A' ' 116' ' ' GLY . 84.4 tttt -117.34 112.84 21.27 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-O 121.085 0.469 . . . . 0.0 110.552 -178.253 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 75.4 m -97.98 73.02 2.23 Favored 'General case' 0 C--N 1.31 -1.13 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.888 178.295 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.577 ' O ' ' HE2' ' A' ' 114' ' ' LYS . . . 80.97 -98.9 1.87 Allowed Glycine 0 N--CA 1.437 -1.256 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -178.822 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 50.2 m -114.54 5.39 15.49 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 120.856 0.36 . . . . 0.0 110.122 177.282 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 50.1 tp -114.85 121.34 42.94 Favored 'General case' 0 C--O 1.222 -0.383 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.49 -178.062 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 57.4 m95 -89.45 132.5 34.99 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 121.045 0.45 . . . . 0.0 111.932 179.504 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -110.6 126.31 54.32 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.884 175.096 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.476 ' O ' HD12 ' A' ' 121' ' ' ILE . 2.5 pp -126.28 150.62 32.0 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.129 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.709 -179.012 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 26.9 m -151.72 123.57 8.03 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.569 177.487 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 5.3 p -93.64 112.01 25.91 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.324 0 CA-C-O 121.58 0.705 . . . . 0.0 110.912 179.087 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 6.4 mmt -113.54 144.15 30.79 Favored Pre-proline 0 C--N 1.318 -0.792 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.399 -178.807 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -88.01 144.71 6.22 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 122.564 2.176 . . . . 0.0 112.648 178.666 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 126' ' ' CYS . . . . . 0.44 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 26.3 m -83.26 171.83 13.2 Favored 'General case' 0 C--O 1.244 0.779 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.069 176.066 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 35.7 t -61.15 151.77 30.35 Favored 'General case' 0 N--CA 1.445 -0.687 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 177.451 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 128' ' ' ILE . . . . . 0.43 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.8 mp -64.21 124.69 19.48 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.193 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.664 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 99.69 -12.96 61.18 Favored Glycine 0 N--CA 1.44 -1.042 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.439 -177.279 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 76.5 p -111.67 149.7 31.21 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-O 121.158 0.504 . . . . 0.0 111.784 179.782 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.421 ' HB2' HG12 ' A' ' 106' ' ' VAL . 58.8 pttt -121.37 144.71 48.51 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 178.869 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.44 ' HB2' ' SG ' ' A' ' 126' ' ' CYS . 45.0 t80 -82.53 136.15 34.93 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-O 121.178 0.513 . . . . 0.0 111.927 -177.497 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 133' ' ' ASP . . . . . 0.42 ' HB3' ' OG ' ' A' ' 136' ' ' SER . 19.8 t70 -105.16 130.2 23.51 Favored Pre-proline 0 C--N 1.321 -0.659 0 CA-C-N 115.945 -0.571 . . . . 0.0 109.786 177.366 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 134' ' ' PRO . . . . . 0.401 ' HD3' ' HG3' ' A' ' 101' ' ' PRO . 28.2 Cg_endo -64.68 -42.95 14.13 Favored 'Trans proline' 0 N--CA 1.473 0.317 0 C-N-CA 123.018 2.479 . . . . 0.0 114.236 -176.17 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 2.0 mp -77.61 -50.64 19.74 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 N-CA-C 111.943 0.349 . . . . 0.0 111.943 -175.752 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 136' ' ' SER . . . . . 0.42 ' OG ' ' HB3' ' A' ' 133' ' ' ASP . 64.1 p -70.44 -29.68 66.33 Favored 'General case' 0 C--N 1.325 -0.498 0 C-N-CA 121.037 -0.265 . . . . 0.0 111.184 -179.058 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 71.21 48.83 0.34 Allowed 'General case' 0 C--O 1.234 0.251 0 CA-C-N 115.813 -0.63 . . . . 0.0 111.783 175.331 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 -160.83 176.58 11.31 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 177.976 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 17.3 m -101.43 124.72 47.56 Favored 'General case' 0 C--N 1.313 -1.02 0 C-N-CA 120.414 -0.514 . . . . 0.0 109.969 -178.907 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 31.7 m -111.66 160.05 11.26 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.889 0 CA-C-N 116.062 -0.517 . . . . 0.0 109.802 -179.588 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 78.7 mt -63.22 132.94 53.36 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-O 121.1 0.476 . . . . 0.0 111.367 -179.037 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 24.5 t70 . . . . . 0 C--N 1.313 -1.001 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 177.493 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 32.1 t70 . . . . . 0 C--O 1.235 0.298 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.423 ' CD2' HD11 ' A' ' 121' ' ' ILE . 52.9 tp -111.57 135.78 51.67 Favored 'General case' 0 C--N 1.312 -1.043 0 C-N-CA 120.939 -0.305 . . . . 0.0 110.687 179.562 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.44 HG22 HG22 ' A' ' 89' ' ' THR . 3.8 mt -100.1 145.95 9.88 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.163 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 179.323 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.563 ' O ' ' HA ' ' A' ' 89' ' ' THR . 30.9 m -141.22 170.83 13.11 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 -179.822 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' HIS . . . . . 0.402 ' HA ' ' O ' ' A' ' 88' ' ' LYS . 50.3 m-70 -114.13 113.27 24.48 Favored 'General case' 0 C--N 1.316 -0.888 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 -179.085 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.409 ' OE1' ' HA ' ' A' ' 85' ' ' GLU . 4.3 mm-40 -112.31 111.84 23.0 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 174.839 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 71.76 13.22 75.02 Favored Glycine 0 N--CA 1.452 -0.235 0 N-CA-C 110.679 -0.968 . . . . 0.0 110.679 -176.633 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 99.76 -17.46 57.39 Favored Glycine 0 N--CA 1.437 -1.295 0 CA-C-N 114.999 -0.601 . . . . 0.0 111.905 -178.18 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' LYS . . . . . 0.402 ' O ' ' HA ' ' A' ' 84' ' ' HIS . 35.3 mmtp -87.16 143.05 27.47 Favored 'General case' 0 CA--C 1.515 -0.397 0 CA-C-O 120.712 0.292 . . . . 0.0 110.691 -177.728 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.563 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.1 OUTLIER -85.62 130.71 34.5 Favored 'General case' 0 N--CA 1.434 -1.234 0 N-CA-C 112.541 0.571 . . . . 0.0 112.541 -179.076 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.454 ' CD1' ' HA3' ' A' ' 104' ' ' GLY . 82.3 m-85 -128.58 138.68 52.34 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 115.608 -0.723 . . . . 0.0 109.854 176.76 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 17.6 m-70 -88.82 143.5 26.86 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 120.831 0.348 . . . . 0.0 110.668 -179.784 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 62.2 t -117.17 122.72 70.64 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.064 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 177.724 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 52.8 t -125.37 131.13 72.64 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.176 0 CA-C-N 116.079 -0.509 . . . . 0.0 109.671 -178.805 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 87.2 m -104.8 114.28 28.39 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-O 121.182 0.515 . . . . 0.0 109.892 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 26.5 m80 -84.25 -23.46 30.39 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.151 -177.71 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -160.67 176.58 11.38 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.692 -0.686 . . . . 0.0 109.389 -179.043 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -79.89 142.8 34.84 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.885 0.374 . . . . 0.0 110.217 178.291 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 130.71 167.77 12.08 Favored Glycine 0 N--CA 1.442 -0.955 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.405 -178.412 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.416 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 87.7 Cg_endo -89.59 133.13 2.17 Favored 'Trans proline' 0 N--CA 1.449 -1.116 0 C-N-CA 122.918 2.412 . . . . 0.0 112.93 179.415 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -138.04 157.31 73.25 Favored Pre-proline 0 C--N 1.318 -0.776 0 CA-C-N 115.71 -0.677 . . . . 0.0 109.463 177.891 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.484 ' HG3' ' HD3' ' A' ' 134' ' ' PRO . 59.4 Cg_endo -68.8 171.14 13.9 Favored 'Trans proline' 0 CA--C 1.515 -0.427 0 C-N-CA 122.234 1.956 . . . . 0.0 112.234 -178.021 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 102' ' ' HIS . . . . . 0.644 ' HB3' ' O ' ' A' ' 105' ' ' ASN . 50.2 t-80 -90.35 126.68 55.78 Favored Pre-proline 0 N--CA 1.43 -1.434 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 178.943 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -54.58 -43.74 56.14 Favored 'Trans proline' 0 N--CA 1.474 0.38 0 C-N-CA 122.959 2.439 . . . . 0.0 113.126 -174.03 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.454 ' HA3' ' CD1' ' A' ' 90' ' ' TYR . . . -96.68 4.54 63.76 Favored Glycine 0 N--CA 1.442 -0.951 0 C-N-CA 120.057 -1.068 . . . . 0.0 113.633 -178.452 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.644 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 52.2 t30 -163.84 87.3 0.51 Allowed 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 117.683 0.741 . . . . 0.0 111.17 -179.534 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.9 m -54.93 -11.95 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 N-CA-C 113.859 1.059 . . . . 0.0 113.859 178.177 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 19.1 t-80 -77.21 0.39 22.05 Favored 'General case' 0 CA--C 1.543 0.704 0 CA-C-O 121.413 0.625 . . . . 0.0 110.203 177.169 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 39.8 mttp -133.8 156.29 48.29 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.576 178.516 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 9.1 p90 -141.92 162.54 35.22 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 176.497 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.416 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.3 mp -123.83 140.03 48.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 -178.327 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -99.29 118.84 46.48 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 176.259 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 65.3 m -100.25 123.23 44.23 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 120.743 0.306 . . . . 0.0 110.571 -178.015 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 34.0 t -130.84 139.8 50.19 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.328 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.416 ' HD2' ' CZ2' ' A' ' 119' ' ' TRP . 88.6 tttt -113.92 113.63 25.11 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 120.999 0.428 . . . . 0.0 110.541 -178.707 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 73.4 m -100.52 80.72 2.24 Favored 'General case' 0 N--CA 1.441 -0.887 0 CA-C-O 121.356 0.598 . . . . 0.0 109.974 178.954 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 76.1 -99.62 1.3 Allowed Glycine 0 N--CA 1.442 -0.914 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.367 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 32.8 m -112.55 4.58 17.44 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.772 0.32 . . . . 0.0 110.59 -179.436 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 12.4 mt -122.77 133.28 54.47 Favored 'General case' 0 N--CA 1.439 -0.995 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.238 -176.998 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 119' ' ' TRP . . . . . 0.416 ' CZ2' ' HD2' ' A' ' 114' ' ' LYS . 70.7 m95 -96.04 133.5 40.22 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-O 121.076 0.465 . . . . 0.0 111.472 179.549 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -121.25 122.63 40.35 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 115.785 -0.643 . . . . 0.0 109.38 176.12 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.423 HD11 ' CD2' ' A' ' 81' ' ' LEU . 2.4 pp -122.5 156.22 27.59 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.86 -175.343 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 22.6 m -140.95 123.17 15.72 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.935 178.415 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 5.2 p -95.95 105.29 16.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-O 121.621 0.725 . . . . 0.0 110.841 -179.742 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 3.5 mmt -106.18 139.48 20.32 Favored Pre-proline 0 C--N 1.314 -0.973 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.139 -178.885 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -85.09 144.63 9.56 Favored 'Trans proline' 0 N--CA 1.448 -1.151 0 C-N-CA 122.2 1.934 . . . . 0.0 112.324 178.617 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 126' ' ' CYS . . . . . 0.537 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 65.7 m -80.61 164.24 23.04 Favored 'General case' 0 C--O 1.242 0.675 0 CA-C-N 116.247 -0.433 . . . . 0.0 109.857 176.987 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 32.3 t -56.29 148.36 18.8 Favored 'General case' 0 N--CA 1.443 -0.82 0 CA-C-N 116.056 -0.52 . . . . 0.0 109.66 177.082 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 128' ' ' ILE . . . . . 0.483 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.8 mp -62.97 128.92 25.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.333 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 96.37 -9.04 67.08 Favored Glycine 0 N--CA 1.443 -0.871 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.625 -177.028 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 72.1 p -118.46 153.88 33.39 Favored 'General case' 0 C--O 1.236 0.342 0 CA-C-N 117.292 0.546 . . . . 0.0 111.127 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.419 ' HE2' ' HA ' ' A' ' 142' ' ' ASP . 49.3 pttt -130.0 145.28 51.64 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 116.022 -0.535 . . . . 0.0 109.606 -179.248 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.537 ' HB2' ' SG ' ' A' ' 126' ' ' CYS . 29.4 t80 -84.46 136.88 33.65 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-O 121.088 0.471 . . . . 0.0 111.988 -176.329 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 32.2 t70 -108.56 134.78 20.15 Favored Pre-proline 0 C--N 1.323 -0.556 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.52 177.056 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 134' ' ' PRO . . . . . 0.484 ' HD3' ' HG3' ' A' ' 101' ' ' PRO . 42.0 Cg_endo -68.82 -37.36 11.87 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.577 2.185 . . . . 0.0 113.27 -176.045 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 22.7 mm -77.85 -53.55 14.08 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.881 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.827 -176.426 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 67.0 m -68.98 -29.98 68.3 Favored 'General case' 0 C--N 1.321 -0.662 0 C-N-CA 120.822 -0.351 . . . . 0.0 111.307 178.476 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 89.0 mtm180 70.76 41.57 0.88 Allowed 'General case' 0 N--CA 1.473 0.704 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.656 175.665 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -155.66 174.35 15.42 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 177.404 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 139' ' ' CYS . . . . . 0.442 ' HA ' ' HA ' ' A' ' 132' ' ' PHE . 6.4 m -101.26 124.88 47.64 Favored 'General case' 0 C--N 1.314 -0.943 0 C-N-CA 120.341 -0.544 . . . . 0.0 109.62 -179.28 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 33.9 m -107.01 159.8 6.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.833 -179.236 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 55.4 tp -63.47 119.82 10.5 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-O 120.972 0.415 . . . . 0.0 111.456 -178.781 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 142' ' ' ASP . . . . . 0.419 ' HA ' ' HE2' ' A' ' 131' ' ' LYS . 21.2 t70 . . . . . 0 N--CA 1.442 -0.85 0 CA-C-O 121.463 0.649 . . . . 0.0 109.309 176.653 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' ASP . . . . . 0.636 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 7.6 p-10 . . . . . 0 N--CA 1.451 -0.392 0 CA-C-O 121.352 0.596 . . . . 0.0 111.028 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 47.0 tp -97.04 140.47 31.51 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.417 177.833 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.591 HG22 HG22 ' A' ' 89' ' ' THR . 5.5 mt -100.26 145.95 9.97 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.996 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 179.745 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.473 ' O ' ' HA ' ' A' ' 89' ' ' THR . 17.1 m -142.87 176.01 3.76 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.88 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -179.611 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 41.7 m-70 -117.13 120.93 39.81 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-O 121.108 0.48 . . . . 0.0 111.9 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.433 ' HB2' ' CE1' ' A' ' 90' ' ' TYR . 45.2 mt-10 -126.17 116.09 20.79 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.264 176.51 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 67.16 23.76 73.17 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.624 -0.798 . . . . 0.0 111.232 -178.557 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 93.55 -28.0 11.0 Favored Glycine 0 N--CA 1.443 -0.858 0 C-N-CA 121.437 -0.411 . . . . 0.0 112.725 -178.282 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 44.3 mmtm -84.91 155.01 21.86 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.69 0.281 . . . . 0.0 111.136 -177.058 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.591 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -92.42 137.4 32.4 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.488 -179.949 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.433 ' CE1' ' HB2' ' A' ' 85' ' ' GLU . 89.7 m-85 -131.6 145.38 51.67 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 178.583 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 20.0 m-70 -98.88 143.6 29.01 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-O 120.951 0.405 . . . . 0.0 110.579 179.606 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.636 ' O ' ' HA ' ' A' ' 80' ' ' ASP . 57.2 t -113.93 118.55 58.68 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.161 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 177.109 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 37.3 t -121.15 137.54 54.52 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.242 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 -178.282 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 72.4 m -114.53 113.61 24.66 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-O 120.988 0.423 . . . . 0.0 111.13 -179.751 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 20.8 t60 -81.03 -24.14 38.1 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.769 -0.651 . . . . 0.0 111.076 -178.846 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -154.34 169.6 23.3 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.551 -0.295 . . . . 0.0 110.615 -178.281 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 21.0 mp0 -76.61 110.61 11.32 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.378 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 161.87 165.84 19.52 Favored Glycine 0 N--CA 1.446 -0.663 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.315 179.85 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.446 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 92.3 Cg_endo -85.75 135.11 4.81 Favored 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 122.907 2.404 . . . . 0.0 112.503 178.628 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -139.92 156.95 70.39 Favored Pre-proline 0 C--N 1.319 -0.724 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.525 179.394 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -63.51 169.21 10.1 Favored 'Trans proline' 0 C--N 1.353 0.775 0 C-N-CA 122.683 2.255 . . . . 0.0 112.54 -179.649 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' HIS . . . . . 0.474 ' CD2' HD11 ' A' ' 110' ' ' ILE . 5.2 t-80 -94.31 138.46 22.47 Favored Pre-proline 0 C--N 1.322 -0.602 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 -178.108 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -53.45 -50.2 14.72 Favored 'Trans proline' 0 CA--C 1.536 0.584 0 C-N-CA 123.109 2.539 . . . . 0.0 113.121 -178.624 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -71.1 -65.21 2.53 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.591 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 43.7 m-80 -115.06 104.94 12.38 Favored 'General case' 0 C--N 1.321 -0.658 0 O-C-N 122.865 -0.197 . . . . 0.0 111.365 -179.806 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 18.5 m -56.25 -12.04 0.99 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 N-CA-C 112.011 0.374 . . . . 0.0 112.011 173.976 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 24.3 t-80 -66.36 -8.26 24.28 Favored 'General case' 0 CA--C 1.544 0.719 0 CA-C-O 121.407 0.622 . . . . 0.0 110.076 175.58 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 48.4 mtmt -129.55 157.25 42.55 Favored 'General case' 0 N--CA 1.439 -1.001 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.623 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 12.9 p90 -142.14 167.38 22.26 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 120.181 -0.608 . . . . 0.0 111.133 -179.804 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.474 HD11 ' CD2' ' A' ' 102' ' ' HIS . 2.3 mp -126.43 139.4 51.78 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.112 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.173 -179.146 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.7 mp -98.74 116.45 41.73 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.144 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 175.336 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 39.9 m -95.99 121.82 38.14 Favored 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 16.6 t -130.36 149.4 52.06 Favored 'General case' 0 N--CA 1.437 -1.098 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.117 -178.624 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.508 ' HE3' ' CE2' ' A' ' 119' ' ' TRP . 9.1 mmtp -103.23 140.46 37.34 Favored 'General case' 0 C--N 1.308 -1.203 0 CA-C-O 121.224 0.535 . . . . 0.0 111.732 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 57.7 m -124.26 79.92 1.78 Allowed 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 174.207 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 73.39 -104.4 1.58 Allowed Glycine 0 N--CA 1.431 -1.68 0 CA-C-N 114.788 -1.096 . . . . 0.0 110.517 -174.851 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 12.1 p -113.01 16.39 19.35 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-O 120.899 0.38 . . . . 0.0 111.134 178.719 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 24.2 tp -122.14 142.92 49.89 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.289 -177.924 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 119' ' ' TRP . . . . . 0.508 ' CE2' ' HE3' ' A' ' 114' ' ' LYS . 91.1 m95 -92.15 133.39 35.82 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 120.984 0.421 . . . . 0.0 111.67 179.161 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 49.2 m-85 -124.19 122.81 38.81 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.123 172.3 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.5 pp -119.78 155.95 22.46 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.44 -176.949 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 25.7 m -141.06 119.74 12.49 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.655 178.353 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 4.2 p -94.02 109.06 21.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-O 121.684 0.754 . . . . 0.0 111.108 -179.138 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 5.3 mmt -107.82 127.4 27.79 Favored Pre-proline 0 C--N 1.309 -1.183 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.288 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -78.75 142.08 17.64 Favored 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 122.325 2.017 . . . . 0.0 110.819 176.21 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 10.4 t -93.62 -179.08 4.91 Favored 'General case' 0 C--N 1.317 -0.824 0 C-N-CA 120.484 -0.487 . . . . 0.0 110.382 179.745 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 34.0 t -62.94 146.51 52.86 Favored 'General case' 0 N--CA 1.438 -1.035 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.691 -179.472 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 128' ' ' ILE . . . . . 0.422 ' N ' HD12 ' A' ' 128' ' ' ILE . 2.0 mp -62.91 129.82 26.78 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-N 116.131 -0.486 . . . . 0.0 109.839 179.397 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.86 -4.04 68.05 Favored Glycine 0 N--CA 1.44 -1.099 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.949 -178.343 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 34.9 p -128.14 150.39 50.01 Favored 'General case' 0 C--O 1.237 0.447 0 CA-C-N 117.28 0.54 . . . . 0.0 110.885 178.896 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.421 ' O ' ' HA ' ' A' ' 139' ' ' CYS . 62.7 pttt -127.03 154.96 43.98 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.966 -179.616 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 40.3 t80 -87.18 136.87 32.76 Favored 'General case' 0 C--N 1.311 -1.078 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.109 -178.682 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -99.01 134.41 21.44 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.782 178.748 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 26.6 Cg_endo -62.04 -51.3 3.85 Favored 'Trans proline' 0 CA--C 1.532 0.39 0 C-N-CA 123.017 2.478 . . . . 0.0 114.116 -176.63 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 47.2 mm -81.23 -47.25 20.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 112.112 0.412 . . . . 0.0 112.112 -175.803 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.5 m -65.98 -34.46 78.15 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.833 0.349 . . . . 0.0 110.446 -179.228 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 87.7 mtm180 66.14 53.05 1.1 Allowed 'General case' 0 CA--C 1.516 -0.337 0 CA-C-N 115.404 -0.817 . . . . 0.0 110.554 177.757 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 28.2 p-10 -157.47 176.52 12.55 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.034 -0.985 . . . . 0.0 109.191 179.443 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 139' ' ' CYS . . . . . 0.421 ' HA ' ' O ' ' A' ' 131' ' ' LYS . 68.0 m -102.62 131.07 49.64 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-O 121.006 0.431 . . . . 0.0 111.91 178.628 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 33.8 m -125.55 165.85 22.42 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.216 177.288 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -50.26 118.18 2.82 Favored 'General case' 0 N--CA 1.474 0.739 0 CA-C-O 121.108 0.48 . . . . 0.0 111.644 179.809 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 15.3 t0 . . . . . 0 N--CA 1.445 -0.698 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 177.35 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 11.0 t70 . . . . . 0 N--CA 1.454 -0.232 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.461 HD22 ' CD1' ' A' ' 121' ' ' ILE . 23.9 tp -90.54 148.57 22.63 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-O 120.865 0.364 . . . . 0.0 110.978 -177.387 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.529 HG22 HG22 ' A' ' 89' ' ' THR . 7.7 mt -105.92 144.77 14.79 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 175.835 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.459 HG21 ' NE2' ' A' ' 102' ' ' HIS . 16.1 m -132.27 158.16 43.23 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 -178.473 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 6.8 p80 -116.49 101.98 9.1 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-O 121.226 0.536 . . . . 0.0 111.571 -177.721 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -117.27 114.09 23.11 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.12 179.116 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 67.05 22.58 72.48 Favored Glycine 0 CA--C 1.519 0.337 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.478 179.67 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 90.02 -4.71 83.23 Favored Glycine 0 N--CA 1.445 -0.707 0 C-N-CA 121.174 -0.536 . . . . 0.0 112.365 -179.686 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 35.0 mmtp -100.26 134.34 43.34 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 120.716 0.293 . . . . 0.0 110.349 -179.411 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.529 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -88.03 107.74 18.89 Favored 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.257 179.466 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -101.23 146.91 26.9 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.598 178.364 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 18.2 m-70 -98.22 140.04 33.1 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-O 120.881 0.372 . . . . 0.0 110.612 177.653 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 44.5 t -122.04 118.43 55.48 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.481 178.323 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.3 p -129.44 132.76 66.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.494 179.356 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 77.2 m -111.96 123.1 49.53 Favored 'General case' 0 C--N 1.308 -1.228 0 CA-C-O 121.059 0.457 . . . . 0.0 111.11 -178.47 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 34.2 m80 -100.7 -21.6 15.16 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 178.436 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -129.14 144.2 51.12 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.14 -0.937 . . . . 0.0 109.526 -178.83 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' GLU . . . . . 0.479 ' HG3' ' HA ' ' A' ' 113' ' ' SER . 42.3 tt0 -76.23 138.73 40.79 Favored 'General case' 0 N--CA 1.43 -1.432 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 177.883 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 132.17 173.86 13.45 Favored Glycine 0 N--CA 1.439 -1.107 0 C-N-CA 120.902 -0.666 . . . . 0.0 111.77 -178.21 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -87.36 134.07 3.39 Favored 'Trans proline' 0 N--CA 1.452 -0.961 0 C-N-CA 122.912 2.408 . . . . 0.0 112.951 179.142 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.8 pp -137.02 157.24 75.0 Favored Pre-proline 0 C--N 1.323 -0.544 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.899 178.43 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -65.34 162.58 32.89 Favored 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.41 2.073 . . . . 0.0 113.126 -177.794 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' HIS . . . . . 0.459 ' NE2' HG21 ' A' ' 83' ' ' VAL . 59.5 t-80 -91.78 120.93 67.83 Favored Pre-proline 0 C--N 1.316 -0.881 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.536 179.676 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_endo -60.72 -16.93 46.71 Favored 'Trans proline' 0 N--CA 1.482 0.841 0 C-N-CA 123.132 2.555 . . . . 0.0 113.466 -175.842 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -89.99 -24.09 30.73 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.556 -0.83 . . . . 0.0 112.563 179.874 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 25.7 p-10 -167.4 106.89 0.57 Allowed 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 110.108 -0.33 . . . . 0.0 110.108 -179.174 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 31.2 m -53.09 -11.32 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.045 0 N-CA-C 114.01 1.115 . . . . 0.0 114.01 -179.936 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -80.48 2.31 25.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.154 0.502 . . . . 0.0 110.935 178.49 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 34.1 mtmt -133.76 156.5 47.86 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 177.736 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 6.6 p90 -142.51 166.21 25.28 Favored 'General case' 0 C--N 1.311 -1.099 0 C-N-CA 120.871 -0.332 . . . . 0.0 110.476 179.331 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 3.7 mp -123.74 137.67 56.09 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.474 ' O ' ' HA ' ' A' ' 121' ' ' ILE . 4.2 mp -95.64 121.74 46.47 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.997 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 176.696 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 25.4 m -105.46 127.16 52.85 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 -178.859 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 113' ' ' SER . . . . . 0.479 ' HA ' ' HG3' ' A' ' 97' ' ' GLU . 52.5 m -126.52 131.79 51.51 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.402 179.251 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.632 ' HE2' ' O ' ' A' ' 116' ' ' GLY . 23.7 tptm -97.49 113.57 25.28 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 120.705 0.288 . . . . 0.0 110.659 -178.87 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 72.1 m -112.99 80.03 1.3 Allowed 'General case' 0 N--CA 1.442 -0.863 0 CA-C-O 121.265 0.555 . . . . 0.0 110.286 178.447 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.632 ' O ' ' HE2' ' A' ' 114' ' ' LYS . . . 74.35 -99.28 1.07 Allowed Glycine 0 N--CA 1.446 -0.679 0 CA-C-N 115.349 -0.841 . . . . 0.0 111.037 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 48.8 p -113.52 4.1 16.05 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 121.12 0.486 . . . . 0.0 110.433 178.065 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 26.8 tp -117.5 132.16 56.59 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.954 -175.479 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 119' ' ' TRP . . . . . 0.447 ' CE2' ' HD3' ' A' ' 114' ' ' LYS . 86.3 m95 -94.78 132.06 39.96 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 120.883 0.373 . . . . 0.0 110.746 177.116 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 51.0 m-85 -108.65 128.04 54.5 Favored 'General case' 0 C--N 1.309 -1.162 0 N-CA-C 108.876 -0.786 . . . . 0.0 108.876 174.156 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.474 ' HA ' ' O ' ' A' ' 111' ' ' ILE . 1.8 pp -133.2 153.4 37.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-O 121.367 0.603 . . . . 0.0 112.616 -175.695 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 19.4 m -150.44 127.58 11.24 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.188 178.074 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 4.0 p -98.77 106.74 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 CA-C-O 121.57 0.7 . . . . 0.0 111.061 -178.504 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 3.5 mmt -108.03 140.27 21.49 Favored Pre-proline 0 C--N 1.309 -1.166 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.654 -179.325 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_endo -82.48 141.47 11.23 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 122.386 2.058 . . . . 0.0 111.36 176.649 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 5.9 t -94.16 -174.87 3.51 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 120.648 -0.421 . . . . 0.0 110.667 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 15.5 m -61.53 137.16 58.23 Favored 'General case' 0 N--CA 1.441 -0.896 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.627 178.413 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 2.4 mp -65.84 139.35 21.41 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.914 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 178.33 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 93.55 -13.93 66.42 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.313 -176.03 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 73.6 p -117.41 159.53 22.64 Favored 'General case' 0 N--CA 1.447 -0.614 0 O-C-N 122.479 -0.424 . . . . 0.0 110.735 179.319 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 59.8 pttt -129.07 148.29 51.0 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.698 179.609 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.441 ' HD1' ' SG ' ' A' ' 139' ' ' CYS . 25.5 t80 -87.68 135.63 33.29 Favored 'General case' 0 C--N 1.308 -1.229 0 CA-C-O 120.825 0.345 . . . . 0.0 110.714 -178.58 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 30.5 t70 -102.47 134.99 19.64 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.015 178.706 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.23 -41.16 13.28 Favored 'Trans proline' 0 C--N 1.346 0.419 0 C-N-CA 123.021 2.481 . . . . 0.0 113.862 -176.963 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 33.1 mm -81.39 -52.69 13.57 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 C-N-CA 120.819 -0.353 . . . . 0.0 111.525 -176.934 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 7.2 m -62.69 -36.79 84.06 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 120.855 0.359 . . . . 0.0 110.394 179.153 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 80.5 mtm180 69.36 42.83 1.12 Allowed 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 115.356 -0.838 . . . . 0.0 111.157 177.24 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -154.39 177.57 11.01 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 108.393 -0.965 . . . . 0.0 108.393 177.197 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 139' ' ' CYS . . . . . 0.441 ' SG ' ' HD1' ' A' ' 132' ' ' PHE . 78.1 m -101.77 126.68 48.68 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-O 121.385 0.612 . . . . 0.0 111.737 -177.91 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 26.8 m -115.2 159.1 15.26 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-N 115.185 -0.916 . . . . 0.0 109.553 179.436 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 2.3 tm? -55.41 123.24 13.23 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 120.963 0.411 . . . . 0.0 110.915 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 16.5 t70 . . . . . 0 C--N 1.324 -0.539 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.045 -179.467 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 10.2 t70 . . . . . 0 C--O 1.237 0.396 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.431 ' CD2' HD11 ' A' ' 121' ' ' ILE . 35.3 tp -101.26 147.14 26.64 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.244 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.548 HG22 HG22 ' A' ' 89' ' ' THR . 4.0 mt -110.24 148.29 13.88 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.869 0 C-N-CA 120.561 -0.455 . . . . 0.0 110.374 178.553 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.477 ' O ' ' HA ' ' A' ' 89' ' ' THR . 4.8 m -142.44 174.72 5.39 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 179.58 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 11.0 p80 -128.21 108.36 10.55 Favored 'General case' 0 C--N 1.313 -1.0 0 N-CA-C 112.503 0.557 . . . . 0.0 112.503 -177.751 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 3.9 mp0 -116.65 113.63 22.94 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.105 178.708 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 66.68 31.64 79.05 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.628 178.895 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 86.19 -11.75 62.15 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.839 -0.696 . . . . 0.0 113.201 179.243 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 30.2 mmtp -99.09 136.94 38.32 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.871 0.336 . . . . 0.0 111.166 -179.775 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.548 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -86.54 107.77 18.27 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.474 179.268 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -100.3 145.14 28.48 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.816 179.258 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 27.1 m-70 -99.43 144.09 28.94 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.36 178.355 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 46.2 t -120.51 118.38 56.39 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.078 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 178.452 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 44.1 t -124.56 132.6 71.1 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.274 179.478 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 71.3 m -104.43 113.77 27.55 Favored 'General case' 0 C--N 1.31 -1.141 0 CA-C-O 121.113 0.482 . . . . 0.0 110.305 -179.564 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 19.0 t60 -79.49 -21.2 45.66 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.509 -178.144 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -161.53 175.81 11.72 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.654 179.714 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -77.92 144.6 36.73 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 120.735 0.302 . . . . 0.0 110.461 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 126.45 164.41 11.74 Favored Glycine 0 N--CA 1.446 -0.658 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.41 -179.685 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.413 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 92.1 Cg_endo -86.78 138.28 5.09 Favored 'Trans proline' 0 CA--C 1.54 0.814 0 C-N-CA 122.869 2.379 . . . . 0.0 113.179 179.376 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -140.91 157.27 67.75 Favored Pre-proline 0 C--N 1.325 -0.482 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.169 177.829 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -64.22 166.94 15.54 Favored 'Trans proline' 0 C--N 1.353 0.763 0 C-N-CA 122.666 2.244 . . . . 0.0 112.848 -179.138 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' HIS . . . . . . . . . . . . . 56.5 t-80 -92.82 128.36 44.09 Favored Pre-proline 0 C--N 1.318 -0.769 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.592 -179.088 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -63.09 -19.25 68.46 Favored 'Trans proline' 0 N--CA 1.484 0.934 0 C-N-CA 123.146 2.564 . . . . 0.0 113.398 -176.841 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -96.81 -17.54 32.58 Favored Glycine 0 C--O 1.228 -0.275 0 C-N-CA 120.485 -0.865 . . . . 0.0 113.226 -178.846 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.404 HD21 ' HE2' ' A' ' 108' ' ' LYS . 28.2 p-10 -169.23 104.21 0.37 Allowed 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.698 0.285 . . . . 0.0 110.8 -179.36 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 26.0 m -53.82 -13.14 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 N-CA-C 113.935 1.087 . . . . 0.0 113.935 179.069 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 36.4 m170 -74.88 0.11 16.7 Favored 'General case' 0 N--CA 1.471 0.621 0 CA-C-O 121.081 0.467 . . . . 0.0 110.858 177.043 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.404 ' HE2' HD21 ' A' ' 105' ' ' ASN . 31.2 mtmt -134.91 156.69 48.52 Favored 'General case' 0 CA--C 1.507 -0.705 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 178.555 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 9.9 p90 -142.47 168.74 19.01 Favored 'General case' 0 C--N 1.31 -1.135 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.433 178.828 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.413 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.5 mp -126.2 140.02 49.89 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 -179.82 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -98.7 118.16 44.83 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 176.287 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 68.8 m -100.4 123.61 44.85 Favored 'General case' 0 C--N 1.308 -1.232 0 CA-C-O 120.873 0.368 . . . . 0.0 110.418 -178.462 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 56.0 p -131.87 141.19 49.32 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 178.42 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 81.2 tttt -116.52 106.24 13.36 Favored 'General case' 0 C--N 1.311 -1.087 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.621 -178.611 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 69.6 m -88.59 84.48 6.75 Favored 'General case' 0 N--CA 1.436 -1.154 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.52 179.094 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 73.98 -100.2 1.11 Allowed Glycine 0 N--CA 1.439 -1.103 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -178.153 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 50.3 m -115.04 3.62 14.49 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-O 121.203 0.525 . . . . 0.0 109.826 178.633 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 92.2 mt -108.54 122.82 47.85 Favored 'General case' 0 N--CA 1.435 -1.209 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.542 -176.248 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 86.6 m95 -87.65 130.51 34.76 Favored 'General case' 0 C--N 1.315 -0.903 0 C-N-CA 120.414 -0.514 . . . . 0.0 111.315 179.145 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 85.6 m-85 -122.61 125.73 46.25 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.585 174.133 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.431 HD11 ' CD2' ' A' ' 81' ' ' LEU . 2.2 pp -124.95 157.88 33.06 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.177 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.035 -178.918 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 32.7 m -145.32 121.66 10.93 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 116.148 -0.478 . . . . 0.0 109.718 177.178 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.5 p -93.81 106.41 18.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 CA-C-O 121.491 0.663 . . . . 0.0 110.775 -178.685 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 4.2 mmt -106.75 136.3 19.44 Favored Pre-proline 0 C--N 1.31 -1.111 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.97 -178.662 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -82.54 139.3 10.09 Favored 'Trans proline' 0 N--CA 1.45 -1.062 0 C-N-CA 122.411 2.074 . . . . 0.0 110.87 176.078 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 4.7 t -94.61 -178.62 4.61 Favored 'General case' 0 C--N 1.311 -1.071 0 C-N-CA 120.104 -0.639 . . . . 0.0 109.325 177.831 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 15.4 m -63.56 135.1 56.58 Favored 'General case' 0 N--CA 1.435 -1.204 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.408 179.756 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 128' ' ' ILE . . . . . 0.401 ' N ' HD12 ' A' ' 128' ' ' ILE . 2.2 mp -62.62 141.36 18.07 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 N-CA-C 109.014 -0.735 . . . . 0.0 109.014 178.264 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.8 -10.61 74.17 Favored Glycine 0 N--CA 1.441 -0.985 0 C-N-CA 120.285 -0.959 . . . . 0.0 112.551 -175.186 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 73.5 p -125.02 152.96 43.57 Favored 'General case' 0 N--CA 1.45 -0.438 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 177.003 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 60.5 pttt -126.85 146.69 50.18 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 110.327 -0.249 . . . . 0.0 110.327 -178.366 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 37.9 t80 -84.42 131.38 34.68 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.87 -178.998 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 23.1 t70 -97.41 133.84 23.32 Favored Pre-proline 0 C--N 1.321 -0.65 0 CA-C-N 116.068 -0.515 . . . . 0.0 109.907 179.29 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -68.02 -40.83 8.43 Favored 'Trans proline' 0 CA--C 1.531 0.371 0 C-N-CA 122.69 2.26 . . . . 0.0 113.842 -177.242 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.8 mp -80.3 -52.05 15.09 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 111.778 0.288 . . . . 0.0 111.778 -177.961 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 2.1 m -67.03 -35.11 79.17 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.079 0.466 . . . . 0.0 110.092 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 50.7 mtm180 66.37 56.22 0.8 Allowed 'General case' 0 C--O 1.238 0.464 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.645 178.402 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 29.4 p-10 -162.18 174.92 12.26 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 114.647 -1.16 . . . . 0.0 108.75 178.785 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 79.2 m -102.72 126.48 49.84 Favored 'General case' 0 C--N 1.311 -1.068 0 CA-C-O 121.023 0.44 . . . . 0.0 110.805 179.152 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 32.3 m -120.33 170.29 10.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.738 -0.664 . . . . 0.0 110.293 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -51.11 116.89 2.22 Favored 'General case' 0 C--O 1.241 0.615 0 O-C-N 123.545 0.528 . . . . 0.0 110.722 178.794 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 9.7 t70 . . . . . 0 CA--C 1.508 -0.669 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.606 179.766 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 . . . . . 0 N--CA 1.447 -0.594 0 CA-C-O 121.244 0.545 . . . . 0.0 110.012 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.453 HD23 HD11 ' A' ' 121' ' ' ILE . 49.4 tp -127.2 135.73 51.06 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 115.417 -0.811 . . . . 0.0 111.276 178.312 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.505 HG22 HG22 ' A' ' 89' ' ' THR . 22.1 mt -94.84 144.58 9.52 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.131 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 176.017 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.553 HG21 ' CE1' ' A' ' 102' ' ' HIS . 20.5 m -131.34 174.22 13.44 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 N-CA-C 109.997 -0.371 . . . . 0.0 109.997 -177.261 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 27.2 m-70 -122.07 101.92 7.83 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 116.528 -0.305 . . . . 0.0 110.93 -178.822 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 34.8 mm-40 -111.32 117.57 33.5 Favored 'General case' 0 C--N 1.32 -0.697 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 178.121 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 63.33 29.24 73.91 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.863 -0.684 . . . . 0.0 111.867 -179.427 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 84.96 -9.35 66.35 Favored Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 121.087 -0.578 . . . . 0.0 113.132 -179.79 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 13.6 mptt -100.57 141.58 33.23 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.993 0.425 . . . . 0.0 111.327 -179.359 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.505 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -82.97 122.24 28.03 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.67 179.47 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 76.1 m-85 -118.21 143.08 46.82 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 176.895 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 17.7 m-70 -94.46 139.59 30.94 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-O 120.65 0.262 . . . . 0.0 110.664 -178.275 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 60.4 t -119.46 118.14 56.36 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.88 0 N-CA-C 108.99 -0.745 . . . . 0.0 108.99 177.126 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 53.3 t -126.21 133.96 67.58 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.945 -178.741 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 66.6 m -114.64 121.25 42.83 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-O 120.779 0.323 . . . . 0.0 110.372 -178.819 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 39.1 m80 -90.23 -18.45 25.66 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.183 -179.811 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -150.11 170.05 19.82 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.648 -177.509 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -87.46 114.23 23.88 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.182 177.414 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 167.46 166.11 25.99 Favored Glycine 0 N--CA 1.436 -1.351 0 C-N-CA 121.049 -0.596 . . . . 0.0 111.624 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.501 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 87.6 Cg_endo -87.21 130.98 3.0 Favored 'Trans proline' 0 N--CA 1.45 -1.068 0 C-N-CA 122.761 2.307 . . . . 0.0 112.773 178.763 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.5 pp -140.94 156.74 68.41 Favored Pre-proline 0 C--N 1.319 -0.751 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.908 178.264 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -64.72 167.32 15.69 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 122.824 2.349 . . . . 0.0 113.163 -177.538 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' HIS . . . . . 0.553 ' CE1' HG21 ' A' ' 83' ' ' VAL . 4.9 t-80 -93.18 123.77 59.85 Favored Pre-proline 0 C--N 1.316 -0.87 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 -179.207 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 23.2 Cg_endo -58.64 -29.56 89.62 Favored 'Trans proline' 0 N--CA 1.482 0.817 0 C-N-CA 123.147 2.565 . . . . 0.0 114.155 -174.326 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -90.21 -16.08 56.29 Favored Glycine 0 C--N 1.319 -0.389 0 C-N-CA 120.085 -1.055 . . . . 0.0 113.238 -178.547 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 9.3 p-10 -168.07 97.47 0.44 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 120.773 0.321 . . . . 0.0 110.61 -177.122 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 30.5 m -56.07 -10.52 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 N-CA-C 113.768 1.025 . . . . 0.0 113.768 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 32.2 m170 -70.38 0.23 6.95 Favored 'General case' 0 N--CA 1.478 0.927 0 CA-C-O 121.352 0.596 . . . . 0.0 110.327 175.499 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.415 ' HG2' ' HA ' ' A' ' 125' ' ' PRO . 86.5 mttt -134.16 157.99 44.81 Favored 'General case' 0 CA--C 1.505 -0.758 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.021 178.91 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 12.3 p90 -143.44 165.83 26.45 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.391 176.616 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.501 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 2.3 mp -124.52 140.59 47.32 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.166 0 CA-C-O 120.798 0.333 . . . . 0.0 110.233 -178.758 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.4 mp -103.33 114.09 41.96 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 175.595 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 34.4 m -96.88 123.02 40.48 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -178.119 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 29.7 p -134.62 145.65 48.82 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-O 120.955 0.407 . . . . 0.0 111.087 -178.497 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 114' ' ' LYS . . . . . 0.534 ' HE2' ' O ' ' A' ' 116' ' ' GLY . 87.2 tttt -111.3 120.46 42.31 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-N 115.99 -0.55 . . . . 0.0 109.545 179.195 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 57.6 m -103.33 85.86 2.56 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.75 178.828 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.534 ' O ' ' HE2' ' A' ' 114' ' ' LYS . . . 66.91 -100.65 0.58 Allowed Glycine 0 N--CA 1.442 -0.958 0 CA-C-N 115.221 -0.899 . . . . 0.0 111.882 -178.58 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 15.1 m -110.3 6.58 22.56 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 120.741 0.305 . . . . 0.0 111.332 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -124.89 135.67 53.08 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 122.235 -0.291 . . . . 0.0 110.469 -178.768 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 52.6 m95 -94.65 135.79 35.71 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 120.945 0.402 . . . . 0.0 111.73 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -129.23 129.58 45.19 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.999 176.485 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.453 HD11 HD23 ' A' ' 81' ' ' LEU . 2.6 pp -123.86 147.63 28.21 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 120.82 0.343 . . . . 0.0 110.819 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 25.0 m -132.01 124.35 29.13 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.515 -179.326 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 4.4 p -98.25 108.71 22.46 Favored 'Isoleucine or valine' 0 C--O 1.236 0.373 0 CA-C-O 121.496 0.665 . . . . 0.0 110.813 179.38 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 5.5 mmt -107.33 129.95 23.54 Favored Pre-proline 0 C--N 1.307 -1.253 0 CA-C-N 115.424 -0.807 . . . . 0.0 110.658 -179.054 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 125' ' ' PRO . . . . . 0.415 ' HA ' ' HG2' ' A' ' 108' ' ' LYS . 74.5 Cg_endo -79.52 134.48 11.16 Favored 'Trans proline' 0 N--CA 1.452 -0.92 0 C-N-CA 122.244 1.963 . . . . 0.0 110.817 176.463 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 5.0 t -88.57 -177.51 5.6 Favored 'General case' 0 C--N 1.311 -1.095 0 C-N-CA 120.267 -0.573 . . . . 0.0 110.354 -179.075 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 4.9 m -63.41 147.61 50.77 Favored 'General case' 0 N--CA 1.441 -0.894 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.188 -179.838 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 128' ' ' ILE . . . . . 0.408 ' N ' HD12 ' A' ' 128' ' ' ILE . 2.1 mp -65.97 139.13 21.75 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.584 178.36 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 88.72 -12.21 66.26 Favored Glycine 0 N--CA 1.441 -1.018 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.556 -177.781 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 64.1 p -118.41 156.48 28.91 Favored 'General case' 0 N--CA 1.448 -0.547 0 CA-C-N 117.163 0.481 . . . . 0.0 110.847 178.73 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.456 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 62.1 pttt -133.28 152.16 51.92 Favored 'General case' 0 C--N 1.316 -0.886 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 20.8 t80 -86.1 136.16 33.33 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-O 121.004 0.431 . . . . 0.0 111.348 -179.062 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -101.48 134.64 20.13 Favored Pre-proline 0 C--N 1.325 -0.461 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.909 178.05 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -71.99 -33.06 10.26 Favored 'Trans proline' 0 CA--C 1.533 0.467 0 C-N-CA 122.65 2.233 . . . . 0.0 113.924 -177.258 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.7 mp -81.04 -55.12 8.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 111.697 0.258 . . . . 0.0 111.697 -177.737 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 49.9 m -72.84 -30.82 64.32 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.602 0.239 . . . . 0.0 111.073 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 68.54 50.32 0.7 Allowed 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.102 178.73 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 30.1 p-10 -151.96 176.43 11.49 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-N 115.262 -0.881 . . . . 0.0 108.954 178.855 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 139' ' ' CYS . . . . . 0.414 ' HA ' ' O ' ' A' ' 131' ' ' LYS . 85.5 m -102.36 126.18 49.3 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-O 121.037 0.446 . . . . 0.0 110.474 178.333 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.6 m -118.62 166.6 12.83 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.919 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.917 179.791 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -54.25 117.28 3.15 Favored 'General case' 0 CA--C 1.537 0.467 0 CA-C-O 121.003 0.43 . . . . 0.0 110.361 179.244 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 142' ' ' ASP . . . . . 0.456 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 18.9 t70 . . . . . 0 C--N 1.325 -0.483 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.449 -178.456 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' ASP . . . . . 0.523 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 4.8 p-10 . . . . . 0 N--CA 1.446 -0.645 0 CA-C-O 121.537 0.684 . . . . 0.0 111.255 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -98.19 127.55 44.19 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.068 -0.969 . . . . 0.0 108.45 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.464 ' CG2' HG22 ' A' ' 89' ' ' THR . 24.9 mt -90.5 145.09 7.84 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.958 0 CA-C-O 120.952 0.406 . . . . 0.0 111.247 -177.128 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.42 HG21 ' CE1' ' A' ' 102' ' ' HIS . 20.7 m -131.82 168.22 24.5 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.007 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 179.441 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 12.1 p80 -127.15 113.18 16.04 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-O 121.035 0.445 . . . . 0.0 111.601 -178.614 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 64.1 mm-40 -119.95 102.42 8.54 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.663 -179.47 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 65.29 40.16 96.41 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.934 -0.651 . . . . 0.0 112.589 178.734 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 84.66 -8.66 68.03 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.976 179.777 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 34.7 mmtp -100.69 128.68 46.65 Favored 'General case' 0 CA--C 1.511 -0.526 0 CA-C-O 120.95 0.405 . . . . 0.0 110.91 -178.972 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.464 HG22 ' CG2' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -86.4 127.31 34.81 Favored 'General case' 0 C--N 1.307 -1.281 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.102 178.607 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 88.0 m-85 -121.51 148.96 43.78 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.048 178.782 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 25.1 m-70 -102.4 143.24 32.39 Favored 'General case' 0 C--N 1.307 -1.249 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.049 179.217 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.523 ' O ' ' HA ' ' A' ' 80' ' ' ASP . 99.1 t -118.76 126.29 75.13 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.379 179.534 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.4 p -143.21 131.59 19.59 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.959 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.6 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 64.7 m -128.62 131.25 48.09 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 120.838 0.351 . . . . 0.0 110.858 179.804 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 28.5 m80 -105.02 -11.07 16.8 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.117 0.484 . . . . 0.0 109.961 179.71 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 6.9 mp0 -127.35 143.36 51.23 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.206 179.911 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -78.46 109.99 13.12 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-O 120.917 0.389 . . . . 0.0 110.896 -179.565 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 167.94 168.35 29.94 Favored Glycine 0 N--CA 1.434 -1.434 0 N-CA-C 111.566 -0.614 . . . . 0.0 111.566 -179.645 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.458 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 83.1 Cg_endo -87.12 137.75 4.58 Favored 'Trans proline' 0 N--CA 1.451 -1.016 0 C-N-CA 122.841 2.361 . . . . 0.0 112.559 178.447 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.8 pp -139.01 157.64 71.09 Favored Pre-proline 0 C--N 1.317 -0.812 0 CA-C-N 115.987 -0.551 . . . . 0.0 109.586 178.36 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -63.16 168.65 10.52 Favored 'Trans proline' 0 C--N 1.35 0.609 0 C-N-CA 122.471 2.114 . . . . 0.0 112.856 -178.175 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' HIS . . . . . 0.42 ' CE1' HG21 ' A' ' 83' ' ' VAL . 3.6 t-80 -92.87 122.95 62.78 Favored Pre-proline 0 C--N 1.315 -0.899 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 -179.617 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -59.83 -21.8 65.47 Favored 'Trans proline' 0 N--CA 1.483 0.888 0 C-N-CA 122.99 2.46 . . . . 0.0 113.786 -176.361 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -95.93 -16.57 38.18 Favored Glycine 0 CA--C 1.519 0.283 0 C-N-CA 120.165 -1.017 . . . . 0.0 113.216 -178.798 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 3.0 p30 -168.24 101.86 0.44 Allowed 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 122.596 0.358 . . . . 0.0 110.904 -178.736 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.602 HG12 ' HB2' ' A' ' 131' ' ' LYS . 6.0 t -53.23 -16.86 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.064 0 N-CA-C 113.596 0.962 . . . . 0.0 113.596 -179.584 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 8.5 m170 -72.88 5.48 3.22 Favored 'General case' 0 N--CA 1.479 0.999 0 O-C-N 121.936 -0.478 . . . . 0.0 111.39 177.732 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 46.4 mtmt -139.74 158.93 43.29 Favored 'General case' 0 N--CA 1.44 -0.958 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 178.773 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 6.5 p90 -142.87 173.73 11.28 Favored 'General case' 0 C--N 1.302 -1.463 0 CA-C-O 120.866 0.365 . . . . 0.0 110.849 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.458 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 4.1 mt -130.6 138.55 53.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.936 -179.156 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -102.31 117.45 47.69 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 176.334 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 74.0 m -107.46 123.7 48.79 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-O 121.231 0.539 . . . . 0.0 110.709 -177.905 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 13.9 t -131.05 148.44 52.74 Favored 'General case' 0 C--N 1.311 -1.107 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.53 -178.955 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 34.1 tttm -116.87 112.1 20.6 Favored 'General case' 0 N--CA 1.435 -1.191 0 CA-C-O 121.28 0.562 . . . . 0.0 110.624 -178.969 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 8.5 t -94.44 100.49 12.49 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 179.598 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 64.29 -104.63 0.93 Allowed Glycine 0 N--CA 1.439 -1.101 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -175.852 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 31.3 m -114.11 9.51 17.24 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 116.674 0.237 . . . . 0.0 111.624 178.798 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 6.9 tt -121.54 135.79 54.99 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.809 0.337 . . . . 0.0 110.636 -176.725 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 84.2 m95 -93.74 133.27 37.28 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.141 0.496 . . . . 0.0 112.295 -177.615 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -117.65 127.31 53.82 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.65 -0.704 . . . . 0.0 109.161 174.38 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.5 pp -123.41 146.72 28.34 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.944 0 CA-C-O 121.1 0.476 . . . . 0.0 111.22 -178.596 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 18.6 m -136.83 122.85 20.25 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.765 179.231 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 2.7 p -94.99 111.31 25.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 121.344 0.593 . . . . 0.0 110.782 179.279 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 5.3 mmt -112.25 151.23 43.54 Favored Pre-proline 0 C--N 1.314 -0.977 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.512 -178.844 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -89.18 143.84 4.82 Favored 'Trans proline' 0 N--CA 1.452 -0.913 0 C-N-CA 122.409 2.072 . . . . 0.0 112.414 177.9 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 126' ' ' CYS . . . . . 0.507 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 56.9 m -80.42 169.61 17.48 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.396 176.937 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 23.9 m -54.77 146.21 17.66 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.156 176.542 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 128' ' ' ILE . . . . . 0.447 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.8 mp -61.86 123.57 14.83 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.146 0 CA-C-O 121.026 0.441 . . . . 0.0 110.598 -178.712 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.02 5.48 62.47 Favored Glycine 0 N--CA 1.445 -0.706 0 CA-C-N 115.731 -0.668 . . . . 0.0 113.048 -177.873 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 48.2 p -121.14 167.34 12.76 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 117.117 0.458 . . . . 0.0 111.265 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.602 ' HB2' HG12 ' A' ' 106' ' ' VAL . 61.4 pttt -138.56 145.56 40.79 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 178.755 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.539 ' HD1' ' SG ' ' A' ' 139' ' ' CYS . 33.3 t80 -85.32 132.75 34.2 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 121.018 0.437 . . . . 0.0 111.995 -176.86 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -99.83 130.9 25.45 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.729 177.681 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_endo -62.78 -42.68 24.02 Favored 'Trans proline' 0 C--N 1.346 0.445 0 C-N-CA 123.087 2.525 . . . . 0.0 113.993 -176.06 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 35.5 mm -81.04 -48.73 18.94 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 C-N-CA 120.879 -0.328 . . . . 0.0 111.567 -176.668 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.6 m -63.69 -34.06 77.03 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.704 0.288 . . . . 0.0 110.705 179.248 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 79.5 mtm180 68.66 42.53 1.45 Allowed 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.454 177.6 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -157.27 171.35 20.57 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.301 -0.863 . . . . 0.0 108.766 176.706 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 139' ' ' CYS . . . . . 0.539 ' SG ' ' HD1' ' A' ' 132' ' ' PHE . 8.9 m -101.36 125.45 48.0 Favored 'General case' 0 C--N 1.318 -0.79 0 C-N-CA 120.696 -0.402 . . . . 0.0 110.405 -178.286 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.6 m -110.06 163.41 7.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.657 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 32.0 tp -59.74 119.98 8.66 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.799 0.333 . . . . 0.0 111.111 -178.758 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 142' ' ' ASP . . . . . 0.502 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 18.9 t70 . . . . . 0 C--N 1.32 -0.71 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.407 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' ASP . . . . . 0.46 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 4.3 p-10 . . . . . 0 N--CA 1.452 -0.332 0 CA-C-O 121.54 0.686 . . . . 0.0 109.658 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -103.44 133.97 47.59 Favored 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 -179.62 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.536 ' CG2' HG22 ' A' ' 89' ' ' THR . 20.9 mt -94.66 140.65 16.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-O 121.076 0.465 . . . . 0.0 111.223 -177.63 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.448 HG21 ' NE2' ' A' ' 102' ' ' HIS . 28.2 m -129.68 160.84 40.27 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.122 -179.182 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 84.3 m-70 -116.72 102.59 9.56 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.312 -179.446 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 53.6 mm-40 -109.81 104.76 13.77 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.258 -179.845 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 60.2 40.64 97.55 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.797 -179.786 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 81.75 -14.21 32.2 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 121.193 -0.527 . . . . 0.0 113.076 -178.737 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 35.5 mmtp -90.2 126.85 35.96 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 117.062 0.431 . . . . 0.0 110.838 -178.972 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.536 HG22 ' CG2' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -83.49 121.95 27.88 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.985 178.742 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 78.9 m-85 -117.78 154.4 31.8 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 116.241 -0.436 . . . . 0.0 109.977 177.943 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 28.3 m-70 -106.2 141.1 38.12 Favored 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 176.891 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' VAL . . . . . 0.46 ' O ' ' HA ' ' A' ' 80' ' ' ASP . 55.1 t -115.86 120.66 65.45 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 178.494 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 57.2 t -124.44 131.21 73.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 -178.733 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 81.5 m -113.66 112.56 23.69 Favored 'General case' 0 C--N 1.313 -1.019 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 179.373 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 27.9 t60 -91.77 -17.06 25.94 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.086 -178.924 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -137.12 150.84 48.24 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.769 -178.63 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -75.23 141.19 43.58 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.39 179.015 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 125.37 172.09 13.38 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.528 -0.844 . . . . 0.0 112.522 -179.616 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.419 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 86.2 Cg_endo -84.25 131.02 4.83 Favored 'Trans proline' 0 CA--C 1.537 0.666 0 C-N-CA 122.919 2.413 . . . . 0.0 112.857 178.757 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.9 pp -137.69 158.94 70.81 Favored Pre-proline 0 C--N 1.32 -0.68 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.395 178.367 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -64.66 168.96 12.19 Favored 'Trans proline' 0 C--N 1.351 0.686 0 C-N-CA 122.674 2.25 . . . . 0.0 112.821 -179.275 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' HIS . . . . . 0.493 ' HA ' HD11 ' A' ' 110' ' ' ILE . 8.5 t-80 -92.21 129.93 39.63 Favored Pre-proline 0 C--N 1.318 -0.804 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 -178.71 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_endo -53.45 -44.09 51.97 Favored 'Trans proline' 0 C--N 1.356 0.967 0 C-N-CA 123.164 2.576 . . . . 0.0 113.42 -175.907 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -71.02 -62.31 3.61 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.235 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.485 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 2.7 p30 -122.91 107.59 12.02 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-O 120.819 0.342 . . . . 0.0 111.382 -179.542 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 30.1 m -57.28 -10.18 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 113.064 0.765 . . . . 0.0 113.064 177.825 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 94.7 m-70 -74.13 3.74 6.63 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-O 121.505 0.669 . . . . 0.0 110.375 177.02 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 58.7 mttp -131.2 156.75 44.81 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 177.228 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 7.1 p90 -142.28 161.74 37.25 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 120.334 -0.546 . . . . 0.0 110.352 177.22 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.493 HD11 ' HA ' ' A' ' 102' ' ' HIS . 2.9 mp -123.47 141.31 44.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 -178.624 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.6 mp -97.45 112.48 29.6 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 175.371 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 42.0 m -97.93 122.04 40.58 Favored 'General case' 0 C--N 1.311 -1.081 0 CA-C-O 120.989 0.423 . . . . 0.0 110.675 -177.455 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 27.6 t -126.35 137.34 53.45 Favored 'General case' 0 N--CA 1.437 -1.116 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 178.898 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -108.49 122.15 46.44 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-O 120.817 0.342 . . . . 0.0 110.423 -179.143 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 43.1 m -116.42 105.82 12.93 Favored 'General case' 0 N--CA 1.434 -1.274 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.173 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 59.89 -110.9 3.12 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.343 -175.961 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 20.8 m -113.2 16.27 19.18 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.095 0.474 . . . . 0.0 110.144 179.143 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 6.0 mp -124.51 141.79 51.82 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.474 -177.168 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 47.3 m95 -107.18 138.02 44.15 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-O 121.329 0.585 . . . . 0.0 111.61 179.513 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 78.7 m-85 -121.31 121.94 38.78 Favored 'General case' 0 C--N 1.309 -1.184 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.608 176.597 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.417 ' HB ' ' CG2' ' A' ' 110' ' ' ILE . 2.4 pp -123.28 159.25 27.75 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.755 -176.439 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 37.3 m -146.25 120.99 9.86 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.848 177.443 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 5.1 p -93.46 110.44 23.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 121.601 0.715 . . . . 0.0 111.22 -178.299 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 3.6 mmt -108.71 125.18 32.31 Favored Pre-proline 0 C--N 1.307 -1.248 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.111 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -75.14 135.43 18.83 Favored 'Trans proline' 0 N--CA 1.456 -0.726 0 C-N-CA 122.149 1.9 . . . . 0.0 111.288 178.419 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 6.2 t -90.71 -173.52 3.76 Favored 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 -179.573 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 46.8 m -64.69 137.66 57.94 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 120.928 0.395 . . . . 0.0 111.004 179.665 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 2.0 mp -60.5 134.56 25.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.819 178.609 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.2 -17.72 58.31 Favored Glycine 0 N--CA 1.444 -0.772 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.918 -177.007 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 77.0 p -109.72 158.18 18.36 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 117.456 0.628 . . . . 0.0 110.541 178.833 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 59.2 pttt -130.19 144.8 51.57 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.089 -179.041 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 39.9 t80 -83.71 134.52 34.75 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.849 -179.218 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -99.16 130.52 27.08 Favored Pre-proline 0 C--N 1.321 -0.647 0 CA-C-N 116.243 -0.435 . . . . 0.0 109.939 178.963 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -65.49 -43.98 9.5 Favored 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.792 2.328 . . . . 0.0 113.607 -176.579 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.8 mp -76.5 -50.48 21.77 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 116.632 -0.258 . . . . 0.0 111.605 -177.18 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.1 m -68.65 -33.2 73.59 Favored 'General case' 0 C--O 1.239 0.52 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.025 -179.022 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 89.3 mtm180 70.33 43.22 0.84 Allowed 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.067 177.771 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 26.0 p-10 -152.5 176.27 11.87 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 179.267 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 95.8 m -102.41 126.51 49.46 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 121.179 0.514 . . . . 0.0 111.315 179.411 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 27.0 m -114.88 159.94 14.5 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 CA-C-N 115.698 -0.683 . . . . 0.0 109.22 177.87 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 55.8 tp -63.65 135.5 56.8 Favored 'General case' 0 C--N 1.312 -1.045 0 CA-C-O 121.054 0.454 . . . . 0.0 111.364 -179.637 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 30.3 t70 . . . . . 0 CA--C 1.507 -0.688 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 177.709 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 31.8 t70 . . . . . 0 CA--C 1.515 -0.378 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.507 ' HG ' ' CD1' ' A' ' 121' ' ' ILE . 3.1 tm? -101.93 130.33 48.42 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 -179.676 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.541 ' CG2' HG22 ' A' ' 89' ' ' THR . 23.3 mt -94.29 144.04 10.46 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 CA-C-O 120.742 0.306 . . . . 0.0 110.435 -178.439 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 29.8 m -134.78 165.63 30.7 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.9 0 CA-C-N 116.212 -0.449 . . . . 0.0 109.952 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 85.3 m-70 -114.93 121.82 44.38 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 179.452 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 3.8 tp10 -145.62 115.45 7.33 Favored 'General case' 0 C--N 1.318 -0.765 0 C-N-CA 120.693 -0.403 . . . . 0.0 111.008 -178.948 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 62.16 29.74 73.75 Favored Glycine 0 CA--C 1.518 0.274 0 CA-C-N 116.129 -0.487 . . . . 0.0 113.359 177.593 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 89.51 -5.94 83.52 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.351 179.087 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 88' ' ' LYS . . . . . 0.501 ' HB2' ' CE1' ' A' ' 90' ' ' TYR . 68.4 mmtt -102.16 153.07 20.29 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-O 120.593 0.235 . . . . 0.0 110.685 179.878 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.541 HG22 ' CG2' ' A' ' 82' ' ' ILE . 0.2 OUTLIER -106.82 106.75 17.42 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 177.024 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.501 ' CE1' ' HB2' ' A' ' 88' ' ' LYS . 96.1 m-85 -98.19 145.84 26.21 Favored 'General case' 0 C--N 1.313 -1.022 0 CA-C-O 120.983 0.421 . . . . 0.0 111.183 -177.035 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 31.1 m-70 -101.72 134.66 44.53 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 177.068 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 46.7 t -113.25 118.47 58.16 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 179.141 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 91.4 t -119.27 131.71 71.19 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.518 -179.045 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 73.8 m -114.76 113.18 23.92 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-O 120.994 0.426 . . . . 0.0 109.956 -179.579 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 67.9 t60 -93.2 -17.46 23.68 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.819 -178.758 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -145.24 158.58 43.79 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.887 -178.034 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -74.24 129.92 38.73 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.48 179.378 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 137.07 158.81 8.07 Favored Glycine 0 N--CA 1.44 -1.05 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.192 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.442 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 77.3 Cg_endo -78.02 140.1 17.75 Favored 'Trans proline' 0 CA--C 1.537 0.649 0 C-N-CA 122.791 2.327 . . . . 0.0 112.987 178.751 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.8 pp -138.02 157.7 72.56 Favored Pre-proline 0 C--N 1.32 -0.687 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.701 177.983 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -62.22 164.75 16.5 Favored 'Trans proline' 0 C--N 1.35 0.633 0 C-N-CA 122.4 2.067 . . . . 0.0 113.107 -178.409 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 102' ' ' HIS . . . . . 0.415 ' HA ' HD11 ' A' ' 110' ' ' ILE . 42.0 t-80 -89.66 120.1 69.51 Favored Pre-proline 0 C--N 1.319 -0.721 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.479 -179.087 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 14.1 Cg_endo -56.62 -21.97 41.43 Favored 'Trans proline' 0 N--CA 1.482 0.847 0 C-N-CA 123.08 2.52 . . . . 0.0 113.376 -176.816 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -89.33 -20.57 44.71 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.36 -0.924 . . . . 0.0 113.308 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 16.7 p30 -169.15 109.85 0.47 Allowed 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 122.69 0.396 . . . . 0.0 110.361 -179.134 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 34.8 m -57.17 -11.37 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.076 0 N-CA-C 113.833 1.049 . . . . 0.0 113.833 -179.629 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 42.5 m170 -76.29 3.71 10.32 Favored 'General case' 0 N--CA 1.475 0.786 0 CA-C-O 121.145 0.498 . . . . 0.0 111.266 177.556 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.402 ' HG2' ' HA ' ' A' ' 125' ' ' PRO . 42.2 mtmt -138.87 161.03 38.3 Favored 'General case' 0 CA--C 1.506 -0.72 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 178.634 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 9.3 p90 -143.83 172.31 13.02 Favored 'General case' 0 C--N 1.313 -0.988 0 C-N-CA 120.647 -0.421 . . . . 0.0 111.246 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.442 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.9 mp -129.3 140.64 48.64 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.965 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 178.652 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -96.44 122.08 47.59 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 176.872 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 57.9 m -106.0 125.23 50.75 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-O 120.679 0.276 . . . . 0.0 110.279 -178.405 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 19.8 m -130.83 139.7 50.2 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.253 179.044 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -112.12 104.37 12.6 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-O 120.994 0.426 . . . . 0.0 110.041 179.482 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 14.2 t -91.79 88.8 6.8 Favored 'General case' 0 C--N 1.309 -1.185 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 179.508 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 70.37 -100.79 0.83 Allowed Glycine 0 N--CA 1.443 -0.85 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 -177.581 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 50.6 m -114.58 5.62 15.52 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.895 0.379 . . . . 0.0 110.735 178.357 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 21.4 tp -116.68 129.53 56.19 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.622 -176.32 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 83.1 m95 -92.97 132.04 37.42 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -178.832 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 51.2 m-85 -113.06 137.27 51.67 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 115.457 -0.792 . . . . 0.0 109.422 175.942 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.507 ' CD1' ' HG ' ' A' ' 81' ' ' LEU . 2.1 pp -134.28 152.27 33.64 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.998 0 N-CA-C 112.364 0.505 . . . . 0.0 112.364 -176.576 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 25.7 m -151.35 122.14 7.53 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.293 176.909 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.406 ' HA ' ' HA ' ' A' ' 110' ' ' ILE . 3.8 p -95.07 112.91 28.37 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 CA-C-O 121.348 0.594 . . . . 0.0 111.305 -179.13 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 4.5 mmt -112.1 139.8 22.81 Favored Pre-proline 0 C--N 1.316 -0.867 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.621 -179.165 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 125' ' ' PRO . . . . . 0.402 ' HA ' ' HG2' ' A' ' 108' ' ' LYS . 91.6 Cg_endo -83.85 140.56 9.16 Favored 'Trans proline' 0 N--CA 1.452 -0.958 0 C-N-CA 122.408 2.072 . . . . 0.0 111.551 177.168 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 7.1 t -94.36 -179.19 4.83 Favored 'General case' 0 C--N 1.319 -0.75 0 C-N-CA 120.381 -0.527 . . . . 0.0 109.828 177.906 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 10.4 t -68.33 140.22 55.91 Favored 'General case' 0 N--CA 1.436 -1.129 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.238 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 2.1 mp -61.56 141.78 17.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 178.393 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.22 -19.85 51.07 Favored Glycine 0 N--CA 1.438 -1.229 0 C-N-CA 120.592 -0.813 . . . . 0.0 112.499 -176.865 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 68.8 p -114.76 154.72 28.02 Favored 'General case' 0 N--CA 1.448 -0.528 0 CA-C-N 117.261 0.53 . . . . 0.0 111.104 179.655 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 59.8 pttt -126.63 145.03 50.71 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.959 179.369 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -83.94 132.74 34.74 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-O 120.874 0.369 . . . . 0.0 110.963 -178.486 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -94.57 133.59 26.63 Favored Pre-proline 0 C--N 1.323 -0.576 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.418 179.576 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -67.77 -41.33 8.25 Favored 'Trans proline' 0 CA--C 1.535 0.57 0 C-N-CA 122.919 2.413 . . . . 0.0 114.512 -177.541 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.8 mp -82.5 -51.81 14.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 N-CA-C 111.82 0.304 . . . . 0.0 111.82 -177.029 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 4.2 m -69.24 -35.7 76.41 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.139 0.495 . . . . 0.0 110.194 -179.232 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 137' ' ' ARG . . . . . 0.439 ' HD2' ' HD2' ' A' ' 99' ' ' PRO . 56.1 mtm180 66.81 62.87 0.5 Allowed 'General case' 0 N--CA 1.452 -0.341 0 CA-C-N 115.274 -0.875 . . . . 0.0 111.528 178.458 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -165.42 173.16 11.37 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 114.559 -1.2 . . . . 0.0 108.118 176.717 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 88.9 m -100.49 126.5 46.92 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-O 121.083 0.468 . . . . 0.0 111.118 -179.177 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.8 m -113.13 158.3 13.54 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.804 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.279 178.341 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -61.31 117.38 5.56 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.796 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 35.3 t0 . . . . . 0 C--N 1.323 -0.569 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.473 -178.641 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 . . . . . 0 N--CA 1.452 -0.374 0 CA-C-O 121.44 0.638 . . . . 0.0 110.78 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.417 ' HG ' HD11 ' A' ' 121' ' ' ILE . 2.5 tm? -100.23 134.57 42.97 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.468 ' CG2' HG22 ' A' ' 89' ' ' THR . 20.8 mt -95.51 142.63 13.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-O 120.937 0.399 . . . . 0.0 110.897 -177.215 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.472 HG21 ' NE2' ' A' ' 102' ' ' HIS . 31.2 m -130.39 154.2 40.17 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.964 -179.358 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 42.6 m-70 -114.57 101.49 9.15 Favored 'General case' 0 C--N 1.311 -1.1 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.115 -178.942 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.466 ' HB2' ' CE1' ' A' ' 90' ' ' TYR . 50.2 mm-40 -105.86 110.42 22.7 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.052 178.119 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 64.73 30.54 78.21 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 121.148 -0.549 . . . . 0.0 111.951 -179.235 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 86.05 -9.3 69.92 Favored Glycine 0 N--CA 1.444 -0.771 0 C-N-CA 120.928 -0.654 . . . . 0.0 112.385 -179.299 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 1.3 mptm? -91.74 140.52 29.62 Favored 'General case' 0 CA--C 1.507 -0.698 0 CA-C-O 120.911 0.386 . . . . 0.0 110.463 -179.731 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.468 HG22 ' CG2' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -91.21 129.8 37.16 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.767 179.165 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.466 ' CE1' ' HB2' ' A' ' 85' ' ' GLU . 88.1 m-85 -127.3 148.28 50.23 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 177.887 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 40.1 m-70 -103.89 138.3 40.67 Favored 'General case' 0 C--N 1.305 -1.343 0 N-CA-C 110.059 -0.348 . . . . 0.0 110.059 178.473 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 58.3 t -111.23 122.75 66.24 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.217 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 178.446 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 38.3 t -126.04 132.18 70.89 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 -179.057 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 88.8 m -102.0 126.5 48.94 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.019 0.438 . . . . 0.0 111.033 -179.155 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 77.9 m-70 -90.12 -30.51 17.62 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.573 -179.083 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -151.88 172.95 15.4 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-N 115.747 -0.66 . . . . 0.0 109.886 -177.384 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 5.3 mp0 -74.81 137.13 41.7 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.138 178.143 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 124.57 158.83 10.19 Favored Glycine 0 N--CA 1.443 -0.889 0 C-N-CA 120.681 -0.771 . . . . 0.0 111.973 -179.597 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.445 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 78.1 Cg_endo -77.32 139.56 18.75 Favored 'Trans proline' 0 N--CA 1.46 -0.482 0 C-N-CA 122.613 2.209 . . . . 0.0 113.259 179.13 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.8 pp -137.36 158.13 72.82 Favored Pre-proline 0 C--N 1.319 -0.723 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.64 178.107 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -64.24 169.39 10.89 Favored 'Trans proline' 0 C--N 1.351 0.692 0 C-N-CA 122.593 2.195 . . . . 0.0 113.207 -177.784 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' HIS . . . . . 0.472 ' NE2' HG21 ' A' ' 83' ' ' VAL . 2.3 t-80 -88.73 128.49 52.3 Favored Pre-proline 0 C--N 1.317 -0.827 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 -179.613 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_endo -53.28 -42.5 64.74 Favored 'Trans proline' 0 C--N 1.351 0.699 0 C-N-CA 122.994 2.463 . . . . 0.0 113.032 -177.141 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -74.62 -61.74 3.05 Favored Glycine 0 C--N 1.316 -0.565 0 C-N-CA 120.713 -0.756 . . . . 0.0 113.002 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 105' ' ' ASN . . . . . 0.429 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 6.1 p-10 -125.03 107.95 11.33 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-O 120.973 0.416 . . . . 0.0 111.97 -176.757 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 8.5 p -56.65 -11.97 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.12 0 N-CA-C 113.607 0.965 . . . . 0.0 113.607 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 51.6 m170 -70.42 -4.19 21.31 Favored 'General case' 0 N--CA 1.474 0.748 0 CA-C-O 121.135 0.493 . . . . 0.0 111.055 178.502 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.423 ' O ' ' HB2' ' A' ' 102' ' ' HIS . 39.8 mtmt -135.2 159.91 40.04 Favored 'General case' 0 N--CA 1.44 -0.972 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 177.692 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 14.6 p90 -142.8 173.57 11.43 Favored 'General case' 0 C--N 1.307 -1.281 0 CA-C-N 116.577 -0.283 . . . . 0.0 110.78 -178.974 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.445 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 2.3 mp -130.19 140.33 49.17 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.166 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 178.753 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.431 HG13 ' HB3' ' A' ' 99' ' ' PRO . 4.9 mp -97.47 118.47 44.0 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 177.299 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 62.8 m -97.17 121.71 39.37 Favored 'General case' 0 N--CA 1.437 -1.102 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 17.3 m -124.11 136.85 54.51 Favored 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.706 -179.531 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 23.0 ttmt -112.02 109.41 19.14 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-O 121.157 0.504 . . . . 0.0 111.143 -179.488 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 15.8 t -92.28 88.89 6.62 Favored 'General case' 0 N--CA 1.43 -1.432 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 176.915 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 72.1 -99.87 0.9 Allowed Glycine 0 N--CA 1.437 -1.294 0 N-CA-C 110.705 -0.958 . . . . 0.0 110.705 -176.416 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 24.3 p -116.41 6.24 13.6 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-O 120.893 0.378 . . . . 0.0 111.298 177.824 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 53.6 tp -113.04 135.88 53.3 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.818 0.342 . . . . 0.0 111.255 -175.644 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 96.4 m95 -89.62 131.85 35.41 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 121.336 0.588 . . . . 0.0 112.466 -179.707 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 73.5 m-85 -119.34 124.19 46.02 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 170.423 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.417 HD11 ' HG ' ' A' ' 81' ' ' LEU . 2.0 pp -124.45 146.87 29.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 120.502 -0.479 . . . . 0.0 111.689 -176.828 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 20.2 m -137.06 122.63 19.69 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.375 178.81 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 4.0 p -93.39 113.72 28.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 121.346 0.593 . . . . 0.0 111.211 -179.385 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 3.6 mmt -117.23 151.44 47.82 Favored Pre-proline 0 C--N 1.322 -0.628 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.805 -179.088 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 90.7 Cg_endo -92.25 151.36 3.1 Favored 'Trans proline' 0 N--CA 1.448 -1.156 0 C-N-CA 122.399 2.066 . . . . 0.0 112.441 177.989 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 56.2 m -84.99 167.92 15.42 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 174.515 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 10.9 p -59.89 144.23 49.35 Favored 'General case' 0 N--CA 1.439 -0.996 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 176.998 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 128' ' ' ILE . . . . . 0.454 ' N ' HD12 ' A' ' 128' ' ' ILE . 2.0 mp -60.74 122.51 11.38 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 CA-C-O 121.175 0.512 . . . . 0.0 110.327 -178.186 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 103.26 1.91 47.86 Favored Glycine 0 N--CA 1.437 -1.248 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.995 -176.397 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 130' ' ' THR . . . . . 0.411 HG22 ' HA ' ' A' ' 141' ' ' LEU . 80.7 p -126.77 160.08 31.89 Favored 'General case' 0 CA--C 1.539 0.533 0 CA-C-N 117.456 0.628 . . . . 0.0 111.634 179.773 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 55.0 pttt -125.87 145.54 50.2 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.384 179.633 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.463 ' HD1' ' SG ' ' A' ' 139' ' ' CYS . 29.1 t80 -85.64 137.53 32.77 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-O 121.01 0.434 . . . . 0.0 111.556 -179.23 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -103.48 132.18 21.33 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.181 179.246 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -69.5 -45.06 1.89 Allowed 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 123.11 2.54 . . . . 0.0 114.393 -177.222 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 34.9 mm -74.7 -46.62 41.31 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 N-CA-C 112.035 0.383 . . . . 0.0 112.035 -176.326 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 39.5 t -75.63 -31.79 59.99 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-O 120.861 0.362 . . . . 0.0 110.146 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 137' ' ' ARG . . . . . 0.421 ' HB3' ' HG2' ' A' ' 99' ' ' PRO . 66.0 mtm180 66.42 62.02 0.56 Allowed 'General case' 0 N--CA 1.463 0.223 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.354 178.59 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 23.5 p-10 -165.31 172.45 12.31 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.175 -0.92 . . . . 0.0 109.082 179.603 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 139' ' ' CYS . . . . . 0.463 ' SG ' ' HD1' ' A' ' 132' ' ' PHE . 38.6 m -101.05 124.58 46.99 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 178.862 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 36.0 m -113.96 164.38 10.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.807 0 CA-C-N 115.883 -0.598 . . . . 0.0 109.759 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 141' ' ' LEU . . . . . 0.411 ' HA ' HG22 ' A' ' 130' ' ' THR . 34.2 tp -58.46 123.86 17.63 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-O 121.024 0.44 . . . . 0.0 111.75 -178.324 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 142' ' ' ASP . . . . . 0.409 ' H ' ' HA ' ' A' ' 130' ' ' THR . 18.0 t70 . . . . . 0 C--N 1.321 -0.668 0 CA-C-N 115.879 -0.6 . . . . 0.0 109.642 178.104 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.384 0 N-CA-C 112.123 -0.391 . . . . 0.0 112.123 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -87.36 28.7 0.51 Allowed 'Trans proline' 0 CA--C 1.533 0.441 0 C-N-CA 123.036 2.49 . . . . 0.0 112.848 -177.924 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 7.6 tt -71.18 113.75 8.53 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.734 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -130.3 9.46 5.92 Favored Glycine 0 N--CA 1.441 -1.015 0 C-N-CA 120.86 -0.686 . . . . 0.0 111.915 -179.293 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.443 ' O ' HG23 ' A' ' 93' ' ' VAL . 57.6 p -60.23 -52.73 64.04 Favored 'General case' 0 N--CA 1.446 -0.634 0 CA-C-O 120.601 0.239 . . . . 0.0 110.812 179.098 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.582 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 8.2 p-10 -158.03 127.62 5.91 Favored 'General case' 0 N--CA 1.448 -0.53 0 CA-C-O 121.362 0.601 . . . . 0.0 111.571 -177.793 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.422 HD23 HD11 ' A' ' 121' ' ' ILE . 48.8 tp -102.79 145.47 29.7 Favored 'General case' 0 C--N 1.308 -1.236 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.148 176.472 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.457 ' CG2' HG22 ' A' ' 89' ' ' THR . 14.0 mt -97.54 143.96 11.75 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.111 0 C-N-CA 120.599 -0.44 . . . . 0.0 111.083 -178.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 30.7 m -135.75 174.37 12.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.828 -179.285 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' HIS . . . . . 0.429 ' CE1' HG23 ' A' ' 89' ' ' THR . 45.9 m-70 -122.89 115.88 22.69 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 120.967 0.413 . . . . 0.0 111.704 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 59.6 mm-40 -109.12 104.19 13.32 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.209 176.677 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 59.98 45.33 96.08 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.321 -0.942 . . . . 0.0 111.713 -178.755 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 85.4 -31.7 3.77 Favored Glycine 0 CA--C 1.524 0.619 0 C-N-CA 121.036 -0.602 . . . . 0.0 113.593 -179.143 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 14.2 mptt -82.07 141.77 32.88 Favored 'General case' 0 CA--C 1.51 -0.59 0 CA-C-N 117.373 0.587 . . . . 0.0 111.555 -176.126 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.457 HG22 ' CG2' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -84.63 134.19 34.39 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.908 179.856 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 63.9 m-85 -132.22 154.29 49.75 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.761 176.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 19.2 m-70 -102.42 144.8 30.42 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-O 120.823 0.344 . . . . 0.0 110.57 179.469 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.582 ' O ' ' HA ' ' A' ' 80' ' ' ASP . 93.7 t -120.06 117.87 55.03 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.19 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 177.547 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.443 HG23 ' O ' ' A' ' 79' ' ' SER . 3.3 p -124.6 138.8 52.81 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 CA-C-N 116.112 -0.495 . . . . 0.0 109.93 -178.52 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 92.3 m -110.94 123.92 51.1 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 120.895 0.379 . . . . 0.0 110.946 179.514 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 52.1 m80 -102.15 -22.35 14.22 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.376 -179.766 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -141.03 152.47 44.89 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.478 -178.804 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -76.23 106.35 7.79 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.659 -0.701 . . . . 0.0 110.508 177.851 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 156.24 169.51 20.46 Favored Glycine 0 N--CA 1.434 -1.474 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 -179.581 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_endo -78.53 132.91 11.35 Favored 'Trans proline' 0 N--CA 1.456 -0.691 0 C-N-CA 122.406 2.071 . . . . 0.0 112.394 178.62 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 2.0 pp -137.12 157.82 73.75 Favored Pre-proline 0 C--N 1.319 -0.726 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.517 178.21 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -69.51 171.86 13.43 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.271 1.981 . . . . 0.0 112.492 -178.29 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' HIS . . . . . 0.585 ' HB3' ' O ' ' A' ' 105' ' ' ASN . 30.3 t-80 -89.85 128.1 51.48 Favored Pre-proline 0 C--N 1.309 -1.177 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 179.727 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -50.52 -54.91 4.67 Favored 'Trans proline' 0 N--CA 1.477 0.524 0 C-N-CA 122.932 2.421 . . . . 0.0 112.604 -176.883 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -63.17 -62.2 5.65 Favored Glycine 0 CA--C 1.526 0.776 0 CA-C-N 115.813 -0.63 . . . . 0.0 113.15 178.237 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.585 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 9.9 p-10 -122.8 103.22 8.5 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 -177.004 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 31.1 m -58.29 -10.67 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.089 0 N-CA-C 114.0 1.111 . . . . 0.0 114.0 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 14.0 t-80 -66.27 -10.39 41.93 Favored 'General case' 0 N--CA 1.47 0.56 0 CA-C-O 121.451 0.643 . . . . 0.0 110.299 176.802 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.404 ' HE2' HD21 ' A' ' 105' ' ' ASN . 44.7 mtmt -126.55 158.69 35.53 Favored 'General case' 0 N--CA 1.434 -1.237 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 178.196 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 7.7 p90 -141.72 165.49 27.34 Favored 'General case' 0 C--N 1.302 -1.492 0 C-N-CA 120.642 -0.423 . . . . 0.0 110.517 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.405 HG12 HG11 ' A' ' 92' ' ' VAL . 3.9 mp -123.32 139.81 48.84 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 -179.062 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.411 ' N ' HD12 ' A' ' 111' ' ' ILE . 4.3 mp -99.98 118.09 46.12 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.179 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 177.502 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 23.5 m -101.78 122.72 44.48 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.222 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 49.1 m -131.7 146.73 52.33 Favored 'General case' 0 C--N 1.312 -1.064 0 CA-C-O 121.074 0.464 . . . . 0.0 111.44 -177.752 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 5.0 tppp? -97.28 139.6 33.0 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.527 179.312 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 68.2 m -128.71 85.78 2.37 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 174.474 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 72.68 -104.53 1.55 Allowed Glycine 0 N--CA 1.437 -1.296 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 -174.55 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 50.6 m -115.07 11.81 16.5 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-O 120.779 0.323 . . . . 0.0 110.885 175.17 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 34.0 tp -111.36 143.39 42.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.672 -0.24 . . . . 0.0 110.627 -177.367 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 54.0 m95 -100.23 133.14 45.08 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.034 0.445 . . . . 0.0 112.128 179.198 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -119.53 132.35 55.74 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.647 -0.706 . . . . 0.0 109.463 174.044 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.422 HD11 HD23 ' A' ' 81' ' ' LEU . 1.9 pp -123.72 149.89 27.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-O 120.78 0.324 . . . . 0.0 111.074 -179.1 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 28.4 m -146.06 122.93 11.3 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.152 178.312 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.6 p -95.93 111.13 25.65 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.417 0 CA-C-O 121.363 0.601 . . . . 0.0 111.34 -178.333 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 5.5 mmt -114.36 142.59 28.33 Favored Pre-proline 0 C--N 1.318 -0.762 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.525 -179.314 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -86.5 143.11 7.32 Favored 'Trans proline' 0 N--CA 1.449 -1.092 0 C-N-CA 122.378 2.052 . . . . 0.0 111.641 176.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 4.9 t -92.98 -179.6 5.16 Favored 'General case' 0 C--N 1.319 -0.756 0 C-N-CA 120.541 -0.463 . . . . 0.0 109.91 178.228 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 34.3 m -65.32 144.53 57.06 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-O 120.881 0.372 . . . . 0.0 110.579 -178.85 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' ILE . . . . . 0.426 ' N ' HD12 ' A' ' 128' ' ' ILE . 2.8 mp -68.04 132.33 32.75 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.786 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 103.68 -18.45 47.28 Favored Glycine 0 N--CA 1.439 -1.11 0 CA-C-N 115.797 -0.638 . . . . 0.0 112.019 -176.141 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 40.3 p -116.76 158.53 23.73 Favored 'General case' 0 N--CA 1.445 -0.713 0 O-C-N 122.67 -0.312 . . . . 0.0 110.854 179.02 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.4 ' HE2' ' HA ' ' A' ' 142' ' ' ASP . 49.9 pttt -132.17 148.64 52.48 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 116.146 -0.479 . . . . 0.0 109.863 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 23.4 t80 -86.4 139.67 30.72 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-O 121.015 0.436 . . . . 0.0 111.691 -177.319 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -107.6 136.58 19.62 Favored Pre-proline 0 N--CA 1.469 0.502 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.784 177.345 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -68.11 -44.7 3.51 Favored 'Trans proline' 0 C--N 1.347 0.468 0 C-N-CA 122.948 2.432 . . . . 0.0 114.285 -176.464 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 39.5 mm -78.55 -46.34 24.99 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 CA-C-O 120.823 0.344 . . . . 0.0 111.715 -176.857 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.7 m -69.06 -34.89 75.9 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 120.909 0.385 . . . . 0.0 110.199 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 81.8 mtt-85 69.01 41.34 1.45 Allowed 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.144 177.479 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -152.54 176.28 11.87 Favored 'General case' 0 C--N 1.316 -0.863 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 178.49 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 87.8 m -100.93 126.82 47.58 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 120.888 0.375 . . . . 0.0 110.538 -179.825 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.2 m -109.41 157.78 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.018 0 CA-C-N 115.811 -0.632 . . . . 0.0 109.824 179.584 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 58.5 tp -69.55 115.58 8.97 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-O 120.94 0.4 . . . . 0.0 111.138 -179.374 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 142' ' ' ASP . . . . . 0.4 ' HA ' ' HE2' ' A' ' 131' ' ' LYS . 30.9 t70 -73.57 101.57 3.62 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.619 177.215 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 27.3 t-20 . . . . . 0 C--N 1.307 -1.262 0 CA-C-O 118.195 -0.907 . . . . 0.0 109.099 -177.28 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.413 0 N-CA-C 111.694 -0.562 . . . . 0.0 111.694 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_exo -65.62 99.83 0.39 Allowed 'Trans proline' 0 C--O 1.241 0.668 0 C-N-CA 122.646 2.231 . . . . 0.0 111.271 179.308 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 85.7 mt -83.27 167.79 17.31 Favored 'General case' 0 C--N 1.314 -0.935 0 CA-C-N 115.72 -0.673 . . . . 0.0 111.199 -177.917 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -150.84 -31.1 0.05 OUTLIER Glycine 0 C--N 1.314 -0.681 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.856 -179.469 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 5.0 m -74.6 -35.45 62.97 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 110.168 -0.308 . . . . 0.0 110.168 178.744 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -160.14 104.8 1.5 Allowed 'General case' 0 CA--C 1.52 -0.199 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.215 -179.059 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.526 HD23 HD11 ' A' ' 121' ' ' ILE . 39.4 tp -117.53 132.63 56.5 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.13 176.254 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.473 HG22 HG22 ' A' ' 89' ' ' THR . 10.4 mt -98.73 144.41 11.72 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.09 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 178.734 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 19.1 m -136.88 162.86 33.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-O 120.765 0.317 . . . . 0.0 110.296 -177.857 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 12.7 m-70 -94.34 115.32 27.52 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.334 178.229 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -128.8 106.65 9.07 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 -178.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 67.18 29.89 74.96 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 110.794 -0.923 . . . . 0.0 110.794 -177.092 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 85.29 -22.95 8.94 Favored Glycine 0 N--CA 1.443 -0.892 0 CA-C-N 115.318 -0.441 . . . . 0.0 112.672 -178.357 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 75.1 mmtt -91.85 146.59 23.63 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.843 0.354 . . . . 0.0 111.14 -177.69 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.473 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -82.22 125.98 31.56 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.601 179.602 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -124.48 143.36 50.69 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 176.823 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 22.0 m-70 -90.05 146.6 24.21 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-O 121.097 0.475 . . . . 0.0 111.465 -178.553 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 49.5 t -120.44 119.0 58.52 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 175.562 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 58.0 t -130.4 135.64 60.2 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.256 0 CA-C-N 116.141 -0.481 . . . . 0.0 109.972 -177.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 91.5 m -119.11 113.3 20.7 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.03 0.443 . . . . 0.0 110.645 178.68 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 43.0 t-80 -91.89 -22.07 20.27 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.223 179.823 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 -146.58 157.82 43.79 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.769 -176.755 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -79.18 145.66 33.54 Favored 'General case' 0 C--N 1.312 -1.032 0 CA-C-O 120.955 0.407 . . . . 0.0 110.962 -177.222 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 125.39 163.65 11.66 Favored Glycine 0 N--CA 1.437 -1.261 0 C-N-CA 120.976 -0.63 . . . . 0.0 111.926 -178.441 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.415 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 84.4 Cg_endo -84.4 135.19 6.03 Favored 'Trans proline' 0 CA--C 1.538 0.7 0 C-N-CA 122.721 2.28 . . . . 0.0 112.997 179.168 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -142.28 154.96 64.76 Favored Pre-proline 0 C--O 1.216 -0.707 0 CA-C-N 115.76 -0.654 . . . . 0.0 109.724 177.796 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -67.85 169.29 16.53 Favored 'Trans proline' 0 C--N 1.348 0.54 0 C-N-CA 122.349 2.033 . . . . 0.0 112.365 -178.537 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' HIS . . . . . 0.41 ' CD2' HD11 ' A' ' 110' ' ' ILE . 12.1 t-80 -85.54 135.5 38.37 Favored Pre-proline 0 C--N 1.319 -0.719 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -178.906 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -57.8 -25.33 68.34 Favored 'Trans proline' 0 C--N 1.353 0.779 0 C-N-CA 122.93 2.42 . . . . 0.0 112.028 -179.368 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -84.35 -65.86 1.5 Allowed Glycine 0 N--CA 1.441 -0.971 0 CA-C-N 115.522 -0.763 . . . . 0.0 111.765 178.212 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.431 ' OD1' ' HE2' ' A' ' 108' ' ' LYS . 36.8 p-10 -124.37 114.02 18.97 Favored 'General case' 0 CA--C 1.543 0.693 0 CA-C-O 121.364 0.602 . . . . 0.0 111.878 -179.616 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 15.9 m -58.76 -10.63 1.58 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 N-CA-C 112.854 0.687 . . . . 0.0 112.854 177.284 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 35.5 m80 -68.22 -7.17 28.1 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 121.06 0.457 . . . . 0.0 110.362 176.44 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.444 ' HG2' ' HA ' ' A' ' 125' ' ' PRO . 47.4 mtmt -131.5 157.07 44.51 Favored 'General case' 0 CA--C 1.5 -0.953 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.465 179.045 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 8.5 p90 -142.15 161.73 37.26 Favored 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 120.773 -0.371 . . . . 0.0 110.71 179.436 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.415 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.2 mp -119.78 137.22 54.37 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 -179.505 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -96.71 116.85 39.91 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.359 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 175.551 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 56.2 m -95.77 122.13 38.23 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 109.333 -0.618 . . . . 0.0 109.333 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 49.6 m -122.56 127.56 49.61 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.314 -179.733 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 85.4 tttt -100.29 116.22 31.77 Favored 'General case' 0 N--CA 1.432 -1.366 0 CA-C-O 121.118 0.485 . . . . 0.0 109.926 178.735 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 53.7 m -106.18 83.57 1.91 Allowed 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.581 179.149 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 67.77 -100.24 0.6 Allowed Glycine 0 N--CA 1.44 -1.082 0 CA-C-N 115.521 -0.763 . . . . 0.0 111.593 -178.348 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 16.2 m -111.52 5.73 19.68 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-O 120.828 0.347 . . . . 0.0 110.46 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 22.8 tp -118.51 134.49 55.04 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.092 -177.643 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 77.4 m95 -97.3 132.76 42.72 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-O 121.105 0.479 . . . . 0.0 111.978 178.654 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 51.5 m-85 -115.95 130.21 56.72 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.828 174.879 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.526 HD11 HD23 ' A' ' 81' ' ' LEU . 2.2 pp -119.87 148.98 22.6 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-O 121.172 0.511 . . . . 0.0 110.786 179.646 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 16.5 m -142.99 114.05 7.72 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.7 178.007 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.9 p -96.04 103.72 15.01 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-O 121.747 0.784 . . . . 0.0 111.06 -177.897 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 3.7 mmt -107.37 137.65 19.69 Favored Pre-proline 0 C--N 1.313 -1.02 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.922 -178.462 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 125' ' ' PRO . . . . . 0.444 ' HA ' ' HG2' ' A' ' 108' ' ' LYS . 72.9 Cg_endo -80.72 142.79 14.46 Favored 'Trans proline' 0 N--CA 1.448 -1.199 0 C-N-CA 122.142 1.894 . . . . 0.0 111.315 176.543 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 9.6 t -91.97 -178.24 4.95 Favored 'General case' 0 C--N 1.313 -1.021 0 C-N-CA 120.393 -0.523 . . . . 0.0 109.779 178.03 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 7.6 t -61.3 138.64 58.24 Favored 'General case' 0 N--CA 1.434 -1.23 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.016 179.396 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 128' ' ' ILE . . . . . 0.407 ' N ' HD12 ' A' ' 128' ' ' ILE . 2.7 mp -64.24 138.75 22.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 178.384 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 92.89 -12.74 69.26 Favored Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 120.421 -0.895 . . . . 0.0 112.606 -175.779 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 63.9 p -120.45 161.43 21.26 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 117.045 0.422 . . . . 0.0 110.696 178.424 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.483 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 58.9 pttt -133.57 146.62 51.16 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 116.338 -0.392 . . . . 0.0 109.985 179.476 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 31.4 t80 -85.9 136.62 33.22 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.688 -178.375 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -97.68 136.04 21.38 Favored Pre-proline 0 C--N 1.319 -0.741 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.569 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -68.48 -46.33 2.02 Favored 'Trans proline' 0 C--N 1.346 0.447 0 C-N-CA 122.684 2.256 . . . . 0.0 113.591 -178.66 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.9 mp -77.56 -54.27 12.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 111.706 0.261 . . . . 0.0 111.706 -177.779 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 21.5 m -68.02 -32.32 72.61 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 120.645 0.26 . . . . 0.0 110.916 -178.621 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 137' ' ' ARG . . . . . 0.403 ' HD3' ' HD2' ' A' ' 99' ' ' PRO . 98.4 mtt180 66.47 48.55 1.51 Allowed 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 121.411 0.624 . . . . 0.0 111.29 177.62 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 23.9 p-10 -151.42 172.9 15.23 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 115.254 -0.884 . . . . 0.0 108.762 177.731 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 67.9 m -101.82 126.94 48.8 Favored 'General case' 0 C--N 1.308 -1.208 0 CA-C-O 121.222 0.534 . . . . 0.0 111.154 179.041 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 35.1 m -116.46 161.35 15.27 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-N 115.43 -0.805 . . . . 0.0 108.941 178.053 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 45.2 tp -54.03 125.79 20.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.054 0.454 . . . . 0.0 110.113 178.6 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 142' ' ' ASP . . . . . 0.483 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 9.8 t70 -77.9 91.27 4.16 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 115.999 -0.546 . . . . 0.0 112.289 -175.916 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 . . . . . 0 C--N 1.314 -0.967 0 CA-C-O 118.196 -0.907 . . . . 0.0 108.861 172.758 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.468 0.795 0 N-CA-C 111.757 -0.537 . . . . 0.0 111.757 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_exo -64.98 124.89 13.73 Favored 'Trans proline' 0 N--CA 1.462 -0.376 0 C-N-CA 122.583 2.189 . . . . 0.0 111.545 178.58 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.426 ' O ' HD12 ' A' ' 77' ' ' LEU . 4.1 pp -77.21 139.57 39.91 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.809 179.6 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -117.48 35.1 4.25 Favored Glycine 0 N--CA 1.437 -1.267 0 N-CA-C 110.874 -0.891 . . . . 0.0 110.874 179.526 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 43.4 t -75.45 -20.44 58.84 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 179.418 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -161.8 94.57 0.95 Allowed 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.397 -0.819 . . . . 0.0 109.341 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.415 HD23 HD11 ' A' ' 121' ' ' ILE . 45.7 tp -109.9 135.39 50.85 Favored 'General case' 0 C--N 1.31 -1.152 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 177.919 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.605 HG22 HG22 ' A' ' 89' ' ' THR . 11.5 mt -96.82 142.55 13.85 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 C-N-CA 120.57 -0.452 . . . . 0.0 110.391 179.658 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.405 HG21 ' CE1' ' A' ' 102' ' ' HIS . 22.9 m -139.35 178.27 3.92 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 -178.106 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' HIS . . . . . 0.478 ' HA ' ' O ' ' A' ' 88' ' ' LYS . 66.3 m-70 -117.99 124.61 48.6 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-O 121.253 0.549 . . . . 0.0 111.868 179.49 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 -114.62 103.91 11.47 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.062 -0.972 . . . . 0.0 108.967 177.841 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 67.73 18.36 70.18 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.607 -0.806 . . . . 0.0 111.329 -177.739 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 106.75 -29.39 10.93 Favored Glycine 0 N--CA 1.445 -0.753 0 C-N-CA 121.28 -0.486 . . . . 0.0 112.635 -179.206 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' LYS . . . . . 0.478 ' O ' ' HA ' ' A' ' 84' ' ' HIS . 47.5 mmtm -80.79 154.03 27.41 Favored 'General case' 0 C--O 1.22 -0.457 0 CA-C-N 116.732 0.266 . . . . 0.0 110.534 -178.103 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.605 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -87.7 128.44 35.3 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.306 0.574 . . . . 0.0 112.512 -178.774 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 17.9 m-85 -125.74 152.2 45.65 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.34 -0.846 . . . . 0.0 109.985 177.399 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 24.3 m-70 -100.88 149.06 24.27 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-O 121.016 0.436 . . . . 0.0 111.361 -179.516 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 44.1 t -120.79 118.35 56.12 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.002 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 176.187 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 58.8 t -132.16 131.39 61.1 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.532 -179.242 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 94.9 m -113.76 138.69 49.9 Favored 'General case' 0 C--N 1.313 -1.012 0 CA-C-O 120.799 0.333 . . . . 0.0 110.894 -179.424 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 77.8 m-70 -119.03 -19.63 8.39 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.364 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 5.4 mp0 -126.05 142.21 51.62 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.011 -0.54 . . . . 0.0 109.699 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 -76.97 103.8 7.1 Favored 'General case' 0 C--N 1.314 -0.937 0 N-CA-C 109.794 -0.446 . . . . 0.0 109.794 177.177 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 164.26 169.35 27.69 Favored Glycine 0 N--CA 1.436 -1.349 0 N-CA-C 111.267 -0.733 . . . . 0.0 111.267 -179.178 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.465 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 95.4 Cg_endo -83.34 133.51 6.37 Favored 'Trans proline' 0 N--CA 1.454 -0.806 0 C-N-CA 122.582 2.188 . . . . 0.0 112.709 179.031 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.9 pp -140.12 156.6 70.13 Favored Pre-proline 0 C--N 1.32 -0.704 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.996 178.287 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -62.96 167.29 12.45 Favored 'Trans proline' 0 C--N 1.351 0.695 0 C-N-CA 122.743 2.296 . . . . 0.0 112.87 -178.547 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' HIS . . . . . 0.405 ' CE1' HG21 ' A' ' 83' ' ' VAL . 5.0 t-80 -91.68 133.15 31.46 Favored Pre-proline 0 C--N 1.322 -0.597 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.822 -178.366 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_endo -53.46 -37.62 82.31 Favored 'Trans proline' 0 C--N 1.353 0.799 0 C-N-CA 123.414 2.743 . . . . 0.0 113.344 -177.654 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -70.8 -64.82 2.68 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.087 179.462 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 3.0 p30 -132.6 120.29 21.61 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 121.045 0.45 . . . . 0.0 111.421 178.531 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 28.3 m -57.07 -10.25 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 CA-C-N 115.573 -0.74 . . . . 0.0 112.835 177.768 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 66.4 m170 -69.84 -1.03 8.24 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-O 121.158 0.504 . . . . 0.0 110.636 176.553 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 33.1 mtmm -137.31 157.72 46.01 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.109 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -143.47 173.33 11.72 Favored 'General case' 0 C--N 1.308 -1.21 0 C-N-CA 120.825 -0.35 . . . . 0.0 110.921 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.465 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 1.9 mp -131.04 142.82 42.58 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.966 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 178.786 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -99.68 115.17 39.99 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.968 0 N-CA-C 107.424 -1.325 . . . . 0.0 107.424 174.885 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 29.2 m -95.41 121.75 37.41 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 -178.526 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 16.4 m -126.56 140.79 52.17 Favored 'General case' 0 C--N 1.307 -1.282 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 -179.32 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -118.19 104.86 11.21 Favored 'General case' 0 C--N 1.308 -1.23 0 CA-C-O 121.083 0.468 . . . . 0.0 110.569 -178.435 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 67.5 m -82.89 89.06 6.8 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.444 178.704 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 68.78 -100.26 0.67 Allowed Glycine 0 N--CA 1.432 -1.575 0 C-N-CA 120.461 -0.876 . . . . 0.0 111.084 -177.702 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 14.5 t -114.5 7.46 16.19 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-O 120.9 0.381 . . . . 0.0 110.383 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 21.8 tp -117.1 131.11 56.99 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.584 -0.28 . . . . 0.0 110.438 -177.712 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 77.0 m95 -92.14 131.75 37.15 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 121.038 0.447 . . . . 0.0 111.84 -179.457 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 64.4 m-85 -120.89 129.79 53.64 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.471 174.085 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.415 HD11 HD23 ' A' ' 81' ' ' LEU . 2.5 pp -120.82 151.51 23.78 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.043 0 CA-C-O 121.129 0.49 . . . . 0.0 111.736 -179.518 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 27.8 m -139.66 118.81 12.69 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.892 178.495 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 6.0 p -92.09 124.6 44.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 120.951 0.405 . . . . 0.0 111.081 -178.621 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 4.0 mmt -125.77 139.22 33.62 Favored Pre-proline 0 C--N 1.318 -0.766 0 CA-C-N 115.822 -0.627 . . . . 0.0 109.838 -179.48 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -86.8 143.14 6.97 Favored 'Trans proline' 0 N--CA 1.453 -0.911 0 C-N-CA 122.241 1.961 . . . . 0.0 111.883 177.786 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' CYS . . . . . 0.498 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 55.3 m -81.81 169.39 16.95 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 176.529 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 1.6 p -58.36 148.52 27.45 Favored 'General case' 0 N--CA 1.435 -1.198 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.604 176.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' ILE . . . . . 0.416 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.9 mp -62.74 129.0 25.56 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 CA-C-O 121.135 0.493 . . . . 0.0 110.445 -179.348 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 92.04 5.31 66.1 Favored Glycine 0 N--CA 1.44 -1.061 0 CA-C-N 115.694 -0.684 . . . . 0.0 112.882 -178.21 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 60.5 p -126.33 162.6 25.13 Favored 'General case' 0 C--O 1.236 0.347 0 CA-C-N 117.269 0.534 . . . . 0.0 111.133 179.166 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 58.0 pttt -131.9 143.99 50.54 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 179.387 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.498 ' HB2' ' SG ' ' A' ' 126' ' ' CYS . 46.5 t80 -82.74 133.6 35.15 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-O 120.919 0.39 . . . . 0.0 111.712 -178.489 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -100.55 128.57 29.81 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 115.877 -0.601 . . . . 0.0 109.907 177.453 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -64.56 -41.22 20.44 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.973 2.449 . . . . 0.0 113.514 -176.73 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 28.1 mm -75.89 -53.01 16.58 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 N-CA-C 112.097 0.406 . . . . 0.0 112.097 -175.738 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 4.8 m -68.78 -31.96 71.35 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.727 -178.899 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 57.5 mtm180 70.73 51.02 0.33 Allowed 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 121.428 0.632 . . . . 0.0 110.752 178.328 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 29.7 p-10 -159.23 173.41 16.39 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-N 115.483 -0.78 . . . . 0.0 109.004 179.067 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 139' ' ' CYS . . . . . 0.423 ' HA ' ' HA ' ' A' ' 132' ' ' PHE . 21.1 m -101.85 125.26 48.49 Favored 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 178.503 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 27.2 m -112.8 163.2 10.2 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.767 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.159 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 6.9 tt -57.56 123.6 16.13 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-O 121.081 0.467 . . . . 0.0 111.225 -178.692 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 17.1 t70 -91.46 99.28 12.25 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.209 178.836 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 25.0 t-20 . . . . . 0 C--N 1.313 -1.007 0 CA-C-O 118.59 -0.719 . . . . 0.0 109.808 -179.891 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.105 0 N-CA-C 111.521 -0.632 . . . . 0.0 111.521 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.501 ' HA ' ' OD1' ' A' ' 80' ' ' ASP . 8.7 Cg_endo -88.63 89.55 0.45 Allowed 'Trans proline' 0 N--CA 1.449 -1.126 0 C-N-CA 122.937 2.425 . . . . 0.0 111.912 179.172 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -173.04 136.73 0.67 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.674 -179.379 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 81.33 -65.01 4.08 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.872 -0.68 . . . . 0.0 111.752 178.061 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.414 ' O ' HG23 ' A' ' 93' ' ' VAL . 66.9 m -71.83 -30.26 65.29 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 115.434 -0.383 . . . . 0.0 111.234 179.108 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.525 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 11.9 p-10 -139.74 132.99 29.85 Favored 'General case' 0 N--CA 1.44 -0.944 0 CA-C-O 121.604 0.716 . . . . 0.0 111.437 -176.495 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.504 HD23 HD11 ' A' ' 121' ' ' ILE . 39.0 tp -107.25 137.88 44.47 Favored 'General case' 0 C--N 1.301 -1.504 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.502 177.224 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.469 HG22 HG22 ' A' ' 89' ' ' THR . 16.8 mt -96.81 143.29 12.62 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.07 0 C-N-CA 120.511 -0.476 . . . . 0.0 110.187 -179.547 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 28.7 m -138.41 157.37 30.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-N 116.174 -0.466 . . . . 0.0 109.804 -179.203 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 60.8 m-70 -104.2 104.33 14.23 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 116.468 -0.333 . . . . 0.0 111.019 179.454 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 70.4 mm-40 -100.79 104.97 16.23 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 177.529 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 66.37 30.62 76.95 Favored Glycine 0 N--CA 1.444 -0.776 0 C-N-CA 120.262 -0.971 . . . . 0.0 110.783 -176.901 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 89.42 -21.89 26.57 Favored Glycine 0 N--CA 1.442 -0.947 0 CA-C-N 115.195 -0.502 . . . . 0.0 112.726 -178.549 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 14.0 mmmm -83.75 135.2 34.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.799 0.333 . . . . 0.0 111.024 -176.027 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.469 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -81.42 112.26 18.52 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -178.52 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -112.26 146.68 37.77 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.744 -0.662 . . . . 0.0 109.649 176.301 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 21.6 m-70 -99.05 142.44 30.53 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-O 120.715 0.293 . . . . 0.0 110.498 178.921 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.67 HG13 HD13 ' A' ' 110' ' ' ILE . 79.5 t -117.65 120.33 64.4 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.955 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 179.097 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.414 HG23 ' O ' ' A' ' 79' ' ' SER . 14.9 p -138.79 142.21 34.97 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.028 -178.031 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 33.1 m -138.31 127.95 25.01 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.662 177.854 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 14.0 p80 -101.71 -0.32 34.7 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-O 121.447 0.641 . . . . 0.0 109.701 177.71 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 56.5 mt-10 -142.67 157.95 44.15 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 114.755 -1.111 . . . . 0.0 109.702 178.846 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -85.46 153.75 22.27 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 120.917 0.389 . . . . 0.0 110.77 178.295 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 126.8 161.77 10.99 Favored Glycine 0 N--CA 1.438 -1.168 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.037 178.34 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.494 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 72.9 Cg_endo -82.62 134.59 7.58 Favored 'Trans proline' 0 N--CA 1.447 -1.248 0 C-N-CA 122.376 2.051 . . . . 0.0 111.855 177.896 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -141.65 157.4 65.22 Favored Pre-proline 0 C--N 1.314 -0.968 0 CA-C-N 115.934 -0.576 . . . . 0.0 109.733 178.515 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -62.42 164.64 17.31 Favored 'Trans proline' 0 C--N 1.348 0.544 0 C-N-CA 122.356 2.038 . . . . 0.0 112.468 -178.813 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' HIS . . . . . . . . . . . . . 27.6 t-80 -92.02 121.95 65.95 Favored Pre-proline 0 C--N 1.315 -0.899 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 -179.506 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -59.0 -19.3 47.58 Favored 'Trans proline' 0 N--CA 1.486 1.041 0 C-N-CA 123.116 2.544 . . . . 0.0 113.543 -176.581 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -93.35 -19.3 35.98 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.469 -0.872 . . . . 0.0 112.809 -179.843 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 2.4 p30 -167.32 102.04 0.52 Allowed 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 122.479 0.311 . . . . 0.0 110.985 -177.894 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 28.3 m -54.91 -14.34 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 N-CA-C 113.674 0.99 . . . . 0.0 113.674 179.552 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 17.2 t-80 -73.21 -0.52 14.57 Favored 'General case' 0 CA--C 1.542 0.655 0 CA-C-O 121.61 0.719 . . . . 0.0 110.435 176.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 47.4 mtmt -136.89 160.88 37.58 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.473 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 11.1 p90 -142.37 173.67 11.32 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.546 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.67 HD13 HG13 ' A' ' 92' ' ' VAL . 3.7 mt -131.91 142.24 43.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 -178.584 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.6 mp -101.89 112.5 35.24 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.12 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 175.783 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 86.3 m -102.3 123.52 46.26 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-O 121.181 0.515 . . . . 0.0 111.178 -176.945 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 19.3 m -128.56 144.61 51.18 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.529 -179.057 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.597 ' HD3' ' CE2' ' A' ' 119' ' ' TRP . 24.1 tptm -113.16 103.84 11.75 Favored 'General case' 0 C--N 1.313 -0.985 0 N-CA-C 109.152 -0.685 . . . . 0.0 109.152 179.247 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 62.2 m -91.28 78.92 5.72 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-O 121.436 0.636 . . . . 0.0 109.524 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.523 ' O ' ' HE2' ' A' ' 114' ' ' LYS . . . 75.44 -99.06 1.18 Allowed Glycine 0 N--CA 1.433 -1.507 0 N-CA-C 110.593 -1.003 . . . . 0.0 110.593 -178.897 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 20.4 m -113.46 0.92 14.88 Favored 'General case' 0 N--CA 1.445 -0.722 0 CA-C-O 121.312 0.577 . . . . 0.0 110.068 -179.752 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 87.6 mt -112.02 122.97 49.23 Favored 'General case' 0 N--CA 1.435 -1.21 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.555 -176.538 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 119' ' ' TRP . . . . . 0.597 ' CE2' ' HD3' ' A' ' 114' ' ' LYS . 81.3 m95 -85.32 131.34 34.42 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 121.015 0.436 . . . . 0.0 111.107 177.37 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -125.48 124.0 40.41 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 115.881 -0.6 . . . . 0.0 109.849 174.55 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.504 HD11 HD23 ' A' ' 81' ' ' LEU . 2.5 pp -126.45 146.97 31.38 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.955 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.33 -178.494 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 34.5 m -134.24 124.93 26.75 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 116.013 -0.54 . . . . 0.0 109.672 178.212 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 2.8 p -95.68 110.99 25.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-O 121.393 0.615 . . . . 0.0 111.252 -179.057 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 9.1 mmt -113.32 145.8 33.98 Favored Pre-proline 0 C--N 1.318 -0.767 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.062 -178.719 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 79.4 Cg_endo -89.25 151.15 5.55 Favored 'Trans proline' 0 N--CA 1.453 -0.865 0 C-N-CA 122.353 2.035 . . . . 0.0 113.074 179.605 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 35.9 m -90.87 171.14 9.52 Favored 'General case' 0 C--O 1.243 0.727 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.153 175.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 22.9 t -54.28 148.32 11.74 Favored 'General case' 0 C--O 1.237 0.413 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 177.298 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 128' ' ' ILE . . . . . 0.455 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.9 mp -63.7 129.07 26.97 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 CA-C-O 120.912 0.387 . . . . 0.0 110.234 -179.032 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 89.38 6.03 71.55 Favored Glycine 0 N--CA 1.444 -0.791 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.783 -177.669 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 46.2 p -121.33 158.94 27.1 Favored 'General case' 0 N--CA 1.452 -0.36 0 O-C-N 122.343 -0.504 . . . . 0.0 110.757 178.236 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 59.0 pttt -128.0 144.26 51.1 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 32.8 t80 -84.46 137.22 33.48 Favored 'General case' 0 C--N 1.311 -1.098 0 C-N-CA 120.9 -0.32 . . . . 0.0 110.743 -179.644 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -100.05 133.83 21.31 Favored Pre-proline 0 C--N 1.325 -0.472 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.333 179.314 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -67.68 -41.84 7.71 Favored 'Trans proline' 0 C--N 1.346 0.418 0 C-N-CA 122.877 2.385 . . . . 0.0 113.949 -177.51 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 34.8 mm -82.35 -49.25 17.45 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 N-CA-C 111.951 0.352 . . . . 0.0 111.951 -176.45 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 2.4 m -69.1 -37.49 78.42 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.847 0.356 . . . . 0.0 110.1 179.512 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 67.5 mtt180 68.36 55.36 0.52 Allowed 'General case' 0 CA--C 1.514 -0.414 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.572 178.686 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 29.4 p-10 -154.61 172.93 17.06 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 114.86 -1.064 . . . . 0.0 108.374 178.221 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 27.3 m -101.03 124.83 47.36 Favored 'General case' 0 C--N 1.316 -0.891 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 177.912 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 35.8 m -117.54 157.16 18.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.296 -178.301 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 7.2 mp -64.56 119.75 11.06 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 112.186 0.439 . . . . 0.0 112.186 -178.328 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -83.5 90.87 7.28 Favored 'General case' 0 C--N 1.319 -0.734 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 174.032 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 10.2 t30 . . . . . 0 C--N 1.306 -1.298 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.44 -174.488 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.27 0 N-CA-C 111.93 -0.468 . . . . 0.0 111.93 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.468 ' HA ' ' O ' ' A' ' 80' ' ' ASP . 81.0 Cg_endo -76.51 34.57 0.44 Allowed 'Trans proline' 0 C--N 1.349 0.557 0 C-N-CA 123.227 2.618 . . . . 0.0 112.498 -178.741 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 20.4 mt -88.52 33.99 0.76 Allowed 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.006 -178.391 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 87.58 -22.75 15.26 Favored Glycine 0 N--CA 1.449 -0.488 0 N-CA-C 111.069 -0.812 . . . . 0.0 111.069 -176.9 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 15.0 m -74.33 -49.49 22.69 Favored 'General case' 0 N--CA 1.443 -0.802 0 CA-C-N 115.482 -0.359 . . . . 0.0 111.264 179.758 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.468 ' O ' ' HA ' ' A' ' 76' ' ' PRO . 24.3 t70 -139.26 106.8 5.57 Favored 'General case' 0 CA--C 1.517 -0.297 0 CA-C-O 120.722 0.296 . . . . 0.0 110.386 -179.191 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.475 HD23 HD11 ' A' ' 121' ' ' ILE . 54.6 tp -108.6 131.65 54.65 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 178.298 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.548 HG22 HG22 ' A' ' 89' ' ' THR . 12.3 mt -91.69 139.97 16.9 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 C-N-CA 120.408 -0.517 . . . . 0.0 109.651 179.068 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 29.4 m -136.52 175.12 10.98 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 CA-C-N 116.137 -0.483 . . . . 0.0 109.84 -177.536 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 16.2 m-70 -114.57 117.24 30.36 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.109 0.48 . . . . 0.0 111.426 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.45 ' HB2' ' CD1' ' A' ' 90' ' ' TYR . 11.8 mm-40 -115.19 104.45 11.86 Favored 'General case' 0 C--N 1.311 -1.074 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 177.228 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 64.39 34.05 88.87 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.382 -0.913 . . . . 0.0 111.448 -177.889 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 88.28 -26.9 7.34 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 121.436 -0.411 . . . . 0.0 113.021 -178.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -82.23 146.74 29.33 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.818 0.342 . . . . 0.0 111.169 -178.341 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.548 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -85.08 122.42 29.26 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-O 121.233 0.54 . . . . 0.0 112.153 -179.79 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.45 ' CD1' ' HB2' ' A' ' 85' ' ' GLU . 18.0 m-85 -117.03 148.79 41.18 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.252 176.711 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 31.4 m-70 -97.74 144.22 27.58 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-N 116.526 -0.306 . . . . 0.0 110.202 178.731 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 44.2 t -121.12 117.54 53.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.256 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 178.413 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.6 p -130.77 131.32 64.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 CA-C-N 115.424 -0.807 . . . . 0.0 109.096 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -106.3 138.44 42.48 Favored 'General case' 0 N--CA 1.435 -1.223 0 C-N-CA 119.579 -0.848 . . . . 0.0 111.456 -177.874 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 36.1 m80 -108.84 -25.07 10.97 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 115.329 -0.851 . . . . 0.0 110.365 -178.388 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -131.98 143.43 50.08 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.776 -177.664 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -74.67 108.6 7.53 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.203 178.317 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' GLY . . . . . 0.424 ' H ' ' HB2' ' A' ' 112' ' ' CYS . . . 156.25 -178.64 32.65 Favored Glycine 0 N--CA 1.439 -1.135 0 N-CA-C 111.637 -0.585 . . . . 0.0 111.637 -178.18 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.493 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 69.5 Cg_endo -91.12 127.31 1.16 Allowed 'Trans proline' 0 N--CA 1.445 -1.333 0 C-N-CA 123.149 2.566 . . . . 0.0 112.742 179.529 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.6 pp -138.02 156.12 74.21 Favored Pre-proline 0 C--N 1.313 -0.993 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.387 179.232 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.408 ' HG3' ' HD3' ' A' ' 134' ' ' PRO . 37.3 Cg_endo -62.92 165.25 16.86 Favored 'Trans proline' 0 C--N 1.352 0.746 0 C-N-CA 122.634 2.223 . . . . 0.0 112.522 -178.435 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 102' ' ' HIS . . . . . 0.421 ' CD2' HD11 ' A' ' 110' ' ' ILE . 11.9 t-80 -88.51 132.6 38.47 Favored Pre-proline 0 C--N 1.32 -0.716 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -178.601 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 17.5 Cg_endo -58.65 -19.95 48.12 Favored 'Trans proline' 0 C--N 1.35 0.631 0 C-N-CA 123.0 2.467 . . . . 0.0 112.806 -179.26 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -91.13 -67.68 1.17 Allowed Glycine 0 N--CA 1.447 -0.591 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.101 179.13 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 45.6 m-80 -118.56 109.95 16.78 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.592 0.196 . . . . 0.0 111.053 179.441 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 32.8 m -55.41 -13.62 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.791 0 N-CA-C 113.075 0.769 . . . . 0.0 113.075 176.755 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 41.1 m170 -73.92 3.78 6.26 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-O 120.934 0.397 . . . . 0.0 110.547 177.12 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 47.7 mtmt -140.62 157.75 45.0 Favored 'General case' 0 CA--C 1.506 -0.743 0 CA-C-N 115.833 -0.622 . . . . 0.0 109.43 179.78 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 8.5 p90 -143.03 170.07 16.39 Favored 'General case' 0 C--N 1.306 -1.284 0 C-N-CA 120.829 -0.348 . . . . 0.0 111.264 -179.433 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.493 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.1 mp -125.09 139.13 52.06 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.598 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -100.96 113.13 36.05 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 175.357 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 112' ' ' CYS . . . . . 0.424 ' HB2' ' H ' ' A' ' 98' ' ' GLY . 59.6 m -95.14 123.18 38.49 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 109.314 -0.625 . . . . 0.0 109.314 179.132 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 52.7 p -122.56 136.7 54.95 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.835 -176.714 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 19.5 tptm -96.41 115.54 27.59 Favored 'General case' 0 N--CA 1.435 -1.202 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.682 -179.032 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 59.7 m -108.23 79.81 1.3 Allowed 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 176.856 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 73.45 -104.57 1.61 Allowed Glycine 0 N--CA 1.438 -1.189 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 -176.273 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 8.4 t -113.33 13.02 18.98 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 121.226 0.536 . . . . 0.0 109.865 179.229 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 81.4 mt -116.96 135.4 53.73 Favored 'General case' 0 N--CA 1.435 -1.223 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.043 -177.378 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 50.1 m95 -96.98 131.69 43.53 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.005 0.431 . . . . 0.0 111.069 178.395 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -129.24 128.59 43.6 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 174.855 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.475 HD11 HD23 ' A' ' 81' ' ' LEU . 2.5 pp -119.05 158.91 20.05 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-O 120.952 0.406 . . . . 0.0 111.698 -176.915 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 44.2 m -146.01 121.65 10.46 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.882 177.369 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.7 p -94.62 110.13 23.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 121.549 0.69 . . . . 0.0 111.411 -179.024 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 7.2 mmt -111.86 142.8 27.39 Favored Pre-proline 0 C--N 1.313 -1.007 0 CA-C-N 115.49 -0.777 . . . . 0.0 110.004 -179.459 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -86.71 144.62 7.61 Favored 'Trans proline' 0 N--CA 1.453 -0.89 0 C-N-CA 122.461 2.107 . . . . 0.0 112.722 178.922 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 12.2 m -82.65 174.69 10.78 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.488 177.133 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 13.1 m -61.8 144.45 54.76 Favored 'General case' 0 N--CA 1.436 -1.16 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.88 176.678 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' ILE . . . . . 0.423 ' N ' HD12 ' A' ' 128' ' ' ILE . 2.2 mp -63.34 126.74 22.41 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.553 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 99.25 -6.87 59.83 Favored Glycine 0 N--CA 1.441 -1.0 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.735 -176.483 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 69.1 p -121.66 157.2 31.38 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-N 117.183 0.492 . . . . 0.0 111.449 179.139 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.418 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 62.4 pttt -124.35 147.64 48.06 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 179.0 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 46.9 t80 -81.46 134.37 35.53 Favored 'General case' 0 C--N 1.31 -1.132 0 C-N-CA 120.459 -0.496 . . . . 0.0 111.125 -179.363 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -104.33 127.83 28.29 Favored Pre-proline 0 C--N 1.317 -0.843 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.533 178.76 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 134' ' ' PRO . . . . . 0.408 ' HD3' ' HG3' ' A' ' 101' ' ' PRO . 27.3 Cg_endo -61.99 -42.43 30.49 Favored 'Trans proline' 0 C--O 1.235 0.338 0 C-N-CA 123.024 2.483 . . . . 0.0 113.48 -176.035 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 33.9 mm -79.03 -49.63 19.76 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.612 -176.87 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 136' ' ' SER . . . . . 0.412 ' O ' ' HB2' ' A' ' 137' ' ' ARG . 5.1 m -62.41 -37.51 86.11 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.54 0.209 . . . . 0.0 111.134 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 137' ' ' ARG . . . . . 0.412 ' HB2' ' O ' ' A' ' 136' ' ' SER . 44.2 mtp180 74.62 41.91 0.32 Allowed 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 123.407 0.683 . . . . 0.0 111.33 178.763 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 -161.55 -179.27 7.18 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 178.828 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 10.6 m -100.45 125.93 46.8 Favored 'General case' 0 C--N 1.31 -1.147 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 -178.681 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.5 m -113.34 165.9 7.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.704 -178.253 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -55.08 116.02 2.55 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.625 -179.78 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 142' ' ' ASP . . . . . 0.418 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 21.4 t70 -91.47 101.23 13.9 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.58 -178.85 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 20.9 m120 . . . . . 0 C--N 1.312 -1.055 0 CA-C-O 118.501 -0.761 . . . . 0.0 109.399 176.596 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.377 0 N-CA-C 111.99 -0.444 . . . . 0.0 111.99 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -78.66 92.73 1.12 Allowed 'Trans proline' 0 C--O 1.238 0.511 0 C-N-CA 122.739 2.292 . . . . 0.0 112.376 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -120.05 105.15 10.75 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.19 0.519 . . . . 0.0 111.395 -179.365 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -133.43 9.64 5.0 Favored Glycine 0 C--N 1.312 -0.771 0 N-CA-C 109.797 -1.321 . . . . 0.0 109.797 176.314 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 17.3 m -76.53 -20.4 56.94 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 114.766 -0.717 . . . . 0.0 110.951 -177.07 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -144.46 104.19 4.04 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 -178.39 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -107.2 127.79 53.83 Favored 'General case' 0 C--N 1.31 -1.131 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.407 ' CG2' HG22 ' A' ' 89' ' ' THR . 12.5 mt -98.19 144.5 11.24 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.918 0 C-N-CA 120.951 -0.3 . . . . 0.0 110.419 -178.071 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.46 HG21 ' CE1' ' A' ' 102' ' ' HIS . 22.2 m -128.74 151.41 35.49 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.009 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 179.792 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 22.3 m-70 -107.76 100.09 9.5 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-O 120.879 0.371 . . . . 0.0 110.709 179.741 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 79.4 mm-40 -105.54 105.21 15.14 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.95 179.718 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 62.47 37.67 95.06 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.73 -0.748 . . . . 0.0 111.873 -179.622 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 80.52 -6.11 62.19 Favored Glycine 0 CA--C 1.52 0.376 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.612 -178.905 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 32.0 mmmt -96.97 129.02 44.49 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.922 0.391 . . . . 0.0 110.288 -178.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.407 HG22 ' CG2' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -86.07 124.28 32.32 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.408 179.714 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 89.8 m-85 -121.48 141.04 51.41 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 177.538 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 37.8 m-70 -98.85 138.46 35.95 Favored 'General case' 0 C--N 1.312 -1.062 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.29 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 49.4 t -115.58 122.68 69.89 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.015 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 178.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 84.6 t -132.38 128.08 57.83 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.027 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 -179.421 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 66.9 m -98.61 131.6 44.68 Favored 'General case' 0 C--N 1.307 -1.277 0 CA-C-O 120.893 0.378 . . . . 0.0 110.899 -178.201 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 37.1 m80 -80.53 -29.45 37.18 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 179.597 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -158.32 -179.09 7.78 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 114.81 -1.086 . . . . 0.0 108.168 -177.528 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -84.55 154.25 22.75 Favored 'General case' 0 C--N 1.31 -1.138 0 CA-C-O 121.002 0.43 . . . . 0.0 111.001 -179.538 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 124.96 167.17 12.54 Favored Glycine 0 N--CA 1.442 -0.945 0 N-CA-C 111.478 -0.649 . . . . 0.0 111.478 -178.263 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.42 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 93.4 Cg_endo -87.18 134.36 3.55 Favored 'Trans proline' 0 N--CA 1.454 -0.85 0 C-N-CA 122.681 2.254 . . . . 0.0 112.816 178.898 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.5 pp -140.56 156.21 69.38 Favored Pre-proline 0 C--N 1.323 -0.575 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.168 178.416 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo -61.46 165.97 12.25 Favored 'Trans proline' 0 C--N 1.352 0.746 0 C-N-CA 122.895 2.397 . . . . 0.0 113.577 -177.687 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' HIS . . . . . 0.46 ' CE1' HG21 ' A' ' 83' ' ' VAL . 3.5 t-80 -89.06 128.13 52.97 Favored Pre-proline 0 C--N 1.321 -0.645 0 CA-C-N 115.329 -0.85 . . . . 0.0 108.93 -179.407 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 10.5 Cg_endo -51.56 -50.53 13.64 Favored 'Trans proline' 0 C--N 1.352 0.73 0 C-N-CA 123.123 2.549 . . . . 0.0 113.25 -176.432 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -67.44 -64.44 3.22 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.677 -179.672 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.446 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 2.6 p30 -119.89 105.0 10.66 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 120.972 0.415 . . . . 0.0 111.705 -178.824 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 27.3 m -56.08 -10.6 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 N-CA-C 113.574 0.953 . . . . 0.0 113.574 178.791 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 23.6 m170 -73.45 4.55 4.64 Favored 'General case' 0 N--CA 1.472 0.675 0 CA-C-O 121.245 0.545 . . . . 0.0 110.646 176.7 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 45.1 mtmt -138.1 160.38 39.54 Favored 'General case' 0 N--CA 1.445 -0.708 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 177.844 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 13.4 p90 -143.5 173.18 11.86 Favored 'General case' 0 C--N 1.313 -0.982 0 C-N-CA 120.466 -0.494 . . . . 0.0 111.611 179.668 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.431 ' CG2' ' HB ' ' A' ' 121' ' ' ILE . 2.9 mp -129.57 142.36 44.11 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.908 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.065 179.688 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -100.32 119.44 48.41 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.88 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 175.203 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 61.9 m -98.22 123.8 42.48 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-O 120.927 0.394 . . . . 0.0 111.177 -177.324 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 23.5 t -130.82 137.63 49.5 Favored 'General case' 0 C--N 1.312 -1.056 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 177.929 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.461 ' HE2' ' O ' ' A' ' 116' ' ' GLY . 86.6 tttt -116.34 109.61 17.59 Favored 'General case' 0 C--N 1.316 -0.872 0 C-N-CA 120.552 -0.459 . . . . 0.0 110.515 -178.881 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 53.4 m -92.09 76.76 5.38 Favored 'General case' 0 C--N 1.31 -1.128 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.018 178.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.461 ' O ' ' HE2' ' A' ' 114' ' ' LYS . . . 77.99 -98.93 1.49 Allowed Glycine 0 N--CA 1.44 -1.052 0 C-N-CA 120.434 -0.888 . . . . 0.0 111.199 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 25.3 m -114.09 8.94 17.15 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 121.086 0.47 . . . . 0.0 110.177 179.746 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 19.7 tp -122.69 125.64 45.99 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.66 -177.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' TRP . . . . . 0.446 ' CZ2' ' HD2' ' A' ' 114' ' ' LYS . 86.6 m95 -89.86 133.13 34.91 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-O 121.045 0.45 . . . . 0.0 111.632 179.363 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 87.6 m-85 -118.22 120.88 39.01 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 173.839 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.431 ' HB ' ' CG2' ' A' ' 110' ' ' ILE . 2.3 pp -125.51 142.94 40.76 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 CA-C-O 121.001 0.429 . . . . 0.0 111.14 -178.539 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 49.8 m -129.54 123.77 32.24 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-N 115.958 -0.564 . . . . 0.0 109.875 179.394 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.7 p -94.08 112.37 26.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 121.513 0.673 . . . . 0.0 111.342 -178.978 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 5.8 mmt -110.7 138.8 21.15 Favored Pre-proline 0 C--N 1.318 -0.786 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.289 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -86.11 140.39 6.64 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 122.455 2.103 . . . . 0.0 112.359 178.61 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 126' ' ' CYS . . . . . 0.435 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 65.6 m -83.26 170.97 14.08 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.283 177.825 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 30.9 m -57.08 141.51 45.69 Favored 'General case' 0 N--CA 1.446 -0.64 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.173 176.491 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 128' ' ' ILE . . . . . 0.415 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.9 mp -59.9 131.76 24.73 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 179.37 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.28 -7.26 72.24 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.762 -0.732 . . . . 0.0 113.045 -176.618 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 59.7 p -117.2 164.91 14.07 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-N 117.174 0.487 . . . . 0.0 111.114 179.664 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.554 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 65.0 pttt -132.03 148.59 52.51 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 178.896 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.435 ' HB2' ' SG ' ' A' ' 126' ' ' CYS . 44.4 t80 -84.63 130.4 34.72 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 120.571 -0.452 . . . . 0.0 110.559 178.715 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -98.34 129.8 29.72 Favored Pre-proline 0 C--N 1.314 -0.948 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.924 179.271 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -64.21 -40.83 24.09 Favored 'Trans proline' 0 C--N 1.342 0.224 0 C-N-CA 122.803 2.335 . . . . 0.0 113.28 -176.805 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 27.6 mm -78.96 -51.67 16.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.599 -176.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 14.0 m -64.0 -32.73 74.38 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.836 0.351 . . . . 0.0 110.657 178.937 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 67.6 mtm180 68.83 41.95 1.45 Allowed 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 115.509 -0.769 . . . . 0.0 111.274 176.919 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 2.3 p-10 -157.64 176.77 12.19 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.249 -0.887 . . . . 0.0 108.779 177.556 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 139' ' ' CYS . . . . . 0.412 ' HA ' ' HA ' ' A' ' 132' ' ' PHE . 9.2 m -100.28 124.92 46.33 Favored 'General case' 0 C--N 1.319 -0.727 0 C-N-CA 120.209 -0.596 . . . . 0.0 109.734 -178.612 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.0 m -117.88 167.87 10.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.201 -178.295 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -57.35 120.85 8.89 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 178.873 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 142' ' ' ASP . . . . . 0.554 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 8.8 t70 -74.89 90.15 2.39 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 113.674 0.99 . . . . 0.0 113.674 -173.721 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 22.2 m120 . . . . . 0 C--O 1.248 1.017 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 169.328 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.326 0 N-CA-C 112.143 -0.383 . . . . 0.0 112.143 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 151.45 69.26 Favored 'Trans proline' 0 C--O 1.235 0.37 0 C-N-CA 122.638 2.225 . . . . 0.0 112.287 -179.803 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 73.8 mt -77.81 -18.64 56.13 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.499 -179.645 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.41 ' HA3' ' O ' ' A' ' 119' ' ' TRP . . . 103.18 -13.24 55.48 Favored Glycine 0 C--N 1.313 -0.715 0 CA-C-N 115.39 -0.823 . . . . 0.0 112.037 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 21.9 p -74.99 -32.88 61.78 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.211 0.529 . . . . 0.0 110.401 179.632 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -145.17 120.87 10.5 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.316 -0.857 . . . . 0.0 110.299 -177.526 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.446 ' HG ' HD11 ' A' ' 121' ' ' ILE . 2.6 tm? -129.97 126.1 37.0 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.024 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.435 ' CG2' HG22 ' A' ' 89' ' ' THR . 26.0 mt -93.79 147.94 5.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.226 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.597 HG21 ' CE1' ' A' ' 102' ' ' HIS . 10.9 m -138.92 167.14 21.18 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 N-CA-C 110.103 -0.332 . . . . 0.0 110.103 -178.902 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 73.2 m-70 -114.75 99.96 7.89 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.579 177.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.425 ' OE2' ' ND1' ' A' ' 102' ' ' HIS . 1.0 OUTLIER -87.1 98.28 11.21 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 179.775 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 74.27 1.79 61.26 Favored Glycine 0 C--N 1.324 -0.136 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 -177.622 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 123.28 -23.17 6.9 Favored Glycine 0 N--CA 1.437 -1.292 0 N-CA-C 111.374 -0.691 . . . . 0.0 111.374 -178.624 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 32.2 mmmt -85.08 137.83 32.8 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 110.218 -0.29 . . . . 0.0 110.218 -178.165 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.463 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.0 OUTLIER -76.84 128.16 34.08 Favored 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 112.748 0.647 . . . . 0.0 112.748 -178.502 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.538 ' CE2' ' HA2' ' A' ' 104' ' ' GLY . 35.2 m-85 -126.29 148.8 49.45 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 176.385 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 17.6 m-70 -101.37 139.27 37.26 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-O 120.792 0.33 . . . . 0.0 110.587 -178.079 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 60.5 t -122.3 118.04 54.09 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 179.127 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 49.0 t -128.78 132.96 67.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.145 179.431 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 82.8 m -110.38 118.94 37.63 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 -178.682 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 43.7 m80 -103.17 -15.95 15.87 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.987 -179.786 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -131.21 144.33 51.25 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.985 0.422 . . . . 0.0 111.059 -179.307 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -71.02 112.96 7.58 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.31 177.542 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 146.74 168.7 13.86 Favored Glycine 0 N--CA 1.437 -1.245 0 C-N-CA 121.092 -0.575 . . . . 0.0 111.953 179.502 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.433 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 73.4 Cg_endo -78.64 136.08 13.43 Favored 'Trans proline' 0 N--CA 1.457 -0.623 0 C-N-CA 122.656 2.237 . . . . 0.0 112.644 178.321 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -138.24 158.1 71.48 Favored Pre-proline 0 C--N 1.32 -0.688 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.846 178.072 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo -62.05 166.04 13.31 Favored 'Trans proline' 0 C--N 1.353 0.795 0 C-N-CA 122.69 2.26 . . . . 0.0 113.083 -177.821 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' HIS . . . . . 0.597 ' CE1' HG21 ' A' ' 83' ' ' VAL . 7.2 t-80 -92.35 133.7 29.46 Favored Pre-proline 0 C--N 1.321 -0.673 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.1 -178.041 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -57.89 -31.72 93.28 Favored 'Trans proline' 0 C--N 1.353 0.766 0 C-N-CA 123.039 2.493 . . . . 0.0 112.94 -178.581 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.538 ' HA2' ' CE2' ' A' ' 90' ' ' TYR . . . -70.29 -63.65 3.18 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.751 -0.738 . . . . 0.0 111.803 179.324 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.531 ' OD1' ' HB2' ' A' ' 107' ' ' HIS . 10.5 p30 -139.6 130.06 25.6 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-O 121.058 0.456 . . . . 0.0 110.743 176.96 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 29.5 m -58.73 -10.43 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.555 0 N-CA-C 113.487 0.921 . . . . 0.0 113.487 178.817 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' HIS . . . . . 0.531 ' HB2' ' OD1' ' A' ' 105' ' ' ASN . 36.8 m80 -71.11 -6.93 43.03 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 121.127 0.489 . . . . 0.0 110.193 177.686 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 43.1 mtmt -130.51 159.11 38.08 Favored 'General case' 0 CA--C 1.507 -0.71 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.835 177.795 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 9.6 p90 -143.33 173.18 11.83 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.724 179.675 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.433 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 2.4 mp -128.61 141.22 47.13 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.121 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 177.934 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.7 mp -97.58 117.35 42.15 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 N-CA-C 107.753 -1.202 . . . . 0.0 107.753 175.732 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 21.3 m -104.51 121.46 43.52 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 -179.197 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 36.7 m -122.92 133.33 54.4 Favored 'General case' 0 C--N 1.308 -1.203 0 CA-C-N 116.07 -0.513 . . . . 0.0 109.69 179.673 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.486 ' HD2' ' CZ2' ' A' ' 119' ' ' TRP . 80.8 tttt -105.53 112.24 25.25 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 120.489 -0.484 . . . . 0.0 110.179 -179.705 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 68.2 m -102.15 77.98 1.73 Allowed 'General case' 0 C--N 1.308 -1.213 0 CA-C-N 115.738 -0.664 . . . . 0.0 109.962 179.078 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 77.89 -99.67 1.54 Allowed Glycine 0 N--CA 1.44 -1.062 0 CA-C-N 115.317 -0.856 . . . . 0.0 111.485 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 31.7 t -114.48 3.97 15.1 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-O 121.051 0.453 . . . . 0.0 109.807 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 19.5 mt -119.13 125.83 50.18 Favored 'General case' 0 N--CA 1.432 -1.35 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.11 -177.865 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' TRP . . . . . 0.486 ' CZ2' ' HD2' ' A' ' 114' ' ' LYS . 60.6 m95 -91.82 134.01 35.13 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-O 121.071 0.463 . . . . 0.0 111.083 178.942 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 87.5 m-85 -117.51 128.39 54.93 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.259 175.647 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.446 HD11 ' HG ' ' A' ' 81' ' ' LEU . 2.8 pp -127.73 156.36 39.53 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 N-CA-C 112.189 0.44 . . . . 0.0 112.189 -176.054 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 38.9 m -151.24 123.21 8.14 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.132 176.051 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.8 p -92.06 115.23 30.6 Favored 'Isoleucine or valine' 0 C--O 1.235 0.322 0 CA-C-O 121.301 0.572 . . . . 0.0 111.245 179.903 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.454 ' HA ' ' HE2' ' A' ' 124' ' ' MET . 4.6 mmt -117.16 149.7 44.86 Favored Pre-proline 0 C--N 1.32 -0.678 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.198 -179.542 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -92.07 147.76 3.09 Favored 'Trans proline' 0 N--CA 1.45 -1.074 0 C-N-CA 122.433 2.089 . . . . 0.0 112.431 177.647 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 18.2 m -80.94 174.38 11.68 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 120.911 0.386 . . . . 0.0 110.197 176.672 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 18.9 m -62.38 147.08 49.57 Favored 'General case' 0 N--CA 1.437 -1.08 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.79 176.982 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 128' ' ' ILE . . . . . 0.421 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.8 mp -59.11 123.72 11.94 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 CA-C-O 121.167 0.508 . . . . 0.0 110.218 -179.204 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 97.26 -1.67 60.74 Favored Glycine 0 N--CA 1.438 -1.22 0 CA-C-N 115.56 -0.745 . . . . 0.0 113.175 -178.786 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 80.8 p -120.81 162.88 19.03 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 117.447 0.624 . . . . 0.0 111.472 179.477 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.428 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 60.7 pttt -132.51 145.93 51.53 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.469 179.151 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 26.2 t80 -81.58 137.74 35.48 Favored 'General case' 0 C--N 1.31 -1.144 0 CA-C-O 121.15 0.5 . . . . 0.0 111.685 -178.339 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -103.35 132.5 21.04 Favored Pre-proline 0 C--N 1.323 -0.569 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.144 177.878 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -68.77 -39.82 8.06 Favored 'Trans proline' 0 CA--C 1.531 0.347 0 C-N-CA 122.871 2.38 . . . . 0.0 113.885 -176.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 27.2 mm -78.17 -52.49 15.79 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 N-CA-C 112.121 0.415 . . . . 0.0 112.121 -176.433 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 35.5 p -73.75 -29.84 62.46 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 120.695 0.283 . . . . 0.0 111.154 -178.326 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 95.6 mtt180 68.24 57.84 0.46 Allowed 'General case' 0 N--CA 1.465 0.28 0 C-N-CA 123.471 0.709 . . . . 0.0 112.288 176.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 4.1 p-10 -164.09 177.09 8.7 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 176.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 31.5 m -100.35 125.35 46.58 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 -178.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 33.1 m -112.75 167.59 5.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.561 -177.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -58.01 117.08 3.96 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.997 0.427 . . . . 0.0 111.177 179.309 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 142' ' ' ASP . . . . . 0.428 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 17.2 t70 -93.85 104.64 16.7 Favored 'General case' 0 CA--C 1.506 -0.713 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.399 178.997 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 31.4 t-20 . . . . . 0 C--N 1.303 -1.429 0 CA-C-O 118.789 -0.624 . . . . 0.0 109.379 179.229 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.382 0 N-CA-C 111.89 -0.484 . . . . 0.0 111.89 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 94.8 Cg_endo -79.83 166.4 21.38 Favored 'Trans proline' 0 CA--C 1.533 0.452 0 C-N-CA 122.739 2.292 . . . . 0.0 112.238 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.495 ' N ' HD13 ' A' ' 77' ' ' LEU . 0.0 OUTLIER -135.2 36.3 3.0 Favored 'General case' 0 CA--C 1.535 0.38 0 CA-C-O 121.297 0.57 . . . . 0.0 112.053 -179.564 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 77.9 -62.96 3.55 Favored Glycine 0 C--O 1.225 -0.433 0 CA-C-N 115.851 -0.613 . . . . 0.0 113.859 178.636 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 7.1 m -73.51 -20.97 60.53 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.289 0.566 . . . . 0.0 110.469 -178.601 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.432 ' OD1' ' HB3' ' A' ' 91' ' ' HIS . 25.4 t70 -134.61 116.01 14.51 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.468 -179.389 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -107.66 123.86 49.12 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 108.92 -0.771 . . . . 0.0 108.92 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.624 HG22 HG22 ' A' ' 89' ' ' THR . 3.2 mt -101.49 145.3 11.77 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.677 -177.157 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.429 ' O ' ' HA ' ' A' ' 89' ' ' THR . 16.7 m -134.36 165.53 31.25 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 116.084 -0.507 . . . . 0.0 109.812 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 18.6 m-70 -114.7 113.0 23.72 Favored 'General case' 0 C--N 1.31 -1.118 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.407 179.014 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 76.5 mm-40 -107.63 95.9 6.02 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.603 179.235 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 73.94 -6.17 21.3 Favored Glycine 0 CA--C 1.52 0.347 0 C-N-CA 121.093 -0.575 . . . . 0.0 112.932 178.655 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 134.64 -12.71 4.55 Favored Glycine 0 N--CA 1.443 -0.883 0 N-CA-C 111.698 -0.561 . . . . 0.0 111.698 -179.25 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -96.32 130.99 43.3 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 110.368 -0.234 . . . . 0.0 110.368 178.56 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.624 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -85.75 107.34 17.56 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-O 120.969 0.414 . . . . 0.0 111.452 179.391 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 78.1 m-85 -102.21 146.87 27.36 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.914 178.261 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' HIS . . . . . 0.432 ' HB3' ' OD1' ' A' ' 80' ' ' ASP . 36.1 m-70 -101.96 143.73 31.45 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.543 -178.669 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.499 HG13 HD13 ' A' ' 110' ' ' ILE . 89.8 t -114.29 122.18 67.9 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.461 179.102 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 64.2 t -136.77 124.99 34.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.24 0 CA-C-N 115.48 -0.782 . . . . 0.0 108.903 -179.681 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 81.7 m -101.9 127.98 48.5 Favored 'General case' 0 C--N 1.31 -1.139 0 CA-C-O 120.932 0.396 . . . . 0.0 111.059 -179.09 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 68.3 t60 -91.08 -25.45 19.63 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.291 0.567 . . . . 0.0 109.518 178.337 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -149.1 164.69 33.94 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.218 -177.871 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -78.69 142.13 37.37 Favored 'General case' 0 N--CA 1.438 -1.065 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.001 178.08 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 130.05 167.31 12.03 Favored Glycine 0 N--CA 1.438 -1.223 0 C-N-CA 120.907 -0.663 . . . . 0.0 111.621 -178.174 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.402 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 98.5 Cg_endo -85.6 137.99 6.04 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 122.582 2.188 . . . . 0.0 112.766 179.462 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.8 pp -142.86 158.04 60.16 Favored Pre-proline 0 C--N 1.319 -0.747 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.628 178.713 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -64.56 166.63 17.08 Favored 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 122.462 2.108 . . . . 0.0 112.75 -177.619 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' HIS . . . . . . . . . . . . . 14.1 t-80 -89.49 130.09 44.81 Favored Pre-proline 0 C--N 1.318 -0.762 0 CA-C-N 115.923 -0.581 . . . . 0.0 109.906 -178.206 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -62.19 -24.32 76.14 Favored 'Trans proline' 0 N--CA 1.48 0.716 0 C-N-CA 123.013 2.475 . . . . 0.0 113.456 -177.317 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -93.44 -17.87 40.81 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.201 -1.0 . . . . 0.0 113.482 -178.571 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 1.9 p30 -167.63 105.31 0.52 Allowed 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.657 0.265 . . . . 0.0 111.199 -177.905 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 27.0 m -55.05 -11.69 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 N-CA-C 113.509 0.929 . . . . 0.0 113.509 178.145 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 91.0 m-70 -77.57 7.03 6.06 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 121.194 0.521 . . . . 0.0 110.951 178.016 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 47.9 mtmt -143.29 162.84 34.63 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.221 179.342 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 11.1 p90 -142.64 173.72 11.28 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-O 120.919 0.39 . . . . 0.0 111.238 179.727 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.499 HD13 HG13 ' A' ' 92' ' ' VAL . 3.8 mt -132.87 143.62 39.01 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.651 -179.24 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.414 ' N ' HD12 ' A' ' 111' ' ' ILE . 4.3 mp -103.09 122.28 55.34 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 176.641 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 58.7 m -103.08 122.51 44.82 Favored 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 178.847 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 29.1 t -133.59 140.25 47.02 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-O 120.894 0.378 . . . . 0.0 110.672 -177.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.427 ' HD2' ' CZ2' ' A' ' 119' ' ' TRP . 59.9 tttm -107.54 104.74 14.36 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-O 121.106 0.479 . . . . 0.0 110.178 179.125 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 23.3 t -90.76 88.45 7.08 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.58 -179.48 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 66.1 -100.76 0.54 Allowed Glycine 0 N--CA 1.438 -1.195 0 CA-C-N 115.474 -0.784 . . . . 0.0 111.664 -178.835 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 16.3 m -109.32 3.8 21.97 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -179.054 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 35.5 tp -126.98 141.01 51.9 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 120.563 -0.455 . . . . 0.0 111.452 -178.654 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 119' ' ' TRP . . . . . 0.427 ' CZ2' ' HD2' ' A' ' 114' ' ' LYS . 72.6 m95 -93.8 133.47 37.15 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.348 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 77.4 m-85 -121.7 130.78 53.69 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.606 175.898 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.4 pp -125.11 146.96 29.91 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 CA-C-O 120.973 0.416 . . . . 0.0 110.891 179.706 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 22.9 m -137.98 125.43 21.97 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-N 115.964 -0.562 . . . . 0.0 109.94 179.4 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.3 p -94.9 112.02 26.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 121.424 0.63 . . . . 0.0 111.018 179.167 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 6.8 mmt -111.49 141.92 25.48 Favored Pre-proline 0 C--N 1.314 -0.942 0 CA-C-N 115.454 -0.793 . . . . 0.0 110.182 -179.442 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -87.05 154.4 8.37 Favored 'Trans proline' 0 N--CA 1.457 -0.664 0 C-N-CA 122.587 2.191 . . . . 0.0 113.365 -179.72 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 56.5 m -92.72 165.09 13.13 Favored 'General case' 0 C--O 1.241 0.653 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.448 175.618 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 14.9 m -59.93 148.88 33.5 Favored 'General case' 0 N--CA 1.445 -0.693 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.304 176.738 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 128' ' ' ILE . . . . . 0.409 HD12 ' N ' ' A' ' 128' ' ' ILE . 1.8 mp -60.04 129.73 22.85 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.246 179.749 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 93.9 -2.13 69.0 Favored Glycine 0 N--CA 1.439 -1.136 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.883 -178.242 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 68.7 p -121.06 164.02 17.45 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-N 117.257 0.528 . . . . 0.0 111.382 179.422 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.523 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 57.8 pttt -139.18 145.07 38.88 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 178.67 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.406 ' HA ' ' HA ' ' A' ' 139' ' ' CYS . 38.3 t80 -82.8 137.79 34.21 Favored 'General case' 0 C--N 1.311 -1.084 0 N-CA-C 112.365 0.505 . . . . 0.0 112.365 -176.034 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -106.52 131.55 21.62 Favored Pre-proline 0 C--N 1.327 -0.408 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.811 176.264 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.05 -36.58 21.59 Favored 'Trans proline' 0 N--CA 1.471 0.203 0 C-N-CA 122.904 2.403 . . . . 0.0 113.935 -176.803 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 34.3 mm -79.28 -56.34 7.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 N-CA-C 111.932 0.345 . . . . 0.0 111.932 -176.061 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 26.8 p -66.69 -31.76 72.63 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 120.528 0.204 . . . . 0.0 110.911 179.629 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 72.25 48.6 0.25 Allowed 'General case' 0 CA--C 1.518 -0.268 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.342 176.909 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 32.9 p30 -154.9 175.98 13.09 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.434 178.814 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 139' ' ' CYS . . . . . 0.406 ' HA ' ' HA ' ' A' ' 132' ' ' PHE . 27.8 m -100.86 124.65 46.85 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 177.622 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 29.8 m -107.65 160.58 6.75 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.877 -177.69 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -61.45 119.02 7.75 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.187 179.79 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 142' ' ' ASP . . . . . 0.523 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 28.2 t70 -85.97 101.35 12.82 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.934 179.188 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 17.7 m120 . . . . . 0 C--N 1.314 -0.951 0 CA-C-O 118.398 -0.811 . . . . 0.0 110.156 179.997 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.246 0 N-CA-C 112.01 -0.436 . . . . 0.0 112.01 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -84.06 170.75 10.81 Favored 'Trans proline' 0 N--CA 1.457 -0.659 0 C-N-CA 122.698 2.265 . . . . 0.0 112.189 179.64 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 93.0 mt -87.95 -177.08 5.68 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.345 179.325 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.66 ' HA3' ' O ' ' A' ' 119' ' ' TRP . . . -155.48 -33.19 0.03 OUTLIER Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 120.267 -0.968 . . . . 0.0 112.741 -178.706 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 11.3 t -67.86 -44.43 77.11 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 178.742 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -140.41 101.33 4.09 Favored 'General case' 0 C--N 1.317 -0.831 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -112.14 126.31 55.05 Favored 'General case' 0 C--N 1.306 -1.288 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 -177.43 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 15.0 mt -94.4 140.14 17.21 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 C-N-CA 120.869 -0.333 . . . . 0.0 110.395 -178.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 27.1 m -127.82 162.53 33.46 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.171 -178.831 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 35.7 m170 -108.87 112.66 25.01 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.293 179.817 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.548 ' HB2' ' CE1' ' A' ' 90' ' ' TYR . 71.8 mm-40 -116.81 103.96 10.85 Favored 'General case' 0 C--N 1.312 -1.033 0 N-CA-C 109.206 -0.665 . . . . 0.0 109.206 178.28 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 69.38 23.9 76.26 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.631 -0.795 . . . . 0.0 111.971 -179.261 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 95.53 -19.28 55.04 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.627 -179.421 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 56.4 mtmt -91.16 157.37 17.23 Favored 'General case' 0 CA--C 1.512 -0.486 0 CA-C-O 120.797 0.332 . . . . 0.0 111.357 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -94.68 132.62 39.23 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-N 115.879 -0.6 . . . . 0.0 112.602 -177.621 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.548 ' CE1' ' HB2' ' A' ' 85' ' ' GLU . 42.4 m-85 -127.04 140.54 52.22 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 115.133 -0.94 . . . . 0.0 108.915 176.68 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 21.2 m-70 -97.83 145.36 26.48 Favored 'General case' 0 C--N 1.307 -1.246 0 CA-C-O 120.826 0.345 . . . . 0.0 110.672 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.548 HG13 HD13 ' A' ' 110' ' ' ILE . 81.8 t -114.81 126.38 72.36 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.001 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.074 178.477 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 91.2 t -136.43 123.5 32.22 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 179.227 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 73.0 m -94.64 132.05 39.78 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-O 121.435 0.636 . . . . 0.0 112.345 -175.667 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 70.7 m-70 -86.31 -31.22 21.7 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.036 -0.984 . . . . 0.0 110.783 -178.828 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -148.36 167.39 25.35 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.282 -178.861 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -79.21 103.36 9.09 Favored 'General case' 0 N--CA 1.446 -0.66 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 174.627 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 163.92 169.85 28.0 Favored Glycine 0 N--CA 1.431 -1.698 0 N-CA-C 111.126 -0.79 . . . . 0.0 111.126 -178.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.566 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 72.1 Cg_endo -81.55 128.73 6.22 Favored 'Trans proline' 0 N--CA 1.443 -1.485 0 C-N-CA 122.283 1.989 . . . . 0.0 112.256 178.563 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -135.04 157.64 76.55 Favored Pre-proline 0 C--N 1.312 -1.058 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.654 178.569 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -64.55 167.21 15.6 Favored 'Trans proline' 0 C--O 1.233 0.263 0 C-N-CA 122.49 2.127 . . . . 0.0 112.72 -177.573 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' HIS . . . . . 0.45 ' HB3' ' O ' ' A' ' 105' ' ' ASN . 4.5 t-80 -88.85 125.08 63.84 Favored Pre-proline 0 C--N 1.315 -0.891 0 N-CA-C 108.814 -0.809 . . . . 0.0 108.814 -179.007 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -53.41 -37.69 82.06 Favored 'Trans proline' 0 N--CA 1.485 0.984 0 C-N-CA 123.286 2.657 . . . . 0.0 113.417 -176.275 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -74.57 -61.81 3.04 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.335 179.127 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.45 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 2.4 p30 -125.21 109.27 12.65 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 120.992 0.425 . . . . 0.0 111.63 -179.13 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.3 t -56.21 -13.91 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.172 0 C-N-CA 123.584 0.754 . . . . 0.0 112.747 179.278 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 12.1 t-80 -69.06 -1.72 8.29 Favored 'General case' 0 CA--C 1.551 1.019 0 CA-C-O 121.533 0.682 . . . . 0.0 110.644 177.316 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 46.4 mtmt -134.83 160.72 37.31 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 178.604 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 11.3 p90 -142.41 173.33 11.63 Favored 'General case' 0 C--N 1.307 -1.269 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.674 179.178 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.566 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.4 mt -132.03 142.48 42.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -178.383 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.7 mp -101.7 114.17 40.19 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 176.16 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 61.8 m -102.15 122.88 45.01 Favored 'General case' 0 C--N 1.307 -1.273 0 CA-C-O 120.989 0.423 . . . . 0.0 111.252 -177.057 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 28.0 m -131.01 145.64 52.11 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 178.02 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -118.17 114.1 22.55 Favored 'General case' 0 C--N 1.31 -1.132 0 CA-C-O 121.201 0.524 . . . . 0.0 110.3 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 63.1 m -88.2 79.94 7.72 Favored 'General case' 0 N--CA 1.432 -1.366 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.354 179.039 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 75.8 -99.06 1.22 Allowed Glycine 0 N--CA 1.435 -1.392 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 -178.442 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 18.8 m -114.06 6.32 16.37 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 120.844 0.355 . . . . 0.0 110.47 179.341 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 18.2 tp -119.12 124.62 47.3 Favored 'General case' 0 C--O 1.221 -0.405 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.768 -177.251 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 119' ' ' TRP . . . . . 0.66 ' O ' ' HA3' ' A' ' 78' ' ' GLY . 88.4 m95 -84.41 133.89 34.49 Favored 'General case' 0 C--N 1.317 -0.832 0 N-CA-C 112.069 0.396 . . . . 0.0 112.069 -179.423 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 71.9 m-85 -123.38 124.83 43.81 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.531 172.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.4 pp -123.91 155.93 30.91 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.86 0 CA-C-O 121.23 0.538 . . . . 0.0 112.06 -177.338 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 34.3 m -142.6 121.21 12.53 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.712 177.535 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.8 p -95.25 117.68 39.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 121.231 0.539 . . . . 0.0 111.268 -178.951 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.411 ' HA ' ' HE2' ' A' ' 124' ' ' MET . 5.0 mmt -120.16 149.66 49.73 Favored Pre-proline 0 C--N 1.32 -0.692 0 CA-C-N 115.703 -0.68 . . . . 0.0 109.999 -178.55 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -91.64 148.02 3.37 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 122.415 2.076 . . . . 0.0 113.483 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 58.7 m -90.84 172.51 8.57 Favored 'General case' 0 C--O 1.242 0.677 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.783 175.828 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 39.0 m -65.23 147.87 52.69 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.498 178.931 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 128' ' ' ILE . . . . . 0.418 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.9 mp -65.2 129.08 29.0 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.001 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 178.713 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 99.81 -16.22 58.79 Favored Glycine 0 N--CA 1.439 -1.112 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.079 -177.023 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 65.8 p -108.85 159.41 16.81 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-O 120.887 0.375 . . . . 0.0 110.93 178.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.473 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 63.7 pttt -128.83 143.58 50.94 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 178.723 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.444 ' HA ' ' HA ' ' A' ' 139' ' ' CYS . 36.8 t80 -80.73 137.06 36.26 Favored 'General case' 0 C--N 1.314 -0.956 0 C-N-CA 120.294 -0.562 . . . . 0.0 111.324 -179.34 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -108.36 127.13 28.09 Favored Pre-proline 0 C--N 1.32 -0.707 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.105 178.47 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -65.99 -36.89 28.41 Favored 'Trans proline' 0 CA--C 1.53 0.292 0 C-N-CA 122.96 2.44 . . . . 0.0 113.553 -177.062 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.8 mp -77.0 -49.99 21.85 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.322 -177.897 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 13.1 m -67.83 -35.65 78.98 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 120.728 0.299 . . . . 0.0 110.378 178.893 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 137' ' ' ARG . . . . . 0.4 HH11 ' HD2' ' A' ' 137' ' ' ARG . 66.5 mtt85 71.31 46.21 0.44 Allowed 'General case' 0 CA--C 1.517 -0.297 0 CA-C-N 115.692 -0.685 . . . . 0.0 111.217 178.555 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -162.37 177.72 9.3 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 177.7 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 139' ' ' CYS . . . . . 0.444 ' HA ' ' HA ' ' A' ' 132' ' ' PHE . 6.3 m -100.45 125.26 46.73 Favored 'General case' 0 C--N 1.313 -1.019 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -178.914 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 28.4 m -111.97 163.48 8.86 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.09 -178.169 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -70.52 127.3 32.24 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 -179.256 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 142' ' ' ASP . . . . . 0.473 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 22.5 t70 -94.83 100.58 12.44 Favored 'General case' 0 CA--C 1.502 -0.882 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.271 -179.312 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 34.7 t30 . . . . . 0 C--N 1.302 -1.465 0 N-CA-C 109.041 -0.725 . . . . 0.0 109.041 177.917 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.133 0 N-CA-C 111.662 -0.575 . . . . 0.0 111.662 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -79.51 155.21 24.49 Favored 'Trans proline' 0 N--CA 1.455 -0.771 0 C-N-CA 122.874 2.382 . . . . 0.0 111.978 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 55.4 tp -84.21 114.17 21.62 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.85 -0.613 . . . . 0.0 109.904 178.608 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -145.22 -16.82 0.18 Allowed Glycine 0 C--N 1.318 -0.431 0 C-N-CA 120.573 -0.822 . . . . 0.0 112.834 -179.391 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 14.5 m -75.48 -34.27 60.87 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.789 0.328 . . . . 0.0 110.689 -178.737 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 27.0 t70 -147.37 97.35 2.84 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.06 -177.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.452 HD23 HD11 ' A' ' 121' ' ' ILE . 38.6 tp -92.37 145.88 24.13 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.046 179.759 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.585 HG22 HG22 ' A' ' 89' ' ' THR . 4.9 mt -105.1 144.7 14.43 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 178.427 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 15.3 m -141.9 130.69 22.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.042 0.449 . . . . 0.0 110.778 -177.921 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 8.6 p80 -78.9 122.98 26.8 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.27 177.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.442 ' HG2' HD22 ' A' ' 105' ' ' ASN . 7.5 tp10 -136.88 113.87 10.54 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 116.109 -0.496 . . . . 0.0 109.85 179.028 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 68.04 24.19 74.52 Favored Glycine 0 N--CA 1.447 -0.584 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.043 -179.6 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 91.2 -10.53 74.7 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.997 -0.62 . . . . 0.0 112.688 -179.862 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -102.77 139.6 38.14 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.666 0.269 . . . . 0.0 110.359 -179.749 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.585 HG22 HG22 ' A' ' 82' ' ' ILE . 0.1 OUTLIER -87.53 106.67 18.15 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-O 120.821 0.343 . . . . 0.0 110.505 179.676 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 75.6 m-85 -96.2 151.99 18.98 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.562 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 36.4 m-70 -106.85 138.86 42.24 Favored 'General case' 0 C--N 1.308 -1.206 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.041 178.814 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 57.4 t -119.13 118.21 56.8 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 177.435 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.8 p -125.52 138.89 52.97 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.072 -178.774 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 82.1 m -121.97 115.11 21.96 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.213 0.53 . . . . 0.0 111.069 -179.355 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 42.8 t60 -92.67 -18.17 23.36 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.565 178.31 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 74.5 mm-40 -142.02 159.85 41.4 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.452 -0.795 . . . . 0.0 109.835 -178.358 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 -79.66 148.37 31.64 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-O 120.992 0.425 . . . . 0.0 110.549 177.784 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 128.06 164.83 11.69 Favored Glycine 0 N--CA 1.434 -1.488 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 -179.528 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.484 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 91.9 Cg_endo -88.5 142.34 5.04 Favored 'Trans proline' 0 N--CA 1.441 -1.591 0 C-N-CA 122.565 2.176 . . . . 0.0 112.817 179.323 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.41 ' O ' ' HB2' ' A' ' 109' ' ' TYR . 1.7 pp -141.36 156.53 67.21 Favored Pre-proline 0 C--N 1.316 -0.876 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.19 177.752 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -62.66 165.65 15.4 Favored 'Trans proline' 0 C--N 1.346 0.437 0 C-N-CA 122.316 2.011 . . . . 0.0 112.901 -177.767 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' HIS . . . . . 0.481 ' HB3' ' O ' ' A' ' 105' ' ' ASN . 42.8 t-80 -87.12 121.77 71.34 Favored Pre-proline 0 C--N 1.315 -0.913 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.399 -179.266 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 13.7 Cg_endo -56.41 -25.44 57.56 Favored 'Trans proline' 0 N--CA 1.48 0.678 0 C-N-CA 122.887 2.391 . . . . 0.0 112.938 -176.604 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -87.06 -20.14 53.87 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.506 -0.854 . . . . 0.0 113.205 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.481 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 9.5 p30 -168.88 117.7 0.68 Allowed 'General case' 0 N--CA 1.472 0.639 0 CA-C-N 117.213 0.506 . . . . 0.0 110.909 -179.74 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 35.1 m -56.32 -11.38 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 N-CA-C 113.756 1.021 . . . . 0.0 113.756 177.205 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 44.7 m170 -76.76 -0.72 24.84 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 111.957 0.354 . . . . 0.0 111.957 179.67 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.41 ' HG2' ' HA ' ' A' ' 125' ' ' PRO . 39.1 mtmt -139.3 163.82 31.47 Favored 'General case' 0 CA--C 1.503 -0.863 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 179.164 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.41 ' HB2' ' O ' ' A' ' 100' ' ' ILE . 12.4 p90 -144.02 173.27 11.87 Favored 'General case' 0 C--N 1.311 -1.094 0 CA-C-N 116.555 -0.293 . . . . 0.0 111.112 179.533 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.484 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.7 mp -131.18 141.19 46.67 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.968 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 178.276 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.6 mp -99.04 122.72 51.1 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 176.824 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 112' ' ' CYS . . . . . 0.419 ' HA ' HG22 ' A' ' 121' ' ' ILE . 58.8 m -98.14 123.35 42.14 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -178.995 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 18.9 m -130.1 134.24 47.22 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 120.797 0.332 . . . . 0.0 111.226 -178.729 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.471 ' HE3' ' O ' ' A' ' 116' ' ' GLY . 58.9 tptt -107.31 103.3 12.62 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 178.458 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 51.0 m -101.78 103.01 13.72 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.88 179.757 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.471 ' O ' ' HE3' ' A' ' 114' ' ' LYS . . . 59.8 -106.19 0.92 Allowed Glycine 0 N--CA 1.443 -0.857 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.256 -176.852 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 11.6 t -111.28 3.48 18.38 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-O 120.818 0.342 . . . . 0.0 110.683 178.73 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -113.16 132.37 55.5 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 120.89 0.376 . . . . 0.0 111.426 -176.928 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 119' ' ' TRP . . . . . 0.449 ' CE2' ' HD3' ' A' ' 114' ' ' LYS . 67.1 m95 -90.85 132.1 36.1 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.894 0.378 . . . . 0.0 110.092 175.847 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -123.36 124.64 43.39 Favored 'General case' 0 C--N 1.309 -1.181 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.631 175.801 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.452 HD11 HD23 ' A' ' 81' ' ' LEU . 2.4 pp -124.46 142.13 42.28 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.52 -178.871 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 33.5 m -130.13 126.5 37.67 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-N 116.18 -0.464 . . . . 0.0 109.778 179.377 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.1 p -95.26 110.38 23.98 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 121.413 0.625 . . . . 0.0 110.746 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 3.6 mmt -111.02 144.29 30.07 Favored Pre-proline 0 C--N 1.316 -0.856 0 CA-C-N 115.367 -0.833 . . . . 0.0 109.772 -179.8 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' PRO . . . . . 0.41 ' HA ' ' HG2' ' A' ' 108' ' ' LYS . 83.6 Cg_endo -89.26 148.62 5.43 Favored 'Trans proline' 0 N--CA 1.45 -1.075 0 C-N-CA 122.237 1.958 . . . . 0.0 112.737 178.388 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 126' ' ' CYS . . . . . 0.407 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 53.3 m -81.97 161.06 23.17 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.095 -0.502 . . . . 0.0 109.794 176.465 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 16.7 t -61.07 142.38 56.7 Favored 'General case' 0 N--CA 1.442 -0.833 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 177.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 128' ' ' ILE . . . . . 0.405 HD12 ' N ' ' A' ' 128' ' ' ILE . 1.8 mp -54.22 129.6 15.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.468 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 100.15 -7.91 58.84 Favored Glycine 0 N--CA 1.444 -0.79 0 C-N-CA 120.934 -0.65 . . . . 0.0 113.269 -177.776 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 69.5 p -123.49 164.82 18.19 Favored 'General case' 0 C--O 1.237 0.405 0 CA-C-N 117.087 0.443 . . . . 0.0 111.383 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 60.1 pttt -134.74 147.39 50.02 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 178.762 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.42 ' HA ' ' HA ' ' A' ' 139' ' ' CYS . 30.4 t80 -81.78 138.89 35.08 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-O 121.23 0.538 . . . . 0.0 112.355 -177.168 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -108.01 126.98 28.51 Favored Pre-proline 0 C--N 1.324 -0.5 0 CA-C-N 115.51 -0.768 . . . . 0.0 109.533 177.059 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -63.97 -40.17 28.88 Favored 'Trans proline' 0 N--CA 1.474 0.369 0 C-N-CA 122.961 2.441 . . . . 0.0 113.561 -176.55 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 30.8 mm -77.4 -51.96 17.39 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.46 -176.787 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 8.7 m -62.86 -36.12 82.24 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.741 0.305 . . . . 0.0 110.508 178.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 85.9 mtm180 73.11 41.52 0.49 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.909 178.625 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 3.5 p-10 -158.03 178.0 10.7 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 178.543 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 139' ' ' CYS . . . . . 0.42 ' HA ' ' HA ' ' A' ' 132' ' ' PHE . 31.4 m -100.51 125.54 46.85 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-O 121.146 0.498 . . . . 0.0 110.034 -178.74 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.3 m -111.9 165.03 7.23 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 CA-C-N 115.859 -0.61 . . . . 0.0 109.881 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 54.9 tp -57.29 125.0 20.81 Favored 'General case' 0 C--N 1.313 -0.979 0 CA-C-O 121.152 0.501 . . . . 0.0 111.842 -178.873 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 18.0 t0 -90.45 94.53 9.76 Favored 'General case' 0 N--CA 1.442 -0.873 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.958 178.002 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 . . . . . 0 C--N 1.312 -1.033 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 178.579 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.375 0 N-CA-C 112.058 -0.417 . . . . 0.0 112.058 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_exo -63.61 135.12 47.5 Favored 'Trans proline' 0 C--O 1.242 0.7 0 C-N-CA 122.643 2.229 . . . . 0.0 111.839 178.564 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 84.0 mt -122.74 172.4 8.46 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.711 -179.709 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -140.82 -36.43 0.1 Allowed Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.133 -1.032 . . . . 0.0 112.929 -179.346 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 26.4 t -73.14 -45.25 57.86 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 120.537 0.208 . . . . 0.0 110.629 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.409 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 15.1 t70 -147.81 96.05 2.6 Favored 'General case' 0 C--O 1.233 0.229 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 179.013 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.42 ' HG ' HD11 ' A' ' 121' ' ' ILE . 2.9 tm? -102.63 130.74 49.61 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.147 -179.16 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.42 HG22 HG22 ' A' ' 89' ' ' THR . 6.8 mt -96.17 143.84 11.4 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.848 0 C-N-CA 120.707 -0.397 . . . . 0.0 110.486 -177.931 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 20.6 m -133.94 167.21 26.79 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 179.796 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' HIS . . . . . 0.448 ' HA ' ' O ' ' A' ' 88' ' ' LYS . 72.0 m-70 -106.95 115.02 29.46 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-O 121.053 0.454 . . . . 0.0 110.969 178.559 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.408 ' HB2' ' CD1' ' A' ' 90' ' ' TYR . 66.4 mm-40 -109.04 104.56 13.79 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 177.378 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 68.0 27.35 73.7 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.301 -0.952 . . . . 0.0 111.224 -178.428 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 95.1 -25.03 26.01 Favored Glycine 0 N--CA 1.443 -0.872 0 C-N-CA 121.41 -0.424 . . . . 0.0 112.73 -179.123 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' LYS . . . . . 0.448 ' O ' ' HA ' ' A' ' 84' ' ' HIS . 33.4 mmtp -85.93 149.68 25.03 Favored 'General case' 0 C--O 1.222 -0.368 0 CA-C-O 120.64 0.257 . . . . 0.0 110.618 -176.356 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.42 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -87.97 121.44 30.38 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-O 121.155 0.502 . . . . 0.0 112.108 -179.314 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.408 ' CD1' ' HB2' ' A' ' 85' ' ' GLU . 38.2 m-85 -119.19 141.95 48.42 Favored 'General case' 0 C--N 1.313 -1.02 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 176.691 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 32.9 m-70 -92.09 144.77 25.1 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-O 121.051 0.453 . . . . 0.0 111.376 -177.911 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.409 ' O ' ' HA ' ' A' ' 80' ' ' ASP . 97.9 t -118.04 117.9 56.4 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 176.046 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.6 p -125.83 137.92 56.16 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.847 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.259 -178.072 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 84.9 m -120.73 113.25 19.92 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 46.7 t60 -92.86 -19.2 21.93 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.921 -179.919 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -138.77 157.36 46.22 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.548 -178.025 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 35.7 mt-10 -77.68 135.79 38.12 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.871 176.812 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 130.03 168.37 12.28 Favored Glycine 0 C--N 1.313 -0.7 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.12 -178.102 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -85.0 135.33 5.49 Favored 'Trans proline' 0 N--CA 1.453 -0.872 0 C-N-CA 122.636 2.224 . . . . 0.0 112.613 178.845 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.412 ' O ' ' HB2' ' A' ' 109' ' ' TYR . 1.9 pp -138.76 157.07 72.5 Favored Pre-proline 0 C--N 1.321 -0.666 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.028 178.359 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.401 ' HG3' ' HD3' ' A' ' 134' ' ' PRO . 56.6 Cg_endo -68.06 171.17 12.93 Favored 'Trans proline' 0 C--N 1.348 0.523 0 C-N-CA 122.286 1.991 . . . . 0.0 112.081 -179.527 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 102' ' ' HIS . . . . . 0.416 ' HB3' ' O ' ' A' ' 105' ' ' ASN . 62.5 t-80 -92.34 132.62 31.6 Favored Pre-proline 0 C--N 1.314 -0.943 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -53.34 -49.52 17.15 Favored 'Trans proline' 0 CA--C 1.536 0.594 0 C-N-CA 122.957 2.438 . . . . 0.0 112.533 -177.874 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -63.33 -66.22 2.66 Favored Glycine 0 CA--C 1.526 0.721 0 C-N-CA 121.067 -0.587 . . . . 0.0 113.086 178.787 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.416 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 4.2 p30 -120.95 111.79 17.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.825 0.345 . . . . 0.0 111.63 -179.558 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.421 HG12 ' HB2' ' A' ' 131' ' ' LYS . 20.0 t -59.2 -14.6 5.6 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.904 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.529 177.345 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 22.5 t-80 -66.92 -5.52 12.94 Favored 'General case' 0 CA--C 1.543 0.686 0 CA-C-O 121.355 0.597 . . . . 0.0 110.694 177.739 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 7.5 mtmp? -135.04 156.17 49.49 Favored 'General case' 0 N--CA 1.439 -0.996 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 178.46 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' TYR . . . . . 0.412 ' HB2' ' O ' ' A' ' 100' ' ' ILE . 12.6 p90 -141.56 170.08 16.39 Favored 'General case' 0 C--N 1.306 -1.284 0 CA-C-O 120.689 0.281 . . . . 0.0 110.405 -178.968 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 3.3 mp -126.3 140.68 48.04 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 -179.675 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.422 ' O ' ' HA ' ' A' ' 121' ' ' ILE . 4.6 mp -97.9 117.69 43.12 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.031 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 176.076 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 34.7 m -104.38 123.69 47.86 Favored 'General case' 0 C--N 1.312 -1.022 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -178.957 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 14.3 p -135.87 147.86 48.39 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.55 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.577 ' HE2' ' O ' ' A' ' 116' ' ' GLY . 84.4 tttt -117.34 112.84 21.27 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-O 121.085 0.469 . . . . 0.0 110.552 -178.253 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 75.4 m -97.98 73.02 2.23 Favored 'General case' 0 C--N 1.31 -1.13 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.888 178.295 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.577 ' O ' ' HE2' ' A' ' 114' ' ' LYS . . . 80.97 -98.9 1.87 Allowed Glycine 0 N--CA 1.437 -1.256 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -178.822 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 50.2 m -114.54 5.39 15.49 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 120.856 0.36 . . . . 0.0 110.122 177.282 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 50.1 tp -114.85 121.34 42.94 Favored 'General case' 0 C--O 1.222 -0.383 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.49 -178.062 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 57.4 m95 -89.45 132.5 34.99 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 121.045 0.45 . . . . 0.0 111.932 179.504 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -110.6 126.31 54.32 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.884 175.096 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.476 ' O ' HD12 ' A' ' 121' ' ' ILE . 2.5 pp -126.28 150.62 32.0 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.129 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.709 -179.012 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 26.9 m -151.72 123.57 8.03 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.569 177.487 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 5.3 p -93.64 112.01 25.91 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.324 0 CA-C-O 121.58 0.705 . . . . 0.0 110.912 179.087 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 6.4 mmt -113.54 144.15 30.79 Favored Pre-proline 0 C--N 1.318 -0.792 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.399 -178.807 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -88.01 144.71 6.22 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 122.564 2.176 . . . . 0.0 112.648 178.666 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 126' ' ' CYS . . . . . 0.44 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 26.3 m -83.26 171.83 13.2 Favored 'General case' 0 C--O 1.244 0.779 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.069 176.066 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 35.7 t -61.15 151.77 30.35 Favored 'General case' 0 N--CA 1.445 -0.687 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 177.451 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 128' ' ' ILE . . . . . 0.43 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.8 mp -64.21 124.69 19.48 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.193 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.664 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 99.69 -12.96 61.18 Favored Glycine 0 N--CA 1.44 -1.042 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.439 -177.279 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 76.5 p -111.67 149.7 31.21 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-O 121.158 0.504 . . . . 0.0 111.784 179.782 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.421 ' HB2' HG12 ' A' ' 106' ' ' VAL . 58.8 pttt -121.37 144.71 48.51 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 178.869 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.44 ' HB2' ' SG ' ' A' ' 126' ' ' CYS . 45.0 t80 -82.53 136.15 34.93 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-O 121.178 0.513 . . . . 0.0 111.927 -177.497 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 133' ' ' ASP . . . . . 0.42 ' HB3' ' OG ' ' A' ' 136' ' ' SER . 19.8 t70 -105.16 130.2 23.51 Favored Pre-proline 0 C--N 1.321 -0.659 0 CA-C-N 115.945 -0.571 . . . . 0.0 109.786 177.366 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 134' ' ' PRO . . . . . 0.401 ' HD3' ' HG3' ' A' ' 101' ' ' PRO . 28.2 Cg_endo -64.68 -42.95 14.13 Favored 'Trans proline' 0 N--CA 1.473 0.317 0 C-N-CA 123.018 2.479 . . . . 0.0 114.236 -176.17 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 2.0 mp -77.61 -50.64 19.74 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 N-CA-C 111.943 0.349 . . . . 0.0 111.943 -175.752 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 136' ' ' SER . . . . . 0.42 ' OG ' ' HB3' ' A' ' 133' ' ' ASP . 64.1 p -70.44 -29.68 66.33 Favored 'General case' 0 C--N 1.325 -0.498 0 C-N-CA 121.037 -0.265 . . . . 0.0 111.184 -179.058 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 71.21 48.83 0.34 Allowed 'General case' 0 C--O 1.234 0.251 0 CA-C-N 115.813 -0.63 . . . . 0.0 111.783 175.331 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 -160.83 176.58 11.31 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 177.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 17.3 m -101.43 124.72 47.56 Favored 'General case' 0 C--N 1.313 -1.02 0 C-N-CA 120.414 -0.514 . . . . 0.0 109.969 -178.907 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 31.7 m -111.66 160.05 11.26 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.889 0 CA-C-N 116.062 -0.517 . . . . 0.0 109.802 -179.588 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 78.7 mt -63.22 132.94 53.36 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-O 121.1 0.476 . . . . 0.0 111.367 -179.037 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -97.61 91.09 5.25 Favored 'General case' 0 C--N 1.313 -1.001 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 177.493 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 . . . . . 0 C--N 1.304 -1.397 0 CA-C-O 118.295 -0.859 . . . . 0.0 109.537 -177.157 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.539 0 N-CA-C 111.889 -0.484 . . . . 0.0 111.889 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_exo -58.15 129.67 34.16 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.929 2.42 . . . . 0.0 112.286 179.428 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 4.8 mp -96.52 1.91 51.89 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.82 -179.113 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 101.62 -10.92 57.82 Favored Glycine 0 C--O 1.225 -0.448 0 C-N-CA 120.496 -0.859 . . . . 0.0 111.451 -179.128 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 6.3 m -75.33 -32.64 60.97 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.019 0.438 . . . . 0.0 110.701 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -151.9 98.93 2.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.573 -0.74 . . . . 0.0 109.538 -179.448 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.423 ' CD2' HD11 ' A' ' 121' ' ' ILE . 52.9 tp -111.57 135.78 51.67 Favored 'General case' 0 C--N 1.312 -1.043 0 C-N-CA 120.939 -0.305 . . . . 0.0 110.687 179.562 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.44 HG22 HG22 ' A' ' 89' ' ' THR . 3.8 mt -100.1 145.95 9.88 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.163 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 179.323 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.563 ' O ' ' HA ' ' A' ' 89' ' ' THR . 30.9 m -141.22 170.83 13.11 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 -179.822 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' HIS . . . . . 0.402 ' HA ' ' O ' ' A' ' 88' ' ' LYS . 50.3 m-70 -114.13 113.27 24.48 Favored 'General case' 0 C--N 1.316 -0.888 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 -179.085 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.409 ' OE1' ' HA ' ' A' ' 85' ' ' GLU . 4.3 mm-40 -112.31 111.84 23.0 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 174.839 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 71.76 13.22 75.02 Favored Glycine 0 N--CA 1.452 -0.235 0 N-CA-C 110.679 -0.968 . . . . 0.0 110.679 -176.633 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 99.76 -17.46 57.39 Favored Glycine 0 N--CA 1.437 -1.295 0 CA-C-N 114.999 -0.601 . . . . 0.0 111.905 -178.18 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' LYS . . . . . 0.402 ' O ' ' HA ' ' A' ' 84' ' ' HIS . 35.3 mmtp -87.16 143.05 27.47 Favored 'General case' 0 CA--C 1.515 -0.397 0 CA-C-O 120.712 0.292 . . . . 0.0 110.691 -177.728 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.563 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.1 OUTLIER -85.62 130.71 34.5 Favored 'General case' 0 N--CA 1.434 -1.234 0 N-CA-C 112.541 0.571 . . . . 0.0 112.541 -179.076 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.454 ' CD1' ' HA3' ' A' ' 104' ' ' GLY . 82.3 m-85 -128.58 138.68 52.34 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 115.608 -0.723 . . . . 0.0 109.854 176.76 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 17.6 m-70 -88.82 143.5 26.86 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 120.831 0.348 . . . . 0.0 110.668 -179.784 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 62.2 t -117.17 122.72 70.64 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.064 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 177.724 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 52.8 t -125.37 131.13 72.64 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.176 0 CA-C-N 116.079 -0.509 . . . . 0.0 109.671 -178.805 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 87.2 m -104.8 114.28 28.39 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-O 121.182 0.515 . . . . 0.0 109.892 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 26.5 m80 -84.25 -23.46 30.39 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.151 -177.71 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -160.67 176.58 11.38 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.692 -0.686 . . . . 0.0 109.389 -179.043 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -79.89 142.8 34.84 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.885 0.374 . . . . 0.0 110.217 178.291 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 130.71 167.77 12.08 Favored Glycine 0 N--CA 1.442 -0.955 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.405 -178.412 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.416 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 87.7 Cg_endo -89.59 133.13 2.17 Favored 'Trans proline' 0 N--CA 1.449 -1.116 0 C-N-CA 122.918 2.412 . . . . 0.0 112.93 179.415 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -138.04 157.31 73.25 Favored Pre-proline 0 C--N 1.318 -0.776 0 CA-C-N 115.71 -0.677 . . . . 0.0 109.463 177.891 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.484 ' HG3' ' HD3' ' A' ' 134' ' ' PRO . 59.4 Cg_endo -68.8 171.14 13.9 Favored 'Trans proline' 0 CA--C 1.515 -0.427 0 C-N-CA 122.234 1.956 . . . . 0.0 112.234 -178.021 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 102' ' ' HIS . . . . . 0.644 ' HB3' ' O ' ' A' ' 105' ' ' ASN . 50.2 t-80 -90.35 126.68 55.78 Favored Pre-proline 0 N--CA 1.43 -1.434 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 178.943 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -54.58 -43.74 56.14 Favored 'Trans proline' 0 N--CA 1.474 0.38 0 C-N-CA 122.959 2.439 . . . . 0.0 113.126 -174.03 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.454 ' HA3' ' CD1' ' A' ' 90' ' ' TYR . . . -96.68 4.54 63.76 Favored Glycine 0 N--CA 1.442 -0.951 0 C-N-CA 120.057 -1.068 . . . . 0.0 113.633 -178.452 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.644 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 52.2 t30 -163.84 87.3 0.51 Allowed 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 117.683 0.741 . . . . 0.0 111.17 -179.534 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.9 m -54.93 -11.95 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 N-CA-C 113.859 1.059 . . . . 0.0 113.859 178.177 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 19.1 t-80 -77.21 0.39 22.05 Favored 'General case' 0 CA--C 1.543 0.704 0 CA-C-O 121.413 0.625 . . . . 0.0 110.203 177.169 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 39.8 mttp -133.8 156.29 48.29 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.576 178.516 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 9.1 p90 -141.92 162.54 35.22 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 176.497 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.416 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.3 mp -123.83 140.03 48.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 -178.327 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -99.29 118.84 46.48 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 176.259 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 65.3 m -100.25 123.23 44.23 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 120.743 0.306 . . . . 0.0 110.571 -178.015 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 34.0 t -130.84 139.8 50.19 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.328 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.416 ' HD2' ' CZ2' ' A' ' 119' ' ' TRP . 88.6 tttt -113.92 113.63 25.11 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 120.999 0.428 . . . . 0.0 110.541 -178.707 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 73.4 m -100.52 80.72 2.24 Favored 'General case' 0 N--CA 1.441 -0.887 0 CA-C-O 121.356 0.598 . . . . 0.0 109.974 178.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 76.1 -99.62 1.3 Allowed Glycine 0 N--CA 1.442 -0.914 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.367 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 32.8 m -112.55 4.58 17.44 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.772 0.32 . . . . 0.0 110.59 -179.436 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 12.4 mt -122.77 133.28 54.47 Favored 'General case' 0 N--CA 1.439 -0.995 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.238 -176.998 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 119' ' ' TRP . . . . . 0.416 ' CZ2' ' HD2' ' A' ' 114' ' ' LYS . 70.7 m95 -96.04 133.5 40.22 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-O 121.076 0.465 . . . . 0.0 111.472 179.549 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -121.25 122.63 40.35 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 115.785 -0.643 . . . . 0.0 109.38 176.12 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.423 HD11 ' CD2' ' A' ' 81' ' ' LEU . 2.4 pp -122.5 156.22 27.59 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.86 -175.343 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 22.6 m -140.95 123.17 15.72 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.935 178.415 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 5.2 p -95.95 105.29 16.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-O 121.621 0.725 . . . . 0.0 110.841 -179.742 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 3.5 mmt -106.18 139.48 20.32 Favored Pre-proline 0 C--N 1.314 -0.973 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.139 -178.885 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -85.09 144.63 9.56 Favored 'Trans proline' 0 N--CA 1.448 -1.151 0 C-N-CA 122.2 1.934 . . . . 0.0 112.324 178.617 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 126' ' ' CYS . . . . . 0.537 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 65.7 m -80.61 164.24 23.04 Favored 'General case' 0 C--O 1.242 0.675 0 CA-C-N 116.247 -0.433 . . . . 0.0 109.857 176.987 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 32.3 t -56.29 148.36 18.8 Favored 'General case' 0 N--CA 1.443 -0.82 0 CA-C-N 116.056 -0.52 . . . . 0.0 109.66 177.082 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 128' ' ' ILE . . . . . 0.483 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.8 mp -62.97 128.92 25.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.333 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 96.37 -9.04 67.08 Favored Glycine 0 N--CA 1.443 -0.871 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.625 -177.028 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 72.1 p -118.46 153.88 33.39 Favored 'General case' 0 C--O 1.236 0.342 0 CA-C-N 117.292 0.546 . . . . 0.0 111.127 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.419 ' HE2' ' HA ' ' A' ' 142' ' ' ASP . 49.3 pttt -130.0 145.28 51.64 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 116.022 -0.535 . . . . 0.0 109.606 -179.248 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.537 ' HB2' ' SG ' ' A' ' 126' ' ' CYS . 29.4 t80 -84.46 136.88 33.65 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-O 121.088 0.471 . . . . 0.0 111.988 -176.329 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 32.2 t70 -108.56 134.78 20.15 Favored Pre-proline 0 C--N 1.323 -0.556 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.52 177.056 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 134' ' ' PRO . . . . . 0.484 ' HD3' ' HG3' ' A' ' 101' ' ' PRO . 42.0 Cg_endo -68.82 -37.36 11.87 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.577 2.185 . . . . 0.0 113.27 -176.045 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 22.7 mm -77.85 -53.55 14.08 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.881 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.827 -176.426 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 67.0 m -68.98 -29.98 68.3 Favored 'General case' 0 C--N 1.321 -0.662 0 C-N-CA 120.822 -0.351 . . . . 0.0 111.307 178.476 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 89.0 mtm180 70.76 41.57 0.88 Allowed 'General case' 0 N--CA 1.473 0.704 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.656 175.665 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -155.66 174.35 15.42 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 177.404 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 139' ' ' CYS . . . . . 0.442 ' HA ' ' HA ' ' A' ' 132' ' ' PHE . 6.4 m -101.26 124.88 47.64 Favored 'General case' 0 C--N 1.314 -0.943 0 C-N-CA 120.341 -0.544 . . . . 0.0 109.62 -179.28 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 33.9 m -107.01 159.8 6.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.833 -179.236 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 55.4 tp -63.47 119.82 10.5 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-O 120.972 0.415 . . . . 0.0 111.456 -178.781 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 142' ' ' ASP . . . . . 0.419 ' HA ' ' HE2' ' A' ' 131' ' ' LYS . 21.2 t70 -78.76 91.53 4.71 Favored 'General case' 0 N--CA 1.442 -0.85 0 CA-C-O 121.463 0.649 . . . . 0.0 109.309 176.653 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 65.5 t30 . . . . . 0 C--N 1.305 -1.326 0 CA-C-N 114.978 -1.01 . . . . 0.0 110.41 -177.22 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.314 0 N-CA-C 111.866 -0.494 . . . . 0.0 111.866 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -76.73 154.75 34.72 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 122.541 2.161 . . . . 0.0 111.577 178.569 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 89.3 mt -135.62 157.05 47.83 Favored 'General case' 0 C--N 1.316 -0.871 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.494 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -109.11 -48.58 0.82 Allowed Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.595 -178.258 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 22.7 t -61.71 -45.47 93.83 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 120.687 0.28 . . . . 0.0 110.648 -179.189 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.636 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 7.6 p-10 -155.43 114.93 3.64 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.352 0.596 . . . . 0.0 111.028 178.025 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 47.0 tp -97.04 140.47 31.51 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.417 177.833 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.591 HG22 HG22 ' A' ' 89' ' ' THR . 5.5 mt -100.26 145.95 9.97 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.996 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 179.745 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.473 ' O ' ' HA ' ' A' ' 89' ' ' THR . 17.1 m -142.87 176.01 3.76 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.88 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -179.611 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 41.7 m-70 -117.13 120.93 39.81 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-O 121.108 0.48 . . . . 0.0 111.9 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.433 ' HB2' ' CE1' ' A' ' 90' ' ' TYR . 45.2 mt-10 -126.17 116.09 20.79 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.264 176.51 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 67.16 23.76 73.17 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.624 -0.798 . . . . 0.0 111.232 -178.557 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 93.55 -28.0 11.0 Favored Glycine 0 N--CA 1.443 -0.858 0 C-N-CA 121.437 -0.411 . . . . 0.0 112.725 -178.282 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 44.3 mmtm -84.91 155.01 21.86 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.69 0.281 . . . . 0.0 111.136 -177.058 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.591 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -92.42 137.4 32.4 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.488 -179.949 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.433 ' CE1' ' HB2' ' A' ' 85' ' ' GLU . 89.7 m-85 -131.6 145.38 51.67 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 178.583 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 20.0 m-70 -98.88 143.6 29.01 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-O 120.951 0.405 . . . . 0.0 110.579 179.606 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.636 ' O ' ' HA ' ' A' ' 80' ' ' ASP . 57.2 t -113.93 118.55 58.68 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.161 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 177.109 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 37.3 t -121.15 137.54 54.52 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.242 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 -178.282 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 72.4 m -114.53 113.61 24.66 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-O 120.988 0.423 . . . . 0.0 111.13 -179.751 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 20.8 t60 -81.03 -24.14 38.1 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.769 -0.651 . . . . 0.0 111.076 -178.846 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -154.34 169.6 23.3 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.551 -0.295 . . . . 0.0 110.615 -178.281 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 21.0 mp0 -76.61 110.61 11.32 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.378 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 161.87 165.84 19.52 Favored Glycine 0 N--CA 1.446 -0.663 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.315 179.85 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.446 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 92.3 Cg_endo -85.75 135.11 4.81 Favored 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 122.907 2.404 . . . . 0.0 112.503 178.628 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -139.92 156.95 70.39 Favored Pre-proline 0 C--N 1.319 -0.724 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.525 179.394 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -63.51 169.21 10.1 Favored 'Trans proline' 0 C--N 1.353 0.775 0 C-N-CA 122.683 2.255 . . . . 0.0 112.54 -179.649 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' HIS . . . . . 0.474 ' CD2' HD11 ' A' ' 110' ' ' ILE . 5.2 t-80 -94.31 138.46 22.47 Favored Pre-proline 0 C--N 1.322 -0.602 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 -178.108 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -53.45 -50.2 14.72 Favored 'Trans proline' 0 CA--C 1.536 0.584 0 C-N-CA 123.109 2.539 . . . . 0.0 113.121 -178.624 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -71.1 -65.21 2.53 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.591 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 43.7 m-80 -115.06 104.94 12.38 Favored 'General case' 0 C--N 1.321 -0.658 0 O-C-N 122.865 -0.197 . . . . 0.0 111.365 -179.806 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 18.5 m -56.25 -12.04 0.99 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 N-CA-C 112.011 0.374 . . . . 0.0 112.011 173.976 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 24.3 t-80 -66.36 -8.26 24.28 Favored 'General case' 0 CA--C 1.544 0.719 0 CA-C-O 121.407 0.622 . . . . 0.0 110.076 175.58 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 48.4 mtmt -129.55 157.25 42.55 Favored 'General case' 0 N--CA 1.439 -1.001 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.623 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 12.9 p90 -142.14 167.38 22.26 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 120.181 -0.608 . . . . 0.0 111.133 -179.804 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.474 HD11 ' CD2' ' A' ' 102' ' ' HIS . 2.3 mp -126.43 139.4 51.78 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.112 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.173 -179.146 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.7 mp -98.74 116.45 41.73 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.144 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 175.336 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 39.9 m -95.99 121.82 38.14 Favored 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 16.6 t -130.36 149.4 52.06 Favored 'General case' 0 N--CA 1.437 -1.098 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.117 -178.624 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.508 ' HE3' ' CE2' ' A' ' 119' ' ' TRP . 9.1 mmtp -103.23 140.46 37.34 Favored 'General case' 0 C--N 1.308 -1.203 0 CA-C-O 121.224 0.535 . . . . 0.0 111.732 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 57.7 m -124.26 79.92 1.78 Allowed 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 174.207 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 73.39 -104.4 1.58 Allowed Glycine 0 N--CA 1.431 -1.68 0 CA-C-N 114.788 -1.096 . . . . 0.0 110.517 -174.851 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 12.1 p -113.01 16.39 19.35 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-O 120.899 0.38 . . . . 0.0 111.134 178.719 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 24.2 tp -122.14 142.92 49.89 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.289 -177.924 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 119' ' ' TRP . . . . . 0.508 ' CE2' ' HE3' ' A' ' 114' ' ' LYS . 91.1 m95 -92.15 133.39 35.82 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 120.984 0.421 . . . . 0.0 111.67 179.161 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 49.2 m-85 -124.19 122.81 38.81 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.123 172.3 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.5 pp -119.78 155.95 22.46 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.44 -176.949 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 25.7 m -141.06 119.74 12.49 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.655 178.353 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 4.2 p -94.02 109.06 21.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-O 121.684 0.754 . . . . 0.0 111.108 -179.138 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 5.3 mmt -107.82 127.4 27.79 Favored Pre-proline 0 C--N 1.309 -1.183 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.288 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -78.75 142.08 17.64 Favored 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 122.325 2.017 . . . . 0.0 110.819 176.21 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 10.4 t -93.62 -179.08 4.91 Favored 'General case' 0 C--N 1.317 -0.824 0 C-N-CA 120.484 -0.487 . . . . 0.0 110.382 179.745 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 34.0 t -62.94 146.51 52.86 Favored 'General case' 0 N--CA 1.438 -1.035 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.691 -179.472 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 128' ' ' ILE . . . . . 0.422 ' N ' HD12 ' A' ' 128' ' ' ILE . 2.0 mp -62.91 129.82 26.78 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-N 116.131 -0.486 . . . . 0.0 109.839 179.397 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.86 -4.04 68.05 Favored Glycine 0 N--CA 1.44 -1.099 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.949 -178.343 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 34.9 p -128.14 150.39 50.01 Favored 'General case' 0 C--O 1.237 0.447 0 CA-C-N 117.28 0.54 . . . . 0.0 110.885 178.896 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.421 ' O ' ' HA ' ' A' ' 139' ' ' CYS . 62.7 pttt -127.03 154.96 43.98 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.966 -179.616 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 40.3 t80 -87.18 136.87 32.76 Favored 'General case' 0 C--N 1.311 -1.078 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.109 -178.682 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -99.01 134.41 21.44 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.782 178.748 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 26.6 Cg_endo -62.04 -51.3 3.85 Favored 'Trans proline' 0 CA--C 1.532 0.39 0 C-N-CA 123.017 2.478 . . . . 0.0 114.116 -176.63 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 47.2 mm -81.23 -47.25 20.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 112.112 0.412 . . . . 0.0 112.112 -175.803 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.5 m -65.98 -34.46 78.15 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.833 0.349 . . . . 0.0 110.446 -179.228 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 87.7 mtm180 66.14 53.05 1.1 Allowed 'General case' 0 CA--C 1.516 -0.337 0 CA-C-N 115.404 -0.817 . . . . 0.0 110.554 177.757 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 28.2 p-10 -157.47 176.52 12.55 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.034 -0.985 . . . . 0.0 109.191 179.443 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 139' ' ' CYS . . . . . 0.421 ' HA ' ' O ' ' A' ' 131' ' ' LYS . 68.0 m -102.62 131.07 49.64 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-O 121.006 0.431 . . . . 0.0 111.91 178.628 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 33.8 m -125.55 165.85 22.42 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.216 177.288 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -50.26 118.18 2.82 Favored 'General case' 0 N--CA 1.474 0.739 0 CA-C-O 121.108 0.48 . . . . 0.0 111.644 179.809 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 15.3 t0 -84.98 90.77 7.9 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 177.35 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 52.5 t30 . . . . . 0 C--N 1.308 -1.212 0 CA-C-N 115.354 -0.839 . . . . 0.0 109.744 -177.622 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.34 0 N-CA-C 111.851 -0.5 . . . . 0.0 111.851 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_exo -65.34 108.47 1.18 Allowed 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 122.836 2.357 . . . . 0.0 111.863 -179.311 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.416 HD22 ' O ' ' A' ' 80' ' ' ASP . 65.6 mt -88.9 170.6 10.57 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-O 121.309 0.575 . . . . 0.0 111.88 -179.133 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 157.77 -42.61 0.51 Allowed Glycine 0 CA--C 1.499 -0.958 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 -178.578 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 17.2 m -75.43 -40.31 57.81 Favored 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 176.847 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.416 ' O ' HD22 ' A' ' 77' ' ' LEU . 11.0 t70 -136.21 86.4 2.22 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 177.848 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.461 HD22 ' CD1' ' A' ' 121' ' ' ILE . 23.9 tp -90.54 148.57 22.63 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-O 120.865 0.364 . . . . 0.0 110.978 -177.387 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.529 HG22 HG22 ' A' ' 89' ' ' THR . 7.7 mt -105.92 144.77 14.79 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 175.835 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.459 HG21 ' NE2' ' A' ' 102' ' ' HIS . 16.1 m -132.27 158.16 43.23 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 -178.473 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 6.8 p80 -116.49 101.98 9.1 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-O 121.226 0.536 . . . . 0.0 111.571 -177.721 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -117.27 114.09 23.11 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.12 179.116 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 67.05 22.58 72.48 Favored Glycine 0 CA--C 1.519 0.337 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.478 179.67 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 90.02 -4.71 83.23 Favored Glycine 0 N--CA 1.445 -0.707 0 C-N-CA 121.174 -0.536 . . . . 0.0 112.365 -179.686 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 35.0 mmtp -100.26 134.34 43.34 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 120.716 0.293 . . . . 0.0 110.349 -179.411 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.529 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -88.03 107.74 18.89 Favored 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.257 179.466 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -101.23 146.91 26.9 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.598 178.364 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 18.2 m-70 -98.22 140.04 33.1 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-O 120.881 0.372 . . . . 0.0 110.612 177.653 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 44.5 t -122.04 118.43 55.48 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.481 178.323 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.3 p -129.44 132.76 66.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.494 179.356 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 77.2 m -111.96 123.1 49.53 Favored 'General case' 0 C--N 1.308 -1.228 0 CA-C-O 121.059 0.457 . . . . 0.0 111.11 -178.47 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 34.2 m80 -100.7 -21.6 15.16 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 178.436 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -129.14 144.2 51.12 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.14 -0.937 . . . . 0.0 109.526 -178.83 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' GLU . . . . . 0.479 ' HG3' ' HA ' ' A' ' 113' ' ' SER . 42.3 tt0 -76.23 138.73 40.79 Favored 'General case' 0 N--CA 1.43 -1.432 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 177.883 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 132.17 173.86 13.45 Favored Glycine 0 N--CA 1.439 -1.107 0 C-N-CA 120.902 -0.666 . . . . 0.0 111.77 -178.21 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -87.36 134.07 3.39 Favored 'Trans proline' 0 N--CA 1.452 -0.961 0 C-N-CA 122.912 2.408 . . . . 0.0 112.951 179.142 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.8 pp -137.02 157.24 75.0 Favored Pre-proline 0 C--N 1.323 -0.544 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.899 178.43 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -65.34 162.58 32.89 Favored 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.41 2.073 . . . . 0.0 113.126 -177.794 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' HIS . . . . . 0.459 ' NE2' HG21 ' A' ' 83' ' ' VAL . 59.5 t-80 -91.78 120.93 67.83 Favored Pre-proline 0 C--N 1.316 -0.881 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.536 179.676 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_endo -60.72 -16.93 46.71 Favored 'Trans proline' 0 N--CA 1.482 0.841 0 C-N-CA 123.132 2.555 . . . . 0.0 113.466 -175.842 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -89.99 -24.09 30.73 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.556 -0.83 . . . . 0.0 112.563 179.874 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 25.7 p-10 -167.4 106.89 0.57 Allowed 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 110.108 -0.33 . . . . 0.0 110.108 -179.174 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 31.2 m -53.09 -11.32 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.045 0 N-CA-C 114.01 1.115 . . . . 0.0 114.01 -179.936 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -80.48 2.31 25.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.154 0.502 . . . . 0.0 110.935 178.49 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 34.1 mtmt -133.76 156.5 47.86 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 177.736 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 6.6 p90 -142.51 166.21 25.28 Favored 'General case' 0 C--N 1.311 -1.099 0 C-N-CA 120.871 -0.332 . . . . 0.0 110.476 179.331 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 3.7 mp -123.74 137.67 56.09 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.474 ' O ' ' HA ' ' A' ' 121' ' ' ILE . 4.2 mp -95.64 121.74 46.47 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.997 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 176.696 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 25.4 m -105.46 127.16 52.85 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 -178.859 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' SER . . . . . 0.479 ' HA ' ' HG3' ' A' ' 97' ' ' GLU . 52.5 m -126.52 131.79 51.51 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.402 179.251 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.632 ' HE2' ' O ' ' A' ' 116' ' ' GLY . 23.7 tptm -97.49 113.57 25.28 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 120.705 0.288 . . . . 0.0 110.659 -178.87 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 72.1 m -112.99 80.03 1.3 Allowed 'General case' 0 N--CA 1.442 -0.863 0 CA-C-O 121.265 0.555 . . . . 0.0 110.286 178.447 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.632 ' O ' ' HE2' ' A' ' 114' ' ' LYS . . . 74.35 -99.28 1.07 Allowed Glycine 0 N--CA 1.446 -0.679 0 CA-C-N 115.349 -0.841 . . . . 0.0 111.037 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 48.8 p -113.52 4.1 16.05 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 121.12 0.486 . . . . 0.0 110.433 178.065 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 26.8 tp -117.5 132.16 56.59 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.954 -175.479 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 119' ' ' TRP . . . . . 0.447 ' CE2' ' HD3' ' A' ' 114' ' ' LYS . 86.3 m95 -94.78 132.06 39.96 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 120.883 0.373 . . . . 0.0 110.746 177.116 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 51.0 m-85 -108.65 128.04 54.5 Favored 'General case' 0 C--N 1.309 -1.162 0 N-CA-C 108.876 -0.786 . . . . 0.0 108.876 174.156 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.474 ' HA ' ' O ' ' A' ' 111' ' ' ILE . 1.8 pp -133.2 153.4 37.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-O 121.367 0.603 . . . . 0.0 112.616 -175.695 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 19.4 m -150.44 127.58 11.24 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.188 178.074 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 4.0 p -98.77 106.74 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 CA-C-O 121.57 0.7 . . . . 0.0 111.061 -178.504 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 3.5 mmt -108.03 140.27 21.49 Favored Pre-proline 0 C--N 1.309 -1.166 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.654 -179.325 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_endo -82.48 141.47 11.23 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 122.386 2.058 . . . . 0.0 111.36 176.649 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 5.9 t -94.16 -174.87 3.51 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 120.648 -0.421 . . . . 0.0 110.667 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 15.5 m -61.53 137.16 58.23 Favored 'General case' 0 N--CA 1.441 -0.896 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.627 178.413 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 2.4 mp -65.84 139.35 21.41 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.914 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 178.33 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 93.55 -13.93 66.42 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.313 -176.03 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 73.6 p -117.41 159.53 22.64 Favored 'General case' 0 N--CA 1.447 -0.614 0 O-C-N 122.479 -0.424 . . . . 0.0 110.735 179.319 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 59.8 pttt -129.07 148.29 51.0 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.698 179.609 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.441 ' HD1' ' SG ' ' A' ' 139' ' ' CYS . 25.5 t80 -87.68 135.63 33.29 Favored 'General case' 0 C--N 1.308 -1.229 0 CA-C-O 120.825 0.345 . . . . 0.0 110.714 -178.58 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 30.5 t70 -102.47 134.99 19.64 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.015 178.706 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.23 -41.16 13.28 Favored 'Trans proline' 0 C--N 1.346 0.419 0 C-N-CA 123.021 2.481 . . . . 0.0 113.862 -176.963 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 33.1 mm -81.39 -52.69 13.57 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 C-N-CA 120.819 -0.353 . . . . 0.0 111.525 -176.934 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 7.2 m -62.69 -36.79 84.06 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 120.855 0.359 . . . . 0.0 110.394 179.153 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 80.5 mtm180 69.36 42.83 1.12 Allowed 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 115.356 -0.838 . . . . 0.0 111.157 177.24 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -154.39 177.57 11.01 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 108.393 -0.965 . . . . 0.0 108.393 177.197 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 139' ' ' CYS . . . . . 0.441 ' SG ' ' HD1' ' A' ' 132' ' ' PHE . 78.1 m -101.77 126.68 48.68 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-O 121.385 0.612 . . . . 0.0 111.737 -177.91 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 26.8 m -115.2 159.1 15.26 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-N 115.185 -0.916 . . . . 0.0 109.553 179.436 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 2.3 tm? -55.41 123.24 13.23 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 120.963 0.411 . . . . 0.0 110.915 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -89.17 101.42 14.08 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.045 -179.467 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 37.8 t30 . . . . . 0 C--O 1.251 1.171 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.619 177.58 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.349 0 N-CA-C 111.892 -0.483 . . . . 0.0 111.892 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -78.46 44.11 1.56 Allowed 'Trans proline' 0 C--N 1.348 0.53 0 C-N-CA 123.116 2.544 . . . . 0.0 112.416 -178.242 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 84.8 mt -89.54 -175.02 4.56 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.496 -179.089 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -119.74 -38.59 0.7 Allowed Glycine 0 N--CA 1.442 -0.901 0 C-N-CA 120.8 -0.714 . . . . 0.0 111.534 179.607 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 20.1 m -77.85 -32.15 51.9 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.893 0.378 . . . . 0.0 111.108 179.823 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -138.13 100.2 4.08 Favored 'General case' 0 C--O 1.237 0.396 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 -176.161 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.431 ' CD2' HD11 ' A' ' 121' ' ' ILE . 35.3 tp -101.26 147.14 26.64 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.244 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.548 HG22 HG22 ' A' ' 89' ' ' THR . 4.0 mt -110.24 148.29 13.88 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.869 0 C-N-CA 120.561 -0.455 . . . . 0.0 110.374 178.553 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.477 ' O ' ' HA ' ' A' ' 89' ' ' THR . 4.8 m -142.44 174.72 5.39 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 179.58 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 11.0 p80 -128.21 108.36 10.55 Favored 'General case' 0 C--N 1.313 -1.0 0 N-CA-C 112.503 0.557 . . . . 0.0 112.503 -177.751 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 3.9 mp0 -116.65 113.63 22.94 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.105 178.708 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 66.68 31.64 79.05 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.628 178.895 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 86.19 -11.75 62.15 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.839 -0.696 . . . . 0.0 113.201 179.243 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 30.2 mmtp -99.09 136.94 38.32 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.871 0.336 . . . . 0.0 111.166 -179.775 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.548 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -86.54 107.77 18.27 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.474 179.268 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -100.3 145.14 28.48 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.816 179.258 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 27.1 m-70 -99.43 144.09 28.94 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.36 178.355 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 46.2 t -120.51 118.38 56.39 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.078 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 178.452 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 44.1 t -124.56 132.6 71.1 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.274 179.478 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 71.3 m -104.43 113.77 27.55 Favored 'General case' 0 C--N 1.31 -1.141 0 CA-C-O 121.113 0.482 . . . . 0.0 110.305 -179.564 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 19.0 t60 -79.49 -21.2 45.66 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.509 -178.144 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -161.53 175.81 11.72 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.654 179.714 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -77.92 144.6 36.73 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 120.735 0.302 . . . . 0.0 110.461 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 126.45 164.41 11.74 Favored Glycine 0 N--CA 1.446 -0.658 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.41 -179.685 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.413 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 92.1 Cg_endo -86.78 138.28 5.09 Favored 'Trans proline' 0 CA--C 1.54 0.814 0 C-N-CA 122.869 2.379 . . . . 0.0 113.179 179.376 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -140.91 157.27 67.75 Favored Pre-proline 0 C--N 1.325 -0.482 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.169 177.829 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -64.22 166.94 15.54 Favored 'Trans proline' 0 C--N 1.353 0.763 0 C-N-CA 122.666 2.244 . . . . 0.0 112.848 -179.138 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' HIS . . . . . . . . . . . . . 56.5 t-80 -92.82 128.36 44.09 Favored Pre-proline 0 C--N 1.318 -0.769 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.592 -179.088 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -63.09 -19.25 68.46 Favored 'Trans proline' 0 N--CA 1.484 0.934 0 C-N-CA 123.146 2.564 . . . . 0.0 113.398 -176.841 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -96.81 -17.54 32.58 Favored Glycine 0 C--O 1.228 -0.275 0 C-N-CA 120.485 -0.865 . . . . 0.0 113.226 -178.846 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.404 HD21 ' HE2' ' A' ' 108' ' ' LYS . 28.2 p-10 -169.23 104.21 0.37 Allowed 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.698 0.285 . . . . 0.0 110.8 -179.36 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 26.0 m -53.82 -13.14 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 N-CA-C 113.935 1.087 . . . . 0.0 113.935 179.069 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 36.4 m170 -74.88 0.11 16.7 Favored 'General case' 0 N--CA 1.471 0.621 0 CA-C-O 121.081 0.467 . . . . 0.0 110.858 177.043 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.404 ' HE2' HD21 ' A' ' 105' ' ' ASN . 31.2 mtmt -134.91 156.69 48.52 Favored 'General case' 0 CA--C 1.507 -0.705 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 178.555 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 9.9 p90 -142.47 168.74 19.01 Favored 'General case' 0 C--N 1.31 -1.135 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.433 178.828 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.413 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.5 mp -126.2 140.02 49.89 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 -179.82 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -98.7 118.16 44.83 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 176.287 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 68.8 m -100.4 123.61 44.85 Favored 'General case' 0 C--N 1.308 -1.232 0 CA-C-O 120.873 0.368 . . . . 0.0 110.418 -178.462 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 56.0 p -131.87 141.19 49.32 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 178.42 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 81.2 tttt -116.52 106.24 13.36 Favored 'General case' 0 C--N 1.311 -1.087 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.621 -178.611 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 69.6 m -88.59 84.48 6.75 Favored 'General case' 0 N--CA 1.436 -1.154 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.52 179.094 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 73.98 -100.2 1.11 Allowed Glycine 0 N--CA 1.439 -1.103 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -178.153 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 50.3 m -115.04 3.62 14.49 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-O 121.203 0.525 . . . . 0.0 109.826 178.633 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 92.2 mt -108.54 122.82 47.85 Favored 'General case' 0 N--CA 1.435 -1.209 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.542 -176.248 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 86.6 m95 -87.65 130.51 34.76 Favored 'General case' 0 C--N 1.315 -0.903 0 C-N-CA 120.414 -0.514 . . . . 0.0 111.315 179.145 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 85.6 m-85 -122.61 125.73 46.25 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.585 174.133 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.431 HD11 ' CD2' ' A' ' 81' ' ' LEU . 2.2 pp -124.95 157.88 33.06 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.177 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.035 -178.918 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 32.7 m -145.32 121.66 10.93 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 116.148 -0.478 . . . . 0.0 109.718 177.178 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.5 p -93.81 106.41 18.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 CA-C-O 121.491 0.663 . . . . 0.0 110.775 -178.685 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 4.2 mmt -106.75 136.3 19.44 Favored Pre-proline 0 C--N 1.31 -1.111 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.97 -178.662 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -82.54 139.3 10.09 Favored 'Trans proline' 0 N--CA 1.45 -1.062 0 C-N-CA 122.411 2.074 . . . . 0.0 110.87 176.078 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 4.7 t -94.61 -178.62 4.61 Favored 'General case' 0 C--N 1.311 -1.071 0 C-N-CA 120.104 -0.639 . . . . 0.0 109.325 177.831 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 15.4 m -63.56 135.1 56.58 Favored 'General case' 0 N--CA 1.435 -1.204 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.408 179.756 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 128' ' ' ILE . . . . . 0.401 ' N ' HD12 ' A' ' 128' ' ' ILE . 2.2 mp -62.62 141.36 18.07 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 N-CA-C 109.014 -0.735 . . . . 0.0 109.014 178.264 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.8 -10.61 74.17 Favored Glycine 0 N--CA 1.441 -0.985 0 C-N-CA 120.285 -0.959 . . . . 0.0 112.551 -175.186 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 73.5 p -125.02 152.96 43.57 Favored 'General case' 0 N--CA 1.45 -0.438 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 177.003 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 60.5 pttt -126.85 146.69 50.18 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 110.327 -0.249 . . . . 0.0 110.327 -178.366 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 37.9 t80 -84.42 131.38 34.68 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.87 -178.998 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 23.1 t70 -97.41 133.84 23.32 Favored Pre-proline 0 C--N 1.321 -0.65 0 CA-C-N 116.068 -0.515 . . . . 0.0 109.907 179.29 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -68.02 -40.83 8.43 Favored 'Trans proline' 0 CA--C 1.531 0.371 0 C-N-CA 122.69 2.26 . . . . 0.0 113.842 -177.242 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.8 mp -80.3 -52.05 15.09 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 111.778 0.288 . . . . 0.0 111.778 -177.961 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 2.1 m -67.03 -35.11 79.17 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.079 0.466 . . . . 0.0 110.092 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 50.7 mtm180 66.37 56.22 0.8 Allowed 'General case' 0 C--O 1.238 0.464 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.645 178.402 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 29.4 p-10 -162.18 174.92 12.26 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 114.647 -1.16 . . . . 0.0 108.75 178.785 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 79.2 m -102.72 126.48 49.84 Favored 'General case' 0 C--N 1.311 -1.068 0 CA-C-O 121.023 0.44 . . . . 0.0 110.805 179.152 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 32.3 m -120.33 170.29 10.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.738 -0.664 . . . . 0.0 110.293 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -51.11 116.89 2.22 Favored 'General case' 0 C--O 1.241 0.615 0 O-C-N 123.545 0.528 . . . . 0.0 110.722 178.794 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -85.41 100.02 11.58 Favored 'General case' 0 CA--C 1.508 -0.669 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.606 179.766 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 9.9 p-10 . . . . . 0 C--N 1.3 -1.547 0 CA-C-O 118.417 -0.801 . . . . 0.0 109.497 174.719 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.974 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_endo -61.97 -31.46 84.27 Favored 'Trans proline' 0 C--N 1.347 0.45 0 C-N-CA 122.478 2.119 . . . . 0.0 111.648 178.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 96.1 mt -93.3 168.78 10.86 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.46 179.599 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 158.44 -29.35 0.45 Allowed Glycine 0 C--N 1.308 -1.002 0 N-CA-C 110.709 -0.956 . . . . 0.0 110.709 -179.367 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 58.7 m -75.44 -28.63 59.42 Favored 'General case' 0 C--O 1.241 0.657 0 CA-C-O 121.34 0.591 . . . . 0.0 109.429 177.864 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -148.75 129.52 14.19 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-N 115.045 -0.98 . . . . 0.0 110.012 178.775 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.453 HD23 HD11 ' A' ' 121' ' ' ILE . 49.4 tp -127.2 135.73 51.06 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 115.417 -0.811 . . . . 0.0 111.276 178.312 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.505 HG22 HG22 ' A' ' 89' ' ' THR . 22.1 mt -94.84 144.58 9.52 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.131 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 176.017 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.553 HG21 ' CE1' ' A' ' 102' ' ' HIS . 20.5 m -131.34 174.22 13.44 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 N-CA-C 109.997 -0.371 . . . . 0.0 109.997 -177.261 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 27.2 m-70 -122.07 101.92 7.83 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 116.528 -0.305 . . . . 0.0 110.93 -178.822 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 34.8 mm-40 -111.32 117.57 33.5 Favored 'General case' 0 C--N 1.32 -0.697 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 178.121 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 63.33 29.24 73.91 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.863 -0.684 . . . . 0.0 111.867 -179.427 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 84.96 -9.35 66.35 Favored Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 121.087 -0.578 . . . . 0.0 113.132 -179.79 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 13.6 mptt -100.57 141.58 33.23 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.993 0.425 . . . . 0.0 111.327 -179.359 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.505 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -82.97 122.24 28.03 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.67 179.47 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 76.1 m-85 -118.21 143.08 46.82 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 176.895 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 17.7 m-70 -94.46 139.59 30.94 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-O 120.65 0.262 . . . . 0.0 110.664 -178.275 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 60.4 t -119.46 118.14 56.36 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.88 0 N-CA-C 108.99 -0.745 . . . . 0.0 108.99 177.126 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 53.3 t -126.21 133.96 67.58 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.945 -178.741 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 66.6 m -114.64 121.25 42.83 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-O 120.779 0.323 . . . . 0.0 110.372 -178.819 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 39.1 m80 -90.23 -18.45 25.66 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.183 -179.811 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -150.11 170.05 19.82 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.648 -177.509 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -87.46 114.23 23.88 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.182 177.414 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 167.46 166.11 25.99 Favored Glycine 0 N--CA 1.436 -1.351 0 C-N-CA 121.049 -0.596 . . . . 0.0 111.624 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.501 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 87.6 Cg_endo -87.21 130.98 3.0 Favored 'Trans proline' 0 N--CA 1.45 -1.068 0 C-N-CA 122.761 2.307 . . . . 0.0 112.773 178.763 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.5 pp -140.94 156.74 68.41 Favored Pre-proline 0 C--N 1.319 -0.751 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.908 178.264 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -64.72 167.32 15.69 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 122.824 2.349 . . . . 0.0 113.163 -177.538 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' HIS . . . . . 0.553 ' CE1' HG21 ' A' ' 83' ' ' VAL . 4.9 t-80 -93.18 123.77 59.85 Favored Pre-proline 0 C--N 1.316 -0.87 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 -179.207 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 23.2 Cg_endo -58.64 -29.56 89.62 Favored 'Trans proline' 0 N--CA 1.482 0.817 0 C-N-CA 123.147 2.565 . . . . 0.0 114.155 -174.326 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -90.21 -16.08 56.29 Favored Glycine 0 C--N 1.319 -0.389 0 C-N-CA 120.085 -1.055 . . . . 0.0 113.238 -178.547 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 9.3 p-10 -168.07 97.47 0.44 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 120.773 0.321 . . . . 0.0 110.61 -177.122 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 30.5 m -56.07 -10.52 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 N-CA-C 113.768 1.025 . . . . 0.0 113.768 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 32.2 m170 -70.38 0.23 6.95 Favored 'General case' 0 N--CA 1.478 0.927 0 CA-C-O 121.352 0.596 . . . . 0.0 110.327 175.499 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.415 ' HG2' ' HA ' ' A' ' 125' ' ' PRO . 86.5 mttt -134.16 157.99 44.81 Favored 'General case' 0 CA--C 1.505 -0.758 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.021 178.91 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 12.3 p90 -143.44 165.83 26.45 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.391 176.616 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.501 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 2.3 mp -124.52 140.59 47.32 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.166 0 CA-C-O 120.798 0.333 . . . . 0.0 110.233 -178.758 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.4 mp -103.33 114.09 41.96 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 175.595 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 34.4 m -96.88 123.02 40.48 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -178.119 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 29.7 p -134.62 145.65 48.82 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-O 120.955 0.407 . . . . 0.0 111.087 -178.497 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' LYS . . . . . 0.534 ' HE2' ' O ' ' A' ' 116' ' ' GLY . 87.2 tttt -111.3 120.46 42.31 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-N 115.99 -0.55 . . . . 0.0 109.545 179.195 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 57.6 m -103.33 85.86 2.56 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.75 178.828 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.534 ' O ' ' HE2' ' A' ' 114' ' ' LYS . . . 66.91 -100.65 0.58 Allowed Glycine 0 N--CA 1.442 -0.958 0 CA-C-N 115.221 -0.899 . . . . 0.0 111.882 -178.58 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 15.1 m -110.3 6.58 22.56 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 120.741 0.305 . . . . 0.0 111.332 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -124.89 135.67 53.08 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 122.235 -0.291 . . . . 0.0 110.469 -178.768 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 52.6 m95 -94.65 135.79 35.71 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 120.945 0.402 . . . . 0.0 111.73 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -129.23 129.58 45.19 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.999 176.485 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.453 HD11 HD23 ' A' ' 81' ' ' LEU . 2.6 pp -123.86 147.63 28.21 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 120.82 0.343 . . . . 0.0 110.819 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 25.0 m -132.01 124.35 29.13 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.515 -179.326 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 4.4 p -98.25 108.71 22.46 Favored 'Isoleucine or valine' 0 C--O 1.236 0.373 0 CA-C-O 121.496 0.665 . . . . 0.0 110.813 179.38 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 5.5 mmt -107.33 129.95 23.54 Favored Pre-proline 0 C--N 1.307 -1.253 0 CA-C-N 115.424 -0.807 . . . . 0.0 110.658 -179.054 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 125' ' ' PRO . . . . . 0.415 ' HA ' ' HG2' ' A' ' 108' ' ' LYS . 74.5 Cg_endo -79.52 134.48 11.16 Favored 'Trans proline' 0 N--CA 1.452 -0.92 0 C-N-CA 122.244 1.963 . . . . 0.0 110.817 176.463 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 5.0 t -88.57 -177.51 5.6 Favored 'General case' 0 C--N 1.311 -1.095 0 C-N-CA 120.267 -0.573 . . . . 0.0 110.354 -179.075 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 4.9 m -63.41 147.61 50.77 Favored 'General case' 0 N--CA 1.441 -0.894 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.188 -179.838 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 128' ' ' ILE . . . . . 0.408 ' N ' HD12 ' A' ' 128' ' ' ILE . 2.1 mp -65.97 139.13 21.75 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.584 178.36 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 88.72 -12.21 66.26 Favored Glycine 0 N--CA 1.441 -1.018 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.556 -177.781 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 64.1 p -118.41 156.48 28.91 Favored 'General case' 0 N--CA 1.448 -0.547 0 CA-C-N 117.163 0.481 . . . . 0.0 110.847 178.73 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.456 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 62.1 pttt -133.28 152.16 51.92 Favored 'General case' 0 C--N 1.316 -0.886 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 20.8 t80 -86.1 136.16 33.33 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-O 121.004 0.431 . . . . 0.0 111.348 -179.062 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -101.48 134.64 20.13 Favored Pre-proline 0 C--N 1.325 -0.461 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.909 178.05 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -71.99 -33.06 10.26 Favored 'Trans proline' 0 CA--C 1.533 0.467 0 C-N-CA 122.65 2.233 . . . . 0.0 113.924 -177.258 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.7 mp -81.04 -55.12 8.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 111.697 0.258 . . . . 0.0 111.697 -177.737 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 49.9 m -72.84 -30.82 64.32 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.602 0.239 . . . . 0.0 111.073 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 68.54 50.32 0.7 Allowed 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.102 178.73 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 30.1 p-10 -151.96 176.43 11.49 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-N 115.262 -0.881 . . . . 0.0 108.954 178.855 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 139' ' ' CYS . . . . . 0.414 ' HA ' ' O ' ' A' ' 131' ' ' LYS . 85.5 m -102.36 126.18 49.3 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-O 121.037 0.446 . . . . 0.0 110.474 178.333 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.6 m -118.62 166.6 12.83 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.919 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.917 179.791 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -54.25 117.28 3.15 Favored 'General case' 0 CA--C 1.537 0.467 0 CA-C-O 121.003 0.43 . . . . 0.0 110.361 179.244 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 142' ' ' ASP . . . . . 0.456 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 18.9 t70 -81.63 91.94 6.49 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.449 -178.456 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 47.4 t30 . . . . . 0 C--O 1.244 0.801 0 CA-C-O 118.543 -0.742 . . . . 0.0 109.703 176.843 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.393 0 N-CA-C 111.829 -0.509 . . . . 0.0 111.829 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -69.36 125.06 11.89 Favored 'Trans proline' 0 C--O 1.236 0.381 0 C-N-CA 122.674 2.249 . . . . 0.0 112.068 -179.878 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -70.96 156.83 39.15 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.56 179.627 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -103.56 -48.13 1.23 Allowed Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 120.453 -0.88 . . . . 0.0 113.365 -176.768 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 25.0 t -59.33 -39.99 84.88 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.871 0.367 . . . . 0.0 110.669 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.523 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 4.8 p-10 -150.2 122.74 8.53 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-O 121.537 0.684 . . . . 0.0 111.255 178.973 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -98.19 127.55 44.19 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.068 -0.969 . . . . 0.0 108.45 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.464 ' CG2' HG22 ' A' ' 89' ' ' THR . 24.9 mt -90.5 145.09 7.84 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.958 0 CA-C-O 120.952 0.406 . . . . 0.0 111.247 -177.128 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.42 HG21 ' CE1' ' A' ' 102' ' ' HIS . 20.7 m -131.82 168.22 24.5 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.007 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 179.441 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 12.1 p80 -127.15 113.18 16.04 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-O 121.035 0.445 . . . . 0.0 111.601 -178.614 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 64.1 mm-40 -119.95 102.42 8.54 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.663 -179.47 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 65.29 40.16 96.41 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.934 -0.651 . . . . 0.0 112.589 178.734 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 84.66 -8.66 68.03 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.976 179.777 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 34.7 mmtp -100.69 128.68 46.65 Favored 'General case' 0 CA--C 1.511 -0.526 0 CA-C-O 120.95 0.405 . . . . 0.0 110.91 -178.972 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.464 HG22 ' CG2' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -86.4 127.31 34.81 Favored 'General case' 0 C--N 1.307 -1.281 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.102 178.607 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 88.0 m-85 -121.51 148.96 43.78 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.048 178.782 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 25.1 m-70 -102.4 143.24 32.39 Favored 'General case' 0 C--N 1.307 -1.249 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.049 179.217 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.523 ' O ' ' HA ' ' A' ' 80' ' ' ASP . 99.1 t -118.76 126.29 75.13 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.379 179.534 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.4 p -143.21 131.59 19.59 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.959 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.6 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 64.7 m -128.62 131.25 48.09 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 120.838 0.351 . . . . 0.0 110.858 179.804 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 28.5 m80 -105.02 -11.07 16.8 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.117 0.484 . . . . 0.0 109.961 179.71 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 6.9 mp0 -127.35 143.36 51.23 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.206 179.911 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -78.46 109.99 13.12 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-O 120.917 0.389 . . . . 0.0 110.896 -179.565 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 167.94 168.35 29.94 Favored Glycine 0 N--CA 1.434 -1.434 0 N-CA-C 111.566 -0.614 . . . . 0.0 111.566 -179.645 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.458 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 83.1 Cg_endo -87.12 137.75 4.58 Favored 'Trans proline' 0 N--CA 1.451 -1.016 0 C-N-CA 122.841 2.361 . . . . 0.0 112.559 178.447 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.8 pp -139.01 157.64 71.09 Favored Pre-proline 0 C--N 1.317 -0.812 0 CA-C-N 115.987 -0.551 . . . . 0.0 109.586 178.36 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -63.16 168.65 10.52 Favored 'Trans proline' 0 C--N 1.35 0.609 0 C-N-CA 122.471 2.114 . . . . 0.0 112.856 -178.175 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' HIS . . . . . 0.42 ' CE1' HG21 ' A' ' 83' ' ' VAL . 3.6 t-80 -92.87 122.95 62.78 Favored Pre-proline 0 C--N 1.315 -0.899 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 -179.617 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -59.83 -21.8 65.47 Favored 'Trans proline' 0 N--CA 1.483 0.888 0 C-N-CA 122.99 2.46 . . . . 0.0 113.786 -176.361 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -95.93 -16.57 38.18 Favored Glycine 0 CA--C 1.519 0.283 0 C-N-CA 120.165 -1.017 . . . . 0.0 113.216 -178.798 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 3.0 p30 -168.24 101.86 0.44 Allowed 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 122.596 0.358 . . . . 0.0 110.904 -178.736 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.602 HG12 ' HB2' ' A' ' 131' ' ' LYS . 6.0 t -53.23 -16.86 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.064 0 N-CA-C 113.596 0.962 . . . . 0.0 113.596 -179.584 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 8.5 m170 -72.88 5.48 3.22 Favored 'General case' 0 N--CA 1.479 0.999 0 O-C-N 121.936 -0.478 . . . . 0.0 111.39 177.732 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 46.4 mtmt -139.74 158.93 43.29 Favored 'General case' 0 N--CA 1.44 -0.958 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 178.773 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 6.5 p90 -142.87 173.73 11.28 Favored 'General case' 0 C--N 1.302 -1.463 0 CA-C-O 120.866 0.365 . . . . 0.0 110.849 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.458 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 4.1 mt -130.6 138.55 53.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.936 -179.156 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -102.31 117.45 47.69 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 176.334 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 74.0 m -107.46 123.7 48.79 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-O 121.231 0.539 . . . . 0.0 110.709 -177.905 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 13.9 t -131.05 148.44 52.74 Favored 'General case' 0 C--N 1.311 -1.107 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.53 -178.955 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 34.1 tttm -116.87 112.1 20.6 Favored 'General case' 0 N--CA 1.435 -1.191 0 CA-C-O 121.28 0.562 . . . . 0.0 110.624 -178.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 8.5 t -94.44 100.49 12.49 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 179.598 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 64.29 -104.63 0.93 Allowed Glycine 0 N--CA 1.439 -1.101 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -175.852 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 31.3 m -114.11 9.51 17.24 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 116.674 0.237 . . . . 0.0 111.624 178.798 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 6.9 tt -121.54 135.79 54.99 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.809 0.337 . . . . 0.0 110.636 -176.725 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 84.2 m95 -93.74 133.27 37.28 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.141 0.496 . . . . 0.0 112.295 -177.615 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -117.65 127.31 53.82 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.65 -0.704 . . . . 0.0 109.161 174.38 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.5 pp -123.41 146.72 28.34 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.944 0 CA-C-O 121.1 0.476 . . . . 0.0 111.22 -178.596 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 18.6 m -136.83 122.85 20.25 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.765 179.231 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 2.7 p -94.99 111.31 25.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 121.344 0.593 . . . . 0.0 110.782 179.279 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 5.3 mmt -112.25 151.23 43.54 Favored Pre-proline 0 C--N 1.314 -0.977 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.512 -178.844 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -89.18 143.84 4.82 Favored 'Trans proline' 0 N--CA 1.452 -0.913 0 C-N-CA 122.409 2.072 . . . . 0.0 112.414 177.9 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 126' ' ' CYS . . . . . 0.507 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 56.9 m -80.42 169.61 17.48 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.396 176.937 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 23.9 m -54.77 146.21 17.66 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.156 176.542 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 128' ' ' ILE . . . . . 0.447 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.8 mp -61.86 123.57 14.83 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.146 0 CA-C-O 121.026 0.441 . . . . 0.0 110.598 -178.712 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.02 5.48 62.47 Favored Glycine 0 N--CA 1.445 -0.706 0 CA-C-N 115.731 -0.668 . . . . 0.0 113.048 -177.873 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 48.2 p -121.14 167.34 12.76 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 117.117 0.458 . . . . 0.0 111.265 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.602 ' HB2' HG12 ' A' ' 106' ' ' VAL . 61.4 pttt -138.56 145.56 40.79 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 178.755 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.539 ' HD1' ' SG ' ' A' ' 139' ' ' CYS . 33.3 t80 -85.32 132.75 34.2 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 121.018 0.437 . . . . 0.0 111.995 -176.86 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -99.83 130.9 25.45 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.729 177.681 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_endo -62.78 -42.68 24.02 Favored 'Trans proline' 0 C--N 1.346 0.445 0 C-N-CA 123.087 2.525 . . . . 0.0 113.993 -176.06 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 35.5 mm -81.04 -48.73 18.94 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 C-N-CA 120.879 -0.328 . . . . 0.0 111.567 -176.668 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.6 m -63.69 -34.06 77.03 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.704 0.288 . . . . 0.0 110.705 179.248 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 79.5 mtm180 68.66 42.53 1.45 Allowed 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.454 177.6 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -157.27 171.35 20.57 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.301 -0.863 . . . . 0.0 108.766 176.706 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 139' ' ' CYS . . . . . 0.539 ' SG ' ' HD1' ' A' ' 132' ' ' PHE . 8.9 m -101.36 125.45 48.0 Favored 'General case' 0 C--N 1.318 -0.79 0 C-N-CA 120.696 -0.402 . . . . 0.0 110.405 -178.286 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.6 m -110.06 163.41 7.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.657 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 32.0 tp -59.74 119.98 8.66 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.799 0.333 . . . . 0.0 111.111 -178.758 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 142' ' ' ASP . . . . . 0.502 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 18.9 t70 -83.4 97.34 8.9 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.407 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 7.3 p30 . . . . . 0 C--N 1.317 -0.826 0 CA-C-O 118.229 -0.891 . . . . 0.0 110.77 -178.03 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.129 0 N-CA-C 111.676 -0.57 . . . . 0.0 111.676 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 20.6 Cg_exo -66.21 100.06 0.44 Allowed 'Trans proline' 0 C--O 1.237 0.454 0 C-N-CA 122.566 2.177 . . . . 0.0 111.861 178.503 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 38.8 tp -87.6 -17.12 32.66 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-O 121.418 0.628 . . . . 0.0 110.409 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.532 ' HA3' ' HB2' ' A' ' 119' ' ' TRP . . . 93.72 -19.98 49.66 Favored Glycine 0 N--CA 1.444 -0.785 0 CA-C-N 115.534 -0.757 . . . . 0.0 113.367 178.114 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 50.5 m -65.61 -32.87 74.68 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.871 0.367 . . . . 0.0 110.151 178.708 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.46 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 4.3 p-10 -164.44 113.21 1.13 Allowed 'General case' 0 N--CA 1.452 -0.332 0 CA-C-O 121.54 0.686 . . . . 0.0 109.658 174.428 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -103.44 133.97 47.59 Favored 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 -179.62 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.536 ' CG2' HG22 ' A' ' 89' ' ' THR . 20.9 mt -94.66 140.65 16.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-O 121.076 0.465 . . . . 0.0 111.223 -177.63 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.448 HG21 ' NE2' ' A' ' 102' ' ' HIS . 28.2 m -129.68 160.84 40.27 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.122 -179.182 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 84.3 m-70 -116.72 102.59 9.56 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.312 -179.446 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 53.6 mm-40 -109.81 104.76 13.77 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.258 -179.845 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 60.2 40.64 97.55 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.797 -179.786 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 81.75 -14.21 32.2 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 121.193 -0.527 . . . . 0.0 113.076 -178.737 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 35.5 mmtp -90.2 126.85 35.96 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 117.062 0.431 . . . . 0.0 110.838 -178.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.536 HG22 ' CG2' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -83.49 121.95 27.88 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.985 178.742 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 78.9 m-85 -117.78 154.4 31.8 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 116.241 -0.436 . . . . 0.0 109.977 177.943 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 28.3 m-70 -106.2 141.1 38.12 Favored 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 176.891 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' VAL . . . . . 0.46 ' O ' ' HA ' ' A' ' 80' ' ' ASP . 55.1 t -115.86 120.66 65.45 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 178.494 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 57.2 t -124.44 131.21 73.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 -178.733 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 81.5 m -113.66 112.56 23.69 Favored 'General case' 0 C--N 1.313 -1.019 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 179.373 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 27.9 t60 -91.77 -17.06 25.94 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.086 -178.924 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -137.12 150.84 48.24 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.769 -178.63 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -75.23 141.19 43.58 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.39 179.015 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 125.37 172.09 13.38 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.528 -0.844 . . . . 0.0 112.522 -179.616 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.419 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 86.2 Cg_endo -84.25 131.02 4.83 Favored 'Trans proline' 0 CA--C 1.537 0.666 0 C-N-CA 122.919 2.413 . . . . 0.0 112.857 178.757 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.9 pp -137.69 158.94 70.81 Favored Pre-proline 0 C--N 1.32 -0.68 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.395 178.367 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -64.66 168.96 12.19 Favored 'Trans proline' 0 C--N 1.351 0.686 0 C-N-CA 122.674 2.25 . . . . 0.0 112.821 -179.275 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' HIS . . . . . 0.493 ' HA ' HD11 ' A' ' 110' ' ' ILE . 8.5 t-80 -92.21 129.93 39.63 Favored Pre-proline 0 C--N 1.318 -0.804 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 -178.71 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_endo -53.45 -44.09 51.97 Favored 'Trans proline' 0 C--N 1.356 0.967 0 C-N-CA 123.164 2.576 . . . . 0.0 113.42 -175.907 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -71.02 -62.31 3.61 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.235 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.485 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 2.7 p30 -122.91 107.59 12.02 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-O 120.819 0.342 . . . . 0.0 111.382 -179.542 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 30.1 m -57.28 -10.18 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 113.064 0.765 . . . . 0.0 113.064 177.825 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 94.7 m-70 -74.13 3.74 6.63 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-O 121.505 0.669 . . . . 0.0 110.375 177.02 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 58.7 mttp -131.2 156.75 44.81 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 177.228 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 7.1 p90 -142.28 161.74 37.25 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 120.334 -0.546 . . . . 0.0 110.352 177.22 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.493 HD11 ' HA ' ' A' ' 102' ' ' HIS . 2.9 mp -123.47 141.31 44.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 -178.624 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.6 mp -97.45 112.48 29.6 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 175.371 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 42.0 m -97.93 122.04 40.58 Favored 'General case' 0 C--N 1.311 -1.081 0 CA-C-O 120.989 0.423 . . . . 0.0 110.675 -177.455 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 27.6 t -126.35 137.34 53.45 Favored 'General case' 0 N--CA 1.437 -1.116 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 178.898 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -108.49 122.15 46.44 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-O 120.817 0.342 . . . . 0.0 110.423 -179.143 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 43.1 m -116.42 105.82 12.93 Favored 'General case' 0 N--CA 1.434 -1.274 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.173 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 59.89 -110.9 3.12 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.343 -175.961 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 20.8 m -113.2 16.27 19.18 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.095 0.474 . . . . 0.0 110.144 179.143 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 6.0 mp -124.51 141.79 51.82 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.474 -177.168 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 119' ' ' TRP . . . . . 0.532 ' HB2' ' HA3' ' A' ' 78' ' ' GLY . 47.3 m95 -107.18 138.02 44.15 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-O 121.329 0.585 . . . . 0.0 111.61 179.513 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 78.7 m-85 -121.31 121.94 38.78 Favored 'General case' 0 C--N 1.309 -1.184 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.608 176.597 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.417 ' HB ' ' CG2' ' A' ' 110' ' ' ILE . 2.4 pp -123.28 159.25 27.75 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.755 -176.439 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 37.3 m -146.25 120.99 9.86 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.848 177.443 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 5.1 p -93.46 110.44 23.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 121.601 0.715 . . . . 0.0 111.22 -178.299 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 3.6 mmt -108.71 125.18 32.31 Favored Pre-proline 0 C--N 1.307 -1.248 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.111 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -75.14 135.43 18.83 Favored 'Trans proline' 0 N--CA 1.456 -0.726 0 C-N-CA 122.149 1.9 . . . . 0.0 111.288 178.419 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 6.2 t -90.71 -173.52 3.76 Favored 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 -179.573 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 46.8 m -64.69 137.66 57.94 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 120.928 0.395 . . . . 0.0 111.004 179.665 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 2.0 mp -60.5 134.56 25.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.819 178.609 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.2 -17.72 58.31 Favored Glycine 0 N--CA 1.444 -0.772 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.918 -177.007 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 77.0 p -109.72 158.18 18.36 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 117.456 0.628 . . . . 0.0 110.541 178.833 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 59.2 pttt -130.19 144.8 51.57 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.089 -179.041 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 39.9 t80 -83.71 134.52 34.75 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.849 -179.218 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -99.16 130.52 27.08 Favored Pre-proline 0 C--N 1.321 -0.647 0 CA-C-N 116.243 -0.435 . . . . 0.0 109.939 178.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -65.49 -43.98 9.5 Favored 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.792 2.328 . . . . 0.0 113.607 -176.579 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.8 mp -76.5 -50.48 21.77 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 116.632 -0.258 . . . . 0.0 111.605 -177.18 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.1 m -68.65 -33.2 73.59 Favored 'General case' 0 C--O 1.239 0.52 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.025 -179.022 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 89.3 mtm180 70.33 43.22 0.84 Allowed 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.067 177.771 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 26.0 p-10 -152.5 176.27 11.87 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 179.267 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 95.8 m -102.41 126.51 49.46 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 121.179 0.514 . . . . 0.0 111.315 179.411 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 27.0 m -114.88 159.94 14.5 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 CA-C-N 115.698 -0.683 . . . . 0.0 109.22 177.87 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 55.8 tp -63.65 135.5 56.8 Favored 'General case' 0 C--N 1.312 -1.045 0 CA-C-O 121.054 0.454 . . . . 0.0 111.364 -179.637 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -97.22 96.23 8.27 Favored 'General case' 0 CA--C 1.507 -0.688 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 177.709 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 60.7 t30 . . . . . 0 C--N 1.313 -0.999 0 CA-C-O 118.399 -0.81 . . . . 0.0 109.728 -179.297 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.371 0 N-CA-C 111.577 -0.609 . . . . 0.0 111.577 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -65.91 -47.29 3.84 Favored 'Trans proline' 0 C--N 1.346 0.428 0 C-N-CA 122.459 2.106 . . . . 0.0 112.343 -179.27 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 58.9 tp -94.92 123.8 38.6 Favored 'General case' 0 C--N 1.307 -1.241 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.19 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -107.8 40.93 2.35 Favored Glycine 0 N--CA 1.438 -1.213 0 N-CA-C 111.124 -0.79 . . . . 0.0 111.124 -179.904 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 23.3 t -75.96 -20.79 57.64 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 178.704 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -157.54 93.09 1.27 Allowed 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 114.539 -1.21 . . . . 0.0 108.554 178.375 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.507 ' HG ' ' CD1' ' A' ' 121' ' ' ILE . 3.1 tm? -101.93 130.33 48.42 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 -179.676 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.541 ' CG2' HG22 ' A' ' 89' ' ' THR . 23.3 mt -94.29 144.04 10.46 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 CA-C-O 120.742 0.306 . . . . 0.0 110.435 -178.439 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 29.8 m -134.78 165.63 30.7 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.9 0 CA-C-N 116.212 -0.449 . . . . 0.0 109.952 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 85.3 m-70 -114.93 121.82 44.38 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 179.452 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 3.8 tp10 -145.62 115.45 7.33 Favored 'General case' 0 C--N 1.318 -0.765 0 C-N-CA 120.693 -0.403 . . . . 0.0 111.008 -178.948 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 62.16 29.74 73.75 Favored Glycine 0 CA--C 1.518 0.274 0 CA-C-N 116.129 -0.487 . . . . 0.0 113.359 177.593 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 89.51 -5.94 83.52 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.351 179.087 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' LYS . . . . . 0.501 ' HB2' ' CE1' ' A' ' 90' ' ' TYR . 68.4 mmtt -102.16 153.07 20.29 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-O 120.593 0.235 . . . . 0.0 110.685 179.878 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.541 HG22 ' CG2' ' A' ' 82' ' ' ILE . 0.2 OUTLIER -106.82 106.75 17.42 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 177.024 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.501 ' CE1' ' HB2' ' A' ' 88' ' ' LYS . 96.1 m-85 -98.19 145.84 26.21 Favored 'General case' 0 C--N 1.313 -1.022 0 CA-C-O 120.983 0.421 . . . . 0.0 111.183 -177.035 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 31.1 m-70 -101.72 134.66 44.53 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 177.068 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 46.7 t -113.25 118.47 58.16 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 179.141 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 91.4 t -119.27 131.71 71.19 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.518 -179.045 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 73.8 m -114.76 113.18 23.92 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-O 120.994 0.426 . . . . 0.0 109.956 -179.579 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 67.9 t60 -93.2 -17.46 23.68 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.819 -178.758 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -145.24 158.58 43.79 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.887 -178.034 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -74.24 129.92 38.73 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.48 179.378 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 137.07 158.81 8.07 Favored Glycine 0 N--CA 1.44 -1.05 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.192 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.442 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 77.3 Cg_endo -78.02 140.1 17.75 Favored 'Trans proline' 0 CA--C 1.537 0.649 0 C-N-CA 122.791 2.327 . . . . 0.0 112.987 178.751 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.8 pp -138.02 157.7 72.56 Favored Pre-proline 0 C--N 1.32 -0.687 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.701 177.983 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -62.22 164.75 16.5 Favored 'Trans proline' 0 C--N 1.35 0.633 0 C-N-CA 122.4 2.067 . . . . 0.0 113.107 -178.409 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' HIS . . . . . 0.415 ' HA ' HD11 ' A' ' 110' ' ' ILE . 42.0 t-80 -89.66 120.1 69.51 Favored Pre-proline 0 C--N 1.319 -0.721 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.479 -179.087 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 14.1 Cg_endo -56.62 -21.97 41.43 Favored 'Trans proline' 0 N--CA 1.482 0.847 0 C-N-CA 123.08 2.52 . . . . 0.0 113.376 -176.816 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -89.33 -20.57 44.71 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.36 -0.924 . . . . 0.0 113.308 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 16.7 p30 -169.15 109.85 0.47 Allowed 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 122.69 0.396 . . . . 0.0 110.361 -179.134 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 34.8 m -57.17 -11.37 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.076 0 N-CA-C 113.833 1.049 . . . . 0.0 113.833 -179.629 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 42.5 m170 -76.29 3.71 10.32 Favored 'General case' 0 N--CA 1.475 0.786 0 CA-C-O 121.145 0.498 . . . . 0.0 111.266 177.556 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.402 ' HG2' ' HA ' ' A' ' 125' ' ' PRO . 42.2 mtmt -138.87 161.03 38.3 Favored 'General case' 0 CA--C 1.506 -0.72 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 178.634 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 9.3 p90 -143.83 172.31 13.02 Favored 'General case' 0 C--N 1.313 -0.988 0 C-N-CA 120.647 -0.421 . . . . 0.0 111.246 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.442 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.9 mp -129.3 140.64 48.64 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.965 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 178.652 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -96.44 122.08 47.59 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 176.872 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 57.9 m -106.0 125.23 50.75 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-O 120.679 0.276 . . . . 0.0 110.279 -178.405 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 19.8 m -130.83 139.7 50.2 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.253 179.044 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -112.12 104.37 12.6 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-O 120.994 0.426 . . . . 0.0 110.041 179.482 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 14.2 t -91.79 88.8 6.8 Favored 'General case' 0 C--N 1.309 -1.185 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 179.508 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 70.37 -100.79 0.83 Allowed Glycine 0 N--CA 1.443 -0.85 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 -177.581 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 50.6 m -114.58 5.62 15.52 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.895 0.379 . . . . 0.0 110.735 178.357 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 21.4 tp -116.68 129.53 56.19 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.622 -176.32 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 83.1 m95 -92.97 132.04 37.42 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -178.832 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 51.2 m-85 -113.06 137.27 51.67 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 115.457 -0.792 . . . . 0.0 109.422 175.942 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.507 ' CD1' ' HG ' ' A' ' 81' ' ' LEU . 2.1 pp -134.28 152.27 33.64 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.998 0 N-CA-C 112.364 0.505 . . . . 0.0 112.364 -176.576 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 25.7 m -151.35 122.14 7.53 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.293 176.909 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.406 ' HA ' ' HA ' ' A' ' 110' ' ' ILE . 3.8 p -95.07 112.91 28.37 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 CA-C-O 121.348 0.594 . . . . 0.0 111.305 -179.13 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 4.5 mmt -112.1 139.8 22.81 Favored Pre-proline 0 C--N 1.316 -0.867 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.621 -179.165 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 125' ' ' PRO . . . . . 0.402 ' HA ' ' HG2' ' A' ' 108' ' ' LYS . 91.6 Cg_endo -83.85 140.56 9.16 Favored 'Trans proline' 0 N--CA 1.452 -0.958 0 C-N-CA 122.408 2.072 . . . . 0.0 111.551 177.168 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 7.1 t -94.36 -179.19 4.83 Favored 'General case' 0 C--N 1.319 -0.75 0 C-N-CA 120.381 -0.527 . . . . 0.0 109.828 177.906 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 10.4 t -68.33 140.22 55.91 Favored 'General case' 0 N--CA 1.436 -1.129 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.238 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 2.1 mp -61.56 141.78 17.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 178.393 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.22 -19.85 51.07 Favored Glycine 0 N--CA 1.438 -1.229 0 C-N-CA 120.592 -0.813 . . . . 0.0 112.499 -176.865 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 68.8 p -114.76 154.72 28.02 Favored 'General case' 0 N--CA 1.448 -0.528 0 CA-C-N 117.261 0.53 . . . . 0.0 111.104 179.655 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 59.8 pttt -126.63 145.03 50.71 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.959 179.369 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -83.94 132.74 34.74 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-O 120.874 0.369 . . . . 0.0 110.963 -178.486 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -94.57 133.59 26.63 Favored Pre-proline 0 C--N 1.323 -0.576 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.418 179.576 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -67.77 -41.33 8.25 Favored 'Trans proline' 0 CA--C 1.535 0.57 0 C-N-CA 122.919 2.413 . . . . 0.0 114.512 -177.541 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.8 mp -82.5 -51.81 14.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 N-CA-C 111.82 0.304 . . . . 0.0 111.82 -177.029 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 4.2 m -69.24 -35.7 76.41 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.139 0.495 . . . . 0.0 110.194 -179.232 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 137' ' ' ARG . . . . . 0.439 ' HD2' ' HD2' ' A' ' 99' ' ' PRO . 56.1 mtm180 66.81 62.87 0.5 Allowed 'General case' 0 N--CA 1.452 -0.341 0 CA-C-N 115.274 -0.875 . . . . 0.0 111.528 178.458 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -165.42 173.16 11.37 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 114.559 -1.2 . . . . 0.0 108.118 176.717 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 88.9 m -100.49 126.5 46.92 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-O 121.083 0.468 . . . . 0.0 111.118 -179.177 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.8 m -113.13 158.3 13.54 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.804 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.279 178.341 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -61.31 117.38 5.56 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.796 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 35.3 t0 -78.59 92.11 4.67 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.473 -178.641 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 52.7 t-20 . . . . . 0 C--O 1.247 0.938 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 179.079 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.24 0 N-CA-C 112.186 -0.366 . . . . 0.0 112.186 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_exo -68.17 -34.23 22.64 Favored 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.453 2.102 . . . . 0.0 110.947 179.496 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 76.2 mt -123.49 151.8 42.39 Favored 'General case' 0 C--N 1.31 -1.115 0 CA-C-N 115.165 -0.925 . . . . 0.0 109.624 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -119.47 -37.16 0.8 Allowed Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 120.933 -0.651 . . . . 0.0 111.996 -179.735 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 34.1 m -60.41 -52.81 63.62 Favored 'General case' 0 C--O 1.236 0.392 0 CA-C-O 120.692 0.282 . . . . 0.0 111.15 179.174 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -153.78 121.53 5.96 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.44 0.638 . . . . 0.0 110.78 177.363 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.417 ' HG ' HD11 ' A' ' 121' ' ' ILE . 2.5 tm? -100.23 134.57 42.97 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.468 ' CG2' HG22 ' A' ' 89' ' ' THR . 20.8 mt -95.51 142.63 13.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-O 120.937 0.399 . . . . 0.0 110.897 -177.215 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.472 HG21 ' NE2' ' A' ' 102' ' ' HIS . 31.2 m -130.39 154.2 40.17 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.964 -179.358 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 42.6 m-70 -114.57 101.49 9.15 Favored 'General case' 0 C--N 1.311 -1.1 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.115 -178.942 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.466 ' HB2' ' CE1' ' A' ' 90' ' ' TYR . 50.2 mm-40 -105.86 110.42 22.7 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.052 178.119 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 64.73 30.54 78.21 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 121.148 -0.549 . . . . 0.0 111.951 -179.235 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 86.05 -9.3 69.92 Favored Glycine 0 N--CA 1.444 -0.771 0 C-N-CA 120.928 -0.654 . . . . 0.0 112.385 -179.299 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 1.3 mptm? -91.74 140.52 29.62 Favored 'General case' 0 CA--C 1.507 -0.698 0 CA-C-O 120.911 0.386 . . . . 0.0 110.463 -179.731 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.468 HG22 ' CG2' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -91.21 129.8 37.16 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.767 179.165 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.466 ' CE1' ' HB2' ' A' ' 85' ' ' GLU . 88.1 m-85 -127.3 148.28 50.23 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 177.887 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 40.1 m-70 -103.89 138.3 40.67 Favored 'General case' 0 C--N 1.305 -1.343 0 N-CA-C 110.059 -0.348 . . . . 0.0 110.059 178.473 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 58.3 t -111.23 122.75 66.24 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.217 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 178.446 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 38.3 t -126.04 132.18 70.89 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 -179.057 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 88.8 m -102.0 126.5 48.94 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.019 0.438 . . . . 0.0 111.033 -179.155 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 77.9 m-70 -90.12 -30.51 17.62 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.573 -179.083 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -151.88 172.95 15.4 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-N 115.747 -0.66 . . . . 0.0 109.886 -177.384 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 5.3 mp0 -74.81 137.13 41.7 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.138 178.143 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 124.57 158.83 10.19 Favored Glycine 0 N--CA 1.443 -0.889 0 C-N-CA 120.681 -0.771 . . . . 0.0 111.973 -179.597 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.445 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 78.1 Cg_endo -77.32 139.56 18.75 Favored 'Trans proline' 0 N--CA 1.46 -0.482 0 C-N-CA 122.613 2.209 . . . . 0.0 113.259 179.13 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.8 pp -137.36 158.13 72.82 Favored Pre-proline 0 C--N 1.319 -0.723 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.64 178.107 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -64.24 169.39 10.89 Favored 'Trans proline' 0 C--N 1.351 0.692 0 C-N-CA 122.593 2.195 . . . . 0.0 113.207 -177.784 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' HIS . . . . . 0.472 ' NE2' HG21 ' A' ' 83' ' ' VAL . 2.3 t-80 -88.73 128.49 52.3 Favored Pre-proline 0 C--N 1.317 -0.827 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 -179.613 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_endo -53.28 -42.5 64.74 Favored 'Trans proline' 0 C--N 1.351 0.699 0 C-N-CA 122.994 2.463 . . . . 0.0 113.032 -177.141 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -74.62 -61.74 3.05 Favored Glycine 0 C--N 1.316 -0.565 0 C-N-CA 120.713 -0.756 . . . . 0.0 113.002 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 105' ' ' ASN . . . . . 0.429 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 6.1 p-10 -125.03 107.95 11.33 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-O 120.973 0.416 . . . . 0.0 111.97 -176.757 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 8.5 p -56.65 -11.97 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.12 0 N-CA-C 113.607 0.965 . . . . 0.0 113.607 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 51.6 m170 -70.42 -4.19 21.31 Favored 'General case' 0 N--CA 1.474 0.748 0 CA-C-O 121.135 0.493 . . . . 0.0 111.055 178.502 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.423 ' O ' ' HB2' ' A' ' 102' ' ' HIS . 39.8 mtmt -135.2 159.91 40.04 Favored 'General case' 0 N--CA 1.44 -0.972 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 177.692 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 14.6 p90 -142.8 173.57 11.43 Favored 'General case' 0 C--N 1.307 -1.281 0 CA-C-N 116.577 -0.283 . . . . 0.0 110.78 -178.974 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.445 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 2.3 mp -130.19 140.33 49.17 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.166 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 178.753 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.431 HG13 ' HB3' ' A' ' 99' ' ' PRO . 4.9 mp -97.47 118.47 44.0 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 177.299 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 62.8 m -97.17 121.71 39.37 Favored 'General case' 0 N--CA 1.437 -1.102 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 17.3 m -124.11 136.85 54.51 Favored 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.706 -179.531 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 23.0 ttmt -112.02 109.41 19.14 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-O 121.157 0.504 . . . . 0.0 111.143 -179.488 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 15.8 t -92.28 88.89 6.62 Favored 'General case' 0 N--CA 1.43 -1.432 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 176.915 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 72.1 -99.87 0.9 Allowed Glycine 0 N--CA 1.437 -1.294 0 N-CA-C 110.705 -0.958 . . . . 0.0 110.705 -176.416 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 24.3 p -116.41 6.24 13.6 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-O 120.893 0.378 . . . . 0.0 111.298 177.824 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 53.6 tp -113.04 135.88 53.3 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.818 0.342 . . . . 0.0 111.255 -175.644 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 96.4 m95 -89.62 131.85 35.41 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 121.336 0.588 . . . . 0.0 112.466 -179.707 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 73.5 m-85 -119.34 124.19 46.02 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 170.423 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.417 HD11 ' HG ' ' A' ' 81' ' ' LEU . 2.0 pp -124.45 146.87 29.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 120.502 -0.479 . . . . 0.0 111.689 -176.828 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 20.2 m -137.06 122.63 19.69 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.375 178.81 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 4.0 p -93.39 113.72 28.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 121.346 0.593 . . . . 0.0 111.211 -179.385 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 3.6 mmt -117.23 151.44 47.82 Favored Pre-proline 0 C--N 1.322 -0.628 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.805 -179.088 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 90.7 Cg_endo -92.25 151.36 3.1 Favored 'Trans proline' 0 N--CA 1.448 -1.156 0 C-N-CA 122.399 2.066 . . . . 0.0 112.441 177.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 56.2 m -84.99 167.92 15.42 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 174.515 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 10.9 p -59.89 144.23 49.35 Favored 'General case' 0 N--CA 1.439 -0.996 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 176.998 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 128' ' ' ILE . . . . . 0.454 ' N ' HD12 ' A' ' 128' ' ' ILE . 2.0 mp -60.74 122.51 11.38 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 CA-C-O 121.175 0.512 . . . . 0.0 110.327 -178.186 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 103.26 1.91 47.86 Favored Glycine 0 N--CA 1.437 -1.248 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.995 -176.397 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 130' ' ' THR . . . . . 0.411 HG22 ' HA ' ' A' ' 141' ' ' LEU . 80.7 p -126.77 160.08 31.89 Favored 'General case' 0 CA--C 1.539 0.533 0 CA-C-N 117.456 0.628 . . . . 0.0 111.634 179.773 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 55.0 pttt -125.87 145.54 50.2 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.384 179.633 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.463 ' HD1' ' SG ' ' A' ' 139' ' ' CYS . 29.1 t80 -85.64 137.53 32.77 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-O 121.01 0.434 . . . . 0.0 111.556 -179.23 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -103.48 132.18 21.33 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.181 179.246 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -69.5 -45.06 1.89 Allowed 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 123.11 2.54 . . . . 0.0 114.393 -177.222 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 34.9 mm -74.7 -46.62 41.31 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 N-CA-C 112.035 0.383 . . . . 0.0 112.035 -176.326 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 39.5 t -75.63 -31.79 59.99 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-O 120.861 0.362 . . . . 0.0 110.146 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 137' ' ' ARG . . . . . 0.421 ' HB3' ' HG2' ' A' ' 99' ' ' PRO . 66.0 mtm180 66.42 62.02 0.56 Allowed 'General case' 0 N--CA 1.463 0.223 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.354 178.59 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 23.5 p-10 -165.31 172.45 12.31 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.175 -0.92 . . . . 0.0 109.082 179.603 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 139' ' ' CYS . . . . . 0.463 ' SG ' ' HD1' ' A' ' 132' ' ' PHE . 38.6 m -101.05 124.58 46.99 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 178.862 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 36.0 m -113.96 164.38 10.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.807 0 CA-C-N 115.883 -0.598 . . . . 0.0 109.759 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 141' ' ' LEU . . . . . 0.411 ' HA ' HG22 ' A' ' 130' ' ' THR . 34.2 tp -58.46 123.86 17.63 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-O 121.024 0.44 . . . . 0.0 111.75 -178.324 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 142' ' ' ASP . . . . . 0.409 ' H ' ' HA ' ' A' ' 130' ' ' THR . 18.0 t70 -93.37 98.18 11.06 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.879 -0.6 . . . . 0.0 109.642 178.104 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 48.5 t30 . . . . . 0 C--N 1.305 -1.367 0 CA-C-O 118.475 -0.774 . . . . 0.0 110.051 -178.758 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . 0.582 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 8.2 p-10 . . . . . 0 N--CA 1.448 -0.53 0 CA-C-O 121.362 0.601 . . . . 0.0 111.571 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.422 HD23 HD11 ' A' ' 121' ' ' ILE . 48.8 tp -102.79 145.47 29.7 Favored 'General case' 0 C--N 1.308 -1.236 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.148 176.472 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.457 ' CG2' HG22 ' A' ' 89' ' ' THR . 14.0 mt -97.54 143.96 11.75 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.111 0 C-N-CA 120.599 -0.44 . . . . 0.0 111.083 -178.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 30.7 m -135.75 174.37 12.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.828 -179.285 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' HIS . . . . . 0.429 ' CE1' HG23 ' A' ' 89' ' ' THR . 45.9 m-70 -122.89 115.88 22.69 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 120.967 0.413 . . . . 0.0 111.704 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 59.6 mm-40 -109.12 104.19 13.32 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.209 176.677 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 59.98 45.33 96.08 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.321 -0.942 . . . . 0.0 111.713 -178.755 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 85.4 -31.7 3.77 Favored Glycine 0 CA--C 1.524 0.619 0 C-N-CA 121.036 -0.602 . . . . 0.0 113.593 -179.143 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 14.2 mptt -82.07 141.77 32.88 Favored 'General case' 0 CA--C 1.51 -0.59 0 CA-C-N 117.373 0.587 . . . . 0.0 111.555 -176.126 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.457 HG22 ' CG2' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -84.63 134.19 34.39 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.908 179.856 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 63.9 m-85 -132.22 154.29 49.75 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.761 176.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 19.2 m-70 -102.42 144.8 30.42 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-O 120.823 0.344 . . . . 0.0 110.57 179.469 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.582 ' O ' ' HA ' ' A' ' 80' ' ' ASP . 93.7 t -120.06 117.87 55.03 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.19 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 177.547 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 3.3 p -124.6 138.8 52.81 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 CA-C-N 116.112 -0.495 . . . . 0.0 109.93 -178.52 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 92.3 m -110.94 123.92 51.1 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 120.895 0.379 . . . . 0.0 110.946 179.514 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 52.1 m80 -102.15 -22.35 14.22 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.376 -179.766 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -141.03 152.47 44.89 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.478 -178.804 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -76.23 106.35 7.79 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.659 -0.701 . . . . 0.0 110.508 177.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 156.24 169.51 20.46 Favored Glycine 0 N--CA 1.434 -1.474 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 -179.581 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_endo -78.53 132.91 11.35 Favored 'Trans proline' 0 N--CA 1.456 -0.691 0 C-N-CA 122.406 2.071 . . . . 0.0 112.394 178.62 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 2.0 pp -137.12 157.82 73.75 Favored Pre-proline 0 C--N 1.319 -0.726 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.517 178.21 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -69.51 171.86 13.43 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.271 1.981 . . . . 0.0 112.492 -178.29 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' HIS . . . . . 0.585 ' HB3' ' O ' ' A' ' 105' ' ' ASN . 30.3 t-80 -89.85 128.1 51.48 Favored Pre-proline 0 C--N 1.309 -1.177 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 179.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -50.52 -54.91 4.67 Favored 'Trans proline' 0 N--CA 1.477 0.524 0 C-N-CA 122.932 2.421 . . . . 0.0 112.604 -176.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -63.17 -62.2 5.65 Favored Glycine 0 CA--C 1.526 0.776 0 CA-C-N 115.813 -0.63 . . . . 0.0 113.15 178.237 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.585 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 9.9 p-10 -122.8 103.22 8.5 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 -177.004 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 31.1 m -58.29 -10.67 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.089 0 N-CA-C 114.0 1.111 . . . . 0.0 114.0 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 14.0 t-80 -66.27 -10.39 41.93 Favored 'General case' 0 N--CA 1.47 0.56 0 CA-C-O 121.451 0.643 . . . . 0.0 110.299 176.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.404 ' HE2' HD21 ' A' ' 105' ' ' ASN . 44.7 mtmt -126.55 158.69 35.53 Favored 'General case' 0 N--CA 1.434 -1.237 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 178.196 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 7.7 p90 -141.72 165.49 27.34 Favored 'General case' 0 C--N 1.302 -1.492 0 C-N-CA 120.642 -0.423 . . . . 0.0 110.517 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.405 HG12 HG11 ' A' ' 92' ' ' VAL . 3.9 mp -123.32 139.81 48.84 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 -179.062 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.411 ' N ' HD12 ' A' ' 111' ' ' ILE . 4.3 mp -99.98 118.09 46.12 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.179 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 177.502 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 23.5 m -101.78 122.72 44.48 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.222 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 49.1 m -131.7 146.73 52.33 Favored 'General case' 0 C--N 1.312 -1.064 0 CA-C-O 121.074 0.464 . . . . 0.0 111.44 -177.752 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 5.0 tppp? -97.28 139.6 33.0 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.527 179.312 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 68.2 m -128.71 85.78 2.37 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 174.474 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 72.68 -104.53 1.55 Allowed Glycine 0 N--CA 1.437 -1.296 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 -174.55 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 50.6 m -115.07 11.81 16.5 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-O 120.779 0.323 . . . . 0.0 110.885 175.17 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 34.0 tp -111.36 143.39 42.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.672 -0.24 . . . . 0.0 110.627 -177.367 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 54.0 m95 -100.23 133.14 45.08 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.034 0.445 . . . . 0.0 112.128 179.198 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -119.53 132.35 55.74 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.647 -0.706 . . . . 0.0 109.463 174.044 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.422 HD11 HD23 ' A' ' 81' ' ' LEU . 1.9 pp -123.72 149.89 27.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-O 120.78 0.324 . . . . 0.0 111.074 -179.1 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 28.4 m -146.06 122.93 11.3 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.152 178.312 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.6 p -95.93 111.13 25.65 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.417 0 CA-C-O 121.363 0.601 . . . . 0.0 111.34 -178.333 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 5.5 mmt -114.36 142.59 28.33 Favored Pre-proline 0 C--N 1.318 -0.762 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.525 -179.314 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -86.5 143.11 7.32 Favored 'Trans proline' 0 N--CA 1.449 -1.092 0 C-N-CA 122.378 2.052 . . . . 0.0 111.641 176.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 4.9 t -92.98 -179.6 5.16 Favored 'General case' 0 C--N 1.319 -0.756 0 C-N-CA 120.541 -0.463 . . . . 0.0 109.91 178.228 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 34.3 m -65.32 144.53 57.06 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-O 120.881 0.372 . . . . 0.0 110.579 -178.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . 0.426 ' N ' HD12 ' A' ' 128' ' ' ILE . 2.8 mp -68.04 132.33 32.75 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.786 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 103.68 -18.45 47.28 Favored Glycine 0 N--CA 1.439 -1.11 0 CA-C-N 115.797 -0.638 . . . . 0.0 112.019 -176.141 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 40.3 p -116.76 158.53 23.73 Favored 'General case' 0 N--CA 1.445 -0.713 0 O-C-N 122.67 -0.312 . . . . 0.0 110.854 179.02 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.4 ' HE2' ' HA ' ' A' ' 142' ' ' ASP . 49.9 pttt -132.17 148.64 52.48 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 116.146 -0.479 . . . . 0.0 109.863 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 23.4 t80 -86.4 139.67 30.72 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-O 121.015 0.436 . . . . 0.0 111.691 -177.319 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -107.6 136.58 19.62 Favored Pre-proline 0 N--CA 1.469 0.502 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.784 177.345 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -68.11 -44.7 3.51 Favored 'Trans proline' 0 C--N 1.347 0.468 0 C-N-CA 122.948 2.432 . . . . 0.0 114.285 -176.464 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 39.5 mm -78.55 -46.34 24.99 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 CA-C-O 120.823 0.344 . . . . 0.0 111.715 -176.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.7 m -69.06 -34.89 75.9 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 120.909 0.385 . . . . 0.0 110.199 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 81.8 mtt-85 69.01 41.34 1.45 Allowed 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.144 177.479 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -152.54 176.28 11.87 Favored 'General case' 0 C--N 1.316 -0.863 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 178.49 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 87.8 m -100.93 126.82 47.58 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 120.888 0.375 . . . . 0.0 110.538 -179.825 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.2 m -109.41 157.78 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.018 0 CA-C-N 115.811 -0.632 . . . . 0.0 109.824 179.584 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 58.5 tp -69.55 115.58 8.97 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-O 120.94 0.4 . . . . 0.0 111.138 -179.374 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' ASP . . . . . 0.4 ' HA ' ' HE2' ' A' ' 131' ' ' LYS . 30.9 t70 . . . . . 0 C--N 1.321 -0.673 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.619 177.215 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 22.1 t70 . . . . . 0 CA--C 1.52 -0.199 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.526 HD23 HD11 ' A' ' 121' ' ' ILE . 39.4 tp -117.53 132.63 56.5 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.13 176.254 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.473 HG22 HG22 ' A' ' 89' ' ' THR . 10.4 mt -98.73 144.41 11.72 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.09 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 178.734 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 19.1 m -136.88 162.86 33.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-O 120.765 0.317 . . . . 0.0 110.296 -177.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 12.7 m-70 -94.34 115.32 27.52 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.334 178.229 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -128.8 106.65 9.07 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 -178.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 67.18 29.89 74.96 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 110.794 -0.923 . . . . 0.0 110.794 -177.092 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 85.29 -22.95 8.94 Favored Glycine 0 N--CA 1.443 -0.892 0 CA-C-N 115.318 -0.441 . . . . 0.0 112.672 -178.357 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 75.1 mmtt -91.85 146.59 23.63 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.843 0.354 . . . . 0.0 111.14 -177.69 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.473 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -82.22 125.98 31.56 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.601 179.602 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -124.48 143.36 50.69 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 176.823 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 22.0 m-70 -90.05 146.6 24.21 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-O 121.097 0.475 . . . . 0.0 111.465 -178.553 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 49.5 t -120.44 119.0 58.52 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 175.562 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 58.0 t -130.4 135.64 60.2 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.256 0 CA-C-N 116.141 -0.481 . . . . 0.0 109.972 -177.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 91.5 m -119.11 113.3 20.7 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.03 0.443 . . . . 0.0 110.645 178.68 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 43.0 t-80 -91.89 -22.07 20.27 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.223 179.823 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 -146.58 157.82 43.79 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.769 -176.755 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -79.18 145.66 33.54 Favored 'General case' 0 C--N 1.312 -1.032 0 CA-C-O 120.955 0.407 . . . . 0.0 110.962 -177.222 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 125.39 163.65 11.66 Favored Glycine 0 N--CA 1.437 -1.261 0 C-N-CA 120.976 -0.63 . . . . 0.0 111.926 -178.441 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.415 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 84.4 Cg_endo -84.4 135.19 6.03 Favored 'Trans proline' 0 CA--C 1.538 0.7 0 C-N-CA 122.721 2.28 . . . . 0.0 112.997 179.168 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -142.28 154.96 64.76 Favored Pre-proline 0 C--O 1.216 -0.707 0 CA-C-N 115.76 -0.654 . . . . 0.0 109.724 177.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -67.85 169.29 16.53 Favored 'Trans proline' 0 C--N 1.348 0.54 0 C-N-CA 122.349 2.033 . . . . 0.0 112.365 -178.537 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' HIS . . . . . 0.41 ' CD2' HD11 ' A' ' 110' ' ' ILE . 12.1 t-80 -85.54 135.5 38.37 Favored Pre-proline 0 C--N 1.319 -0.719 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -178.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -57.8 -25.33 68.34 Favored 'Trans proline' 0 C--N 1.353 0.779 0 C-N-CA 122.93 2.42 . . . . 0.0 112.028 -179.368 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -84.35 -65.86 1.5 Allowed Glycine 0 N--CA 1.441 -0.971 0 CA-C-N 115.522 -0.763 . . . . 0.0 111.765 178.212 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.431 ' OD1' ' HE2' ' A' ' 108' ' ' LYS . 36.8 p-10 -124.37 114.02 18.97 Favored 'General case' 0 CA--C 1.543 0.693 0 CA-C-O 121.364 0.602 . . . . 0.0 111.878 -179.616 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 15.9 m -58.76 -10.63 1.58 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 N-CA-C 112.854 0.687 . . . . 0.0 112.854 177.284 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 35.5 m80 -68.22 -7.17 28.1 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 121.06 0.457 . . . . 0.0 110.362 176.44 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.444 ' HG2' ' HA ' ' A' ' 125' ' ' PRO . 47.4 mtmt -131.5 157.07 44.51 Favored 'General case' 0 CA--C 1.5 -0.953 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.465 179.045 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 8.5 p90 -142.15 161.73 37.26 Favored 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 120.773 -0.371 . . . . 0.0 110.71 179.436 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.415 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.2 mp -119.78 137.22 54.37 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 -179.505 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -96.71 116.85 39.91 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.359 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 175.551 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 56.2 m -95.77 122.13 38.23 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 109.333 -0.618 . . . . 0.0 109.333 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 49.6 m -122.56 127.56 49.61 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.314 -179.733 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 85.4 tttt -100.29 116.22 31.77 Favored 'General case' 0 N--CA 1.432 -1.366 0 CA-C-O 121.118 0.485 . . . . 0.0 109.926 178.735 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 53.7 m -106.18 83.57 1.91 Allowed 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.581 179.149 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 67.77 -100.24 0.6 Allowed Glycine 0 N--CA 1.44 -1.082 0 CA-C-N 115.521 -0.763 . . . . 0.0 111.593 -178.348 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 16.2 m -111.52 5.73 19.68 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-O 120.828 0.347 . . . . 0.0 110.46 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 22.8 tp -118.51 134.49 55.04 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.092 -177.643 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 77.4 m95 -97.3 132.76 42.72 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-O 121.105 0.479 . . . . 0.0 111.978 178.654 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 51.5 m-85 -115.95 130.21 56.72 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.828 174.879 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.526 HD11 HD23 ' A' ' 81' ' ' LEU . 2.2 pp -119.87 148.98 22.6 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-O 121.172 0.511 . . . . 0.0 110.786 179.646 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 16.5 m -142.99 114.05 7.72 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.7 178.007 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.9 p -96.04 103.72 15.01 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-O 121.747 0.784 . . . . 0.0 111.06 -177.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 3.7 mmt -107.37 137.65 19.69 Favored Pre-proline 0 C--N 1.313 -1.02 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.922 -178.462 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . 0.444 ' HA ' ' HG2' ' A' ' 108' ' ' LYS . 72.9 Cg_endo -80.72 142.79 14.46 Favored 'Trans proline' 0 N--CA 1.448 -1.199 0 C-N-CA 122.142 1.894 . . . . 0.0 111.315 176.543 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 9.6 t -91.97 -178.24 4.95 Favored 'General case' 0 C--N 1.313 -1.021 0 C-N-CA 120.393 -0.523 . . . . 0.0 109.779 178.03 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 7.6 t -61.3 138.64 58.24 Favored 'General case' 0 N--CA 1.434 -1.23 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.016 179.396 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . 0.407 ' N ' HD12 ' A' ' 128' ' ' ILE . 2.7 mp -64.24 138.75 22.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 178.384 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 92.89 -12.74 69.26 Favored Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 120.421 -0.895 . . . . 0.0 112.606 -175.779 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 63.9 p -120.45 161.43 21.26 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 117.045 0.422 . . . . 0.0 110.696 178.424 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.483 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 58.9 pttt -133.57 146.62 51.16 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 116.338 -0.392 . . . . 0.0 109.985 179.476 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 31.4 t80 -85.9 136.62 33.22 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.688 -178.375 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -97.68 136.04 21.38 Favored Pre-proline 0 C--N 1.319 -0.741 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.569 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -68.48 -46.33 2.02 Favored 'Trans proline' 0 C--N 1.346 0.447 0 C-N-CA 122.684 2.256 . . . . 0.0 113.591 -178.66 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.9 mp -77.56 -54.27 12.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 111.706 0.261 . . . . 0.0 111.706 -177.779 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 21.5 m -68.02 -32.32 72.61 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 120.645 0.26 . . . . 0.0 110.916 -178.621 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' ARG . . . . . 0.403 ' HD3' ' HD2' ' A' ' 99' ' ' PRO . 98.4 mtt180 66.47 48.55 1.51 Allowed 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 121.411 0.624 . . . . 0.0 111.29 177.62 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 23.9 p-10 -151.42 172.9 15.23 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 115.254 -0.884 . . . . 0.0 108.762 177.731 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 67.9 m -101.82 126.94 48.8 Favored 'General case' 0 C--N 1.308 -1.208 0 CA-C-O 121.222 0.534 . . . . 0.0 111.154 179.041 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 35.1 m -116.46 161.35 15.27 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-N 115.43 -0.805 . . . . 0.0 108.941 178.053 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 45.2 tp -54.03 125.79 20.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.054 0.454 . . . . 0.0 110.113 178.6 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' ASP . . . . . 0.483 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 9.8 t70 . . . . . 0 C--N 1.316 -0.85 0 CA-C-N 115.999 -0.546 . . . . 0.0 112.289 -175.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 24.9 t70 . . . . . 0 CA--C 1.512 -0.498 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.415 HD23 HD11 ' A' ' 121' ' ' ILE . 45.7 tp -109.9 135.39 50.85 Favored 'General case' 0 C--N 1.31 -1.152 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 177.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.605 HG22 HG22 ' A' ' 89' ' ' THR . 11.5 mt -96.82 142.55 13.85 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 C-N-CA 120.57 -0.452 . . . . 0.0 110.391 179.658 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.405 HG21 ' CE1' ' A' ' 102' ' ' HIS . 22.9 m -139.35 178.27 3.92 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 -178.106 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' HIS . . . . . 0.478 ' HA ' ' O ' ' A' ' 88' ' ' LYS . 66.3 m-70 -117.99 124.61 48.6 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-O 121.253 0.549 . . . . 0.0 111.868 179.49 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 -114.62 103.91 11.47 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.062 -0.972 . . . . 0.0 108.967 177.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 67.73 18.36 70.18 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.607 -0.806 . . . . 0.0 111.329 -177.739 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 106.75 -29.39 10.93 Favored Glycine 0 N--CA 1.445 -0.753 0 C-N-CA 121.28 -0.486 . . . . 0.0 112.635 -179.206 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . 0.478 ' O ' ' HA ' ' A' ' 84' ' ' HIS . 47.5 mmtm -80.79 154.03 27.41 Favored 'General case' 0 C--O 1.22 -0.457 0 CA-C-N 116.732 0.266 . . . . 0.0 110.534 -178.103 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.605 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -87.7 128.44 35.3 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.306 0.574 . . . . 0.0 112.512 -178.774 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 17.9 m-85 -125.74 152.2 45.65 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.34 -0.846 . . . . 0.0 109.985 177.399 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 24.3 m-70 -100.88 149.06 24.27 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-O 121.016 0.436 . . . . 0.0 111.361 -179.516 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 44.1 t -120.79 118.35 56.12 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.002 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 176.187 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 58.8 t -132.16 131.39 61.1 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.532 -179.242 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 94.9 m -113.76 138.69 49.9 Favored 'General case' 0 C--N 1.313 -1.012 0 CA-C-O 120.799 0.333 . . . . 0.0 110.894 -179.424 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 77.8 m-70 -119.03 -19.63 8.39 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.364 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 5.4 mp0 -126.05 142.21 51.62 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.011 -0.54 . . . . 0.0 109.699 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 -76.97 103.8 7.1 Favored 'General case' 0 C--N 1.314 -0.937 0 N-CA-C 109.794 -0.446 . . . . 0.0 109.794 177.177 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 164.26 169.35 27.69 Favored Glycine 0 N--CA 1.436 -1.349 0 N-CA-C 111.267 -0.733 . . . . 0.0 111.267 -179.178 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.465 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 95.4 Cg_endo -83.34 133.51 6.37 Favored 'Trans proline' 0 N--CA 1.454 -0.806 0 C-N-CA 122.582 2.188 . . . . 0.0 112.709 179.031 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.9 pp -140.12 156.6 70.13 Favored Pre-proline 0 C--N 1.32 -0.704 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.996 178.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -62.96 167.29 12.45 Favored 'Trans proline' 0 C--N 1.351 0.695 0 C-N-CA 122.743 2.296 . . . . 0.0 112.87 -178.547 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' HIS . . . . . 0.405 ' CE1' HG21 ' A' ' 83' ' ' VAL . 5.0 t-80 -91.68 133.15 31.46 Favored Pre-proline 0 C--N 1.322 -0.597 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.822 -178.366 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_endo -53.46 -37.62 82.31 Favored 'Trans proline' 0 C--N 1.353 0.799 0 C-N-CA 123.414 2.743 . . . . 0.0 113.344 -177.654 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -70.8 -64.82 2.68 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.087 179.462 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 3.0 p30 -132.6 120.29 21.61 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 121.045 0.45 . . . . 0.0 111.421 178.531 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 28.3 m -57.07 -10.25 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 CA-C-N 115.573 -0.74 . . . . 0.0 112.835 177.768 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 66.4 m170 -69.84 -1.03 8.24 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-O 121.158 0.504 . . . . 0.0 110.636 176.553 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 33.1 mtmm -137.31 157.72 46.01 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.109 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -143.47 173.33 11.72 Favored 'General case' 0 C--N 1.308 -1.21 0 C-N-CA 120.825 -0.35 . . . . 0.0 110.921 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.465 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 1.9 mp -131.04 142.82 42.58 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.966 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 178.786 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -99.68 115.17 39.99 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.968 0 N-CA-C 107.424 -1.325 . . . . 0.0 107.424 174.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 29.2 m -95.41 121.75 37.41 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 -178.526 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 16.4 m -126.56 140.79 52.17 Favored 'General case' 0 C--N 1.307 -1.282 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 -179.32 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -118.19 104.86 11.21 Favored 'General case' 0 C--N 1.308 -1.23 0 CA-C-O 121.083 0.468 . . . . 0.0 110.569 -178.435 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 67.5 m -82.89 89.06 6.8 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.444 178.704 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 68.78 -100.26 0.67 Allowed Glycine 0 N--CA 1.432 -1.575 0 C-N-CA 120.461 -0.876 . . . . 0.0 111.084 -177.702 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 14.5 t -114.5 7.46 16.19 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-O 120.9 0.381 . . . . 0.0 110.383 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 21.8 tp -117.1 131.11 56.99 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.584 -0.28 . . . . 0.0 110.438 -177.712 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 77.0 m95 -92.14 131.75 37.15 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 121.038 0.447 . . . . 0.0 111.84 -179.457 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 64.4 m-85 -120.89 129.79 53.64 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.471 174.085 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.415 HD11 HD23 ' A' ' 81' ' ' LEU . 2.5 pp -120.82 151.51 23.78 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.043 0 CA-C-O 121.129 0.49 . . . . 0.0 111.736 -179.518 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 27.8 m -139.66 118.81 12.69 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.892 178.495 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 6.0 p -92.09 124.6 44.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 120.951 0.405 . . . . 0.0 111.081 -178.621 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 4.0 mmt -125.77 139.22 33.62 Favored Pre-proline 0 C--N 1.318 -0.766 0 CA-C-N 115.822 -0.627 . . . . 0.0 109.838 -179.48 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -86.8 143.14 6.97 Favored 'Trans proline' 0 N--CA 1.453 -0.911 0 C-N-CA 122.241 1.961 . . . . 0.0 111.883 177.786 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' CYS . . . . . 0.498 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 55.3 m -81.81 169.39 16.95 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 176.529 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 1.6 p -58.36 148.52 27.45 Favored 'General case' 0 N--CA 1.435 -1.198 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.604 176.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . 0.416 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.9 mp -62.74 129.0 25.56 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 CA-C-O 121.135 0.493 . . . . 0.0 110.445 -179.348 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 92.04 5.31 66.1 Favored Glycine 0 N--CA 1.44 -1.061 0 CA-C-N 115.694 -0.684 . . . . 0.0 112.882 -178.21 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 60.5 p -126.33 162.6 25.13 Favored 'General case' 0 C--O 1.236 0.347 0 CA-C-N 117.269 0.534 . . . . 0.0 111.133 179.166 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 58.0 pttt -131.9 143.99 50.54 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 179.387 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.498 ' HB2' ' SG ' ' A' ' 126' ' ' CYS . 46.5 t80 -82.74 133.6 35.15 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-O 120.919 0.39 . . . . 0.0 111.712 -178.489 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -100.55 128.57 29.81 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 115.877 -0.601 . . . . 0.0 109.907 177.453 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -64.56 -41.22 20.44 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.973 2.449 . . . . 0.0 113.514 -176.73 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 28.1 mm -75.89 -53.01 16.58 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 N-CA-C 112.097 0.406 . . . . 0.0 112.097 -175.738 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 4.8 m -68.78 -31.96 71.35 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.727 -178.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 57.5 mtm180 70.73 51.02 0.33 Allowed 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 121.428 0.632 . . . . 0.0 110.752 178.328 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 29.7 p-10 -159.23 173.41 16.39 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-N 115.483 -0.78 . . . . 0.0 109.004 179.067 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' CYS . . . . . 0.423 ' HA ' ' HA ' ' A' ' 132' ' ' PHE . 21.1 m -101.85 125.26 48.49 Favored 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 178.503 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 27.2 m -112.8 163.2 10.2 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.767 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.159 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 6.9 tt -57.56 123.6 16.13 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-O 121.081 0.467 . . . . 0.0 111.225 -178.692 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 17.1 t70 . . . . . 0 C--N 1.322 -0.594 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.209 178.836 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . 0.525 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 11.9 p-10 . . . . . 0 N--CA 1.44 -0.944 0 CA-C-O 121.604 0.716 . . . . 0.0 111.437 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.504 HD23 HD11 ' A' ' 121' ' ' ILE . 39.0 tp -107.25 137.88 44.47 Favored 'General case' 0 C--N 1.301 -1.504 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.502 177.224 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.469 HG22 HG22 ' A' ' 89' ' ' THR . 16.8 mt -96.81 143.29 12.62 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.07 0 C-N-CA 120.511 -0.476 . . . . 0.0 110.187 -179.547 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 28.7 m -138.41 157.37 30.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-N 116.174 -0.466 . . . . 0.0 109.804 -179.203 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 60.8 m-70 -104.2 104.33 14.23 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 116.468 -0.333 . . . . 0.0 111.019 179.454 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 70.4 mm-40 -100.79 104.97 16.23 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 177.529 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 66.37 30.62 76.95 Favored Glycine 0 N--CA 1.444 -0.776 0 C-N-CA 120.262 -0.971 . . . . 0.0 110.783 -176.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 89.42 -21.89 26.57 Favored Glycine 0 N--CA 1.442 -0.947 0 CA-C-N 115.195 -0.502 . . . . 0.0 112.726 -178.549 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 14.0 mmmm -83.75 135.2 34.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.799 0.333 . . . . 0.0 111.024 -176.027 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.469 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -81.42 112.26 18.52 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -178.52 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -112.26 146.68 37.77 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.744 -0.662 . . . . 0.0 109.649 176.301 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 21.6 m-70 -99.05 142.44 30.53 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-O 120.715 0.293 . . . . 0.0 110.498 178.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.67 HG13 HD13 ' A' ' 110' ' ' ILE . 79.5 t -117.65 120.33 64.4 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.955 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 179.097 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 14.9 p -138.79 142.21 34.97 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.028 -178.031 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 33.1 m -138.31 127.95 25.01 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.662 177.854 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 14.0 p80 -101.71 -0.32 34.7 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-O 121.447 0.641 . . . . 0.0 109.701 177.71 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 56.5 mt-10 -142.67 157.95 44.15 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 114.755 -1.111 . . . . 0.0 109.702 178.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -85.46 153.75 22.27 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 120.917 0.389 . . . . 0.0 110.77 178.295 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 126.8 161.77 10.99 Favored Glycine 0 N--CA 1.438 -1.168 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.037 178.34 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.494 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 72.9 Cg_endo -82.62 134.59 7.58 Favored 'Trans proline' 0 N--CA 1.447 -1.248 0 C-N-CA 122.376 2.051 . . . . 0.0 111.855 177.896 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -141.65 157.4 65.22 Favored Pre-proline 0 C--N 1.314 -0.968 0 CA-C-N 115.934 -0.576 . . . . 0.0 109.733 178.515 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -62.42 164.64 17.31 Favored 'Trans proline' 0 C--N 1.348 0.544 0 C-N-CA 122.356 2.038 . . . . 0.0 112.468 -178.813 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' HIS . . . . . . . . . . . . . 27.6 t-80 -92.02 121.95 65.95 Favored Pre-proline 0 C--N 1.315 -0.899 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 -179.506 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -59.0 -19.3 47.58 Favored 'Trans proline' 0 N--CA 1.486 1.041 0 C-N-CA 123.116 2.544 . . . . 0.0 113.543 -176.581 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -93.35 -19.3 35.98 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.469 -0.872 . . . . 0.0 112.809 -179.843 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 2.4 p30 -167.32 102.04 0.52 Allowed 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 122.479 0.311 . . . . 0.0 110.985 -177.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 28.3 m -54.91 -14.34 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 N-CA-C 113.674 0.99 . . . . 0.0 113.674 179.552 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 17.2 t-80 -73.21 -0.52 14.57 Favored 'General case' 0 CA--C 1.542 0.655 0 CA-C-O 121.61 0.719 . . . . 0.0 110.435 176.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 47.4 mtmt -136.89 160.88 37.58 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.473 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 11.1 p90 -142.37 173.67 11.32 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.546 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.67 HD13 HG13 ' A' ' 92' ' ' VAL . 3.7 mt -131.91 142.24 43.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 -178.584 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.6 mp -101.89 112.5 35.24 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.12 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 175.783 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 86.3 m -102.3 123.52 46.26 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-O 121.181 0.515 . . . . 0.0 111.178 -176.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 19.3 m -128.56 144.61 51.18 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.529 -179.057 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.597 ' HD3' ' CE2' ' A' ' 119' ' ' TRP . 24.1 tptm -113.16 103.84 11.75 Favored 'General case' 0 C--N 1.313 -0.985 0 N-CA-C 109.152 -0.685 . . . . 0.0 109.152 179.247 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 62.2 m -91.28 78.92 5.72 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-O 121.436 0.636 . . . . 0.0 109.524 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.523 ' O ' ' HE2' ' A' ' 114' ' ' LYS . . . 75.44 -99.06 1.18 Allowed Glycine 0 N--CA 1.433 -1.507 0 N-CA-C 110.593 -1.003 . . . . 0.0 110.593 -178.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 20.4 m -113.46 0.92 14.88 Favored 'General case' 0 N--CA 1.445 -0.722 0 CA-C-O 121.312 0.577 . . . . 0.0 110.068 -179.752 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 87.6 mt -112.02 122.97 49.23 Favored 'General case' 0 N--CA 1.435 -1.21 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.555 -176.538 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . 0.597 ' CE2' ' HD3' ' A' ' 114' ' ' LYS . 81.3 m95 -85.32 131.34 34.42 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 121.015 0.436 . . . . 0.0 111.107 177.37 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -125.48 124.0 40.41 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 115.881 -0.6 . . . . 0.0 109.849 174.55 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.504 HD11 HD23 ' A' ' 81' ' ' LEU . 2.5 pp -126.45 146.97 31.38 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.955 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.33 -178.494 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 34.5 m -134.24 124.93 26.75 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 116.013 -0.54 . . . . 0.0 109.672 178.212 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 2.8 p -95.68 110.99 25.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-O 121.393 0.615 . . . . 0.0 111.252 -179.057 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 9.1 mmt -113.32 145.8 33.98 Favored Pre-proline 0 C--N 1.318 -0.767 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.062 -178.719 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 79.4 Cg_endo -89.25 151.15 5.55 Favored 'Trans proline' 0 N--CA 1.453 -0.865 0 C-N-CA 122.353 2.035 . . . . 0.0 113.074 179.605 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 35.9 m -90.87 171.14 9.52 Favored 'General case' 0 C--O 1.243 0.727 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.153 175.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 22.9 t -54.28 148.32 11.74 Favored 'General case' 0 C--O 1.237 0.413 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 177.298 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . 0.455 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.9 mp -63.7 129.07 26.97 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 CA-C-O 120.912 0.387 . . . . 0.0 110.234 -179.032 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 89.38 6.03 71.55 Favored Glycine 0 N--CA 1.444 -0.791 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.783 -177.669 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 46.2 p -121.33 158.94 27.1 Favored 'General case' 0 N--CA 1.452 -0.36 0 O-C-N 122.343 -0.504 . . . . 0.0 110.757 178.236 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 59.0 pttt -128.0 144.26 51.1 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 32.8 t80 -84.46 137.22 33.48 Favored 'General case' 0 C--N 1.311 -1.098 0 C-N-CA 120.9 -0.32 . . . . 0.0 110.743 -179.644 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -100.05 133.83 21.31 Favored Pre-proline 0 C--N 1.325 -0.472 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.333 179.314 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -67.68 -41.84 7.71 Favored 'Trans proline' 0 C--N 1.346 0.418 0 C-N-CA 122.877 2.385 . . . . 0.0 113.949 -177.51 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 34.8 mm -82.35 -49.25 17.45 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 N-CA-C 111.951 0.352 . . . . 0.0 111.951 -176.45 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 2.4 m -69.1 -37.49 78.42 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.847 0.356 . . . . 0.0 110.1 179.512 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 67.5 mtt180 68.36 55.36 0.52 Allowed 'General case' 0 CA--C 1.514 -0.414 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.572 178.686 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 29.4 p-10 -154.61 172.93 17.06 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 114.86 -1.064 . . . . 0.0 108.374 178.221 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 27.3 m -101.03 124.83 47.36 Favored 'General case' 0 C--N 1.316 -0.891 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 177.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 35.8 m -117.54 157.16 18.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.296 -178.301 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 7.2 mp -64.56 119.75 11.06 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 112.186 0.439 . . . . 0.0 112.186 -178.328 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 38.7 t70 . . . . . 0 C--N 1.319 -0.734 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 174.032 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 24.3 t70 . . . . . 0 CA--C 1.517 -0.297 0 CA-C-O 120.722 0.296 . . . . 0.0 110.386 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.475 HD23 HD11 ' A' ' 121' ' ' ILE . 54.6 tp -108.6 131.65 54.65 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 178.298 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.548 HG22 HG22 ' A' ' 89' ' ' THR . 12.3 mt -91.69 139.97 16.9 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 C-N-CA 120.408 -0.517 . . . . 0.0 109.651 179.068 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 29.4 m -136.52 175.12 10.98 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 CA-C-N 116.137 -0.483 . . . . 0.0 109.84 -177.536 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 16.2 m-70 -114.57 117.24 30.36 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.109 0.48 . . . . 0.0 111.426 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.45 ' HB2' ' CD1' ' A' ' 90' ' ' TYR . 11.8 mm-40 -115.19 104.45 11.86 Favored 'General case' 0 C--N 1.311 -1.074 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 177.228 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 64.39 34.05 88.87 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.382 -0.913 . . . . 0.0 111.448 -177.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 88.28 -26.9 7.34 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 121.436 -0.411 . . . . 0.0 113.021 -178.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -82.23 146.74 29.33 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.818 0.342 . . . . 0.0 111.169 -178.341 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.548 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -85.08 122.42 29.26 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-O 121.233 0.54 . . . . 0.0 112.153 -179.79 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.45 ' CD1' ' HB2' ' A' ' 85' ' ' GLU . 18.0 m-85 -117.03 148.79 41.18 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.252 176.711 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 31.4 m-70 -97.74 144.22 27.58 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-N 116.526 -0.306 . . . . 0.0 110.202 178.731 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 44.2 t -121.12 117.54 53.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.256 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 178.413 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.6 p -130.77 131.32 64.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 CA-C-N 115.424 -0.807 . . . . 0.0 109.096 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -106.3 138.44 42.48 Favored 'General case' 0 N--CA 1.435 -1.223 0 C-N-CA 119.579 -0.848 . . . . 0.0 111.456 -177.874 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 36.1 m80 -108.84 -25.07 10.97 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 115.329 -0.851 . . . . 0.0 110.365 -178.388 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -131.98 143.43 50.08 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.776 -177.664 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -74.67 108.6 7.53 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.203 178.317 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . 0.424 ' H ' ' HB2' ' A' ' 112' ' ' CYS . . . 156.25 -178.64 32.65 Favored Glycine 0 N--CA 1.439 -1.135 0 N-CA-C 111.637 -0.585 . . . . 0.0 111.637 -178.18 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.493 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 69.5 Cg_endo -91.12 127.31 1.16 Allowed 'Trans proline' 0 N--CA 1.445 -1.333 0 C-N-CA 123.149 2.566 . . . . 0.0 112.742 179.529 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.6 pp -138.02 156.12 74.21 Favored Pre-proline 0 C--N 1.313 -0.993 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.387 179.232 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.408 ' HG3' ' HD3' ' A' ' 134' ' ' PRO . 37.3 Cg_endo -62.92 165.25 16.86 Favored 'Trans proline' 0 C--N 1.352 0.746 0 C-N-CA 122.634 2.223 . . . . 0.0 112.522 -178.435 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' HIS . . . . . 0.421 ' CD2' HD11 ' A' ' 110' ' ' ILE . 11.9 t-80 -88.51 132.6 38.47 Favored Pre-proline 0 C--N 1.32 -0.716 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -178.601 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 17.5 Cg_endo -58.65 -19.95 48.12 Favored 'Trans proline' 0 C--N 1.35 0.631 0 C-N-CA 123.0 2.467 . . . . 0.0 112.806 -179.26 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -91.13 -67.68 1.17 Allowed Glycine 0 N--CA 1.447 -0.591 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.101 179.13 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 45.6 m-80 -118.56 109.95 16.78 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.592 0.196 . . . . 0.0 111.053 179.441 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 32.8 m -55.41 -13.62 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.791 0 N-CA-C 113.075 0.769 . . . . 0.0 113.075 176.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 41.1 m170 -73.92 3.78 6.26 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-O 120.934 0.397 . . . . 0.0 110.547 177.12 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 47.7 mtmt -140.62 157.75 45.0 Favored 'General case' 0 CA--C 1.506 -0.743 0 CA-C-N 115.833 -0.622 . . . . 0.0 109.43 179.78 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 8.5 p90 -143.03 170.07 16.39 Favored 'General case' 0 C--N 1.306 -1.284 0 C-N-CA 120.829 -0.348 . . . . 0.0 111.264 -179.433 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.493 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.1 mp -125.09 139.13 52.06 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.598 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -100.96 113.13 36.05 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 175.357 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' CYS . . . . . 0.424 ' HB2' ' H ' ' A' ' 98' ' ' GLY . 59.6 m -95.14 123.18 38.49 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 109.314 -0.625 . . . . 0.0 109.314 179.132 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 52.7 p -122.56 136.7 54.95 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.835 -176.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 19.5 tptm -96.41 115.54 27.59 Favored 'General case' 0 N--CA 1.435 -1.202 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.682 -179.032 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 59.7 m -108.23 79.81 1.3 Allowed 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 176.856 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 73.45 -104.57 1.61 Allowed Glycine 0 N--CA 1.438 -1.189 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 -176.273 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 8.4 t -113.33 13.02 18.98 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 121.226 0.536 . . . . 0.0 109.865 179.229 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 81.4 mt -116.96 135.4 53.73 Favored 'General case' 0 N--CA 1.435 -1.223 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.043 -177.378 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 50.1 m95 -96.98 131.69 43.53 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.005 0.431 . . . . 0.0 111.069 178.395 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -129.24 128.59 43.6 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 174.855 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.475 HD11 HD23 ' A' ' 81' ' ' LEU . 2.5 pp -119.05 158.91 20.05 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-O 120.952 0.406 . . . . 0.0 111.698 -176.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 44.2 m -146.01 121.65 10.46 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.882 177.369 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.7 p -94.62 110.13 23.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 121.549 0.69 . . . . 0.0 111.411 -179.024 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 7.2 mmt -111.86 142.8 27.39 Favored Pre-proline 0 C--N 1.313 -1.007 0 CA-C-N 115.49 -0.777 . . . . 0.0 110.004 -179.459 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -86.71 144.62 7.61 Favored 'Trans proline' 0 N--CA 1.453 -0.89 0 C-N-CA 122.461 2.107 . . . . 0.0 112.722 178.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 12.2 m -82.65 174.69 10.78 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.488 177.133 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 13.1 m -61.8 144.45 54.76 Favored 'General case' 0 N--CA 1.436 -1.16 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.88 176.678 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . 0.423 ' N ' HD12 ' A' ' 128' ' ' ILE . 2.2 mp -63.34 126.74 22.41 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.553 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 99.25 -6.87 59.83 Favored Glycine 0 N--CA 1.441 -1.0 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.735 -176.483 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 69.1 p -121.66 157.2 31.38 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-N 117.183 0.492 . . . . 0.0 111.449 179.139 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.418 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 62.4 pttt -124.35 147.64 48.06 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 179.0 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 46.9 t80 -81.46 134.37 35.53 Favored 'General case' 0 C--N 1.31 -1.132 0 C-N-CA 120.459 -0.496 . . . . 0.0 111.125 -179.363 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -104.33 127.83 28.29 Favored Pre-proline 0 C--N 1.317 -0.843 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.533 178.76 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' PRO . . . . . 0.408 ' HD3' ' HG3' ' A' ' 101' ' ' PRO . 27.3 Cg_endo -61.99 -42.43 30.49 Favored 'Trans proline' 0 C--O 1.235 0.338 0 C-N-CA 123.024 2.483 . . . . 0.0 113.48 -176.035 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 33.9 mm -79.03 -49.63 19.76 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.612 -176.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . 0.412 ' O ' ' HB2' ' A' ' 137' ' ' ARG . 5.1 m -62.41 -37.51 86.11 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.54 0.209 . . . . 0.0 111.134 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' ARG . . . . . 0.412 ' HB2' ' O ' ' A' ' 136' ' ' SER . 44.2 mtp180 74.62 41.91 0.32 Allowed 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 123.407 0.683 . . . . 0.0 111.33 178.763 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 -161.55 -179.27 7.18 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 178.828 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 10.6 m -100.45 125.93 46.8 Favored 'General case' 0 C--N 1.31 -1.147 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 -178.681 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.5 m -113.34 165.9 7.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.704 -178.253 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -55.08 116.02 2.55 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.625 -179.78 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' ASP . . . . . 0.418 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 21.4 t70 . . . . . 0 C--N 1.323 -0.558 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.58 -178.85 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 18.4 t70 . . . . . 0 N--CA 1.45 -0.44 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -107.2 127.79 53.83 Favored 'General case' 0 C--N 1.31 -1.131 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.407 ' CG2' HG22 ' A' ' 89' ' ' THR . 12.5 mt -98.19 144.5 11.24 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.918 0 C-N-CA 120.951 -0.3 . . . . 0.0 110.419 -178.071 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.46 HG21 ' CE1' ' A' ' 102' ' ' HIS . 22.2 m -128.74 151.41 35.49 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.009 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 179.792 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 22.3 m-70 -107.76 100.09 9.5 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-O 120.879 0.371 . . . . 0.0 110.709 179.741 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 79.4 mm-40 -105.54 105.21 15.14 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.95 179.718 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 62.47 37.67 95.06 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.73 -0.748 . . . . 0.0 111.873 -179.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 80.52 -6.11 62.19 Favored Glycine 0 CA--C 1.52 0.376 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.612 -178.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 32.0 mmmt -96.97 129.02 44.49 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.922 0.391 . . . . 0.0 110.288 -178.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.407 HG22 ' CG2' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -86.07 124.28 32.32 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.408 179.714 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 89.8 m-85 -121.48 141.04 51.41 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 177.538 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 37.8 m-70 -98.85 138.46 35.95 Favored 'General case' 0 C--N 1.312 -1.062 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.29 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 49.4 t -115.58 122.68 69.89 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.015 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 178.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 84.6 t -132.38 128.08 57.83 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.027 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 -179.421 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 66.9 m -98.61 131.6 44.68 Favored 'General case' 0 C--N 1.307 -1.277 0 CA-C-O 120.893 0.378 . . . . 0.0 110.899 -178.201 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 37.1 m80 -80.53 -29.45 37.18 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 179.597 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -158.32 -179.09 7.78 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 114.81 -1.086 . . . . 0.0 108.168 -177.528 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -84.55 154.25 22.75 Favored 'General case' 0 C--N 1.31 -1.138 0 CA-C-O 121.002 0.43 . . . . 0.0 111.001 -179.538 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 124.96 167.17 12.54 Favored Glycine 0 N--CA 1.442 -0.945 0 N-CA-C 111.478 -0.649 . . . . 0.0 111.478 -178.263 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.42 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 93.4 Cg_endo -87.18 134.36 3.55 Favored 'Trans proline' 0 N--CA 1.454 -0.85 0 C-N-CA 122.681 2.254 . . . . 0.0 112.816 178.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.5 pp -140.56 156.21 69.38 Favored Pre-proline 0 C--N 1.323 -0.575 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.168 178.416 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo -61.46 165.97 12.25 Favored 'Trans proline' 0 C--N 1.352 0.746 0 C-N-CA 122.895 2.397 . . . . 0.0 113.577 -177.687 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' HIS . . . . . 0.46 ' CE1' HG21 ' A' ' 83' ' ' VAL . 3.5 t-80 -89.06 128.13 52.97 Favored Pre-proline 0 C--N 1.321 -0.645 0 CA-C-N 115.329 -0.85 . . . . 0.0 108.93 -179.407 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 10.5 Cg_endo -51.56 -50.53 13.64 Favored 'Trans proline' 0 C--N 1.352 0.73 0 C-N-CA 123.123 2.549 . . . . 0.0 113.25 -176.432 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -67.44 -64.44 3.22 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.677 -179.672 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.446 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 2.6 p30 -119.89 105.0 10.66 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 120.972 0.415 . . . . 0.0 111.705 -178.824 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 27.3 m -56.08 -10.6 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 N-CA-C 113.574 0.953 . . . . 0.0 113.574 178.791 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 23.6 m170 -73.45 4.55 4.64 Favored 'General case' 0 N--CA 1.472 0.675 0 CA-C-O 121.245 0.545 . . . . 0.0 110.646 176.7 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 45.1 mtmt -138.1 160.38 39.54 Favored 'General case' 0 N--CA 1.445 -0.708 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 177.844 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 13.4 p90 -143.5 173.18 11.86 Favored 'General case' 0 C--N 1.313 -0.982 0 C-N-CA 120.466 -0.494 . . . . 0.0 111.611 179.668 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.431 ' CG2' ' HB ' ' A' ' 121' ' ' ILE . 2.9 mp -129.57 142.36 44.11 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.908 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.065 179.688 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -100.32 119.44 48.41 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.88 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 175.203 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 61.9 m -98.22 123.8 42.48 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-O 120.927 0.394 . . . . 0.0 111.177 -177.324 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 23.5 t -130.82 137.63 49.5 Favored 'General case' 0 C--N 1.312 -1.056 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 177.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.461 ' HE2' ' O ' ' A' ' 116' ' ' GLY . 86.6 tttt -116.34 109.61 17.59 Favored 'General case' 0 C--N 1.316 -0.872 0 C-N-CA 120.552 -0.459 . . . . 0.0 110.515 -178.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 53.4 m -92.09 76.76 5.38 Favored 'General case' 0 C--N 1.31 -1.128 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.018 178.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.461 ' O ' ' HE2' ' A' ' 114' ' ' LYS . . . 77.99 -98.93 1.49 Allowed Glycine 0 N--CA 1.44 -1.052 0 C-N-CA 120.434 -0.888 . . . . 0.0 111.199 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 25.3 m -114.09 8.94 17.15 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 121.086 0.47 . . . . 0.0 110.177 179.746 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 19.7 tp -122.69 125.64 45.99 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.66 -177.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . 0.446 ' CZ2' ' HD2' ' A' ' 114' ' ' LYS . 86.6 m95 -89.86 133.13 34.91 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-O 121.045 0.45 . . . . 0.0 111.632 179.363 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 87.6 m-85 -118.22 120.88 39.01 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 173.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.431 ' HB ' ' CG2' ' A' ' 110' ' ' ILE . 2.3 pp -125.51 142.94 40.76 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 CA-C-O 121.001 0.429 . . . . 0.0 111.14 -178.539 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 49.8 m -129.54 123.77 32.24 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-N 115.958 -0.564 . . . . 0.0 109.875 179.394 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.7 p -94.08 112.37 26.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 121.513 0.673 . . . . 0.0 111.342 -178.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 5.8 mmt -110.7 138.8 21.15 Favored Pre-proline 0 C--N 1.318 -0.786 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.289 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -86.11 140.39 6.64 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 122.455 2.103 . . . . 0.0 112.359 178.61 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' CYS . . . . . 0.435 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 65.6 m -83.26 170.97 14.08 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.283 177.825 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 30.9 m -57.08 141.51 45.69 Favored 'General case' 0 N--CA 1.446 -0.64 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.173 176.491 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . 0.415 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.9 mp -59.9 131.76 24.73 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 179.37 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.28 -7.26 72.24 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.762 -0.732 . . . . 0.0 113.045 -176.618 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 59.7 p -117.2 164.91 14.07 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-N 117.174 0.487 . . . . 0.0 111.114 179.664 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.554 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 65.0 pttt -132.03 148.59 52.51 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 178.896 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.435 ' HB2' ' SG ' ' A' ' 126' ' ' CYS . 44.4 t80 -84.63 130.4 34.72 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 120.571 -0.452 . . . . 0.0 110.559 178.715 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -98.34 129.8 29.72 Favored Pre-proline 0 C--N 1.314 -0.948 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.924 179.271 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -64.21 -40.83 24.09 Favored 'Trans proline' 0 C--N 1.342 0.224 0 C-N-CA 122.803 2.335 . . . . 0.0 113.28 -176.805 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 27.6 mm -78.96 -51.67 16.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.599 -176.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 14.0 m -64.0 -32.73 74.38 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.836 0.351 . . . . 0.0 110.657 178.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 67.6 mtm180 68.83 41.95 1.45 Allowed 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 115.509 -0.769 . . . . 0.0 111.274 176.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 10.7 p30 -157.64 176.77 12.19 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.249 -0.887 . . . . 0.0 108.779 177.556 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' CYS . . . . . 0.412 ' HA ' ' HA ' ' A' ' 132' ' ' PHE . 9.2 m -100.28 124.92 46.33 Favored 'General case' 0 C--N 1.319 -0.727 0 C-N-CA 120.209 -0.596 . . . . 0.0 109.734 -178.612 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.0 m -117.88 167.87 10.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.201 -178.295 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -57.35 120.85 8.89 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 178.873 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' ASP . . . . . 0.554 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 8.8 t70 . . . . . 0 C--N 1.317 -0.835 0 N-CA-C 113.674 0.99 . . . . 0.0 113.674 -173.721 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 . . . . . 0 N--CA 1.449 -0.494 0 CA-C-O 121.188 0.518 . . . . 0.0 110.299 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.446 ' HG ' HD11 ' A' ' 121' ' ' ILE . 2.6 tm? -129.97 126.1 37.0 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.024 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.435 ' CG2' HG22 ' A' ' 89' ' ' THR . 26.0 mt -93.79 147.94 5.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.226 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.597 HG21 ' CE1' ' A' ' 102' ' ' HIS . 10.9 m -138.92 167.14 21.18 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 N-CA-C 110.103 -0.332 . . . . 0.0 110.103 -178.902 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 73.2 m-70 -114.75 99.96 7.89 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.579 177.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.425 ' OE2' ' ND1' ' A' ' 102' ' ' HIS . 1.0 OUTLIER -87.1 98.28 11.21 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 179.775 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 74.27 1.79 61.26 Favored Glycine 0 C--N 1.324 -0.136 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 -177.622 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 123.28 -23.17 6.9 Favored Glycine 0 N--CA 1.437 -1.292 0 N-CA-C 111.374 -0.691 . . . . 0.0 111.374 -178.624 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 32.2 mmmt -85.08 137.83 32.8 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 110.218 -0.29 . . . . 0.0 110.218 -178.165 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.463 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.0 OUTLIER -76.84 128.16 34.08 Favored 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 112.748 0.647 . . . . 0.0 112.748 -178.502 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.538 ' CE2' ' HA2' ' A' ' 104' ' ' GLY . 35.2 m-85 -126.29 148.8 49.45 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 176.385 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 17.6 m-70 -101.37 139.27 37.26 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-O 120.792 0.33 . . . . 0.0 110.587 -178.079 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 60.5 t -122.3 118.04 54.09 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 179.127 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 49.0 t -128.78 132.96 67.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.145 179.431 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 82.8 m -110.38 118.94 37.63 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 -178.682 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 43.7 m80 -103.17 -15.95 15.87 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.987 -179.786 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -131.21 144.33 51.25 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.985 0.422 . . . . 0.0 111.059 -179.307 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -71.02 112.96 7.58 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.31 177.542 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 146.74 168.7 13.86 Favored Glycine 0 N--CA 1.437 -1.245 0 C-N-CA 121.092 -0.575 . . . . 0.0 111.953 179.502 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.433 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 73.4 Cg_endo -78.64 136.08 13.43 Favored 'Trans proline' 0 N--CA 1.457 -0.623 0 C-N-CA 122.656 2.237 . . . . 0.0 112.644 178.321 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -138.24 158.1 71.48 Favored Pre-proline 0 C--N 1.32 -0.688 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.846 178.072 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo -62.05 166.04 13.31 Favored 'Trans proline' 0 C--N 1.353 0.795 0 C-N-CA 122.69 2.26 . . . . 0.0 113.083 -177.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' HIS . . . . . 0.597 ' CE1' HG21 ' A' ' 83' ' ' VAL . 7.2 t-80 -92.35 133.7 29.46 Favored Pre-proline 0 C--N 1.321 -0.673 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.1 -178.041 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -57.89 -31.72 93.28 Favored 'Trans proline' 0 C--N 1.353 0.766 0 C-N-CA 123.039 2.493 . . . . 0.0 112.94 -178.581 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.538 ' HA2' ' CE2' ' A' ' 90' ' ' TYR . . . -70.29 -63.65 3.18 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.751 -0.738 . . . . 0.0 111.803 179.324 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.531 ' OD1' ' HB2' ' A' ' 107' ' ' HIS . 10.5 p30 -139.6 130.06 25.6 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-O 121.058 0.456 . . . . 0.0 110.743 176.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 29.5 m -58.73 -10.43 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.555 0 N-CA-C 113.487 0.921 . . . . 0.0 113.487 178.817 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . 0.531 ' HB2' ' OD1' ' A' ' 105' ' ' ASN . 36.8 m80 -71.11 -6.93 43.03 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 121.127 0.489 . . . . 0.0 110.193 177.686 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 43.1 mtmt -130.51 159.11 38.08 Favored 'General case' 0 CA--C 1.507 -0.71 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.835 177.795 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 9.6 p90 -143.33 173.18 11.83 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.724 179.675 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.433 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 2.4 mp -128.61 141.22 47.13 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.121 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 177.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.7 mp -97.58 117.35 42.15 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 N-CA-C 107.753 -1.202 . . . . 0.0 107.753 175.732 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 21.3 m -104.51 121.46 43.52 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 -179.197 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 36.7 m -122.92 133.33 54.4 Favored 'General case' 0 C--N 1.308 -1.203 0 CA-C-N 116.07 -0.513 . . . . 0.0 109.69 179.673 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.486 ' HD2' ' CZ2' ' A' ' 119' ' ' TRP . 80.8 tttt -105.53 112.24 25.25 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 120.489 -0.484 . . . . 0.0 110.179 -179.705 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 68.2 m -102.15 77.98 1.73 Allowed 'General case' 0 C--N 1.308 -1.213 0 CA-C-N 115.738 -0.664 . . . . 0.0 109.962 179.078 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 77.89 -99.67 1.54 Allowed Glycine 0 N--CA 1.44 -1.062 0 CA-C-N 115.317 -0.856 . . . . 0.0 111.485 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 31.7 t -114.48 3.97 15.1 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-O 121.051 0.453 . . . . 0.0 109.807 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 19.5 mt -119.13 125.83 50.18 Favored 'General case' 0 N--CA 1.432 -1.35 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.11 -177.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . 0.486 ' CZ2' ' HD2' ' A' ' 114' ' ' LYS . 60.6 m95 -91.82 134.01 35.13 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-O 121.071 0.463 . . . . 0.0 111.083 178.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 87.5 m-85 -117.51 128.39 54.93 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.259 175.647 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.446 HD11 ' HG ' ' A' ' 81' ' ' LEU . 2.8 pp -127.73 156.36 39.53 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 N-CA-C 112.189 0.44 . . . . 0.0 112.189 -176.054 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 38.9 m -151.24 123.21 8.14 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.132 176.051 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.8 p -92.06 115.23 30.6 Favored 'Isoleucine or valine' 0 C--O 1.235 0.322 0 CA-C-O 121.301 0.572 . . . . 0.0 111.245 179.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.454 ' HA ' ' HE2' ' A' ' 124' ' ' MET . 4.6 mmt -117.16 149.7 44.86 Favored Pre-proline 0 C--N 1.32 -0.678 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.198 -179.542 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -92.07 147.76 3.09 Favored 'Trans proline' 0 N--CA 1.45 -1.074 0 C-N-CA 122.433 2.089 . . . . 0.0 112.431 177.647 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 18.2 m -80.94 174.38 11.68 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 120.911 0.386 . . . . 0.0 110.197 176.672 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 18.9 m -62.38 147.08 49.57 Favored 'General case' 0 N--CA 1.437 -1.08 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.79 176.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . 0.421 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.8 mp -59.11 123.72 11.94 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 CA-C-O 121.167 0.508 . . . . 0.0 110.218 -179.204 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 97.26 -1.67 60.74 Favored Glycine 0 N--CA 1.438 -1.22 0 CA-C-N 115.56 -0.745 . . . . 0.0 113.175 -178.786 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 80.8 p -120.81 162.88 19.03 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 117.447 0.624 . . . . 0.0 111.472 179.477 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.428 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 60.7 pttt -132.51 145.93 51.53 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.469 179.151 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 26.2 t80 -81.58 137.74 35.48 Favored 'General case' 0 C--N 1.31 -1.144 0 CA-C-O 121.15 0.5 . . . . 0.0 111.685 -178.339 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -103.35 132.5 21.04 Favored Pre-proline 0 C--N 1.323 -0.569 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.144 177.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -68.77 -39.82 8.06 Favored 'Trans proline' 0 CA--C 1.531 0.347 0 C-N-CA 122.871 2.38 . . . . 0.0 113.885 -176.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 27.2 mm -78.17 -52.49 15.79 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 N-CA-C 112.121 0.415 . . . . 0.0 112.121 -176.433 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 35.5 p -73.75 -29.84 62.46 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 120.695 0.283 . . . . 0.0 111.154 -178.326 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 95.6 mtt180 68.24 57.84 0.46 Allowed 'General case' 0 N--CA 1.465 0.28 0 C-N-CA 123.471 0.709 . . . . 0.0 112.288 176.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 4.1 p-10 -164.09 177.09 8.7 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 176.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 31.5 m -100.35 125.35 46.58 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 -178.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 33.1 m -112.75 167.59 5.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.561 -177.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -58.01 117.08 3.96 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.997 0.427 . . . . 0.0 111.177 179.309 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' ASP . . . . . 0.428 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 17.2 t70 . . . . . 0 CA--C 1.506 -0.713 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.399 178.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . 0.432 ' OD1' ' HB3' ' A' ' 91' ' ' HIS . 25.4 t70 . . . . . 0 N--CA 1.446 -0.633 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -107.66 123.86 49.12 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 108.92 -0.771 . . . . 0.0 108.92 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.624 HG22 HG22 ' A' ' 89' ' ' THR . 3.2 mt -101.49 145.3 11.77 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.677 -177.157 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.429 ' O ' ' HA ' ' A' ' 89' ' ' THR . 16.7 m -134.36 165.53 31.25 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 116.084 -0.507 . . . . 0.0 109.812 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 18.6 m-70 -114.7 113.0 23.72 Favored 'General case' 0 C--N 1.31 -1.118 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.407 179.014 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 76.5 mm-40 -107.63 95.9 6.02 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.603 179.235 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 73.94 -6.17 21.3 Favored Glycine 0 CA--C 1.52 0.347 0 C-N-CA 121.093 -0.575 . . . . 0.0 112.932 178.655 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 134.64 -12.71 4.55 Favored Glycine 0 N--CA 1.443 -0.883 0 N-CA-C 111.698 -0.561 . . . . 0.0 111.698 -179.25 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -96.32 130.99 43.3 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 110.368 -0.234 . . . . 0.0 110.368 178.56 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.624 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -85.75 107.34 17.56 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-O 120.969 0.414 . . . . 0.0 111.452 179.391 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 78.1 m-85 -102.21 146.87 27.36 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.914 178.261 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . 0.432 ' HB3' ' OD1' ' A' ' 80' ' ' ASP . 36.1 m-70 -101.96 143.73 31.45 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.543 -178.669 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.499 HG13 HD13 ' A' ' 110' ' ' ILE . 89.8 t -114.29 122.18 67.9 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.461 179.102 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 64.2 t -136.77 124.99 34.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.24 0 CA-C-N 115.48 -0.782 . . . . 0.0 108.903 -179.681 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 81.7 m -101.9 127.98 48.5 Favored 'General case' 0 C--N 1.31 -1.139 0 CA-C-O 120.932 0.396 . . . . 0.0 111.059 -179.09 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 68.3 t60 -91.08 -25.45 19.63 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.291 0.567 . . . . 0.0 109.518 178.337 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -149.1 164.69 33.94 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.218 -177.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -78.69 142.13 37.37 Favored 'General case' 0 N--CA 1.438 -1.065 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.001 178.08 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 130.05 167.31 12.03 Favored Glycine 0 N--CA 1.438 -1.223 0 C-N-CA 120.907 -0.663 . . . . 0.0 111.621 -178.174 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.402 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 98.5 Cg_endo -85.6 137.99 6.04 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 122.582 2.188 . . . . 0.0 112.766 179.462 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.8 pp -142.86 158.04 60.16 Favored Pre-proline 0 C--N 1.319 -0.747 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.628 178.713 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -64.56 166.63 17.08 Favored 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 122.462 2.108 . . . . 0.0 112.75 -177.619 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' HIS . . . . . . . . . . . . . 14.1 t-80 -89.49 130.09 44.81 Favored Pre-proline 0 C--N 1.318 -0.762 0 CA-C-N 115.923 -0.581 . . . . 0.0 109.906 -178.206 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -62.19 -24.32 76.14 Favored 'Trans proline' 0 N--CA 1.48 0.716 0 C-N-CA 123.013 2.475 . . . . 0.0 113.456 -177.317 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -93.44 -17.87 40.81 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.201 -1.0 . . . . 0.0 113.482 -178.571 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 1.9 p30 -167.63 105.31 0.52 Allowed 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.657 0.265 . . . . 0.0 111.199 -177.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 27.0 m -55.05 -11.69 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 N-CA-C 113.509 0.929 . . . . 0.0 113.509 178.145 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 91.0 m-70 -77.57 7.03 6.06 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 121.194 0.521 . . . . 0.0 110.951 178.016 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 47.9 mtmt -143.29 162.84 34.63 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.221 179.342 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 11.1 p90 -142.64 173.72 11.28 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-O 120.919 0.39 . . . . 0.0 111.238 179.727 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.499 HD13 HG13 ' A' ' 92' ' ' VAL . 3.8 mt -132.87 143.62 39.01 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.651 -179.24 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.414 ' N ' HD12 ' A' ' 111' ' ' ILE . 4.3 mp -103.09 122.28 55.34 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 176.641 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 58.7 m -103.08 122.51 44.82 Favored 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 178.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 29.1 t -133.59 140.25 47.02 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-O 120.894 0.378 . . . . 0.0 110.672 -177.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.427 ' HD2' ' CZ2' ' A' ' 119' ' ' TRP . 59.9 tttm -107.54 104.74 14.36 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-O 121.106 0.479 . . . . 0.0 110.178 179.125 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 23.3 t -90.76 88.45 7.08 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.58 -179.48 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 66.1 -100.76 0.54 Allowed Glycine 0 N--CA 1.438 -1.195 0 CA-C-N 115.474 -0.784 . . . . 0.0 111.664 -178.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 16.3 m -109.32 3.8 21.97 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -179.054 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 35.5 tp -126.98 141.01 51.9 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 120.563 -0.455 . . . . 0.0 111.452 -178.654 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . 0.427 ' CZ2' ' HD2' ' A' ' 114' ' ' LYS . 72.6 m95 -93.8 133.47 37.15 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.348 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 77.4 m-85 -121.7 130.78 53.69 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.606 175.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.4 pp -125.11 146.96 29.91 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 CA-C-O 120.973 0.416 . . . . 0.0 110.891 179.706 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 22.9 m -137.98 125.43 21.97 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-N 115.964 -0.562 . . . . 0.0 109.94 179.4 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.3 p -94.9 112.02 26.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 121.424 0.63 . . . . 0.0 111.018 179.167 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 6.8 mmt -111.49 141.92 25.48 Favored Pre-proline 0 C--N 1.314 -0.942 0 CA-C-N 115.454 -0.793 . . . . 0.0 110.182 -179.442 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -87.05 154.4 8.37 Favored 'Trans proline' 0 N--CA 1.457 -0.664 0 C-N-CA 122.587 2.191 . . . . 0.0 113.365 -179.72 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 56.5 m -92.72 165.09 13.13 Favored 'General case' 0 C--O 1.241 0.653 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.448 175.618 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 14.9 m -59.93 148.88 33.5 Favored 'General case' 0 N--CA 1.445 -0.693 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.304 176.738 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . 0.409 HD12 ' N ' ' A' ' 128' ' ' ILE . 1.8 mp -60.04 129.73 22.85 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.246 179.749 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 93.9 -2.13 69.0 Favored Glycine 0 N--CA 1.439 -1.136 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.883 -178.242 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 68.7 p -121.06 164.02 17.45 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-N 117.257 0.528 . . . . 0.0 111.382 179.422 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.523 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 57.8 pttt -139.18 145.07 38.88 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 178.67 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.406 ' HA ' ' HA ' ' A' ' 139' ' ' CYS . 38.3 t80 -82.8 137.79 34.21 Favored 'General case' 0 C--N 1.311 -1.084 0 N-CA-C 112.365 0.505 . . . . 0.0 112.365 -176.034 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -106.52 131.55 21.62 Favored Pre-proline 0 C--N 1.327 -0.408 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.811 176.264 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.05 -36.58 21.59 Favored 'Trans proline' 0 N--CA 1.471 0.203 0 C-N-CA 122.904 2.403 . . . . 0.0 113.935 -176.803 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 34.3 mm -79.28 -56.34 7.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 N-CA-C 111.932 0.345 . . . . 0.0 111.932 -176.061 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 26.8 p -66.69 -31.76 72.63 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 120.528 0.204 . . . . 0.0 110.911 179.629 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 72.25 48.6 0.25 Allowed 'General case' 0 CA--C 1.518 -0.268 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.342 176.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 32.9 p30 -154.9 175.98 13.09 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.434 178.814 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' CYS . . . . . 0.406 ' HA ' ' HA ' ' A' ' 132' ' ' PHE . 27.8 m -100.86 124.65 46.85 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 177.622 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 29.8 m -107.65 160.58 6.75 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.877 -177.69 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -61.45 119.02 7.75 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.187 179.79 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' ASP . . . . . 0.523 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 28.2 t70 . . . . . 0 C--N 1.32 -0.717 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.934 179.188 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 27.1 t70 . . . . . 0 CA--C 1.509 -0.598 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -112.14 126.31 55.05 Favored 'General case' 0 C--N 1.306 -1.288 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 -177.43 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 15.0 mt -94.4 140.14 17.21 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 C-N-CA 120.869 -0.333 . . . . 0.0 110.395 -178.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 27.1 m -127.82 162.53 33.46 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.171 -178.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 35.7 m170 -108.87 112.66 25.01 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.293 179.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.548 ' HB2' ' CE1' ' A' ' 90' ' ' TYR . 71.8 mm-40 -116.81 103.96 10.85 Favored 'General case' 0 C--N 1.312 -1.033 0 N-CA-C 109.206 -0.665 . . . . 0.0 109.206 178.28 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 69.38 23.9 76.26 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.631 -0.795 . . . . 0.0 111.971 -179.261 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 95.53 -19.28 55.04 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.627 -179.421 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 56.4 mtmt -91.16 157.37 17.23 Favored 'General case' 0 CA--C 1.512 -0.486 0 CA-C-O 120.797 0.332 . . . . 0.0 111.357 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -94.68 132.62 39.23 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-N 115.879 -0.6 . . . . 0.0 112.602 -177.621 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.548 ' CE1' ' HB2' ' A' ' 85' ' ' GLU . 42.4 m-85 -127.04 140.54 52.22 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 115.133 -0.94 . . . . 0.0 108.915 176.68 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 21.2 m-70 -97.83 145.36 26.48 Favored 'General case' 0 C--N 1.307 -1.246 0 CA-C-O 120.826 0.345 . . . . 0.0 110.672 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.548 HG13 HD13 ' A' ' 110' ' ' ILE . 81.8 t -114.81 126.38 72.36 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.001 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.074 178.477 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 91.2 t -136.43 123.5 32.22 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 179.227 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 73.0 m -94.64 132.05 39.78 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-O 121.435 0.636 . . . . 0.0 112.345 -175.667 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 70.7 m-70 -86.31 -31.22 21.7 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.036 -0.984 . . . . 0.0 110.783 -178.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -148.36 167.39 25.35 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.282 -178.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -79.21 103.36 9.09 Favored 'General case' 0 N--CA 1.446 -0.66 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 174.627 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 163.92 169.85 28.0 Favored Glycine 0 N--CA 1.431 -1.698 0 N-CA-C 111.126 -0.79 . . . . 0.0 111.126 -178.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.566 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 72.1 Cg_endo -81.55 128.73 6.22 Favored 'Trans proline' 0 N--CA 1.443 -1.485 0 C-N-CA 122.283 1.989 . . . . 0.0 112.256 178.563 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -135.04 157.64 76.55 Favored Pre-proline 0 C--N 1.312 -1.058 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.654 178.569 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -64.55 167.21 15.6 Favored 'Trans proline' 0 C--O 1.233 0.263 0 C-N-CA 122.49 2.127 . . . . 0.0 112.72 -177.573 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' HIS . . . . . 0.45 ' HB3' ' O ' ' A' ' 105' ' ' ASN . 4.5 t-80 -88.85 125.08 63.84 Favored Pre-proline 0 C--N 1.315 -0.891 0 N-CA-C 108.814 -0.809 . . . . 0.0 108.814 -179.007 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -53.41 -37.69 82.06 Favored 'Trans proline' 0 N--CA 1.485 0.984 0 C-N-CA 123.286 2.657 . . . . 0.0 113.417 -176.275 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -74.57 -61.81 3.04 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.335 179.127 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.45 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 2.4 p30 -125.21 109.27 12.65 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 120.992 0.425 . . . . 0.0 111.63 -179.13 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.3 t -56.21 -13.91 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.172 0 C-N-CA 123.584 0.754 . . . . 0.0 112.747 179.278 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 12.1 t-80 -69.06 -1.72 8.29 Favored 'General case' 0 CA--C 1.551 1.019 0 CA-C-O 121.533 0.682 . . . . 0.0 110.644 177.316 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 46.4 mtmt -134.83 160.72 37.31 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 178.604 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 11.3 p90 -142.41 173.33 11.63 Favored 'General case' 0 C--N 1.307 -1.269 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.674 179.178 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.566 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.4 mt -132.03 142.48 42.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -178.383 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.7 mp -101.7 114.17 40.19 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 176.16 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 61.8 m -102.15 122.88 45.01 Favored 'General case' 0 C--N 1.307 -1.273 0 CA-C-O 120.989 0.423 . . . . 0.0 111.252 -177.057 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 28.0 m -131.01 145.64 52.11 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 178.02 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -118.17 114.1 22.55 Favored 'General case' 0 C--N 1.31 -1.132 0 CA-C-O 121.201 0.524 . . . . 0.0 110.3 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 63.1 m -88.2 79.94 7.72 Favored 'General case' 0 N--CA 1.432 -1.366 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.354 179.039 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 75.8 -99.06 1.22 Allowed Glycine 0 N--CA 1.435 -1.392 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 -178.442 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 18.8 m -114.06 6.32 16.37 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 120.844 0.355 . . . . 0.0 110.47 179.341 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 18.2 tp -119.12 124.62 47.3 Favored 'General case' 0 C--O 1.221 -0.405 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.768 -177.251 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 88.4 m95 -84.41 133.89 34.49 Favored 'General case' 0 C--N 1.317 -0.832 0 N-CA-C 112.069 0.396 . . . . 0.0 112.069 -179.423 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 71.9 m-85 -123.38 124.83 43.81 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.531 172.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.4 pp -123.91 155.93 30.91 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.86 0 CA-C-O 121.23 0.538 . . . . 0.0 112.06 -177.338 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 34.3 m -142.6 121.21 12.53 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.712 177.535 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.8 p -95.25 117.68 39.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 121.231 0.539 . . . . 0.0 111.268 -178.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.411 ' HA ' ' HE2' ' A' ' 124' ' ' MET . 5.0 mmt -120.16 149.66 49.73 Favored Pre-proline 0 C--N 1.32 -0.692 0 CA-C-N 115.703 -0.68 . . . . 0.0 109.999 -178.55 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -91.64 148.02 3.37 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 122.415 2.076 . . . . 0.0 113.483 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 58.7 m -90.84 172.51 8.57 Favored 'General case' 0 C--O 1.242 0.677 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.783 175.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 39.0 m -65.23 147.87 52.69 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.498 178.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . 0.418 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.9 mp -65.2 129.08 29.0 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.001 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 178.713 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 99.81 -16.22 58.79 Favored Glycine 0 N--CA 1.439 -1.112 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.079 -177.023 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 65.8 p -108.85 159.41 16.81 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-O 120.887 0.375 . . . . 0.0 110.93 178.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.473 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 63.7 pttt -128.83 143.58 50.94 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 178.723 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.444 ' HA ' ' HA ' ' A' ' 139' ' ' CYS . 36.8 t80 -80.73 137.06 36.26 Favored 'General case' 0 C--N 1.314 -0.956 0 C-N-CA 120.294 -0.562 . . . . 0.0 111.324 -179.34 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -108.36 127.13 28.09 Favored Pre-proline 0 C--N 1.32 -0.707 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.105 178.47 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -65.99 -36.89 28.41 Favored 'Trans proline' 0 CA--C 1.53 0.292 0 C-N-CA 122.96 2.44 . . . . 0.0 113.553 -177.062 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.8 mp -77.0 -49.99 21.85 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.322 -177.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 13.1 m -67.83 -35.65 78.98 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 120.728 0.299 . . . . 0.0 110.378 178.893 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' ARG . . . . . 0.4 HH11 ' HD2' ' A' ' 137' ' ' ARG . 66.5 mtt85 71.31 46.21 0.44 Allowed 'General case' 0 CA--C 1.517 -0.297 0 CA-C-N 115.692 -0.685 . . . . 0.0 111.217 178.555 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 11.4 p30 -162.37 177.72 9.3 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 177.7 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' CYS . . . . . 0.444 ' HA ' ' HA ' ' A' ' 132' ' ' PHE . 6.3 m -100.45 125.26 46.73 Favored 'General case' 0 C--N 1.313 -1.019 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -178.914 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 28.4 m -111.97 163.48 8.86 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.09 -178.169 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -70.52 127.3 32.24 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 -179.256 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' ASP . . . . . 0.473 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 22.5 t70 . . . . . 0 CA--C 1.502 -0.882 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.271 -179.312 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 27.0 t70 . . . . . 0 C--O 1.233 0.201 0 CA-C-O 120.863 0.363 . . . . 0.0 110.06 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.452 HD23 HD11 ' A' ' 121' ' ' ILE . 38.6 tp -92.37 145.88 24.13 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.046 179.759 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.585 HG22 HG22 ' A' ' 89' ' ' THR . 4.9 mt -105.1 144.7 14.43 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 178.427 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 15.3 m -141.9 130.69 22.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.042 0.449 . . . . 0.0 110.778 -177.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 8.6 p80 -78.9 122.98 26.8 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.27 177.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.442 ' HG2' HD22 ' A' ' 105' ' ' ASN . 7.5 tp10 -136.88 113.87 10.54 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 116.109 -0.496 . . . . 0.0 109.85 179.028 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 68.04 24.19 74.52 Favored Glycine 0 N--CA 1.447 -0.584 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.043 -179.6 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 91.2 -10.53 74.7 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.997 -0.62 . . . . 0.0 112.688 -179.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -102.77 139.6 38.14 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.666 0.269 . . . . 0.0 110.359 -179.749 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.585 HG22 HG22 ' A' ' 82' ' ' ILE . 0.1 OUTLIER -87.53 106.67 18.15 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-O 120.821 0.343 . . . . 0.0 110.505 179.676 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 75.6 m-85 -96.2 151.99 18.98 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.562 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 36.4 m-70 -106.85 138.86 42.24 Favored 'General case' 0 C--N 1.308 -1.206 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.041 178.814 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 57.4 t -119.13 118.21 56.8 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 177.435 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.8 p -125.52 138.89 52.97 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.072 -178.774 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 82.1 m -121.97 115.11 21.96 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.213 0.53 . . . . 0.0 111.069 -179.355 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 42.8 t60 -92.67 -18.17 23.36 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.565 178.31 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 74.5 mm-40 -142.02 159.85 41.4 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.452 -0.795 . . . . 0.0 109.835 -178.358 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 -79.66 148.37 31.64 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-O 120.992 0.425 . . . . 0.0 110.549 177.784 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 128.06 164.83 11.69 Favored Glycine 0 N--CA 1.434 -1.488 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 -179.528 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.484 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 91.9 Cg_endo -88.5 142.34 5.04 Favored 'Trans proline' 0 N--CA 1.441 -1.591 0 C-N-CA 122.565 2.176 . . . . 0.0 112.817 179.323 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.41 ' O ' ' HB2' ' A' ' 109' ' ' TYR . 1.7 pp -141.36 156.53 67.21 Favored Pre-proline 0 C--N 1.316 -0.876 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.19 177.752 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -62.66 165.65 15.4 Favored 'Trans proline' 0 C--N 1.346 0.437 0 C-N-CA 122.316 2.011 . . . . 0.0 112.901 -177.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' HIS . . . . . 0.481 ' HB3' ' O ' ' A' ' 105' ' ' ASN . 42.8 t-80 -87.12 121.77 71.34 Favored Pre-proline 0 C--N 1.315 -0.913 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.399 -179.266 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 13.7 Cg_endo -56.41 -25.44 57.56 Favored 'Trans proline' 0 N--CA 1.48 0.678 0 C-N-CA 122.887 2.391 . . . . 0.0 112.938 -176.604 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -87.06 -20.14 53.87 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.506 -0.854 . . . . 0.0 113.205 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.481 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 9.5 p30 -168.88 117.7 0.68 Allowed 'General case' 0 N--CA 1.472 0.639 0 CA-C-N 117.213 0.506 . . . . 0.0 110.909 -179.74 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 35.1 m -56.32 -11.38 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 N-CA-C 113.756 1.021 . . . . 0.0 113.756 177.205 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 44.7 m170 -76.76 -0.72 24.84 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 111.957 0.354 . . . . 0.0 111.957 179.67 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.41 ' HG2' ' HA ' ' A' ' 125' ' ' PRO . 39.1 mtmt -139.3 163.82 31.47 Favored 'General case' 0 CA--C 1.503 -0.863 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 179.164 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . 0.41 ' HB2' ' O ' ' A' ' 100' ' ' ILE . 12.4 p90 -144.02 173.27 11.87 Favored 'General case' 0 C--N 1.311 -1.094 0 CA-C-N 116.555 -0.293 . . . . 0.0 111.112 179.533 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.484 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.7 mp -131.18 141.19 46.67 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.968 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 178.276 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.6 mp -99.04 122.72 51.1 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 176.824 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' CYS . . . . . 0.419 ' HA ' HG22 ' A' ' 121' ' ' ILE . 58.8 m -98.14 123.35 42.14 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -178.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 18.9 m -130.1 134.24 47.22 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 120.797 0.332 . . . . 0.0 111.226 -178.729 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.471 ' HE3' ' O ' ' A' ' 116' ' ' GLY . 58.9 tptt -107.31 103.3 12.62 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 178.458 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 51.0 m -101.78 103.01 13.72 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.88 179.757 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.471 ' O ' ' HE3' ' A' ' 114' ' ' LYS . . . 59.8 -106.19 0.92 Allowed Glycine 0 N--CA 1.443 -0.857 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.256 -176.852 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 11.6 t -111.28 3.48 18.38 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-O 120.818 0.342 . . . . 0.0 110.683 178.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -113.16 132.37 55.5 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 120.89 0.376 . . . . 0.0 111.426 -176.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . 0.449 ' CE2' ' HD3' ' A' ' 114' ' ' LYS . 67.1 m95 -90.85 132.1 36.1 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.894 0.378 . . . . 0.0 110.092 175.847 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -123.36 124.64 43.39 Favored 'General case' 0 C--N 1.309 -1.181 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.631 175.801 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.452 HD11 HD23 ' A' ' 81' ' ' LEU . 2.4 pp -124.46 142.13 42.28 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.52 -178.871 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 33.5 m -130.13 126.5 37.67 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-N 116.18 -0.464 . . . . 0.0 109.778 179.377 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.1 p -95.26 110.38 23.98 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 121.413 0.625 . . . . 0.0 110.746 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 3.6 mmt -111.02 144.29 30.07 Favored Pre-proline 0 C--N 1.316 -0.856 0 CA-C-N 115.367 -0.833 . . . . 0.0 109.772 -179.8 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . 0.41 ' HA ' ' HG2' ' A' ' 108' ' ' LYS . 83.6 Cg_endo -89.26 148.62 5.43 Favored 'Trans proline' 0 N--CA 1.45 -1.075 0 C-N-CA 122.237 1.958 . . . . 0.0 112.737 178.388 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' CYS . . . . . 0.407 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 53.3 m -81.97 161.06 23.17 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.095 -0.502 . . . . 0.0 109.794 176.465 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 16.7 t -61.07 142.38 56.7 Favored 'General case' 0 N--CA 1.442 -0.833 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 177.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . 0.405 HD12 ' N ' ' A' ' 128' ' ' ILE . 1.8 mp -54.22 129.6 15.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.468 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 100.15 -7.91 58.84 Favored Glycine 0 N--CA 1.444 -0.79 0 C-N-CA 120.934 -0.65 . . . . 0.0 113.269 -177.776 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 69.5 p -123.49 164.82 18.19 Favored 'General case' 0 C--O 1.237 0.405 0 CA-C-N 117.087 0.443 . . . . 0.0 111.383 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 60.1 pttt -134.74 147.39 50.02 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 178.762 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.42 ' HA ' ' HA ' ' A' ' 139' ' ' CYS . 30.4 t80 -81.78 138.89 35.08 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-O 121.23 0.538 . . . . 0.0 112.355 -177.168 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -108.01 126.98 28.51 Favored Pre-proline 0 C--N 1.324 -0.5 0 CA-C-N 115.51 -0.768 . . . . 0.0 109.533 177.059 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -63.97 -40.17 28.88 Favored 'Trans proline' 0 N--CA 1.474 0.369 0 C-N-CA 122.961 2.441 . . . . 0.0 113.561 -176.55 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 30.8 mm -77.4 -51.96 17.39 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.46 -176.787 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 8.7 m -62.86 -36.12 82.24 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.741 0.305 . . . . 0.0 110.508 178.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 85.9 mtm180 73.11 41.52 0.49 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.909 178.625 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 3.5 p-10 -158.03 178.0 10.7 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 178.543 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' CYS . . . . . 0.42 ' HA ' ' HA ' ' A' ' 132' ' ' PHE . 31.4 m -100.51 125.54 46.85 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-O 121.146 0.498 . . . . 0.0 110.034 -178.74 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.3 m -111.9 165.03 7.23 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 CA-C-N 115.859 -0.61 . . . . 0.0 109.881 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 54.9 tp -57.29 125.0 20.81 Favored 'General case' 0 C--N 1.313 -0.979 0 CA-C-O 121.152 0.501 . . . . 0.0 111.842 -178.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 18.0 t0 . . . . . 0 N--CA 1.442 -0.873 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.958 178.002 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . 0.409 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 15.1 t70 . . . . . 0 C--O 1.233 0.229 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.42 ' HG ' HD11 ' A' ' 121' ' ' ILE . 2.9 tm? -102.63 130.74 49.61 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.147 -179.16 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.42 HG22 HG22 ' A' ' 89' ' ' THR . 6.8 mt -96.17 143.84 11.4 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.848 0 C-N-CA 120.707 -0.397 . . . . 0.0 110.486 -177.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 20.6 m -133.94 167.21 26.79 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 179.796 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' HIS . . . . . 0.448 ' HA ' ' O ' ' A' ' 88' ' ' LYS . 72.0 m-70 -106.95 115.02 29.46 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-O 121.053 0.454 . . . . 0.0 110.969 178.559 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.408 ' HB2' ' CD1' ' A' ' 90' ' ' TYR . 66.4 mm-40 -109.04 104.56 13.79 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 177.378 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 68.0 27.35 73.7 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.301 -0.952 . . . . 0.0 111.224 -178.428 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 95.1 -25.03 26.01 Favored Glycine 0 N--CA 1.443 -0.872 0 C-N-CA 121.41 -0.424 . . . . 0.0 112.73 -179.123 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . 0.448 ' O ' ' HA ' ' A' ' 84' ' ' HIS . 33.4 mmtp -85.93 149.68 25.03 Favored 'General case' 0 C--O 1.222 -0.368 0 CA-C-O 120.64 0.257 . . . . 0.0 110.618 -176.356 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.42 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -87.97 121.44 30.38 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-O 121.155 0.502 . . . . 0.0 112.108 -179.314 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.408 ' CD1' ' HB2' ' A' ' 85' ' ' GLU . 38.2 m-85 -119.19 141.95 48.42 Favored 'General case' 0 C--N 1.313 -1.02 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 176.691 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 32.9 m-70 -92.09 144.77 25.1 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-O 121.051 0.453 . . . . 0.0 111.376 -177.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.409 ' O ' ' HA ' ' A' ' 80' ' ' ASP . 97.9 t -118.04 117.9 56.4 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 176.046 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.6 p -125.83 137.92 56.16 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.847 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.259 -178.072 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 84.9 m -120.73 113.25 19.92 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 46.7 t60 -92.86 -19.2 21.93 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.921 -179.919 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -138.77 157.36 46.22 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.548 -178.025 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 35.7 mt-10 -77.68 135.79 38.12 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.871 176.812 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 130.03 168.37 12.28 Favored Glycine 0 C--N 1.313 -0.7 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.12 -178.102 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -85.0 135.33 5.49 Favored 'Trans proline' 0 N--CA 1.453 -0.872 0 C-N-CA 122.636 2.224 . . . . 0.0 112.613 178.845 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.412 ' O ' ' HB2' ' A' ' 109' ' ' TYR . 1.9 pp -138.76 157.07 72.5 Favored Pre-proline 0 C--N 1.321 -0.666 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.028 178.359 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.401 ' HG3' ' HD3' ' A' ' 134' ' ' PRO . 56.6 Cg_endo -68.06 171.17 12.93 Favored 'Trans proline' 0 C--N 1.348 0.523 0 C-N-CA 122.286 1.991 . . . . 0.0 112.081 -179.527 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' HIS . . . . . 0.416 ' HB3' ' O ' ' A' ' 105' ' ' ASN . 62.5 t-80 -92.34 132.62 31.6 Favored Pre-proline 0 C--N 1.314 -0.943 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -53.34 -49.52 17.15 Favored 'Trans proline' 0 CA--C 1.536 0.594 0 C-N-CA 122.957 2.438 . . . . 0.0 112.533 -177.874 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -63.33 -66.22 2.66 Favored Glycine 0 CA--C 1.526 0.721 0 C-N-CA 121.067 -0.587 . . . . 0.0 113.086 178.787 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.416 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 4.2 p30 -120.95 111.79 17.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.825 0.345 . . . . 0.0 111.63 -179.558 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.421 HG12 ' HB2' ' A' ' 131' ' ' LYS . 20.0 t -59.2 -14.6 5.6 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.904 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.529 177.345 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 22.5 t-80 -66.92 -5.52 12.94 Favored 'General case' 0 CA--C 1.543 0.686 0 CA-C-O 121.355 0.597 . . . . 0.0 110.694 177.739 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 7.5 mtmp? -135.04 156.17 49.49 Favored 'General case' 0 N--CA 1.439 -0.996 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 178.46 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . 0.412 ' HB2' ' O ' ' A' ' 100' ' ' ILE . 12.6 p90 -141.56 170.08 16.39 Favored 'General case' 0 C--N 1.306 -1.284 0 CA-C-O 120.689 0.281 . . . . 0.0 110.405 -178.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 3.3 mp -126.3 140.68 48.04 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 -179.675 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.422 ' O ' ' HA ' ' A' ' 121' ' ' ILE . 4.6 mp -97.9 117.69 43.12 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.031 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 176.076 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 34.7 m -104.38 123.69 47.86 Favored 'General case' 0 C--N 1.312 -1.022 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -178.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 14.3 p -135.87 147.86 48.39 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.55 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.577 ' HE2' ' O ' ' A' ' 116' ' ' GLY . 84.4 tttt -117.34 112.84 21.27 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-O 121.085 0.469 . . . . 0.0 110.552 -178.253 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 75.4 m -97.98 73.02 2.23 Favored 'General case' 0 C--N 1.31 -1.13 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.888 178.295 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.577 ' O ' ' HE2' ' A' ' 114' ' ' LYS . . . 80.97 -98.9 1.87 Allowed Glycine 0 N--CA 1.437 -1.256 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -178.822 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 50.2 m -114.54 5.39 15.49 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 120.856 0.36 . . . . 0.0 110.122 177.282 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 50.1 tp -114.85 121.34 42.94 Favored 'General case' 0 C--O 1.222 -0.383 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.49 -178.062 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 57.4 m95 -89.45 132.5 34.99 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 121.045 0.45 . . . . 0.0 111.932 179.504 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -110.6 126.31 54.32 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.884 175.096 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.476 ' O ' HD12 ' A' ' 121' ' ' ILE . 2.5 pp -126.28 150.62 32.0 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.129 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.709 -179.012 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 26.9 m -151.72 123.57 8.03 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.569 177.487 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 5.3 p -93.64 112.01 25.91 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.324 0 CA-C-O 121.58 0.705 . . . . 0.0 110.912 179.087 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 6.4 mmt -113.54 144.15 30.79 Favored Pre-proline 0 C--N 1.318 -0.792 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.399 -178.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -88.01 144.71 6.22 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 122.564 2.176 . . . . 0.0 112.648 178.666 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' CYS . . . . . 0.44 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 26.3 m -83.26 171.83 13.2 Favored 'General case' 0 C--O 1.244 0.779 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.069 176.066 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 35.7 t -61.15 151.77 30.35 Favored 'General case' 0 N--CA 1.445 -0.687 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 177.451 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . 0.43 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.8 mp -64.21 124.69 19.48 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.193 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.664 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 99.69 -12.96 61.18 Favored Glycine 0 N--CA 1.44 -1.042 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.439 -177.279 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 76.5 p -111.67 149.7 31.21 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-O 121.158 0.504 . . . . 0.0 111.784 179.782 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.421 ' HB2' HG12 ' A' ' 106' ' ' VAL . 58.8 pttt -121.37 144.71 48.51 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 178.869 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.44 ' HB2' ' SG ' ' A' ' 126' ' ' CYS . 45.0 t80 -82.53 136.15 34.93 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-O 121.178 0.513 . . . . 0.0 111.927 -177.497 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . 0.42 ' HB3' ' OG ' ' A' ' 136' ' ' SER . 19.8 t70 -105.16 130.2 23.51 Favored Pre-proline 0 C--N 1.321 -0.659 0 CA-C-N 115.945 -0.571 . . . . 0.0 109.786 177.366 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' PRO . . . . . 0.401 ' HD3' ' HG3' ' A' ' 101' ' ' PRO . 28.2 Cg_endo -64.68 -42.95 14.13 Favored 'Trans proline' 0 N--CA 1.473 0.317 0 C-N-CA 123.018 2.479 . . . . 0.0 114.236 -176.17 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 2.0 mp -77.61 -50.64 19.74 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 N-CA-C 111.943 0.349 . . . . 0.0 111.943 -175.752 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . 0.42 ' OG ' ' HB3' ' A' ' 133' ' ' ASP . 64.1 p -70.44 -29.68 66.33 Favored 'General case' 0 C--N 1.325 -0.498 0 C-N-CA 121.037 -0.265 . . . . 0.0 111.184 -179.058 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 71.21 48.83 0.34 Allowed 'General case' 0 C--O 1.234 0.251 0 CA-C-N 115.813 -0.63 . . . . 0.0 111.783 175.331 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 9.5 p30 -160.83 176.58 11.31 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 177.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 17.3 m -101.43 124.72 47.56 Favored 'General case' 0 C--N 1.313 -1.02 0 C-N-CA 120.414 -0.514 . . . . 0.0 109.969 -178.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 31.7 m -111.66 160.05 11.26 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.889 0 CA-C-N 116.062 -0.517 . . . . 0.0 109.802 -179.588 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 78.7 mt -63.22 132.94 53.36 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-O 121.1 0.476 . . . . 0.0 111.367 -179.037 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 24.5 t70 . . . . . 0 C--N 1.313 -1.001 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 177.493 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 32.1 t70 . . . . . 0 C--O 1.235 0.298 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.423 ' CD2' HD11 ' A' ' 121' ' ' ILE . 52.9 tp -111.57 135.78 51.67 Favored 'General case' 0 C--N 1.312 -1.043 0 C-N-CA 120.939 -0.305 . . . . 0.0 110.687 179.562 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.44 HG22 HG22 ' A' ' 89' ' ' THR . 3.8 mt -100.1 145.95 9.88 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.163 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 179.323 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.563 ' O ' ' HA ' ' A' ' 89' ' ' THR . 30.9 m -141.22 170.83 13.11 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 -179.822 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' HIS . . . . . 0.402 ' HA ' ' O ' ' A' ' 88' ' ' LYS . 50.3 m-70 -114.13 113.27 24.48 Favored 'General case' 0 C--N 1.316 -0.888 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 -179.085 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.409 ' OE1' ' HA ' ' A' ' 85' ' ' GLU . 4.3 mm-40 -112.31 111.84 23.0 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 174.839 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 71.76 13.22 75.02 Favored Glycine 0 N--CA 1.452 -0.235 0 N-CA-C 110.679 -0.968 . . . . 0.0 110.679 -176.633 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 99.76 -17.46 57.39 Favored Glycine 0 N--CA 1.437 -1.295 0 CA-C-N 114.999 -0.601 . . . . 0.0 111.905 -178.18 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . 0.402 ' O ' ' HA ' ' A' ' 84' ' ' HIS . 35.3 mmtp -87.16 143.05 27.47 Favored 'General case' 0 CA--C 1.515 -0.397 0 CA-C-O 120.712 0.292 . . . . 0.0 110.691 -177.728 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.563 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.1 OUTLIER -85.62 130.71 34.5 Favored 'General case' 0 N--CA 1.434 -1.234 0 N-CA-C 112.541 0.571 . . . . 0.0 112.541 -179.076 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.454 ' CD1' ' HA3' ' A' ' 104' ' ' GLY . 82.3 m-85 -128.58 138.68 52.34 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 115.608 -0.723 . . . . 0.0 109.854 176.76 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 17.6 m-70 -88.82 143.5 26.86 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 120.831 0.348 . . . . 0.0 110.668 -179.784 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 62.2 t -117.17 122.72 70.64 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.064 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 177.724 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 52.8 t -125.37 131.13 72.64 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.176 0 CA-C-N 116.079 -0.509 . . . . 0.0 109.671 -178.805 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 87.2 m -104.8 114.28 28.39 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-O 121.182 0.515 . . . . 0.0 109.892 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 26.5 m80 -84.25 -23.46 30.39 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.151 -177.71 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -160.67 176.58 11.38 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.692 -0.686 . . . . 0.0 109.389 -179.043 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -79.89 142.8 34.84 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.885 0.374 . . . . 0.0 110.217 178.291 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 130.71 167.77 12.08 Favored Glycine 0 N--CA 1.442 -0.955 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.405 -178.412 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.416 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 87.7 Cg_endo -89.59 133.13 2.17 Favored 'Trans proline' 0 N--CA 1.449 -1.116 0 C-N-CA 122.918 2.412 . . . . 0.0 112.93 179.415 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -138.04 157.31 73.25 Favored Pre-proline 0 C--N 1.318 -0.776 0 CA-C-N 115.71 -0.677 . . . . 0.0 109.463 177.891 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.484 ' HG3' ' HD3' ' A' ' 134' ' ' PRO . 59.4 Cg_endo -68.8 171.14 13.9 Favored 'Trans proline' 0 CA--C 1.515 -0.427 0 C-N-CA 122.234 1.956 . . . . 0.0 112.234 -178.021 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' HIS . . . . . 0.644 ' HB3' ' O ' ' A' ' 105' ' ' ASN . 50.2 t-80 -90.35 126.68 55.78 Favored Pre-proline 0 N--CA 1.43 -1.434 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 178.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -54.58 -43.74 56.14 Favored 'Trans proline' 0 N--CA 1.474 0.38 0 C-N-CA 122.959 2.439 . . . . 0.0 113.126 -174.03 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.454 ' HA3' ' CD1' ' A' ' 90' ' ' TYR . . . -96.68 4.54 63.76 Favored Glycine 0 N--CA 1.442 -0.951 0 C-N-CA 120.057 -1.068 . . . . 0.0 113.633 -178.452 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.644 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 52.2 t30 -163.84 87.3 0.51 Allowed 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 117.683 0.741 . . . . 0.0 111.17 -179.534 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.9 m -54.93 -11.95 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 N-CA-C 113.859 1.059 . . . . 0.0 113.859 178.177 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 19.1 t-80 -77.21 0.39 22.05 Favored 'General case' 0 CA--C 1.543 0.704 0 CA-C-O 121.413 0.625 . . . . 0.0 110.203 177.169 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 39.8 mttp -133.8 156.29 48.29 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.576 178.516 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 9.1 p90 -141.92 162.54 35.22 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 176.497 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.416 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.3 mp -123.83 140.03 48.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 -178.327 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -99.29 118.84 46.48 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 176.259 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 65.3 m -100.25 123.23 44.23 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 120.743 0.306 . . . . 0.0 110.571 -178.015 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 34.0 t -130.84 139.8 50.19 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.328 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.416 ' HD2' ' CZ2' ' A' ' 119' ' ' TRP . 88.6 tttt -113.92 113.63 25.11 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 120.999 0.428 . . . . 0.0 110.541 -178.707 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 73.4 m -100.52 80.72 2.24 Favored 'General case' 0 N--CA 1.441 -0.887 0 CA-C-O 121.356 0.598 . . . . 0.0 109.974 178.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 76.1 -99.62 1.3 Allowed Glycine 0 N--CA 1.442 -0.914 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.367 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 32.8 m -112.55 4.58 17.44 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.772 0.32 . . . . 0.0 110.59 -179.436 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 12.4 mt -122.77 133.28 54.47 Favored 'General case' 0 N--CA 1.439 -0.995 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.238 -176.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . 0.416 ' CZ2' ' HD2' ' A' ' 114' ' ' LYS . 70.7 m95 -96.04 133.5 40.22 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-O 121.076 0.465 . . . . 0.0 111.472 179.549 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -121.25 122.63 40.35 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 115.785 -0.643 . . . . 0.0 109.38 176.12 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.423 HD11 ' CD2' ' A' ' 81' ' ' LEU . 2.4 pp -122.5 156.22 27.59 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.86 -175.343 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 22.6 m -140.95 123.17 15.72 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.935 178.415 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 5.2 p -95.95 105.29 16.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-O 121.621 0.725 . . . . 0.0 110.841 -179.742 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 3.5 mmt -106.18 139.48 20.32 Favored Pre-proline 0 C--N 1.314 -0.973 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.139 -178.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -85.09 144.63 9.56 Favored 'Trans proline' 0 N--CA 1.448 -1.151 0 C-N-CA 122.2 1.934 . . . . 0.0 112.324 178.617 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' CYS . . . . . 0.537 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 65.7 m -80.61 164.24 23.04 Favored 'General case' 0 C--O 1.242 0.675 0 CA-C-N 116.247 -0.433 . . . . 0.0 109.857 176.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 32.3 t -56.29 148.36 18.8 Favored 'General case' 0 N--CA 1.443 -0.82 0 CA-C-N 116.056 -0.52 . . . . 0.0 109.66 177.082 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . 0.483 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.8 mp -62.97 128.92 25.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.333 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 96.37 -9.04 67.08 Favored Glycine 0 N--CA 1.443 -0.871 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.625 -177.028 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 72.1 p -118.46 153.88 33.39 Favored 'General case' 0 C--O 1.236 0.342 0 CA-C-N 117.292 0.546 . . . . 0.0 111.127 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.419 ' HE2' ' HA ' ' A' ' 142' ' ' ASP . 49.3 pttt -130.0 145.28 51.64 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 116.022 -0.535 . . . . 0.0 109.606 -179.248 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.537 ' HB2' ' SG ' ' A' ' 126' ' ' CYS . 29.4 t80 -84.46 136.88 33.65 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-O 121.088 0.471 . . . . 0.0 111.988 -176.329 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 32.2 t70 -108.56 134.78 20.15 Favored Pre-proline 0 C--N 1.323 -0.556 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.52 177.056 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' PRO . . . . . 0.484 ' HD3' ' HG3' ' A' ' 101' ' ' PRO . 42.0 Cg_endo -68.82 -37.36 11.87 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.577 2.185 . . . . 0.0 113.27 -176.045 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 22.7 mm -77.85 -53.55 14.08 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.881 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.827 -176.426 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 67.0 m -68.98 -29.98 68.3 Favored 'General case' 0 C--N 1.321 -0.662 0 C-N-CA 120.822 -0.351 . . . . 0.0 111.307 178.476 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 89.0 mtm180 70.76 41.57 0.88 Allowed 'General case' 0 N--CA 1.473 0.704 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.656 175.665 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 10.7 p30 -155.66 174.35 15.42 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 177.404 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' CYS . . . . . 0.442 ' HA ' ' HA ' ' A' ' 132' ' ' PHE . 6.4 m -101.26 124.88 47.64 Favored 'General case' 0 C--N 1.314 -0.943 0 C-N-CA 120.341 -0.544 . . . . 0.0 109.62 -179.28 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 33.9 m -107.01 159.8 6.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.833 -179.236 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 55.4 tp -63.47 119.82 10.5 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-O 120.972 0.415 . . . . 0.0 111.456 -178.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' ASP . . . . . 0.419 ' HA ' ' HE2' ' A' ' 131' ' ' LYS . 21.2 t70 . . . . . 0 N--CA 1.442 -0.85 0 CA-C-O 121.463 0.649 . . . . 0.0 109.309 176.653 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . 0.636 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 7.6 p-10 . . . . . 0 N--CA 1.451 -0.392 0 CA-C-O 121.352 0.596 . . . . 0.0 111.028 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 47.0 tp -97.04 140.47 31.51 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.417 177.833 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.591 HG22 HG22 ' A' ' 89' ' ' THR . 5.5 mt -100.26 145.95 9.97 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.996 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 179.745 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.473 ' O ' ' HA ' ' A' ' 89' ' ' THR . 17.1 m -142.87 176.01 3.76 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.88 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -179.611 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 41.7 m-70 -117.13 120.93 39.81 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-O 121.108 0.48 . . . . 0.0 111.9 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.433 ' HB2' ' CE1' ' A' ' 90' ' ' TYR . 45.2 mt-10 -126.17 116.09 20.79 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.264 176.51 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 67.16 23.76 73.17 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.624 -0.798 . . . . 0.0 111.232 -178.557 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 93.55 -28.0 11.0 Favored Glycine 0 N--CA 1.443 -0.858 0 C-N-CA 121.437 -0.411 . . . . 0.0 112.725 -178.282 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 44.3 mmtm -84.91 155.01 21.86 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.69 0.281 . . . . 0.0 111.136 -177.058 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.591 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -92.42 137.4 32.4 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.488 -179.949 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.433 ' CE1' ' HB2' ' A' ' 85' ' ' GLU . 89.7 m-85 -131.6 145.38 51.67 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 178.583 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 20.0 m-70 -98.88 143.6 29.01 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-O 120.951 0.405 . . . . 0.0 110.579 179.606 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.636 ' O ' ' HA ' ' A' ' 80' ' ' ASP . 57.2 t -113.93 118.55 58.68 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.161 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 177.109 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 37.3 t -121.15 137.54 54.52 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.242 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 -178.282 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 72.4 m -114.53 113.61 24.66 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-O 120.988 0.423 . . . . 0.0 111.13 -179.751 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 20.8 t60 -81.03 -24.14 38.1 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.769 -0.651 . . . . 0.0 111.076 -178.846 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -154.34 169.6 23.3 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.551 -0.295 . . . . 0.0 110.615 -178.281 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 21.0 mp0 -76.61 110.61 11.32 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.378 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 161.87 165.84 19.52 Favored Glycine 0 N--CA 1.446 -0.663 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.315 179.85 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.446 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 92.3 Cg_endo -85.75 135.11 4.81 Favored 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 122.907 2.404 . . . . 0.0 112.503 178.628 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -139.92 156.95 70.39 Favored Pre-proline 0 C--N 1.319 -0.724 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.525 179.394 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -63.51 169.21 10.1 Favored 'Trans proline' 0 C--N 1.353 0.775 0 C-N-CA 122.683 2.255 . . . . 0.0 112.54 -179.649 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' HIS . . . . . 0.474 ' CD2' HD11 ' A' ' 110' ' ' ILE . 5.2 t-80 -94.31 138.46 22.47 Favored Pre-proline 0 C--N 1.322 -0.602 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 -178.108 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -53.45 -50.2 14.72 Favored 'Trans proline' 0 CA--C 1.536 0.584 0 C-N-CA 123.109 2.539 . . . . 0.0 113.121 -178.624 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -71.1 -65.21 2.53 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.591 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 43.7 m-80 -115.06 104.94 12.38 Favored 'General case' 0 C--N 1.321 -0.658 0 O-C-N 122.865 -0.197 . . . . 0.0 111.365 -179.806 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 18.5 m -56.25 -12.04 0.99 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 N-CA-C 112.011 0.374 . . . . 0.0 112.011 173.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 24.3 t-80 -66.36 -8.26 24.28 Favored 'General case' 0 CA--C 1.544 0.719 0 CA-C-O 121.407 0.622 . . . . 0.0 110.076 175.58 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 48.4 mtmt -129.55 157.25 42.55 Favored 'General case' 0 N--CA 1.439 -1.001 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.623 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 12.9 p90 -142.14 167.38 22.26 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 120.181 -0.608 . . . . 0.0 111.133 -179.804 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.474 HD11 ' CD2' ' A' ' 102' ' ' HIS . 2.3 mp -126.43 139.4 51.78 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.112 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.173 -179.146 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.7 mp -98.74 116.45 41.73 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.144 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 175.336 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 39.9 m -95.99 121.82 38.14 Favored 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 16.6 t -130.36 149.4 52.06 Favored 'General case' 0 N--CA 1.437 -1.098 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.117 -178.624 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.508 ' HE3' ' CE2' ' A' ' 119' ' ' TRP . 9.1 mmtp -103.23 140.46 37.34 Favored 'General case' 0 C--N 1.308 -1.203 0 CA-C-O 121.224 0.535 . . . . 0.0 111.732 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 57.7 m -124.26 79.92 1.78 Allowed 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 174.207 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 73.39 -104.4 1.58 Allowed Glycine 0 N--CA 1.431 -1.68 0 CA-C-N 114.788 -1.096 . . . . 0.0 110.517 -174.851 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 12.1 p -113.01 16.39 19.35 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-O 120.899 0.38 . . . . 0.0 111.134 178.719 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 24.2 tp -122.14 142.92 49.89 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.289 -177.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . 0.508 ' CE2' ' HE3' ' A' ' 114' ' ' LYS . 91.1 m95 -92.15 133.39 35.82 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 120.984 0.421 . . . . 0.0 111.67 179.161 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 49.2 m-85 -124.19 122.81 38.81 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.123 172.3 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.5 pp -119.78 155.95 22.46 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.44 -176.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 25.7 m -141.06 119.74 12.49 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.655 178.353 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 4.2 p -94.02 109.06 21.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-O 121.684 0.754 . . . . 0.0 111.108 -179.138 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 5.3 mmt -107.82 127.4 27.79 Favored Pre-proline 0 C--N 1.309 -1.183 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.288 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -78.75 142.08 17.64 Favored 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 122.325 2.017 . . . . 0.0 110.819 176.21 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 10.4 t -93.62 -179.08 4.91 Favored 'General case' 0 C--N 1.317 -0.824 0 C-N-CA 120.484 -0.487 . . . . 0.0 110.382 179.745 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 34.0 t -62.94 146.51 52.86 Favored 'General case' 0 N--CA 1.438 -1.035 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.691 -179.472 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . 0.422 ' N ' HD12 ' A' ' 128' ' ' ILE . 2.0 mp -62.91 129.82 26.78 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-N 116.131 -0.486 . . . . 0.0 109.839 179.397 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.86 -4.04 68.05 Favored Glycine 0 N--CA 1.44 -1.099 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.949 -178.343 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 34.9 p -128.14 150.39 50.01 Favored 'General case' 0 C--O 1.237 0.447 0 CA-C-N 117.28 0.54 . . . . 0.0 110.885 178.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.421 ' O ' ' HA ' ' A' ' 139' ' ' CYS . 62.7 pttt -127.03 154.96 43.98 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.966 -179.616 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 40.3 t80 -87.18 136.87 32.76 Favored 'General case' 0 C--N 1.311 -1.078 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.109 -178.682 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -99.01 134.41 21.44 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.782 178.748 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 26.6 Cg_endo -62.04 -51.3 3.85 Favored 'Trans proline' 0 CA--C 1.532 0.39 0 C-N-CA 123.017 2.478 . . . . 0.0 114.116 -176.63 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 47.2 mm -81.23 -47.25 20.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 112.112 0.412 . . . . 0.0 112.112 -175.803 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.5 m -65.98 -34.46 78.15 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.833 0.349 . . . . 0.0 110.446 -179.228 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 87.7 mtm180 66.14 53.05 1.1 Allowed 'General case' 0 CA--C 1.516 -0.337 0 CA-C-N 115.404 -0.817 . . . . 0.0 110.554 177.757 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 28.2 p-10 -157.47 176.52 12.55 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.034 -0.985 . . . . 0.0 109.191 179.443 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' CYS . . . . . 0.421 ' HA ' ' O ' ' A' ' 131' ' ' LYS . 68.0 m -102.62 131.07 49.64 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-O 121.006 0.431 . . . . 0.0 111.91 178.628 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 33.8 m -125.55 165.85 22.42 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.216 177.288 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -50.26 118.18 2.82 Favored 'General case' 0 N--CA 1.474 0.739 0 CA-C-O 121.108 0.48 . . . . 0.0 111.644 179.809 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 15.3 t0 . . . . . 0 N--CA 1.445 -0.698 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 177.35 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 11.0 t70 . . . . . 0 N--CA 1.454 -0.232 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.461 HD22 ' CD1' ' A' ' 121' ' ' ILE . 23.9 tp -90.54 148.57 22.63 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-O 120.865 0.364 . . . . 0.0 110.978 -177.387 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.529 HG22 HG22 ' A' ' 89' ' ' THR . 7.7 mt -105.92 144.77 14.79 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 175.835 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.459 HG21 ' NE2' ' A' ' 102' ' ' HIS . 16.1 m -132.27 158.16 43.23 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 -178.473 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 6.8 p80 -116.49 101.98 9.1 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-O 121.226 0.536 . . . . 0.0 111.571 -177.721 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -117.27 114.09 23.11 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.12 179.116 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 67.05 22.58 72.48 Favored Glycine 0 CA--C 1.519 0.337 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.478 179.67 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 90.02 -4.71 83.23 Favored Glycine 0 N--CA 1.445 -0.707 0 C-N-CA 121.174 -0.536 . . . . 0.0 112.365 -179.686 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 35.0 mmtp -100.26 134.34 43.34 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 120.716 0.293 . . . . 0.0 110.349 -179.411 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.529 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -88.03 107.74 18.89 Favored 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.257 179.466 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -101.23 146.91 26.9 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.598 178.364 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 18.2 m-70 -98.22 140.04 33.1 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-O 120.881 0.372 . . . . 0.0 110.612 177.653 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 44.5 t -122.04 118.43 55.48 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.481 178.323 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.3 p -129.44 132.76 66.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.494 179.356 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 77.2 m -111.96 123.1 49.53 Favored 'General case' 0 C--N 1.308 -1.228 0 CA-C-O 121.059 0.457 . . . . 0.0 111.11 -178.47 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 34.2 m80 -100.7 -21.6 15.16 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 178.436 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -129.14 144.2 51.12 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.14 -0.937 . . . . 0.0 109.526 -178.83 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . 0.479 ' HG3' ' HA ' ' A' ' 113' ' ' SER . 42.3 tt0 -76.23 138.73 40.79 Favored 'General case' 0 N--CA 1.43 -1.432 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 177.883 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 132.17 173.86 13.45 Favored Glycine 0 N--CA 1.439 -1.107 0 C-N-CA 120.902 -0.666 . . . . 0.0 111.77 -178.21 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -87.36 134.07 3.39 Favored 'Trans proline' 0 N--CA 1.452 -0.961 0 C-N-CA 122.912 2.408 . . . . 0.0 112.951 179.142 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.8 pp -137.02 157.24 75.0 Favored Pre-proline 0 C--N 1.323 -0.544 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.899 178.43 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -65.34 162.58 32.89 Favored 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.41 2.073 . . . . 0.0 113.126 -177.794 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' HIS . . . . . 0.459 ' NE2' HG21 ' A' ' 83' ' ' VAL . 59.5 t-80 -91.78 120.93 67.83 Favored Pre-proline 0 C--N 1.316 -0.881 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.536 179.676 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_endo -60.72 -16.93 46.71 Favored 'Trans proline' 0 N--CA 1.482 0.841 0 C-N-CA 123.132 2.555 . . . . 0.0 113.466 -175.842 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -89.99 -24.09 30.73 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.556 -0.83 . . . . 0.0 112.563 179.874 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 25.7 p-10 -167.4 106.89 0.57 Allowed 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 110.108 -0.33 . . . . 0.0 110.108 -179.174 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 31.2 m -53.09 -11.32 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.045 0 N-CA-C 114.01 1.115 . . . . 0.0 114.01 -179.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -80.48 2.31 25.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.154 0.502 . . . . 0.0 110.935 178.49 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 34.1 mtmt -133.76 156.5 47.86 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 177.736 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 6.6 p90 -142.51 166.21 25.28 Favored 'General case' 0 C--N 1.311 -1.099 0 C-N-CA 120.871 -0.332 . . . . 0.0 110.476 179.331 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 3.7 mp -123.74 137.67 56.09 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.474 ' O ' ' HA ' ' A' ' 121' ' ' ILE . 4.2 mp -95.64 121.74 46.47 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.997 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 176.696 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 25.4 m -105.46 127.16 52.85 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 -178.859 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . 0.479 ' HA ' ' HG3' ' A' ' 97' ' ' GLU . 52.5 m -126.52 131.79 51.51 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.402 179.251 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.632 ' HE2' ' O ' ' A' ' 116' ' ' GLY . 23.7 tptm -97.49 113.57 25.28 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 120.705 0.288 . . . . 0.0 110.659 -178.87 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 72.1 m -112.99 80.03 1.3 Allowed 'General case' 0 N--CA 1.442 -0.863 0 CA-C-O 121.265 0.555 . . . . 0.0 110.286 178.447 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.632 ' O ' ' HE2' ' A' ' 114' ' ' LYS . . . 74.35 -99.28 1.07 Allowed Glycine 0 N--CA 1.446 -0.679 0 CA-C-N 115.349 -0.841 . . . . 0.0 111.037 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 48.8 p -113.52 4.1 16.05 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 121.12 0.486 . . . . 0.0 110.433 178.065 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 26.8 tp -117.5 132.16 56.59 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.954 -175.479 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . 0.447 ' CE2' ' HD3' ' A' ' 114' ' ' LYS . 86.3 m95 -94.78 132.06 39.96 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 120.883 0.373 . . . . 0.0 110.746 177.116 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 51.0 m-85 -108.65 128.04 54.5 Favored 'General case' 0 C--N 1.309 -1.162 0 N-CA-C 108.876 -0.786 . . . . 0.0 108.876 174.156 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.474 ' HA ' ' O ' ' A' ' 111' ' ' ILE . 1.8 pp -133.2 153.4 37.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-O 121.367 0.603 . . . . 0.0 112.616 -175.695 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 19.4 m -150.44 127.58 11.24 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.188 178.074 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 4.0 p -98.77 106.74 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 CA-C-O 121.57 0.7 . . . . 0.0 111.061 -178.504 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 3.5 mmt -108.03 140.27 21.49 Favored Pre-proline 0 C--N 1.309 -1.166 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.654 -179.325 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_endo -82.48 141.47 11.23 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 122.386 2.058 . . . . 0.0 111.36 176.649 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 5.9 t -94.16 -174.87 3.51 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 120.648 -0.421 . . . . 0.0 110.667 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 15.5 m -61.53 137.16 58.23 Favored 'General case' 0 N--CA 1.441 -0.896 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.627 178.413 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 2.4 mp -65.84 139.35 21.41 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.914 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 178.33 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 93.55 -13.93 66.42 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.313 -176.03 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 73.6 p -117.41 159.53 22.64 Favored 'General case' 0 N--CA 1.447 -0.614 0 O-C-N 122.479 -0.424 . . . . 0.0 110.735 179.319 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 59.8 pttt -129.07 148.29 51.0 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.698 179.609 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.441 ' HD1' ' SG ' ' A' ' 139' ' ' CYS . 25.5 t80 -87.68 135.63 33.29 Favored 'General case' 0 C--N 1.308 -1.229 0 CA-C-O 120.825 0.345 . . . . 0.0 110.714 -178.58 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 30.5 t70 -102.47 134.99 19.64 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.015 178.706 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.23 -41.16 13.28 Favored 'Trans proline' 0 C--N 1.346 0.419 0 C-N-CA 123.021 2.481 . . . . 0.0 113.862 -176.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 33.1 mm -81.39 -52.69 13.57 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 C-N-CA 120.819 -0.353 . . . . 0.0 111.525 -176.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 7.2 m -62.69 -36.79 84.06 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 120.855 0.359 . . . . 0.0 110.394 179.153 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 80.5 mtm180 69.36 42.83 1.12 Allowed 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 115.356 -0.838 . . . . 0.0 111.157 177.24 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 10.5 p30 -154.39 177.57 11.01 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 108.393 -0.965 . . . . 0.0 108.393 177.197 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' CYS . . . . . 0.441 ' SG ' ' HD1' ' A' ' 132' ' ' PHE . 78.1 m -101.77 126.68 48.68 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-O 121.385 0.612 . . . . 0.0 111.737 -177.91 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 26.8 m -115.2 159.1 15.26 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-N 115.185 -0.916 . . . . 0.0 109.553 179.436 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 2.3 tm? -55.41 123.24 13.23 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 120.963 0.411 . . . . 0.0 110.915 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 16.5 t70 . . . . . 0 C--N 1.324 -0.539 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.045 -179.467 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 10.2 t70 . . . . . 0 C--O 1.237 0.396 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.431 ' CD2' HD11 ' A' ' 121' ' ' ILE . 35.3 tp -101.26 147.14 26.64 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.244 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.548 HG22 HG22 ' A' ' 89' ' ' THR . 4.0 mt -110.24 148.29 13.88 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.869 0 C-N-CA 120.561 -0.455 . . . . 0.0 110.374 178.553 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.477 ' O ' ' HA ' ' A' ' 89' ' ' THR . 4.8 m -142.44 174.72 5.39 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 179.58 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 11.0 p80 -128.21 108.36 10.55 Favored 'General case' 0 C--N 1.313 -1.0 0 N-CA-C 112.503 0.557 . . . . 0.0 112.503 -177.751 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 3.9 mp0 -116.65 113.63 22.94 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.105 178.708 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 66.68 31.64 79.05 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.628 178.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 86.19 -11.75 62.15 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.839 -0.696 . . . . 0.0 113.201 179.243 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 30.2 mmtp -99.09 136.94 38.32 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.871 0.336 . . . . 0.0 111.166 -179.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.548 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -86.54 107.77 18.27 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.474 179.268 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -100.3 145.14 28.48 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.816 179.258 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 27.1 m-70 -99.43 144.09 28.94 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.36 178.355 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 46.2 t -120.51 118.38 56.39 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.078 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 178.452 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 44.1 t -124.56 132.6 71.1 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.274 179.478 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 71.3 m -104.43 113.77 27.55 Favored 'General case' 0 C--N 1.31 -1.141 0 CA-C-O 121.113 0.482 . . . . 0.0 110.305 -179.564 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 19.0 t60 -79.49 -21.2 45.66 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.509 -178.144 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -161.53 175.81 11.72 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.654 179.714 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -77.92 144.6 36.73 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 120.735 0.302 . . . . 0.0 110.461 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 126.45 164.41 11.74 Favored Glycine 0 N--CA 1.446 -0.658 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.41 -179.685 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.413 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 92.1 Cg_endo -86.78 138.28 5.09 Favored 'Trans proline' 0 CA--C 1.54 0.814 0 C-N-CA 122.869 2.379 . . . . 0.0 113.179 179.376 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -140.91 157.27 67.75 Favored Pre-proline 0 C--N 1.325 -0.482 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.169 177.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -64.22 166.94 15.54 Favored 'Trans proline' 0 C--N 1.353 0.763 0 C-N-CA 122.666 2.244 . . . . 0.0 112.848 -179.138 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' HIS . . . . . . . . . . . . . 56.5 t-80 -92.82 128.36 44.09 Favored Pre-proline 0 C--N 1.318 -0.769 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.592 -179.088 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -63.09 -19.25 68.46 Favored 'Trans proline' 0 N--CA 1.484 0.934 0 C-N-CA 123.146 2.564 . . . . 0.0 113.398 -176.841 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -96.81 -17.54 32.58 Favored Glycine 0 C--O 1.228 -0.275 0 C-N-CA 120.485 -0.865 . . . . 0.0 113.226 -178.846 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.404 HD21 ' HE2' ' A' ' 108' ' ' LYS . 28.2 p-10 -169.23 104.21 0.37 Allowed 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.698 0.285 . . . . 0.0 110.8 -179.36 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 26.0 m -53.82 -13.14 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 N-CA-C 113.935 1.087 . . . . 0.0 113.935 179.069 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 36.4 m170 -74.88 0.11 16.7 Favored 'General case' 0 N--CA 1.471 0.621 0 CA-C-O 121.081 0.467 . . . . 0.0 110.858 177.043 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.404 ' HE2' HD21 ' A' ' 105' ' ' ASN . 31.2 mtmt -134.91 156.69 48.52 Favored 'General case' 0 CA--C 1.507 -0.705 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 178.555 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 9.9 p90 -142.47 168.74 19.01 Favored 'General case' 0 C--N 1.31 -1.135 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.433 178.828 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.413 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.5 mp -126.2 140.02 49.89 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 -179.82 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -98.7 118.16 44.83 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 176.287 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 68.8 m -100.4 123.61 44.85 Favored 'General case' 0 C--N 1.308 -1.232 0 CA-C-O 120.873 0.368 . . . . 0.0 110.418 -178.462 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 56.0 p -131.87 141.19 49.32 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 178.42 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 81.2 tttt -116.52 106.24 13.36 Favored 'General case' 0 C--N 1.311 -1.087 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.621 -178.611 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 69.6 m -88.59 84.48 6.75 Favored 'General case' 0 N--CA 1.436 -1.154 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.52 179.094 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 73.98 -100.2 1.11 Allowed Glycine 0 N--CA 1.439 -1.103 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -178.153 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 50.3 m -115.04 3.62 14.49 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-O 121.203 0.525 . . . . 0.0 109.826 178.633 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 92.2 mt -108.54 122.82 47.85 Favored 'General case' 0 N--CA 1.435 -1.209 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.542 -176.248 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 86.6 m95 -87.65 130.51 34.76 Favored 'General case' 0 C--N 1.315 -0.903 0 C-N-CA 120.414 -0.514 . . . . 0.0 111.315 179.145 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 85.6 m-85 -122.61 125.73 46.25 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.585 174.133 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.431 HD11 ' CD2' ' A' ' 81' ' ' LEU . 2.2 pp -124.95 157.88 33.06 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.177 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.035 -178.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 32.7 m -145.32 121.66 10.93 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 116.148 -0.478 . . . . 0.0 109.718 177.178 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.5 p -93.81 106.41 18.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 CA-C-O 121.491 0.663 . . . . 0.0 110.775 -178.685 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 4.2 mmt -106.75 136.3 19.44 Favored Pre-proline 0 C--N 1.31 -1.111 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.97 -178.662 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -82.54 139.3 10.09 Favored 'Trans proline' 0 N--CA 1.45 -1.062 0 C-N-CA 122.411 2.074 . . . . 0.0 110.87 176.078 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 4.7 t -94.61 -178.62 4.61 Favored 'General case' 0 C--N 1.311 -1.071 0 C-N-CA 120.104 -0.639 . . . . 0.0 109.325 177.831 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 15.4 m -63.56 135.1 56.58 Favored 'General case' 0 N--CA 1.435 -1.204 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.408 179.756 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . 0.401 ' N ' HD12 ' A' ' 128' ' ' ILE . 2.2 mp -62.62 141.36 18.07 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 N-CA-C 109.014 -0.735 . . . . 0.0 109.014 178.264 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.8 -10.61 74.17 Favored Glycine 0 N--CA 1.441 -0.985 0 C-N-CA 120.285 -0.959 . . . . 0.0 112.551 -175.186 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 73.5 p -125.02 152.96 43.57 Favored 'General case' 0 N--CA 1.45 -0.438 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 177.003 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 60.5 pttt -126.85 146.69 50.18 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 110.327 -0.249 . . . . 0.0 110.327 -178.366 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 37.9 t80 -84.42 131.38 34.68 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.87 -178.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 23.1 t70 -97.41 133.84 23.32 Favored Pre-proline 0 C--N 1.321 -0.65 0 CA-C-N 116.068 -0.515 . . . . 0.0 109.907 179.29 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -68.02 -40.83 8.43 Favored 'Trans proline' 0 CA--C 1.531 0.371 0 C-N-CA 122.69 2.26 . . . . 0.0 113.842 -177.242 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.8 mp -80.3 -52.05 15.09 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 111.778 0.288 . . . . 0.0 111.778 -177.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 2.1 m -67.03 -35.11 79.17 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.079 0.466 . . . . 0.0 110.092 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 50.7 mtm180 66.37 56.22 0.8 Allowed 'General case' 0 C--O 1.238 0.464 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.645 178.402 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 29.4 p-10 -162.18 174.92 12.26 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 114.647 -1.16 . . . . 0.0 108.75 178.785 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 79.2 m -102.72 126.48 49.84 Favored 'General case' 0 C--N 1.311 -1.068 0 CA-C-O 121.023 0.44 . . . . 0.0 110.805 179.152 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 32.3 m -120.33 170.29 10.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.738 -0.664 . . . . 0.0 110.293 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -51.11 116.89 2.22 Favored 'General case' 0 C--O 1.241 0.615 0 O-C-N 123.545 0.528 . . . . 0.0 110.722 178.794 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 9.7 t70 . . . . . 0 CA--C 1.508 -0.669 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.606 179.766 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 . . . . . 0 N--CA 1.447 -0.594 0 CA-C-O 121.244 0.545 . . . . 0.0 110.012 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.453 HD23 HD11 ' A' ' 121' ' ' ILE . 49.4 tp -127.2 135.73 51.06 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 115.417 -0.811 . . . . 0.0 111.276 178.312 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.505 HG22 HG22 ' A' ' 89' ' ' THR . 22.1 mt -94.84 144.58 9.52 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.131 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 176.017 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.553 HG21 ' CE1' ' A' ' 102' ' ' HIS . 20.5 m -131.34 174.22 13.44 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 N-CA-C 109.997 -0.371 . . . . 0.0 109.997 -177.261 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 27.2 m-70 -122.07 101.92 7.83 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 116.528 -0.305 . . . . 0.0 110.93 -178.822 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 34.8 mm-40 -111.32 117.57 33.5 Favored 'General case' 0 C--N 1.32 -0.697 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 178.121 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 63.33 29.24 73.91 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.863 -0.684 . . . . 0.0 111.867 -179.427 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 84.96 -9.35 66.35 Favored Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 121.087 -0.578 . . . . 0.0 113.132 -179.79 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 13.6 mptt -100.57 141.58 33.23 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.993 0.425 . . . . 0.0 111.327 -179.359 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.505 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -82.97 122.24 28.03 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.67 179.47 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 76.1 m-85 -118.21 143.08 46.82 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 176.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 17.7 m-70 -94.46 139.59 30.94 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-O 120.65 0.262 . . . . 0.0 110.664 -178.275 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 60.4 t -119.46 118.14 56.36 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.88 0 N-CA-C 108.99 -0.745 . . . . 0.0 108.99 177.126 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 53.3 t -126.21 133.96 67.58 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.945 -178.741 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 66.6 m -114.64 121.25 42.83 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-O 120.779 0.323 . . . . 0.0 110.372 -178.819 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 39.1 m80 -90.23 -18.45 25.66 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.183 -179.811 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -150.11 170.05 19.82 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.648 -177.509 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -87.46 114.23 23.88 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.182 177.414 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 167.46 166.11 25.99 Favored Glycine 0 N--CA 1.436 -1.351 0 C-N-CA 121.049 -0.596 . . . . 0.0 111.624 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.501 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 87.6 Cg_endo -87.21 130.98 3.0 Favored 'Trans proline' 0 N--CA 1.45 -1.068 0 C-N-CA 122.761 2.307 . . . . 0.0 112.773 178.763 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.5 pp -140.94 156.74 68.41 Favored Pre-proline 0 C--N 1.319 -0.751 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.908 178.264 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -64.72 167.32 15.69 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 122.824 2.349 . . . . 0.0 113.163 -177.538 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' HIS . . . . . 0.553 ' CE1' HG21 ' A' ' 83' ' ' VAL . 4.9 t-80 -93.18 123.77 59.85 Favored Pre-proline 0 C--N 1.316 -0.87 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 -179.207 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 23.2 Cg_endo -58.64 -29.56 89.62 Favored 'Trans proline' 0 N--CA 1.482 0.817 0 C-N-CA 123.147 2.565 . . . . 0.0 114.155 -174.326 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -90.21 -16.08 56.29 Favored Glycine 0 C--N 1.319 -0.389 0 C-N-CA 120.085 -1.055 . . . . 0.0 113.238 -178.547 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 9.3 p-10 -168.07 97.47 0.44 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 120.773 0.321 . . . . 0.0 110.61 -177.122 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 30.5 m -56.07 -10.52 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 N-CA-C 113.768 1.025 . . . . 0.0 113.768 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 32.2 m170 -70.38 0.23 6.95 Favored 'General case' 0 N--CA 1.478 0.927 0 CA-C-O 121.352 0.596 . . . . 0.0 110.327 175.499 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.415 ' HG2' ' HA ' ' A' ' 125' ' ' PRO . 86.5 mttt -134.16 157.99 44.81 Favored 'General case' 0 CA--C 1.505 -0.758 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.021 178.91 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 12.3 p90 -143.44 165.83 26.45 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.391 176.616 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.501 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 2.3 mp -124.52 140.59 47.32 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.166 0 CA-C-O 120.798 0.333 . . . . 0.0 110.233 -178.758 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.4 mp -103.33 114.09 41.96 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 175.595 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 34.4 m -96.88 123.02 40.48 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -178.119 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 29.7 p -134.62 145.65 48.82 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-O 120.955 0.407 . . . . 0.0 111.087 -178.497 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . 0.534 ' HE2' ' O ' ' A' ' 116' ' ' GLY . 87.2 tttt -111.3 120.46 42.31 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-N 115.99 -0.55 . . . . 0.0 109.545 179.195 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 57.6 m -103.33 85.86 2.56 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.75 178.828 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.534 ' O ' ' HE2' ' A' ' 114' ' ' LYS . . . 66.91 -100.65 0.58 Allowed Glycine 0 N--CA 1.442 -0.958 0 CA-C-N 115.221 -0.899 . . . . 0.0 111.882 -178.58 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 15.1 m -110.3 6.58 22.56 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 120.741 0.305 . . . . 0.0 111.332 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -124.89 135.67 53.08 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 122.235 -0.291 . . . . 0.0 110.469 -178.768 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 52.6 m95 -94.65 135.79 35.71 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 120.945 0.402 . . . . 0.0 111.73 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -129.23 129.58 45.19 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.999 176.485 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.453 HD11 HD23 ' A' ' 81' ' ' LEU . 2.6 pp -123.86 147.63 28.21 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 120.82 0.343 . . . . 0.0 110.819 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 25.0 m -132.01 124.35 29.13 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.515 -179.326 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 4.4 p -98.25 108.71 22.46 Favored 'Isoleucine or valine' 0 C--O 1.236 0.373 0 CA-C-O 121.496 0.665 . . . . 0.0 110.813 179.38 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 5.5 mmt -107.33 129.95 23.54 Favored Pre-proline 0 C--N 1.307 -1.253 0 CA-C-N 115.424 -0.807 . . . . 0.0 110.658 -179.054 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . 0.415 ' HA ' ' HG2' ' A' ' 108' ' ' LYS . 74.5 Cg_endo -79.52 134.48 11.16 Favored 'Trans proline' 0 N--CA 1.452 -0.92 0 C-N-CA 122.244 1.963 . . . . 0.0 110.817 176.463 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 5.0 t -88.57 -177.51 5.6 Favored 'General case' 0 C--N 1.311 -1.095 0 C-N-CA 120.267 -0.573 . . . . 0.0 110.354 -179.075 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 4.9 m -63.41 147.61 50.77 Favored 'General case' 0 N--CA 1.441 -0.894 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.188 -179.838 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . 0.408 ' N ' HD12 ' A' ' 128' ' ' ILE . 2.1 mp -65.97 139.13 21.75 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.584 178.36 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 88.72 -12.21 66.26 Favored Glycine 0 N--CA 1.441 -1.018 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.556 -177.781 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 64.1 p -118.41 156.48 28.91 Favored 'General case' 0 N--CA 1.448 -0.547 0 CA-C-N 117.163 0.481 . . . . 0.0 110.847 178.73 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.456 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 62.1 pttt -133.28 152.16 51.92 Favored 'General case' 0 C--N 1.316 -0.886 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 20.8 t80 -86.1 136.16 33.33 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-O 121.004 0.431 . . . . 0.0 111.348 -179.062 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -101.48 134.64 20.13 Favored Pre-proline 0 C--N 1.325 -0.461 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.909 178.05 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -71.99 -33.06 10.26 Favored 'Trans proline' 0 CA--C 1.533 0.467 0 C-N-CA 122.65 2.233 . . . . 0.0 113.924 -177.258 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.7 mp -81.04 -55.12 8.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 111.697 0.258 . . . . 0.0 111.697 -177.737 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 49.9 m -72.84 -30.82 64.32 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.602 0.239 . . . . 0.0 111.073 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 68.54 50.32 0.7 Allowed 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.102 178.73 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 30.1 p-10 -151.96 176.43 11.49 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-N 115.262 -0.881 . . . . 0.0 108.954 178.855 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' CYS . . . . . 0.414 ' HA ' ' O ' ' A' ' 131' ' ' LYS . 85.5 m -102.36 126.18 49.3 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-O 121.037 0.446 . . . . 0.0 110.474 178.333 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.6 m -118.62 166.6 12.83 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.919 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.917 179.791 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -54.25 117.28 3.15 Favored 'General case' 0 CA--C 1.537 0.467 0 CA-C-O 121.003 0.43 . . . . 0.0 110.361 179.244 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' ASP . . . . . 0.456 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 18.9 t70 . . . . . 0 C--N 1.325 -0.483 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.449 -178.456 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . 0.523 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 4.8 p-10 . . . . . 0 N--CA 1.446 -0.645 0 CA-C-O 121.537 0.684 . . . . 0.0 111.255 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -98.19 127.55 44.19 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.068 -0.969 . . . . 0.0 108.45 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.464 ' CG2' HG22 ' A' ' 89' ' ' THR . 24.9 mt -90.5 145.09 7.84 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.958 0 CA-C-O 120.952 0.406 . . . . 0.0 111.247 -177.128 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.42 HG21 ' CE1' ' A' ' 102' ' ' HIS . 20.7 m -131.82 168.22 24.5 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.007 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 179.441 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 12.1 p80 -127.15 113.18 16.04 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-O 121.035 0.445 . . . . 0.0 111.601 -178.614 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 64.1 mm-40 -119.95 102.42 8.54 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.663 -179.47 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 65.29 40.16 96.41 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.934 -0.651 . . . . 0.0 112.589 178.734 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 84.66 -8.66 68.03 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.976 179.777 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 34.7 mmtp -100.69 128.68 46.65 Favored 'General case' 0 CA--C 1.511 -0.526 0 CA-C-O 120.95 0.405 . . . . 0.0 110.91 -178.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.464 HG22 ' CG2' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -86.4 127.31 34.81 Favored 'General case' 0 C--N 1.307 -1.281 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.102 178.607 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 88.0 m-85 -121.51 148.96 43.78 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.048 178.782 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 25.1 m-70 -102.4 143.24 32.39 Favored 'General case' 0 C--N 1.307 -1.249 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.049 179.217 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.523 ' O ' ' HA ' ' A' ' 80' ' ' ASP . 99.1 t -118.76 126.29 75.13 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.379 179.534 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.4 p -143.21 131.59 19.59 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.959 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.6 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 64.7 m -128.62 131.25 48.09 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 120.838 0.351 . . . . 0.0 110.858 179.804 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 28.5 m80 -105.02 -11.07 16.8 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.117 0.484 . . . . 0.0 109.961 179.71 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 6.9 mp0 -127.35 143.36 51.23 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.206 179.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -78.46 109.99 13.12 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-O 120.917 0.389 . . . . 0.0 110.896 -179.565 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 167.94 168.35 29.94 Favored Glycine 0 N--CA 1.434 -1.434 0 N-CA-C 111.566 -0.614 . . . . 0.0 111.566 -179.645 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.458 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 83.1 Cg_endo -87.12 137.75 4.58 Favored 'Trans proline' 0 N--CA 1.451 -1.016 0 C-N-CA 122.841 2.361 . . . . 0.0 112.559 178.447 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.8 pp -139.01 157.64 71.09 Favored Pre-proline 0 C--N 1.317 -0.812 0 CA-C-N 115.987 -0.551 . . . . 0.0 109.586 178.36 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -63.16 168.65 10.52 Favored 'Trans proline' 0 C--N 1.35 0.609 0 C-N-CA 122.471 2.114 . . . . 0.0 112.856 -178.175 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' HIS . . . . . 0.42 ' CE1' HG21 ' A' ' 83' ' ' VAL . 3.6 t-80 -92.87 122.95 62.78 Favored Pre-proline 0 C--N 1.315 -0.899 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 -179.617 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -59.83 -21.8 65.47 Favored 'Trans proline' 0 N--CA 1.483 0.888 0 C-N-CA 122.99 2.46 . . . . 0.0 113.786 -176.361 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -95.93 -16.57 38.18 Favored Glycine 0 CA--C 1.519 0.283 0 C-N-CA 120.165 -1.017 . . . . 0.0 113.216 -178.798 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 3.0 p30 -168.24 101.86 0.44 Allowed 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 122.596 0.358 . . . . 0.0 110.904 -178.736 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.602 HG12 ' HB2' ' A' ' 131' ' ' LYS . 6.0 t -53.23 -16.86 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.064 0 N-CA-C 113.596 0.962 . . . . 0.0 113.596 -179.584 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 8.5 m170 -72.88 5.48 3.22 Favored 'General case' 0 N--CA 1.479 0.999 0 O-C-N 121.936 -0.478 . . . . 0.0 111.39 177.732 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 46.4 mtmt -139.74 158.93 43.29 Favored 'General case' 0 N--CA 1.44 -0.958 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 178.773 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 6.5 p90 -142.87 173.73 11.28 Favored 'General case' 0 C--N 1.302 -1.463 0 CA-C-O 120.866 0.365 . . . . 0.0 110.849 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.458 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 4.1 mt -130.6 138.55 53.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.936 -179.156 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -102.31 117.45 47.69 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 176.334 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 74.0 m -107.46 123.7 48.79 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-O 121.231 0.539 . . . . 0.0 110.709 -177.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 13.9 t -131.05 148.44 52.74 Favored 'General case' 0 C--N 1.311 -1.107 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.53 -178.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 34.1 tttm -116.87 112.1 20.6 Favored 'General case' 0 N--CA 1.435 -1.191 0 CA-C-O 121.28 0.562 . . . . 0.0 110.624 -178.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 8.5 t -94.44 100.49 12.49 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 179.598 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 64.29 -104.63 0.93 Allowed Glycine 0 N--CA 1.439 -1.101 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -175.852 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 31.3 m -114.11 9.51 17.24 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 116.674 0.237 . . . . 0.0 111.624 178.798 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 6.9 tt -121.54 135.79 54.99 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.809 0.337 . . . . 0.0 110.636 -176.725 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 84.2 m95 -93.74 133.27 37.28 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.141 0.496 . . . . 0.0 112.295 -177.615 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -117.65 127.31 53.82 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.65 -0.704 . . . . 0.0 109.161 174.38 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.5 pp -123.41 146.72 28.34 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.944 0 CA-C-O 121.1 0.476 . . . . 0.0 111.22 -178.596 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 18.6 m -136.83 122.85 20.25 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.765 179.231 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 2.7 p -94.99 111.31 25.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 121.344 0.593 . . . . 0.0 110.782 179.279 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 5.3 mmt -112.25 151.23 43.54 Favored Pre-proline 0 C--N 1.314 -0.977 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.512 -178.844 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -89.18 143.84 4.82 Favored 'Trans proline' 0 N--CA 1.452 -0.913 0 C-N-CA 122.409 2.072 . . . . 0.0 112.414 177.9 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' CYS . . . . . 0.507 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 56.9 m -80.42 169.61 17.48 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.396 176.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 23.9 m -54.77 146.21 17.66 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.156 176.542 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . 0.447 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.8 mp -61.86 123.57 14.83 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.146 0 CA-C-O 121.026 0.441 . . . . 0.0 110.598 -178.712 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.02 5.48 62.47 Favored Glycine 0 N--CA 1.445 -0.706 0 CA-C-N 115.731 -0.668 . . . . 0.0 113.048 -177.873 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 48.2 p -121.14 167.34 12.76 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 117.117 0.458 . . . . 0.0 111.265 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.602 ' HB2' HG12 ' A' ' 106' ' ' VAL . 61.4 pttt -138.56 145.56 40.79 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 178.755 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.539 ' HD1' ' SG ' ' A' ' 139' ' ' CYS . 33.3 t80 -85.32 132.75 34.2 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 121.018 0.437 . . . . 0.0 111.995 -176.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -99.83 130.9 25.45 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.729 177.681 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_endo -62.78 -42.68 24.02 Favored 'Trans proline' 0 C--N 1.346 0.445 0 C-N-CA 123.087 2.525 . . . . 0.0 113.993 -176.06 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 35.5 mm -81.04 -48.73 18.94 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 C-N-CA 120.879 -0.328 . . . . 0.0 111.567 -176.668 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.6 m -63.69 -34.06 77.03 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.704 0.288 . . . . 0.0 110.705 179.248 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 79.5 mtm180 68.66 42.53 1.45 Allowed 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.454 177.6 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 10.5 p30 -157.27 171.35 20.57 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.301 -0.863 . . . . 0.0 108.766 176.706 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' CYS . . . . . 0.539 ' SG ' ' HD1' ' A' ' 132' ' ' PHE . 8.9 m -101.36 125.45 48.0 Favored 'General case' 0 C--N 1.318 -0.79 0 C-N-CA 120.696 -0.402 . . . . 0.0 110.405 -178.286 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.6 m -110.06 163.41 7.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.657 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 32.0 tp -59.74 119.98 8.66 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.799 0.333 . . . . 0.0 111.111 -178.758 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' ASP . . . . . 0.502 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 18.9 t70 . . . . . 0 C--N 1.32 -0.71 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.407 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . 0.46 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 4.3 p-10 . . . . . 0 N--CA 1.452 -0.332 0 CA-C-O 121.54 0.686 . . . . 0.0 109.658 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -103.44 133.97 47.59 Favored 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 -179.62 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.536 ' CG2' HG22 ' A' ' 89' ' ' THR . 20.9 mt -94.66 140.65 16.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-O 121.076 0.465 . . . . 0.0 111.223 -177.63 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.448 HG21 ' NE2' ' A' ' 102' ' ' HIS . 28.2 m -129.68 160.84 40.27 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.122 -179.182 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 84.3 m-70 -116.72 102.59 9.56 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.312 -179.446 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 53.6 mm-40 -109.81 104.76 13.77 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.258 -179.845 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 60.2 40.64 97.55 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.797 -179.786 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 81.75 -14.21 32.2 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 121.193 -0.527 . . . . 0.0 113.076 -178.737 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 35.5 mmtp -90.2 126.85 35.96 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 117.062 0.431 . . . . 0.0 110.838 -178.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.536 HG22 ' CG2' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -83.49 121.95 27.88 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.985 178.742 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 78.9 m-85 -117.78 154.4 31.8 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 116.241 -0.436 . . . . 0.0 109.977 177.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 28.3 m-70 -106.2 141.1 38.12 Favored 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 176.891 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . 0.46 ' O ' ' HA ' ' A' ' 80' ' ' ASP . 55.1 t -115.86 120.66 65.45 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 178.494 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 57.2 t -124.44 131.21 73.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 -178.733 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 81.5 m -113.66 112.56 23.69 Favored 'General case' 0 C--N 1.313 -1.019 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 179.373 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 27.9 t60 -91.77 -17.06 25.94 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.086 -178.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -137.12 150.84 48.24 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.769 -178.63 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -75.23 141.19 43.58 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.39 179.015 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 125.37 172.09 13.38 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.528 -0.844 . . . . 0.0 112.522 -179.616 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.419 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 86.2 Cg_endo -84.25 131.02 4.83 Favored 'Trans proline' 0 CA--C 1.537 0.666 0 C-N-CA 122.919 2.413 . . . . 0.0 112.857 178.757 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.9 pp -137.69 158.94 70.81 Favored Pre-proline 0 C--N 1.32 -0.68 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.395 178.367 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -64.66 168.96 12.19 Favored 'Trans proline' 0 C--N 1.351 0.686 0 C-N-CA 122.674 2.25 . . . . 0.0 112.821 -179.275 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' HIS . . . . . 0.493 ' HA ' HD11 ' A' ' 110' ' ' ILE . 8.5 t-80 -92.21 129.93 39.63 Favored Pre-proline 0 C--N 1.318 -0.804 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 -178.71 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_endo -53.45 -44.09 51.97 Favored 'Trans proline' 0 C--N 1.356 0.967 0 C-N-CA 123.164 2.576 . . . . 0.0 113.42 -175.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -71.02 -62.31 3.61 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.235 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.485 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 2.7 p30 -122.91 107.59 12.02 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-O 120.819 0.342 . . . . 0.0 111.382 -179.542 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 30.1 m -57.28 -10.18 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 113.064 0.765 . . . . 0.0 113.064 177.825 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 94.7 m-70 -74.13 3.74 6.63 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-O 121.505 0.669 . . . . 0.0 110.375 177.02 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 58.7 mttp -131.2 156.75 44.81 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 177.228 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 7.1 p90 -142.28 161.74 37.25 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 120.334 -0.546 . . . . 0.0 110.352 177.22 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.493 HD11 ' HA ' ' A' ' 102' ' ' HIS . 2.9 mp -123.47 141.31 44.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 -178.624 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.6 mp -97.45 112.48 29.6 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 175.371 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 42.0 m -97.93 122.04 40.58 Favored 'General case' 0 C--N 1.311 -1.081 0 CA-C-O 120.989 0.423 . . . . 0.0 110.675 -177.455 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 27.6 t -126.35 137.34 53.45 Favored 'General case' 0 N--CA 1.437 -1.116 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 178.898 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -108.49 122.15 46.44 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-O 120.817 0.342 . . . . 0.0 110.423 -179.143 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 43.1 m -116.42 105.82 12.93 Favored 'General case' 0 N--CA 1.434 -1.274 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.173 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 59.89 -110.9 3.12 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.343 -175.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 20.8 m -113.2 16.27 19.18 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.095 0.474 . . . . 0.0 110.144 179.143 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 6.0 mp -124.51 141.79 51.82 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.474 -177.168 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 47.3 m95 -107.18 138.02 44.15 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-O 121.329 0.585 . . . . 0.0 111.61 179.513 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 78.7 m-85 -121.31 121.94 38.78 Favored 'General case' 0 C--N 1.309 -1.184 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.608 176.597 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.417 ' HB ' ' CG2' ' A' ' 110' ' ' ILE . 2.4 pp -123.28 159.25 27.75 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.755 -176.439 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 37.3 m -146.25 120.99 9.86 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.848 177.443 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 5.1 p -93.46 110.44 23.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 121.601 0.715 . . . . 0.0 111.22 -178.299 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 3.6 mmt -108.71 125.18 32.31 Favored Pre-proline 0 C--N 1.307 -1.248 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.111 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -75.14 135.43 18.83 Favored 'Trans proline' 0 N--CA 1.456 -0.726 0 C-N-CA 122.149 1.9 . . . . 0.0 111.288 178.419 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 6.2 t -90.71 -173.52 3.76 Favored 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 -179.573 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 46.8 m -64.69 137.66 57.94 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 120.928 0.395 . . . . 0.0 111.004 179.665 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 2.0 mp -60.5 134.56 25.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.819 178.609 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.2 -17.72 58.31 Favored Glycine 0 N--CA 1.444 -0.772 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.918 -177.007 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 77.0 p -109.72 158.18 18.36 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 117.456 0.628 . . . . 0.0 110.541 178.833 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 59.2 pttt -130.19 144.8 51.57 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.089 -179.041 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 39.9 t80 -83.71 134.52 34.75 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.849 -179.218 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -99.16 130.52 27.08 Favored Pre-proline 0 C--N 1.321 -0.647 0 CA-C-N 116.243 -0.435 . . . . 0.0 109.939 178.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -65.49 -43.98 9.5 Favored 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.792 2.328 . . . . 0.0 113.607 -176.579 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.8 mp -76.5 -50.48 21.77 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 116.632 -0.258 . . . . 0.0 111.605 -177.18 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.1 m -68.65 -33.2 73.59 Favored 'General case' 0 C--O 1.239 0.52 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.025 -179.022 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 89.3 mtm180 70.33 43.22 0.84 Allowed 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.067 177.771 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 26.0 p-10 -152.5 176.27 11.87 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 179.267 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 95.8 m -102.41 126.51 49.46 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 121.179 0.514 . . . . 0.0 111.315 179.411 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 27.0 m -114.88 159.94 14.5 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 CA-C-N 115.698 -0.683 . . . . 0.0 109.22 177.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 55.8 tp -63.65 135.5 56.8 Favored 'General case' 0 C--N 1.312 -1.045 0 CA-C-O 121.054 0.454 . . . . 0.0 111.364 -179.637 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 30.3 t70 . . . . . 0 CA--C 1.507 -0.688 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 177.709 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 31.8 t70 . . . . . 0 CA--C 1.515 -0.378 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.507 ' HG ' ' CD1' ' A' ' 121' ' ' ILE . 3.1 tm? -101.93 130.33 48.42 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 -179.676 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.541 ' CG2' HG22 ' A' ' 89' ' ' THR . 23.3 mt -94.29 144.04 10.46 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 CA-C-O 120.742 0.306 . . . . 0.0 110.435 -178.439 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 29.8 m -134.78 165.63 30.7 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.9 0 CA-C-N 116.212 -0.449 . . . . 0.0 109.952 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 85.3 m-70 -114.93 121.82 44.38 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 179.452 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 3.8 tp10 -145.62 115.45 7.33 Favored 'General case' 0 C--N 1.318 -0.765 0 C-N-CA 120.693 -0.403 . . . . 0.0 111.008 -178.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 62.16 29.74 73.75 Favored Glycine 0 CA--C 1.518 0.274 0 CA-C-N 116.129 -0.487 . . . . 0.0 113.359 177.593 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 89.51 -5.94 83.52 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.351 179.087 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . 0.501 ' HB2' ' CE1' ' A' ' 90' ' ' TYR . 68.4 mmtt -102.16 153.07 20.29 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-O 120.593 0.235 . . . . 0.0 110.685 179.878 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.541 HG22 ' CG2' ' A' ' 82' ' ' ILE . 0.2 OUTLIER -106.82 106.75 17.42 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 177.024 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.501 ' CE1' ' HB2' ' A' ' 88' ' ' LYS . 96.1 m-85 -98.19 145.84 26.21 Favored 'General case' 0 C--N 1.313 -1.022 0 CA-C-O 120.983 0.421 . . . . 0.0 111.183 -177.035 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 31.1 m-70 -101.72 134.66 44.53 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 177.068 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 46.7 t -113.25 118.47 58.16 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 179.141 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 91.4 t -119.27 131.71 71.19 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.518 -179.045 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 73.8 m -114.76 113.18 23.92 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-O 120.994 0.426 . . . . 0.0 109.956 -179.579 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 67.9 t60 -93.2 -17.46 23.68 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.819 -178.758 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -145.24 158.58 43.79 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.887 -178.034 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -74.24 129.92 38.73 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.48 179.378 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 137.07 158.81 8.07 Favored Glycine 0 N--CA 1.44 -1.05 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.192 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.442 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 77.3 Cg_endo -78.02 140.1 17.75 Favored 'Trans proline' 0 CA--C 1.537 0.649 0 C-N-CA 122.791 2.327 . . . . 0.0 112.987 178.751 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.8 pp -138.02 157.7 72.56 Favored Pre-proline 0 C--N 1.32 -0.687 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.701 177.983 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -62.22 164.75 16.5 Favored 'Trans proline' 0 C--N 1.35 0.633 0 C-N-CA 122.4 2.067 . . . . 0.0 113.107 -178.409 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' HIS . . . . . 0.415 ' HA ' HD11 ' A' ' 110' ' ' ILE . 42.0 t-80 -89.66 120.1 69.51 Favored Pre-proline 0 C--N 1.319 -0.721 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.479 -179.087 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 14.1 Cg_endo -56.62 -21.97 41.43 Favored 'Trans proline' 0 N--CA 1.482 0.847 0 C-N-CA 123.08 2.52 . . . . 0.0 113.376 -176.816 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -89.33 -20.57 44.71 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.36 -0.924 . . . . 0.0 113.308 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 16.7 p30 -169.15 109.85 0.47 Allowed 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 122.69 0.396 . . . . 0.0 110.361 -179.134 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 34.8 m -57.17 -11.37 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.076 0 N-CA-C 113.833 1.049 . . . . 0.0 113.833 -179.629 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 42.5 m170 -76.29 3.71 10.32 Favored 'General case' 0 N--CA 1.475 0.786 0 CA-C-O 121.145 0.498 . . . . 0.0 111.266 177.556 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.402 ' HG2' ' HA ' ' A' ' 125' ' ' PRO . 42.2 mtmt -138.87 161.03 38.3 Favored 'General case' 0 CA--C 1.506 -0.72 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 178.634 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 9.3 p90 -143.83 172.31 13.02 Favored 'General case' 0 C--N 1.313 -0.988 0 C-N-CA 120.647 -0.421 . . . . 0.0 111.246 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.442 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.9 mp -129.3 140.64 48.64 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.965 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 178.652 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -96.44 122.08 47.59 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 176.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 57.9 m -106.0 125.23 50.75 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-O 120.679 0.276 . . . . 0.0 110.279 -178.405 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 19.8 m -130.83 139.7 50.2 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.253 179.044 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -112.12 104.37 12.6 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-O 120.994 0.426 . . . . 0.0 110.041 179.482 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 14.2 t -91.79 88.8 6.8 Favored 'General case' 0 C--N 1.309 -1.185 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 179.508 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 70.37 -100.79 0.83 Allowed Glycine 0 N--CA 1.443 -0.85 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 -177.581 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 50.6 m -114.58 5.62 15.52 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.895 0.379 . . . . 0.0 110.735 178.357 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 21.4 tp -116.68 129.53 56.19 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.622 -176.32 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 83.1 m95 -92.97 132.04 37.42 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -178.832 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 51.2 m-85 -113.06 137.27 51.67 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 115.457 -0.792 . . . . 0.0 109.422 175.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.507 ' CD1' ' HG ' ' A' ' 81' ' ' LEU . 2.1 pp -134.28 152.27 33.64 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.998 0 N-CA-C 112.364 0.505 . . . . 0.0 112.364 -176.576 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 25.7 m -151.35 122.14 7.53 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.293 176.909 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.406 ' HA ' ' HA ' ' A' ' 110' ' ' ILE . 3.8 p -95.07 112.91 28.37 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 CA-C-O 121.348 0.594 . . . . 0.0 111.305 -179.13 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 4.5 mmt -112.1 139.8 22.81 Favored Pre-proline 0 C--N 1.316 -0.867 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.621 -179.165 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . 0.402 ' HA ' ' HG2' ' A' ' 108' ' ' LYS . 91.6 Cg_endo -83.85 140.56 9.16 Favored 'Trans proline' 0 N--CA 1.452 -0.958 0 C-N-CA 122.408 2.072 . . . . 0.0 111.551 177.168 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 7.1 t -94.36 -179.19 4.83 Favored 'General case' 0 C--N 1.319 -0.75 0 C-N-CA 120.381 -0.527 . . . . 0.0 109.828 177.906 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 10.4 t -68.33 140.22 55.91 Favored 'General case' 0 N--CA 1.436 -1.129 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.238 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 2.1 mp -61.56 141.78 17.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 178.393 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.22 -19.85 51.07 Favored Glycine 0 N--CA 1.438 -1.229 0 C-N-CA 120.592 -0.813 . . . . 0.0 112.499 -176.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 68.8 p -114.76 154.72 28.02 Favored 'General case' 0 N--CA 1.448 -0.528 0 CA-C-N 117.261 0.53 . . . . 0.0 111.104 179.655 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 59.8 pttt -126.63 145.03 50.71 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.959 179.369 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -83.94 132.74 34.74 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-O 120.874 0.369 . . . . 0.0 110.963 -178.486 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -94.57 133.59 26.63 Favored Pre-proline 0 C--N 1.323 -0.576 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.418 179.576 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -67.77 -41.33 8.25 Favored 'Trans proline' 0 CA--C 1.535 0.57 0 C-N-CA 122.919 2.413 . . . . 0.0 114.512 -177.541 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.8 mp -82.5 -51.81 14.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 N-CA-C 111.82 0.304 . . . . 0.0 111.82 -177.029 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 4.2 m -69.24 -35.7 76.41 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.139 0.495 . . . . 0.0 110.194 -179.232 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' ARG . . . . . 0.439 ' HD2' ' HD2' ' A' ' 99' ' ' PRO . 56.1 mtm180 66.81 62.87 0.5 Allowed 'General case' 0 N--CA 1.452 -0.341 0 CA-C-N 115.274 -0.875 . . . . 0.0 111.528 178.458 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -165.42 173.16 11.37 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 114.559 -1.2 . . . . 0.0 108.118 176.717 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 88.9 m -100.49 126.5 46.92 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-O 121.083 0.468 . . . . 0.0 111.118 -179.177 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.8 m -113.13 158.3 13.54 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.804 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.279 178.341 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -61.31 117.38 5.56 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.796 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 35.3 t0 . . . . . 0 C--N 1.323 -0.569 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.473 -178.641 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 . . . . . 0 N--CA 1.452 -0.374 0 CA-C-O 121.44 0.638 . . . . 0.0 110.78 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.417 ' HG ' HD11 ' A' ' 121' ' ' ILE . 2.5 tm? -100.23 134.57 42.97 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.468 ' CG2' HG22 ' A' ' 89' ' ' THR . 20.8 mt -95.51 142.63 13.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-O 120.937 0.399 . . . . 0.0 110.897 -177.215 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.472 HG21 ' NE2' ' A' ' 102' ' ' HIS . 31.2 m -130.39 154.2 40.17 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.964 -179.358 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 42.6 m-70 -114.57 101.49 9.15 Favored 'General case' 0 C--N 1.311 -1.1 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.115 -178.942 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.466 ' HB2' ' CE1' ' A' ' 90' ' ' TYR . 50.2 mm-40 -105.86 110.42 22.7 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.052 178.119 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 64.73 30.54 78.21 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 121.148 -0.549 . . . . 0.0 111.951 -179.235 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 86.05 -9.3 69.92 Favored Glycine 0 N--CA 1.444 -0.771 0 C-N-CA 120.928 -0.654 . . . . 0.0 112.385 -179.299 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 1.3 mptm? -91.74 140.52 29.62 Favored 'General case' 0 CA--C 1.507 -0.698 0 CA-C-O 120.911 0.386 . . . . 0.0 110.463 -179.731 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.468 HG22 ' CG2' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -91.21 129.8 37.16 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.767 179.165 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.466 ' CE1' ' HB2' ' A' ' 85' ' ' GLU . 88.1 m-85 -127.3 148.28 50.23 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 177.887 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 40.1 m-70 -103.89 138.3 40.67 Favored 'General case' 0 C--N 1.305 -1.343 0 N-CA-C 110.059 -0.348 . . . . 0.0 110.059 178.473 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 58.3 t -111.23 122.75 66.24 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.217 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 178.446 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 38.3 t -126.04 132.18 70.89 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 -179.057 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 88.8 m -102.0 126.5 48.94 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.019 0.438 . . . . 0.0 111.033 -179.155 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 77.9 m-70 -90.12 -30.51 17.62 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.573 -179.083 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -151.88 172.95 15.4 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-N 115.747 -0.66 . . . . 0.0 109.886 -177.384 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 5.3 mp0 -74.81 137.13 41.7 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.138 178.143 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 124.57 158.83 10.19 Favored Glycine 0 N--CA 1.443 -0.889 0 C-N-CA 120.681 -0.771 . . . . 0.0 111.973 -179.597 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.445 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 78.1 Cg_endo -77.32 139.56 18.75 Favored 'Trans proline' 0 N--CA 1.46 -0.482 0 C-N-CA 122.613 2.209 . . . . 0.0 113.259 179.13 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.8 pp -137.36 158.13 72.82 Favored Pre-proline 0 C--N 1.319 -0.723 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.64 178.107 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -64.24 169.39 10.89 Favored 'Trans proline' 0 C--N 1.351 0.692 0 C-N-CA 122.593 2.195 . . . . 0.0 113.207 -177.784 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' HIS . . . . . 0.472 ' NE2' HG21 ' A' ' 83' ' ' VAL . 2.3 t-80 -88.73 128.49 52.3 Favored Pre-proline 0 C--N 1.317 -0.827 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 -179.613 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_endo -53.28 -42.5 64.74 Favored 'Trans proline' 0 C--N 1.351 0.699 0 C-N-CA 122.994 2.463 . . . . 0.0 113.032 -177.141 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -74.62 -61.74 3.05 Favored Glycine 0 C--N 1.316 -0.565 0 C-N-CA 120.713 -0.756 . . . . 0.0 113.002 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' ASN . . . . . 0.429 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 6.1 p-10 -125.03 107.95 11.33 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-O 120.973 0.416 . . . . 0.0 111.97 -176.757 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 8.5 p -56.65 -11.97 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.12 0 N-CA-C 113.607 0.965 . . . . 0.0 113.607 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 51.6 m170 -70.42 -4.19 21.31 Favored 'General case' 0 N--CA 1.474 0.748 0 CA-C-O 121.135 0.493 . . . . 0.0 111.055 178.502 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.423 ' O ' ' HB2' ' A' ' 102' ' ' HIS . 39.8 mtmt -135.2 159.91 40.04 Favored 'General case' 0 N--CA 1.44 -0.972 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 177.692 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 14.6 p90 -142.8 173.57 11.43 Favored 'General case' 0 C--N 1.307 -1.281 0 CA-C-N 116.577 -0.283 . . . . 0.0 110.78 -178.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.445 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 2.3 mp -130.19 140.33 49.17 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.166 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 178.753 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.431 HG13 ' HB3' ' A' ' 99' ' ' PRO . 4.9 mp -97.47 118.47 44.0 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 177.299 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 62.8 m -97.17 121.71 39.37 Favored 'General case' 0 N--CA 1.437 -1.102 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 17.3 m -124.11 136.85 54.51 Favored 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.706 -179.531 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 23.0 ttmt -112.02 109.41 19.14 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-O 121.157 0.504 . . . . 0.0 111.143 -179.488 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 15.8 t -92.28 88.89 6.62 Favored 'General case' 0 N--CA 1.43 -1.432 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 176.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 72.1 -99.87 0.9 Allowed Glycine 0 N--CA 1.437 -1.294 0 N-CA-C 110.705 -0.958 . . . . 0.0 110.705 -176.416 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 24.3 p -116.41 6.24 13.6 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-O 120.893 0.378 . . . . 0.0 111.298 177.824 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 53.6 tp -113.04 135.88 53.3 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.818 0.342 . . . . 0.0 111.255 -175.644 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 96.4 m95 -89.62 131.85 35.41 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 121.336 0.588 . . . . 0.0 112.466 -179.707 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 73.5 m-85 -119.34 124.19 46.02 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 170.423 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.417 HD11 ' HG ' ' A' ' 81' ' ' LEU . 2.0 pp -124.45 146.87 29.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 120.502 -0.479 . . . . 0.0 111.689 -176.828 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 20.2 m -137.06 122.63 19.69 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.375 178.81 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 4.0 p -93.39 113.72 28.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 121.346 0.593 . . . . 0.0 111.211 -179.385 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 3.6 mmt -117.23 151.44 47.82 Favored Pre-proline 0 C--N 1.322 -0.628 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.805 -179.088 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 90.7 Cg_endo -92.25 151.36 3.1 Favored 'Trans proline' 0 N--CA 1.448 -1.156 0 C-N-CA 122.399 2.066 . . . . 0.0 112.441 177.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 56.2 m -84.99 167.92 15.42 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 174.515 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 10.9 p -59.89 144.23 49.35 Favored 'General case' 0 N--CA 1.439 -0.996 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 176.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' ILE . . . . . 0.454 ' N ' HD12 ' A' ' 128' ' ' ILE . 2.0 mp -60.74 122.51 11.38 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 CA-C-O 121.175 0.512 . . . . 0.0 110.327 -178.186 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 103.26 1.91 47.86 Favored Glycine 0 N--CA 1.437 -1.248 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.995 -176.397 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . 0.411 HG22 ' HA ' ' A' ' 141' ' ' LEU . 80.7 p -126.77 160.08 31.89 Favored 'General case' 0 CA--C 1.539 0.533 0 CA-C-N 117.456 0.628 . . . . 0.0 111.634 179.773 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 55.0 pttt -125.87 145.54 50.2 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.384 179.633 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.463 ' HD1' ' SG ' ' A' ' 139' ' ' CYS . 29.1 t80 -85.64 137.53 32.77 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-O 121.01 0.434 . . . . 0.0 111.556 -179.23 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -103.48 132.18 21.33 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.181 179.246 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -69.5 -45.06 1.89 Allowed 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 123.11 2.54 . . . . 0.0 114.393 -177.222 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 34.9 mm -74.7 -46.62 41.31 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 N-CA-C 112.035 0.383 . . . . 0.0 112.035 -176.326 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 39.5 t -75.63 -31.79 59.99 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-O 120.861 0.362 . . . . 0.0 110.146 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' ARG . . . . . 0.421 ' HB3' ' HG2' ' A' ' 99' ' ' PRO . 66.0 mtm180 66.42 62.02 0.56 Allowed 'General case' 0 N--CA 1.463 0.223 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.354 178.59 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' ASN . . . . . 0.456 HD22 ' N ' ' A' ' 138' ' ' ASN . 0.1 OUTLIER -165.31 172.45 12.31 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.175 -0.92 . . . . 0.0 109.082 179.603 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' CYS . . . . . 0.463 ' SG ' ' HD1' ' A' ' 132' ' ' PHE . 38.6 m -101.05 124.58 46.99 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 178.862 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 36.0 m -113.96 164.38 10.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.807 0 CA-C-N 115.883 -0.598 . . . . 0.0 109.759 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' LEU . . . . . 0.411 ' HA ' HG22 ' A' ' 130' ' ' THR . 34.2 tp -58.46 123.86 17.63 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-O 121.024 0.44 . . . . 0.0 111.75 -178.324 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' ASP . . . . . 0.409 ' H ' ' HA ' ' A' ' 130' ' ' THR . 18.0 t70 . . . . . 0 C--N 1.321 -0.668 0 CA-C-N 115.879 -0.6 . . . . 0.0 109.642 178.104 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.384 0 N-CA-C 112.123 -0.391 . . . . 0.0 112.123 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -87.36 28.7 0.51 Allowed 'Trans proline' 0 CA--C 1.533 0.441 0 C-N-CA 123.036 2.49 . . . . 0.0 112.848 -177.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 7.6 tt -71.18 113.75 8.53 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.734 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -130.3 9.46 5.92 Favored Glycine 0 N--CA 1.441 -1.015 0 C-N-CA 120.86 -0.686 . . . . 0.0 111.915 -179.293 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.443 ' O ' HG23 ' A' ' 93' ' ' VAL . 57.6 p -60.23 -52.73 64.04 Favored 'General case' 0 N--CA 1.446 -0.634 0 CA-C-O 120.601 0.239 . . . . 0.0 110.812 179.098 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.582 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 8.2 p-10 -158.03 127.62 5.91 Favored 'General case' 0 N--CA 1.448 -0.53 0 CA-C-O 121.362 0.601 . . . . 0.0 111.571 -177.793 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.422 HD23 HD11 ' A' ' 121' ' ' ILE . 48.8 tp -102.79 145.47 29.7 Favored 'General case' 0 C--N 1.308 -1.236 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.148 176.472 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.457 ' CG2' HG22 ' A' ' 89' ' ' THR . 14.0 mt -97.54 143.96 11.75 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.111 0 C-N-CA 120.599 -0.44 . . . . 0.0 111.083 -178.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 30.7 m -135.75 174.37 12.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.828 -179.285 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' HIS . . . . . 0.429 ' CE1' HG23 ' A' ' 89' ' ' THR . 45.9 m-70 -122.89 115.88 22.69 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 120.967 0.413 . . . . 0.0 111.704 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 59.6 mm-40 -109.12 104.19 13.32 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.209 176.677 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 59.98 45.33 96.08 Favored Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.321 -0.942 . . . . 0.0 111.713 -178.755 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 85.4 -31.7 3.77 Favored Glycine 0 CA--C 1.524 0.619 0 C-N-CA 121.036 -0.602 . . . . 0.0 113.593 -179.143 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 14.2 mptt -82.07 141.77 32.88 Favored 'General case' 0 CA--C 1.51 -0.59 0 CA-C-N 117.373 0.587 . . . . 0.0 111.555 -176.126 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.457 HG22 ' CG2' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -84.63 134.19 34.39 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.908 179.856 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 63.9 m-85 -132.22 154.29 49.75 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.761 176.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 19.2 m-70 -102.42 144.8 30.42 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-O 120.823 0.344 . . . . 0.0 110.57 179.469 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.582 ' O ' ' HA ' ' A' ' 80' ' ' ASP . 93.7 t -120.06 117.87 55.03 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.19 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 177.547 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.443 HG23 ' O ' ' A' ' 79' ' ' SER . 3.3 p -124.6 138.8 52.81 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 CA-C-N 116.112 -0.495 . . . . 0.0 109.93 -178.52 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 92.3 m -110.94 123.92 51.1 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 120.895 0.379 . . . . 0.0 110.946 179.514 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 52.1 m80 -102.15 -22.35 14.22 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.376 -179.766 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -141.03 152.47 44.89 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.478 -178.804 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -76.23 106.35 7.79 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.659 -0.701 . . . . 0.0 110.508 177.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 156.24 169.51 20.46 Favored Glycine 0 N--CA 1.434 -1.474 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 -179.581 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_endo -78.53 132.91 11.35 Favored 'Trans proline' 0 N--CA 1.456 -0.691 0 C-N-CA 122.406 2.071 . . . . 0.0 112.394 178.62 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 2.0 pp -137.12 157.82 73.75 Favored Pre-proline 0 C--N 1.319 -0.726 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.517 178.21 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -69.51 171.86 13.43 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.271 1.981 . . . . 0.0 112.492 -178.29 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' HIS . . . . . 0.585 ' HB3' ' O ' ' A' ' 105' ' ' ASN . 30.3 t-80 -89.85 128.1 51.48 Favored Pre-proline 0 C--N 1.309 -1.177 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 179.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -50.52 -54.91 4.67 Favored 'Trans proline' 0 N--CA 1.477 0.524 0 C-N-CA 122.932 2.421 . . . . 0.0 112.604 -176.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -63.17 -62.2 5.65 Favored Glycine 0 CA--C 1.526 0.776 0 CA-C-N 115.813 -0.63 . . . . 0.0 113.15 178.237 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.585 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 9.9 p-10 -122.8 103.22 8.5 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 -177.004 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 31.1 m -58.29 -10.67 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.089 0 N-CA-C 114.0 1.111 . . . . 0.0 114.0 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 14.0 t-80 -66.27 -10.39 41.93 Favored 'General case' 0 N--CA 1.47 0.56 0 CA-C-O 121.451 0.643 . . . . 0.0 110.299 176.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.404 ' HE2' HD21 ' A' ' 105' ' ' ASN . 44.7 mtmt -126.55 158.69 35.53 Favored 'General case' 0 N--CA 1.434 -1.237 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 178.196 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 7.7 p90 -141.72 165.49 27.34 Favored 'General case' 0 C--N 1.302 -1.492 0 C-N-CA 120.642 -0.423 . . . . 0.0 110.517 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.405 HG12 HG11 ' A' ' 92' ' ' VAL . 3.9 mp -123.32 139.81 48.84 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 -179.062 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.411 ' N ' HD12 ' A' ' 111' ' ' ILE . 4.3 mp -99.98 118.09 46.12 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.179 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 177.502 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 23.5 m -101.78 122.72 44.48 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.222 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 49.1 m -131.7 146.73 52.33 Favored 'General case' 0 C--N 1.312 -1.064 0 CA-C-O 121.074 0.464 . . . . 0.0 111.44 -177.752 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 5.0 tppp? -97.28 139.6 33.0 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.527 179.312 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 68.2 m -128.71 85.78 2.37 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 174.474 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 72.68 -104.53 1.55 Allowed Glycine 0 N--CA 1.437 -1.296 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 -174.55 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 50.6 m -115.07 11.81 16.5 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-O 120.779 0.323 . . . . 0.0 110.885 175.17 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 34.0 tp -111.36 143.39 42.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.672 -0.24 . . . . 0.0 110.627 -177.367 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 54.0 m95 -100.23 133.14 45.08 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.034 0.445 . . . . 0.0 112.128 179.198 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -119.53 132.35 55.74 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.647 -0.706 . . . . 0.0 109.463 174.044 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.422 HD11 HD23 ' A' ' 81' ' ' LEU . 1.9 pp -123.72 149.89 27.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-O 120.78 0.324 . . . . 0.0 111.074 -179.1 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 28.4 m -146.06 122.93 11.3 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.152 178.312 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.6 p -95.93 111.13 25.65 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.417 0 CA-C-O 121.363 0.601 . . . . 0.0 111.34 -178.333 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 5.5 mmt -114.36 142.59 28.33 Favored Pre-proline 0 C--N 1.318 -0.762 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.525 -179.314 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -86.5 143.11 7.32 Favored 'Trans proline' 0 N--CA 1.449 -1.092 0 C-N-CA 122.378 2.052 . . . . 0.0 111.641 176.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 4.9 t -92.98 -179.6 5.16 Favored 'General case' 0 C--N 1.319 -0.756 0 C-N-CA 120.541 -0.463 . . . . 0.0 109.91 178.228 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 34.3 m -65.32 144.53 57.06 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-O 120.881 0.372 . . . . 0.0 110.579 -178.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . 0.426 ' N ' HD12 ' A' ' 128' ' ' ILE . 2.8 mp -68.04 132.33 32.75 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-N 116.072 -0.513 . . . . 0.0 109.786 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 103.68 -18.45 47.28 Favored Glycine 0 N--CA 1.439 -1.11 0 CA-C-N 115.797 -0.638 . . . . 0.0 112.019 -176.141 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 40.3 p -116.76 158.53 23.73 Favored 'General case' 0 N--CA 1.445 -0.713 0 O-C-N 122.67 -0.312 . . . . 0.0 110.854 179.02 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.4 ' HE2' ' HA ' ' A' ' 142' ' ' ASP . 49.9 pttt -132.17 148.64 52.48 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 116.146 -0.479 . . . . 0.0 109.863 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 23.4 t80 -86.4 139.67 30.72 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-O 121.015 0.436 . . . . 0.0 111.691 -177.319 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -107.6 136.58 19.62 Favored Pre-proline 0 N--CA 1.469 0.502 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.784 177.345 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -68.11 -44.7 3.51 Favored 'Trans proline' 0 C--N 1.347 0.468 0 C-N-CA 122.948 2.432 . . . . 0.0 114.285 -176.464 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 39.5 mm -78.55 -46.34 24.99 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 CA-C-O 120.823 0.344 . . . . 0.0 111.715 -176.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.7 m -69.06 -34.89 75.9 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 120.909 0.385 . . . . 0.0 110.199 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 81.8 mtt-85 69.01 41.34 1.45 Allowed 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.144 177.479 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -152.54 176.28 11.87 Favored 'General case' 0 C--N 1.316 -0.863 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 178.49 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 87.8 m -100.93 126.82 47.58 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 120.888 0.375 . . . . 0.0 110.538 -179.825 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.2 m -109.41 157.78 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.018 0 CA-C-N 115.811 -0.632 . . . . 0.0 109.824 179.584 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 58.5 tp -69.55 115.58 8.97 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-O 120.94 0.4 . . . . 0.0 111.138 -179.374 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' ASP . . . . . 0.4 ' HA ' ' HE2' ' A' ' 131' ' ' LYS . 30.9 t70 -73.57 101.57 3.62 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.619 177.215 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 27.3 t-20 . . . . . 0 C--N 1.307 -1.262 0 CA-C-O 118.195 -0.907 . . . . 0.0 109.099 -177.28 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.413 0 N-CA-C 111.694 -0.562 . . . . 0.0 111.694 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_exo -65.62 99.83 0.39 Allowed 'Trans proline' 0 C--O 1.241 0.668 0 C-N-CA 122.646 2.231 . . . . 0.0 111.271 179.308 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 85.7 mt -83.27 167.79 17.31 Favored 'General case' 0 C--N 1.314 -0.935 0 CA-C-N 115.72 -0.673 . . . . 0.0 111.199 -177.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -150.84 -31.1 0.05 OUTLIER Glycine 0 C--N 1.314 -0.681 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.856 -179.469 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 5.0 m -74.6 -35.45 62.97 Favored 'General case' 0 N--CA 1.448 -0.564 0 N-CA-C 110.168 -0.308 . . . . 0.0 110.168 178.744 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -160.14 104.8 1.5 Allowed 'General case' 0 CA--C 1.52 -0.199 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.215 -179.059 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.526 HD23 HD11 ' A' ' 121' ' ' ILE . 39.4 tp -117.53 132.63 56.5 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.13 176.254 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.473 HG22 HG22 ' A' ' 89' ' ' THR . 10.4 mt -98.73 144.41 11.72 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.09 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 178.734 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 19.1 m -136.88 162.86 33.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-O 120.765 0.317 . . . . 0.0 110.296 -177.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 12.7 m-70 -94.34 115.32 27.52 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.334 178.229 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 12.5 tt0 -128.8 106.65 9.07 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 -178.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 67.18 29.89 74.96 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 110.794 -0.923 . . . . 0.0 110.794 -177.092 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 85.29 -22.95 8.94 Favored Glycine 0 N--CA 1.443 -0.892 0 CA-C-N 115.318 -0.441 . . . . 0.0 112.672 -178.357 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 75.1 mmtt -91.85 146.59 23.63 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.843 0.354 . . . . 0.0 111.14 -177.69 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.473 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -82.22 125.98 31.56 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.601 179.602 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -124.48 143.36 50.69 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 176.823 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 22.0 m-70 -90.05 146.6 24.21 Favored 'General case' 0 C--N 1.312 -1.048 0 CA-C-O 121.097 0.475 . . . . 0.0 111.465 -178.553 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 49.5 t -120.44 119.0 58.52 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 175.562 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 58.0 t -130.4 135.64 60.2 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.256 0 CA-C-N 116.141 -0.481 . . . . 0.0 109.972 -177.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 91.5 m -119.11 113.3 20.7 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.03 0.443 . . . . 0.0 110.645 178.68 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 43.0 t-80 -91.89 -22.07 20.27 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.223 179.823 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 -146.58 157.82 43.79 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.769 -176.755 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -79.18 145.66 33.54 Favored 'General case' 0 C--N 1.312 -1.032 0 CA-C-O 120.955 0.407 . . . . 0.0 110.962 -177.222 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 125.39 163.65 11.66 Favored Glycine 0 N--CA 1.437 -1.261 0 C-N-CA 120.976 -0.63 . . . . 0.0 111.926 -178.441 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.415 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 84.4 Cg_endo -84.4 135.19 6.03 Favored 'Trans proline' 0 CA--C 1.538 0.7 0 C-N-CA 122.721 2.28 . . . . 0.0 112.997 179.168 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -142.28 154.96 64.76 Favored Pre-proline 0 C--O 1.216 -0.707 0 CA-C-N 115.76 -0.654 . . . . 0.0 109.724 177.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -67.85 169.29 16.53 Favored 'Trans proline' 0 C--N 1.348 0.54 0 C-N-CA 122.349 2.033 . . . . 0.0 112.365 -178.537 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' HIS . . . . . 0.41 ' CD2' HD11 ' A' ' 110' ' ' ILE . 12.1 t-80 -85.54 135.5 38.37 Favored Pre-proline 0 C--N 1.319 -0.719 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -178.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -57.8 -25.33 68.34 Favored 'Trans proline' 0 C--N 1.353 0.779 0 C-N-CA 122.93 2.42 . . . . 0.0 112.028 -179.368 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -84.35 -65.86 1.5 Allowed Glycine 0 N--CA 1.441 -0.971 0 CA-C-N 115.522 -0.763 . . . . 0.0 111.765 178.212 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.431 ' OD1' ' HE2' ' A' ' 108' ' ' LYS . 36.8 p-10 -124.37 114.02 18.97 Favored 'General case' 0 CA--C 1.543 0.693 0 CA-C-O 121.364 0.602 . . . . 0.0 111.878 -179.616 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 15.9 m -58.76 -10.63 1.58 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 N-CA-C 112.854 0.687 . . . . 0.0 112.854 177.284 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 35.5 m80 -68.22 -7.17 28.1 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 121.06 0.457 . . . . 0.0 110.362 176.44 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.444 ' HG2' ' HA ' ' A' ' 125' ' ' PRO . 47.4 mtmt -131.5 157.07 44.51 Favored 'General case' 0 CA--C 1.5 -0.953 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.465 179.045 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 8.5 p90 -142.15 161.73 37.26 Favored 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 120.773 -0.371 . . . . 0.0 110.71 179.436 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.415 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.2 mp -119.78 137.22 54.37 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 -179.505 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -96.71 116.85 39.91 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.359 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 175.551 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 56.2 m -95.77 122.13 38.23 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 109.333 -0.618 . . . . 0.0 109.333 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 49.6 m -122.56 127.56 49.61 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.314 -179.733 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 85.4 tttt -100.29 116.22 31.77 Favored 'General case' 0 N--CA 1.432 -1.366 0 CA-C-O 121.118 0.485 . . . . 0.0 109.926 178.735 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 53.7 m -106.18 83.57 1.91 Allowed 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.581 179.149 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 67.77 -100.24 0.6 Allowed Glycine 0 N--CA 1.44 -1.082 0 CA-C-N 115.521 -0.763 . . . . 0.0 111.593 -178.348 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 16.2 m -111.52 5.73 19.68 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-O 120.828 0.347 . . . . 0.0 110.46 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 22.8 tp -118.51 134.49 55.04 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.092 -177.643 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 77.4 m95 -97.3 132.76 42.72 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-O 121.105 0.479 . . . . 0.0 111.978 178.654 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 51.5 m-85 -115.95 130.21 56.72 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.828 174.879 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.526 HD11 HD23 ' A' ' 81' ' ' LEU . 2.2 pp -119.87 148.98 22.6 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-O 121.172 0.511 . . . . 0.0 110.786 179.646 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 16.5 m -142.99 114.05 7.72 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.7 178.007 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.9 p -96.04 103.72 15.01 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-O 121.747 0.784 . . . . 0.0 111.06 -177.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 3.7 mmt -107.37 137.65 19.69 Favored Pre-proline 0 C--N 1.313 -1.02 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.922 -178.462 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . 0.444 ' HA ' ' HG2' ' A' ' 108' ' ' LYS . 72.9 Cg_endo -80.72 142.79 14.46 Favored 'Trans proline' 0 N--CA 1.448 -1.199 0 C-N-CA 122.142 1.894 . . . . 0.0 111.315 176.543 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 9.6 t -91.97 -178.24 4.95 Favored 'General case' 0 C--N 1.313 -1.021 0 C-N-CA 120.393 -0.523 . . . . 0.0 109.779 178.03 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 7.6 t -61.3 138.64 58.24 Favored 'General case' 0 N--CA 1.434 -1.23 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.016 179.396 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . 0.407 ' N ' HD12 ' A' ' 128' ' ' ILE . 2.7 mp -64.24 138.75 22.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 178.384 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 92.89 -12.74 69.26 Favored Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 120.421 -0.895 . . . . 0.0 112.606 -175.779 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 63.9 p -120.45 161.43 21.26 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 117.045 0.422 . . . . 0.0 110.696 178.424 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.483 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 58.9 pttt -133.57 146.62 51.16 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 116.338 -0.392 . . . . 0.0 109.985 179.476 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 31.4 t80 -85.9 136.62 33.22 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.688 -178.375 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 16.2 t70 -97.68 136.04 21.38 Favored Pre-proline 0 C--N 1.319 -0.741 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.569 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -68.48 -46.33 2.02 Favored 'Trans proline' 0 C--N 1.346 0.447 0 C-N-CA 122.684 2.256 . . . . 0.0 113.591 -178.66 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.9 mp -77.56 -54.27 12.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 111.706 0.261 . . . . 0.0 111.706 -177.779 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 21.5 m -68.02 -32.32 72.61 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 120.645 0.26 . . . . 0.0 110.916 -178.621 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' ARG . . . . . 0.403 ' HD3' ' HD2' ' A' ' 99' ' ' PRO . 98.4 mtt180 66.47 48.55 1.51 Allowed 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 121.411 0.624 . . . . 0.0 111.29 177.62 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 23.9 p-10 -151.42 172.9 15.23 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 115.254 -0.884 . . . . 0.0 108.762 177.731 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 67.9 m -101.82 126.94 48.8 Favored 'General case' 0 C--N 1.308 -1.208 0 CA-C-O 121.222 0.534 . . . . 0.0 111.154 179.041 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 35.1 m -116.46 161.35 15.27 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-N 115.43 -0.805 . . . . 0.0 108.941 178.053 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 45.2 tp -54.03 125.79 20.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.054 0.454 . . . . 0.0 110.113 178.6 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' ASP . . . . . 0.483 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 9.8 t70 -77.9 91.27 4.16 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 115.999 -0.546 . . . . 0.0 112.289 -175.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 . . . . . 0 C--N 1.314 -0.967 0 CA-C-O 118.196 -0.907 . . . . 0.0 108.861 172.758 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.468 0.795 0 N-CA-C 111.757 -0.537 . . . . 0.0 111.757 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_exo -64.98 124.89 13.73 Favored 'Trans proline' 0 N--CA 1.462 -0.376 0 C-N-CA 122.583 2.189 . . . . 0.0 111.545 178.58 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.426 ' O ' HD12 ' A' ' 77' ' ' LEU . 4.1 pp -77.21 139.57 39.91 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.809 179.6 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -117.48 35.1 4.25 Favored Glycine 0 N--CA 1.437 -1.267 0 N-CA-C 110.874 -0.891 . . . . 0.0 110.874 179.526 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 43.4 t -75.45 -20.44 58.84 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 179.418 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -161.8 94.57 0.95 Allowed 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.397 -0.819 . . . . 0.0 109.341 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.415 HD23 HD11 ' A' ' 121' ' ' ILE . 45.7 tp -109.9 135.39 50.85 Favored 'General case' 0 C--N 1.31 -1.152 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 177.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.605 HG22 HG22 ' A' ' 89' ' ' THR . 11.5 mt -96.82 142.55 13.85 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 C-N-CA 120.57 -0.452 . . . . 0.0 110.391 179.658 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.405 HG21 ' CE1' ' A' ' 102' ' ' HIS . 22.9 m -139.35 178.27 3.92 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 -178.106 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' HIS . . . . . 0.478 ' HA ' ' O ' ' A' ' 88' ' ' LYS . 66.3 m-70 -117.99 124.61 48.6 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-O 121.253 0.549 . . . . 0.0 111.868 179.49 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 -114.62 103.91 11.47 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.062 -0.972 . . . . 0.0 108.967 177.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 67.73 18.36 70.18 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.607 -0.806 . . . . 0.0 111.329 -177.739 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 106.75 -29.39 10.93 Favored Glycine 0 N--CA 1.445 -0.753 0 C-N-CA 121.28 -0.486 . . . . 0.0 112.635 -179.206 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . 0.478 ' O ' ' HA ' ' A' ' 84' ' ' HIS . 47.5 mmtm -80.79 154.03 27.41 Favored 'General case' 0 C--O 1.22 -0.457 0 CA-C-N 116.732 0.266 . . . . 0.0 110.534 -178.103 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.605 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -87.7 128.44 35.3 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.306 0.574 . . . . 0.0 112.512 -178.774 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 17.9 m-85 -125.74 152.2 45.65 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.34 -0.846 . . . . 0.0 109.985 177.399 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 24.3 m-70 -100.88 149.06 24.27 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-O 121.016 0.436 . . . . 0.0 111.361 -179.516 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 44.1 t -120.79 118.35 56.12 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.002 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 176.187 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 58.8 t -132.16 131.39 61.1 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.532 -179.242 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 94.9 m -113.76 138.69 49.9 Favored 'General case' 0 C--N 1.313 -1.012 0 CA-C-O 120.799 0.333 . . . . 0.0 110.894 -179.424 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 77.8 m-70 -119.03 -19.63 8.39 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.364 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 5.4 mp0 -126.05 142.21 51.62 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.011 -0.54 . . . . 0.0 109.699 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 3.1 mp0 -76.97 103.8 7.1 Favored 'General case' 0 C--N 1.314 -0.937 0 N-CA-C 109.794 -0.446 . . . . 0.0 109.794 177.177 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 164.26 169.35 27.69 Favored Glycine 0 N--CA 1.436 -1.349 0 N-CA-C 111.267 -0.733 . . . . 0.0 111.267 -179.178 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.465 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 95.4 Cg_endo -83.34 133.51 6.37 Favored 'Trans proline' 0 N--CA 1.454 -0.806 0 C-N-CA 122.582 2.188 . . . . 0.0 112.709 179.031 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.9 pp -140.12 156.6 70.13 Favored Pre-proline 0 C--N 1.32 -0.704 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.996 178.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -62.96 167.29 12.45 Favored 'Trans proline' 0 C--N 1.351 0.695 0 C-N-CA 122.743 2.296 . . . . 0.0 112.87 -178.547 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' HIS . . . . . 0.405 ' CE1' HG21 ' A' ' 83' ' ' VAL . 5.0 t-80 -91.68 133.15 31.46 Favored Pre-proline 0 C--N 1.322 -0.597 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.822 -178.366 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_endo -53.46 -37.62 82.31 Favored 'Trans proline' 0 C--N 1.353 0.799 0 C-N-CA 123.414 2.743 . . . . 0.0 113.344 -177.654 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -70.8 -64.82 2.68 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.087 179.462 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 3.0 p30 -132.6 120.29 21.61 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 121.045 0.45 . . . . 0.0 111.421 178.531 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 28.3 m -57.07 -10.25 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 CA-C-N 115.573 -0.74 . . . . 0.0 112.835 177.768 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 66.4 m170 -69.84 -1.03 8.24 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-O 121.158 0.504 . . . . 0.0 110.636 176.553 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 33.1 mtmm -137.31 157.72 46.01 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.109 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -143.47 173.33 11.72 Favored 'General case' 0 C--N 1.308 -1.21 0 C-N-CA 120.825 -0.35 . . . . 0.0 110.921 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.465 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 1.9 mp -131.04 142.82 42.58 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.966 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 178.786 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -99.68 115.17 39.99 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.968 0 N-CA-C 107.424 -1.325 . . . . 0.0 107.424 174.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 29.2 m -95.41 121.75 37.41 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 -178.526 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 16.4 m -126.56 140.79 52.17 Favored 'General case' 0 C--N 1.307 -1.282 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 -179.32 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -118.19 104.86 11.21 Favored 'General case' 0 C--N 1.308 -1.23 0 CA-C-O 121.083 0.468 . . . . 0.0 110.569 -178.435 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 67.5 m -82.89 89.06 6.8 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.444 178.704 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 68.78 -100.26 0.67 Allowed Glycine 0 N--CA 1.432 -1.575 0 C-N-CA 120.461 -0.876 . . . . 0.0 111.084 -177.702 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 14.5 t -114.5 7.46 16.19 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-O 120.9 0.381 . . . . 0.0 110.383 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 21.8 tp -117.1 131.11 56.99 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.584 -0.28 . . . . 0.0 110.438 -177.712 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 77.0 m95 -92.14 131.75 37.15 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 121.038 0.447 . . . . 0.0 111.84 -179.457 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 64.4 m-85 -120.89 129.79 53.64 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.471 174.085 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.415 HD11 HD23 ' A' ' 81' ' ' LEU . 2.5 pp -120.82 151.51 23.78 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.043 0 CA-C-O 121.129 0.49 . . . . 0.0 111.736 -179.518 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 27.8 m -139.66 118.81 12.69 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.892 178.495 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 6.0 p -92.09 124.6 44.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 120.951 0.405 . . . . 0.0 111.081 -178.621 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 4.0 mmt -125.77 139.22 33.62 Favored Pre-proline 0 C--N 1.318 -0.766 0 CA-C-N 115.822 -0.627 . . . . 0.0 109.838 -179.48 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -86.8 143.14 6.97 Favored 'Trans proline' 0 N--CA 1.453 -0.911 0 C-N-CA 122.241 1.961 . . . . 0.0 111.883 177.786 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' CYS . . . . . 0.498 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 55.3 m -81.81 169.39 16.95 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 176.529 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 1.6 p -58.36 148.52 27.45 Favored 'General case' 0 N--CA 1.435 -1.198 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.604 176.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . 0.416 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.9 mp -62.74 129.0 25.56 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 CA-C-O 121.135 0.493 . . . . 0.0 110.445 -179.348 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 92.04 5.31 66.1 Favored Glycine 0 N--CA 1.44 -1.061 0 CA-C-N 115.694 -0.684 . . . . 0.0 112.882 -178.21 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 60.5 p -126.33 162.6 25.13 Favored 'General case' 0 C--O 1.236 0.347 0 CA-C-N 117.269 0.534 . . . . 0.0 111.133 179.166 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 58.0 pttt -131.9 143.99 50.54 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 179.387 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.498 ' HB2' ' SG ' ' A' ' 126' ' ' CYS . 46.5 t80 -82.74 133.6 35.15 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-O 120.919 0.39 . . . . 0.0 111.712 -178.489 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -100.55 128.57 29.81 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 115.877 -0.601 . . . . 0.0 109.907 177.453 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -64.56 -41.22 20.44 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.973 2.449 . . . . 0.0 113.514 -176.73 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 28.1 mm -75.89 -53.01 16.58 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 N-CA-C 112.097 0.406 . . . . 0.0 112.097 -175.738 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 4.8 m -68.78 -31.96 71.35 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.727 -178.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 57.5 mtm180 70.73 51.02 0.33 Allowed 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 121.428 0.632 . . . . 0.0 110.752 178.328 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 29.7 p-10 -159.23 173.41 16.39 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-N 115.483 -0.78 . . . . 0.0 109.004 179.067 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' CYS . . . . . 0.423 ' HA ' ' HA ' ' A' ' 132' ' ' PHE . 21.1 m -101.85 125.26 48.49 Favored 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 178.503 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 27.2 m -112.8 163.2 10.2 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.767 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.159 -179.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 6.9 tt -57.56 123.6 16.13 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-O 121.081 0.467 . . . . 0.0 111.225 -178.692 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 17.1 t70 -91.46 99.28 12.25 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.209 178.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 25.0 t-20 . . . . . 0 C--N 1.313 -1.007 0 CA-C-O 118.59 -0.719 . . . . 0.0 109.808 -179.891 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.105 0 N-CA-C 111.521 -0.632 . . . . 0.0 111.521 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.501 ' HA ' ' OD1' ' A' ' 80' ' ' ASP . 8.7 Cg_endo -88.63 89.55 0.45 Allowed 'Trans proline' 0 N--CA 1.449 -1.126 0 C-N-CA 122.937 2.425 . . . . 0.0 111.912 179.172 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -173.04 136.73 0.67 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.674 -179.379 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 81.33 -65.01 4.08 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.872 -0.68 . . . . 0.0 111.752 178.061 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.414 ' O ' HG23 ' A' ' 93' ' ' VAL . 66.9 m -71.83 -30.26 65.29 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 115.434 -0.383 . . . . 0.0 111.234 179.108 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.525 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 11.9 p-10 -139.74 132.99 29.85 Favored 'General case' 0 N--CA 1.44 -0.944 0 CA-C-O 121.604 0.716 . . . . 0.0 111.437 -176.495 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.504 HD23 HD11 ' A' ' 121' ' ' ILE . 39.0 tp -107.25 137.88 44.47 Favored 'General case' 0 C--N 1.301 -1.504 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.502 177.224 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.469 HG22 HG22 ' A' ' 89' ' ' THR . 16.8 mt -96.81 143.29 12.62 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.07 0 C-N-CA 120.511 -0.476 . . . . 0.0 110.187 -179.547 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 28.7 m -138.41 157.37 30.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-N 116.174 -0.466 . . . . 0.0 109.804 -179.203 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 60.8 m-70 -104.2 104.33 14.23 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 116.468 -0.333 . . . . 0.0 111.019 179.454 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 70.4 mm-40 -100.79 104.97 16.23 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 177.529 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 66.37 30.62 76.95 Favored Glycine 0 N--CA 1.444 -0.776 0 C-N-CA 120.262 -0.971 . . . . 0.0 110.783 -176.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 89.42 -21.89 26.57 Favored Glycine 0 N--CA 1.442 -0.947 0 CA-C-N 115.195 -0.502 . . . . 0.0 112.726 -178.549 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 14.0 mmmm -83.75 135.2 34.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.799 0.333 . . . . 0.0 111.024 -176.027 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.469 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -81.42 112.26 18.52 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -178.52 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -112.26 146.68 37.77 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.744 -0.662 . . . . 0.0 109.649 176.301 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 21.6 m-70 -99.05 142.44 30.53 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-O 120.715 0.293 . . . . 0.0 110.498 178.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.67 HG13 HD13 ' A' ' 110' ' ' ILE . 79.5 t -117.65 120.33 64.4 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.955 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 179.097 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.414 HG23 ' O ' ' A' ' 79' ' ' SER . 14.9 p -138.79 142.21 34.97 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.028 -178.031 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 33.1 m -138.31 127.95 25.01 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.662 177.854 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 14.0 p80 -101.71 -0.32 34.7 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-O 121.447 0.641 . . . . 0.0 109.701 177.71 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 56.5 mt-10 -142.67 157.95 44.15 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 114.755 -1.111 . . . . 0.0 109.702 178.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -85.46 153.75 22.27 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 120.917 0.389 . . . . 0.0 110.77 178.295 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 126.8 161.77 10.99 Favored Glycine 0 N--CA 1.438 -1.168 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.037 178.34 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.494 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 72.9 Cg_endo -82.62 134.59 7.58 Favored 'Trans proline' 0 N--CA 1.447 -1.248 0 C-N-CA 122.376 2.051 . . . . 0.0 111.855 177.896 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -141.65 157.4 65.22 Favored Pre-proline 0 C--N 1.314 -0.968 0 CA-C-N 115.934 -0.576 . . . . 0.0 109.733 178.515 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_endo -62.42 164.64 17.31 Favored 'Trans proline' 0 C--N 1.348 0.544 0 C-N-CA 122.356 2.038 . . . . 0.0 112.468 -178.813 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' HIS . . . . . . . . . . . . . 27.6 t-80 -92.02 121.95 65.95 Favored Pre-proline 0 C--N 1.315 -0.899 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 -179.506 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -59.0 -19.3 47.58 Favored 'Trans proline' 0 N--CA 1.486 1.041 0 C-N-CA 123.116 2.544 . . . . 0.0 113.543 -176.581 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -93.35 -19.3 35.98 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.469 -0.872 . . . . 0.0 112.809 -179.843 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 2.4 p30 -167.32 102.04 0.52 Allowed 'General case' 0 C--N 1.326 -0.443 0 C-N-CA 122.479 0.311 . . . . 0.0 110.985 -177.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 28.3 m -54.91 -14.34 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 N-CA-C 113.674 0.99 . . . . 0.0 113.674 179.552 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 17.2 t-80 -73.21 -0.52 14.57 Favored 'General case' 0 CA--C 1.542 0.655 0 CA-C-O 121.61 0.719 . . . . 0.0 110.435 176.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 47.4 mtmt -136.89 160.88 37.58 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.473 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 11.1 p90 -142.37 173.67 11.32 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.546 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.67 HD13 HG13 ' A' ' 92' ' ' VAL . 3.7 mt -131.91 142.24 43.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 -178.584 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.6 mp -101.89 112.5 35.24 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.12 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 175.783 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 86.3 m -102.3 123.52 46.26 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-O 121.181 0.515 . . . . 0.0 111.178 -176.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 19.3 m -128.56 144.61 51.18 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.529 -179.057 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.597 ' HD3' ' CE2' ' A' ' 119' ' ' TRP . 24.1 tptm -113.16 103.84 11.75 Favored 'General case' 0 C--N 1.313 -0.985 0 N-CA-C 109.152 -0.685 . . . . 0.0 109.152 179.247 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 62.2 m -91.28 78.92 5.72 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-O 121.436 0.636 . . . . 0.0 109.524 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.523 ' O ' ' HE2' ' A' ' 114' ' ' LYS . . . 75.44 -99.06 1.18 Allowed Glycine 0 N--CA 1.433 -1.507 0 N-CA-C 110.593 -1.003 . . . . 0.0 110.593 -178.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 20.4 m -113.46 0.92 14.88 Favored 'General case' 0 N--CA 1.445 -0.722 0 CA-C-O 121.312 0.577 . . . . 0.0 110.068 -179.752 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 87.6 mt -112.02 122.97 49.23 Favored 'General case' 0 N--CA 1.435 -1.21 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.555 -176.538 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . 0.597 ' CE2' ' HD3' ' A' ' 114' ' ' LYS . 81.3 m95 -85.32 131.34 34.42 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 121.015 0.436 . . . . 0.0 111.107 177.37 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -125.48 124.0 40.41 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 115.881 -0.6 . . . . 0.0 109.849 174.55 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.504 HD11 HD23 ' A' ' 81' ' ' LEU . 2.5 pp -126.45 146.97 31.38 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.955 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.33 -178.494 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 34.5 m -134.24 124.93 26.75 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 116.013 -0.54 . . . . 0.0 109.672 178.212 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 2.8 p -95.68 110.99 25.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-O 121.393 0.615 . . . . 0.0 111.252 -179.057 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 9.1 mmt -113.32 145.8 33.98 Favored Pre-proline 0 C--N 1.318 -0.767 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.062 -178.719 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 79.4 Cg_endo -89.25 151.15 5.55 Favored 'Trans proline' 0 N--CA 1.453 -0.865 0 C-N-CA 122.353 2.035 . . . . 0.0 113.074 179.605 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 35.9 m -90.87 171.14 9.52 Favored 'General case' 0 C--O 1.243 0.727 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.153 175.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 22.9 t -54.28 148.32 11.74 Favored 'General case' 0 C--O 1.237 0.413 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 177.298 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . 0.455 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.9 mp -63.7 129.07 26.97 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 CA-C-O 120.912 0.387 . . . . 0.0 110.234 -179.032 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 89.38 6.03 71.55 Favored Glycine 0 N--CA 1.444 -0.791 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.783 -177.669 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 46.2 p -121.33 158.94 27.1 Favored 'General case' 0 N--CA 1.452 -0.36 0 O-C-N 122.343 -0.504 . . . . 0.0 110.757 178.236 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 59.0 pttt -128.0 144.26 51.1 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 32.8 t80 -84.46 137.22 33.48 Favored 'General case' 0 C--N 1.311 -1.098 0 C-N-CA 120.9 -0.32 . . . . 0.0 110.743 -179.644 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -100.05 133.83 21.31 Favored Pre-proline 0 C--N 1.325 -0.472 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.333 179.314 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -67.68 -41.84 7.71 Favored 'Trans proline' 0 C--N 1.346 0.418 0 C-N-CA 122.877 2.385 . . . . 0.0 113.949 -177.51 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 34.8 mm -82.35 -49.25 17.45 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 N-CA-C 111.951 0.352 . . . . 0.0 111.951 -176.45 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 2.4 m -69.1 -37.49 78.42 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.847 0.356 . . . . 0.0 110.1 179.512 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 67.5 mtt180 68.36 55.36 0.52 Allowed 'General case' 0 CA--C 1.514 -0.414 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.572 178.686 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 29.4 p-10 -154.61 172.93 17.06 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 114.86 -1.064 . . . . 0.0 108.374 178.221 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 27.3 m -101.03 124.83 47.36 Favored 'General case' 0 C--N 1.316 -0.891 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 177.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 35.8 m -117.54 157.16 18.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.296 -178.301 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 7.2 mp -64.56 119.75 11.06 Favored 'General case' 0 C--N 1.318 -0.8 0 N-CA-C 112.186 0.439 . . . . 0.0 112.186 -178.328 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -83.5 90.87 7.28 Favored 'General case' 0 C--N 1.319 -0.734 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 174.032 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 10.2 t30 . . . . . 0 C--N 1.306 -1.298 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.44 -174.488 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.27 0 N-CA-C 111.93 -0.468 . . . . 0.0 111.93 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.468 ' HA ' ' O ' ' A' ' 80' ' ' ASP . 81.0 Cg_endo -76.51 34.57 0.44 Allowed 'Trans proline' 0 C--N 1.349 0.557 0 C-N-CA 123.227 2.618 . . . . 0.0 112.498 -178.741 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 20.4 mt -88.52 33.99 0.76 Allowed 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.006 -178.391 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 87.58 -22.75 15.26 Favored Glycine 0 N--CA 1.449 -0.488 0 N-CA-C 111.069 -0.812 . . . . 0.0 111.069 -176.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 15.0 m -74.33 -49.49 22.69 Favored 'General case' 0 N--CA 1.443 -0.802 0 CA-C-N 115.482 -0.359 . . . . 0.0 111.264 179.758 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.468 ' O ' ' HA ' ' A' ' 76' ' ' PRO . 24.3 t70 -139.26 106.8 5.57 Favored 'General case' 0 CA--C 1.517 -0.297 0 CA-C-O 120.722 0.296 . . . . 0.0 110.386 -179.191 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.475 HD23 HD11 ' A' ' 121' ' ' ILE . 54.6 tp -108.6 131.65 54.65 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 178.298 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.548 HG22 HG22 ' A' ' 89' ' ' THR . 12.3 mt -91.69 139.97 16.9 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 C-N-CA 120.408 -0.517 . . . . 0.0 109.651 179.068 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 29.4 m -136.52 175.12 10.98 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 CA-C-N 116.137 -0.483 . . . . 0.0 109.84 -177.536 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 16.2 m-70 -114.57 117.24 30.36 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.109 0.48 . . . . 0.0 111.426 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.45 ' HB2' ' CD1' ' A' ' 90' ' ' TYR . 11.8 mm-40 -115.19 104.45 11.86 Favored 'General case' 0 C--N 1.311 -1.074 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 177.228 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 64.39 34.05 88.87 Favored Glycine 0 N--CA 1.446 -0.634 0 C-N-CA 120.382 -0.913 . . . . 0.0 111.448 -177.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 88.28 -26.9 7.34 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 121.436 -0.411 . . . . 0.0 113.021 -178.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -82.23 146.74 29.33 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.818 0.342 . . . . 0.0 111.169 -178.341 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.548 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -85.08 122.42 29.26 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-O 121.233 0.54 . . . . 0.0 112.153 -179.79 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.45 ' CD1' ' HB2' ' A' ' 85' ' ' GLU . 18.0 m-85 -117.03 148.79 41.18 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.252 176.711 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 31.4 m-70 -97.74 144.22 27.58 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-N 116.526 -0.306 . . . . 0.0 110.202 178.731 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 44.2 t -121.12 117.54 53.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.256 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 178.413 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.6 p -130.77 131.32 64.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 CA-C-N 115.424 -0.807 . . . . 0.0 109.096 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -106.3 138.44 42.48 Favored 'General case' 0 N--CA 1.435 -1.223 0 C-N-CA 119.579 -0.848 . . . . 0.0 111.456 -177.874 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 36.1 m80 -108.84 -25.07 10.97 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 115.329 -0.851 . . . . 0.0 110.365 -178.388 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -131.98 143.43 50.08 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.776 -177.664 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -74.67 108.6 7.53 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.203 178.317 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . 0.424 ' H ' ' HB2' ' A' ' 112' ' ' CYS . . . 156.25 -178.64 32.65 Favored Glycine 0 N--CA 1.439 -1.135 0 N-CA-C 111.637 -0.585 . . . . 0.0 111.637 -178.18 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.493 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 69.5 Cg_endo -91.12 127.31 1.16 Allowed 'Trans proline' 0 N--CA 1.445 -1.333 0 C-N-CA 123.149 2.566 . . . . 0.0 112.742 179.529 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.6 pp -138.02 156.12 74.21 Favored Pre-proline 0 C--N 1.313 -0.993 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.387 179.232 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.408 ' HG3' ' HD3' ' A' ' 134' ' ' PRO . 37.3 Cg_endo -62.92 165.25 16.86 Favored 'Trans proline' 0 C--N 1.352 0.746 0 C-N-CA 122.634 2.223 . . . . 0.0 112.522 -178.435 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' HIS . . . . . 0.421 ' CD2' HD11 ' A' ' 110' ' ' ILE . 11.9 t-80 -88.51 132.6 38.47 Favored Pre-proline 0 C--N 1.32 -0.716 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -178.601 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 17.5 Cg_endo -58.65 -19.95 48.12 Favored 'Trans proline' 0 C--N 1.35 0.631 0 C-N-CA 123.0 2.467 . . . . 0.0 112.806 -179.26 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -91.13 -67.68 1.17 Allowed Glycine 0 N--CA 1.447 -0.591 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.101 179.13 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 45.6 m-80 -118.56 109.95 16.78 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.592 0.196 . . . . 0.0 111.053 179.441 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 32.8 m -55.41 -13.62 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.791 0 N-CA-C 113.075 0.769 . . . . 0.0 113.075 176.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 41.1 m170 -73.92 3.78 6.26 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-O 120.934 0.397 . . . . 0.0 110.547 177.12 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 47.7 mtmt -140.62 157.75 45.0 Favored 'General case' 0 CA--C 1.506 -0.743 0 CA-C-N 115.833 -0.622 . . . . 0.0 109.43 179.78 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 8.5 p90 -143.03 170.07 16.39 Favored 'General case' 0 C--N 1.306 -1.284 0 C-N-CA 120.829 -0.348 . . . . 0.0 111.264 -179.433 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.493 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.1 mp -125.09 139.13 52.06 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.598 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -100.96 113.13 36.05 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 175.357 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' CYS . . . . . 0.424 ' HB2' ' H ' ' A' ' 98' ' ' GLY . 59.6 m -95.14 123.18 38.49 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 109.314 -0.625 . . . . 0.0 109.314 179.132 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 52.7 p -122.56 136.7 54.95 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.835 -176.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 19.5 tptm -96.41 115.54 27.59 Favored 'General case' 0 N--CA 1.435 -1.202 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.682 -179.032 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 59.7 m -108.23 79.81 1.3 Allowed 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 176.856 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 73.45 -104.57 1.61 Allowed Glycine 0 N--CA 1.438 -1.189 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 -176.273 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 8.4 t -113.33 13.02 18.98 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 121.226 0.536 . . . . 0.0 109.865 179.229 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 81.4 mt -116.96 135.4 53.73 Favored 'General case' 0 N--CA 1.435 -1.223 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.043 -177.378 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 50.1 m95 -96.98 131.69 43.53 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.005 0.431 . . . . 0.0 111.069 178.395 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -129.24 128.59 43.6 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 174.855 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.475 HD11 HD23 ' A' ' 81' ' ' LEU . 2.5 pp -119.05 158.91 20.05 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-O 120.952 0.406 . . . . 0.0 111.698 -176.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 44.2 m -146.01 121.65 10.46 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.882 177.369 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.7 p -94.62 110.13 23.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 121.549 0.69 . . . . 0.0 111.411 -179.024 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 7.2 mmt -111.86 142.8 27.39 Favored Pre-proline 0 C--N 1.313 -1.007 0 CA-C-N 115.49 -0.777 . . . . 0.0 110.004 -179.459 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -86.71 144.62 7.61 Favored 'Trans proline' 0 N--CA 1.453 -0.89 0 C-N-CA 122.461 2.107 . . . . 0.0 112.722 178.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 12.2 m -82.65 174.69 10.78 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.488 177.133 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 13.1 m -61.8 144.45 54.76 Favored 'General case' 0 N--CA 1.436 -1.16 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.88 176.678 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . 0.423 ' N ' HD12 ' A' ' 128' ' ' ILE . 2.2 mp -63.34 126.74 22.41 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.553 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 99.25 -6.87 59.83 Favored Glycine 0 N--CA 1.441 -1.0 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.735 -176.483 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 69.1 p -121.66 157.2 31.38 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-N 117.183 0.492 . . . . 0.0 111.449 179.139 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.418 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 62.4 pttt -124.35 147.64 48.06 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 179.0 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 46.9 t80 -81.46 134.37 35.53 Favored 'General case' 0 C--N 1.31 -1.132 0 C-N-CA 120.459 -0.496 . . . . 0.0 111.125 -179.363 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -104.33 127.83 28.29 Favored Pre-proline 0 C--N 1.317 -0.843 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.533 178.76 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' PRO . . . . . 0.408 ' HD3' ' HG3' ' A' ' 101' ' ' PRO . 27.3 Cg_endo -61.99 -42.43 30.49 Favored 'Trans proline' 0 C--O 1.235 0.338 0 C-N-CA 123.024 2.483 . . . . 0.0 113.48 -176.035 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 33.9 mm -79.03 -49.63 19.76 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.612 -176.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . 0.412 ' O ' ' HB2' ' A' ' 137' ' ' ARG . 5.1 m -62.41 -37.51 86.11 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.54 0.209 . . . . 0.0 111.134 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' ARG . . . . . 0.412 ' HB2' ' O ' ' A' ' 136' ' ' SER . 44.2 mtp180 74.62 41.91 0.32 Allowed 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 123.407 0.683 . . . . 0.0 111.33 178.763 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 -161.55 -179.27 7.18 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 178.828 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 10.6 m -100.45 125.93 46.8 Favored 'General case' 0 C--N 1.31 -1.147 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 -178.681 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.5 m -113.34 165.9 7.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.704 -178.253 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -55.08 116.02 2.55 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.625 -179.78 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' ASP . . . . . 0.418 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 21.4 t70 -91.47 101.23 13.9 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.58 -178.85 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 48.8 m-80 . . . . . 0 C--N 1.312 -1.055 0 CA-C-O 118.501 -0.761 . . . . 0.0 109.399 176.596 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.377 0 N-CA-C 111.99 -0.444 . . . . 0.0 111.99 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -78.66 92.73 1.12 Allowed 'Trans proline' 0 C--O 1.238 0.511 0 C-N-CA 122.739 2.292 . . . . 0.0 112.376 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -120.05 105.15 10.75 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.19 0.519 . . . . 0.0 111.395 -179.365 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -133.43 9.64 5.0 Favored Glycine 0 C--N 1.312 -0.771 0 N-CA-C 109.797 -1.321 . . . . 0.0 109.797 176.314 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 17.3 m -76.53 -20.4 56.94 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 114.766 -0.717 . . . . 0.0 110.951 -177.07 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -144.46 104.19 4.04 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 -178.39 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -107.2 127.79 53.83 Favored 'General case' 0 C--N 1.31 -1.131 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.407 ' CG2' HG22 ' A' ' 89' ' ' THR . 12.5 mt -98.19 144.5 11.24 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.918 0 C-N-CA 120.951 -0.3 . . . . 0.0 110.419 -178.071 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.46 HG21 ' CE1' ' A' ' 102' ' ' HIS . 22.2 m -128.74 151.41 35.49 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.009 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 179.792 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 22.3 m-70 -107.76 100.09 9.5 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-O 120.879 0.371 . . . . 0.0 110.709 179.741 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 79.4 mm-40 -105.54 105.21 15.14 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.95 179.718 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 62.47 37.67 95.06 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.73 -0.748 . . . . 0.0 111.873 -179.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 80.52 -6.11 62.19 Favored Glycine 0 CA--C 1.52 0.376 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.612 -178.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 32.0 mmmt -96.97 129.02 44.49 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.922 0.391 . . . . 0.0 110.288 -178.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.407 HG22 ' CG2' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -86.07 124.28 32.32 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.408 179.714 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 89.8 m-85 -121.48 141.04 51.41 Favored 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 177.538 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 37.8 m-70 -98.85 138.46 35.95 Favored 'General case' 0 C--N 1.312 -1.062 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.29 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 49.4 t -115.58 122.68 69.89 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.015 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 178.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 84.6 t -132.38 128.08 57.83 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.027 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 -179.421 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 66.9 m -98.61 131.6 44.68 Favored 'General case' 0 C--N 1.307 -1.277 0 CA-C-O 120.893 0.378 . . . . 0.0 110.899 -178.201 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 37.1 m80 -80.53 -29.45 37.18 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 179.597 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -158.32 -179.09 7.78 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 114.81 -1.086 . . . . 0.0 108.168 -177.528 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -84.55 154.25 22.75 Favored 'General case' 0 C--N 1.31 -1.138 0 CA-C-O 121.002 0.43 . . . . 0.0 111.001 -179.538 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 124.96 167.17 12.54 Favored Glycine 0 N--CA 1.442 -0.945 0 N-CA-C 111.478 -0.649 . . . . 0.0 111.478 -178.263 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.42 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 93.4 Cg_endo -87.18 134.36 3.55 Favored 'Trans proline' 0 N--CA 1.454 -0.85 0 C-N-CA 122.681 2.254 . . . . 0.0 112.816 178.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.5 pp -140.56 156.21 69.38 Favored Pre-proline 0 C--N 1.323 -0.575 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.168 178.416 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo -61.46 165.97 12.25 Favored 'Trans proline' 0 C--N 1.352 0.746 0 C-N-CA 122.895 2.397 . . . . 0.0 113.577 -177.687 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' HIS . . . . . 0.46 ' CE1' HG21 ' A' ' 83' ' ' VAL . 3.5 t-80 -89.06 128.13 52.97 Favored Pre-proline 0 C--N 1.321 -0.645 0 CA-C-N 115.329 -0.85 . . . . 0.0 108.93 -179.407 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 10.5 Cg_endo -51.56 -50.53 13.64 Favored 'Trans proline' 0 C--N 1.352 0.73 0 C-N-CA 123.123 2.549 . . . . 0.0 113.25 -176.432 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -67.44 -64.44 3.22 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.677 -179.672 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.446 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 2.6 p30 -119.89 105.0 10.66 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 120.972 0.415 . . . . 0.0 111.705 -178.824 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 27.3 m -56.08 -10.6 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 N-CA-C 113.574 0.953 . . . . 0.0 113.574 178.791 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 23.6 m170 -73.45 4.55 4.64 Favored 'General case' 0 N--CA 1.472 0.675 0 CA-C-O 121.245 0.545 . . . . 0.0 110.646 176.7 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 45.1 mtmt -138.1 160.38 39.54 Favored 'General case' 0 N--CA 1.445 -0.708 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 177.844 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 13.4 p90 -143.5 173.18 11.86 Favored 'General case' 0 C--N 1.313 -0.982 0 C-N-CA 120.466 -0.494 . . . . 0.0 111.611 179.668 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.431 ' CG2' ' HB ' ' A' ' 121' ' ' ILE . 2.9 mp -129.57 142.36 44.11 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.908 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.065 179.688 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -100.32 119.44 48.41 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.88 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 175.203 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 61.9 m -98.22 123.8 42.48 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-O 120.927 0.394 . . . . 0.0 111.177 -177.324 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 23.5 t -130.82 137.63 49.5 Favored 'General case' 0 C--N 1.312 -1.056 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 177.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.461 ' HE2' ' O ' ' A' ' 116' ' ' GLY . 86.6 tttt -116.34 109.61 17.59 Favored 'General case' 0 C--N 1.316 -0.872 0 C-N-CA 120.552 -0.459 . . . . 0.0 110.515 -178.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 53.4 m -92.09 76.76 5.38 Favored 'General case' 0 C--N 1.31 -1.128 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.018 178.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.461 ' O ' ' HE2' ' A' ' 114' ' ' LYS . . . 77.99 -98.93 1.49 Allowed Glycine 0 N--CA 1.44 -1.052 0 C-N-CA 120.434 -0.888 . . . . 0.0 111.199 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 25.3 m -114.09 8.94 17.15 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 121.086 0.47 . . . . 0.0 110.177 179.746 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 19.7 tp -122.69 125.64 45.99 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.66 -177.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . 0.446 ' CZ2' ' HD2' ' A' ' 114' ' ' LYS . 86.6 m95 -89.86 133.13 34.91 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-O 121.045 0.45 . . . . 0.0 111.632 179.363 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 87.6 m-85 -118.22 120.88 39.01 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 173.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.431 ' HB ' ' CG2' ' A' ' 110' ' ' ILE . 2.3 pp -125.51 142.94 40.76 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 CA-C-O 121.001 0.429 . . . . 0.0 111.14 -178.539 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 49.8 m -129.54 123.77 32.24 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-N 115.958 -0.564 . . . . 0.0 109.875 179.394 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.7 p -94.08 112.37 26.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 121.513 0.673 . . . . 0.0 111.342 -178.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 5.8 mmt -110.7 138.8 21.15 Favored Pre-proline 0 C--N 1.318 -0.786 0 CA-C-N 115.397 -0.82 . . . . 0.0 110.289 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -86.11 140.39 6.64 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 122.455 2.103 . . . . 0.0 112.359 178.61 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' CYS . . . . . 0.435 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 65.6 m -83.26 170.97 14.08 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.283 177.825 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 30.9 m -57.08 141.51 45.69 Favored 'General case' 0 N--CA 1.446 -0.64 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.173 176.491 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . 0.415 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.9 mp -59.9 131.76 24.73 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 179.37 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.28 -7.26 72.24 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.762 -0.732 . . . . 0.0 113.045 -176.618 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 59.7 p -117.2 164.91 14.07 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-N 117.174 0.487 . . . . 0.0 111.114 179.664 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.554 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 65.0 pttt -132.03 148.59 52.51 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 178.896 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.435 ' HB2' ' SG ' ' A' ' 126' ' ' CYS . 44.4 t80 -84.63 130.4 34.72 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 120.571 -0.452 . . . . 0.0 110.559 178.715 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -98.34 129.8 29.72 Favored Pre-proline 0 C--N 1.314 -0.948 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.924 179.271 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -64.21 -40.83 24.09 Favored 'Trans proline' 0 C--N 1.342 0.224 0 C-N-CA 122.803 2.335 . . . . 0.0 113.28 -176.805 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 27.6 mm -78.96 -51.67 16.53 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.599 -176.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 14.0 m -64.0 -32.73 74.38 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.836 0.351 . . . . 0.0 110.657 178.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 67.6 mtm180 68.83 41.95 1.45 Allowed 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 115.509 -0.769 . . . . 0.0 111.274 176.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 10.7 p30 -157.64 176.77 12.19 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.249 -0.887 . . . . 0.0 108.779 177.556 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' CYS . . . . . 0.412 ' HA ' ' HA ' ' A' ' 132' ' ' PHE . 9.2 m -100.28 124.92 46.33 Favored 'General case' 0 C--N 1.319 -0.727 0 C-N-CA 120.209 -0.596 . . . . 0.0 109.734 -178.612 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.0 m -117.88 167.87 10.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.201 -178.295 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -57.35 120.85 8.89 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 178.873 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' ASP . . . . . 0.554 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 8.8 t70 -74.89 90.15 2.39 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 113.674 0.99 . . . . 0.0 113.674 -173.721 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 47.3 m-80 . . . . . 0 C--O 1.248 1.017 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 169.328 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.326 0 N-CA-C 112.143 -0.383 . . . . 0.0 112.143 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 151.45 69.26 Favored 'Trans proline' 0 C--O 1.235 0.37 0 C-N-CA 122.638 2.225 . . . . 0.0 112.287 -179.803 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 73.8 mt -77.81 -18.64 56.13 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.499 -179.645 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.41 ' HA3' ' O ' ' A' ' 119' ' ' TRP . . . 103.18 -13.24 55.48 Favored Glycine 0 C--N 1.313 -0.715 0 CA-C-N 115.39 -0.823 . . . . 0.0 112.037 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 21.9 p -74.99 -32.88 61.78 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.211 0.529 . . . . 0.0 110.401 179.632 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -145.17 120.87 10.5 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.316 -0.857 . . . . 0.0 110.299 -177.526 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.446 ' HG ' HD11 ' A' ' 121' ' ' ILE . 2.6 tm? -129.97 126.1 37.0 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.024 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.435 ' CG2' HG22 ' A' ' 89' ' ' THR . 26.0 mt -93.79 147.94 5.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.226 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.597 HG21 ' CE1' ' A' ' 102' ' ' HIS . 10.9 m -138.92 167.14 21.18 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 N-CA-C 110.103 -0.332 . . . . 0.0 110.103 -178.902 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 73.2 m-70 -114.75 99.96 7.89 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.579 177.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.425 ' OE2' ' ND1' ' A' ' 102' ' ' HIS . 1.0 OUTLIER -87.1 98.28 11.21 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 179.775 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 74.27 1.79 61.26 Favored Glycine 0 C--N 1.324 -0.136 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 -177.622 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 123.28 -23.17 6.9 Favored Glycine 0 N--CA 1.437 -1.292 0 N-CA-C 111.374 -0.691 . . . . 0.0 111.374 -178.624 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 32.2 mmmt -85.08 137.83 32.8 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 110.218 -0.29 . . . . 0.0 110.218 -178.165 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.463 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.0 OUTLIER -76.84 128.16 34.08 Favored 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 112.748 0.647 . . . . 0.0 112.748 -178.502 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.538 ' CE2' ' HA2' ' A' ' 104' ' ' GLY . 35.2 m-85 -126.29 148.8 49.45 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 176.385 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 17.6 m-70 -101.37 139.27 37.26 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-O 120.792 0.33 . . . . 0.0 110.587 -178.079 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 60.5 t -122.3 118.04 54.09 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 179.127 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 49.0 t -128.78 132.96 67.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.145 179.431 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 82.8 m -110.38 118.94 37.63 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 -178.682 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 43.7 m80 -103.17 -15.95 15.87 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.987 -179.786 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -131.21 144.33 51.25 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.985 0.422 . . . . 0.0 111.059 -179.307 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -71.02 112.96 7.58 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.31 177.542 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 146.74 168.7 13.86 Favored Glycine 0 N--CA 1.437 -1.245 0 C-N-CA 121.092 -0.575 . . . . 0.0 111.953 179.502 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.433 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 73.4 Cg_endo -78.64 136.08 13.43 Favored 'Trans proline' 0 N--CA 1.457 -0.623 0 C-N-CA 122.656 2.237 . . . . 0.0 112.644 178.321 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -138.24 158.1 71.48 Favored Pre-proline 0 C--N 1.32 -0.688 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.846 178.072 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo -62.05 166.04 13.31 Favored 'Trans proline' 0 C--N 1.353 0.795 0 C-N-CA 122.69 2.26 . . . . 0.0 113.083 -177.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' HIS . . . . . 0.597 ' CE1' HG21 ' A' ' 83' ' ' VAL . 7.2 t-80 -92.35 133.7 29.46 Favored Pre-proline 0 C--N 1.321 -0.673 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.1 -178.041 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -57.89 -31.72 93.28 Favored 'Trans proline' 0 C--N 1.353 0.766 0 C-N-CA 123.039 2.493 . . . . 0.0 112.94 -178.581 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.538 ' HA2' ' CE2' ' A' ' 90' ' ' TYR . . . -70.29 -63.65 3.18 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.751 -0.738 . . . . 0.0 111.803 179.324 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.531 ' OD1' ' HB2' ' A' ' 107' ' ' HIS . 10.5 p30 -139.6 130.06 25.6 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-O 121.058 0.456 . . . . 0.0 110.743 176.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 29.5 m -58.73 -10.43 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.555 0 N-CA-C 113.487 0.921 . . . . 0.0 113.487 178.817 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . 0.531 ' HB2' ' OD1' ' A' ' 105' ' ' ASN . 36.8 m80 -71.11 -6.93 43.03 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 121.127 0.489 . . . . 0.0 110.193 177.686 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 43.1 mtmt -130.51 159.11 38.08 Favored 'General case' 0 CA--C 1.507 -0.71 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.835 177.795 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 9.6 p90 -143.33 173.18 11.83 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.724 179.675 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.433 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 2.4 mp -128.61 141.22 47.13 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.121 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 177.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.7 mp -97.58 117.35 42.15 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 N-CA-C 107.753 -1.202 . . . . 0.0 107.753 175.732 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 21.3 m -104.51 121.46 43.52 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 -179.197 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 36.7 m -122.92 133.33 54.4 Favored 'General case' 0 C--N 1.308 -1.203 0 CA-C-N 116.07 -0.513 . . . . 0.0 109.69 179.673 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.486 ' HD2' ' CZ2' ' A' ' 119' ' ' TRP . 80.8 tttt -105.53 112.24 25.25 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 120.489 -0.484 . . . . 0.0 110.179 -179.705 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 68.2 m -102.15 77.98 1.73 Allowed 'General case' 0 C--N 1.308 -1.213 0 CA-C-N 115.738 -0.664 . . . . 0.0 109.962 179.078 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 77.89 -99.67 1.54 Allowed Glycine 0 N--CA 1.44 -1.062 0 CA-C-N 115.317 -0.856 . . . . 0.0 111.485 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 31.7 t -114.48 3.97 15.1 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-O 121.051 0.453 . . . . 0.0 109.807 179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 19.5 mt -119.13 125.83 50.18 Favored 'General case' 0 N--CA 1.432 -1.35 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.11 -177.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . 0.486 ' CZ2' ' HD2' ' A' ' 114' ' ' LYS . 60.6 m95 -91.82 134.01 35.13 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-O 121.071 0.463 . . . . 0.0 111.083 178.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 87.5 m-85 -117.51 128.39 54.93 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-N 115.524 -0.762 . . . . 0.0 109.259 175.647 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.446 HD11 ' HG ' ' A' ' 81' ' ' LEU . 2.8 pp -127.73 156.36 39.53 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 N-CA-C 112.189 0.44 . . . . 0.0 112.189 -176.054 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 38.9 m -151.24 123.21 8.14 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.132 176.051 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.8 p -92.06 115.23 30.6 Favored 'Isoleucine or valine' 0 C--O 1.235 0.322 0 CA-C-O 121.301 0.572 . . . . 0.0 111.245 179.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.454 ' HA ' ' HE2' ' A' ' 124' ' ' MET . 4.6 mmt -117.16 149.7 44.86 Favored Pre-proline 0 C--N 1.32 -0.678 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.198 -179.542 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -92.07 147.76 3.09 Favored 'Trans proline' 0 N--CA 1.45 -1.074 0 C-N-CA 122.433 2.089 . . . . 0.0 112.431 177.647 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 18.2 m -80.94 174.38 11.68 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 120.911 0.386 . . . . 0.0 110.197 176.672 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 18.9 m -62.38 147.08 49.57 Favored 'General case' 0 N--CA 1.437 -1.08 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.79 176.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . 0.421 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.8 mp -59.11 123.72 11.94 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 CA-C-O 121.167 0.508 . . . . 0.0 110.218 -179.204 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 97.26 -1.67 60.74 Favored Glycine 0 N--CA 1.438 -1.22 0 CA-C-N 115.56 -0.745 . . . . 0.0 113.175 -178.786 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 80.8 p -120.81 162.88 19.03 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 117.447 0.624 . . . . 0.0 111.472 179.477 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.428 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 60.7 pttt -132.51 145.93 51.53 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.469 179.151 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 26.2 t80 -81.58 137.74 35.48 Favored 'General case' 0 C--N 1.31 -1.144 0 CA-C-O 121.15 0.5 . . . . 0.0 111.685 -178.339 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -103.35 132.5 21.04 Favored Pre-proline 0 C--N 1.323 -0.569 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.144 177.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -68.77 -39.82 8.06 Favored 'Trans proline' 0 CA--C 1.531 0.347 0 C-N-CA 122.871 2.38 . . . . 0.0 113.885 -176.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 27.2 mm -78.17 -52.49 15.79 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 N-CA-C 112.121 0.415 . . . . 0.0 112.121 -176.433 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 35.5 p -73.75 -29.84 62.46 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 120.695 0.283 . . . . 0.0 111.154 -178.326 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 95.6 mtt180 68.24 57.84 0.46 Allowed 'General case' 0 N--CA 1.465 0.28 0 C-N-CA 123.471 0.709 . . . . 0.0 112.288 176.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 4.1 p-10 -164.09 177.09 8.7 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 176.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 31.5 m -100.35 125.35 46.58 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 -178.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 33.1 m -112.75 167.59 5.84 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.561 -177.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -58.01 117.08 3.96 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.997 0.427 . . . . 0.0 111.177 179.309 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' ASP . . . . . 0.428 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 17.2 t70 -93.85 104.64 16.7 Favored 'General case' 0 CA--C 1.506 -0.713 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.399 178.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 31.4 t-20 . . . . . 0 C--N 1.303 -1.429 0 CA-C-O 118.789 -0.624 . . . . 0.0 109.379 179.229 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.382 0 N-CA-C 111.89 -0.484 . . . . 0.0 111.89 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 94.8 Cg_endo -79.83 166.4 21.38 Favored 'Trans proline' 0 CA--C 1.533 0.452 0 C-N-CA 122.739 2.292 . . . . 0.0 112.238 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.495 HD13 ' N ' ' A' ' 77' ' ' LEU . 0.0 OUTLIER -135.2 36.3 3.0 Favored 'General case' 0 CA--C 1.535 0.38 0 CA-C-O 121.297 0.57 . . . . 0.0 112.053 -179.564 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 77.9 -62.96 3.55 Favored Glycine 0 C--O 1.225 -0.433 0 CA-C-N 115.851 -0.613 . . . . 0.0 113.859 178.636 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 7.1 m -73.51 -20.97 60.53 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.289 0.566 . . . . 0.0 110.469 -178.601 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.432 ' OD1' ' HB3' ' A' ' 91' ' ' HIS . 25.4 t70 -134.61 116.01 14.51 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.468 -179.389 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -107.66 123.86 49.12 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 108.92 -0.771 . . . . 0.0 108.92 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.624 HG22 HG22 ' A' ' 89' ' ' THR . 3.2 mt -101.49 145.3 11.77 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.677 -177.157 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.429 ' O ' ' HA ' ' A' ' 89' ' ' THR . 16.7 m -134.36 165.53 31.25 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 116.084 -0.507 . . . . 0.0 109.812 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 18.6 m-70 -114.7 113.0 23.72 Favored 'General case' 0 C--N 1.31 -1.118 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.407 179.014 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 76.5 mm-40 -107.63 95.9 6.02 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.603 179.235 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 73.94 -6.17 21.3 Favored Glycine 0 CA--C 1.52 0.347 0 C-N-CA 121.093 -0.575 . . . . 0.0 112.932 178.655 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 134.64 -12.71 4.55 Favored Glycine 0 N--CA 1.443 -0.883 0 N-CA-C 111.698 -0.561 . . . . 0.0 111.698 -179.25 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -96.32 130.99 43.3 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 110.368 -0.234 . . . . 0.0 110.368 178.56 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.624 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -85.75 107.34 17.56 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-O 120.969 0.414 . . . . 0.0 111.452 179.391 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 78.1 m-85 -102.21 146.87 27.36 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.914 178.261 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . 0.432 ' HB3' ' OD1' ' A' ' 80' ' ' ASP . 36.1 m-70 -101.96 143.73 31.45 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.543 -178.669 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.499 HG13 HD13 ' A' ' 110' ' ' ILE . 89.8 t -114.29 122.18 67.9 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.461 179.102 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 64.2 t -136.77 124.99 34.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.24 0 CA-C-N 115.48 -0.782 . . . . 0.0 108.903 -179.681 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 81.7 m -101.9 127.98 48.5 Favored 'General case' 0 C--N 1.31 -1.139 0 CA-C-O 120.932 0.396 . . . . 0.0 111.059 -179.09 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 68.3 t60 -91.08 -25.45 19.63 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.291 0.567 . . . . 0.0 109.518 178.337 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -149.1 164.69 33.94 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.218 -177.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -78.69 142.13 37.37 Favored 'General case' 0 N--CA 1.438 -1.065 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.001 178.08 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 130.05 167.31 12.03 Favored Glycine 0 N--CA 1.438 -1.223 0 C-N-CA 120.907 -0.663 . . . . 0.0 111.621 -178.174 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.402 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 98.5 Cg_endo -85.6 137.99 6.04 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 122.582 2.188 . . . . 0.0 112.766 179.462 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.8 pp -142.86 158.04 60.16 Favored Pre-proline 0 C--N 1.319 -0.747 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.628 178.713 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -64.56 166.63 17.08 Favored 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 122.462 2.108 . . . . 0.0 112.75 -177.619 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' HIS . . . . . . . . . . . . . 14.1 t-80 -89.49 130.09 44.81 Favored Pre-proline 0 C--N 1.318 -0.762 0 CA-C-N 115.923 -0.581 . . . . 0.0 109.906 -178.206 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -62.19 -24.32 76.14 Favored 'Trans proline' 0 N--CA 1.48 0.716 0 C-N-CA 123.013 2.475 . . . . 0.0 113.456 -177.317 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -93.44 -17.87 40.81 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.201 -1.0 . . . . 0.0 113.482 -178.571 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 1.9 p30 -167.63 105.31 0.52 Allowed 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.657 0.265 . . . . 0.0 111.199 -177.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 27.0 m -55.05 -11.69 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 N-CA-C 113.509 0.929 . . . . 0.0 113.509 178.145 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 91.0 m-70 -77.57 7.03 6.06 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 121.194 0.521 . . . . 0.0 110.951 178.016 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 47.9 mtmt -143.29 162.84 34.63 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.221 179.342 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 11.1 p90 -142.64 173.72 11.28 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-O 120.919 0.39 . . . . 0.0 111.238 179.727 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.499 HD13 HG13 ' A' ' 92' ' ' VAL . 3.8 mt -132.87 143.62 39.01 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.651 -179.24 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.414 ' N ' HD12 ' A' ' 111' ' ' ILE . 4.3 mp -103.09 122.28 55.34 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 176.641 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 58.7 m -103.08 122.51 44.82 Favored 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 178.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 29.1 t -133.59 140.25 47.02 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-O 120.894 0.378 . . . . 0.0 110.672 -177.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.427 ' HD2' ' CZ2' ' A' ' 119' ' ' TRP . 59.9 tttm -107.54 104.74 14.36 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-O 121.106 0.479 . . . . 0.0 110.178 179.125 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 23.3 t -90.76 88.45 7.08 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.58 -179.48 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 66.1 -100.76 0.54 Allowed Glycine 0 N--CA 1.438 -1.195 0 CA-C-N 115.474 -0.784 . . . . 0.0 111.664 -178.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 16.3 m -109.32 3.8 21.97 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -179.054 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 35.5 tp -126.98 141.01 51.9 Favored 'General case' 0 C--N 1.327 -0.396 0 C-N-CA 120.563 -0.455 . . . . 0.0 111.452 -178.654 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . 0.427 ' CZ2' ' HD2' ' A' ' 114' ' ' LYS . 72.6 m95 -93.8 133.47 37.15 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.348 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 77.4 m-85 -121.7 130.78 53.69 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.606 175.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.4 pp -125.11 146.96 29.91 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 CA-C-O 120.973 0.416 . . . . 0.0 110.891 179.706 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 22.9 m -137.98 125.43 21.97 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-N 115.964 -0.562 . . . . 0.0 109.94 179.4 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.3 p -94.9 112.02 26.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 121.424 0.63 . . . . 0.0 111.018 179.167 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 6.8 mmt -111.49 141.92 25.48 Favored Pre-proline 0 C--N 1.314 -0.942 0 CA-C-N 115.454 -0.793 . . . . 0.0 110.182 -179.442 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -87.05 154.4 8.37 Favored 'Trans proline' 0 N--CA 1.457 -0.664 0 C-N-CA 122.587 2.191 . . . . 0.0 113.365 -179.72 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 56.5 m -92.72 165.09 13.13 Favored 'General case' 0 C--O 1.241 0.653 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.448 175.618 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 14.9 m -59.93 148.88 33.5 Favored 'General case' 0 N--CA 1.445 -0.693 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.304 176.738 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . 0.409 HD12 ' N ' ' A' ' 128' ' ' ILE . 1.8 mp -60.04 129.73 22.85 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.246 179.749 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 93.9 -2.13 69.0 Favored Glycine 0 N--CA 1.439 -1.136 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.883 -178.242 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 68.7 p -121.06 164.02 17.45 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-N 117.257 0.528 . . . . 0.0 111.382 179.422 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.523 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 57.8 pttt -139.18 145.07 38.88 Favored 'General case' 0 C--N 1.318 -0.768 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 178.67 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.406 ' HA ' ' HA ' ' A' ' 139' ' ' CYS . 38.3 t80 -82.8 137.79 34.21 Favored 'General case' 0 C--N 1.311 -1.084 0 N-CA-C 112.365 0.505 . . . . 0.0 112.365 -176.034 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -106.52 131.55 21.62 Favored Pre-proline 0 C--N 1.327 -0.408 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.811 176.264 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.05 -36.58 21.59 Favored 'Trans proline' 0 N--CA 1.471 0.203 0 C-N-CA 122.904 2.403 . . . . 0.0 113.935 -176.803 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 34.3 mm -79.28 -56.34 7.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 N-CA-C 111.932 0.345 . . . . 0.0 111.932 -176.061 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 26.8 p -66.69 -31.76 72.63 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 120.528 0.204 . . . . 0.0 110.911 179.629 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 72.25 48.6 0.25 Allowed 'General case' 0 CA--C 1.518 -0.268 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.342 176.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 32.9 p30 -154.9 175.98 13.09 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.434 178.814 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' CYS . . . . . 0.406 ' HA ' ' HA ' ' A' ' 132' ' ' PHE . 27.8 m -100.86 124.65 46.85 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 177.622 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 29.8 m -107.65 160.58 6.75 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.877 -177.69 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -61.45 119.02 7.75 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.187 179.79 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' ASP . . . . . 0.523 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 28.2 t70 -85.97 101.35 12.82 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.934 179.188 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 17.7 m120 . . . . . 0 C--N 1.314 -0.951 0 CA-C-O 118.398 -0.811 . . . . 0.0 110.156 179.997 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.246 0 N-CA-C 112.01 -0.436 . . . . 0.0 112.01 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -84.06 170.75 10.81 Favored 'Trans proline' 0 N--CA 1.457 -0.659 0 C-N-CA 122.698 2.265 . . . . 0.0 112.189 179.64 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 93.0 mt -87.95 -177.08 5.68 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.345 179.325 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.66 ' HA3' ' O ' ' A' ' 119' ' ' TRP . . . -155.48 -33.19 0.03 OUTLIER Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 120.267 -0.968 . . . . 0.0 112.741 -178.706 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 11.3 t -67.86 -44.43 77.11 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 178.742 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -140.41 101.33 4.09 Favored 'General case' 0 C--N 1.317 -0.831 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -112.14 126.31 55.05 Favored 'General case' 0 C--N 1.306 -1.288 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 -177.43 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 15.0 mt -94.4 140.14 17.21 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 C-N-CA 120.869 -0.333 . . . . 0.0 110.395 -178.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 27.1 m -127.82 162.53 33.46 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.171 -178.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 35.7 m170 -108.87 112.66 25.01 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.293 179.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.548 ' HB2' ' CE1' ' A' ' 90' ' ' TYR . 71.8 mm-40 -116.81 103.96 10.85 Favored 'General case' 0 C--N 1.312 -1.033 0 N-CA-C 109.206 -0.665 . . . . 0.0 109.206 178.28 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 69.38 23.9 76.26 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.631 -0.795 . . . . 0.0 111.971 -179.261 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 95.53 -19.28 55.04 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.845 -0.693 . . . . 0.0 112.627 -179.421 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 56.4 mtmt -91.16 157.37 17.23 Favored 'General case' 0 CA--C 1.512 -0.486 0 CA-C-O 120.797 0.332 . . . . 0.0 111.357 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -94.68 132.62 39.23 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-N 115.879 -0.6 . . . . 0.0 112.602 -177.621 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.548 ' CE1' ' HB2' ' A' ' 85' ' ' GLU . 42.4 m-85 -127.04 140.54 52.22 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 115.133 -0.94 . . . . 0.0 108.915 176.68 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 21.2 m-70 -97.83 145.36 26.48 Favored 'General case' 0 C--N 1.307 -1.246 0 CA-C-O 120.826 0.345 . . . . 0.0 110.672 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.548 HG13 HD13 ' A' ' 110' ' ' ILE . 81.8 t -114.81 126.38 72.36 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.001 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.074 178.477 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 91.2 t -136.43 123.5 32.22 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 179.227 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 73.0 m -94.64 132.05 39.78 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-O 121.435 0.636 . . . . 0.0 112.345 -175.667 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 70.7 m-70 -86.31 -31.22 21.7 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.036 -0.984 . . . . 0.0 110.783 -178.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -148.36 167.39 25.35 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.282 -178.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 43.6 mt-10 -79.21 103.36 9.09 Favored 'General case' 0 N--CA 1.446 -0.66 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 174.627 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 163.92 169.85 28.0 Favored Glycine 0 N--CA 1.431 -1.698 0 N-CA-C 111.126 -0.79 . . . . 0.0 111.126 -178.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.566 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 72.1 Cg_endo -81.55 128.73 6.22 Favored 'Trans proline' 0 N--CA 1.443 -1.485 0 C-N-CA 122.283 1.989 . . . . 0.0 112.256 178.563 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -135.04 157.64 76.55 Favored Pre-proline 0 C--N 1.312 -1.058 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.654 178.569 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -64.55 167.21 15.6 Favored 'Trans proline' 0 C--O 1.233 0.263 0 C-N-CA 122.49 2.127 . . . . 0.0 112.72 -177.573 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' HIS . . . . . 0.45 ' HB3' ' O ' ' A' ' 105' ' ' ASN . 4.5 t-80 -88.85 125.08 63.84 Favored Pre-proline 0 C--N 1.315 -0.891 0 N-CA-C 108.814 -0.809 . . . . 0.0 108.814 -179.007 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -53.41 -37.69 82.06 Favored 'Trans proline' 0 N--CA 1.485 0.984 0 C-N-CA 123.286 2.657 . . . . 0.0 113.417 -176.275 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -74.57 -61.81 3.04 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.335 179.127 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.45 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 2.4 p30 -125.21 109.27 12.65 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 120.992 0.425 . . . . 0.0 111.63 -179.13 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.3 t -56.21 -13.91 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.172 0 C-N-CA 123.584 0.754 . . . . 0.0 112.747 179.278 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 12.1 t-80 -69.06 -1.72 8.29 Favored 'General case' 0 CA--C 1.551 1.019 0 CA-C-O 121.533 0.682 . . . . 0.0 110.644 177.316 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 46.4 mtmt -134.83 160.72 37.31 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 178.604 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 11.3 p90 -142.41 173.33 11.63 Favored 'General case' 0 C--N 1.307 -1.269 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.674 179.178 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.566 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.4 mt -132.03 142.48 42.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 -178.383 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.7 mp -101.7 114.17 40.19 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 176.16 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 61.8 m -102.15 122.88 45.01 Favored 'General case' 0 C--N 1.307 -1.273 0 CA-C-O 120.989 0.423 . . . . 0.0 111.252 -177.057 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 28.0 m -131.01 145.64 52.11 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 178.02 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -118.17 114.1 22.55 Favored 'General case' 0 C--N 1.31 -1.132 0 CA-C-O 121.201 0.524 . . . . 0.0 110.3 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 63.1 m -88.2 79.94 7.72 Favored 'General case' 0 N--CA 1.432 -1.366 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.354 179.039 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 75.8 -99.06 1.22 Allowed Glycine 0 N--CA 1.435 -1.392 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 -178.442 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 18.8 m -114.06 6.32 16.37 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 120.844 0.355 . . . . 0.0 110.47 179.341 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 18.2 tp -119.12 124.62 47.3 Favored 'General case' 0 C--O 1.221 -0.405 0 CA-C-N 116.524 -0.307 . . . . 0.0 110.768 -177.251 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . 0.66 ' O ' ' HA3' ' A' ' 78' ' ' GLY . 88.4 m95 -84.41 133.89 34.49 Favored 'General case' 0 C--N 1.317 -0.832 0 N-CA-C 112.069 0.396 . . . . 0.0 112.069 -179.423 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 71.9 m-85 -123.38 124.83 43.81 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.531 172.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.4 pp -123.91 155.93 30.91 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.86 0 CA-C-O 121.23 0.538 . . . . 0.0 112.06 -177.338 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 34.3 m -142.6 121.21 12.53 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.712 177.535 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.8 p -95.25 117.68 39.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 121.231 0.539 . . . . 0.0 111.268 -178.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.411 ' HA ' ' HE2' ' A' ' 124' ' ' MET . 5.0 mmt -120.16 149.66 49.73 Favored Pre-proline 0 C--N 1.32 -0.692 0 CA-C-N 115.703 -0.68 . . . . 0.0 109.999 -178.55 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -91.64 148.02 3.37 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 122.415 2.076 . . . . 0.0 113.483 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 58.7 m -90.84 172.51 8.57 Favored 'General case' 0 C--O 1.242 0.677 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.783 175.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 39.0 m -65.23 147.87 52.69 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.498 178.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . 0.418 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.9 mp -65.2 129.08 29.0 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.001 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 178.713 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 99.81 -16.22 58.79 Favored Glycine 0 N--CA 1.439 -1.112 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.079 -177.023 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 65.8 p -108.85 159.41 16.81 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-O 120.887 0.375 . . . . 0.0 110.93 178.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.473 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 63.7 pttt -128.83 143.58 50.94 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 178.723 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.444 ' HA ' ' HA ' ' A' ' 139' ' ' CYS . 36.8 t80 -80.73 137.06 36.26 Favored 'General case' 0 C--N 1.314 -0.956 0 C-N-CA 120.294 -0.562 . . . . 0.0 111.324 -179.34 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -108.36 127.13 28.09 Favored Pre-proline 0 C--N 1.32 -0.707 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.105 178.47 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -65.99 -36.89 28.41 Favored 'Trans proline' 0 CA--C 1.53 0.292 0 C-N-CA 122.96 2.44 . . . . 0.0 113.553 -177.062 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.8 mp -77.0 -49.99 21.85 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.322 -177.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 13.1 m -67.83 -35.65 78.98 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 120.728 0.299 . . . . 0.0 110.378 178.893 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' ARG . . . . . 0.4 HH11 ' HD2' ' A' ' 137' ' ' ARG . 66.5 mtt85 71.31 46.21 0.44 Allowed 'General case' 0 CA--C 1.517 -0.297 0 CA-C-N 115.692 -0.685 . . . . 0.0 111.217 178.555 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 11.4 p30 -162.37 177.72 9.3 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 177.7 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' CYS . . . . . 0.444 ' HA ' ' HA ' ' A' ' 132' ' ' PHE . 6.3 m -100.45 125.26 46.73 Favored 'General case' 0 C--N 1.313 -1.019 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -178.914 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 28.4 m -111.97 163.48 8.86 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.09 -178.169 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -70.52 127.3 32.24 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 -179.256 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' ASP . . . . . 0.473 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 22.5 t70 -94.83 100.58 12.44 Favored 'General case' 0 CA--C 1.502 -0.882 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.271 -179.312 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 34.7 t30 . . . . . 0 C--N 1.302 -1.465 0 N-CA-C 109.041 -0.725 . . . . 0.0 109.041 177.917 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.133 0 N-CA-C 111.662 -0.575 . . . . 0.0 111.662 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -79.51 155.21 24.49 Favored 'Trans proline' 0 N--CA 1.455 -0.771 0 C-N-CA 122.874 2.382 . . . . 0.0 111.978 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 55.4 tp -84.21 114.17 21.62 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.85 -0.613 . . . . 0.0 109.904 178.608 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -145.22 -16.82 0.18 Allowed Glycine 0 C--N 1.318 -0.431 0 C-N-CA 120.573 -0.822 . . . . 0.0 112.834 -179.391 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 14.5 m -75.48 -34.27 60.87 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 120.789 0.328 . . . . 0.0 110.689 -178.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 27.0 t70 -147.37 97.35 2.84 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.06 -177.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.452 HD23 HD11 ' A' ' 121' ' ' ILE . 38.6 tp -92.37 145.88 24.13 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.046 179.759 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.585 HG22 HG22 ' A' ' 89' ' ' THR . 4.9 mt -105.1 144.7 14.43 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 178.427 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 15.3 m -141.9 130.69 22.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.042 0.449 . . . . 0.0 110.778 -177.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 8.6 p80 -78.9 122.98 26.8 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.27 177.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.442 ' HG2' HD22 ' A' ' 105' ' ' ASN . 7.5 tp10 -136.88 113.87 10.54 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 116.109 -0.496 . . . . 0.0 109.85 179.028 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 68.04 24.19 74.52 Favored Glycine 0 N--CA 1.447 -0.584 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.043 -179.6 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 91.2 -10.53 74.7 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.997 -0.62 . . . . 0.0 112.688 -179.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -102.77 139.6 38.14 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.666 0.269 . . . . 0.0 110.359 -179.749 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.585 HG22 HG22 ' A' ' 82' ' ' ILE . 0.1 OUTLIER -87.53 106.67 18.15 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-O 120.821 0.343 . . . . 0.0 110.505 179.676 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 75.6 m-85 -96.2 151.99 18.98 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.562 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 36.4 m-70 -106.85 138.86 42.24 Favored 'General case' 0 C--N 1.308 -1.206 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.041 178.814 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 57.4 t -119.13 118.21 56.8 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 177.435 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.8 p -125.52 138.89 52.97 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.072 -178.774 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 82.1 m -121.97 115.11 21.96 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.213 0.53 . . . . 0.0 111.069 -179.355 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 42.8 t60 -92.67 -18.17 23.36 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.565 178.31 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 74.5 mm-40 -142.02 159.85 41.4 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.452 -0.795 . . . . 0.0 109.835 -178.358 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 -79.66 148.37 31.64 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-O 120.992 0.425 . . . . 0.0 110.549 177.784 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 128.06 164.83 11.69 Favored Glycine 0 N--CA 1.434 -1.488 0 N-CA-C 111.185 -0.766 . . . . 0.0 111.185 -179.528 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.484 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 91.9 Cg_endo -88.5 142.34 5.04 Favored 'Trans proline' 0 N--CA 1.441 -1.591 0 C-N-CA 122.565 2.176 . . . . 0.0 112.817 179.323 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.41 ' O ' ' HB2' ' A' ' 109' ' ' TYR . 1.7 pp -141.36 156.53 67.21 Favored Pre-proline 0 C--N 1.316 -0.876 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.19 177.752 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -62.66 165.65 15.4 Favored 'Trans proline' 0 C--N 1.346 0.437 0 C-N-CA 122.316 2.011 . . . . 0.0 112.901 -177.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' HIS . . . . . 0.481 ' HB3' ' O ' ' A' ' 105' ' ' ASN . 42.8 t-80 -87.12 121.77 71.34 Favored Pre-proline 0 C--N 1.315 -0.913 0 CA-C-N 115.754 -0.657 . . . . 0.0 109.399 -179.266 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 13.7 Cg_endo -56.41 -25.44 57.56 Favored 'Trans proline' 0 N--CA 1.48 0.678 0 C-N-CA 122.887 2.391 . . . . 0.0 112.938 -176.604 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -87.06 -20.14 53.87 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.506 -0.854 . . . . 0.0 113.205 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.481 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 9.5 p30 -168.88 117.7 0.68 Allowed 'General case' 0 N--CA 1.472 0.639 0 CA-C-N 117.213 0.506 . . . . 0.0 110.909 -179.74 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 35.1 m -56.32 -11.38 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 N-CA-C 113.756 1.021 . . . . 0.0 113.756 177.205 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 44.7 m170 -76.76 -0.72 24.84 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 111.957 0.354 . . . . 0.0 111.957 179.67 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.41 ' HG2' ' HA ' ' A' ' 125' ' ' PRO . 39.1 mtmt -139.3 163.82 31.47 Favored 'General case' 0 CA--C 1.503 -0.863 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 179.164 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.41 ' HB2' ' O ' ' A' ' 100' ' ' ILE . 12.4 p90 -144.02 173.27 11.87 Favored 'General case' 0 C--N 1.311 -1.094 0 CA-C-N 116.555 -0.293 . . . . 0.0 111.112 179.533 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.484 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.7 mp -131.18 141.19 46.67 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.968 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 178.276 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.6 mp -99.04 122.72 51.1 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 176.824 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' CYS . . . . . 0.419 ' HA ' HG22 ' A' ' 121' ' ' ILE . 58.8 m -98.14 123.35 42.14 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -178.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 18.9 m -130.1 134.24 47.22 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 120.797 0.332 . . . . 0.0 111.226 -178.729 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.471 ' HE3' ' O ' ' A' ' 116' ' ' GLY . 58.9 tptt -107.31 103.3 12.62 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 178.458 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 51.0 m -101.78 103.01 13.72 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.88 179.757 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.471 ' O ' ' HE3' ' A' ' 114' ' ' LYS . . . 59.8 -106.19 0.92 Allowed Glycine 0 N--CA 1.443 -0.857 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.256 -176.852 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 11.6 t -111.28 3.48 18.38 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-O 120.818 0.342 . . . . 0.0 110.683 178.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -113.16 132.37 55.5 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 120.89 0.376 . . . . 0.0 111.426 -176.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . 0.449 ' CE2' ' HD3' ' A' ' 114' ' ' LYS . 67.1 m95 -90.85 132.1 36.1 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.894 0.378 . . . . 0.0 110.092 175.847 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -123.36 124.64 43.39 Favored 'General case' 0 C--N 1.309 -1.181 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.631 175.801 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.452 HD11 HD23 ' A' ' 81' ' ' LEU . 2.4 pp -124.46 142.13 42.28 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.52 -178.871 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 33.5 m -130.13 126.5 37.67 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-N 116.18 -0.464 . . . . 0.0 109.778 179.377 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.1 p -95.26 110.38 23.98 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 121.413 0.625 . . . . 0.0 110.746 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 3.6 mmt -111.02 144.29 30.07 Favored Pre-proline 0 C--N 1.316 -0.856 0 CA-C-N 115.367 -0.833 . . . . 0.0 109.772 -179.8 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . 0.41 ' HA ' ' HG2' ' A' ' 108' ' ' LYS . 83.6 Cg_endo -89.26 148.62 5.43 Favored 'Trans proline' 0 N--CA 1.45 -1.075 0 C-N-CA 122.237 1.958 . . . . 0.0 112.737 178.388 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' CYS . . . . . 0.407 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 53.3 m -81.97 161.06 23.17 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.095 -0.502 . . . . 0.0 109.794 176.465 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 16.7 t -61.07 142.38 56.7 Favored 'General case' 0 N--CA 1.442 -0.833 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 177.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . 0.405 HD12 ' N ' ' A' ' 128' ' ' ILE . 1.8 mp -54.22 129.6 15.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.468 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 100.15 -7.91 58.84 Favored Glycine 0 N--CA 1.444 -0.79 0 C-N-CA 120.934 -0.65 . . . . 0.0 113.269 -177.776 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 69.5 p -123.49 164.82 18.19 Favored 'General case' 0 C--O 1.237 0.405 0 CA-C-N 117.087 0.443 . . . . 0.0 111.383 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 60.1 pttt -134.74 147.39 50.02 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 178.762 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.42 ' HA ' ' HA ' ' A' ' 139' ' ' CYS . 30.4 t80 -81.78 138.89 35.08 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-O 121.23 0.538 . . . . 0.0 112.355 -177.168 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -108.01 126.98 28.51 Favored Pre-proline 0 C--N 1.324 -0.5 0 CA-C-N 115.51 -0.768 . . . . 0.0 109.533 177.059 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -63.97 -40.17 28.88 Favored 'Trans proline' 0 N--CA 1.474 0.369 0 C-N-CA 122.961 2.441 . . . . 0.0 113.561 -176.55 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 30.8 mm -77.4 -51.96 17.39 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.46 -176.787 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 8.7 m -62.86 -36.12 82.24 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 120.741 0.305 . . . . 0.0 110.508 178.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 85.9 mtm180 73.11 41.52 0.49 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.909 178.625 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 3.5 p-10 -158.03 178.0 10.7 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 178.543 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' CYS . . . . . 0.42 ' HA ' ' HA ' ' A' ' 132' ' ' PHE . 31.4 m -100.51 125.54 46.85 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-O 121.146 0.498 . . . . 0.0 110.034 -178.74 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.3 m -111.9 165.03 7.23 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 CA-C-N 115.859 -0.61 . . . . 0.0 109.881 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 54.9 tp -57.29 125.0 20.81 Favored 'General case' 0 C--N 1.313 -0.979 0 CA-C-O 121.152 0.501 . . . . 0.0 111.842 -178.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 18.0 t0 -90.45 94.53 9.76 Favored 'General case' 0 N--CA 1.442 -0.873 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.958 178.002 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 . . . . . 0 C--N 1.312 -1.033 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 178.579 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.375 0 N-CA-C 112.058 -0.417 . . . . 0.0 112.058 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_exo -63.61 135.12 47.5 Favored 'Trans proline' 0 C--O 1.242 0.7 0 C-N-CA 122.643 2.229 . . . . 0.0 111.839 178.564 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 84.0 mt -122.74 172.4 8.46 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.711 -179.709 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -140.82 -36.43 0.1 Allowed Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.133 -1.032 . . . . 0.0 112.929 -179.346 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 26.4 t -73.14 -45.25 57.86 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 120.537 0.208 . . . . 0.0 110.629 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.409 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 15.1 t70 -147.81 96.05 2.6 Favored 'General case' 0 C--O 1.233 0.229 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 179.013 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.42 ' HG ' HD11 ' A' ' 121' ' ' ILE . 2.9 tm? -102.63 130.74 49.61 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.147 -179.16 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.42 HG22 HG22 ' A' ' 89' ' ' THR . 6.8 mt -96.17 143.84 11.4 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.848 0 C-N-CA 120.707 -0.397 . . . . 0.0 110.486 -177.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 20.6 m -133.94 167.21 26.79 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 179.796 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' HIS . . . . . 0.448 ' HA ' ' O ' ' A' ' 88' ' ' LYS . 72.0 m-70 -106.95 115.02 29.46 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-O 121.053 0.454 . . . . 0.0 110.969 178.559 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.408 ' HB2' ' CD1' ' A' ' 90' ' ' TYR . 66.4 mm-40 -109.04 104.56 13.79 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 177.378 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 68.0 27.35 73.7 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.301 -0.952 . . . . 0.0 111.224 -178.428 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 95.1 -25.03 26.01 Favored Glycine 0 N--CA 1.443 -0.872 0 C-N-CA 121.41 -0.424 . . . . 0.0 112.73 -179.123 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . 0.448 ' O ' ' HA ' ' A' ' 84' ' ' HIS . 33.4 mmtp -85.93 149.68 25.03 Favored 'General case' 0 C--O 1.222 -0.368 0 CA-C-O 120.64 0.257 . . . . 0.0 110.618 -176.356 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.42 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -87.97 121.44 30.38 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-O 121.155 0.502 . . . . 0.0 112.108 -179.314 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.408 ' CD1' ' HB2' ' A' ' 85' ' ' GLU . 38.2 m-85 -119.19 141.95 48.42 Favored 'General case' 0 C--N 1.313 -1.02 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 176.691 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 32.9 m-70 -92.09 144.77 25.1 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-O 121.051 0.453 . . . . 0.0 111.376 -177.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.409 ' O ' ' HA ' ' A' ' 80' ' ' ASP . 97.9 t -118.04 117.9 56.4 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 176.046 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.6 p -125.83 137.92 56.16 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.847 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.259 -178.072 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 84.9 m -120.73 113.25 19.92 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 46.7 t60 -92.86 -19.2 21.93 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.921 -179.919 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -138.77 157.36 46.22 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.548 -178.025 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 35.7 mt-10 -77.68 135.79 38.12 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.871 176.812 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 130.03 168.37 12.28 Favored Glycine 0 C--N 1.313 -0.7 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.12 -178.102 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -85.0 135.33 5.49 Favored 'Trans proline' 0 N--CA 1.453 -0.872 0 C-N-CA 122.636 2.224 . . . . 0.0 112.613 178.845 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.412 ' O ' ' HB2' ' A' ' 109' ' ' TYR . 1.9 pp -138.76 157.07 72.5 Favored Pre-proline 0 C--N 1.321 -0.666 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.028 178.359 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.401 ' HG3' ' HD3' ' A' ' 134' ' ' PRO . 56.6 Cg_endo -68.06 171.17 12.93 Favored 'Trans proline' 0 C--N 1.348 0.523 0 C-N-CA 122.286 1.991 . . . . 0.0 112.081 -179.527 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' HIS . . . . . 0.416 ' HB3' ' O ' ' A' ' 105' ' ' ASN . 62.5 t-80 -92.34 132.62 31.6 Favored Pre-proline 0 C--N 1.314 -0.943 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -53.34 -49.52 17.15 Favored 'Trans proline' 0 CA--C 1.536 0.594 0 C-N-CA 122.957 2.438 . . . . 0.0 112.533 -177.874 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -63.33 -66.22 2.66 Favored Glycine 0 CA--C 1.526 0.721 0 C-N-CA 121.067 -0.587 . . . . 0.0 113.086 178.787 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.416 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 4.2 p30 -120.95 111.79 17.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.825 0.345 . . . . 0.0 111.63 -179.558 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.421 HG12 ' HB2' ' A' ' 131' ' ' LYS . 20.0 t -59.2 -14.6 5.6 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.904 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.529 177.345 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 22.5 t-80 -66.92 -5.52 12.94 Favored 'General case' 0 CA--C 1.543 0.686 0 CA-C-O 121.355 0.597 . . . . 0.0 110.694 177.739 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 7.5 mtmp? -135.04 156.17 49.49 Favored 'General case' 0 N--CA 1.439 -0.996 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 178.46 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . 0.412 ' HB2' ' O ' ' A' ' 100' ' ' ILE . 12.6 p90 -141.56 170.08 16.39 Favored 'General case' 0 C--N 1.306 -1.284 0 CA-C-O 120.689 0.281 . . . . 0.0 110.405 -178.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 3.3 mp -126.3 140.68 48.04 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 -179.675 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.422 ' O ' ' HA ' ' A' ' 121' ' ' ILE . 4.6 mp -97.9 117.69 43.12 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.031 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 176.076 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 34.7 m -104.38 123.69 47.86 Favored 'General case' 0 C--N 1.312 -1.022 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -178.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 14.3 p -135.87 147.86 48.39 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.55 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.577 ' HE2' ' O ' ' A' ' 116' ' ' GLY . 84.4 tttt -117.34 112.84 21.27 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-O 121.085 0.469 . . . . 0.0 110.552 -178.253 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 75.4 m -97.98 73.02 2.23 Favored 'General case' 0 C--N 1.31 -1.13 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.888 178.295 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.577 ' O ' ' HE2' ' A' ' 114' ' ' LYS . . . 80.97 -98.9 1.87 Allowed Glycine 0 N--CA 1.437 -1.256 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 -178.822 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 50.2 m -114.54 5.39 15.49 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 120.856 0.36 . . . . 0.0 110.122 177.282 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 50.1 tp -114.85 121.34 42.94 Favored 'General case' 0 C--O 1.222 -0.383 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.49 -178.062 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 57.4 m95 -89.45 132.5 34.99 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 121.045 0.45 . . . . 0.0 111.932 179.504 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 48.2 m-85 -110.6 126.31 54.32 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.884 175.096 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.476 ' O ' HD12 ' A' ' 121' ' ' ILE . 2.5 pp -126.28 150.62 32.0 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.129 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.709 -179.012 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 26.9 m -151.72 123.57 8.03 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.569 177.487 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 5.3 p -93.64 112.01 25.91 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.324 0 CA-C-O 121.58 0.705 . . . . 0.0 110.912 179.087 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 6.4 mmt -113.54 144.15 30.79 Favored Pre-proline 0 C--N 1.318 -0.792 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.399 -178.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -88.01 144.71 6.22 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 122.564 2.176 . . . . 0.0 112.648 178.666 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' CYS . . . . . 0.44 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 26.3 m -83.26 171.83 13.2 Favored 'General case' 0 C--O 1.244 0.779 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.069 176.066 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 35.7 t -61.15 151.77 30.35 Favored 'General case' 0 N--CA 1.445 -0.687 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 177.451 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . 0.43 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.8 mp -64.21 124.69 19.48 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.193 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.664 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 99.69 -12.96 61.18 Favored Glycine 0 N--CA 1.44 -1.042 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.439 -177.279 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 76.5 p -111.67 149.7 31.21 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-O 121.158 0.504 . . . . 0.0 111.784 179.782 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.421 ' HB2' HG12 ' A' ' 106' ' ' VAL . 58.8 pttt -121.37 144.71 48.51 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 178.869 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.44 ' HB2' ' SG ' ' A' ' 126' ' ' CYS . 45.0 t80 -82.53 136.15 34.93 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-O 121.178 0.513 . . . . 0.0 111.927 -177.497 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . 0.42 ' HB3' ' OG ' ' A' ' 136' ' ' SER . 19.8 t70 -105.16 130.2 23.51 Favored Pre-proline 0 C--N 1.321 -0.659 0 CA-C-N 115.945 -0.571 . . . . 0.0 109.786 177.366 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' PRO . . . . . 0.401 ' HD3' ' HG3' ' A' ' 101' ' ' PRO . 28.2 Cg_endo -64.68 -42.95 14.13 Favored 'Trans proline' 0 N--CA 1.473 0.317 0 C-N-CA 123.018 2.479 . . . . 0.0 114.236 -176.17 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 2.0 mp -77.61 -50.64 19.74 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 N-CA-C 111.943 0.349 . . . . 0.0 111.943 -175.752 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . 0.42 ' OG ' ' HB3' ' A' ' 133' ' ' ASP . 64.1 p -70.44 -29.68 66.33 Favored 'General case' 0 C--N 1.325 -0.498 0 C-N-CA 121.037 -0.265 . . . . 0.0 111.184 -179.058 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 71.21 48.83 0.34 Allowed 'General case' 0 C--O 1.234 0.251 0 CA-C-N 115.813 -0.63 . . . . 0.0 111.783 175.331 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 9.5 p30 -160.83 176.58 11.31 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 177.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 17.3 m -101.43 124.72 47.56 Favored 'General case' 0 C--N 1.313 -1.02 0 C-N-CA 120.414 -0.514 . . . . 0.0 109.969 -178.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 31.7 m -111.66 160.05 11.26 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.889 0 CA-C-N 116.062 -0.517 . . . . 0.0 109.802 -179.588 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 78.7 mt -63.22 132.94 53.36 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-O 121.1 0.476 . . . . 0.0 111.367 -179.037 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -97.61 91.09 5.25 Favored 'General case' 0 C--N 1.313 -1.001 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 177.493 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 . . . . . 0 C--N 1.304 -1.397 0 CA-C-O 118.295 -0.859 . . . . 0.0 109.537 -177.157 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.539 0 N-CA-C 111.889 -0.484 . . . . 0.0 111.889 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_exo -58.15 129.67 34.16 Favored 'Trans proline' 0 C--N 1.346 0.414 0 C-N-CA 122.929 2.42 . . . . 0.0 112.286 179.428 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 4.8 mp -96.52 1.91 51.89 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.82 -179.113 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 101.62 -10.92 57.82 Favored Glycine 0 C--O 1.225 -0.448 0 C-N-CA 120.496 -0.859 . . . . 0.0 111.451 -179.128 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 6.3 m -75.33 -32.64 60.97 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.019 0.438 . . . . 0.0 110.701 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -151.9 98.93 2.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.573 -0.74 . . . . 0.0 109.538 -179.448 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.423 ' CD2' HD11 ' A' ' 121' ' ' ILE . 52.9 tp -111.57 135.78 51.67 Favored 'General case' 0 C--N 1.312 -1.043 0 C-N-CA 120.939 -0.305 . . . . 0.0 110.687 179.562 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.44 HG22 HG22 ' A' ' 89' ' ' THR . 3.8 mt -100.1 145.95 9.88 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.163 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 179.323 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.563 ' O ' ' HA ' ' A' ' 89' ' ' THR . 30.9 m -141.22 170.83 13.11 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 -179.822 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' HIS . . . . . 0.402 ' HA ' ' O ' ' A' ' 88' ' ' LYS . 50.3 m-70 -114.13 113.27 24.48 Favored 'General case' 0 C--N 1.316 -0.888 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 -179.085 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.409 ' OE1' ' HA ' ' A' ' 85' ' ' GLU . 4.3 mm-40 -112.31 111.84 23.0 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 174.839 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 71.76 13.22 75.02 Favored Glycine 0 N--CA 1.452 -0.235 0 N-CA-C 110.679 -0.968 . . . . 0.0 110.679 -176.633 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 99.76 -17.46 57.39 Favored Glycine 0 N--CA 1.437 -1.295 0 CA-C-N 114.999 -0.601 . . . . 0.0 111.905 -178.18 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . 0.402 ' O ' ' HA ' ' A' ' 84' ' ' HIS . 35.3 mmtp -87.16 143.05 27.47 Favored 'General case' 0 CA--C 1.515 -0.397 0 CA-C-O 120.712 0.292 . . . . 0.0 110.691 -177.728 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.563 ' HA ' ' O ' ' A' ' 83' ' ' VAL . 0.1 OUTLIER -85.62 130.71 34.5 Favored 'General case' 0 N--CA 1.434 -1.234 0 N-CA-C 112.541 0.571 . . . . 0.0 112.541 -179.076 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.454 ' CD1' ' HA3' ' A' ' 104' ' ' GLY . 82.3 m-85 -128.58 138.68 52.34 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 115.608 -0.723 . . . . 0.0 109.854 176.76 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 17.6 m-70 -88.82 143.5 26.86 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 120.831 0.348 . . . . 0.0 110.668 -179.784 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 62.2 t -117.17 122.72 70.64 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.064 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 177.724 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 52.8 t -125.37 131.13 72.64 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.176 0 CA-C-N 116.079 -0.509 . . . . 0.0 109.671 -178.805 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 87.2 m -104.8 114.28 28.39 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-O 121.182 0.515 . . . . 0.0 109.892 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 26.5 m80 -84.25 -23.46 30.39 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.151 -177.71 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -160.67 176.58 11.38 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.692 -0.686 . . . . 0.0 109.389 -179.043 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -79.89 142.8 34.84 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.885 0.374 . . . . 0.0 110.217 178.291 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 130.71 167.77 12.08 Favored Glycine 0 N--CA 1.442 -0.955 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.405 -178.412 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.416 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 87.7 Cg_endo -89.59 133.13 2.17 Favored 'Trans proline' 0 N--CA 1.449 -1.116 0 C-N-CA 122.918 2.412 . . . . 0.0 112.93 179.415 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -138.04 157.31 73.25 Favored Pre-proline 0 C--N 1.318 -0.776 0 CA-C-N 115.71 -0.677 . . . . 0.0 109.463 177.891 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.484 ' HG3' ' HD3' ' A' ' 134' ' ' PRO . 59.4 Cg_endo -68.8 171.14 13.9 Favored 'Trans proline' 0 CA--C 1.515 -0.427 0 C-N-CA 122.234 1.956 . . . . 0.0 112.234 -178.021 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' HIS . . . . . 0.644 ' HB3' ' O ' ' A' ' 105' ' ' ASN . 50.2 t-80 -90.35 126.68 55.78 Favored Pre-proline 0 N--CA 1.43 -1.434 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 178.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -54.58 -43.74 56.14 Favored 'Trans proline' 0 N--CA 1.474 0.38 0 C-N-CA 122.959 2.439 . . . . 0.0 113.126 -174.03 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.454 ' HA3' ' CD1' ' A' ' 90' ' ' TYR . . . -96.68 4.54 63.76 Favored Glycine 0 N--CA 1.442 -0.951 0 C-N-CA 120.057 -1.068 . . . . 0.0 113.633 -178.452 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.644 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 52.2 t30 -163.84 87.3 0.51 Allowed 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 117.683 0.741 . . . . 0.0 111.17 -179.534 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 21.9 m -54.93 -11.95 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 N-CA-C 113.859 1.059 . . . . 0.0 113.859 178.177 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 19.1 t-80 -77.21 0.39 22.05 Favored 'General case' 0 CA--C 1.543 0.704 0 CA-C-O 121.413 0.625 . . . . 0.0 110.203 177.169 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 39.8 mttp -133.8 156.29 48.29 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.576 178.516 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 9.1 p90 -141.92 162.54 35.22 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 176.497 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.416 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.3 mp -123.83 140.03 48.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 -178.327 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -99.29 118.84 46.48 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 176.259 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 65.3 m -100.25 123.23 44.23 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 120.743 0.306 . . . . 0.0 110.571 -178.015 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 34.0 t -130.84 139.8 50.19 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.328 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.416 ' HD2' ' CZ2' ' A' ' 119' ' ' TRP . 88.6 tttt -113.92 113.63 25.11 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 120.999 0.428 . . . . 0.0 110.541 -178.707 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 73.4 m -100.52 80.72 2.24 Favored 'General case' 0 N--CA 1.441 -0.887 0 CA-C-O 121.356 0.598 . . . . 0.0 109.974 178.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 76.1 -99.62 1.3 Allowed Glycine 0 N--CA 1.442 -0.914 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.367 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 32.8 m -112.55 4.58 17.44 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.772 0.32 . . . . 0.0 110.59 -179.436 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 12.4 mt -122.77 133.28 54.47 Favored 'General case' 0 N--CA 1.439 -0.995 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.238 -176.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . 0.416 ' CZ2' ' HD2' ' A' ' 114' ' ' LYS . 70.7 m95 -96.04 133.5 40.22 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-O 121.076 0.465 . . . . 0.0 111.472 179.549 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -121.25 122.63 40.35 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 115.785 -0.643 . . . . 0.0 109.38 176.12 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.423 HD11 ' CD2' ' A' ' 81' ' ' LEU . 2.4 pp -122.5 156.22 27.59 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.86 -175.343 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 22.6 m -140.95 123.17 15.72 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.935 178.415 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 5.2 p -95.95 105.29 16.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-O 121.621 0.725 . . . . 0.0 110.841 -179.742 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 3.5 mmt -106.18 139.48 20.32 Favored Pre-proline 0 C--N 1.314 -0.973 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.139 -178.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -85.09 144.63 9.56 Favored 'Trans proline' 0 N--CA 1.448 -1.151 0 C-N-CA 122.2 1.934 . . . . 0.0 112.324 178.617 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' CYS . . . . . 0.537 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 65.7 m -80.61 164.24 23.04 Favored 'General case' 0 C--O 1.242 0.675 0 CA-C-N 116.247 -0.433 . . . . 0.0 109.857 176.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 32.3 t -56.29 148.36 18.8 Favored 'General case' 0 N--CA 1.443 -0.82 0 CA-C-N 116.056 -0.52 . . . . 0.0 109.66 177.082 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . 0.483 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.8 mp -62.97 128.92 25.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.333 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 96.37 -9.04 67.08 Favored Glycine 0 N--CA 1.443 -0.871 0 C-N-CA 120.88 -0.676 . . . . 0.0 112.625 -177.028 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 72.1 p -118.46 153.88 33.39 Favored 'General case' 0 C--O 1.236 0.342 0 CA-C-N 117.292 0.546 . . . . 0.0 111.127 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.419 ' HE2' ' HA ' ' A' ' 142' ' ' ASP . 49.3 pttt -130.0 145.28 51.64 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 116.022 -0.535 . . . . 0.0 109.606 -179.248 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.537 ' HB2' ' SG ' ' A' ' 126' ' ' CYS . 29.4 t80 -84.46 136.88 33.65 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-O 121.088 0.471 . . . . 0.0 111.988 -176.329 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 32.2 t70 -108.56 134.78 20.15 Favored Pre-proline 0 C--N 1.323 -0.556 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.52 177.056 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' PRO . . . . . 0.484 ' HD3' ' HG3' ' A' ' 101' ' ' PRO . 42.0 Cg_endo -68.82 -37.36 11.87 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.577 2.185 . . . . 0.0 113.27 -176.045 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 22.7 mm -77.85 -53.55 14.08 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.881 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.827 -176.426 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 67.0 m -68.98 -29.98 68.3 Favored 'General case' 0 C--N 1.321 -0.662 0 C-N-CA 120.822 -0.351 . . . . 0.0 111.307 178.476 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 89.0 mtm180 70.76 41.57 0.88 Allowed 'General case' 0 N--CA 1.473 0.704 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.656 175.665 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 10.7 p30 -155.66 174.35 15.42 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 177.404 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' CYS . . . . . 0.442 ' HA ' ' HA ' ' A' ' 132' ' ' PHE . 6.4 m -101.26 124.88 47.64 Favored 'General case' 0 C--N 1.314 -0.943 0 C-N-CA 120.341 -0.544 . . . . 0.0 109.62 -179.28 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 33.9 m -107.01 159.8 6.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.833 -179.236 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 55.4 tp -63.47 119.82 10.5 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-O 120.972 0.415 . . . . 0.0 111.456 -178.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' ASP . . . . . 0.419 ' HA ' ' HE2' ' A' ' 131' ' ' LYS . 21.2 t70 -78.76 91.53 4.71 Favored 'General case' 0 N--CA 1.442 -0.85 0 CA-C-O 121.463 0.649 . . . . 0.0 109.309 176.653 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 . . . . . 0 C--N 1.305 -1.326 0 CA-C-N 114.978 -1.01 . . . . 0.0 110.41 -177.22 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.314 0 N-CA-C 111.866 -0.494 . . . . 0.0 111.866 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -76.73 154.75 34.72 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 122.541 2.161 . . . . 0.0 111.577 178.569 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 89.3 mt -135.62 157.05 47.83 Favored 'General case' 0 C--N 1.316 -0.871 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.494 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -109.11 -48.58 0.82 Allowed Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.595 -178.258 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 22.7 t -61.71 -45.47 93.83 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 120.687 0.28 . . . . 0.0 110.648 -179.189 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.636 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 7.6 p-10 -155.43 114.93 3.64 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.352 0.596 . . . . 0.0 111.028 178.025 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 47.0 tp -97.04 140.47 31.51 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.417 177.833 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.591 HG22 HG22 ' A' ' 89' ' ' THR . 5.5 mt -100.26 145.95 9.97 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.996 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 179.745 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.473 ' O ' ' HA ' ' A' ' 89' ' ' THR . 17.1 m -142.87 176.01 3.76 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.88 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -179.611 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 41.7 m-70 -117.13 120.93 39.81 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-O 121.108 0.48 . . . . 0.0 111.9 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.433 ' HB2' ' CE1' ' A' ' 90' ' ' TYR . 45.2 mt-10 -126.17 116.09 20.79 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.264 176.51 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 67.16 23.76 73.17 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.624 -0.798 . . . . 0.0 111.232 -178.557 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 93.55 -28.0 11.0 Favored Glycine 0 N--CA 1.443 -0.858 0 C-N-CA 121.437 -0.411 . . . . 0.0 112.725 -178.282 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 44.3 mmtm -84.91 155.01 21.86 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.69 0.281 . . . . 0.0 111.136 -177.058 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.591 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -92.42 137.4 32.4 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.488 -179.949 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.433 ' CE1' ' HB2' ' A' ' 85' ' ' GLU . 89.7 m-85 -131.6 145.38 51.67 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 178.583 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 20.0 m-70 -98.88 143.6 29.01 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-O 120.951 0.405 . . . . 0.0 110.579 179.606 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.636 ' O ' ' HA ' ' A' ' 80' ' ' ASP . 57.2 t -113.93 118.55 58.68 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.161 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 177.109 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 37.3 t -121.15 137.54 54.52 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.242 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 -178.282 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 72.4 m -114.53 113.61 24.66 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-O 120.988 0.423 . . . . 0.0 111.13 -179.751 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 20.8 t60 -81.03 -24.14 38.1 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.769 -0.651 . . . . 0.0 111.076 -178.846 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -154.34 169.6 23.3 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.551 -0.295 . . . . 0.0 110.615 -178.281 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 21.0 mp0 -76.61 110.61 11.32 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.378 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 161.87 165.84 19.52 Favored Glycine 0 N--CA 1.446 -0.663 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.315 179.85 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.446 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 92.3 Cg_endo -85.75 135.11 4.81 Favored 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 122.907 2.404 . . . . 0.0 112.503 178.628 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -139.92 156.95 70.39 Favored Pre-proline 0 C--N 1.319 -0.724 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.525 179.394 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -63.51 169.21 10.1 Favored 'Trans proline' 0 C--N 1.353 0.775 0 C-N-CA 122.683 2.255 . . . . 0.0 112.54 -179.649 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' HIS . . . . . 0.474 ' CD2' HD11 ' A' ' 110' ' ' ILE . 5.2 t-80 -94.31 138.46 22.47 Favored Pre-proline 0 C--N 1.322 -0.602 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 -178.108 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -53.45 -50.2 14.72 Favored 'Trans proline' 0 CA--C 1.536 0.584 0 C-N-CA 123.109 2.539 . . . . 0.0 113.121 -178.624 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -71.1 -65.21 2.53 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.591 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 43.7 m-80 -115.06 104.94 12.38 Favored 'General case' 0 C--N 1.321 -0.658 0 O-C-N 122.865 -0.197 . . . . 0.0 111.365 -179.806 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 18.5 m -56.25 -12.04 0.99 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 N-CA-C 112.011 0.374 . . . . 0.0 112.011 173.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 24.3 t-80 -66.36 -8.26 24.28 Favored 'General case' 0 CA--C 1.544 0.719 0 CA-C-O 121.407 0.622 . . . . 0.0 110.076 175.58 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 48.4 mtmt -129.55 157.25 42.55 Favored 'General case' 0 N--CA 1.439 -1.001 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.623 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 12.9 p90 -142.14 167.38 22.26 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 120.181 -0.608 . . . . 0.0 111.133 -179.804 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.474 HD11 ' CD2' ' A' ' 102' ' ' HIS . 2.3 mp -126.43 139.4 51.78 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.112 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.173 -179.146 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.7 mp -98.74 116.45 41.73 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.144 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 175.336 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 39.9 m -95.99 121.82 38.14 Favored 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 16.6 t -130.36 149.4 52.06 Favored 'General case' 0 N--CA 1.437 -1.098 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.117 -178.624 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.508 ' HE3' ' CE2' ' A' ' 119' ' ' TRP . 9.1 mmtp -103.23 140.46 37.34 Favored 'General case' 0 C--N 1.308 -1.203 0 CA-C-O 121.224 0.535 . . . . 0.0 111.732 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 57.7 m -124.26 79.92 1.78 Allowed 'General case' 0 N--CA 1.43 -1.438 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 174.207 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 73.39 -104.4 1.58 Allowed Glycine 0 N--CA 1.431 -1.68 0 CA-C-N 114.788 -1.096 . . . . 0.0 110.517 -174.851 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 12.1 p -113.01 16.39 19.35 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-O 120.899 0.38 . . . . 0.0 111.134 178.719 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 24.2 tp -122.14 142.92 49.89 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.289 -177.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . 0.508 ' CE2' ' HE3' ' A' ' 114' ' ' LYS . 91.1 m95 -92.15 133.39 35.82 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 120.984 0.421 . . . . 0.0 111.67 179.161 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 49.2 m-85 -124.19 122.81 38.81 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.123 172.3 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.5 pp -119.78 155.95 22.46 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.44 -176.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 25.7 m -141.06 119.74 12.49 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.655 178.353 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 4.2 p -94.02 109.06 21.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-O 121.684 0.754 . . . . 0.0 111.108 -179.138 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 5.3 mmt -107.82 127.4 27.79 Favored Pre-proline 0 C--N 1.309 -1.183 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.288 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -78.75 142.08 17.64 Favored 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 122.325 2.017 . . . . 0.0 110.819 176.21 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 10.4 t -93.62 -179.08 4.91 Favored 'General case' 0 C--N 1.317 -0.824 0 C-N-CA 120.484 -0.487 . . . . 0.0 110.382 179.745 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 34.0 t -62.94 146.51 52.86 Favored 'General case' 0 N--CA 1.438 -1.035 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.691 -179.472 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . 0.422 ' N ' HD12 ' A' ' 128' ' ' ILE . 2.0 mp -62.91 129.82 26.78 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-N 116.131 -0.486 . . . . 0.0 109.839 179.397 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.86 -4.04 68.05 Favored Glycine 0 N--CA 1.44 -1.099 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.949 -178.343 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 34.9 p -128.14 150.39 50.01 Favored 'General case' 0 C--O 1.237 0.447 0 CA-C-N 117.28 0.54 . . . . 0.0 110.885 178.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.421 ' O ' ' HA ' ' A' ' 139' ' ' CYS . 62.7 pttt -127.03 154.96 43.98 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.966 -179.616 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 40.3 t80 -87.18 136.87 32.76 Favored 'General case' 0 C--N 1.311 -1.078 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.109 -178.682 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 21.1 t70 -99.01 134.41 21.44 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.782 178.748 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 26.6 Cg_endo -62.04 -51.3 3.85 Favored 'Trans proline' 0 CA--C 1.532 0.39 0 C-N-CA 123.017 2.478 . . . . 0.0 114.116 -176.63 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 47.2 mm -81.23 -47.25 20.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 112.112 0.412 . . . . 0.0 112.112 -175.803 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.5 m -65.98 -34.46 78.15 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.833 0.349 . . . . 0.0 110.446 -179.228 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 87.7 mtm180 66.14 53.05 1.1 Allowed 'General case' 0 CA--C 1.516 -0.337 0 CA-C-N 115.404 -0.817 . . . . 0.0 110.554 177.757 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 28.2 p-10 -157.47 176.52 12.55 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.034 -0.985 . . . . 0.0 109.191 179.443 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' CYS . . . . . 0.421 ' HA ' ' O ' ' A' ' 131' ' ' LYS . 68.0 m -102.62 131.07 49.64 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-O 121.006 0.431 . . . . 0.0 111.91 178.628 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 33.8 m -125.55 165.85 22.42 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.216 177.288 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -50.26 118.18 2.82 Favored 'General case' 0 N--CA 1.474 0.739 0 CA-C-O 121.108 0.48 . . . . 0.0 111.644 179.809 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 15.3 t0 -84.98 90.77 7.9 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 177.35 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 . . . . . 0 C--N 1.308 -1.212 0 CA-C-N 115.354 -0.839 . . . . 0.0 109.744 -177.622 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.34 0 N-CA-C 111.851 -0.5 . . . . 0.0 111.851 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_exo -65.34 108.47 1.18 Allowed 'Trans proline' 0 C--N 1.346 0.412 0 C-N-CA 122.836 2.357 . . . . 0.0 111.863 -179.311 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.416 HD22 ' O ' ' A' ' 80' ' ' ASP . 65.6 mt -88.9 170.6 10.57 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-O 121.309 0.575 . . . . 0.0 111.88 -179.133 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 157.77 -42.61 0.51 Allowed Glycine 0 CA--C 1.499 -0.958 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 -178.578 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 17.2 m -75.43 -40.31 57.81 Favored 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 176.847 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.416 ' O ' HD22 ' A' ' 77' ' ' LEU . 11.0 t70 -136.21 86.4 2.22 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 177.848 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.461 HD22 ' CD1' ' A' ' 121' ' ' ILE . 23.9 tp -90.54 148.57 22.63 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-O 120.865 0.364 . . . . 0.0 110.978 -177.387 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.529 HG22 HG22 ' A' ' 89' ' ' THR . 7.7 mt -105.92 144.77 14.79 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 175.835 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.459 HG21 ' NE2' ' A' ' 102' ' ' HIS . 16.1 m -132.27 158.16 43.23 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 -178.473 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 6.8 p80 -116.49 101.98 9.1 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-O 121.226 0.536 . . . . 0.0 111.571 -177.721 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -117.27 114.09 23.11 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.12 179.116 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 67.05 22.58 72.48 Favored Glycine 0 CA--C 1.519 0.337 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.478 179.67 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 90.02 -4.71 83.23 Favored Glycine 0 N--CA 1.445 -0.707 0 C-N-CA 121.174 -0.536 . . . . 0.0 112.365 -179.686 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 35.0 mmtp -100.26 134.34 43.34 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-O 120.716 0.293 . . . . 0.0 110.349 -179.411 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.529 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -88.03 107.74 18.89 Favored 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.257 179.466 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -101.23 146.91 26.9 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.598 178.364 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 18.2 m-70 -98.22 140.04 33.1 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-O 120.881 0.372 . . . . 0.0 110.612 177.653 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 44.5 t -122.04 118.43 55.48 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.481 178.323 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.3 p -129.44 132.76 66.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.494 179.356 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 77.2 m -111.96 123.1 49.53 Favored 'General case' 0 C--N 1.308 -1.228 0 CA-C-O 121.059 0.457 . . . . 0.0 111.11 -178.47 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 34.2 m80 -100.7 -21.6 15.16 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 178.436 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -129.14 144.2 51.12 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.14 -0.937 . . . . 0.0 109.526 -178.83 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . 0.479 ' HG3' ' HA ' ' A' ' 113' ' ' SER . 42.3 tt0 -76.23 138.73 40.79 Favored 'General case' 0 N--CA 1.43 -1.432 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 177.883 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 132.17 173.86 13.45 Favored Glycine 0 N--CA 1.439 -1.107 0 C-N-CA 120.902 -0.666 . . . . 0.0 111.77 -178.21 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -87.36 134.07 3.39 Favored 'Trans proline' 0 N--CA 1.452 -0.961 0 C-N-CA 122.912 2.408 . . . . 0.0 112.951 179.142 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.8 pp -137.02 157.24 75.0 Favored Pre-proline 0 C--N 1.323 -0.544 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.899 178.43 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -65.34 162.58 32.89 Favored 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.41 2.073 . . . . 0.0 113.126 -177.794 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' HIS . . . . . 0.459 ' NE2' HG21 ' A' ' 83' ' ' VAL . 59.5 t-80 -91.78 120.93 67.83 Favored Pre-proline 0 C--N 1.316 -0.881 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.536 179.676 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_endo -60.72 -16.93 46.71 Favored 'Trans proline' 0 N--CA 1.482 0.841 0 C-N-CA 123.132 2.555 . . . . 0.0 113.466 -175.842 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -89.99 -24.09 30.73 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.556 -0.83 . . . . 0.0 112.563 179.874 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 25.7 p-10 -167.4 106.89 0.57 Allowed 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 110.108 -0.33 . . . . 0.0 110.108 -179.174 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 31.2 m -53.09 -11.32 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.045 0 N-CA-C 114.01 1.115 . . . . 0.0 114.01 -179.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -80.48 2.31 25.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.154 0.502 . . . . 0.0 110.935 178.49 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 34.1 mtmt -133.76 156.5 47.86 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 177.736 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 6.6 p90 -142.51 166.21 25.28 Favored 'General case' 0 C--N 1.311 -1.099 0 C-N-CA 120.871 -0.332 . . . . 0.0 110.476 179.331 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . . . . . . . . . 3.7 mp -123.74 137.67 56.09 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.037 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.474 ' O ' ' HA ' ' A' ' 121' ' ' ILE . 4.2 mp -95.64 121.74 46.47 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.997 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 176.696 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 25.4 m -105.46 127.16 52.85 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 -178.859 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . 0.479 ' HA ' ' HG3' ' A' ' 97' ' ' GLU . 52.5 m -126.52 131.79 51.51 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.402 179.251 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.632 ' HE2' ' O ' ' A' ' 116' ' ' GLY . 23.7 tptm -97.49 113.57 25.28 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 120.705 0.288 . . . . 0.0 110.659 -178.87 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 72.1 m -112.99 80.03 1.3 Allowed 'General case' 0 N--CA 1.442 -0.863 0 CA-C-O 121.265 0.555 . . . . 0.0 110.286 178.447 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.632 ' O ' ' HE2' ' A' ' 114' ' ' LYS . . . 74.35 -99.28 1.07 Allowed Glycine 0 N--CA 1.446 -0.679 0 CA-C-N 115.349 -0.841 . . . . 0.0 111.037 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 48.8 p -113.52 4.1 16.05 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 121.12 0.486 . . . . 0.0 110.433 178.065 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 26.8 tp -117.5 132.16 56.59 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.954 -175.479 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . 0.447 ' CE2' ' HD3' ' A' ' 114' ' ' LYS . 86.3 m95 -94.78 132.06 39.96 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 120.883 0.373 . . . . 0.0 110.746 177.116 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 51.0 m-85 -108.65 128.04 54.5 Favored 'General case' 0 C--N 1.309 -1.162 0 N-CA-C 108.876 -0.786 . . . . 0.0 108.876 174.156 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.474 ' HA ' ' O ' ' A' ' 111' ' ' ILE . 1.8 pp -133.2 153.4 37.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-O 121.367 0.603 . . . . 0.0 112.616 -175.695 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 19.4 m -150.44 127.58 11.24 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.188 178.074 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 4.0 p -98.77 106.74 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 CA-C-O 121.57 0.7 . . . . 0.0 111.061 -178.504 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 3.5 mmt -108.03 140.27 21.49 Favored Pre-proline 0 C--N 1.309 -1.166 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.654 -179.325 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_endo -82.48 141.47 11.23 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 122.386 2.058 . . . . 0.0 111.36 176.649 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 5.9 t -94.16 -174.87 3.51 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 120.648 -0.421 . . . . 0.0 110.667 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 15.5 m -61.53 137.16 58.23 Favored 'General case' 0 N--CA 1.441 -0.896 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.627 178.413 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 2.4 mp -65.84 139.35 21.41 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.914 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 178.33 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 93.55 -13.93 66.42 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.313 -176.03 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 73.6 p -117.41 159.53 22.64 Favored 'General case' 0 N--CA 1.447 -0.614 0 O-C-N 122.479 -0.424 . . . . 0.0 110.735 179.319 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 59.8 pttt -129.07 148.29 51.0 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.698 179.609 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.441 ' HD1' ' SG ' ' A' ' 139' ' ' CYS . 25.5 t80 -87.68 135.63 33.29 Favored 'General case' 0 C--N 1.308 -1.229 0 CA-C-O 120.825 0.345 . . . . 0.0 110.714 -178.58 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 30.5 t70 -102.47 134.99 19.64 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.015 178.706 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.23 -41.16 13.28 Favored 'Trans proline' 0 C--N 1.346 0.419 0 C-N-CA 123.021 2.481 . . . . 0.0 113.862 -176.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 33.1 mm -81.39 -52.69 13.57 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 C-N-CA 120.819 -0.353 . . . . 0.0 111.525 -176.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 7.2 m -62.69 -36.79 84.06 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 120.855 0.359 . . . . 0.0 110.394 179.153 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 80.5 mtm180 69.36 42.83 1.12 Allowed 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 115.356 -0.838 . . . . 0.0 111.157 177.24 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 10.5 p30 -154.39 177.57 11.01 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 108.393 -0.965 . . . . 0.0 108.393 177.197 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' CYS . . . . . 0.441 ' SG ' ' HD1' ' A' ' 132' ' ' PHE . 78.1 m -101.77 126.68 48.68 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-O 121.385 0.612 . . . . 0.0 111.737 -177.91 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 26.8 m -115.2 159.1 15.26 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-N 115.185 -0.916 . . . . 0.0 109.553 179.436 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 2.3 tm? -55.41 123.24 13.23 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 120.963 0.411 . . . . 0.0 110.915 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -89.17 101.42 14.08 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.045 -179.467 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 37.8 t30 . . . . . 0 C--O 1.251 1.171 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.619 177.58 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.349 0 N-CA-C 111.892 -0.483 . . . . 0.0 111.892 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -78.46 44.11 1.56 Allowed 'Trans proline' 0 C--N 1.348 0.53 0 C-N-CA 123.116 2.544 . . . . 0.0 112.416 -178.242 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 84.8 mt -89.54 -175.02 4.56 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.496 -179.089 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -119.74 -38.59 0.7 Allowed Glycine 0 N--CA 1.442 -0.901 0 C-N-CA 120.8 -0.714 . . . . 0.0 111.534 179.607 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 20.1 m -77.85 -32.15 51.9 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.893 0.378 . . . . 0.0 111.108 179.823 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -138.13 100.2 4.08 Favored 'General case' 0 C--O 1.237 0.396 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 -176.161 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.431 ' CD2' HD11 ' A' ' 121' ' ' ILE . 35.3 tp -101.26 147.14 26.64 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.244 -179.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.548 HG22 HG22 ' A' ' 89' ' ' THR . 4.0 mt -110.24 148.29 13.88 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.869 0 C-N-CA 120.561 -0.455 . . . . 0.0 110.374 178.553 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.477 ' O ' ' HA ' ' A' ' 89' ' ' THR . 4.8 m -142.44 174.72 5.39 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 179.58 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 11.0 p80 -128.21 108.36 10.55 Favored 'General case' 0 C--N 1.313 -1.0 0 N-CA-C 112.503 0.557 . . . . 0.0 112.503 -177.751 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 3.9 mp0 -116.65 113.63 22.94 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.105 178.708 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 66.68 31.64 79.05 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.628 178.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 86.19 -11.75 62.15 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.839 -0.696 . . . . 0.0 113.201 179.243 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 30.2 mmtp -99.09 136.94 38.32 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.871 0.336 . . . . 0.0 111.166 -179.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.548 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -86.54 107.77 18.27 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.474 179.268 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -100.3 145.14 28.48 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.816 179.258 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 27.1 m-70 -99.43 144.09 28.94 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.36 178.355 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 46.2 t -120.51 118.38 56.39 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.078 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 178.452 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 44.1 t -124.56 132.6 71.1 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.274 179.478 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 71.3 m -104.43 113.77 27.55 Favored 'General case' 0 C--N 1.31 -1.141 0 CA-C-O 121.113 0.482 . . . . 0.0 110.305 -179.564 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 19.0 t60 -79.49 -21.2 45.66 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.509 -178.144 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -161.53 175.81 11.72 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.654 179.714 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -77.92 144.6 36.73 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 120.735 0.302 . . . . 0.0 110.461 -179.607 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 126.45 164.41 11.74 Favored Glycine 0 N--CA 1.446 -0.658 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.41 -179.685 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.413 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 92.1 Cg_endo -86.78 138.28 5.09 Favored 'Trans proline' 0 CA--C 1.54 0.814 0 C-N-CA 122.869 2.379 . . . . 0.0 113.179 179.376 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.7 pp -140.91 157.27 67.75 Favored Pre-proline 0 C--N 1.325 -0.482 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.169 177.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -64.22 166.94 15.54 Favored 'Trans proline' 0 C--N 1.353 0.763 0 C-N-CA 122.666 2.244 . . . . 0.0 112.848 -179.138 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' HIS . . . . . . . . . . . . . 56.5 t-80 -92.82 128.36 44.09 Favored Pre-proline 0 C--N 1.318 -0.769 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.592 -179.088 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -63.09 -19.25 68.46 Favored 'Trans proline' 0 N--CA 1.484 0.934 0 C-N-CA 123.146 2.564 . . . . 0.0 113.398 -176.841 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -96.81 -17.54 32.58 Favored Glycine 0 C--O 1.228 -0.275 0 C-N-CA 120.485 -0.865 . . . . 0.0 113.226 -178.846 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.404 HD21 ' HE2' ' A' ' 108' ' ' LYS . 28.2 p-10 -169.23 104.21 0.37 Allowed 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.698 0.285 . . . . 0.0 110.8 -179.36 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 26.0 m -53.82 -13.14 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 N-CA-C 113.935 1.087 . . . . 0.0 113.935 179.069 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 36.4 m170 -74.88 0.11 16.7 Favored 'General case' 0 N--CA 1.471 0.621 0 CA-C-O 121.081 0.467 . . . . 0.0 110.858 177.043 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.404 ' HE2' HD21 ' A' ' 105' ' ' ASN . 31.2 mtmt -134.91 156.69 48.52 Favored 'General case' 0 CA--C 1.507 -0.705 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 178.555 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 9.9 p90 -142.47 168.74 19.01 Favored 'General case' 0 C--N 1.31 -1.135 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.433 178.828 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.413 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.5 mp -126.2 140.02 49.89 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 -179.82 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -98.7 118.16 44.83 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 176.287 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 68.8 m -100.4 123.61 44.85 Favored 'General case' 0 C--N 1.308 -1.232 0 CA-C-O 120.873 0.368 . . . . 0.0 110.418 -178.462 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 56.0 p -131.87 141.19 49.32 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 178.42 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 81.2 tttt -116.52 106.24 13.36 Favored 'General case' 0 C--N 1.311 -1.087 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.621 -178.611 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 69.6 m -88.59 84.48 6.75 Favored 'General case' 0 N--CA 1.436 -1.154 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.52 179.094 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 73.98 -100.2 1.11 Allowed Glycine 0 N--CA 1.439 -1.103 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -178.153 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 50.3 m -115.04 3.62 14.49 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-O 121.203 0.525 . . . . 0.0 109.826 178.633 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 92.2 mt -108.54 122.82 47.85 Favored 'General case' 0 N--CA 1.435 -1.209 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.542 -176.248 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 86.6 m95 -87.65 130.51 34.76 Favored 'General case' 0 C--N 1.315 -0.903 0 C-N-CA 120.414 -0.514 . . . . 0.0 111.315 179.145 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 85.6 m-85 -122.61 125.73 46.25 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.585 174.133 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.431 HD11 ' CD2' ' A' ' 81' ' ' LEU . 2.2 pp -124.95 157.88 33.06 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.177 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.035 -178.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 32.7 m -145.32 121.66 10.93 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 116.148 -0.478 . . . . 0.0 109.718 177.178 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.5 p -93.81 106.41 18.0 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 CA-C-O 121.491 0.663 . . . . 0.0 110.775 -178.685 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 4.2 mmt -106.75 136.3 19.44 Favored Pre-proline 0 C--N 1.31 -1.111 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.97 -178.662 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -82.54 139.3 10.09 Favored 'Trans proline' 0 N--CA 1.45 -1.062 0 C-N-CA 122.411 2.074 . . . . 0.0 110.87 176.078 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 4.7 t -94.61 -178.62 4.61 Favored 'General case' 0 C--N 1.311 -1.071 0 C-N-CA 120.104 -0.639 . . . . 0.0 109.325 177.831 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 15.4 m -63.56 135.1 56.58 Favored 'General case' 0 N--CA 1.435 -1.204 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.408 179.756 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . 0.401 ' N ' HD12 ' A' ' 128' ' ' ILE . 2.2 mp -62.62 141.36 18.07 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 N-CA-C 109.014 -0.735 . . . . 0.0 109.014 178.264 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.8 -10.61 74.17 Favored Glycine 0 N--CA 1.441 -0.985 0 C-N-CA 120.285 -0.959 . . . . 0.0 112.551 -175.186 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 73.5 p -125.02 152.96 43.57 Favored 'General case' 0 N--CA 1.45 -0.438 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 177.003 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 60.5 pttt -126.85 146.69 50.18 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 110.327 -0.249 . . . . 0.0 110.327 -178.366 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 37.9 t80 -84.42 131.38 34.68 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.87 -178.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 23.1 t70 -97.41 133.84 23.32 Favored Pre-proline 0 C--N 1.321 -0.65 0 CA-C-N 116.068 -0.515 . . . . 0.0 109.907 179.29 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -68.02 -40.83 8.43 Favored 'Trans proline' 0 CA--C 1.531 0.371 0 C-N-CA 122.69 2.26 . . . . 0.0 113.842 -177.242 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.8 mp -80.3 -52.05 15.09 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 111.778 0.288 . . . . 0.0 111.778 -177.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 2.1 m -67.03 -35.11 79.17 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.079 0.466 . . . . 0.0 110.092 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 50.7 mtm180 66.37 56.22 0.8 Allowed 'General case' 0 C--O 1.238 0.464 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.645 178.402 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 29.4 p-10 -162.18 174.92 12.26 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 114.647 -1.16 . . . . 0.0 108.75 178.785 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 79.2 m -102.72 126.48 49.84 Favored 'General case' 0 C--N 1.311 -1.068 0 CA-C-O 121.023 0.44 . . . . 0.0 110.805 179.152 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 32.3 m -120.33 170.29 10.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.738 -0.664 . . . . 0.0 110.293 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -51.11 116.89 2.22 Favored 'General case' 0 C--O 1.241 0.615 0 O-C-N 123.545 0.528 . . . . 0.0 110.722 178.794 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -85.41 100.02 11.58 Favored 'General case' 0 CA--C 1.508 -0.669 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.606 179.766 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 9.9 p-10 . . . . . 0 C--N 1.3 -1.547 0 CA-C-O 118.417 -0.801 . . . . 0.0 109.497 174.719 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.974 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_endo -61.97 -31.46 84.27 Favored 'Trans proline' 0 C--N 1.347 0.45 0 C-N-CA 122.478 2.119 . . . . 0.0 111.648 178.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 96.1 mt -93.3 168.78 10.86 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.46 179.599 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 158.44 -29.35 0.45 Allowed Glycine 0 C--N 1.308 -1.002 0 N-CA-C 110.709 -0.956 . . . . 0.0 110.709 -179.367 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 58.7 m -75.44 -28.63 59.42 Favored 'General case' 0 C--O 1.241 0.657 0 CA-C-O 121.34 0.591 . . . . 0.0 109.429 177.864 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -148.75 129.52 14.19 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-N 115.045 -0.98 . . . . 0.0 110.012 178.775 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.453 HD23 HD11 ' A' ' 121' ' ' ILE . 49.4 tp -127.2 135.73 51.06 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 115.417 -0.811 . . . . 0.0 111.276 178.312 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.505 HG22 HG22 ' A' ' 89' ' ' THR . 22.1 mt -94.84 144.58 9.52 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.131 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 176.017 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.553 HG21 ' CE1' ' A' ' 102' ' ' HIS . 20.5 m -131.34 174.22 13.44 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 N-CA-C 109.997 -0.371 . . . . 0.0 109.997 -177.261 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 27.2 m-70 -122.07 101.92 7.83 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 116.528 -0.305 . . . . 0.0 110.93 -178.822 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 34.8 mm-40 -111.32 117.57 33.5 Favored 'General case' 0 C--N 1.32 -0.697 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 178.121 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 63.33 29.24 73.91 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.863 -0.684 . . . . 0.0 111.867 -179.427 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 84.96 -9.35 66.35 Favored Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 121.087 -0.578 . . . . 0.0 113.132 -179.79 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 13.6 mptt -100.57 141.58 33.23 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.993 0.425 . . . . 0.0 111.327 -179.359 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.505 HG22 HG22 ' A' ' 82' ' ' ILE . 0.0 OUTLIER -82.97 122.24 28.03 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.67 179.47 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 76.1 m-85 -118.21 143.08 46.82 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 176.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 17.7 m-70 -94.46 139.59 30.94 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-O 120.65 0.262 . . . . 0.0 110.664 -178.275 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 60.4 t -119.46 118.14 56.36 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.88 0 N-CA-C 108.99 -0.745 . . . . 0.0 108.99 177.126 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 53.3 t -126.21 133.96 67.58 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.945 -178.741 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 66.6 m -114.64 121.25 42.83 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-O 120.779 0.323 . . . . 0.0 110.372 -178.819 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 39.1 m80 -90.23 -18.45 25.66 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.183 -179.811 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -150.11 170.05 19.82 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.648 -177.509 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 41.2 mt-10 -87.46 114.23 23.88 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.182 177.414 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 167.46 166.11 25.99 Favored Glycine 0 N--CA 1.436 -1.351 0 C-N-CA 121.049 -0.596 . . . . 0.0 111.624 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.501 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 87.6 Cg_endo -87.21 130.98 3.0 Favored 'Trans proline' 0 N--CA 1.45 -1.068 0 C-N-CA 122.761 2.307 . . . . 0.0 112.773 178.763 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.5 pp -140.94 156.74 68.41 Favored Pre-proline 0 C--N 1.319 -0.751 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.908 178.264 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -64.72 167.32 15.69 Favored 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 122.824 2.349 . . . . 0.0 113.163 -177.538 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' HIS . . . . . 0.553 ' CE1' HG21 ' A' ' 83' ' ' VAL . 4.9 t-80 -93.18 123.77 59.85 Favored Pre-proline 0 C--N 1.316 -0.87 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 -179.207 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 23.2 Cg_endo -58.64 -29.56 89.62 Favored 'Trans proline' 0 N--CA 1.482 0.817 0 C-N-CA 123.147 2.565 . . . . 0.0 114.155 -174.326 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -90.21 -16.08 56.29 Favored Glycine 0 C--N 1.319 -0.389 0 C-N-CA 120.085 -1.055 . . . . 0.0 113.238 -178.547 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 9.3 p-10 -168.07 97.47 0.44 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 120.773 0.321 . . . . 0.0 110.61 -177.122 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 30.5 m -56.07 -10.52 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 N-CA-C 113.768 1.025 . . . . 0.0 113.768 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 32.2 m170 -70.38 0.23 6.95 Favored 'General case' 0 N--CA 1.478 0.927 0 CA-C-O 121.352 0.596 . . . . 0.0 110.327 175.499 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.415 ' HG2' ' HA ' ' A' ' 125' ' ' PRO . 86.5 mttt -134.16 157.99 44.81 Favored 'General case' 0 CA--C 1.505 -0.758 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.021 178.91 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 12.3 p90 -143.44 165.83 26.45 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.391 176.616 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.501 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 2.3 mp -124.52 140.59 47.32 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.166 0 CA-C-O 120.798 0.333 . . . . 0.0 110.233 -178.758 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.4 mp -103.33 114.09 41.96 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 175.595 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 34.4 m -96.88 123.02 40.48 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -178.119 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 29.7 p -134.62 145.65 48.82 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-O 120.955 0.407 . . . . 0.0 111.087 -178.497 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . 0.534 ' HE2' ' O ' ' A' ' 116' ' ' GLY . 87.2 tttt -111.3 120.46 42.31 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-N 115.99 -0.55 . . . . 0.0 109.545 179.195 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 57.6 m -103.33 85.86 2.56 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.75 178.828 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.534 ' O ' ' HE2' ' A' ' 114' ' ' LYS . . . 66.91 -100.65 0.58 Allowed Glycine 0 N--CA 1.442 -0.958 0 CA-C-N 115.221 -0.899 . . . . 0.0 111.882 -178.58 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 15.1 m -110.3 6.58 22.56 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 120.741 0.305 . . . . 0.0 111.332 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -124.89 135.67 53.08 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 122.235 -0.291 . . . . 0.0 110.469 -178.768 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 52.6 m95 -94.65 135.79 35.71 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 120.945 0.402 . . . . 0.0 111.73 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -129.23 129.58 45.19 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.999 176.485 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.453 HD11 HD23 ' A' ' 81' ' ' LEU . 2.6 pp -123.86 147.63 28.21 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.819 0 CA-C-O 120.82 0.343 . . . . 0.0 110.819 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 25.0 m -132.01 124.35 29.13 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.515 -179.326 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 4.4 p -98.25 108.71 22.46 Favored 'Isoleucine or valine' 0 C--O 1.236 0.373 0 CA-C-O 121.496 0.665 . . . . 0.0 110.813 179.38 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 5.5 mmt -107.33 129.95 23.54 Favored Pre-proline 0 C--N 1.307 -1.253 0 CA-C-N 115.424 -0.807 . . . . 0.0 110.658 -179.054 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . 0.415 ' HA ' ' HG2' ' A' ' 108' ' ' LYS . 74.5 Cg_endo -79.52 134.48 11.16 Favored 'Trans proline' 0 N--CA 1.452 -0.92 0 C-N-CA 122.244 1.963 . . . . 0.0 110.817 176.463 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 5.0 t -88.57 -177.51 5.6 Favored 'General case' 0 C--N 1.311 -1.095 0 C-N-CA 120.267 -0.573 . . . . 0.0 110.354 -179.075 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 4.9 m -63.41 147.61 50.77 Favored 'General case' 0 N--CA 1.441 -0.894 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.188 -179.838 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . 0.408 ' N ' HD12 ' A' ' 128' ' ' ILE . 2.1 mp -65.97 139.13 21.75 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.584 178.36 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 88.72 -12.21 66.26 Favored Glycine 0 N--CA 1.441 -1.018 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.556 -177.781 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 64.1 p -118.41 156.48 28.91 Favored 'General case' 0 N--CA 1.448 -0.547 0 CA-C-N 117.163 0.481 . . . . 0.0 110.847 178.73 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.456 ' HD3' ' OD1' ' A' ' 142' ' ' ASP . 62.1 pttt -133.28 152.16 51.92 Favored 'General case' 0 C--N 1.316 -0.886 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 20.8 t80 -86.1 136.16 33.33 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-O 121.004 0.431 . . . . 0.0 111.348 -179.062 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -101.48 134.64 20.13 Favored Pre-proline 0 C--N 1.325 -0.461 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.909 178.05 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -71.99 -33.06 10.26 Favored 'Trans proline' 0 CA--C 1.533 0.467 0 C-N-CA 122.65 2.233 . . . . 0.0 113.924 -177.258 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.7 mp -81.04 -55.12 8.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 111.697 0.258 . . . . 0.0 111.697 -177.737 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 49.9 m -72.84 -30.82 64.32 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.602 0.239 . . . . 0.0 111.073 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 68.54 50.32 0.7 Allowed 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.102 178.73 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 30.1 p-10 -151.96 176.43 11.49 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-N 115.262 -0.881 . . . . 0.0 108.954 178.855 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' CYS . . . . . 0.414 ' HA ' ' O ' ' A' ' 131' ' ' LYS . 85.5 m -102.36 126.18 49.3 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-O 121.037 0.446 . . . . 0.0 110.474 178.333 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.6 m -118.62 166.6 12.83 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.919 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.917 179.791 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -54.25 117.28 3.15 Favored 'General case' 0 CA--C 1.537 0.467 0 CA-C-O 121.003 0.43 . . . . 0.0 110.361 179.244 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' ASP . . . . . 0.456 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 18.9 t70 -81.63 91.94 6.49 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.449 -178.456 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 47.4 t30 . . . . . 0 C--O 1.244 0.801 0 CA-C-O 118.543 -0.742 . . . . 0.0 109.703 176.843 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.393 0 N-CA-C 111.829 -0.509 . . . . 0.0 111.829 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -69.36 125.06 11.89 Favored 'Trans proline' 0 C--O 1.236 0.381 0 C-N-CA 122.674 2.249 . . . . 0.0 112.068 -179.878 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -70.96 156.83 39.15 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.485 -0.325 . . . . 0.0 110.56 179.627 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -103.56 -48.13 1.23 Allowed Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 120.453 -0.88 . . . . 0.0 113.365 -176.768 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 25.0 t -59.33 -39.99 84.88 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.871 0.367 . . . . 0.0 110.669 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.523 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 4.8 p-10 -150.2 122.74 8.53 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-O 121.537 0.684 . . . . 0.0 111.255 178.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -98.19 127.55 44.19 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.068 -0.969 . . . . 0.0 108.45 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.464 ' CG2' HG22 ' A' ' 89' ' ' THR . 24.9 mt -90.5 145.09 7.84 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.958 0 CA-C-O 120.952 0.406 . . . . 0.0 111.247 -177.128 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.42 HG21 ' CE1' ' A' ' 102' ' ' HIS . 20.7 m -131.82 168.22 24.5 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.007 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 179.441 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 12.1 p80 -127.15 113.18 16.04 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-O 121.035 0.445 . . . . 0.0 111.601 -178.614 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 64.1 mm-40 -119.95 102.42 8.54 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.663 -179.47 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 65.29 40.16 96.41 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.934 -0.651 . . . . 0.0 112.589 178.734 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 84.66 -8.66 68.03 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.976 179.777 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 34.7 mmtp -100.69 128.68 46.65 Favored 'General case' 0 CA--C 1.511 -0.526 0 CA-C-O 120.95 0.405 . . . . 0.0 110.91 -178.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.464 HG22 ' CG2' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -86.4 127.31 34.81 Favored 'General case' 0 C--N 1.307 -1.281 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.102 178.607 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 88.0 m-85 -121.51 148.96 43.78 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.048 178.782 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 25.1 m-70 -102.4 143.24 32.39 Favored 'General case' 0 C--N 1.307 -1.249 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.049 179.217 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.523 ' O ' ' HA ' ' A' ' 80' ' ' ASP . 99.1 t -118.76 126.29 75.13 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.379 179.534 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.4 p -143.21 131.59 19.59 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.959 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.6 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 64.7 m -128.62 131.25 48.09 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-O 120.838 0.351 . . . . 0.0 110.858 179.804 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 28.5 m80 -105.02 -11.07 16.8 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.117 0.484 . . . . 0.0 109.961 179.71 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 6.9 mp0 -127.35 143.36 51.23 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.206 179.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -78.46 109.99 13.12 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-O 120.917 0.389 . . . . 0.0 110.896 -179.565 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 167.94 168.35 29.94 Favored Glycine 0 N--CA 1.434 -1.434 0 N-CA-C 111.566 -0.614 . . . . 0.0 111.566 -179.645 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.458 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 83.1 Cg_endo -87.12 137.75 4.58 Favored 'Trans proline' 0 N--CA 1.451 -1.016 0 C-N-CA 122.841 2.361 . . . . 0.0 112.559 178.447 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.8 pp -139.01 157.64 71.09 Favored Pre-proline 0 C--N 1.317 -0.812 0 CA-C-N 115.987 -0.551 . . . . 0.0 109.586 178.36 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -63.16 168.65 10.52 Favored 'Trans proline' 0 C--N 1.35 0.609 0 C-N-CA 122.471 2.114 . . . . 0.0 112.856 -178.175 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' HIS . . . . . 0.42 ' CE1' HG21 ' A' ' 83' ' ' VAL . 3.6 t-80 -92.87 122.95 62.78 Favored Pre-proline 0 C--N 1.315 -0.899 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 -179.617 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -59.83 -21.8 65.47 Favored 'Trans proline' 0 N--CA 1.483 0.888 0 C-N-CA 122.99 2.46 . . . . 0.0 113.786 -176.361 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -95.93 -16.57 38.18 Favored Glycine 0 CA--C 1.519 0.283 0 C-N-CA 120.165 -1.017 . . . . 0.0 113.216 -178.798 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 3.0 p30 -168.24 101.86 0.44 Allowed 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 122.596 0.358 . . . . 0.0 110.904 -178.736 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.602 HG12 ' HB2' ' A' ' 131' ' ' LYS . 6.0 t -53.23 -16.86 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.064 0 N-CA-C 113.596 0.962 . . . . 0.0 113.596 -179.584 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 8.5 m170 -72.88 5.48 3.22 Favored 'General case' 0 N--CA 1.479 0.999 0 O-C-N 121.936 -0.478 . . . . 0.0 111.39 177.732 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 46.4 mtmt -139.74 158.93 43.29 Favored 'General case' 0 N--CA 1.44 -0.958 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 178.773 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 6.5 p90 -142.87 173.73 11.28 Favored 'General case' 0 C--N 1.302 -1.463 0 CA-C-O 120.866 0.365 . . . . 0.0 110.849 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.458 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 4.1 mt -130.6 138.55 53.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.936 -179.156 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -102.31 117.45 47.69 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 176.334 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 74.0 m -107.46 123.7 48.79 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-O 121.231 0.539 . . . . 0.0 110.709 -177.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 13.9 t -131.05 148.44 52.74 Favored 'General case' 0 C--N 1.311 -1.107 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.53 -178.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 34.1 tttm -116.87 112.1 20.6 Favored 'General case' 0 N--CA 1.435 -1.191 0 CA-C-O 121.28 0.562 . . . . 0.0 110.624 -178.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 8.5 t -94.44 100.49 12.49 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 179.598 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 64.29 -104.63 0.93 Allowed Glycine 0 N--CA 1.439 -1.101 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -175.852 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 31.3 m -114.11 9.51 17.24 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 116.674 0.237 . . . . 0.0 111.624 178.798 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 6.9 tt -121.54 135.79 54.99 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.809 0.337 . . . . 0.0 110.636 -176.725 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 84.2 m95 -93.74 133.27 37.28 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.141 0.496 . . . . 0.0 112.295 -177.615 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -117.65 127.31 53.82 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.65 -0.704 . . . . 0.0 109.161 174.38 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 2.5 pp -123.41 146.72 28.34 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.944 0 CA-C-O 121.1 0.476 . . . . 0.0 111.22 -178.596 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 18.6 m -136.83 122.85 20.25 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.765 179.231 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 2.7 p -94.99 111.31 25.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 121.344 0.593 . . . . 0.0 110.782 179.279 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 5.3 mmt -112.25 151.23 43.54 Favored Pre-proline 0 C--N 1.314 -0.977 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.512 -178.844 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -89.18 143.84 4.82 Favored 'Trans proline' 0 N--CA 1.452 -0.913 0 C-N-CA 122.409 2.072 . . . . 0.0 112.414 177.9 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' CYS . . . . . 0.507 ' SG ' ' HB2' ' A' ' 132' ' ' PHE . 56.9 m -80.42 169.61 17.48 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.396 176.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 23.9 m -54.77 146.21 17.66 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.156 176.542 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . 0.447 ' N ' HD12 ' A' ' 128' ' ' ILE . 1.8 mp -61.86 123.57 14.83 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.146 0 CA-C-O 121.026 0.441 . . . . 0.0 110.598 -178.712 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.02 5.48 62.47 Favored Glycine 0 N--CA 1.445 -0.706 0 CA-C-N 115.731 -0.668 . . . . 0.0 113.048 -177.873 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 48.2 p -121.14 167.34 12.76 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 117.117 0.458 . . . . 0.0 111.265 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.602 ' HB2' HG12 ' A' ' 106' ' ' VAL . 61.4 pttt -138.56 145.56 40.79 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 178.755 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.539 ' HD1' ' SG ' ' A' ' 139' ' ' CYS . 33.3 t80 -85.32 132.75 34.2 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 121.018 0.437 . . . . 0.0 111.995 -176.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -99.83 130.9 25.45 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.729 177.681 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_endo -62.78 -42.68 24.02 Favored 'Trans proline' 0 C--N 1.346 0.445 0 C-N-CA 123.087 2.525 . . . . 0.0 113.993 -176.06 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 35.5 mm -81.04 -48.73 18.94 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 C-N-CA 120.879 -0.328 . . . . 0.0 111.567 -176.668 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.6 m -63.69 -34.06 77.03 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.704 0.288 . . . . 0.0 110.705 179.248 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 79.5 mtm180 68.66 42.53 1.45 Allowed 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.454 177.6 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 10.5 p30 -157.27 171.35 20.57 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.301 -0.863 . . . . 0.0 108.766 176.706 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' CYS . . . . . 0.539 ' SG ' ' HD1' ' A' ' 132' ' ' PHE . 8.9 m -101.36 125.45 48.0 Favored 'General case' 0 C--N 1.318 -0.79 0 C-N-CA 120.696 -0.402 . . . . 0.0 110.405 -178.286 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.6 m -110.06 163.41 7.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.657 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 32.0 tp -59.74 119.98 8.66 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.799 0.333 . . . . 0.0 111.111 -178.758 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' ASP . . . . . 0.502 ' OD1' ' HD3' ' A' ' 131' ' ' LYS . 18.9 t70 -83.4 97.34 8.9 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.407 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 7.3 p30 . . . . . 0 C--N 1.317 -0.826 0 CA-C-O 118.229 -0.891 . . . . 0.0 110.77 -178.03 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.129 0 N-CA-C 111.676 -0.57 . . . . 0.0 111.676 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 20.6 Cg_exo -66.21 100.06 0.44 Allowed 'Trans proline' 0 C--O 1.237 0.454 0 C-N-CA 122.566 2.177 . . . . 0.0 111.861 178.503 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 38.8 tp -87.6 -17.12 32.66 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-O 121.418 0.628 . . . . 0.0 110.409 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.532 ' HA3' ' HB2' ' A' ' 119' ' ' TRP . . . 93.72 -19.98 49.66 Favored Glycine 0 N--CA 1.444 -0.785 0 CA-C-N 115.534 -0.757 . . . . 0.0 113.367 178.114 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 50.5 m -65.61 -32.87 74.68 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.871 0.367 . . . . 0.0 110.151 178.708 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.46 ' HA ' ' O ' ' A' ' 92' ' ' VAL . 4.3 p-10 -164.44 113.21 1.13 Allowed 'General case' 0 N--CA 1.452 -0.332 0 CA-C-O 121.54 0.686 . . . . 0.0 109.658 174.428 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -103.44 133.97 47.59 Favored 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 -179.62 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.536 ' CG2' HG22 ' A' ' 89' ' ' THR . 20.9 mt -94.66 140.65 16.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-O 121.076 0.465 . . . . 0.0 111.223 -177.63 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.448 HG21 ' NE2' ' A' ' 102' ' ' HIS . 28.2 m -129.68 160.84 40.27 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.122 -179.182 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 84.3 m-70 -116.72 102.59 9.56 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 116.475 -0.33 . . . . 0.0 110.312 -179.446 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 53.6 mm-40 -109.81 104.76 13.77 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.258 -179.845 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 60.2 40.64 97.55 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.797 -179.786 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 81.75 -14.21 32.2 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 121.193 -0.527 . . . . 0.0 113.076 -178.737 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 35.5 mmtp -90.2 126.85 35.96 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 117.062 0.431 . . . . 0.0 110.838 -178.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.536 HG22 ' CG2' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -83.49 121.95 27.88 Favored 'General case' 0 C--N 1.302 -1.464 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.985 178.742 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . . . . . . . . . 78.9 m-85 -117.78 154.4 31.8 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 116.241 -0.436 . . . . 0.0 109.977 177.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 28.3 m-70 -106.2 141.1 38.12 Favored 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 176.891 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . 0.46 ' O ' ' HA ' ' A' ' 80' ' ' ASP . 55.1 t -115.86 120.66 65.45 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 178.494 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 57.2 t -124.44 131.21 73.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 -178.733 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 81.5 m -113.66 112.56 23.69 Favored 'General case' 0 C--N 1.313 -1.019 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 179.373 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 27.9 t60 -91.77 -17.06 25.94 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.086 -178.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 41.1 mt-10 -137.12 150.84 48.24 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.769 -178.63 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -75.23 141.19 43.58 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.39 179.015 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 125.37 172.09 13.38 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.528 -0.844 . . . . 0.0 112.522 -179.616 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.419 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 86.2 Cg_endo -84.25 131.02 4.83 Favored 'Trans proline' 0 CA--C 1.537 0.666 0 C-N-CA 122.919 2.413 . . . . 0.0 112.857 178.757 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.9 pp -137.69 158.94 70.81 Favored Pre-proline 0 C--N 1.32 -0.68 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.395 178.367 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -64.66 168.96 12.19 Favored 'Trans proline' 0 C--N 1.351 0.686 0 C-N-CA 122.674 2.25 . . . . 0.0 112.821 -179.275 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' HIS . . . . . 0.493 ' HA ' HD11 ' A' ' 110' ' ' ILE . 8.5 t-80 -92.21 129.93 39.63 Favored Pre-proline 0 C--N 1.318 -0.804 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 -178.71 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_endo -53.45 -44.09 51.97 Favored 'Trans proline' 0 C--N 1.356 0.967 0 C-N-CA 123.164 2.576 . . . . 0.0 113.42 -175.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -71.02 -62.31 3.61 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.235 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.485 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 2.7 p30 -122.91 107.59 12.02 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-O 120.819 0.342 . . . . 0.0 111.382 -179.542 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 30.1 m -57.28 -10.18 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 113.064 0.765 . . . . 0.0 113.064 177.825 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 94.7 m-70 -74.13 3.74 6.63 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-O 121.505 0.669 . . . . 0.0 110.375 177.02 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 58.7 mttp -131.2 156.75 44.81 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 177.228 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 7.1 p90 -142.28 161.74 37.25 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 120.334 -0.546 . . . . 0.0 110.352 177.22 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.493 HD11 ' HA ' ' A' ' 102' ' ' HIS . 2.9 mp -123.47 141.31 44.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 -178.624 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.6 mp -97.45 112.48 29.6 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 175.371 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 42.0 m -97.93 122.04 40.58 Favored 'General case' 0 C--N 1.311 -1.081 0 CA-C-O 120.989 0.423 . . . . 0.0 110.675 -177.455 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 27.6 t -126.35 137.34 53.45 Favored 'General case' 0 N--CA 1.437 -1.116 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 178.898 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -108.49 122.15 46.44 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-O 120.817 0.342 . . . . 0.0 110.423 -179.143 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 43.1 m -116.42 105.82 12.93 Favored 'General case' 0 N--CA 1.434 -1.274 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.173 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 59.89 -110.9 3.12 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.343 -175.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 20.8 m -113.2 16.27 19.18 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.095 0.474 . . . . 0.0 110.144 179.143 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 6.0 mp -124.51 141.79 51.82 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.474 -177.168 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . 0.532 ' HB2' ' HA3' ' A' ' 78' ' ' GLY . 47.3 m95 -107.18 138.02 44.15 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-O 121.329 0.585 . . . . 0.0 111.61 179.513 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 78.7 m-85 -121.31 121.94 38.78 Favored 'General case' 0 C--N 1.309 -1.184 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.608 176.597 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.417 ' HB ' ' CG2' ' A' ' 110' ' ' ILE . 2.4 pp -123.28 159.25 27.75 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.755 -176.439 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 37.3 m -146.25 120.99 9.86 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.848 177.443 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 5.1 p -93.46 110.44 23.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 121.601 0.715 . . . . 0.0 111.22 -178.299 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 3.6 mmt -108.71 125.18 32.31 Favored Pre-proline 0 C--N 1.307 -1.248 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.111 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -75.14 135.43 18.83 Favored 'Trans proline' 0 N--CA 1.456 -0.726 0 C-N-CA 122.149 1.9 . . . . 0.0 111.288 178.419 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 6.2 t -90.71 -173.52 3.76 Favored 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 -179.573 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 46.8 m -64.69 137.66 57.94 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-O 120.928 0.395 . . . . 0.0 111.004 179.665 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 2.0 mp -60.5 134.56 25.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.819 178.609 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.2 -17.72 58.31 Favored Glycine 0 N--CA 1.444 -0.772 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.918 -177.007 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 77.0 p -109.72 158.18 18.36 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 117.456 0.628 . . . . 0.0 110.541 178.833 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 59.2 pttt -130.19 144.8 51.57 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.089 -179.041 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 39.9 t80 -83.71 134.52 34.75 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.849 -179.218 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -99.16 130.52 27.08 Favored Pre-proline 0 C--N 1.321 -0.647 0 CA-C-N 116.243 -0.435 . . . . 0.0 109.939 178.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_endo -65.49 -43.98 9.5 Favored 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.792 2.328 . . . . 0.0 113.607 -176.579 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.8 mp -76.5 -50.48 21.77 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 116.632 -0.258 . . . . 0.0 111.605 -177.18 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.1 m -68.65 -33.2 73.59 Favored 'General case' 0 C--O 1.239 0.52 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.025 -179.022 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' ARG . . . . . . . . . . . . . 89.3 mtm180 70.33 43.22 0.84 Allowed 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.067 177.771 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 26.0 p-10 -152.5 176.27 11.87 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 179.267 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 95.8 m -102.41 126.51 49.46 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 121.179 0.514 . . . . 0.0 111.315 179.411 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 27.0 m -114.88 159.94 14.5 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 CA-C-N 115.698 -0.683 . . . . 0.0 109.22 177.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 55.8 tp -63.65 135.5 56.8 Favored 'General case' 0 C--N 1.312 -1.045 0 CA-C-O 121.054 0.454 . . . . 0.0 111.364 -179.637 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -97.22 96.23 8.27 Favored 'General case' 0 CA--C 1.507 -0.688 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 177.709 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 60.7 t30 . . . . . 0 C--N 1.313 -0.999 0 CA-C-O 118.399 -0.81 . . . . 0.0 109.728 -179.297 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.371 0 N-CA-C 111.577 -0.609 . . . . 0.0 111.577 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -65.91 -47.29 3.84 Favored 'Trans proline' 0 C--N 1.346 0.428 0 C-N-CA 122.459 2.106 . . . . 0.0 112.343 -179.27 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 58.9 tp -94.92 123.8 38.6 Favored 'General case' 0 C--N 1.307 -1.241 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.19 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -107.8 40.93 2.35 Favored Glycine 0 N--CA 1.438 -1.213 0 N-CA-C 111.124 -0.79 . . . . 0.0 111.124 -179.904 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 23.3 t -75.96 -20.79 57.64 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 178.704 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -157.54 93.09 1.27 Allowed 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 114.539 -1.21 . . . . 0.0 108.554 178.375 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.507 ' HG ' ' CD1' ' A' ' 121' ' ' ILE . 3.1 tm? -101.93 130.33 48.42 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 -179.676 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.541 ' CG2' HG22 ' A' ' 89' ' ' THR . 23.3 mt -94.29 144.04 10.46 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 CA-C-O 120.742 0.306 . . . . 0.0 110.435 -178.439 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 29.8 m -134.78 165.63 30.7 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.9 0 CA-C-N 116.212 -0.449 . . . . 0.0 109.952 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 85.3 m-70 -114.93 121.82 44.38 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 179.452 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 3.8 tp10 -145.62 115.45 7.33 Favored 'General case' 0 C--N 1.318 -0.765 0 C-N-CA 120.693 -0.403 . . . . 0.0 111.008 -178.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 62.16 29.74 73.75 Favored Glycine 0 CA--C 1.518 0.274 0 CA-C-N 116.129 -0.487 . . . . 0.0 113.359 177.593 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 89.51 -5.94 83.52 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.351 179.087 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . 0.501 ' HB2' ' CE1' ' A' ' 90' ' ' TYR . 68.4 mmtt -102.16 153.07 20.29 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-O 120.593 0.235 . . . . 0.0 110.685 179.878 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.541 HG22 ' CG2' ' A' ' 82' ' ' ILE . 0.2 OUTLIER -106.82 106.75 17.42 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 177.024 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.501 ' CE1' ' HB2' ' A' ' 88' ' ' LYS . 96.1 m-85 -98.19 145.84 26.21 Favored 'General case' 0 C--N 1.313 -1.022 0 CA-C-O 120.983 0.421 . . . . 0.0 111.183 -177.035 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 31.1 m-70 -101.72 134.66 44.53 Favored 'General case' 0 C--N 1.307 -1.248 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 177.068 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 46.7 t -113.25 118.47 58.16 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 179.141 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 91.4 t -119.27 131.71 71.19 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.518 -179.045 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 73.8 m -114.76 113.18 23.92 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-O 120.994 0.426 . . . . 0.0 109.956 -179.579 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 67.9 t60 -93.2 -17.46 23.68 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.819 -178.758 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -145.24 158.58 43.79 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.887 -178.034 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -74.24 129.92 38.73 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.48 179.378 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 137.07 158.81 8.07 Favored Glycine 0 N--CA 1.44 -1.05 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.192 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.442 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 77.3 Cg_endo -78.02 140.1 17.75 Favored 'Trans proline' 0 CA--C 1.537 0.649 0 C-N-CA 122.791 2.327 . . . . 0.0 112.987 178.751 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.8 pp -138.02 157.7 72.56 Favored Pre-proline 0 C--N 1.32 -0.687 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.701 177.983 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -62.22 164.75 16.5 Favored 'Trans proline' 0 C--N 1.35 0.633 0 C-N-CA 122.4 2.067 . . . . 0.0 113.107 -178.409 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' HIS . . . . . 0.415 ' HA ' HD11 ' A' ' 110' ' ' ILE . 42.0 t-80 -89.66 120.1 69.51 Favored Pre-proline 0 C--N 1.319 -0.721 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.479 -179.087 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 14.1 Cg_endo -56.62 -21.97 41.43 Favored 'Trans proline' 0 N--CA 1.482 0.847 0 C-N-CA 123.08 2.52 . . . . 0.0 113.376 -176.816 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -89.33 -20.57 44.71 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.36 -0.924 . . . . 0.0 113.308 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . . . . . . . . . 16.7 p30 -169.15 109.85 0.47 Allowed 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 122.69 0.396 . . . . 0.0 110.361 -179.134 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 34.8 m -57.17 -11.37 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.076 0 N-CA-C 113.833 1.049 . . . . 0.0 113.833 -179.629 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 42.5 m170 -76.29 3.71 10.32 Favored 'General case' 0 N--CA 1.475 0.786 0 CA-C-O 121.145 0.498 . . . . 0.0 111.266 177.556 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.402 ' HG2' ' HA ' ' A' ' 125' ' ' PRO . 42.2 mtmt -138.87 161.03 38.3 Favored 'General case' 0 CA--C 1.506 -0.72 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 178.634 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 9.3 p90 -143.83 172.31 13.02 Favored 'General case' 0 C--N 1.313 -0.988 0 C-N-CA 120.647 -0.421 . . . . 0.0 111.246 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.442 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 3.9 mp -129.3 140.64 48.64 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.965 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 178.652 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . . . . . . . . . 4.5 mp -96.44 122.08 47.59 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 176.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 57.9 m -106.0 125.23 50.75 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-O 120.679 0.276 . . . . 0.0 110.279 -178.405 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 19.8 m -130.83 139.7 50.2 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.253 179.044 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -112.12 104.37 12.6 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-O 120.994 0.426 . . . . 0.0 110.041 179.482 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 14.2 t -91.79 88.8 6.8 Favored 'General case' 0 C--N 1.309 -1.185 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 179.508 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 70.37 -100.79 0.83 Allowed Glycine 0 N--CA 1.443 -0.85 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 -177.581 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 50.6 m -114.58 5.62 15.52 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.895 0.379 . . . . 0.0 110.735 178.357 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 21.4 tp -116.68 129.53 56.19 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.622 -176.32 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 83.1 m95 -92.97 132.04 37.42 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -178.832 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 51.2 m-85 -113.06 137.27 51.67 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 115.457 -0.792 . . . . 0.0 109.422 175.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.507 ' CD1' ' HG ' ' A' ' 81' ' ' LEU . 2.1 pp -134.28 152.27 33.64 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.998 0 N-CA-C 112.364 0.505 . . . . 0.0 112.364 -176.576 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 25.7 m -151.35 122.14 7.53 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.293 176.909 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.406 ' HA ' ' HA ' ' A' ' 110' ' ' ILE . 3.8 p -95.07 112.91 28.37 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 CA-C-O 121.348 0.594 . . . . 0.0 111.305 -179.13 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 4.5 mmt -112.1 139.8 22.81 Favored Pre-proline 0 C--N 1.316 -0.867 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.621 -179.165 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . 0.402 ' HA ' ' HG2' ' A' ' 108' ' ' LYS . 91.6 Cg_endo -83.85 140.56 9.16 Favored 'Trans proline' 0 N--CA 1.452 -0.958 0 C-N-CA 122.408 2.072 . . . . 0.0 111.551 177.168 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 7.1 t -94.36 -179.19 4.83 Favored 'General case' 0 C--N 1.319 -0.75 0 C-N-CA 120.381 -0.527 . . . . 0.0 109.828 177.906 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 10.4 t -68.33 140.22 55.91 Favored 'General case' 0 N--CA 1.436 -1.129 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.238 179.853 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . . . . . . . . . 2.1 mp -61.56 141.78 17.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 178.393 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 94.22 -19.85 51.07 Favored Glycine 0 N--CA 1.438 -1.229 0 C-N-CA 120.592 -0.813 . . . . 0.0 112.499 -176.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 68.8 p -114.76 154.72 28.02 Favored 'General case' 0 N--CA 1.448 -0.528 0 CA-C-N 117.261 0.53 . . . . 0.0 111.104 179.655 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 59.8 pttt -126.63 145.03 50.71 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.959 179.369 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -83.94 132.74 34.74 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-O 120.874 0.369 . . . . 0.0 110.963 -178.486 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -94.57 133.59 26.63 Favored Pre-proline 0 C--N 1.323 -0.576 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.418 179.576 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -67.77 -41.33 8.25 Favored 'Trans proline' 0 CA--C 1.535 0.57 0 C-N-CA 122.919 2.413 . . . . 0.0 114.512 -177.541 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 1.8 mp -82.5 -51.81 14.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 N-CA-C 111.82 0.304 . . . . 0.0 111.82 -177.029 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 4.2 m -69.24 -35.7 76.41 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.139 0.495 . . . . 0.0 110.194 -179.232 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' ARG . . . . . 0.439 ' HD2' ' HD2' ' A' ' 99' ' ' PRO . 56.1 mtm180 66.81 62.87 0.5 Allowed 'General case' 0 N--CA 1.452 -0.341 0 CA-C-N 115.274 -0.875 . . . . 0.0 111.528 178.458 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -165.42 173.16 11.37 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 114.559 -1.2 . . . . 0.0 108.118 176.717 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' CYS . . . . . . . . . . . . . 88.9 m -100.49 126.5 46.92 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-O 121.083 0.468 . . . . 0.0 111.118 -179.177 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.8 m -113.13 158.3 13.54 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.804 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.279 178.341 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -61.31 117.38 5.56 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.796 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' ASP . . . . . . . . . . . . . 35.3 t0 -78.59 92.11 4.67 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.473 -178.641 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 52.7 t-20 . . . . . 0 C--O 1.247 0.938 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 179.079 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.24 0 N-CA-C 112.186 -0.366 . . . . 0.0 112.186 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_exo -68.17 -34.23 22.64 Favored 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.453 2.102 . . . . 0.0 110.947 179.496 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 76.2 mt -123.49 151.8 42.39 Favored 'General case' 0 C--N 1.31 -1.115 0 CA-C-N 115.165 -0.925 . . . . 0.0 109.624 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -119.47 -37.16 0.8 Allowed Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 120.933 -0.651 . . . . 0.0 111.996 -179.735 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 34.1 m -60.41 -52.81 63.62 Favored 'General case' 0 C--O 1.236 0.392 0 CA-C-O 120.692 0.282 . . . . 0.0 111.15 179.174 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -153.78 121.53 5.96 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.44 0.638 . . . . 0.0 110.78 177.363 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.417 ' HG ' HD11 ' A' ' 121' ' ' ILE . 2.5 tm? -100.23 134.57 42.97 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.468 ' CG2' HG22 ' A' ' 89' ' ' THR . 20.8 mt -95.51 142.63 13.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-O 120.937 0.399 . . . . 0.0 110.897 -177.215 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.472 HG21 ' NE2' ' A' ' 102' ' ' HIS . 31.2 m -130.39 154.2 40.17 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.964 -179.358 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' HIS . . . . . . . . . . . . . 42.6 m-70 -114.57 101.49 9.15 Favored 'General case' 0 C--N 1.311 -1.1 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.115 -178.942 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.466 ' HB2' ' CE1' ' A' ' 90' ' ' TYR . 50.2 mm-40 -105.86 110.42 22.7 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.052 178.119 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 64.73 30.54 78.21 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 121.148 -0.549 . . . . 0.0 111.951 -179.235 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 86.05 -9.3 69.92 Favored Glycine 0 N--CA 1.444 -0.771 0 C-N-CA 120.928 -0.654 . . . . 0.0 112.385 -179.299 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 1.3 mptm? -91.74 140.52 29.62 Favored 'General case' 0 CA--C 1.507 -0.698 0 CA-C-O 120.911 0.386 . . . . 0.0 110.463 -179.731 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.468 HG22 ' CG2' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -91.21 129.8 37.16 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.767 179.165 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.466 ' CE1' ' HB2' ' A' ' 85' ' ' GLU . 88.1 m-85 -127.3 148.28 50.23 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 177.887 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 40.1 m-70 -103.89 138.3 40.67 Favored 'General case' 0 C--N 1.305 -1.343 0 N-CA-C 110.059 -0.348 . . . . 0.0 110.059 178.473 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' VAL . . . . . . . . . . . . . 58.3 t -111.23 122.75 66.24 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.217 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 178.446 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 38.3 t -126.04 132.18 70.89 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 -179.057 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 88.8 m -102.0 126.5 48.94 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.019 0.438 . . . . 0.0 111.033 -179.155 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 77.9 m-70 -90.12 -30.51 17.62 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.573 -179.083 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -151.88 172.95 15.4 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-N 115.747 -0.66 . . . . 0.0 109.886 -177.384 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' GLU . . . . . . . . . . . . . 5.3 mp0 -74.81 137.13 41.7 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.138 178.143 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 124.57 158.83 10.19 Favored Glycine 0 N--CA 1.443 -0.889 0 C-N-CA 120.681 -0.771 . . . . 0.0 111.973 -179.597 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.445 ' HA ' ' O ' ' A' ' 110' ' ' ILE . 78.1 Cg_endo -77.32 139.56 18.75 Favored 'Trans proline' 0 N--CA 1.46 -0.482 0 C-N-CA 122.613 2.209 . . . . 0.0 113.259 179.13 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 1.8 pp -137.36 158.13 72.82 Favored Pre-proline 0 C--N 1.319 -0.723 0 CA-C-N 115.496 -0.774 . . . . 0.0 109.64 178.107 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -64.24 169.39 10.89 Favored 'Trans proline' 0 C--N 1.351 0.692 0 C-N-CA 122.593 2.195 . . . . 0.0 113.207 -177.784 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' HIS . . . . . 0.472 ' NE2' HG21 ' A' ' 83' ' ' VAL . 2.3 t-80 -88.73 128.49 52.3 Favored Pre-proline 0 C--N 1.317 -0.827 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 -179.613 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_endo -53.28 -42.5 64.74 Favored 'Trans proline' 0 C--N 1.351 0.699 0 C-N-CA 122.994 2.463 . . . . 0.0 113.032 -177.141 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -74.62 -61.74 3.05 Favored Glycine 0 C--N 1.316 -0.565 0 C-N-CA 120.713 -0.756 . . . . 0.0 113.002 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' ASN . . . . . 0.429 ' O ' ' HB3' ' A' ' 102' ' ' HIS . 6.1 p-10 -125.03 107.95 11.33 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-O 120.973 0.416 . . . . 0.0 111.97 -176.757 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 8.5 p -56.65 -11.97 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.12 0 N-CA-C 113.607 0.965 . . . . 0.0 113.607 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 51.6 m170 -70.42 -4.19 21.31 Favored 'General case' 0 N--CA 1.474 0.748 0 CA-C-O 121.135 0.493 . . . . 0.0 111.055 178.502 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.423 ' O ' ' HB2' ' A' ' 102' ' ' HIS . 39.8 mtmt -135.2 159.91 40.04 Favored 'General case' 0 N--CA 1.44 -0.972 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 177.692 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' TYR . . . . . . . . . . . . . 14.6 p90 -142.8 173.57 11.43 Favored 'General case' 0 C--N 1.307 -1.281 0 CA-C-N 116.577 -0.283 . . . . 0.0 110.78 -178.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.445 ' O ' ' HA ' ' A' ' 99' ' ' PRO . 2.3 mp -130.19 140.33 49.17 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.166 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 178.753 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.431 HG13 ' HB3' ' A' ' 99' ' ' PRO . 4.9 mp -97.47 118.47 44.0 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 177.299 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' CYS . . . . . . . . . . . . . 62.8 m -97.17 121.71 39.37 Favored 'General case' 0 N--CA 1.437 -1.102 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 17.3 m -124.11 136.85 54.51 Favored 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.706 -179.531 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' LYS . . . . . . . . . . . . . 23.0 ttmt -112.02 109.41 19.14 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-O 121.157 0.504 . . . . 0.0 111.143 -179.488 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 15.8 t -92.28 88.89 6.62 Favored 'General case' 0 N--CA 1.43 -1.432 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 176.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 72.1 -99.87 0.9 Allowed Glycine 0 N--CA 1.437 -1.294 0 N-CA-C 110.705 -0.958 . . . . 0.0 110.705 -176.416 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 24.3 p -116.41 6.24 13.6 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-O 120.893 0.378 . . . . 0.0 111.298 177.824 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 53.6 tp -113.04 135.88 53.3 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.818 0.342 . . . . 0.0 111.255 -175.644 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' TRP . . . . . . . . . . . . . 96.4 m95 -89.62 131.85 35.41 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 121.336 0.588 . . . . 0.0 112.466 -179.707 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 73.5 m-85 -119.34 124.19 46.02 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 170.423 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.417 HD11 ' HG ' ' A' ' 81' ' ' LEU . 2.0 pp -124.45 146.87 29.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 120.502 -0.479 . . . . 0.0 111.689 -176.828 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 20.2 m -137.06 122.63 19.69 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.375 178.81 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 4.0 p -93.39 113.72 28.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 121.346 0.593 . . . . 0.0 111.211 -179.385 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 3.6 mmt -117.23 151.44 47.82 Favored Pre-proline 0 C--N 1.322 -0.628 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.805 -179.088 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 90.7 Cg_endo -92.25 151.36 3.1 Favored 'Trans proline' 0 N--CA 1.448 -1.156 0 C-N-CA 122.399 2.066 . . . . 0.0 112.441 177.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' CYS . . . . . . . . . . . . . 56.2 m -84.99 167.92 15.42 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 174.515 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' SER . . . . . . . . . . . . . 10.9 p -59.89 144.23 49.35 Favored 'General case' 0 N--CA 1.439 -0.996 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 176.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' ILE . . . . . 0.454 ' N ' HD12 ' A' ' 128' ' ' ILE . 2.0 mp -60.74 122.51 11.38 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 CA-C-O 121.175 0.512 . . . . 0.0 110.327 -178.186 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 103.26 1.91 47.86 Favored Glycine 0 N--CA 1.437 -1.248 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.995 -176.397 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . 0.411 HG22 ' HA ' ' A' ' 141' ' ' LEU . 80.7 p -126.77 160.08 31.89 Favored 'General case' 0 CA--C 1.539 0.533 0 CA-C-N 117.456 0.628 . . . . 0.0 111.634 179.773 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 55.0 pttt -125.87 145.54 50.2 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.384 179.633 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.463 ' HD1' ' SG ' ' A' ' 139' ' ' CYS . 29.1 t80 -85.64 137.53 32.77 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-O 121.01 0.434 . . . . 0.0 111.556 -179.23 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -103.48 132.18 21.33 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.181 179.246 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -69.5 -45.06 1.89 Allowed 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 123.11 2.54 . . . . 0.0 114.393 -177.222 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' ILE . . . . . . . . . . . . . 34.9 mm -74.7 -46.62 41.31 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 N-CA-C 112.035 0.383 . . . . 0.0 112.035 -176.326 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 39.5 t -75.63 -31.79 59.99 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-O 120.861 0.362 . . . . 0.0 110.146 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' ARG . . . . . 0.421 ' HB3' ' HG2' ' A' ' 99' ' ' PRO . 66.0 mtm180 66.42 62.02 0.56 Allowed 'General case' 0 N--CA 1.463 0.223 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.354 178.59 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . 0.456 HD22 ' N ' ' A' ' 138' ' ' ASN . 0.1 OUTLIER -165.31 172.45 12.31 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.175 -0.92 . . . . 0.0 109.082 179.603 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' CYS . . . . . 0.463 ' SG ' ' HD1' ' A' ' 132' ' ' PHE . 38.6 m -101.05 124.58 46.99 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 178.862 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 36.0 m -113.96 164.38 10.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.807 0 CA-C-N 115.883 -0.598 . . . . 0.0 109.759 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' LEU . . . . . 0.411 ' HA ' HG22 ' A' ' 130' ' ' THR . 34.2 tp -58.46 123.86 17.63 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-O 121.024 0.44 . . . . 0.0 111.75 -178.324 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' ASP . . . . . 0.409 ' H ' ' HA ' ' A' ' 130' ' ' THR . 18.0 t70 -93.37 98.18 11.06 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.879 -0.6 . . . . 0.0 109.642 178.104 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 48.5 t30 . . . . . 0 C--N 1.305 -1.367 0 CA-C-O 118.475 -0.774 . . . . 0.0 110.051 -178.758 . . . . . . . . 0 0 . 1 stop_ save_